


**CUMULATIVE
SUPPLEMENT 11
November 2024**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

44th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2024

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

44th EDITION

**Cumulative Supplement 11
November 2024**

CONTENTS

PAGE

Contents

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT.....	vi
1.3	APPLICANT NAME CHANGES.....	vii
1.4	LEVOTHYROXINE SODIUM.....	ix
1.5	AVAILABILITY OF THE EDITION.....	x
1.6	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	xi
1.7	CUMULATIVE SUPPLEMENT LEGEND.....	xii
DRUG PRODUCT LISTS		
	Prescription Drug Product List	1-1
	OTC Drug Product List	2-1
	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	3-1
	Orphan Products Designations and Approvals List	4-1
	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM		
A.	Patent and Exclusivity Lists	A-1
B.	Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

44th EDITION

**CUMULATIVE SUPPLEMENT 11
November 2024**

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug

Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOBPR) of any changes or corrections. The DOBPR can be contacted by email at orangebook@fda.hhs.gov.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
ACI HEALTHCARE LTD (ACI)	STRIDES PHARMA GLOBAL PTE LTD (STRIDES PHARMA)
AKORN OPERATING CO LLC (AKORN)	EPIC PHARMA LLC (EPIC PHARMA LLC)
AKORN OPERATING CO LLC (AKORN)	SCIEGEN PHARMACEUTICALS INC (SCIEGEN PHARMS INC)
CADILA HEALTHCARE LTD (CADILA)	ZYDUS LIFESCIENCES LTD (ZYDUS LIFESCIENCES)
EXTROVIS AG (EXTROVIS)	RISING PHARMA HOLDINGS INC (RISING)
GLAXOSMITHKLINE (GLAXOSMITHKLINE)	HALEON US HOLDINGS LLC (HALEON US HOLDINGS)

GLAXOSMITHKLINE CONSUMER HEALTHCARE (GLAXOSMITHKLINE CONS)	HALEON US HOLDINGS LLC (HALEON US HOLDINGS)
GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS US LLC (GLAXOSMITHKLINE)	HALEON US HOLDINGS LLC (HALEON US HOLDINGS)
GLENMARK GENERICS INC USA (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS INC USA (GLENMARK PHARMS INC)
GLENMARK GENERICS LIMITED (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS LTD (GLENMARK PHARMS LTD)
GLENMARK GENERICS LTD (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS INC USA (GLENMARK PHARMS INC)
GLENMARK GENERICS LTD (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS LTD (GLENMARK PHARMS LTD)
GLENMARK GENERICS LTD INDIA (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS LTD (GLENMARK PHARMS LTD)
GLENMARK PHARMACEUTICALS SA (GLENMARK PHARMS)	GLENMARK SPECIALTY SA (GLENMARK SPECLT)
GLENMARK PHARMACEUTICALS SA SWITZERLAND (GLENMARK PHARMS SA)	GLENMARK SPECIALTY SA (GLENMARK SPECLT)
LUPIN LTD (LUPIN LTD)	CHARTWELL RX SCIENCES LLC (CHARTWELL RX)
MYLAN LABORATORIES LTD (MYLAN LABS LTD)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
MYLAN LABORATORIES LTD (MYLAN LABS LTD)	XIROMED LLC (XIROMED)
MYLAN PHARMACEUTICALS INC (MYLAN)	NATCO PHARMA LTD (NATCO)
MYLAN PHARMACEUTICALS INC (MYLAN)	NATCO PHARMA LTD (NATCO PHARMA)
MYLAN PHARMACEUTICALS INC (MYLAN)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
MYLAN PHARMACEUTICALS INC (MYLAN PHARMS INC)	NATCO PHARMA LTD (NATCO PHARMA)
MYLAN PHARMACEUTICALS INC (MYLAN PHARMS INC)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)

MYLAN TECHNOLOGIES INC (MYLAN TECHNOLOGIES)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
PAR PHARMACEUTICAL (PAR PHARM)	ENDO OPERATIONS LTD (ENDO OPERATIONS)
PAR PHARMACEUTICAL INC (PAR PHARM)	ENDO OPERATIONS LTD (ENDO OPERATIONS)
PAR PHARMACEUTICAL INC (PAR PHARM INC)	ENDO OPERATIONS LTD (ENDO OPERATIONS)
PAR STERILE PRODUCTS LLC (PAR STERILE PRODUCTS)	ENDO OPERATIONS LTD (ENDO OPERATIONS)
SAPTALIS PHARMACEUTICALS LLC (SAPTALIS PHARMS)	SCIEGEN PHARMACEUTICALS INC (SCIEGEN PHARMS INC)
STERISCIENCE PTE LTD (STERISCIENCE)	STERISCIENCE SPECIALITIES PTE LTD (STERISCIENCE SPECLTS)
STRIDES PHARMA GLOBAL PTE LTD (STRIDES PHARMA)	ESJAY PHARMA LLC (ESJAY PHARMA)
TARO PHARMACEUTICALS USA INC (TARO)	TARO PHARMACEUTICALS INC (TARO)
VERTICE PHARMA MANAGEMENT CORP (VERTICE)	ENCUBE ETHICALS PRIVATE LTD (ENCUBE)
ZYDUS WORLDWIDE DMCC (ZYDUS)	ZYDUS LIFESCIENCES GLOBAL FZE (ZYDUS LIFESCIENCES)

1.4 LEVOTHYROXINE SODIUM¹

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

¹ In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.²

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM ³	MYLAN	0.3MG	A076187	-	RS

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

² Please consult the Active Section of the Orange Book for information on other strengths.

³ Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with

approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u> <u>COUNTED</u>	<u>DEC</u> <u>2023</u>	<u>MAR</u> <u>2024</u>	<u>JUN</u> <u>2024</u>	<u>SEP</u> <u>2024</u>	<u>DEC</u> <u>2024</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	23099 2784 (12.1%)	23058 2802 (12.2%)	23182 2763 (11.9%)	23346 2741 (11.7%)	
MULTISOURCE	20315 (87.9%)	20256 (87.8%)	20419 (88.1%)	20605 (88.3%)	
THERAPEUTICALLY EQUIVALENT	20252 (87.7%)	20198 (87.6%)	20332 (87.7%)	20522 (87.9%)	
NOT THERAPEUTICALLY EQUIVALENT	63 (0.3%)	58 (0.3%)	87 (0.4%)	83 (0.4%)	
EXCEPTIONS ⁴	46 (0.2%)	46 (0.2%)	47 (0.2%)	47 (0.2%)	
NEW MOLECULAR ENTITIES APPROVED	32	18	14	19	
NUMBER OF APPLICANTS	1214	1219	1214	1191	

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month.

⁴ Amino acid containing products of varying composition (see Introduction, page xx of the List).

The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN ⁵	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

⁵ The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE; LAMIVUDINE

	TABLET;ORAL								
	ABACAVIR SULFATE AND LAMIVUDINE								
AB	!	CIPLA	EQ 600MG BASE;300MG	A091144	001	Mar 28, 2017	Jan	CHRS	
	TABLET, FOR SUSPENSION;ORAL								
	ABACAVIR SULFATE AND LAMIVUDINE								
	+	@ MYLAN LABS LTD	EQ 60MG BASE;30MG	N204311	001	Dec 22, 2023	Jan	DISC	
	+	@ NORVIUM BIOSCIENCE	EQ 60MG BASE;30MG	N204311	001	Dec 22, 2023	Aug	CAHN	

ABIRATERONE ACETATE

	TABLET;ORAL								
	ABIRATERONE ACETATE								
AB		MSN	500MG	A210686	002	Apr 24, 2024	Apr	NEWA	

ACAMPROSATE CALCIUM

	TABLET, DELAYED RELEASE;ORAL								
	ACAMPROSATE CALCIUM								
		@ GLENMARK PHARMS LTD	333MG	A202229	001	Jul 16, 2013	Aug	DISC	
AB	!	ZYDUS PHARMS	333MG	A205995	001	May 26, 2017	Aug	CHRS	

ACARBOSE

	TABLET;ORAL								
	ACARBOSE								
AB		SOMERSET THERAPS LLC	25MG	A091343	001	Oct 17, 2013	Sep	CAHN	
AB			50MG	A091343	002	Oct 17, 2013	Sep	CAHN	
AB			100MG	A091343	003	Oct 17, 2013	Sep	CAHN	

ACETAMINOPHEN; BUTALBITAL

	TABLET;ORAL								
	BUTALBITAL AND ACETAMINOPHEN								
AA		QUAGEN	300MG;50MG	A214305	001	Feb 01, 2024	Jan	NEWA	
AA			325MG;50MG	A214291	001	Jan 18, 2024	Jan	NEWA	

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

	CAPSULE;ORAL								
	BUTALBITAL, ACETAMINOPHEN AND CAFFEINE								
		@ KEY THERAP	300MG;50MG;40MG	A206615	001	Aug 04, 2017	May	DISC	
AA			300MG;50MG;40MG	A206615	001	Aug 04, 2017	Apr	CAHN	
AA		QUAGEN	300MG;50MG;40MG	A214288	001	Feb 08, 2024	Jan	NEWA	
AA			325MG;50MG;40MG	A216376	001	Mar 12, 2024	Mar	NEWA	
AA		SENORES PHARMS	300MG;50MG;40MG	A214087	001	Aug 13, 2021	Feb	CAHN	
AA			325MG;50MG;40MG	A214087	002	Aug 13, 2021	Feb	CAHN	
	TABLET;ORAL								
	BUTALBITAL, ACETAMINOPHEN AND CAFFEINE								
AA		QUAGEN	325MG;50MG;40MG	A214287	001	Jan 18, 2024	Jan	NEWA	

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

	CAPSULE;ORAL								
	BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE								
		@ NOSTRUM LABS INC	325MG;50MG;40MG;30MG	A075929	001	Apr 22, 2002	May	DISC	

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

	CAPSULE;ORAL								
	TREZIX								
		@ KEY THERAP	320.5MG;30MG;16MG	A204785	001	Nov 26, 2014	May	DISC	
			320.5MG;30MG;16MG	A204785	001	Nov 26, 2014	Apr	CAHN	

ACETAMINOPHEN; CODEINE PHOSPHATE

	SOLUTION;ORAL								
	ACETAMINOPHEN AND CODEINE PHOSPHATE								
		@ AKORN	120MG/5ML;12MG/5ML	A040119	001	Apr 26, 1996	Feb	DISC	
		@ PAI HOLDINGS	120MG/5ML;12MG/5ML	A040119	001	Apr 26, 1996	May	CAHN	
		@ STRIDES PHARMA	120MG/5ML;12MG/5ML	A086366	001		Sep	CAHN	
	TABLET;ORAL								
	ACETAMINOPHEN AND CODEINE PHOSPHATE								
AA	!	SPECGX LLC	300MG;60MG	A040419	003	May 31, 2001	Apr	CHRS	
AA		STRIDES PHARMA	300MG;15MG	A089990	001	Sep 30, 1988	Apr	CMFD	
AA			300MG;30MG	A089805	001	Sep 30, 1988	Apr	CMFD	
AA			300MG;60MG	A089828	001	Sep 30, 1988	Apr	CMFD	

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE
 @ SUN PHARM INDS LTD 300MG;30MG

A085868 001 Jan DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	@ AMNEAL PHARMS	300MG;10MG	A207137	001	Nov 29, 2016	Jul DISC
	@ AMNEAL PHARMS NY	300MG;5MG	A206869	001	Jun 23, 2017	Jul DISC
AA	! ASCENT PHARMS INC	325MG;2.5MG	A211487	001	Nov 07, 2018	Oct CTEC
AA	ELITE LABS INC	325MG;2.5MG	A209924	001	Nov 16, 2018	Oct CTEC
	@	325MG;2.5MG	A209924	001	Nov 16, 2018	Jun CAHN
AA		325MG;5MG	A209924	002	Nov 16, 2018	Oct CTEC
	@	325MG;5MG	A209924	002	Nov 16, 2018	Jun CAHN
AA		325MG;7.5MG	A209924	003	Nov 16, 2018	Oct CTEC
	@	325MG;7.5MG	A209924	003	Nov 16, 2018	Jun CAHN
AA		325MG;10MG	A209924	004	Nov 16, 2018	Oct CTEC
	@	325MG;10MG	A209924	004	Nov 16, 2018	Jun CAHN
	@ ENDO OPERATIONS	300MG;5MG	A090415	001	Jan 24, 2011	May CAHN
	@	300MG;7.5MG	A090415	002	Jan 24, 2011	May CAHN
	@	300MG;10MG	A090415	003	Jan 24, 2011	May CAHN
AA	GRANULES	325MG;5MG	A211729	001	Jan 03, 2020	Jul CMFD
AA		325MG;7.5MG	A211729	002	Jan 03, 2020	Jul CMFD
AA		325MG;10MG	A211729	003	Jan 03, 2020	Jul CMFD
	@ PRINSTON INC	325MG;5MG	A214928	001	Dec 30, 2021	Mar DISC
	@	325MG;7.5MG	A214928	002	Dec 30, 2021	Mar DISC
	@	325MG;10MG	A214928	003	Dec 30, 2021	Mar DISC
	@ SANALUZ	325MG;5MG	A211690	001	Feb 07, 2020	Sep CAHN
	@	325MG;7.5MG	A211690	002	Feb 07, 2020	Sep CAHN
	@	325MG;10MG	A211690	003	Feb 07, 2020	Sep CAHN

ACETAMINOPHEN; IBUPROFEN

TABLET;ORAL

COMBOGESIC

+	!	AFT PHARMS LTD	325MG;97.5MG	N209471	001	Mar 01, 2023	Sep CMFD
+	!	AFT PHARMS US	325MG;97.5MG	N209471	001	Mar 01, 2023	Sep CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN

@ ENDO OPERATIONS 325MG/5ML;5MG/5ML A203573 001 Dec 18, 2014 May CAHN

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

AA	ELITE LABS INC	325MG;5MG	A209385	001	Jul 02, 2018	Aug CMFD
	@	325MG;5MG	A209385	001	Jul 02, 2018	Jun CAHN
AA		325MG;7.5MG	A209385	002	Jul 02, 2018	Aug CMFD
	@	325MG;7.5MG	A209385	002	Jul 02, 2018	Jun CAHN
AA		325MG;10MG	A209385	003	Jul 02, 2018	Aug CMFD
	@	325MG;10MG	A209385	003	Jul 02, 2018	Jun CAHN
	@ ENDO OPERATIONS	325MG;2.5MG	A090733	001	Jul 11, 2013	May CAHN
	@	325MG;5MG	A040105	001	Jul 30, 1996	May CAHN
	@	325MG;7.5MG	A090734	001	Jul 11, 2013	May CAHN
	@	325MG;10MG	A090734	002	Jul 11, 2013	May CAHN
AA	GRANULES	325MG;2.5MG	A211708	001	Oct 31, 2019	Jul CMFD
AA		325MG;5MG	A211708	002	Oct 31, 2019	Jul CMFD
AA		325MG;7.5MG	A211708	003	Oct 31, 2019	Jul CMFD
AA		325MG;10MG	A211708	004	Oct 31, 2019	Jul CMFD
	@ SANALUZ	325MG;5MG	A207574	001	Dec 13, 2016	Sep CAHN
	PERCOCET					
AA	! ENDO OPERATIONS	325MG;2.5MG	A040330	001	Jun 25, 1999	Apr CAHN
AA	!	325MG;5MG	A040330	002	Jun 25, 1999	Apr CAHN
	+ @	325MG;5MG	A085106	002		May CAHN
AA	!	325MG;7.5MG	A040330	003	Nov 23, 2001	Apr CAHN
AA	!	325MG;10MG	A040330	004	Nov 23, 2001	Apr CAHN

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

@ SUN PHARM INDS INC 325MG;37.5MG A077184 001 Dec 16, 2005 Aug DISC

ACETAZOLAMIDE

TABLET; ORAL		ACETAZOLAMIDE						
	@ AJANTA PHARMA LTD	125MG		A211151	001	Sep 11, 2023	Feb	DISC
	@	250MG		A211151	002	Sep 11, 2023	Feb	DISC
AB	EPIC PHARMA LLC	125MG		A218023	001	May 14, 2024	May	NEWA
AB		250MG		A218023	002	May 14, 2024	May	NEWA
BX	EYWA PHARMA	125MG		A211556	001	Oct 18, 2019	Jun	CTEC
BX		250MG		A211556	002	Oct 18, 2019	Jun	CTEC
BX	HIBROW HLTHCARE	125MG		A211556	001	Oct 18, 2019	Jul	CAHN
BX		250MG		A211556	002	Oct 18, 2019	Jul	CAHN
	@ TORRENT	125MG		A213706	001	Jan 26, 2024	Jan	DISC
AB		125MG		A213706	001	Jan 26, 2024	Jan	NEWA
	@	250MG		A213706	002	Jan 26, 2024	Jan	DISC
AB		250MG		A213706	002	Jan 26, 2024	Jan	NEWA

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION
ACETAZOLAMIDE SODIUM

@ ENDO OPERATIONS	EQ 500MG BASE/VIAL		A205358	001	Jun 20, 2017	May	CAHN
-------------------	--------------------	--	---------	-----	--------------	-----	------

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC
VOSOL

+ @ HIKMA	2%		N012179	001		Apr	CRLD
@	2%		N012179	001		Apr	DISC

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS
ACETYLCYSTEINE

AP	GLENMARK PHARMS INC	6GM/30ML (200MG/ML)		A213693	001	Feb 03, 2022	Sep	CAHN
AP	SOMERSET THERAPS LLC	6GM/30ML (200MG/ML)		A218397	001	Jun 07, 2024	May	NEWA
SOLUTION; INHALATION, ORAL								
ACETYLCYSTEINE								
@ EXELA PHARMA	20%		A205643	001	Nov 01, 2023	Feb	DISC	

ACETYLCYSTEINE LYSINE

FOR SOLUTION; ORAL
LEGUBETI

+ @ GALEPHAR	EQ 500MG BASE/PACKET		N215040	001	Feb 13, 2024	Jun	DISC
+!	EQ 500MG BASE/PACKET		N215040	001	Feb 13, 2024	Feb	NEWA
+ @	EQ 2.5GM BASE/PACKET		N215040	002	Feb 13, 2024	Jun	DISC
+!	EQ 2.5GM BASE/PACKET		N215040	002	Feb 13, 2024	Feb	NEWA

ACITRETIN

CAPSULE; ORAL
ACITRETIN

AB	ALEMBIC	10MG		A217774	001	Aug 05, 2024	Jul	NEWA
AB		17.5MG		A217774	002	Aug 05, 2024	Jul	NEWA
AB		25MG		A217774	003	Aug 05, 2024	Jul	NEWA

>A> ACORAMIDIS HYDROCHLORIDE

>A> TABLET; ORAL
>A> ATTRUBY

>A>	+! BRIDGEBIO PHARMA	EQ 356MG BASE		N216540	001	Nov 22, 2024	Nov	NEWA
-----	---------------------	---------------	--	---------	-----	--------------	-----	------

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL
SEMPREX-D

+ @ ENDO OPERATIONS	8MG; 60MG		N019806	001	Mar 25, 1994	May	CAHN
---------------------	-----------	--	---------	-----	--------------	-----	------

ACYCLOVIR

CAPSULE; ORAL
ACYCLOVIR

AB	ADAPTIS	200MG		A075090	001	Jan 26, 1999	Sep	CAHN
----	---------	-------	--	---------	-----	--------------	-----	------

CREAM; TOPICAL
ACYCLOVIR

AB	TARO	5%		A205470	001	Jun 12, 2024	Jul	CAHN
AB		5%		A205470	001	Jun 12, 2024	May	NEWA

	OINTMENT; TOPICAL								
	ACYCLOVIR								
	@ COSETTE	5%		A205591	001	Nov 13, 2017	Mar	DISC	
	SUSPENSION; ORAL								
	ACYCLOVIR								
	@ HIKMA	200MG/5ML		A077026	001	Jun 07, 2005	Mar	DISC	
	@ VISTAPHARM LLC	200MG/5ML		A213951	001	Jan 11, 2021	Mar	CAHN	
	<u>ACYCLOVIR SODIUM</u>								
	INJECTABLE; INJECTION								
	ACYCLOVIR SODIUM								
AP	DDREG PHARMA	EQ 50MG BASE/ML		A215404	001	Jun 25, 2024	Jun	NEWA	
AP	FRESENIUS KABI USA	EQ 50MG BASE/ML		A215404	001	Jun 25, 2024	Jul	CAHN	
	@ NORVIUM BIOSCIENCE	EQ 500MG BASE/VIAL		A203927	001	Mar 29, 2017	Jun	CAHN	
	@	EQ 1GM BASE/VIAL		A203927	002	Mar 29, 2017	Jun	CAHN	
AP	SLATE RUN PHARMA	EQ 50MG BASE/ML		A218111	001	Jan 08, 2024	Sep	CAHN	
	<u>ADAGRASIE</u>								
	TABLET; ORAL								
	KRAZATI								
	+! BRISTOL	200MG		N216340	001	Dec 12, 2022	Sep	CAHN	
	<u>ADAPALENE</u>								
	LOTION; TOPICAL								
	DIFFERIN								
	+ @ GALDERMA LABS LP	0.1%		N022502	001	Mar 17, 2010	May	DISC	
	<u>ADEFOVIR DIPIVOXIL</u>								
	TABLET; ORAL								
	ADEFOVIR DIPIVOXIL								
AB	! SIGMAPHARM LABS LLC	10MG		A202051	001	Aug 29, 2013	Jun	CHRS	
	HEPSERA								
	+ @ GILEAD	10MG		N021449	001	Sep 20, 2002	Jun	DISC	
	<u>ADENOSINE</u>								
	INJECTABLE; INJECTION								
	ADENOSINE								
	@ NORVIUM BIOSCIENCE	3MG/ML		A078640	001	Mar 21, 2014	Oct	CAHN	
	SOLUTION; INTRAVENOUS								
	ADENOSINE								
	@ HOSPIRA	60MG/20ML (3MG/ML)		A203883	001	Mar 24, 2014	Feb	DISC	
	@	90MG/30ML (3MG/ML)		A203883	002	Mar 24, 2014	Feb	DISC	
	<u>ALBENDAZOLE</u>								
	TABLET; ORAL								
	ALBENDAZOLE								
AB	ALEMBIC	200MG		A215652	001	Sep 04, 2024	Aug	NEWA	
	@ STRIDES PHARMA	200MG		A210011	001	Dec 07, 2018	Sep	DISC	
	<u>ALBUTEROL SULFATE</u>								
	AEROSOL, METERED; INHALATION								
	ALBUTEROL SULFATE								
AB2	ARMSTRONG PHARMS	EQ 0.09MG BASE/INH		A212447	001	May 21, 2024	May	NEWA	
	POWDER, METERED; INHALATION								
	PROAIR DIGIHALER								
	+ @ TEVA BRANDED PHARM	EQ 0.09MG BASE/INH		N205636	002	Dec 21, 2018	Jun	DISC	
	SOLUTION; INHALATION								
	ACCUNEB								
	+ @ NORVIUM BIOSCIENCE	EQ 0.021% BASE		N020949	002	Apr 30, 2001	Jul	CAHN	
	+ @	EQ 0.042% BASE		N020949	001	Apr 30, 2001	Jul	CAHN	
	ALBUTEROL SULFATE								
AN	LEXENPHARM	EQ 0.021% BASE		A215571	001	May 03, 2024	Apr	NEWA	
AN		EQ 0.042% BASE		A215571	002	May 03, 2024	Apr	NEWA	
AN	LUOXIN AUROVITAS	EQ 0.021% BASE		A211888	001	Apr 20, 2020	Jun	CMFD	
AN		EQ 0.042% BASE		A211888	002	Apr 20, 2020	Jun	CMFD	
	@ NORVIUM BIOSCIENCE	EQ 0.083% BASE		A072652	001	Feb 21, 1992	Jun	CAHN	
	@ WATSON LABS	EQ 0.021% BASE		A077772	001	Sep 25, 2007	Jun	DISC	
	@	EQ 0.042% BASE		A077772	002	Sep 25, 2007	Jun	DISC	
	SYRUP; ORAL								
	ALBUTEROL SULFATE								
	@ HIKMA	EQ 2MG BASE/5ML		A074749	001	Jan 30, 1998	Mar	DISC	

TABLET;ORAL

ALBUTEROL SULFATE							
BX	AIZANT	EQ 2MG BASE	A210948	001	Mar 15, 2019	Jun	CTEC
BX		EQ 4MG BASE	A210948	002	Mar 15, 2019	Jun	CTEC
	@ HIBROW HLTHCARE	EQ 2MG BASE	A213524	001	Oct 08, 2020	Sep	CAHN
	@	EQ 4MG BASE	A213524	002	Oct 08, 2020	Sep	CAHN

ALBUTEROL SULFATE; BUDESONIDE

AEROSOL, METERED; INHALATION
AIRSUPRA

+	ASTRAZENECA	EQ 0.09MG BASE/INH;0.08MG/INH	N214070	001	Jan 10, 2023	Jan	CPOT
---	-------------	-------------------------------	---------	-----	--------------	-----	------

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

	@ AIPING PHARM INC	EQ 0.083% BASE;0.017% DUONEB	A076867	001	Dec 21, 2006	Sep	CAHN
+	@ NORVIUM BIOSCIENCE	EQ 0.083% BASE;0.017%	N020950	001	Mar 21, 2001	Jul	CAHN

ALCOHOL

SOLUTION; INTRA-ARTERIAL
ABLYSINOL

+	@ BPI LABS	99% (1ML)	N207987	001	Jun 21, 2018	Jun	DISC
---	------------	-----------	---------	-----	--------------	-----	------

ALENDRONATE SODIUM

TABLET;ORAL
ALENDRONATE SODIUM

AB	IPCA LABS LTD	EQ 10MG BASE	A206387	001	Jun 04, 2024	May	NEWA
AB		EQ 35MG BASE	A206387	002	Jun 04, 2024	May	NEWA
AB		EQ 40MG BASE	A206387	003	Jun 04, 2024	May	NEWA
AB		EQ 70MG BASE	A206387	004	Jun 04, 2024	May	NEWA

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
ALFUZOSIN HYDROCHLORIDE

	@ NORVIUM BIOSCIENCE	10MG	A079014	001	Jul 18, 2011	Jun	CAHN
>D>	AB SUN PHARM	10MG	A079057	001	Jul 18, 2011	Nov	DISC
>A>	@	10MG	A079057	001	Jul 18, 2011	Nov	DISC

ALISKIREN HEMIFUMARATE

TABLET;ORAL
ALISKIREN HEMIFUMARATE

AB	ENDO OPERATIONS	EQ 150MG BASE	A206665	001	Mar 22, 2019	Apr	CAHN
AB		EQ 300MG BASE	A206665	002	Mar 22, 2019	Apr	CAHN

ALLOPURINOL

TABLET;ORAL
ALLOPURINOL

AB	ENDO OPERATIONS	100MG	A075798	001	Jun 27, 2003	Apr	CAHN
AB		300MG	A075798	002	Jun 27, 2003	Apr	CAHN
AB	HARMAN FINOCHEM	200MG	A214443	003	Jun 17, 2024	Jun	NFTG
	@ LUPIN LTD	100MG	A211807	001	Dec 14, 2023	Apr	DISC
	@	300MG	A211807	002	Dec 14, 2023	Apr	DISC
	LOPURIN						
>A>	AB DR REDDYS	100MG	A071586	001	Apr 02, 1987	Nov	CAHN
>A>	AB	300MG	A071587	001	Apr 02, 1987	Nov	CAHN
>D>	AB DR REDDYS LA	100MG	A071586	001	Apr 02, 1987	Nov	CAHN
>D>	AB	300MG	A071587	001	Apr 02, 1987	Nov	CAHN
	ZYLOPRIM						
AB	+ CASPER PHARMA LLC	200MG	N016084	003	Aug 04, 2022	Jun	CFTG

ALOSETRON HYDROCHLORIDE

TABLET;ORAL
ALOSETRON HYDROCHLORIDE

	@ ENDO OPERATIONS	EQ 0.5MG BASE	A206113	001	Feb 23, 2018	May	CAHN
	@	EQ 1MG BASE	A206113	002	Feb 23, 2018	May	CAHN
	@ EYWA	EQ 0.5MG BASE	A211621	001	Sep 16, 2019	Sep	CAHN
	@	EQ 1MG BASE	A211621	002	Sep 16, 2019	Sep	CAHN
	@ HIBROW HLTHCARE	EQ 0.5MG BASE	A211621	001	Sep 16, 2019	Sep	CAHN
	@	EQ 1MG BASE	A211621	002	Sep 16, 2019	Sep	CAHN

TABLET;ORAL

LOTRONEX

>A>	AB	+	LEGACY PHARMA	EQ 0.5MG BASE	N021107	002	Dec 23, 2003	Nov	CAHN
>A>	AB	+	!	EQ 1MG BASE	N021107	001	Feb 09, 2000	Nov	CAHN
>D>	AB	+	SEBELA IRELAND LTD	EQ 0.5MG BASE	N021107	002	Dec 23, 2003	Nov	CAHN
>D>	AB	+	!	EQ 1MG BASE	N021107	001	Feb 09, 2000	Nov	CAHN

ALPELISIB

GRANULES;ORAL

VIJOICE

+	!	NOVARTIS	50MG/PACKET	N218466	001	Apr 24, 2024	Apr	NEWA
---	---	----------	-------------	---------	-----	--------------	-----	------

ALPRAZOLAM

TABLET;ORAL

ALPRAZOLAM

AB			CHARTWELL RX	0.25MG	A207507	001	Jul 09, 2018	Mar	CAHN
AB				0.5MG	A207507	002	Jul 09, 2018	Mar	CAHN
AB				1MG	A207507	003	Jul 09, 2018	Mar	CAHN
AB				2MG	A207507	004	Jul 09, 2018	Mar	CAHN

TABLET, EXTENDED RELEASE;ORAL

ALPRAZOLAM

@			ANCHEN PHARMS	0.5MG	A078469	001	Sep 29, 2011	Mar	DISC
@				1MG	A078469	002	Sep 29, 2011	Mar	DISC
@				2MG	A078469	003	Sep 29, 2011	Mar	DISC
@				3MG	A078469	004	Sep 29, 2011	Mar	DISC
@			ENDO OPERATIONS	0.5MG	A078442	001	Oct 15, 2007	May	CAHN
@				0.5MG	A078469	001	Sep 29, 2011	May	CAHN
@				1MG	A078442	002	Oct 15, 2007	May	CAHN
@				1MG	A078469	002	Sep 29, 2011	May	CAHN
@				2MG	A078442	003	Oct 15, 2007	May	CAHN
@				2MG	A078469	003	Sep 29, 2011	May	CAHN
@				3MG	A078442	004	Oct 15, 2007	May	CAHN
@				3MG	A078469	004	Sep 29, 2011	May	CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

ALPRAZOLAM

AB			ENDO OPERATIONS	0.25MG	A078088	001	Jan 09, 2009	Apr	CAHN
AB				0.5MG	A078088	002	Jan 09, 2009	Apr	CAHN
AB			!	1MG	A078088	003	Jan 09, 2009	Apr	CAHN
AB				2MG	A078088	004	Jan 09, 2009	Apr	CAHN

ALPROSTADIL

INJECTABLE;INJECTION

EDEX

@			ENDO OPERATIONS	0.005MG/VIAL	N020649	001	Jun 12, 1997	Apr	CAHN
AP			+	0.01MG/VIAL	N020649	002	Jun 12, 1997	Apr	CAHN
			+	0.01MG/VIAL	N020649	005	Jul 30, 1998	Apr	CAHN
AP			+	0.02MG/VIAL	N020649	003	Jun 12, 1997	Apr	CAHN
			+	0.02MG/VIAL	N020649	006	Jul 30, 1998	Apr	CAHN
AP			+	0.04MG/VIAL	N020649	004	Jun 12, 1997	Apr	CAHN
			+	0.04MG/VIAL	N020649	007	Jul 30, 1998	Apr	CAHN

SUPPOSITORY;URETHRAL

MUSE

+	@		MYLAN SPECIALITY LP	0.25MG	N020700	002	Nov 19, 1996	Jun	DISC
+	@			0.5MG	N020700	003	Nov 19, 1996	Jun	DISC
+	@			1MG	N020700	004	Nov 19, 1996	Jun	DISC

AMANTADINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

AMANTADINE HYDROCHLORIDE

AB			ZYDUS	EQ 68.5MG BASE	A214897	001	Aug 26, 2024	Aug	NFTG	
			GOCOVRI							
AB			+	SUPERNUS PHARMS	EQ 68.5MG BASE	N208944	001	Aug 24, 2017	Aug	NFTG
			+		EQ 68.5MG BASE	N208944	001	Aug 24, 2017	Aug	CAHN
			+	!	EQ 137MG BASE	N208944	002	Aug 24, 2017	Aug	CAHN

SYRUP;ORAL

AMANTADINE HYDROCHLORIDE

@			CHARTWELL RX	50MG/5ML	A076352	001	Sep 10, 2004	Aug	CAHN
@			CMP PHARMA INC	50MG/5ML	A075819	001	Sep 11, 2002	Oct	DISC
@			ENDO OPERATIONS	50MG/5ML	A077992	001	Dec 12, 2006	May	CAHN
@			GENUS	50MG/5ML	A076352	001	Sep 10, 2004	Jan	CAHN
AA			XTTRIUM LABS INC	50MG/5ML	A075060	001	Dec 24, 1998	Oct	CMFD

TABLET;ORAL

AMANTADINE HYDROCHLORIDE

	@ ADAPTIS	100MG	A212407	001	May 27, 2022	Sep	CAHN
AB	ZHEJIANG JUTAI PHARM	100MG	A218598	001	Sep 26, 2024	Sep	NEWA

TABLET, EXTENDED RELEASE;ORAL

OSMOLEX ER

	+ @ ADAMAS OPERATIONS	EQ 129MG BASE	N209410	001	Feb 16, 2018	Apr	DISC
	+ @	EQ 193MG BASE	N209410	002	Feb 16, 2018	Apr	DISC
	+ @ SUPERNUS PHARMS	EQ 129MG BASE	N209410	001	Feb 16, 2018	Aug	CAHN
	+ @	EQ 161MG BASE	N209410	004	Apr 22, 2020	Aug	CAHN
	+ @	EQ 193MG BASE	N209410	002	Feb 16, 2018	Aug	CAHN
	+ @	EQ 258MG BASE	N209410	003	Feb 16, 2018	Aug	CAHN

AMBRISENTAN

TABLET;ORAL

AMBRISENTAN

	@ ENDO OPERATIONS	5MG	A209509	001	Apr 10, 2019	May	CAHN
	@	10MG	A209509	002	Apr 10, 2019	May	CAHN
	@ PAR PHARM INC	5MG	A209509	001	Apr 10, 2019	Apr	DISC
	@	10MG	A209509	002	Apr 10, 2019	Apr	DISC

AMCINONIDE

LOTION;TOPICAL

AMCINONIDE

	! GENUS	0.1%	A076329	001	Nov 06, 2002	Jan	CAHN
--	---------	------	---------	-----	--------------	-----	------

OINTMENT;TOPICAL

AMCINONIDE

AB	! GENUS	0.1%	A076096	001	Nov 19, 2002	Jan	CAHN
----	---------	------	---------	-----	--------------	-----	------

AMIFOSTINE

INJECTABLE;INJECTION

ETHYOL

	@ COSETTE	375MG/VIAL	N020221	002	Sep 10, 1999	Oct	CAHN
	+ @	500MG/VIAL	N020221	001	Dec 08, 1995	Oct	DISC
	+!	500MG/VIAL	N020221	001	Dec 08, 1995	Oct	CAHN

AMIKACIN SULFATE

INJECTABLE;INJECTION

AMIKACIN SULFATE

AP	QILU	EQ 250MG BASE/ML	A218146	001	Mar 19, 2024	Mar	NEWA
----	------	------------------	---------	-----	--------------	-----	------

AMILORIDE HYDROCHLORIDE

TABLET;ORAL

AMILORIDE HYDROCHLORIDE

AB	! ENDO OPERATIONS	5MG	A070346	001	Jan 22, 1986	Apr	CAHN
----	-------------------	-----	---------	-----	--------------	-----	------

AMINO ACIDS; DEXTROSE

INJECTABLE;INJECTION

CLINIMIX 8/14 SULFITE FREE IN DEXTROSE 14% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	8%;14GM/100ML	N020734	019	Apr 13, 2021	Apr	NEWA
--	-----------------	---------------	---------	-----	--------------	-----	------

AMINOCAPROIC ACID

SOLUTION;ORAL

AMICAR

>D>	+ @ HIKMA	0.25GM/ML	N015230	002		Nov	CMFD
>A> AA	+	0.25GM/ML	N015230	002		Nov	CMFD
	+ @	0.25GM/ML	N015230	002		Mar	DISC

AMINOCAPROIC ACID

AA	MSN	0.25GM/ML	A215100	001	Sep 26, 2024	Sep	NEWA
AA	! TRUPHARMA	0.25GM/ML	A212494	001	Aug 11, 2020	Sep	CAHN
AA	! TULEX PHARMS INC	0.25GM/ML	A212494	001	Aug 11, 2020	Mar	CHRS
	@ VISTAPHARM LLC	0.25GM/ML	A212814	001	Feb 26, 2020	Mar	CAHN

TABLET;ORAL

AMICAR

>D>	+ @ HIKMA	500MG	N015197	001		Nov	CMFD
>A> AB	+	500MG	N015197	001		Nov	CMFD
	+ @	500MG	N015197	001		Mar	DISC
>D>	+ @	1GM	N015197	002	Jun 24, 2004	Nov	CMFD
>A> AB	+	1GM	N015197	002	Jun 24, 2004	Nov	CMFD
	+ @	1GM	N015197	002	Jun 24, 2004	Mar	DISC

<u>TABLET;ORAL</u>							
AMINOCAPROIC ACID							
	@ ADAPTIS	500MG	A212110	001	Jun 14, 2021	Sep	CAHN
AB	APPCO	500MG	A213944	001	Sep 14, 2022	Sep	CAHN
AB		1GM	A213944	002	Sep 14, 2022	Sep	CAHN
<u>AMINOLEVULINIC ACID HYDROCHLORIDE</u>							
SOLUTION;TOPICAL							
LEVULAN							
	+! SUN PHARM INDS INC	20%	N020965	001	Dec 03, 1999	Oct	CAHN
<u>AMIODARONE HYDROCHLORIDE</u>							
INJECTABLE;INJECTION							
AMIODARONE HYDROCHLORIDE							
	@ HOSPIRA	50MG/ML	A203884	001	Nov 25, 2013	May	DISC
AP	ZHEJIANG POLY PHARM	50MG/ML	A218253	001	Sep 11, 2024	Aug	NEWA
<u>AMITRIPTYLINE HYDROCHLORIDE</u>							
TABLET;ORAL							
AMITRIPTYLINE HYDROCHLORIDE							
AB	AIPING PHARM INC	10MG	A212654	002	Sep 29, 2021	May	CMFD
AB		25MG	A212654	001	Apr 07, 2020	May	CMFD
AB		50MG	A212654	003	Sep 29, 2021	May	CMFD
AB		75MG	A212654	004	Sep 29, 2021	May	CMFD
AB		100MG	A212654	005	Sep 29, 2021	May	CMFD
AB		150MG	A212654	006	Sep 29, 2021	May	CMFD
AB	BRECKENRIDGE	10MG	A216243	001	Jun 06, 2022	Sep	CAHN
AB		25MG	A216243	002	Jun 06, 2022	Sep	CAHN
AB		50MG	A216243	003	Jun 06, 2022	Sep	CAHN
AB		75MG	A216243	004	Jun 06, 2022	Sep	CAHN
AB		100MG	A216243	005	Jun 06, 2022	Sep	CAHN
AB		150MG	A216243	006	Jun 06, 2022	Sep	CAHN
AB	CENTAUR PHARMS PVT	10MG	A216243	001	Jun 06, 2022	Aug	CAHN
AB		25MG	A216243	002	Jun 06, 2022	Aug	CAHN
AB		50MG	A216243	003	Jun 06, 2022	Aug	CAHN
AB		75MG	A216243	004	Jun 06, 2022	Aug	CAHN
AB		100MG	A216243	005	Jun 06, 2022	Aug	CAHN
AB		150MG	A216243	006	Jun 06, 2022	Aug	CAHN
	@ ENDO OPERATIONS	10MG	A040218	001	Sep 11, 1997	May	CAHN
	@	25MG	A040218	002	Sep 11, 1997	May	CAHN
	@	50MG	A040218	003	Sep 11, 1997	May	CAHN
	@	75MG	A040218	004	Sep 11, 1997	May	CAHN
	@	100MG	A040218	005	Sep 11, 1997	May	CAHN
	@	150MG	A040218	006	Sep 11, 1997	May	CAHN
<u>AMLODIPINE BESYLATE</u>							
TABLET;ORAL							
AMLODIPINE BESYLATE							
	@ AIPING PHARM INC	EQ 2.5MG BASE	A077759	001	Jul 09, 2007	Feb	CAHN
	@	EQ 5MG BASE	A077759	002	Jul 09, 2007	Feb	CAHN
	@	EQ 10MG BASE	A077759	003	Jul 09, 2007	Feb	CAHN
	@ SCIEGEN PHARMS INC	EQ 2.5MG BASE	A077759	001	Jul 09, 2007	Sep	CAHN
	@	EQ 5MG BASE	A077759	002	Jul 09, 2007	Sep	CAHN
	@	EQ 10MG BASE	A077759	003	Jul 09, 2007	Sep	CAHN
	@ SUN PHARM INDS LTD	EQ 2.5MG BASE	A077974	001	Jul 09, 2007	Jan	DISC
	@	EQ 5MG BASE	A077974	002	Jul 09, 2007	Jan	DISC
	@	EQ 10MG BASE	A077974	003	Jul 09, 2007	Jan	DISC
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE</u>							
CAPSULE;ORAL							
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE							
	@ AMNEAL	EQ 2.5MG BASE;10MG	A077215	001	Dec 07, 2018	Apr	CAHN
	@	EQ 5MG BASE;10MG	A077215	002	Dec 07, 2018	Apr	CAHN
	@	EQ 5MG BASE;20MG	A077215	003	Dec 07, 2018	Apr	CAHN
	@	EQ 10MG BASE;20MG	A077215	004	Dec 07, 2018	Apr	CAHN
AB	HERITAGE	EQ 2.5MG BASE;10MG	A091431	001	Dec 30, 2013	Sep	CAHN
AB		EQ 5MG BASE;10MG	A091431	002	Dec 30, 2013	Sep	CAHN
AB		EQ 5MG BASE;20MG	A091431	003	Dec 30, 2013	Sep	CAHN
AB		EQ 5MG BASE;40MG	A091431	004	Dec 30, 2013	Sep	CAHN
AB		EQ 10MG BASE;20MG	A091431	005	Dec 30, 2013	Sep	CAHN
AB		EQ 10MG BASE;40MG	A091431	006	Dec 30, 2013	Sep	CAHN

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

	@	GLENMARK PHARMS LTD	EQ 5MG BASE;20MG	A207807	001	Jul 05, 2017	Sep	DISC
	@		EQ 5MG BASE;40MG	A207807	002	Jul 05, 2017	Sep	DISC
	@		EQ 10MG BASE;20MG	A207807	003	Jul 05, 2017	Sep	DISC
	@		EQ 10MG BASE;40MG	A207807	004	Jul 05, 2017	Sep	DISC
AB		SCIEGEN PHARMS INC	EQ 5MG BASE;20MG	A209010	001	Dec 03, 2018	Feb	CMFD
AB			EQ 5MG BASE;40MG	A209010	002	Dec 03, 2018	Feb	CMFD
AB			EQ 10MG BASE;20MG	A209010	003	Dec 03, 2018	Feb	CMFD
AB			EQ 10MG BASE;40MG	A209010	004	Dec 03, 2018	Feb	CMFD

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET; ORAL

PRESTALIA

	+	@	ADHERA	EQ 2.5MG BASE;3.5MG	N205003	001	Jan 21, 2015	Sep	DISC
	+	@		EQ 5MG BASE;7MG	N205003	002	Jan 21, 2015	Sep	DISC
	+	@		EQ 10MG BASE;14MG	N205003	003	Jan 21, 2015	Sep	DISC

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB		MACLEODS PHARMS LTD	EQ 5MG BASE;160MG	A207292	001	Oct 11, 2024	Oct	NEWA
AB			EQ 5MG BASE;320MG	A207292	003	Oct 11, 2024	Oct	NEWA
AB			EQ 10MG BASE;160MG	A207292	002	Oct 11, 2024	Oct	NEWA
AB			EQ 10MG BASE;320MG	A207292	004	Oct 11, 2024	Oct	NEWA

AMOXAPINE

TABLET; ORAL

AMOXAPINE

>D>		@	CHARTWELL RX	25MG	A072879	002	Jun 28, 1991	Nov	CMFD
>A>	AB			25MG	A072879	002	Jun 28, 1991	Nov	CMFD
		@		25MG	A072879	002	Jun 28, 1991	Jun	CMS1
>D>		@		50MG	A072879	003	Jun 28, 1991	Nov	CMFD
>A>	AB			50MG	A072879	003	Jun 28, 1991	Nov	CMFD
		@		50MG	A072879	003	Jun 28, 1991	Jun	CMS1
>D>		@		100MG	A072879	004	Jun 28, 1991	Nov	CMFD
>A>	AB			100MG	A072879	004	Jun 28, 1991	Nov	CMFD
		@		100MG	A072879	004	Jun 28, 1991	Jun	CMS1
>D>		@		150MG	A072879	001	Jun 28, 1991	Nov	CMFD
>A>	AB			150MG	A072879	001	Jun 28, 1991	Nov	CMFD
>D>			WATSON LABS	25MG	A072691	002	Aug 28, 1992	Nov	CTEC
>A>	AB			25MG	A072691	002	Aug 28, 1992	Nov	CTEC
>D>				50MG	A072691	003	Aug 28, 1992	Nov	CTEC
>A>	AB			50MG	A072691	003	Aug 28, 1992	Nov	CTEC
>D>				100MG	A072691	004	Aug 28, 1992	Nov	CTEC
>A>	AB			100MG	A072691	004	Aug 28, 1992	Nov	CTEC
>D>		!		150MG	A072691	001	Aug 28, 1992	Nov	CTEC
>A>	AB	!		150MG	A072691	001	Aug 28, 1992	Nov	CTEC

AMOXICILLIN

FOR SUSPENSION; ORAL

AMOXICILLIN

AB		CHARTWELL RX	400MG/5ML	A065319	002	Jun 18, 2007	May	CAHN	
		@	DAVA PHARMS INC	125MG/5ML	A062927	001	Nov 25, 1988	Mar	DISC
		@		250MG/5ML	A062927	002	Nov 25, 1988	Mar	DISC
		@	ENDO OPERATIONS	125MG/5ML	A062927	001	Nov 25, 1988	May	CAHN
		@		250MG/5ML	A062927	002	Nov 25, 1988	May	CAHN
AB	+		AMOXIL						
		+	US ANTIBIOTICS	400MG/5ML	N050760	002	Apr 15, 1999	Apr	CMFD

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE; ORAL

OMECLAMO-X-PAK

	+	@	CUMBERLAND	500MG, N/A, N/A, N/A, 500MG, N/A, N/A, N/A, 20MG	N050824	001	Feb 08, 2011	Sep	CTNA
--	---	---	------------	--	---------	-----	--------------	-----	------

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	CIPLA	250MG/5ML;EQ 62.5MG BASE/5ML	A 065431	001	Nov 25, 2008	Jul	CAHN
AB		600MG/5ML;EQ 42.9MG BASE/5ML	A 065420	001	Dec 02, 2013	Jul	CAHN

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	! AUROBINDO PHARMA LTD	500MG;EQ 125MG BASE	A 091569	002	Jan 20, 2012	Oct	CHRS
	@ SANDOZ INC	500MG;EQ 125MG BASE	A 065117	001	Nov 27, 2002	Oct	DISC

TABLET, CHEWABLE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

	@ CHARTWELL RX	200MG;EQ 28.5MG BASE	A 065065	001	Apr 18, 2002	Jul	CAHN
	@	400MG;EQ 57MG BASE	A 065065	002	Apr 18, 2002	Jul	CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

ADDERALL XR 10

AB1	+ TAKEDA PHARMS USA	2.5MG; 2.5MG; 2.5MG; 2.5MG	N 021303	001	Oct 11, 2001	Jan	CTEC
-----	---------------------	----------------------------	----------	-----	--------------	-----	------

ADDERALL XR 15

AB1	+ TAKEDA PHARMS USA	3.75MG; 3.75MG; 3.75MG; 3.75MG	N 021303	006	May 22, 2002	Jan	CTEC
-----	---------------------	--------------------------------	----------	-----	--------------	-----	------

ADDERALL XR 20

AB1	+ TAKEDA PHARMS USA	5MG; 5MG; 5MG; 5MG	N 021303	002	Oct 11, 2001	Jan	CTEC
-----	---------------------	--------------------	----------	-----	--------------	-----	------

ADDERALL XR 25

AB1	+ TAKEDA PHARMS USA	6.25MG; 6.25MG; 6.25MG; 6.25MG	N 021303	004	May 22, 2002	Jan	CTEC
-----	---------------------	--------------------------------	----------	-----	--------------	-----	------

ADDERALL XR 30

AB1	+! TAKEDA PHARMS USA	7.5MG; 7.5MG; 7.5MG; 7.5MG	N 021303	003	Oct 11, 2001	Jan	CTEC
-----	----------------------	----------------------------	----------	-----	--------------	-----	------

ADDERALL XR 5

AB1	+ TAKEDA PHARMS USA	1.25MG; 1.25MG; 1.25MG; 1.25MG	N 021303	005	May 22, 2002	Jan	CTEC
-----	---------------------	--------------------------------	----------	-----	--------------	-----	------

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB1	ACTAVIS ELIZABETH	1.25MG; 1.25MG; 1.25MG; 1.25MG	A 077302	001	Jun 22, 2012	Jan	CTEC
-----	-------------------	--------------------------------	----------	-----	--------------	-----	------

AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A 077302	002	Jun 22, 2012	Jan	CTEC
-----	--	----------------------------	----------	-----	--------------	-----	------

AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A 077302	003	Jun 22, 2012	Jan	CTEC
-----	--	--------------------------------	----------	-----	--------------	-----	------

AB1		5MG; 5MG; 5MG; 5MG	A 077302	004	Jun 22, 2012	Jan	CTEC
-----	--	--------------------	----------	-----	--------------	-----	------

AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A 077302	005	Jun 22, 2012	Jan	CTEC
-----	--	--------------------------------	----------	-----	--------------	-----	------

AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A 077302	006	Jun 22, 2012	Jan	CTEC
-----	--	----------------------------	----------	-----	--------------	-----	------

AB1	ANI PHARMS	1.25MG; 1.25MG; 1.25MG; 1.25MG	A 205401	001	Jan 22, 2019	Jan	CTEC
-----	------------	--------------------------------	----------	-----	--------------	-----	------

AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A 205401	002	Jan 22, 2019	Jan	CTEC
-----	--	----------------------------	----------	-----	--------------	-----	------

AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A 205401	003	Jan 22, 2019	Jan	CTEC
-----	--	--------------------------------	----------	-----	--------------	-----	------

AB1		5MG; 5MG; 5MG; 5MG	A 205401	004	Jan 22, 2019	Jan	CTEC
-----	--	--------------------	----------	-----	--------------	-----	------

AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A 205401	005	Jan 22, 2019	Jan	CTEC
-----	--	--------------------------------	----------	-----	--------------	-----	------

AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A 205401	006	Jan 22, 2019	Jan	CTEC
-----	--	----------------------------	----------	-----	--------------	-----	------

AB1	ASCENT PHARMS INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A 214959	001	Sep 29, 2021	Jan	CTEC
-----	-------------------	--------------------------------	----------	-----	--------------	-----	------

AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A 214959	002	Sep 29, 2021	Jan	CTEC
-----	--	----------------------------	----------	-----	--------------	-----	------

AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A 214959	003	Sep 29, 2021	Jan	CTEC
-----	--	--------------------------------	----------	-----	--------------	-----	------

AB1		5MG; 5MG; 5MG; 5MG	A 214959	004	Sep 29, 2021	Jan	CTEC
-----	--	--------------------	----------	-----	--------------	-----	------

AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A 214959	005	Sep 29, 2021	Jan	CTEC
-----	--	--------------------------------	----------	-----	--------------	-----	------

AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A 214959	006	Sep 29, 2021	Jan	CTEC
-----	--	----------------------------	----------	-----	--------------	-----	------

AB1	ELITE LABS INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A 212037	001	Dec 11, 2019	Jan	CTEC
-----	----------------	--------------------------------	----------	-----	--------------	-----	------

AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A 212037	002	Dec 11, 2019	Jan	CTEC
-----	--	----------------------------	----------	-----	--------------	-----	------

AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A 212037	003	Dec 11, 2019	Jan	CTEC
-----	--	--------------------------------	----------	-----	--------------	-----	------

AB1		5MG; 5MG; 5MG; 5MG	A 212037	004	Dec 11, 2019	Jan	CTEC
-----	--	--------------------	----------	-----	--------------	-----	------

AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A 212037	005	Dec 11, 2019	Jan	CTEC
-----	--	--------------------------------	----------	-----	--------------	-----	------

AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A 212037	006	Dec 11, 2019	Jan	CTEC
-----	--	----------------------------	----------	-----	--------------	-----	------

@ ENDO OPERATIONS

	@	1.25MG; 1.25MG; 1.25MG; 1.25MG	A 206159	001	May 31, 2019	May	CAHN
--	---	--------------------------------	----------	-----	--------------	-----	------

	@	2.5MG; 2.5MG; 2.5MG; 2.5MG	A 206159	002	May 31, 2019	May	CAHN
--	---	----------------------------	----------	-----	--------------	-----	------

	@	3.75MG; 3.75MG; 3.75MG; 3.75MG	A 206159	003	May 31, 2019	May	CAHN
--	---	--------------------------------	----------	-----	--------------	-----	------

	@	5MG; 5MG; 5MG; 5MG	A 206159	004	May 31, 2019	May	CAHN
--	---	--------------------	----------	-----	--------------	-----	------

	@	6.25MG; 6.25MG; 6.25MG; 6.25MG	A 206159	005	May 31, 2019	May	CAHN
--	---	--------------------------------	----------	-----	--------------	-----	------

	@	7.5MG; 7.5MG; 7.5MG; 7.5MG	A 206159	006	May 31, 2019	May	CAHN
--	---	----------------------------	----------	-----	--------------	-----	------

AB1	GRANULES	1.25MG; 1.25MG; 1.25MG; 1.25MG	A 217027	001	Jan 23, 2023	Jan	CTEC
-----	----------	--------------------------------	----------	-----	--------------	-----	------

AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A 217027	002	Jan 23, 2023	Jan	CTEC
-----	--	----------------------------	----------	-----	--------------	-----	------

AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A 217027	003	Jan 23, 2023	Jan	CTEC
-----	--	--------------------------------	----------	-----	--------------	-----	------

AB1		5MG; 5MG; 5MG; 5MG	A 217027	004	Jan 23, 2023	Jan	CTEC
-----	--	--------------------	----------	-----	--------------	-----	------

AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A 217027	005	Jan 23, 2023	Jan	CTEC
-----	--	--------------------------------	----------	-----	--------------	-----	------

AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A 217027	006	Jan 23, 2023	Jan	CTEC
-----	--	----------------------------	----------	-----	--------------	-----	------

AB1	IMPAX LABS	1.25MG; 1.25MG; 1.25MG; 1.25MG	A 076852	001	Feb 16, 2016	Jan	CTEC
-----	------------	--------------------------------	----------	-----	--------------	-----	------

AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A 076852	002	Feb 16, 2016	Jan	CTEC
-----	--	----------------------------	----------	-----	--------------	-----	------

AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A 076852	003	Feb 16, 2016	Jan	CTEC
-----	--	--------------------------------	----------	-----	--------------	-----	------

AB1		5MG; 5MG; 5MG; 5MG	A 076852	004	Feb 16, 2016	Jan	CTEC
-----	--	--------------------	----------	-----	--------------	-----	------

AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A 076852	005	Feb 16, 2016	Jan	CTEC
-----	--	--------------------------------	----------	-----	--------------	-----	------

AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A 076852	006	Feb 16, 2016	Jan	CTEC
-----	--	----------------------------	----------	-----	--------------	-----	------

AB1	LANNETT CO INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A 214403	001	Nov 26, 2021	Jan	CTEC
-----	----------------	--------------------------------	----------	-----	--------------	-----	------

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A214403	002	Nov 26, 2021	Jan CTEC
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A214403	003	Nov 26, 2021	Jan CTEC
AB1		5MG; 5MG; 5MG; 5MG	A214403	004	Nov 26, 2021	Jan CTEC
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A214403	005	Nov 26, 2021	Jan CTEC
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A214403	006	Nov 26, 2021	Jan CTEC
>A>	LUPIN	1.25MG; 1.25MG; 1.25MG; 1.25MG	A214777	001	Nov 07, 2024	Nov NEWA
>A>		2.5MG; 2.5MG; 2.5MG; 2.5MG	A214777	002	Nov 07, 2024	Nov NEWA
>A>		3.75MG; 3.75MG; 3.75MG; 3.75MG	A214777	003	Nov 07, 2024	Nov NEWA
>A>		5MG; 5MG; 5MG; 5MG	A214777	004	Nov 07, 2024	Nov NEWA
>A>		6.25MG; 6.25MG; 6.25MG; 6.25MG	A214777	005	Nov 07, 2024	Nov NEWA
>A>		7.5MG; 7.5MG; 7.5MG; 7.5MG	A214777	006	Nov 07, 2024	Nov NEWA
AB1	RHODES PHARMS	1.25MG; 1.25MG; 1.25MG; 1.25MG	A210651	001	May 17, 2019	Jan CTEC
AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A210651	002	May 17, 2019	Jan CTEC
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A210651	003	May 17, 2019	Jan CTEC
AB1		5MG; 5MG; 5MG; 5MG	A210651	004	May 17, 2019	Jan CTEC
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A210651	005	May 17, 2019	Jan CTEC
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A210651	006	May 17, 2019	Jan CTEC
AB1	SPECGX LLC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A211547	001	Apr 22, 2019	Jan CTEC
AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A211547	002	Apr 22, 2019	Jan CTEC
AB2		3.125MG; 3.125MG; 3.125MG; 3.125MG	A211546	001	Aug 31, 2023	Jan CTEC
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A211547	003	Apr 22, 2019	Jan CTEC
AB1		5MG; 5MG; 5MG; 5MG	A211547	004	Apr 22, 2019	Jan CTEC
AB2		6.25MG; 6.25MG; 6.25MG; 6.25MG	A211546	002	Aug 31, 2023	Jan CTEC
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A211547	005	Apr 22, 2019	Jan CTEC
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A211547	006	Apr 22, 2019	Jan CTEC
AB2		9.375MG; 9.375MG; 9.375MG; 9.375MG	A211546	003	Aug 31, 2023	Jan CTEC
AB2		12.5MG; 12.5MG; 12.5MG; 12.5MG	A211546	004	Aug 31, 2023	Jan CTEC
AB2	SUN PHARM INDS INC	3.125MG; 3.125MG; 3.125MG; 3.125MG	A215997	001	Sep 27, 2023	Jan CTEC
AB2		6.25MG; 6.25MG; 6.25MG; 6.25MG	A215997	002	Sep 27, 2023	Jan CTEC
AB2		9.375MG; 9.375MG; 9.375MG; 9.375MG	A215997	003	Sep 27, 2023	Jan CTEC
AB2		12.5MG; 12.5MG; 12.5MG; 12.5MG	A215997	004	Sep 27, 2023	Jan CTEC
	@ SUN PHARM INDUSTRIES	1.25MG; 1.25MG; 1.25MG; 1.25MG	A211715	001	May 17, 2019	Jul DISC
AB1		1.25MG; 1.25MG; 1.25MG; 1.25MG	A211715	001	May 17, 2019	Jan CTEC
	@	2.5MG; 2.5MG; 2.5MG; 2.5MG	A211715	002	May 17, 2019	Jul DISC
AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A211715	002	May 17, 2019	Jan CTEC
	@	3.75MG; 3.75MG; 3.75MG; 3.75MG	A211715	003	May 17, 2019	Jul DISC
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A211715	003	May 17, 2019	Jan CTEC
	@	5MG; 5MG; 5MG; 5MG	A211715	004	May 17, 2019	Jul DISC
AB1		5MG; 5MG; 5MG; 5MG	A211715	004	May 17, 2019	Jan CTEC
	@	6.25MG; 6.25MG; 6.25MG; 6.25MG	A211715	005	May 17, 2019	Jul DISC
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A211715	005	May 17, 2019	Jan CTEC
	@	7.5MG; 7.5MG; 7.5MG; 7.5MG	A211715	006	May 17, 2019	Jul DISC
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A211715	006	May 17, 2019	Jan CTEC
AB2	TEVA PHARMS USA	3.125MG; 3.125MG; 3.125MG; 3.125MG	A210876	001	Jan 31, 2022	Jan CTEC
AB2		6.25MG; 6.25MG; 6.25MG; 6.25MG	A210876	002	Jan 31, 2022	Jan CTEC
AB2		9.375MG; 9.375MG; 9.375MG; 9.375MG	A210876	003	Jan 31, 2022	Jan CTEC
AB2		12.5MG; 12.5MG; 12.5MG; 12.5MG	A210876	004	Jan 31, 2022	Jan CTEC
	MYDAYIS					
AB2	+ TAKEDA PHARMS USA	3.125MG; 3.125MG; 3.125MG; 3.125MG	N022063	001	Jun 20, 2017	Jan CTEC
AB2	+	6.25MG; 6.25MG; 6.25MG; 6.25MG	N022063	002	Jun 20, 2017	Jan CTEC
AB2	+	9.375MG; 9.375MG; 9.375MG; 9.375MG	N022063	003	Jun 20, 2017	Jan CTEC
AB2	+	12.5MG; 12.5MG; 12.5MG; 12.5MG	N022063	004	Jun 20, 2017	Jan CTEC

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ORYZA	1.25MG; 1.25MG; 1.25MG; 1.25MG	A210293	001	Apr 03, 2020	Sep CAHN
AB		1.875MG; 1.875MG; 1.875MG; 1.875MG	A210293	002	Apr 03, 2020	Sep CAHN
AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A210293	003	Apr 03, 2020	Sep CAHN
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A210293	004	Apr 03, 2020	Sep CAHN
AB		5MG; 5MG; 5MG; 5MG	A210293	005	Apr 03, 2020	Sep CAHN
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A210293	006	Apr 03, 2020	Sep CAHN

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE

AA	SANALUZ	5MG	A212582	001	Feb 04, 2020	Sep CAHN
AA		10MG	A212582	002	Feb 04, 2020	Sep CAHN
AA	SENORES PHARMS	5MG	A212901	001	May 22, 2020	Feb CAHN
AA		10MG	A212901	002	May 22, 2020	Feb CAHN
	@ SUN PHARM INDS INC	5MG	A214574	001	Jan 27, 2021	Mar DISC
	@	10MG	A214574	002	Jan 27, 2021	Mar DISC

	TABLET;ORAL							
	EVEKEO							
AA	AZURITY	5MG	A200166	001	Aug 09, 2012	Mar	CAHN	
AA	!	10MG	A200166	002	Aug 09, 2012	Mar	CAHN	
	TABLET, ORALLY DISINTEGRATING;ORAL							
	EVEKEO ODT							
	+ @	AZURITY	5MG	N209905	001	Jan 30, 2019	Apr	DISC
	+ @		10MG	N209905	002	Jan 30, 2019	Apr	DISC
	+ @		15MG	N209905	003	Jan 30, 2019	Apr	DISC
	+ @		20MG	N209905	004	Jan 30, 2019	Apr	DISC
	<u>AMPICILLIN SODIUM; SULBACTAM SODIUM</u>							
	INJECTABLE; INJECTION							
	AMPICILLIN AND SULBACTAM							
	@	MEDIMETRIKS PHARMS	EQ 1GM BASE/VIAL;EQ 500MG	A065316	001	Jun 29, 2007	Sep	CAHN
	@		BASE/VIAL					
	@		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065316	002	Jun 29, 2007	Sep	CAHN
	<u>AMPICILLIN/AMPICILLIN TRIHYDRATE</u>							
	FOR SUSPENSION;ORAL							
	AMPICILLIN TRIHYDRATE							
	@	ENDO OPERATIONS	EQ 125MG BASE/5ML	A062982	001	Feb 10, 1989	May	CAHN
	@		EQ 250MG BASE/5ML	A062982	002	Feb 10, 1989	May	CAHN
	<u>ANAGRELIDE HYDROCHLORIDE</u>							
	CAPSULE;ORAL							
	ANAGRELIDE HYDROCHLORIDE							
>A>	@	ESJAY PHARMA	EQ 0.5MG BASE	A076811	001	Apr 18, 2005	Nov	CAHN
>A>	@		EQ 1MG BASE	A076811	002	Apr 18, 2005	Nov	CAHN
>D>	@	NATCO PHARMA USA	EQ 0.5MG BASE	A076811	001	Apr 18, 2005	Nov	CAHN
>D>	@		EQ 1MG BASE	A076811	002	Apr 18, 2005	Nov	CAHN
	<u>APIXABAN</u>							
	TABLET;ORAL							
	APIXABAN							
AB	@	APOTEX	2.5MG	A210091	001	Feb 16, 2024	May	DISC
			2.5MG	A210091	001	Feb 16, 2024	Feb	NEWA
	@		5MG	A210091	002	Feb 16, 2024	May	DISC
AB			5MG	A210091	002	Feb 16, 2024	Feb	NEWA
	<u>APOMORPHINE HYDROCHLORIDE</u>							
	INJECTABLE;SUBCUTANEOUS							
	APOMORPHINE HYDROCHLORIDE							
AP		TRUPHARMA	30MG/3ML (10MG/ML)	A212025	001	Feb 23, 2022	Sep	CAHN
	<u>APREMILAST</u>							
	TABLET;ORAL							
	APREMILAST							
>A>	AB	MACLEODS PHARMS LTD	10MG	A211788	001	Nov 25, 2024	Nov	NEWA
>A>	AB		20MG	A211788	002	Nov 25, 2024	Nov	NEWA
>A>	AB		30MG	A211788	003	Nov 25, 2024	Nov	NEWA
	AB	MANKIND PHARMA	10MG	A211734	001	Feb 07, 2024	Jan	NEWA
	AB		20MG	A211734	002	Feb 07, 2024	Jan	NEWA
	AB		30MG	A211734	003	Feb 07, 2024	Jan	NEWA
	<u>APROCITENTAN</u>							
	TABLET;ORAL							
	TRYVIO							
	+!	IDORSIA	12.5MG	N217686	001	Mar 19, 2024	Mar	NEWA
	<u>ARFORMOTEROL TARTRATE</u>							
	SOLUTION;INHALATION							
	ARFORMOTEROL TARTRATE							
AN		AIPING PHARM INC	EQ 0.015MG BASE/2ML	A214901	001	Apr 02, 2024	Aug	CAHN
AN		BE PHARMS	EQ 0.015MG BASE/2ML	A213762	001	Jun 22, 2021	Oct	CAHN
AN		CF PHARMTECH	EQ 0.015MG BASE/2ML	A216303	001	May 17, 2024	May	NEWA
AN		DR REDDYS	EQ 0.015MG BASE/2ML	A215032	001	Jun 03, 2024	May	NEWA
>A>	AN	LEXENPHARM	EQ 0.015MG BASE/2ML	A218156	001	Nov 18, 2024	Nov	NEWA
	AN	PHARMAMAX	EQ 0.015MG BASE/2ML	A214901	001	Apr 02, 2024	Mar	NEWA
	AN	WILSHIRE PHARMS INC	EQ 0.015MG BASE/2ML	A216815	001	Nov 25, 2022	Jul	CAHN

ARIMOCLOMOL CITRATE

CAPSULE;ORAL
MIPLYFFA

+	ZEVRA DENMARK	EQ 47MG BASE	N214927	001	Sep 20, 2024	Sep	NEWA
+		EQ 62MG BASE	N214927	002	Sep 20, 2024	Sep	NEWA
+		EQ 93MG BASE	N214927	003	Sep 20, 2024	Sep	NEWA
+!		EQ 124MG BASE	N214927	004	Sep 20, 2024	Sep	NEWA

ARIPIPRAZOLE

FILM;ORAL
OPIPZA

+	XIAMEN LP PHARM CO	2MG	N216655	001	Jul 22, 2024	Jul	NEWA
+		5MG	N216655	002	Jul 22, 2024	Jul	NEWA
+!		10MG	N216655	003	Jul 22, 2024	Jul	NEWA

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
ABILIFY MAINTENA KIT

>D>	+	OTSUKA PHARM CO LTD	300MG/VIAL	N202971	001	Feb 28, 2013	Nov	CFTG
>A>	AP	+	300MG/VIAL	N202971	001	Feb 28, 2013	Nov	CFTG
>D>		+!	400MG/VIAL	N202971	002	Feb 28, 2013	Nov	CFTG
>A>	AP	+!	400MG/VIAL	N202971	002	Feb 28, 2013	Nov	CFTG

ARIPIPRAZOLE

>A>	AP	MYLAN	300MG/VIAL	A216608	001	Dec 03, 2024	Nov	NFTG
>A>	AP		400MG/VIAL	A216608	002	Dec 03, 2024	Nov	NFTG

TABLET;ORAL

ARIPIPRAZOLE

	@	BRECKENRIDGE	2MG	A091279	001	Jan 09, 2017	Aug	DISC
	@		5MG	A091279	002	Jan 09, 2017	Aug	DISC
	@		10MG	A091279	003	Jan 09, 2017	Aug	DISC
	@		15MG	A091279	004	Jan 09, 2017	Aug	DISC
	@		20MG	A091279	005	Jan 09, 2017	Aug	DISC
	@		30MG	A091279	006	Jan 09, 2017	Aug	DISC
AB		LUPIN	2MG	A205589	001	Mar 18, 2024	Mar	NEWA
AB			5MG	A205589	002	Mar 18, 2024	Mar	NEWA
AB			10MG	A205589	003	Mar 18, 2024	Mar	NEWA
AB			15MG	A205589	004	Mar 18, 2024	Mar	NEWA
AB			20MG	A205589	005	Mar 18, 2024	Mar	NEWA
AB			30MG	A205589	006	Mar 18, 2024	Mar	NEWA

ARSENIC TRIOXIDE

INJECTABLE;INJECTION

ARSENIC TRIOXIDE

>D>	AP	EUGIA PHARMA	2MG/ML	A214011	001	Oct 15, 2021	Nov	DISC
>A>		@	2MG/ML	A214011	001	Oct 15, 2021	Nov	DISC

ASCIMINIB HYDROCHLORIDE

TABLET;ORAL

SCEMBLIX

+	NOVARTIS	EQ 100MG BASE	N215358	003	Apr 18, 2024	Apr	NEWA
---	----------	---------------	---------	-----	--------------	-----	------

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION;ORAL

PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID

AA	TARO	4.7GM;100GM;1.015GM;5.9GM;2.691GM; 7.5GM	A207498	001	Jun 28, 2024	Jun	NEWA
----	------	--	---------	-----	--------------	-----	------

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

LANORINAL

AA	!	SANDOZ	325MG;50MG;40MG	A086996	002	Oct 11, 1985	Jan	CAHN
----	---	--------	-----------------	---------	-----	--------------	-----	------

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL

INVAGESIC

>A>	@	CHARTWELL RX	385MG;30MG;25MG	A074817	001	Nov 27, 1996	Nov	CAHN
>D>	@	SANDOZ	385MG;30MG;25MG	A074817	001	Nov 27, 1996	Nov	CAHN
		INVAGESIC FORTE						
>A>	@	CHARTWELL RX	770MG;60MG;50MG	A074817	002	Nov 27, 1996	Nov	CAHN
>D>	@	SANDOZ	770MG;60MG;50MG	A074817	002	Nov 27, 1996	Nov	CAHN

ASPIRIN; CARISOPRODOL

TABLET;ORAL

CARISOPRODOL AND ASPIRIN

@ GENUS

325MG;200MG

A040116 001 Apr 25, 1996 Aug CAHN

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE;ORAL

ASPIRIN AND DIPYRIDAMOLE

AB

ENDO OPERATIONS

25MG;200MG

A207944 001 Jan 18, 2017 Apr CAHN

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

PERCODAN

AA

+! ENDO OPERATIONS

325MG;4.8355MG

N007337 007 Aug 05, 2005 May CAHN

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET;ORAL

PERCODAN

@ ENDO OPERATIONS

325MG;4.5MG;0.38MG

N007337 006

May CAHN

PERCODAN-DEMI

@ ENDO OPERATIONS

325MG;2.25MG;0.19MG

N007337 005

May CAHN

ATAZANAVIR SULFATE

CAPSULE;ORAL

ATAZANAVIR SULFATE

@ AMNEAL

EQ 150MG BASE

A209717 002 Jun 01, 2020 Sep DISC

@

EQ 200MG BASE

A209717 003 Jun 01, 2020 Sep DISC

@

EQ 300MG BASE

A209717 004 Jun 01, 2020 Sep DISC

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB

APOTEX

EQ 10MG BASE

A078983 001 May 30, 2017 Mar CPOT

AB

EQ 18MG BASE

A078983 002 May 30, 2017 Mar CPOT

AB

EQ 25MG BASE

A078983 003 May 30, 2017 Mar CPOT

AB

EQ 40MG BASE

A078983 004 May 30, 2017 Mar CPOT

AB

EQ 60MG BASE

A078983 005 May 30, 2017 Mar CPOT

AB

EQ 80MG BASE

A078983 006 May 30, 2017 Mar CPOT

AB

EQ 100MG BASE

A078983 007 May 30, 2017 Mar CPOT

AB

AUROBINDO PHARMA

EQ 10MG BASE

A079016 001 May 30, 2017 Mar CPOT

AB

EQ 18MG BASE

A079016 002 May 30, 2017 Mar CPOT

AB

EQ 25MG BASE

A079016 003 May 30, 2017 Mar CPOT

AB

EQ 40MG BASE

A079016 004 May 30, 2017 Mar CPOT

AB

EQ 60MG BASE

A079016 005 May 30, 2017 Mar CPOT

AB

EQ 80MG BASE

A079016 006 May 30, 2017 Mar CPOT

AB

EQ 100MG BASE

A079016 007 May 30, 2017 Mar CPOT

AB

DR REDDYS

EQ 10MG BASE

A090609 001 Feb 23, 2018 Mar CPOT

AB

EQ 18MG BASE

A090609 002 Feb 23, 2018 Mar CPOT

AB

EQ 25MG BASE

A090609 003 Feb 23, 2018 Mar CPOT

AB

EQ 40MG BASE

A090609 004 Feb 23, 2018 Mar CPOT

AB

EQ 60MG BASE

A090609 005 Feb 23, 2018 Mar CPOT

AB

EQ 80MG BASE

A090609 006 Feb 23, 2018 Mar CPOT

AB

EQ 100MG BASE

A090609 007 Feb 23, 2018 Mar CPOT

AB

GLENMARK PHARMS LTD

EQ 10MG BASE

A079019 001 May 30, 2017 Mar CPOT

AB

EQ 18MG BASE

A079019 002 May 30, 2017 Mar CPOT

AB

EQ 25MG BASE

A079019 003 May 30, 2017 Mar CPOT

AB

EQ 40MG BASE

A079019 004 May 30, 2017 Mar CPOT

AB

EQ 60MG BASE

A079019 005 May 30, 2017 Mar CPOT

AB

EQ 80MG BASE

A079019 006 May 30, 2017 Mar CPOT

AB

EQ 100MG BASE

A079019 007 May 30, 2017 Mar CPOT

AB

HETERO LABS LTD V

EQ 10MG BASE

A202682 001 Mar 11, 2021 Mar CPOT

AB

EQ 18MG BASE

A202682 002 Mar 11, 2021 Mar CPOT

AB

EQ 25MG BASE

A202682 003 Mar 11, 2021 Mar CPOT

AB

EQ 40MG BASE

A202682 004 Mar 11, 2021 Mar CPOT

AB

EQ 60MG BASE

A202682 005 Mar 11, 2021 Mar CPOT

AB

EQ 80MG BASE

A202682 006 Mar 11, 2021 Mar CPOT

AB

EQ 100MG BASE

A202682 007 Mar 11, 2021 Mar CPOT

AB

STRIDES PHARMA

EQ 10MG BASE

A079021 001 Feb 18, 2021 Aug CMFD

@

EQ 10MG BASE

A079021 001 Feb 18, 2021 Mar CPOT

AB

EQ 18MG BASE

A079021 002 Feb 18, 2021 Aug CMFD

@

EQ 18MG BASE

A079021 002 Feb 18, 2021 Mar CPOT

AB

EQ 25MG BASE

A079021 003 Feb 18, 2021 Aug CMFD

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

	@		EQ 25MG BASE	A079021	003	Feb 18, 2021	Mar	CPOT
AB			EQ 40MG BASE	A079021	004	Feb 18, 2021	Aug	CMFD
	@		EQ 40MG BASE	A079021	004	Feb 18, 2021	Mar	CPOT
AB			EQ 60MG BASE	A079021	005	Feb 18, 2021	Aug	CMFD
	@		EQ 60MG BASE	A079021	005	Feb 18, 2021	Mar	CPOT
AB			EQ 80MG BASE	A079021	006	Feb 18, 2021	Aug	CMFD
	@		EQ 80MG BASE	A079021	006	Feb 18, 2021	Mar	CPOT
AB			EQ 100MG BASE	A079021	007	Feb 18, 2021	Aug	CMFD
	@		EQ 100MG BASE	A079021	007	Feb 18, 2021	Mar	CPOT
AB		TEVA PHARMS USA	EQ 10MG BASE	A079022	001	May 30, 2017	Mar	CPOT
AB			EQ 18MG BASE	A079022	002	May 30, 2017	Mar	CPOT
AB			EQ 25MG BASE	A079022	003	May 30, 2017	Mar	CPOT
AB			EQ 40MG BASE	A079022	004	May 30, 2017	Mar	CPOT
AB			EQ 60MG BASE	A079022	005	May 30, 2017	Mar	CPOT
AB			EQ 80MG BASE	A079022	006	May 30, 2017	Mar	CPOT
AB			EQ 100MG BASE	A079022	007	May 30, 2017	Mar	CPOT
AB		ZYDUS PHARMS USA INC	EQ 10MG BASE	A079017	007	Apr 05, 2023	Mar	CPOT
AB			EQ 18MG BASE	A079017	001	Sep 16, 2010	Mar	CPOT
AB			18MG	A079017	001	Sep 16, 2010	Jan	CMS1
AB			EQ 25MG BASE	A079017	002	Sep 16, 2010	Mar	CPOT
AB			25MG	A079017	002	Sep 16, 2010	Jan	CMS1
AB			EQ 40MG BASE	A079017	003	Sep 16, 2010	Mar	CPOT
AB			40MG	A079017	003	Sep 16, 2010	Jan	CMS1
AB			EQ 60MG BASE	A079017	004	Sep 16, 2010	Mar	CPOT
AB			60MG	A079017	004	Sep 16, 2010	Jan	CMS1
AB			EQ 80MG BASE	A079017	005	Sep 16, 2010	Mar	CPOT
AB			80MG	A079017	005	Sep 16, 2010	Jan	CMS1
AB			EQ 100MG BASE	A079017	006	Sep 16, 2010	Mar	CPOT
AB			100MG	A079017	006	Sep 16, 2010	Jan	CMS1

STRATTERA

	@	LILLY	EQ 5MG BASE	N021411	001	Nov 26, 2002	Mar	CPOT
AB	+		EQ 10MG BASE	N021411	002	Nov 26, 2002	Mar	CPOT
AB	+		EQ 18MG BASE	N021411	003	Nov 26, 2002	Mar	CPOT
AB	+		EQ 25MG BASE	N021411	004	Nov 26, 2002	Mar	CPOT
AB	+		EQ 40MG BASE	N021411	005	Nov 26, 2002	Mar	CPOT
AB	+		EQ 60MG BASE	N021411	006	Nov 26, 2002	Mar	CPOT
AB	+		EQ 80MG BASE	N021411	007	Feb 14, 2005	Mar	CPOT
AB	+		EQ 100MG BASE	N021411	008	Feb 14, 2005	Mar	CPOT

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB		ANBISON LAB	EQ 10MG BASE	A211886	001	Jan 25, 2024	Jan	NEWA
AB			EQ 20MG BASE	A211886	002	Jan 25, 2024	Jan	NEWA
AB			EQ 40MG BASE	A211886	003	Jan 25, 2024	Jan	NEWA
AB			EQ 80MG BASE	A211886	004	Jan 25, 2024	Jan	NEWA
AB		AUROBINDO PHARMA LTD	EQ 10MG BASE	A217118	001	Feb 13, 2024	Feb	NEWA
AB			EQ 20MG BASE	A217118	002	Feb 13, 2024	Feb	NEWA
AB			EQ 40MG BASE	A217118	003	Feb 13, 2024	Feb	NEWA
AB			EQ 80MG BASE	A217118	004	Feb 13, 2024	Feb	NEWA
	@	CADILA PHARMS LTD	EQ 10MG BASE	A212103	001	Oct 16, 2023	Apr	DISC
	@		EQ 20MG BASE	A212103	002	Oct 16, 2023	Apr	DISC
	@		EQ 40MG BASE	A212103	003	Oct 16, 2023	Apr	DISC
	@		EQ 80MG BASE	A212103	004	Oct 16, 2023	Apr	DISC
>A>	AB	CHARTWELL RX	EQ 10MG BASE	A077575	001	May 29, 2012	Nov	CAHN
>A>	AB		EQ 20MG BASE	A077575	002	May 29, 2012	Nov	CAHN
>A>	AB		EQ 40MG BASE	A077575	003	May 29, 2012	Nov	CAHN
>A>	AB		EQ 80MG BASE	A077575	004	May 29, 2012	Nov	CAHN
	@	INVAGEN PHARMS	EQ 10MG BASE	A204846	001	Jan 09, 2017	Mar	DISC
	@		EQ 20MG BASE	A204846	002	Jan 09, 2017	Mar	DISC
	@		EQ 40MG BASE	A204846	003	Jan 09, 2017	Mar	DISC
	@		EQ 80MG BASE	A204846	004	Jan 09, 2017	Mar	DISC
AB		LAURUS	EQ 10MG BASE	A214513	001	Jan 22, 2024	Jan	NEWA
AB			EQ 20MG BASE	A214513	002	Jan 22, 2024	Jan	NEWA
AB			EQ 40MG BASE	A214513	003	Jan 22, 2024	Jan	NEWA
AB			EQ 80MG BASE	A214513	004	Jan 22, 2024	Jan	NEWA
	@	LUPIN LTD	EQ 10MG BASE	A204991	001	Mar 06, 2019	Aug	DISC
BX			EQ 10MG BASE	A204991	001	Mar 06, 2019	Jun	CTEC
	@		EQ 20MG BASE	A204991	002	Mar 06, 2019	Aug	DISC
BX			EQ 20MG BASE	A204991	002	Mar 06, 2019	Jun	CTEC
	@		EQ 40MG BASE	A204991	003	Mar 06, 2019	Aug	DISC
BX			EQ 40MG BASE	A204991	003	Mar 06, 2019	Jun	CTEC

TABLET;ORAL

ATORVASTATIN CALCIUM

	@		EQ 80MG BASE	A204991	004	Mar 06, 2019	Aug	DISC
BX			EQ 80MG BASE	A204991	004	Mar 06, 2019	Jun	CTEC
AB	MACLEODS PHARMS LTD		EQ 10MG BASE	A208480	001	Jun 03, 2024	May	NEWA
AB			EQ 20MG BASE	A208480	002	Jun 03, 2024	May	NEWA
AB			EQ 40MG BASE	A208480	003	Jun 03, 2024	May	NEWA
AB			EQ 80MG BASE	A208480	004	Jun 03, 2024	May	NEWA
>D>	AB	SANDOZ INC	EQ 10MG BASE	A077575	001	May 29, 2012	Nov	CAHN
>D>	AB		EQ 20MG BASE	A077575	002	May 29, 2012	Nov	CAHN
>D>	AB		EQ 40MG BASE	A077575	003	May 29, 2012	Nov	CAHN
>D>	AB		EQ 80MG BASE	A077575	004	May 29, 2012	Nov	CAHN
AB	SHANDONG XINHUA		EQ 10MG BASE	A211886	001	Jan 25, 2024	Mar	CAHN
AB			EQ 20MG BASE	A211886	002	Jan 25, 2024	Mar	CAHN
AB			EQ 40MG BASE	A211886	003	Jan 25, 2024	Mar	CAHN
AB			EQ 80MG BASE	A211886	004	Jan 25, 2024	Mar	CAHN
BX	UMEDICA		EQ 10MG BASE	A213853	001	Aug 19, 2020	Jun	CTEC
BX			EQ 20MG BASE	A213853	002	Aug 19, 2020	Jun	CTEC
BX			EQ 40MG BASE	A213853	003	Aug 19, 2020	Jun	CTEC
BX			EQ 80MG BASE	A213853	004	Aug 19, 2020	Jun	CTEC

ATRACURIUM BESYLATE

INJECTABLE;INJECTION

ATRACURIUM BESYLATE

@	NORVIUM BIOSCIENCE	10MG/ML	A206096	001	Jun 22, 2017	Jun	CAHN
	ATRACURIUM BESYLATE PRESERVATIVE FREE						
@	NORVIUM BIOSCIENCE	10MG/ML	A206001	001	Apr 07, 2017	Jun	CAHN

ATROPINE SULFATE

SOLUTION;INTRAVENOUS

ATROPINE SULFATE

AP	SOMERSET THERAPS LLC	0.4MG/ML (0.4MG/ML)	A215969	001	Jul 03, 2024	Jun	NEWA	
AP		1MG/ML (1MG/ML)	A215969	002	Jul 03, 2024	Jun	NEWA	
	SOLUTION;INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL							
	ATROPINE SULFATE							
>A>	AP	SOMERSET THERAPS LLC	8MG/20ML (0.4MG/ML)	A215005	001	Nov 29, 2024	Nov	NEWA
	SOLUTION/DROPS;OPHTHALMIC							
	ATROPINE SULFATE							
AT1	!	AMNEAL	1%	A214752	001	Jul 14, 2022	Apr	CTEC
AT1		APOTEX	1%	A215624	001	Nov 26, 2021	Apr	CTEC
AT1		MANKIND PHARMA	1%	A218148	001	Jan 08, 2024	Apr	CTEC
AT1	+	RISING	1%	N206289	001	Jul 18, 2014	Apr	CTEC
AT2		SOMERSET	1%	A217791	001	Apr 29, 2024	Apr	NFTG
AT1		SOMERSET THERAPS LLC	1%	A215618	001	Jul 01, 2024	Jun	NEWA
	ISOPTO ATROPINE							
AT2	+	ALCON LABS INC	1%	N208151	001	Dec 01, 2016	Apr	CFTG

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET;ORAL

MOTOFEN

>A>	+	LEGACY PHARMA	0.025MG;1MG	N017744	002		Nov	CAHN
>D>	+	SEBELA IRELAND LTD	0.025MG;1MG	N017744	002		Nov	CAHN
	MOTOFEN HALF-STRENGTH							
>A>	@	LEGACY PHARMA	0.025MG;0.5MG	N017744	001		Nov	CAHN
>D>	@	SEBELA IRELAND LTD	0.025MG;0.5MG	N017744	001		Nov	CAHN

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

	@	ANI PHARMS	0.025MG;2.5MG	A086727	001		Mar	DISC
>D>	AA	BAYSHORE PHARMS LLC	0.025MG;2.5MG	A210819	001	Nov 13, 2018	Nov	CAHN
	@	MYLAN	0.025MG;2.5MG	A085762	001		Apr	DISC
>A>	AA	UNICHEM	0.025MG;2.5MG	A210819	001	Nov 13, 2018	Nov	CAHN

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION

ENLON-PLUS

@	NORVIUM BIOSCIENCE	0.14MG/ML;10MG/ML	N019677	001	Nov 06, 1991	Jul	CAHN
+	@	0.14MG/ML;10MG/ML	N019678	001	Nov 06, 1991	Jul	CAHN

AURANOFIN

	CAPSULE;ORAL						
	RIDAURA						
>A>	+!	LEGACY PHARMA	3MG	N018689	001	May 24, 1985	Nov CAHN
>D>	+!	SEBELA IRELAND LTD	3MG	N018689	001	May 24, 1985	Nov CAHN

AVACINCAPTAD PEGOL SODIUM

	SOLUTION;INTRAVITREAL						
	IZERVAY						
	+!	ASTELLAS	EQ 2MG BASE/0.1ML (EQ 2MG BASE/0.1ML)	N217225	001	Aug 04, 2023	Jan CAHN

AVANAFIL

	TABLET;ORAL						
	AVANAFIL						
AB		HETERO LABS LTD V	50MG	A209266	001	Jun 14, 2024	Jun NFTG
AB			100MG	A209266	002	Jun 14, 2024	Jun NFTG
AB			200MG	A209266	003	Jun 14, 2024	Jun NFTG
	STENDRA						
AB	+	METUCHEN PHARMS	50MG	N202276	001	Apr 27, 2012	Jun CFTG
AB	+		100MG	N202276	002	Apr 27, 2012	Jun CFTG
AB	+!		200MG	N202276	003	Apr 27, 2012	Jun CFTG

AVIBACTAM SODIUM; CEFTAZIDIME

	POWDER;INTRAVENOUS						
	AVYCAZ						
	+!	ABBVIE	EQ 0.5GM BASE;2GM/VIAL	N206494	001	Feb 25, 2015	Sep CAHN

AZACITIDINE

	POWDER;INTRAVENOUS, SUBCUTANEOUS						
	AZACITIDINE						
AP		HETERO LABS LTD VI	100MG/VIAL	A215765	001	Oct 15, 2024	Oct NEWA
AP		MSN LABS PVT LTD	100MG/VIAL	A212580	001	May 16, 2024	May NEWA
	@	NORVIUM BIOSCIENCE	100MG/VIAL	A204949	001	Apr 28, 2016	Oct CAHN

AZATHIOPRINE

	TABLET;ORAL						
	IMURAN						
>A>	+ @	LEGACY PHARMA	25MG	N016324	002		Nov CAHN
>A>	AB	+!	50MG	N016324	001		Nov CAHN
>D>	+ @	SEBELA IRELAND LTD	25MG	N016324	002		Nov CAHN
>D>	AB	+!	50MG	N016324	001		Nov CAHN

AZELAIC ACID

	GEL;TOPICAL						
	AZELAIC ACID						
AB		TARO	15%	A210549	001	Aug 23, 2019	Apr CAHN

AZELASTINE HYDROCHLORIDE

	SOLUTION/DROPS;OPHTHALMIC						
	AZELASTINE HYDROCHLORIDE						
>D>	AT	SUN PHARM	0.05%	A078738	001	Jun 21, 2010	Nov DISC
>A>		@	0.05%	A078738	001	Jun 21, 2010	Nov DISC
	OPTIVAR						
	+ @	NORVIUM BIOSCIENCE	0.05%	N021127	001	May 22, 2000	Jul CAHN
	SPRAY, METERED;NASAL						
	ASTELIN						
	+ @	NORVIUM BIOSCIENCE	0.137MG/SPRAY	N020114	001	Nov 01, 1996	Jul CAHN
	AZELASTINE HYDROCHLORIDE						
	@	HIKMA	0.137MG/SPRAY	A091444	001	Oct 24, 2014	Mar DISC
>D>	AB	SUN PHARM	0.137MG/SPRAY	A090423	001	May 23, 2012	Nov DISC
>A>		@	0.137MG/SPRAY	A090423	001	May 23, 2012	Nov DISC

AZITHROMYCIN

	INJECTABLE;INJECTION						
	AZITHROMYCIN						
	@	NORVIUM BIOSCIENCE	EQ 500MG BASE/VIAL	A065506	001	Mar 24, 2009	Jun CAHN
	@	SUN PHARM INDS LTD	EQ 500MG BASE/VIAL	A090923	001	Apr 02, 2013	May DISC

TABLET;ORAL

AZITHROMYCIN

@ PHARMOBEDIANT	EQ 500MG BASE	A211318	001	Mar 17, 2021	Sep CAHN
@ YUNG SHIN PHARM	EQ 250MG BASE	A211317	001	Jul 26, 2022	Feb DISC

BACLOFEN

INJECTABLE;INTRATHECAL

BACLOFEN

@ ACIC PHARMS	0.5MG/ML	A216309	001	Aug 10, 2023	Jan DISC
@	2MG/ML	A216309	002	Aug 10, 2023	Jan DISC
@ HERITAGE	0.5MG/ML	A216309	001	Aug 10, 2023	Sep CAHN
@	2MG/ML	A216309	002	Aug 10, 2023	Sep CAHN

SOLUTION;ORAL

BACLOFEN

>A>	RUBICON	5MG/5ML	A214445	001	Dec 06, 2024	Nov NFTG
-----	---------	---------	---------	-----	--------------	----------

TABLET;ORAL

BACLOFEN

AB	ANDAS 5 HOLDING	5MG	A212378	003	Apr 30, 2021	Aug CAHN
AB		10MG	A212378	001	Oct 09, 2020	Aug CAHN
AB		20MG	A212378	002	Oct 09, 2020	Aug CAHN
AB	ENDO OPERATIONS	10MG	A077068	002	Aug 30, 2005	Apr CAHN
AB		20MG	A077068	001	Aug 30, 2005	Apr CAHN
AB	GRAVITI PHARMS	5MG	A217788	003	Oct 24, 2024	Oct NEWA
	@ IMPAX	5MG	A077971	003	Jul 07, 2021	Mar DISC
	@	10MG	A077971	001	Oct 26, 2007	Mar DISC
	@	20MG	A077971	002	Oct 26, 2007	Mar DISC
	@ NORVIUM BIOSCIENCE	20MG	A077121	002	Jul 29, 2005	Jul CAHN
AB	RUBICON	15MG	A209102	004	Feb 05, 2024	Feb CTEC
		15MG	A209102	004	Feb 05, 2024	Jan NEWA

BALSALAZIDE DISODIUM

CAPSULE;ORAL

BALSALAZIDE DISODIUM

>D>	@ DASH PHARMS NATCO	750MG	A077807	001	Dec 28, 2007	Nov CAHN
>A>	@ ESJAY PHARMA	750MG	A077807	001	Dec 28, 2007	Nov CAHN
AB	ZYDUS LIFESCIENCES	750MG	A217592	001	Jun 08, 2023	Mar CAHN

BARICITINIB

TABLET;ORAL

BARICITINIB

	@ AUROBINDO PHARMA LTD	1MG	A217542	001	Jul 22, 2024	Aug DISC
AB		1MG	A217542	001	Jul 22, 2024	Jul NFTG
	@	2MG	A217542	002	Jul 22, 2024	Aug DISC
AB		2MG	A217542	002	Jul 22, 2024	Jul NFTG

OLUMIANT

	+ ELI LILLY AND CO	1MG	N207924	002	Oct 08, 2019	Aug CTEC
AB		1MG	N207924	002	Oct 08, 2019	Jul CFTG
		2MG	N207924	001	May 31, 2018	Aug CTEC
AB		2MG	N207924	001	May 31, 2018	Jul CFTG

BENDAMUSTINE HYDROCHLORIDE

POWDER;INTRAVENOUS

BENDAMUSTINE HYDROCHLORIDE

AP	ACCORD HLTHCARE	25MG/VIAL	A205574	001	Dec 07, 2022	Oct CDFR
AP		100MG/VIAL	A205574	002	Dec 07, 2022	Oct CDFR
AP	APOTEX	25MG/VIAL	A204230	001	Jun 05, 2023	Oct CDFR
AP		100MG/VIAL	A204230	002	Jun 05, 2023	Oct CDFR
>D>	AP BRECKENRIDGE	25MG/VIAL	A205447	001	Feb 14, 2023	Nov DISC
>A>	@	25MG/VIAL	A205447	001	Feb 14, 2023	Nov DISC
AP		25MG/VIAL	A205447	001	Feb 14, 2023	Oct CDFR
>D>	AP	100MG/VIAL	A205447	002	Feb 14, 2023	Nov DISC
>A>	@	100MG/VIAL	A205447	002	Feb 14, 2023	Nov DISC
AP		100MG/VIAL	A205447	002	Feb 14, 2023	Oct CDFR
AP	DR REDDYS	25MG/VIAL	A205376	001	Dec 07, 2022	Oct CDFR
AP		100MG/VIAL	A205376	002	Dec 07, 2022	Oct CDFR
AP	EUGIA PHARMA	25MG/VIAL	A214739	001	Jun 05, 2023	Oct CDFR
AP		100MG/VIAL	A214739	002	Jun 05, 2023	Oct CDFR
AP	MEITHEAL	25MG/VIAL	A211001	001	Jun 05, 2023	Oct CDFR
AP		100MG/VIAL	A211001	002	Jun 05, 2023	Oct CDFR
	@ NANG KUANG PHARM CO	25MG/VIAL	A206554	001	Jun 07, 2023	Oct CDFR
	@	100MG/VIAL	A206554	002	Jun 07, 2023	Oct CDFR
	@ NORVIUM BIOSCIENCE	25MG/VIAL	A204104	001	Apr 28, 2023	Oct CDFR
	@	100MG/VIAL	A204104	002	Apr 28, 2023	Oct CDFR

POWDER; INTRAVENOUS

	TREANDA							
AP	+! CEPHALON	25MG/VIAL	N022249	002	May 01, 2009	Oct	CDFR	
AP	+!	100MG/VIAL	N022249	001	Mar 20, 2008	Oct	CDFR	

POWDER; IV (INFUSION)

	BENDAMUSTINE HYDROCHLORIDE							
AP	MEITHEAL	25MG/VIAL	A211001	001	Jun 05, 2023	Jun	CAHN	
AP		100MG/VIAL	A211001	002	Jun 05, 2023	Jun	CAHN	
	@ NORVIUM BIOSCIENCE	25MG/VIAL	A204104	001	Apr 28, 2023	Jun	CAHN	
	@	100MG/VIAL	A204104	002	Apr 28, 2023	Jun	CAHN	

SOLUTION; INTRAVENOUS

	BENDEKA							
	+! EAGLE PHARMS	100MG/4ML (25MG/ML)	N208194	001	Dec 07, 2015	Oct	CDFR	
	TREANDA							
	+ @ CEPHALON	45MG/0.5ML (90MG/ML)	N022249	003	Sep 13, 2013	Oct	CDFR	
	+ @	180MG/2ML (90MG/ML)	N022249	004	Sep 13, 2013	Oct	CDFR	
	VIVIMUSTA							
	+! AZURITY	100MG/4ML (25MG/ML)	N212209	001	Dec 07, 2022	Jul	CAHN	

BENZGALANTAMINE GLUCONATE

TABLET, DELAYED RELEASE; ORAL

	ZUNVEYL							
	+! ALPHA COGNITION	EQ 5MG BASE	N218549	001	Jul 26, 2024	Jul	NEWA	
	+	EQ 10MG BASE	N218549	002	Jul 26, 2024	Jul	NEWA	
	+	EQ 15MG BASE	N218549	003	Jul 26, 2024	Jul	NEWA	

BENZONATATE

CAPSULE; ORAL

	BENZONATATE							
	@ ACELLA	100MG	A091310	001	Jan 16, 2015	Oct	DISC	

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

	CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE							
>D>	@ ENCUBE	2.5%;EQ 1.2% BASE	A207194	001	Aug 19, 2019	Nov	CMFD	
>A>	AB	2.5%;EQ 1.2% BASE	A207194	001	Aug 19, 2019	Nov	CMFD	
	AB	PADAGIS ISRAEL	A209610	001	Aug 20, 2024	Aug	NEWA	

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

	ERYTHROMYCIN AND BENZOYL PEROXIDE							
AB	RISING	5%;3%	A065385	001	Sep 18, 2015	Sep	CAHN	

BENZTROPINE MESYLATE

TABLET; ORAL

	BENZTROPINE MESYLATE							
AA	AIPING PHARM INC	0.5MG	A040103	001	Dec 12, 1996	Aug	CMFD	
AA		1MG	A040103	002	Dec 12, 1996	Aug	CMFD	
AA		2MG	A040103	003	Dec 12, 1996	Aug	CMFD	
AA	ENDO OPERATIONS	0.5MG	A040715	001	Aug 27, 2007	Apr	CAHN	
AA		1MG	A040715	002	Aug 27, 2007	Apr	CAHN	
AA		2MG	A040715	003	Aug 27, 2007	Apr	CAHN	
	@ INVAGEN PHARMS	0.5MG	A090294	001	Mar 29, 2010	Mar	DISC	
	@	1MG	A090294	002	Mar 29, 2010	Mar	DISC	
	@	2MG	A090294	003	Mar 29, 2010	Mar	DISC	
AA	! NUVO PHARM	0.5MG	A204713	001	Apr 14, 2015	Jul	CAHN	
AA	!	1MG	A204713	002	Apr 14, 2015	Jul	CAHN	
AA	!	2MG	A204713	003	Apr 14, 2015	Jul	CAHN	

BEPOTASTINE BESILATE

SOLUTION/DROPS; OPHTHALMIC

	BEPOTASTINE BESILATE							
AT	SOMERSET THERAPS LLC	1.5%	A217770	001	Aug 14, 2024	Aug	NEWA	

BERDAZIMER SODIUM

GEL; TOPICAL

	ZELSUVMI							
	+! LNHC	EQ 10.3% BASE	N217424	001	Jan 05, 2024	Jan	NEWA	

BETAMETHASONE DIPROPIONATE

	LOTION, AUGMENTED;TOPICAL								
	BETAMETHASONE DIPROPIONATE								
	@ HIKMA	EQ 0.05% BASE	A208849	001	Oct 11, 2019	Mar	DISC		
	OINTMENT, AUGMENTED;TOPICAL								
	BETAMETHASONE DIPROPIONATE								
AB	AUROBINDO PHARMA LTD	EQ 0.05% BASE	A218289	001	Apr 10, 2024	Mar	NEWA		
	@ PADAGIS US	EQ 0.05% BASE	A206118	001	Nov 09, 2017	Jan	CAHN		

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

	AEROSOL, FOAM;TOPICAL								
>D>	CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE								
>D> AB	GLENMARK PHARMS LTD	0.064%;0.005%	A214688	001	Mar 21, 2023	Nov	DISC		
>A>	@	0.064%;0.005%	A214688	001	Mar 21, 2023	Nov	DISC		
	ENSTILAR								
>D> AB	+! LEO PHARMA AS	0.064%;0.005%	N207589	001	Oct 16, 2015	Nov	CTEC		
>A>	+!	0.064%;0.005%	N207589	001	Oct 16, 2015	Nov	CTEC		

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

	CREAM;TOPICAL								
	CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE								
AB	! TARO	EQ 0.05% BASE;1%	A075673	001	May 29, 2001	Apr	CAHN		

BETAMETHASONE VALERATE

	AEROSOL, FOAM;TOPICAL								
	BETAMETHASONE VALERATE								
AB	ALEMBIC	0.12%	A215832	001	Aug 22, 2024	Aug	NEWA		
	LOTION;TOPICAL								
	BETAMETHASONE VALERATE								
AB	KANCHAN HLTHCARE	EQ 0.1% BASE	A070052	001	Jul 31, 1985	Aug	CAHN		
AB	SCIEGEN PHARMS INC	EQ 0.1% BASE	A070052	001	Jul 31, 1985	Sep	CAHN		

BEXAROTENE

	CAPSULE;ORAL								
	BEXAROTENE								
AB	ASCENT PHARMS INC	75MG	A208628	001	Sep 06, 2024	Aug	NEWA		
>A> AB	CIPLA	75MG	A210352	001	Dec 10, 2024	Nov	NEWA		

BICALUTAMIDE

	TABLET;ORAL								
	BICALUTAMIDE								
AB	CHARTWELL RX	50MG	A091011	001	Jun 10, 2015	Jan	CAHN		
	@ RISING	50MG	A079185	001	Jul 06, 2009	Feb	CAHN		

BIMATOPROST

	SOLUTION/DROPS;TOPICAL								
	BIMATOPROST								
	@ HIKMA	0.03%	A203051	001	Oct 09, 2018	Mar	DISC		

BIRCH TRITERPENES

	GEL;TOPICAL								
	FILSUVEZ								
	+! CHIESI	10%	N215064	001	Dec 18, 2023	Jan	CAHN		

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

	CAPSULE;ORAL								
	BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE								
AB	NOVAST LABS	140MG;125MG;125MG	A217511	001	Jul 03, 2023	Sep	CAHN		

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

	TABLET, CHEWABLE, TABLET, CAPSULE;ORAL								
	BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE								
	! AILEX PHARMS LLC	262.4MG, N/A, N/A;N/A, 250MG, N/A;N/A, N/A, 500MG	A202584	001	Nov 30, 2018	Oct	CAHN		

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

AB	HARMAN FINOCHEM	5MG	A217617	001	Jan 18, 2024	Jan	NEWA
AB		10MG	A217617	002	Jan 18, 2024	Jan	NEWA
AB	TRUPHARMA	5MG	A075474	001	Oct 25, 2002	Sep	CAHN
AB		10MG	A075474	002	Oct 25, 2002	Sep	CAHN

BIVALIRUDIN

INJECTABLE; INTRAVENOUS

BIVALIRUDIN

@	HOSPIRA	250MG/VIAL	A090811	001	Jul 14, 2015	Aug	DISC
@		250MG/VIAL	A090816	001	Jul 14, 2015	May	DISC

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLEOMYCIN SULFATE

@	TEVA PHARMS USA	EQ 15 UNITS BASE/VIAL	A065033	001	Jun 27, 2000	Jan	DISC
@		EQ 30 UNITS BASE/VIAL	A065033	002	Jun 27, 2000	Jan	DISC

BORTEZOMIB

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

AP	HETERO LABS LTD VI	3.5MG/VIAL	A212204	001	May 03, 2024	Apr	NEWA
	@ NORVIUM BIOSCIENCE	3.5MG/VIAL	A205160	001	Oct 31, 2022	Jun	CAHN
AP	RELIANCE LIFE SCI	3.5MG/VIAL	A211898	001	Oct 11, 2022	May	CAHN

SOLUTION; INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

+	SHILPA	3.5MG/1.4ML (2.5MG/ML)	N212782	001	Aug 26, 2024	Aug	NEWA
---	--------	------------------------	---------	-----	--------------	-----	------

BOSENTAN

TABLET; ORAL

BOSENTAN

@	ENDO OPERATIONS	62.5MG	A205699	001	Apr 26, 2019	Apr	CAHN
@		125MG	A205699	002	Apr 26, 2019	Apr	CAHN

BREMELANOTIDE ACETATE

SOLUTION; SUBCUTANEOUS

VYLEESI (AUTOINJECTOR)

+	COSETTE	EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML)	N210557	001	Jun 21, 2019	Apr	CAHN
---	---------	--	---------	-----	--------------	-----	------

BREXPIRAZOLE

TABLET; ORAL

BREXPIRAZOLE

@	ALKEM LABS LTD	0.25MG	A213782	001	Nov 28, 2023	Sep	DISC
@		0.5MG	A213782	002	Nov 28, 2023	Sep	DISC
@		1MG	A213782	003	Nov 28, 2023	Sep	DISC
@		2MG	A213782	004	Nov 28, 2023	Sep	DISC
@		3MG	A213782	005	Nov 28, 2023	Sep	DISC
@		4MG	A213782	006	Nov 28, 2023	Sep	DISC
@	ANDA REPOSITORY	0.25MG	A213758	001	Oct 25, 2023	Sep	CAHN
@		0.5MG	A213758	002	Oct 25, 2023	Sep	CAHN
@		1MG	A213758	003	Oct 25, 2023	Sep	CAHN
@		2MG	A213758	004	Oct 25, 2023	Sep	CAHN
@		3MG	A213758	005	Oct 25, 2023	Sep	CAHN
@		4MG	A213758	006	Oct 25, 2023	Sep	CAHN
@	CELLTRION	0.25MG	A213758	001	Oct 25, 2023	Sep	CAHN
@		0.5MG	A213758	002	Oct 25, 2023	Sep	CAHN
@		1MG	A213758	003	Oct 25, 2023	Sep	CAHN
@		2MG	A213758	004	Oct 25, 2023	Sep	CAHN
@		3MG	A213758	005	Oct 25, 2023	Sep	CAHN
@		4MG	A213758	006	Oct 25, 2023	Sep	CAHN
@	HETERO LABS LTD V	0.25MG	A213669	001	Nov 20, 2023	Sep	DISC
@		0.5MG	A213669	002	Nov 20, 2023	Sep	DISC
@		1MG	A213669	003	Nov 20, 2023	Sep	DISC
@		2MG	A213669	004	Nov 20, 2023	Sep	DISC
@		3MG	A213669	005	Nov 20, 2023	Sep	DISC
@		4MG	A213669	006	Nov 20, 2023	Sep	DISC
@	OPTIMUS	0.25MG	A213758	001	Oct 25, 2023	Sep	DISC
@		0.5MG	A213758	002	Oct 25, 2023	Sep	DISC
@		1MG	A213758	003	Oct 25, 2023	Sep	DISC

TABLET;ORAL

BREXPIPIRAZOLE

@	2MG	A213758	004	Oct 25, 2023	Sep	DISC
@	3MG	A213758	005	Oct 25, 2023	Sep	DISC
@	4MG	A213758	006	Oct 25, 2023	Sep	DISC

REXULTI

+	OTSUKA	0.25MG	N205422	001	Jul 10, 2015	Sep	CTEC
+		0.5MG	N205422	002	Jul 10, 2015	Sep	CTEC
+		1MG	N205422	003	Jul 10, 2015	Sep	CTEC
+	!	2MG	N205422	004	Jul 10, 2015	Sep	CTEC
+		3MG	N205422	005	Jul 10, 2015	Sep	CTEC
+		4MG	N205422	006	Jul 10, 2015	Sep	CTEC

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE

AB	LUPIN LTD	0.1%	A213215	001	Aug 26, 2024	Aug	NEWA	
AB	SANDOZ	0.1%	A203172	001	Mar 04, 2024	Feb	NEWA	
AB	SOMERSET THERAPS LLC	0.1%	A216906	001	Aug 09, 2024	Aug	NEWA	
>D>	AT	UPSHER SMITH LABS	0.15%	A216772	001	Jun 12, 2024	Nov	DISC
>A>	@		0.15%	A216772	001	Jun 12, 2024	Nov	DISC
AT		0.15%	A216772	001	Jun 12, 2024	May	NEWA	

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE AND TIMOLOL MALEATE

AB	GLENMARK PHARMS LTD	0.2%;EQ 0.5% BASE	A214987	001	May 16, 2024	May	NEWA
AB	SOMERSET	0.2%;EQ 0.5% BASE	A216114	001	Sep 10, 2024	Aug	NEWA

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

BROMFENAC SODIUM

AB	ALEMBIC	EQ 0.07% ACID	A214340	001	Jul 08, 2024	Jun	NEWA	
AB	AMNEAL	EQ 0.07% ACID	A210962	001	Jul 29, 2024	Jul	NEWA	
AB	APOTEX	EQ 0.07% ACID	A207334	001	Jul 08, 2024	Jun	NEWA	
AB	LUPIN LTD	EQ 0.075% ACID	A211239	001	Feb 02, 2024	Jan	NFTG	
AB	+	SUN PHARM	EQ 0.075% ACID	N206911	001	Apr 08, 2016	Jan	CFTG

BROMOCRIPTINE MESYLATE

CAPSULE;ORAL

PARLODEL

AB	+	ESJAY PHARMA	EQ 5MG BASE	N017962	002	Mar 01, 1982	Oct	CAHN
AB	+	ESJAY PHARMA	EQ 2.5MG BASE	N017962	001		Oct	CAHN

BUDESONIDE

AEROSOL, FOAM;RECTAL

BUDESONIDE

AB	!	PADAGIS ISRAEL	2MG/ACTUATION	A215328	001	Apr 12, 2023	Jun	CHRS
AB	+	SALIX	2MG/ACTUATION	N205613	001	Oct 07, 2014	Jun	CHRS
+		CHEPLAPHARM	0.08MG/INH	N021949	001	Jul 12, 2006	Jun	CAHN
+	!		0.16MG/INH	N021949	002	Jul 12, 2006	Jun	CAHN

POWDER, METERED;INHALATION

PULMICORT FLEXHALER

SUSPENSION;INHALATION

BUDESONIDE

@	EUGIA PHARMA	0.5MG/2ML	A216667	001	Nov 29, 2023	May	DISC	
+	!	TAKEDA PHARMS USA	2MG/10ML	N213976	001	Feb 09, 2024	Feb	NEWA

BUMETANIDE

INJECTABLE;INJECTION

BUMETANIDE

@	HOSPIRA	0.25MG/ML	A074332	001	Oct 31, 1994	May	DISC
AP	LUPIN LTD	0.25MG/ML	A217153	001	Sep 17, 2024	Sep	NEWA
AP	QILU PHARM HAINAN	0.25MG/ML	A219116	001	Sep 19, 2024	Sep	NEWA

TABLET; ORAL
BUMETANIDE

AB	APPCO	0.5MG	A212931	001	Sep 18, 2024	Sep	NEWA
AB		1MG	A212931	002	Sep 18, 2024	Sep	NEWA
AB		2MG	A212931	003	Sep 18, 2024	Sep	NEWA
AB	RISING	0.5MG	A212019	001	Dec 12, 2019	Jun	CTEC
AB		1MG	A212019	002	Dec 12, 2019	Jun	CTEC
AB		2MG	A212019	003	Dec 12, 2019	Jun	CTEC

BUPIVACAINE

INJECTABLE, LIPOSOMAL; INJECTION
BUPIVACAINE LIPOSOME

AP	HENGRUI PHARMA	133MG/10ML (13.3MG/ML)	A214348	001	Jul 01, 2024	Jun	NFTG
AP		266MG/20ML (13.3MG/ML)	A214348	002	Jul 01, 2024	Jun	NFTG
	EXPAREL						
AP	+! PACIRA PHARMS INC	133MG/10ML (13.3MG/ML)	N022496	001	Oct 28, 2011	Jun	CFTG
AP	+!	266MG/20ML (13.3MG/ML)	N022496	002	Oct 28, 2011	Jun	CFTG

>D> SOLUTION; INFILTRATION

>D> POSIMIR

>D>	+! INNOCOLL	660MG/5ML (132MG/ML)	N204803	001	Feb 01, 2021	Nov	DISC
>A>	+ @	660MG/5ML (132MG/ML)	N204803	001	Feb 01, 2021	Nov	DISC
	+!	660MG/5ML (132MG/ML)	N204803	001	Feb 01, 2021	Aug	CDFR

BUPIVACAINE HYDROCHLORIDE

>D> IMPLANT; IMPLANTATION

>D> XARACOLL

>D>	+! INNOCOLL PHARMS	100MG	N209511	001	Aug 28, 2020	Nov	DISC
>A>	+ @	100MG	N209511	001	Aug 28, 2020	Nov	DISC

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

AP	ASPIRO	0.25%	A217821	001	Mar 27, 2024	Mar	NEWA
AP		0.5%	A217821	002	Mar 27, 2024	Mar	NEWA
AP		0.75%	A217821	003	Mar 27, 2024	Mar	NEWA
AP	MEITHEAL	0.25%	A216039	001	Jun 23, 2023	Jun	CAHN
AP		0.25%	A216040	001	Dec 27, 2023	Jun	CAHN
AP		0.5%	A216039	002	Jun 23, 2023	Jun	CAHN
AP		0.5%	A216040	002	Dec 27, 2023	Jun	CAHN
AP		0.75%	A216040	003	Dec 27, 2023	Jun	CAHN

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

VIVACAINE

!	SEPTODONT	0.5%; 0.0091MG/ML	A077250	001	Sep 27, 2006	Jan	CTNA
---	-----------	-------------------	---------	-----	--------------	-----	------

BUPRENORPHINE

FILM, EXTENDED RELEASE; TRANSDERMAL

BUPRENORPHINE

AB	DIFGEN PHARMS	5MCG/HR	A210272	001	Sep 23, 2021	Sep	CAHN
AB		7.5MCG/HR	A210272	002	Sep 23, 2021	Sep	CAHN
AB		10MCG/HR	A210272	003	Sep 23, 2021	Sep	CAHN
AB		15MCG/HR	A210272	004	Sep 23, 2021	Sep	CAHN
AB		20MCG/HR	A210272	005	Sep 23, 2021	Sep	CAHN

BUPRENORPHINE HYDROCHLORIDE

IMPLANT; IMPLANTATION

PROBUPHINE

+ @	REACX PHARMS	EQ 80MG BASE/IMPLANT	N204442	001	May 26, 2016	Apr	CAHN
-----	--------------	----------------------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

BUPRENORPHINE HYDROCHLORIDE

@	AM REGENT	EQ 0.3MG BASE/ML	A078331	001	Mar 27, 2007	Jan	DISC
---	-----------	------------------	---------	-----	--------------	-----	------

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

@	NORVIUM BIOSCIENCE	EQ 2MG BASE	A201066	001	Mar 06, 2015	Jun	CAHN
---	--------------------	-------------	---------	-----	--------------	-----	------

@		EQ 8MG BASE	A201066	002	Mar 06, 2015	Jun	CAHN
---	--	-------------	---------	-----	--------------	-----	------

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM; BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	DIFGEN PHARMS	EQ 8MG BASE; EQ 2MG BASE	A212756	001	Jun 02, 2022	Sep	CAHN
AB		EQ 12MG BASE; EQ 3MG BASE	A212756	002	Jun 02, 2022	Sep	CAHN

BUPROPION HYDROCHLORIDE

TABLET; ORAL						
BUPROPION HYDROCHLORIDE						
AB	AUROBINDO PHARMA USA	75MG	A 075491	001	Apr 17, 2000	Apr CMFD
AB		100MG	A 075491	002	Apr 17, 2000	Apr CMFD
	@ INVAGEN PHARMS	75MG	A 207389	001	Sep 18, 2017	Mar DISC
	@	100MG	A 207389	002	Sep 18, 2017	Mar DISC
TABLET, EXTENDED RELEASE; ORAL						
BUPROPION HYDROCHLORIDE						
	@ ANCHEN PHARMS	100MG	A 091459	001	Jun 09, 2011	Feb DISC
	@	150MG	A 091459	002	Jun 09, 2011	Feb DISC
	@	150MG	A 091520	001	Jun 09, 2011	Feb DISC
	@	200MG	A 091459	003	Jun 09, 2011	Feb DISC
	@ ENDO OPERATIONS	100MG	A 091459	001	Jun 09, 2011	May CAHN
	@	150MG	A 077284	001	Dec 14, 2006	May CAHN
	@	150MG	A 091459	002	Jun 09, 2011	May CAHN
	@	150MG	A 091520	001	Jun 09, 2011	May CAHN
	@	200MG	A 091459	003	Jun 09, 2011	May CAHN
	@	300MG	A 077284	002	Dec 14, 2006	May CAHN
AB1	GRANULES	100MG	A 218385	001	Oct 17, 2024	Oct NEWA
AB1		150MG	A 218385	002	Oct 17, 2024	Oct NEWA
AB1		200MG	A 218385	003	Oct 17, 2024	Oct NEWA
	@ INVAGEN PHARMS	100MG	A 206674	001	Feb 09, 2016	Mar DISC
	@	150MG	A 206556	001	Aug 26, 2016	Mar DISC
	@	150MG	A 206674	002	Feb 09, 2016	Mar DISC
	@	200MG	A 206674	003	Feb 09, 2016	Mar DISC
	@	300MG	A 206556	002	Aug 26, 2016	Mar DISC
	@ RISING	150MG	A 090941	001	May 03, 2010	Feb CAHN
	@ SUN PHARM	150MG	A 078866	002	Apr 06, 2010	Jul DISC
	@	200MG	A 078866	003	Apr 06, 2010	May DISC
AB3	TWI PHARMS	150MG	A 210081	001	Nov 03, 2017	Mar CAHN
AB3		300MG	A 210081	002	Nov 03, 2017	Mar CAHN

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL						
BUSPIRONE HYDROCHLORIDE						
AB	AIPING PHARM INC	5MG	A 202087	001	Dec 16, 2015	Jan CAHN
AB		10MG	A 202087	002	Dec 16, 2015	Jan CAHN
AB		15MG	A 202087	003	Dec 16, 2015	Jan CAHN
AB		30MG	A 202087	004	Dec 16, 2015	Jan CAHN
	@ AMNEAL PHARMS CO	5MG	A 208829	001	May 24, 2017	Mar DISC
	@	7.5MG	A 208829	002	May 24, 2017	Mar DISC
	@	10MG	A 208829	003	May 24, 2017	Mar DISC
	@	15MG	A 208829	004	May 24, 2017	Mar DISC
	@	30MG	A 208829	005	May 24, 2017	Mar DISC

BUSULFAN

INJECTABLE; INJECTION						
BUSULFAN						
AP	EUGIA PHARMA	6MG/ML	A 215102	001	Jun 25, 2024	Jun NEWA
	@ NORVIUM BIOSCIENCE	6MG/ML	A 205184	001	Jul 13, 2018	Jun CAHN
AP	PRINSTON INC	6MG/ML	A 215235	001	Sep 11, 2024	Aug NEWA

BUTABARBITAL SODIUM

TABLET; ORAL						
BUTISOL SODIUM						
	@ NORVIUM BIOSCIENCE	15MG	N 000793	002		Jun CAHN
+	@	30MG	N 000793	004		Jun CAHN
	@	50MG	N 000793	003		Jun CAHN
	@	100MG	N 000793	005		Jun CAHN

CABAZITAXEL

SOLUTION; INTRAVENOUS						
CABAZITAXEL						
+	@ ACCORD HLTHCARE	60MG/3ML (20MG/ML)	N 207949	001	Dec 29, 2021	Jun DISC
+	@ ACTAVIS	60MG/6ML (10MG/ML)	N 207970	001	Mar 14, 2024	Sep DISC
+	!	60MG/6ML (10MG/ML)	N 207970	001	Mar 14, 2024	Mar NEWA

CABERGOLINE

TABLET; ORAL		CABERGOLINE							
	@ NORVIUM BIOSCIENCE	0.5MG	A202947	001	Dec 02, 2013	Jun	CAHN		
AB	SKG PHARMA	0.5MG	A218618	001	Jun 26, 2024	Jun	NEWA		
AB	SOMERSET THERAPS LLC	0.5MG	A218109	001	Sep 09, 2024	Oct	CAHN		
AB	WELDING	0.5MG	A218109	001	Sep 09, 2024	Aug	NEWA		

CAFFEINE; ERGOTAMINE TARTRATE

TABLET; ORAL		CAFERGOT							
>A>	+ @ CHARTWELL RX	100MG;1MG	A084294	001		Nov	CAHN		
>D>	+ @ SANDOZ	100MG;1MG	A084294	001		Nov	CAHN		

CALCIPOTRIENE

SOLUTION; TOPICAL		CALCIPOTRIENE							
	@ HIKMA	0.005%	A077579	001	Nov 19, 2009	Mar	DISC		

CALCITONIN SALMON

INJECTABLE; INJECTION		CALCITONIN-SALMON							
AP	CIPLA	200 IU/ML	A213766	001	Sep 20, 2024	Sep	NEWA		
AP	DR REDDYS	200 IU/ML	A215715	001	Apr 11, 2024	Apr	NEWA		
>A> AP	FRESENIUS KABI USA	200 IU/ML	A212675	001	Dec 05, 2024	Nov	NEWA		
SPRAY, METERED; NASAL		CALCITONIN-SALMON							
AB	! APOTEX INC	200 IU/SPRAY	A076396	001	Nov 17, 2008	Jul	CTEC		
AB	ENDO OPERATIONS	200 IU/SPRAY	A076979	001	Jun 08, 2009	Jul	CMFD		
	@ MIACALCIN	200 IU/SPRAY	A076979	001	Jun 08, 2009	May	CAHN		
	+ @ NORVIUM BIOSCIENCE	200 IU/SPRAY	N020313	002	Aug 17, 1995	Jul	CAHN		

CALCITRIOL

CAPSULE; ORAL		CALCITRIOL							
	@ SUN PHARM	0.25MCG	A204556	001	Feb 21, 2019	Oct	DISC		
	@ ROCALTROL	0.5MCG	A204556	002	Feb 21, 2019	Oct	DISC		
AB	+ ESJAY PHARMA	0.25MCG	N018044	001		Oct	CAHN		
AB	+ ROCALTROL	0.5MCG	N018044	002		Oct	CAHN		
SOLUTION; ORAL		CALCITRIOL							
AA	ANDA REPOSITORY	1MCG/ML	A203973	001	Jul 28, 2023	Sep	CAHN		
SOLUTION; ORAL		ROCALTROL							
AA	+! ESJAY PHARMA	1MCG/ML	N021068	001	Nov 20, 1998	Oct	CAHN		

CALCIUM ACETATE

CAPSULE; ORAL		CALCIUM ACETATE							
AB	! INVAGEN PHARMS	667MG	A203135	001	Feb 07, 2013	Apr	CHRS		
	+ @ PHOSLO GELCAPS	667MG	N021160	003	Apr 02, 2001	Apr	DISC		

CALCIUM CHLORIDE

INJECTABLE; INJECTION		CALCIUM CHLORIDE							
>D>	AP AMNEAL	100MG/ML	A217524	001	Jul 08, 2024	Nov	CMS1		
	AP AMNEAL	100MG/ML	A217524	001	Jul 08, 2024	Jun	NEWA		
	CALCIUM CHLORIDE 10%								
>A>	AP AMNEAL	100MG/ML	A217524	001	Jul 08, 2024	Nov	CMS1		
>A>	AP EXTROVIS	100MG/ML	A219342	001	Nov 27, 2024	Nov	NEWA		

CALCIUM GLUCONATE

SOLUTION; INTRAVENOUS		CALCIUM GLUCONATE							
AP	AMNEAL	1GM/10ML (100MG/ML)	A216611	001	May 10, 2024	May	NEWA		
AP	AMNEAL	5GM/50ML (100MG/ML)	A216611	002	May 10, 2024	May	NEWA		
AP	AMNEAL	10GM/100ML (100MG/ML)	A216611	003	May 10, 2024	May	NEWA		
AP	NIVAGEN PHARMS INC	10GM/100ML (100MG/ML)	A213071	003	Apr 30, 2024	Apr	NEWA		

CAPECITABINE

TABLET; ORAL

CAPECITABINE

AB	HETERO LABS LTD V	150MG	A210203	001	Mar 05, 2024	Feb	NEWA
AB		500MG	A210203	002	Mar 05, 2024	Feb	NEWA
	@ HIKMA	150MG	A200483	001	Jul 14, 2016	Sep	DISC
	@	500MG	A200483	002	Jul 14, 2016	Sep	DISC
>D>	AB	SUN PHARM	A204668	001	Jun 21, 2019	Nov	DISC
>A>		150MG	A204668	001	Jun 21, 2019	Nov	DISC
>D>	AB		A204668	002	Jun 21, 2019	Nov	DISC
>A>		500MG	A204668	002	Jun 21, 2019	Nov	DISC

CAPREOMYCIN SULFATE

INJECTABLE; INJECTION

CAPREOMYCIN SULFATE

@ NORVIUM BIOSCIENCE EQ 1GM BASE/VIAL

A202634	001	Nov 27, 2017	Jun	CAHN
---------	-----	--------------	-----	------

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

AB	ANDAS 5 HOLDING	12.5MG	A074677	004	May 30, 1997	Aug	CAHN
AB		25MG	A074677	002	May 30, 1997	Aug	CAHN
AB		50MG	A074677	001	May 30, 1997	Aug	CAHN
AB		100MG	A074677	003	May 30, 1997	Aug	CAHN
AB	INNOGENIX	12.5MG	A074677	004	May 30, 1997	Mar	CAHN
AB		25MG	A074677	002	May 30, 1997	Mar	CAHN
AB		50MG	A074677	001	May 30, 1997	Mar	CAHN
AB		100MG	A074677	003	May 30, 1997	Mar	CAHN
AB	STASON PHARMS	12.5MG	A074677	004	May 30, 1997	Feb	CAHN
AB		25MG	A074677	002	May 30, 1997	Feb	CAHN
AB		50MG	A074677	001	May 30, 1997	Feb	CAHN
AB		100MG	A074677	003	May 30, 1997	Feb	CAHN

CARBAMAZEPINE

TABLET; ORAL

CARBAMAZEPINE

AB	BIONPHARMA	200MG	A218221	001	Feb 16, 2024	Feb	NEWA
BX	UMEDICA	100MG	A207798	001	Apr 15, 2020	Jun	CTEC
BX		200MG	A207798	002	Apr 15, 2020	Jun	CTEC

TABLET, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

	@ AMNEAL PHARMS	100MG	A212704	001	Sep 22, 2023	Feb	DISC
	@	200MG	A212704	002	Sep 22, 2023	Feb	DISC
	@	400MG	A212704	003	Sep 22, 2023	Feb	DISC
	@ APOTEX	100MG	A213159	001	Mar 08, 2024	May	DISC
AB		100MG	A213159	001	Mar 08, 2024	Mar	NEWA
	@	200MG	A213159	002	Mar 08, 2024	May	DISC
AB		200MG	A213159	002	Mar 08, 2024	Mar	NEWA
	@	400MG	A213159	003	Mar 08, 2024	May	DISC
AB		400MG	A213159	003	Mar 08, 2024	Mar	NEWA
AB	EPIC PHARMA LLC	100MG	A216235	001	Mar 02, 2023	Sep	CAHN
AB		200MG	A216235	002	Mar 02, 2023	Sep	CAHN
AB		400MG	A216235	003	Mar 02, 2023	Sep	CAHN
AB	NOVAST LABS	100MG	A216404	001	Dec 02, 2022	Sep	CAHN
AB		200MG	A216404	002	Dec 02, 2022	Sep	CAHN
AB		400MG	A216404	003	Dec 02, 2022	Sep	CAHN
AB	OSMOTICA PHARM US	100MG	A215664	001	Oct 22, 2024	Oct	NEWA
AB		200MG	A215664	002	Oct 22, 2024	Oct	NEWA
AB		400MG	A215664	003	Oct 22, 2024	Oct	NEWA

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

@ NORVIUM BIOSCIENCE 12.5MG; 200MG; 50MG
 @ 18.75MG; 200MG; 75MG
 @ 25MG; 200MG; 100MG
 @ 31.25MG; 200MG; 125MG
 @ 37.5MG; 200MG; 150MG
 @ 50MG; 200MG; 200MG

A203424	001	Aug 13, 2020	Jun	CAHN
A203424	002	Aug 13, 2020	Jun	CAHN
A203424	003	Aug 13, 2020	Jun	CAHN
A203424	004	Aug 13, 2020	Jun	CAHN
A203424	005	Aug 13, 2020	Jun	CAHN
A203424	006	Aug 13, 2020	Jun	CAHN

CARBIDOPA; LEVODOPA

CAPSULE, EXTENDED RELEASE;ORAL
CREXONT

	+	IMPAX	35MG;140MG	N217186	001	Aug 07, 2024	Aug	NEWA
	+		52.5MG;210MG	N217186	002	Aug 07, 2024	Aug	NEWA
	+		70MG;280MG	N217186	003	Aug 07, 2024	Aug	NEWA
	+	!	87.5MG;350MG	N217186	004	Aug 07, 2024	Aug	NEWA

RYTARY

	+	IMPAX	23.75MG;95MG	N203312	001	Jan 07, 2015	May	CAHN
	+		36.25MG;145MG	N203312	002	Jan 07, 2015	May	CAHN
	+		48.75MG;195MG	N203312	003	Jan 07, 2015	May	CAHN
	+	!	61.25MG;245MG	N203312	004	Jan 07, 2015	May	CAHN

TABLET, EXTENDED RELEASE;ORAL

CARBIDOPA AND LEVODOPA

AB		RUBICON	25MG;100MG	A217482	001	Jun 04, 2024	May	NEWA
AB			50MG;200MG	A217482	002	Jun 04, 2024	May	NEWA

CARBINOXAMINE MALEATE

SOLUTION;ORAL

CARBINOXAMINE MALEATE

	@	ENDO OPERATIONS	4MG/5ML	A040814	001	Feb 26, 2008	May	CAHN
--	---	-----------------	---------	---------	-----	--------------	-----	------

TABLET;ORAL

CARBINOXAMINE MALEATE

	@	INVAGEN PHARMS	4MG	A090435	001	Apr 15, 2010	Mar	DISC
--	---	----------------	-----	---------	-----	--------------	-----	------

CARBOPLATIN

INJECTABLE;INTRAVENOUS

CARBOPLATIN

	@	NORVIUM BIOSCIENCE	50MG/5ML (10MG/ML)	A077998	001	Apr 24, 2007	Jul	CAHN
	@		150MG/15ML (10MG/ML)	A077998	002	Apr 24, 2007	Jul	CAHN
	@		450MG/45ML (10MG/ML)	A077998	003	Apr 24, 2007	Jul	CAHN

CARBOPROST TROMETHAMINE

INJECTABLE;INJECTION

CARBOPROST TROMETHAMINE

	@	ANI PHARMS	EQ 0.25MG BASE/ML	A215901	001	Jan 25, 2024	Jul	DISC
AP			EQ 0.25MG BASE/ML	A215901	001	Jan 25, 2024	Jan	NEWA
AP		MICRO LABS	EQ 0.25MG BASE/ML	A218013	001	Apr 03, 2024	Mar	NEWA
AP		STERISCIENCE SPECLTS	EQ 0.25MG BASE/ML	A216897	001	Jul 25, 2023	Aug	CAHN

CARISOPRODOL

TABLET;ORAL

CARISOPRODOL

	@	ALLIED	350MG	A211789	001	Oct 20, 2021	Aug	CAHN
AB		CHARTWELL RX	250MG	A205126	001	Jul 08, 2015	Sep	CAHN
AA			350MG	A205126	002	Jul 08, 2015	Sep	CAHN
	@	MLV	350MG	A211789	001	Oct 20, 2021	Jul	DISC

CARMUSTINE

INJECTABLE;INJECTION

CARMUSTINE

	@	NORVIUM BIOSCIENCE	100MG/VIAL	A215368	001	Mar 03, 2023	Jun	CAHN
--	---	--------------------	------------	---------	-----	--------------	-----	------

POWDER;INTRAVENOUS

CARMUSTINE

	+	@	ACCORD HLTHCARE	50MG/VIAL	N215000	001	May 16, 2022	May	DISC
	+	@		300MG/VIAL	N215000	002	May 16, 2022	May	DISC

CARVEDILOL

TABLET;ORAL

CARVEDILOL

>D>		@	MLV	3.125MG	A078786	001	Dec 22, 2009	Nov	CMFD
>A>	AB			3.125MG	A078786	001	Dec 22, 2009	Nov	CMFD
		@		3.125MG	A078786	001	Dec 22, 2009	Aug	CAHN
>D>		@		6.25MG	A078786	002	Dec 22, 2009	Nov	CMFD
>A>	AB			6.25MG	A078786	002	Dec 22, 2009	Nov	CMFD
		@		6.25MG	A078786	002	Dec 22, 2009	Aug	CAHN
>D>		@		12.5MG	A078786	003	Dec 22, 2009	Nov	CMFD
>A>	AB			12.5MG	A078786	003	Dec 22, 2009	Nov	CMFD
		@		12.5MG	A078786	003	Dec 22, 2009	Aug	CAHN
>D>		@		25MG	A078786	004	Dec 22, 2009	Nov	CMFD
>A>	AB			25MG	A078786	004	Dec 22, 2009	Nov	CMFD

TABLET; ORAL

		CARVEDILOL							
	@		25MG	A078786	004	Dec 22, 2009	Aug	CAHN	
	@	MYLAN	3.125MG	A077316	001	Sep 05, 2007	Apr	DISC	
	@	SUN PHARM INDS LTD	3.125MG	A076989	001	Sep 05, 2007	Jan	DISC	
	@		6.25MG	A076989	002	Sep 05, 2007	Jan	DISC	
	@		12.5MG	A076989	003	Sep 05, 2007	Jan	DISC	
	@		25MG	A076989	004	Sep 05, 2007	Jan	DISC	
		COREG							
AB	+	WAYLIS THERAP	3.125MG	N020297	004	May 29, 1997	Apr	CAHN	
AB	+		6.25MG	N020297	003	Sep 14, 1995	Apr	CAHN	
AB	+		12.5MG	N020297	002	Sep 14, 1995	Apr	CAHN	
AB	+		25MG	N020297	001	Sep 14, 1995	Apr	CAHN	

CASPOFUNGIN ACETATE

		POWDER; INTRAVENOUS							
		CASPOFUNGIN ACETATE							
AP		AREVA PHARMS	50MG/VIAL	A211263	001	Oct 01, 2021	Mar	CAHN	
AP			70MG/VIAL	A211263	002	Oct 01, 2021	Mar	CAHN	

CEFAZOLIN SODIUM

		INJECTABLE; INJECTION							
		CEFAZOLIN SODIUM							
		QILU	EQ 3GM BASE/VIAL	A203661	003	Jan 24, 2024	Jan	NEWA	
		SOLUTION; INTRAVENOUS							
		CEFAZOLIN IN DEXTROSE							
+	!	BAXTER HLTHCARE CORP	EQ 1GM BASE/50ML (EQ 20MG BASE/ML)	N207131	002	Feb 01, 2021	May	CTNA	
+	!		EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131	001	Aug 07, 2015	May	CTNA	
+	!		EQ 3GM BASE/150ML (EQ 20MG BASE/ML)	N207131	003	May 31, 2024	May	NEWA	

CEFDINIR

		CAPSULE; ORAL							
		CEFDINIR							
>A>	AB	!	CHARTWELL RX	300MG	A065330	001	Apr 06, 2007	Nov	CAHN
>D>	AB	!	SANDOZ	300MG	A065330	001	Apr 06, 2007	Nov	CAHN
		FOR SUSPENSION; ORAL							
		CEFDINIR							
>A>	AB		CHARTWELL RX	125MG/5ML	A065337	001	Apr 06, 2007	Nov	CAHN
>A>	AB			250MG/5ML	A065337	002	Apr 06, 2007	Nov	CAHN
>D>	AB		SANDOZ	125MG/5ML	A065337	001	Apr 06, 2007	Nov	CAHN
>D>	AB			250MG/5ML	A065337	002	Apr 06, 2007	Nov	CAHN

CEFEPIME HYDROCHLORIDE

		INJECTABLE; INJECTION							
		CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER							
+	!	B BRAUN	EQ 1GM BASE/VIAL	N050821	001	May 06, 2010	Jul	CHRS	
+			EQ 1GM BASE/VIAL	N050821	001	May 06, 2010	Jul	CRLD	
+	!		EQ 2GM BASE/VIAL	N050821	002	May 06, 2010	Jul	CHRS	
+			EQ 2GM BASE/VIAL	N050821	002	May 06, 2010	Jul	CRLD	
		CEFEPIME HYDROCHLORIDE							
	@	CHARTWELL RX	EQ 500MG BASE/VIAL	A090291	001	Dec 21, 2010	Jun	CAHN	
	@		EQ 1GM BASE/VIAL	A090291	002	Dec 21, 2010	Jun	CAHN	
	@		EQ 2GM BASE/VIAL	A090291	003	Dec 21, 2010	Jun	CAHN	
AP		HIKMA	EQ 1GM BASE/VIAL	A214402	001	May 22, 2024	May	NEWA	
AP			EQ 2GM BASE/VIAL	A214402	002	May 22, 2024	May	NEWA	
		POWDER; INTRAVENOUS							
		CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER							
	!	SAMSON MEDCL	EQ 100GM BASE	A209408	001	Aug 21, 2018	Apr	CHRS	

CEFEPIME HYDROCHLORIDE; ENMETAZOBACTAM

		POWDER; INTRAVENOUS							
		EXBLIFEP							
+	@	ALLECRA THERAPS	EQ 2GM BASE/VIAL; 0.5GM/VIAL	N216165	001	Feb 22, 2024	May	DISC	
+	!		EQ 2GM BASE/VIAL; 0.5GM/VIAL	N216165	001	Feb 22, 2024	Feb	NEWA	

CEFIXIME

FOR SUSPENSION; ORAL

CEFIXIME

@	CHARTWELL RX	100MG/5ML	A206144	001	Nov 17, 2017	Jul	CAHN
@		200MG/5ML	A206144	002	Nov 17, 2017	Jul	CAHN

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CLAFORAN

+	@	STERIMAX	EQ 500MG BASE/VIAL	N050547	001		Jan	CAHN
+	@		EQ 1GM BASE/VIAL	N050547	002		Jan	CAHN
+	@		EQ 2GM BASE/VIAL	N050547	003		Jan	CAHN
+	@		EQ 10GM BASE/VIAL	N050547	004	Dec 29, 1983	Jan	CAHN
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER								
@		STERIMAX	EQ 20MG BASE/ML	N050596	002	May 20, 1985	Jan	CAHN
@			EQ 40MG BASE/ML	N050596	004	May 20, 1985	Jan	CAHN
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER								
@		STERIMAX	EQ 20MG BASE/ML	N050596	001	May 20, 1985	Jan	CAHN
@			EQ 40MG BASE/ML	N050596	003	May 20, 1985	Jan	CAHN

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTAN

AP	+	PAI HOLDINGS PHARM	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Feb	CMFD
AP	+		EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Feb	CMFD
CEFOTETAN								
AP	!	FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A065374	001	Aug 09, 2007	Feb	CTEC
AP	!		EQ 2GM BASE/VIAL	A065374	002	Aug 09, 2007	Feb	CTEC

CEFOXITIN SODIUM

INJECTABLE; INJECTION

MEFOXIN

@		NORVIUM BIOSCIENCE	EQ 1GM BASE/VIAL	A062757	001	Jan 08, 1987	Jul	CAHN
+	@		EQ 1GM BASE/VIAL	N050517	001		Jul	CAHN
	@		EQ 2GM BASE/VIAL	A062757	002	Jan 08, 1987	Jul	CAHN
+	@		EQ 2GM BASE/VIAL	N050517	002		Jul	CAHN
+	@		EQ 10GM BASE/VIAL	N050517	003		Jul	CAHN
MEFOXIN IN PLASTIC CONTAINER								
@		NORVIUM BIOSCIENCE	EQ 20MG BASE/ML	A063182	001	Jan 25, 1993	Jul	CAHN
@			EQ 40MG BASE/ML	A063182	002	Jan 25, 1993	Jul	CAHN

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

CEFPODOXIME PROXETIL

@	CHARTWELL RX	EQ 50MG BASE/5ML	A090031	001	Jan 14, 2009	Jul	CAHN
@		EQ 100MG BASE/5ML	A090031	002	Jan 14, 2009	Jul	CAHN

CEFPROZIL

TABLET; ORAL

CEFPROZIL

AB		ALKEM LABS LTD	250MG	A090857	001	Apr 09, 2024	Mar	NEWA
AB			500MG	A090857	002	Apr 09, 2024	Mar	NEWA

CEFTOBIPROLE MEDOCARIL SODIUM

POWDER; INTRAVENOUS

ZEVTERA

+	@	BASILEA PHARM ALLSCH	667MG/VIAL	N218275	001	Apr 03, 2024	Aug	DISC
+	!		667MG/VIAL	N218275	001	Apr 03, 2024	Apr	NEWA

CEFTRIAZONE SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFTRIAZONE

@		DEVA HOLDING AS	EQ 250MG BASE/VIAL	A210197	001	Jan 12, 2024	Jul	DISC
AP			EQ 250MG BASE/VIAL	A210197	001	Jan 12, 2024	Jan	NEWA
	@		EQ 500MG BASE/VIAL	A210197	002	Jan 12, 2024	Jul	DISC
AP			EQ 500MG BASE/VIAL	A210197	002	Jan 12, 2024	Jan	NEWA
	@		EQ 1GM BASE/VIAL	A210197	003	Jan 12, 2024	Jul	DISC
AP			EQ 1GM BASE/VIAL	A210197	003	Jan 12, 2024	Jan	NEWA
	@		EQ 2GM BASE/VIAL	A210197	004	Jan 12, 2024	Jul	DISC
AP			EQ 2GM BASE/VIAL	A210197	004	Jan 12, 2024	Jan	NEWA

CELECOXIB

CAPSULE;ORAL

CELECOXIB

>D>	BX	AMNEAL PHARMS	50MG	A208833	001	May 31, 2018	Nov	DISC
>A>	@		50MG	A208833	001	May 31, 2018	Nov	DISC
>D>	BX		100MG	A208833	002	May 31, 2018	Nov	DISC
>A>	@		100MG	A208833	002	May 31, 2018	Nov	DISC
>D>	BX		200MG	A208833	003	May 31, 2018	Nov	DISC
>A>	@		200MG	A208833	003	May 31, 2018	Nov	DISC
>D>	BX		400MG	A208833	004	May 31, 2018	Nov	DISC
>A>	@		400MG	A208833	004	May 31, 2018	Nov	DISC

SOLUTION;ORAL

ELYXYB

+	!	SCILEX PHARMS	25MG/ML	N212157	001	May 05, 2020	Jun	CAHN
---	---	---------------	---------	---------	-----	--------------	-----	------

CELECOXIB; TRAMADOL HYDROCHLORIDE

TABLET;ORAL

SEGLENTIS

+	@	KOWA PHARMS	56MG;44MG	N213426	001	Oct 15, 2021	Oct	DISC
---	---	-------------	-----------	---------	-----	--------------	-----	------

CEPHALEXIN

TABLET;ORAL

CEPHALEXIN

AB		ALKEM LABS LTD	EQ 250MG BASE	A218947	001	Sep 27, 2024	Sep	NEWA
AB			EQ 500MG BASE	A218947	002	Sep 27, 2024	Sep	NEWA
AB		AUROBINDO PHARMA LTD	EQ 250MG BASE	A218817	001	Sep 27, 2024	Sep	NEWA
AB			EQ 500MG BASE	A218817	002	Sep 27, 2024	Sep	NEWA
		KEFLET						
+	@	LILLY	EQ 250MG BASE	N050440	003	Feb 26, 1987	Sep	CRLD
+	@		EQ 500MG BASE	N050440	001		Sep	CRLD

CETIRIZINE HYDROCHLORIDE

SOLUTION;ORAL

CETIRIZINE HYDROCHLORIDE

	@	ACTAVIS MID ATLANTIC	5MG/5ML	A078617	001	Feb 02, 2010	Feb	CDFR
AA		AMNEAL PHARMS	5MG/5ML	A090766	001	Oct 07, 2009	Feb	CDFR
AA		APOZEAL PHARMS	5MG/5ML	A078870	001	Apr 27, 2009	Jul	CMFD
	@		5MG/5ML	A078870	001	Apr 27, 2009	Feb	CDFR
	@	AUROBINDO PHARMA LTD	5MG/5ML	A090751	001	Dec 16, 2009	Feb	CDFR
AA		BAJAJ	5MG/5ML	A090191	001	Nov 12, 2009	Feb	CDFR
AA		CHARTWELL MOLECULAR	5MG/5ML	A078876	001	May 11, 2012	Feb	CDFR
	@	LANNETT CO INC	5MG/5ML	A078496	001	Sep 25, 2009	Feb	CDFR
AA	!	PADAGIS US	5MG/5ML	A078398	001	Jun 17, 2008	Feb	CDFR
AA		PHARM ASSOC	5MG/5ML	A078412	001	Jun 18, 2008	Feb	CDFR
	@	RANBAXY LABS LTD	5MG/5ML	A077472	001	Jun 18, 2008	Feb	CDFR
AA		TARO	5MG/5ML	A076601	001	Jun 20, 2008	Feb	CDFR
	@	TEVA PHARMS	5MG/5ML	A077279	001	May 27, 2008	Mar	DISC
AA			5MG/5ML	A077279	001	May 27, 2008	Feb	CDFR
	@	WOCKHARDT	5MG/5ML	A078757	001	Aug 28, 2009	Feb	CDFR
		ZYRTEC						
	@	J AND J CONSUMER INC	5MG/5ML	N020346	001	Sep 27, 1996	Feb	CDFR

SYRUP;ORAL

CETIRIZINE HYDROCHLORIDE

AA		PHARM ASSOC	5MG/5ML	A078412	001	Jun 18, 2008	Jan	CMFD
----	--	-------------	---------	---------	-----	--------------	-----	------

CETRORELIX ACETATE

POWDER;SUBCUTANEOUS

CETRORELIX ACETATE

AP		GLAND	EQ 0.25MG BASE/VIAL	A218150	001	Apr 25, 2024	Apr	NEWA
AP		LIVZON GRP	EQ 0.25MG BASE/VIAL	A214540	001	Apr 24, 2024	Apr	NEWA
AP		QILU	EQ 0.25MG BASE/VIAL	A217776	001	Apr 16, 2024	Apr	NEWA

CEVIMELINE HYDROCHLORIDE

CAPSULE;ORAL

CEVIMELINE HYDROCHLORIDE

AB		MACLEODS PHARMS LTD	30MG	A206808	001	Sep 20, 2024	Sep	NEWA
----	--	---------------------	------	---------	-----	--------------	-----	------

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

CHLORAMPHENICOL SODIUM SUCCINATE

@ FRESENIUS KABI USA EQ 1GM BASE/VIAL

A062365 001 Aug 25, 1982 Feb DISC

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE

AB WINDER LABS LLC 5MG; 2.5MG

A212344 001 Jul 08, 2024 Jun NEWA

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

@ SAPTALIS PHARMS 0.12%

A074356 001 May 07, 1996 Jun CAHN

@ SCIEGEN PHARMS INC 0.12%

A074356 001 May 07, 1996 Aug CAHN

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

NESACAINE

+ @ FRESENIUS KABI USA 1%

N009435 001 Oct DISC

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION

CHLOROTHIAZIDE SODIUM

AP GLAND PHARMA LTD EQ 500MG BASE/VIAL

A218630 001 Oct 03, 2024 Sep NEWA

@ RK PHARMA EQ 500MG BASE/VIAL

A202493 001 Jun 18, 2014 Mar DISC

>D> AP SUN PHARM EQ 500MG BASE/VIAL

A091546 001 Jul 26, 2011 Nov DISC

>A> @ EQ 500MG BASE/VIAL

A091546 001 Jul 26, 2011 Nov DISC

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@ SCIEGEN PHARMS INC 4MG/5ML; 5MG/5ML; 60MG/5ML

A206660 001 May 15, 2017 Sep CAHN

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLORPROMAZINE HYDROCHLORIDE

>A> AP ASPIRO 25MG/ML

A218272 001 Nov 18, 2024 Nov NEWA

AP DEVA HLDING 25MG/ML

A218229 001 Sep 24, 2024 Sep NEWA

AP DR REDDYS 25MG/ML

A080365 001 Apr CMFD

AP GLAND PHARMA LTD 25MG/ML

A216911 001 Oct 04, 2024 Sep NEWA

AP +! HIKMA 25MG/ML

A083329 001 Jun CAHN

>A> AP THINQ PHARM-CRO PVT 25MG/ML

A216724 001 Dec 10, 2024 Nov NEWA

AP ZYDUS PHARMS 25MG/ML

A217275 001 Mar 13, 2024 Mar NEWA

SYRUP; ORAL

SONAZINE

@ CHARTWELL RX 10MG/5ML

A083040 001 May CAHN

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB @ CHARTWELL RX 10MG

A080439 001 Jul CAHN

AB @ 10MG

A212630 001 Nov 29, 2021 Sep CAHN

AB @ 25MG

A080439 002 Jul CAHN

AB @ 25MG

A212630 002 Nov 29, 2021 Sep CAHN

AB @ 50MG

A080439 003 Jul CAHN

AB @ 50MG

A212630 003 Nov 29, 2021 Sep CAHN

AB @ 100MG

A080439 004 Jul CAHN

AB @ 100MG

A212630 004 Nov 29, 2021 Sep CAHN

AB @ 200MG

A080439 005 Jul CAHN

AB @ 200MG

A212630 005 Nov 29, 2021 Sep CAHN

AB ZAMEER PHARMS 10MG

A212630 001 Nov 29, 2021 Feb CAHN

AB 25MG

A212630 002 Nov 29, 2021 Feb CAHN

AB 50MG

A212630 003 Nov 29, 2021 Feb CAHN

AB 100MG

A212630 004 Nov 29, 2021 Feb CAHN

AB 200MG

A212630 005 Nov 29, 2021 Feb CAHN

AB ZYDUS LIFESCIENCES 10MG

A213368 001 Jan 17, 2020 Aug CAHN

AB 25MG

A213368 002 Jan 17, 2020 Aug CAHN

AB 50MG

A213368 003 Jan 17, 2020 Aug CAHN

AB 100MG

A213368 004 Jan 17, 2020 Aug CAHN

AB 200MG

A213368 005 Jan 17, 2020 Aug CAHN

CHLOROTHALIDONE

TABLET; ORAL

CHLOROTHALIDONE

>A>	AB	IPCA LABS LTD	25MG	A209162	001	Nov 12, 2024	Nov	NEWA
>A>	AB		50MG	A209162	002	Nov 12, 2024	Nov	NEWA
	AB	PHARMOBEDIENT	25MG	A212878	001	Feb 24, 2022	Sep	CAHN
	AB		50MG	A212875	001	Feb 24, 2022	Sep	CAHN

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

	@	APTAPHARMA INC	375MG	A212053	001	Sep 14, 2020	Apr	DISC
	@		750MG	A212053	002	Sep 14, 2020	Apr	DISC
	@	CHARTWELL RX	375MG	A212053	001	Sep 14, 2020	Sep	CAHN
	@		750MG	A212053	002	Sep 14, 2020	Sep	CAHN
AB		ENDO OPERATIONS	375MG	A212743	002	Apr 29, 2021	Apr	CAHN
AB			750MG	A212743	001	Nov 02, 2020	Apr	CAHN
AA		HAVIX	500MG	A210961	001	Jan 22, 2024	Jan	NEWA
	@	I3 PHARMS	375MG	A212053	001	Sep 14, 2020	Aug	CAHN
	@		750MG	A212053	002	Sep 14, 2020	Aug	CAHN
AA		RISING	250MG	A216925	001	Aug 09, 2023	Aug	CAHN
AA		SENORES PHARMS	250MG	A215158	001	Jul 29, 2021	Feb	CAHN
AA			500MG	A210961	001	Jan 22, 2024	Feb	CAHN
	@	TEVA PHARMS USA INC	375MG	A212898	001	Jun 17, 2020	Sep	DISC
	@		750MG	A212898	002	Jun 17, 2020	Sep	DISC

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

>A>	AB	MACLEODS PHARMS LTD	EQ 4GM RESIN/PACKET	A207294	001	Nov 21, 2024	Nov	NEWA
>A>	AB		EQ 4GM RESIN/SCOOPFUL	A207294	002	Nov 21, 2024	Nov	NEWA
		CHOLESTYRAMINE LIGHT						
AB		ENDO OPERATIONS	EQ 4GM RESIN/PACKET	A077203	001	Aug 26, 2005	May	CAHN
AB			EQ 4GM RESIN/SCOOPFUL	A077203	002	Aug 26, 2005	May	CAHN
AB		MACLEODS PHARMS LTD	EQ 4GM RESIN/SCOOPFUL	A209109	001	Oct 31, 2024	Oct	NEWA
AB			EQ 4GM RESIN/PACKET	A209109	002	Oct 31, 2024	Oct	NEWA

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID

	@	ANCHEN PHARMS	EQ 45MG FENOFIBRIC ACID	A201573	002	Jul 18, 2013	Mar	DISC
	@		EQ 135MG FENOFIBRIC ACID	A201573	001	Jul 18, 2013	Mar	DISC
	@	ENDO OPERATIONS	EQ 45MG FENOFIBRIC ACID	A201573	002	Jul 18, 2013	May	CAHN
	@		EQ 135MG FENOFIBRIC ACID	A201573	001	Jul 18, 2013	May	CAHN
	@	MACLEODS PHARMS LTD	EQ 45MG FENOFIBRIC ACID	A207796	001	Feb 08, 2024	Aug	DISC
AB			EQ 45MG FENOFIBRIC ACID	A207796	001	Feb 08, 2024	Feb	NEWA
	@		EQ 135MG FENOFIBRIC ACID	A207796	002	Feb 08, 2024	Aug	DISC
AB			EQ 135MG FENOFIBRIC ACID	A207796	002	Feb 08, 2024	Feb	NEWA
AB		RISING	EQ 45MG FENOFIBRIC ACID	A211626	001	Jul 18, 2019	Aug	CAHN
AB			EQ 135MG FENOFIBRIC ACID	A211626	002	Jul 18, 2019	Aug	CAHN
	@	TWI PHARMS	EQ 45MG FENOFIBRIC ACID	A210469	001	Jul 05, 2019	Aug	DISC
AB			EQ 45MG FENOFIBRIC ACID	A210469	001	Jul 05, 2019	Mar	CAHN
	@		EQ 135MG FENOFIBRIC ACID	A210469	002	Jul 05, 2019	Aug	DISC
AB			EQ 135MG FENOFIBRIC ACID	A210469	002	Jul 05, 2019	Mar	CAHN

CHROMIC CHLORIDE

INJECTABLE; INJECTION

CHROMIC CHLORIDE

>A>	AP	STIRA	EQ 0.004MG CHROMIUM/ML	A218538	001	Nov 18, 2024	Nov	NFTG
		CHROMIC CHLORIDE IN PLASTIC CONTAINER						
>D>	+	HOSPIRA	EQ 0.004MG CHROMIUM/ML	N018961	001	Jun 26, 1986	Nov	CFTG
>A>	AP	+	EQ 0.004MG CHROMIUM/ML	N018961	001	Jun 26, 1986	Nov	CFTG

CICLESONIDE

AEROSOL, METERED; NASAL

ZETONNA

	+	@	COVIS	0.037MG/INH	N202129	001	Jan 20, 2012	Aug	DISC
--	---	---	-------	-------------	---------	-----	--------------	-----	------

CICLOPIROX

	CREAM; TOPICAL							
	CICLOPIROX							
AB	TARO	0.77%		A076790	001	Apr 12, 2005	Jan	CAHN
	SOLUTION; TOPICAL							
	CICLOPIROX							
	@ COSETTE	8%		A078233	001	Sep 18, 2007	Jul	DISC
	@ HIKMA	8%		A078270	001	Sep 18, 2007	Mar	DISC

CILOSTAZOL

	TABLET; ORAL							
	CILOSTAZOL							
	@ RISING	50MG		A077323	002	Apr 20, 2006	Feb	CAHN
	@	100MG		A077323	001	Apr 20, 2006	Feb	CAHN

CIMETIDINE

	TABLET; ORAL							
	CIMETIDINE							
>A>	AB AUROBINDO PHARMA LTD	200MG		A218997	001	Nov 12, 2024	Nov	NEWA
>A>	AB	300MG		A218997	002	Nov 12, 2024	Nov	NEWA
>A>	AB	400MG		A218997	003	Nov 12, 2024	Nov	NEWA
>A>	AB	800MG		A218997	004	Nov 12, 2024	Nov	NEWA
>A>	AB BIONPHARMA	200MG		A218220	001	Nov 07, 2024	Nov	NEWA
>A>	AB	300MG		A218220	002	Nov 07, 2024	Nov	NEWA
>A>	AB	400MG		A218220	003	Nov 07, 2024	Nov	NEWA
>A>	AB	800MG		A218220	004	Nov 07, 2024	Nov	NEWA
	AB CHARTWELL MOLECULES	200MG		A074329	002	May 17, 1994	Oct	CMFD
	AB	300MG		A074329	003	May 17, 1994	Oct	CMFD
	AB	400MG		A074329	004	May 17, 1994	Oct	CMFD
	AB	800MG		A074329	001	May 17, 1994	Oct	CMFD

CIMETIDINE HYDROCHLORIDE

	INJECTABLE; INJECTION							
	CIMETIDINE HYDROCHLORIDE							
	@ COSETTE	EQ 300MG BASE/2ML		A074296	001	Mar 28, 1997	Jun	CAHN
	@ ENDO OPERATIONS	EQ 300MG BASE/2ML		A074005	001	Aug 31, 1994	May	CAHN
	@	EQ 300MG BASE/2ML		A074428	001	Apr 25, 1996	May	CAHN
	SOLUTION; ORAL							
	CIMETIDINE HYDROCHLORIDE							
>D>	@ CHARTWELL MOLECULAR	EQ 300MG BASE/5ML		A074251	001	Dec 22, 1994	Nov	CMFD
>A>	AA	EQ 300MG BASE/5ML		A074251	001	Dec 22, 1994	Nov	CMFD
>D>	! PAI HOLDINGS PHARM	EQ 300MG BASE/5ML		A074664	001	Oct 28, 1997	Nov	CTEC
>A>	AA !	EQ 300MG BASE/5ML		A074664	001	Oct 28, 1997	Nov	CTEC
	!	EQ 300MG BASE/5ML		A074664	001	Oct 28, 1997	Sep	CMFD
	@	EQ 300MG BASE/5ML		A074664	001	Oct 28, 1997	Feb	DISC
	@ PHARM ASSOC	EQ 300MG BASE/5ML		A074553	001	Jan 27, 1997	Feb	DISC

CINACALCET HYDROCHLORIDE

	TABLET; ORAL							
	CINACALCET HYDROCHLORIDE							
	@ SUN PHARM	EQ 90MG BASE		A207008	003	Oct 11, 2018	Oct	DISC

CIPROFLOXACIN HYDROCHLORIDE

	SOLUTION/DROPS; OPHTHALMIC							
	CIPROFLOXACIN HYDROCHLORIDE							
	@ THE J MOLNER	EQ 0.3% BASE		A076754	001	Jun 09, 2004	Jun	CAHN
	SOLUTION/DROPS; OTIC							
	CETRAXAL							
AB	+! KEY THERAP	EQ 0.2% BASE		N021918	001	May 01, 2009	Oct	CFTG
	+!	EQ 0.2% BASE		N021918	001	May 01, 2009	Apr	CAHN
	CIPROFLOXACIN HYDROCHLORIDE							
AB	IDENTIRX	EQ 0.2% BASE		A217887	001	Nov 05, 2024	Oct	NFTG
	TABLET; ORAL							
	CIPROFLOXACIN HYDROCHLORIDE							
AB	AIPING PHARM INC	EQ 250MG BASE		A076593	002	Jun 09, 2004	Apr	CMFD
AB		EQ 500MG BASE		A076593	003	Jun 09, 2004	Apr	CMFD
AB		EQ 750MG BASE		A076593	004	Jun 09, 2004	Apr	CMFD

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

		CIPROFLOXACIN EXTENDED RELEASE							
	@ ANCHEN PHARMS	212.6MG;EQ	287.5MG BASE	A 078166	002	Nov 27, 2007	Mar	DISC	
	@	425.2MG;EQ	574.9MG BASE	A 078166	001	Nov 27, 2007	Mar	DISC	
	! DR REDDYS LABS LTD	425.2MG;EQ	574.9MG BASE	A 077701	001	Mar 26, 2007	Mar	CTEC	
AB	!	425.2MG;EQ	574.9MG BASE	A 077701	001	Mar 26, 2007	Mar	CHRS	
	@ ENDO OPERATIONS	212.6MG;EQ	287.5MG BASE	A 078166	002	Nov 27, 2007	May	CAHN	
	@	425.2MG;EQ	574.9MG BASE	A 078166	001	Nov 27, 2007	May	CAHN	

CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS; OTIC

		CIPROFLOXACIN; DEXAMETHASONE							
AB	AMNEAL	0.3%;0.1%		A 216501	001	Mar 22, 2024	Mar	NEWA	

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

		CISATRACURIUM BESYLATE							
AP	HAINAN POLY	EQ 2MG	BASE/ML	A 216538	001	Mar 08, 2024	Mar	NEWA	
AP	! MEITHEAL	EQ 2MG	BASE/ML	A 211668	001	Apr 25, 2019	Apr	CHRS	
AP	!	EQ 2MG	BASE/ML	A 211669	001	Apr 25, 2019	Apr	CHRS	
AP	!	EQ 10MG	BASE/ML	A 211668	002	Apr 25, 2019	Apr	CHRS	
AP	PIRAMAL CRITICAL	EQ 2MG	BASE/ML	A 215516	003	Dec 14, 2022	Mar	CMS1	
		CISATRACURIUM BESYLATE PRESERVATIVE FREE							
AP	HAINAN POLY	EQ 2MG	BASE/ML	A 216539	001	Aug 27, 2024	Aug	NEWA	
AP		EQ 10MG	BASE/ML	A 216539	002	Aug 27, 2024	Aug	NEWA	
		NIMBEX							
	+ @ ABBVIE	EQ 2MG	BASE/ML	N 020551	001	Dec 15, 1995	Apr	DISC	
		NIMBEX PRESERVATIVE FREE							
	+ @ ABBVIE	EQ 2MG	BASE/ML	N 020551	003	Dec 15, 1995	Apr	DISC	
	+ @	EQ 10MG	BASE/ML	N 020551	002	Dec 15, 1995	Apr	DISC	

CISPLATIN

INJECTABLE; INJECTION

		CISPLATIN							
AP	QILU	1MG/ML		A 218868	001	May 10, 2024	May	NEWA	

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

		CITALOPRAM HYDROBROMIDE							
AB	APOTEX	EQ 10MG	BASE	A 077046	001	Nov 24, 2004	Jan	CAHN	
AB		EQ 20MG	BASE	A 077046	002	Nov 24, 2004	Jan	CAHN	
AB		EQ 40MG	BASE	A 077046	003	Nov 24, 2004	Jan	CAHN	
	@ CHARTWELL RX	EQ 10MG	BASE	A 077040	001	Aug 17, 2005	Aug	CAHN	
	@	EQ 20MG	BASE	A 077040	002	Aug 17, 2005	Aug	CAHN	
	@	EQ 40MG	BASE	A 077040	003	Aug 17, 2005	Aug	CAHN	
	@ COSETTE	EQ 10MG	BASE	A 077048	001	Nov 16, 2004	Apr	DISC	
	@	EQ 20MG	BASE	A 077048	002	Nov 16, 2004	Apr	DISC	
	@	EQ 40MG	BASE	A 077048	003	Nov 16, 2004	Apr	DISC	
	@ TARO	EQ 10MG	BASE	A 077278	001	Mar 22, 2006	Jan	CAHN	
	@	EQ 20MG	BASE	A 077278	002	Mar 22, 2006	Jan	CAHN	
	@	EQ 40MG	BASE	A 077278	003	Mar 22, 2006	Jan	CAHN	

CLADRIBINE

INJECTABLE; INJECTION

		CLADRIBINE							
	@ NORVIUM BIOSCIENCE	1MG/ML		A 200510	001	Oct 06, 2011	Jun	CAHN	

CLEMASTINE FUMARATE

SYRUP; ORAL

		CLEMASTINE FUMARATE							
AA	! GENUS	EQ 0.5MG	BASE/5ML	A 073399	001	Jun 30, 1994	Aug	CTEC	
	@ NEW HEIGHTS	EQ 0.5MG	BASE/5ML	A 074884	001	Dec 17, 1997	Jan	CAHN	
AA	NEW HEIGHTSRX	EQ 0.5MG	BASE/5ML	A 074884	001	Dec 17, 1997	Aug	CMFD	
	@	EQ 0.5MG	BASE/5ML	A 074884	001	Dec 17, 1997	Jul	CAHN	

TABLET; ORAL

		CLEMASTINE FUMARATE							
>A>	! GENUS	2.68MG		A 073283	001	Jan 31, 1992	Nov	CAHN	
	@ OMNIVIVUM PHARMS	2.68MG		A 073459	001	Oct 31, 1993	Jun	CAHN	
>D>	! TEVA	2.68MG		A 073283	001	Jan 31, 1992	Nov	CAHN	

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL

CLINDAMYCIN HYDROCHLORIDE

@ COSETTE EQ 150MG BASE
 @ EQ 300MG BASE

A 063029 001 Sep 20, 1989 Apr DISC
 A 063029 002 Aug 05, 2005 Apr DISC

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

>A> AA APPCO EQ 75MG BASE/5ML
 >D> AA HERITAGE PHARMS INC EQ 75MG BASE/5ML
 AA RISING EQ 75MG BASE/5ML

A 207047 001 May 11, 2018 Nov CAHN
 A 207047 001 May 11, 2018 Nov CAHN
 A 201821 001 Aug 28, 2012 Sep CAHN

CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE

AB1 ALEMBIC EQ 1% BASE
 @ AMNEAL EQ 1% BASE
 AB1 QUAGEN EQ 1% BASE

A 212466 001 Apr 02, 2024 Mar NEWA
 A 215219 001 Nov 03, 2022 Feb DISC
 A 211872 001 Jul 29, 2020 Sep CAHN

GEL;VAGINAL

XACIATO

+! ORGANON LLC EQ 2% BASE

N 215650 001 Dec 07, 2021 Jan CAHN

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

@ ENDO OPERATIONS EQ 1% BASE

A 203343 001 May 29, 2015 Apr CAHN

CLOBAZAM

TABLET;ORAL

CLOBAZAM

@ ANDA REPOSITORY 10MG
 @ 20MG

A 211959 001 Dec 09, 2020 Sep CAHN
 A 211959 002 Dec 09, 2020 Sep CAHN

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

CLOBETASOL PROPIONATE

AB2 TARO 0.05%

A 208563 001 Mar 14, 2024 Mar NEWA

CREAM;TOPICAL

CLOBETASOL PROPIONATE

@ COSETTE 0.05%
 >D> @ TORRENT 0.05%
 >A> AB1 0.05%

A 074139 001 Aug 03, 1994 Apr DISC
 A 211836 001 Dec 30, 2019 Nov CMFD
 A 211836 001 Dec 30, 2019 Nov CMFD

CLOBETASOL PROPIONATE (EMOLLIENT)

>D> @ BEACH PRODS 0.05%
 >A> AB2 0.05%

A 209411 001 Aug 21, 2017 Nov CMFD
 A 209411 001 Aug 21, 2017 Nov CMFD
 A 209411 001 Aug 21, 2017 Oct CAHN

CORMAX

@ HIKMA 0.05%

A 074220 001 May 16, 1997 Mar DISC

GEL;TOPICAL

EMBELINE

@ HIKMA 0.05%

A 076141 001 Apr 12, 2002 Mar DISC

OINTMENT;TOPICAL

CLOBETASOL PROPIONATE

AB ! ENCUBE 0.05%

A 211295 001 Nov 15, 2019 Oct CHRS

AB FOUGERA PHARMS 0.05%

A 074407 001 Feb 23, 1996 Oct CHRS

EMBELINE

@ HIKMA 0.05%

A 074221 001 Mar 31, 1995 Mar DISC

SHAMPOO;TOPICAL

CLOBETASOL PROPIONATE

@ HIKMA 0.05%

A 209871 001 Oct 27, 2017 Mar DISC

SOLUTION;TOPICAL

CLOBETASOL PROPIONATE

@ COSETTE 0.05%

A 074331 001 Dec 15, 1995 Apr DISC

AT ENCUBE 0.05%

A 076977 001 Aug 05, 2005 May CMFD

EMBELINE

@ HIKMA 0.05%

A 074222 001 Dec 06, 1995 Mar DISC

SPRAY;TOPICAL

CLOBETASOL PROPIONATE

>A> AT MACLEODS PHARMS LTD 0.05%

A 214345 001 Dec 02, 2024 Nov NEWA

SUSPENSION/DROPS;OPHTHALMIC
CLOBETASOL PROPIONATE

+!	EYENOVIA	0.05%	N218158	001	Mar 04, 2024	May	CAHN
+!	FORMOSA	0.05%	N218158	001	Mar 04, 2024	Mar	NEWA

CLOCORTOLONE PIVALATE

CREAM;TOPICAL
CLODERM

AB	+!	LEGACY PHARMA	0.1%	N017765	001		Apr	CAHN
----	----	---------------	------	---------	-----	--	-----	------

CLOMIPHENE CITRATE

TABLET;ORAL
CLOMIPHENE CITRATE

>A>	AB	APPCO	50MG	A216739	001	Nov 08, 2024	Nov	NEWA
>D>	!	COSETTE	50MG	A075528	001	Aug 30, 1999	Nov	CTEC
>A>	AB	!	50MG	A075528	001	Aug 30, 1999	Nov	CTEC
>A>	AB	RUBICON	50MG	A216545	001	Nov 12, 2024	Nov	NEWA

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL
CLOMIPRAMINE HYDROCHLORIDE

AB		CHARTWELL RX	25MG	A074364	001	Mar 29, 1996	Mar	CAHN
AB			50MG	A074364	002	Mar 29, 1996	Mar	CAHN
AB			75MG	A074364	003	Mar 29, 1996	Mar	CAHN
	@	MYLAN	25MG	A074947	001	Apr 30, 1998	May	DISC
	@		50MG	A074947	002	Apr 30, 1998	May	DISC
	@		75MG	A074947	003	Apr 30, 1998	May	DISC
	@	RK PHARMA	25MG	A213221	001	Jun 22, 2020	Mar	DISC
	@		50MG	A213221	002	Jun 22, 2020	Mar	DISC
	@		75MG	A213221	003	Jun 22, 2020	Mar	DISC
AB		TRUPHARMA	25MG	A210653	001	Apr 03, 2020	Sep	CAHN
AB			50MG	A210653	002	Apr 03, 2020	Sep	CAHN
AB			75MG	A210653	003	Apr 03, 2020	Sep	CAHN

CLONAZEPAM

TABLET, ORALLY DISINTEGRATING;ORAL
CLONAZEPAM

AB		ENDO OPERATIONS	0.125MG	A077171	001	Aug 03, 2005	Apr	CAHN
AB			0.25MG	A077171	002	Aug 03, 2005	Apr	CAHN
AB			0.5MG	A077171	003	Aug 03, 2005	Apr	CAHN
AB	!		1MG	A077171	004	Aug 03, 2005	Apr	CAHN
AB			2MG	A077171	005	Aug 03, 2005	Apr	CAHN

CLONIDINE

SYSTEM;TRANSDERMAL
CLONIDINE

AB		DIFGEN PHARMS	0.1MG/24HR	A076157	001	Aug 18, 2009	Sep	CAHN
AB			0.2MG/24HR	A076157	002	Aug 18, 2009	Sep	CAHN
AB			0.3MG/24HR	A076157	003	Aug 18, 2009	Sep	CAHN

CLONIDINE HYDROCHLORIDE

SUSPENSION, EXTENDED RELEASE;ORAL
ONYDA XR

+!	TRIS PHARMA INC	0.1MG/ML	N217645	001	May 24, 2024	May	NEWA
----	-----------------	----------	---------	-----	--------------	-----	------

TABLET;ORAL
CLONIDINE HYDROCHLORIDE

AB		TRUPHARMA	0.1MG	A070923	003	Sep 04, 1987	Sep	CAHN
AB			0.2MG	A070923	002	Sep 04, 1987	Sep	CAHN
AB			0.3MG	A070923	001	Sep 04, 1987	Sep	CAHN

TABLET, EXTENDED RELEASE;ORAL
CLONIDINE HYDROCHLORIDE

@	ANCHEN PHARMS	0.1MG	A202984	001	Sep 30, 2013	Mar	DISC
@	BLUEPHARMA INDUSTRIA	0.1MG	A211433	001	Oct 12, 2018	Jan	CAHN
@	ENDO OPERATIONS	0.1MG	A202983	001	Apr 02, 2014	May	CAHN
@		0.1MG	A202984	001	Sep 30, 2013	May	CAHN
@		0.2MG	A202983	002	Apr 02, 2014	May	CAHN
@		0.2MG	A202984	002	Sep 30, 2013	May	CAHN
@	SOMERSET THERAPS LLC	0.1MG	A211433	001	Oct 12, 2018	May	CAHN

CLOPIDOGREL BISULFATE

TABLET; ORAL		CLOPIDOGREL BISULFATE							
	@ ACCORD HLTHCARE	EQ 75MG BASE		A202925	001	Mar 27, 2013	May	DISC	
	@	EQ 300MG BASE		A202925	002	Mar 27, 2013	May	DISC	
AB	DR REDDYS LABS LTD	EQ 75MG BASE		A091023	002	Aug 05, 2024	Jul	NEWA	
AB	MSN	EQ 75MG BASE		A215388	001	Sep 20, 2024	Sep	NEWA	

CLOTTRIMAZOLE

SOLUTION; TOPICAL		CLOTTRIMAZOLE							
AT	TRUPHARMA	1%		A212281	001	Jul 25, 2019	Aug	CAHN	
TROCHE/ LOZENGE; ORAL		CLOTTRIMAZOLE							
AB	THINQ PHARM-CRO PVT	10MG		A215641	001	Feb 29, 2024	Feb	NEWA	

CLOZAPINE

TABLET; ORAL		CLOZARIL							
	+ @ HERITAGE LIFE	50MG		N019758	003	May 20, 2019	Aug	DISC	
	+ @	200MG		N019758	004	May 20, 2019	Aug	DISC	
TABLET, ORALLY DISINTEGRATING; ORAL		CLOZAPINE							
AB	BARR LABS INC	150MG		A090308	004	Nov 25, 2015	Jun	CMS1	
AB		200MG		A090308	005	Nov 25, 2015	Jun	CMS1	

COCAINE HYDROCHLORIDE

SOLUTION; NASAL		GOPRELTO							
	+! NODEN PHARMA	4%		N209963	001	Dec 14, 2017	Jan	CAHN	

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL		PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE							
AA	! GENUS	10MG/5ML; 5MG/5ML; 6.25MG/5ML		A040660	001	Dec 07, 2006	Apr	CAHN	
		PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE							
	@ HIKMA	10MG/5ML; 5MG/5ML; 6.25MG/5ML		A040674	001	Dec 23, 2014	Mar	DISC	

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL		PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE							
	@ HIKMA	10MG/5ML; 6.25MG/5ML		A040151	001	Aug 26, 1997	Mar	DISC	

COLCHICINE

CAPSULE; ORAL		COLCHICINE							
AB	ANNORA PHARMA	0.6MG		A217620	001	Apr 29, 2024	Apr	NEWA	
AB	AUROBINDO PHARMA LTD	0.6MG		A215463	001	Apr 29, 2024	Apr	NEWA	
AB	GRANULES	0.6MG		A210757	001	Apr 29, 2024	Apr	NEWA	
TABLET; ORAL		COLCHICINE							
AB	! ENDO OPERATIONS	0.6MG		A203976	001	Aug 12, 2021	May	CHRS	
	@ MYLAN	0.6MG		A209470	001	Sep 16, 2019	Apr	DISC	
		COLCRYS							
	+ @ TAKEDA PHARMS USA	0.6MG		N022352	001	Jul 29, 2009	May	DISC	

COLESEVELAM HYDROCHLORIDE

FOR SUSPENSION; ORAL		COLESEVELAM HYDROCHLORIDE							
	@ IMPAX	3.75GM/PACKET		A212886	001	Jan 18, 2023	May	DISC	

COLESTIPOL HYDROCHLORIDE

GRANULE; ORAL		FLAVORED COLESTID							
	+ @ PFIZER	5GM/PACKET		N017563	001		Jun	DISC	
	+ @	5GM/SCOOPFUL		N017563	002		Jun	DISC	
TABLET; ORAL		COLESTIPOL HYDROCHLORIDE							
AB	EDENBRIDGE PHARMS	1GM		A217667	001	Aug 16, 2024	Aug	NEWA	
>A> AB	RICONPHARMA LLC	1GM		A217462	001	Dec 03, 2024	Nov	NEWA	

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION
COLISTIMETHATE SODIUM
AP ADRASTEIA PHARMA EQ 150MG BASE/VIAL A064216 001 Feb 26, 1999 Jul CAHN

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS; OTIC
COLY-MYCIN S
+! ENDO OPERATIONS EQ 3MG BASE/ML; 10MG/ML; EQ 3.3MG BASE/ML; 0.5MG/ML N050356 001 Apr CAHN

COPPER

SYSTEM; INTRAUTERINE
PARAGARD T 380A
+! COOPERSURGICAL 309MG/COPPER N018680 001 Nov 15, 1984 Jun CDFR

CORTICOTROPIN

INJECTABLE; INJECTION
ACTHAR GEL (AUTOINJECTOR)
+! MALLINCKRODT ARD 40 UNITS/0.5ML N008372 003 Feb 29, 2024 Mar NEWA
+! 80 UNITS/ML N008372 004 Feb 29, 2024 Mar NEWA

COSYNTROPIN

INJECTABLE; INJECTION
COSYNTROPIN
@ MYLAN INSTITUTIONAL 0.25MG/VIAL A090574 001 Dec 17, 2009 May DISC
@ NORVIUM BIOSCIENCE 0.25MG/VIAL A090574 001 Dec 17, 2009 Oct CAHN

CUPRIC CHLORIDE

INJECTABLE; INJECTION
CUPRIC CHLORIDE
AP RK PHARMA EQ 0.4MG COPPER/ML A217626 001 Apr 30, 2024 May CAHN
AP SOMERSET EQ 0.4MG COPPER/ML A216113 001 Apr 30, 2024 Apr NEWA
AP STIRA EQ 0.4MG COPPER/ML A217626 001 Apr 30, 2024 Apr NEWA

CUPRIC SULFATE

INJECTABLE; INJECTION
CUPRIC SULFATE
AP ! AM REGENT EQ 0.4MG COPPER/ML A216324 001 Dec 16, 2022 Aug CTEC
AP APOTEX CORP EQ 0.4MG COPPER/ML A218745 001 Aug 19, 2024 Aug NEWA

CYANOCOBALAMIN

GEL, METERED; NASAL
NASCOBAL
@ ENDO OPERATIONS 0.5MG/INH N019722 001 Nov 05, 1996 May CAHN
INJECTABLE; INJECTION
CYANOCOBALAMIN
@ EUGIA PHARMA 1MG/ML A213874 001 Dec 08, 2020 Jun DISC
AP MANKIND PHARMA 1MG/ML A217839 001 Jul 10, 2024 Jun NEWA
>A> AP NANJING KING-FRIEND 1MG/ML A214316 001 Nov 15, 2024 Nov NEWA
SPRAY, METERED; NASAL
CALOMIST
@ ENDO OPERATIONS 25MCG/SPRAY N022102 001 Jul 27, 2007 May CAHN
CYANOCOBALAMIN
AB ! PADAGIS ISRAEL 0.5MG/SPRAY A212458 001 Sep 09, 2020 Jul CHRS
NASCOBAL
+ @ ENDO OPERATIONS 0.5MG/SPRAY N021642 001 Jan 31, 2005 Jul DISC
AB +! 0.5MG/SPRAY N021642 001 Jan 31, 2005 May CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CYCLOBENZAPRINE HYDROCHLORIDE
AB MACLEODS PHARMS LTD 15MG A207314 001 Jul 22, 2024 Jul NEWA
AB 30MG A207314 002 Jul 22, 2024 Jul NEWA
AB NOVAST LABS 15MG A214732 001 Aug 27, 2024 Aug NEWA
AB 30MG A214732 002 Aug 27, 2024 Aug NEWA

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE
@ AIPING PHARM INC 5MG A072854 002 Feb 03, 2006 Jun CAHN
@ 10MG A072854 001 Nov 19, 1991 Jun CAHN
AB GRAVITI PHARMS 5MG A218936 001 Sep 12, 2024 Sep NEWA

TABLET;ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB		7.5MG	A218936	002	Sep 12, 2024	Sep	NEWA
AB		10MG	A218936	003	Sep 12, 2024	Sep	NEWA

CYCLOPHOSPHAMIDE

CAPSULE;ORAL

CYCLOPHOSPHAMIDE

AB	KANCHAN HLTHCARE	25MG	A209872	001	May 07, 2018	Aug	CAHN
AB		50MG	A209872	002	May 07, 2018	Aug	CAHN
>A>	NEXTSOURCE	25MG	A218282	001	Dec 03, 2024	Nov	NEWA
>A>		50MG	A218282	002	Dec 03, 2024	Nov	NEWA

INJECTABLE;INJECTION

CYCLOPHOSPHAMIDE

AP	HIKMA	500MG/VIAL	A216958	001	Dec 18, 2023	Jan	CAHN
AP		1GM/VIAL	A216958	002	Dec 18, 2023	Jan	CAHN
AP		2GM/VIAL	A216958	003	Dec 18, 2023	Jan	CAHN

SOLUTION;INTRAVENOUS

CYCLOPHOSPHAMIDE

+	AVYXA HOLDINGS	500MG/ML (500MG/ML)	N210852	001	Jun 07, 2023	Jun	CAHN	
+		1GM/2ML (500MG/ML)	N210852	002	Jun 07, 2023	Jun	CAHN	
+		2GM/4ML (500MG/ML)	N210852	003	Jun 07, 2023	Jun	CAHN	
+	BAXTER HLTHCARE CORP	500MG/2.5ML (200MG/ML)	N217651	001	Jun 28, 2023	Oct	CMFD	
+	@	500MG/2.5ML (200MG/ML)	N217651	001	Jun 28, 2023	Jan	CAHN	
+		1GM/5ML (200MG/ML)	N217651	002	Jun 28, 2023	Oct	CMFD	
+	@	1GM/5ML (200MG/ML)	N217651	002	Jun 28, 2023	Jan	CAHN	
AP	+	DR REDDYS	500MG/2.5ML (200MG/ML)	N212501	001	Jul 30, 2020	Oct	CFTG
	+		500MG/2.5ML (200MG/ML)	N212501	001	Jul 30, 2020	Jun	CAHN
AP	+		1GM/5ML (200MG/ML)	N212501	002	Jul 30, 2020	Oct	CFTG
	+		1GM/5ML (200MG/ML)	N212501	002	Jul 30, 2020	Jun	CAHN
	+		2GM/10ML (200MG/ML)	N212501	003	Nov 19, 2021	Jun	CAHN
AP	NEXUS	500MG/2.5ML (200MG/ML)	A216783	001	Oct 29, 2024	Oct	NFTG	
AP		1GM/5ML (200MG/ML)	A216783	002	Oct 29, 2024	Oct	NFTG	

CYCLOSERINE

CAPSULE;ORAL

SEROMYCIN

!	SANALUZ	250MG	A060593	001		Sep	CAHN
---	---------	-------	---------	-----	--	-----	------

CYCLOSPORINE

EMULSION;OPHTHALMIC

CYCLOSPORINE

AB	DEVA HOLDING AS	0.05%	A209811	001	May 21, 2024	May	NEWA
AB	SAPTALIS PHARMS	0.05%	A211943	001	Jul 05, 2024	Jun	NEWA
AB	TEVA PHARMS USA INC	0.05%	A203880	001	Dec 14, 2023	Oct	CMFD
	@	0.05%	A203880	001	Dec 14, 2023	Jun	DISC

CYPROHEPTADINE HYDROCHLORIDE

SYRUP;ORAL

CYPROHEPTADINE HYDROCHLORIDE

	@	PATRIN	2MG/5ML	A204823	001	Dec 27, 2016	Apr	DISC
	@	PHARM ASSOC	2MG/5ML	A091295	001	Mar 28, 2013	Feb	DISC
AA	!	RISING	2MG/5ML	A040668	001	Jun 28, 2006	Sep	CAHN

TABLET;ORAL

CYPROHEPTADINE HYDROCHLORIDE

	@	CHARTWELL RX	4MG	A086808	001		Aug	CAHN
--	---	--------------	-----	---------	-----	--	-----	------

CYSTEINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

ELCYS

+	@	EXELA PHARMA	2500MG/50ML (50MG/ML)	N210660	002	Dec 04, 2023	Jan	DISC
---	---	--------------	-----------------------	---------	-----	--------------	-----	------

DABIGATRAN ETEXILATE MESYLATE

CAPSULE;ORAL

DABIGATRAN ETEXILATE MESYLATE

AB	ALEMBIC	EQ 75MG BASE	A215233	001	Jun 14, 2024	Jun	NEWA
AB		EQ 110MG BASE	A215233	003	Aug 12, 2024	Aug	NEWA
AB		EQ 150MG BASE	A215233	002	Jun 14, 2024	Jun	NEWA
AB	ALKEM LABS LTD	EQ 110MG BASE	A208040	003	Sep 11, 2024	Aug	NEWA
AB	HETERO LABS LTD III	EQ 110MG BASE	A207961	003	Aug 13, 2024	Aug	NEWA
AB	MSN	EQ 75MG BASE	A213879	001	May 22, 2024	May	NEWA
AB		EQ 110MG BASE	A213879	003	Aug 12, 2024	Aug	NEWA

CAPSULE;ORAL

DABIGATRAN ETEXILATE MESYLATE
 AB EQ 150MG BASE A213879 002 May 22, 2024 May NEWA

DACTINOMYCIN

INJECTABLE; INJECTION
 COSMEGEN
 + @ RECORDATI RARE 0.5MG/VIAL N050682 001 Jan DISC
 DACTINOMYCIN
 AP ! EUGIA PHARMA 0.5MG/VIAL A203385 001 Nov 09, 2017 Jan CHRS

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; INTRAVENOUS
 SYNERCID
 + @ KING PHARMS 350MG/VIAL;150MG/VIAL N050748 001 Sep 21, 1999 Sep DISC

DANICOPAN

TABLET; ORAL
 VOYDEYA
 + ALEXION PHARMS INC 50MG N218037 001 Mar 29, 2024 Mar NEWA
 +! 100MG N218037 002 Mar 29, 2024 Mar NEWA

DAPIPRAZOLE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
 DAPIPRAZOLE HYDROCHLORIDE
 @ BARADAINA LLC 0.5% A204902 001 May 30, 2019 Aug CAHN

DAPRODUSTAT

TABLET; ORAL
 JESDUVROQ
 + @ GLAXOSMITHKLINE 1MG N216951 001 Feb 01, 2023 May DISC
 + @ 2MG N216951 002 Feb 01, 2023 May DISC
 + @ 4MG N216951 003 Feb 01, 2023 May DISC
 + @ 6MG N216951 004 Feb 01, 2023 May DISC
 + @ 8MG N216951 005 Feb 01, 2023 May DISC

DAPSONE

GEL; TOPICAL
 DAPSONE
 AB ACRUX DDS 7.5% A213636 001 Aug 26, 2024 Aug NEWA
 @ PADAGIS ISRAEL 5% A215087 001 Oct 31, 2023 Jan DISC
 @ 7.5% A212657 001 Nov 01, 2023 Jan DISC
 AB TARO 5% A209506 001 Oct 16, 2017 Jun CAHN
 AB TRUPHARMA 5% A213907 001 Jun 06, 2023 Sep CAHN
 AB A213636 001 Aug 26, 2024 Sep CAHN
 AB ZYDUS 7.5% A214019 001 May 08, 2024 Apr NEWA
 AB ZYDUS LIFESCIENCES 7.5% A214019 001 May 08, 2024 May CAHN

DAPTOMYCIN

POWDER; INTRAVENOUS
 DAPTOMYCIN
 AP BIOCON PHARMA 500MG/VIAL A217215 001 Aug 29, 2024 Aug NEWA
 AP FRESENIUS KABI USA 350MG/VIAL A213396 001 Aug 01, 2024 Jul NEWA
 >A> +! MAIA PHARMS INC 350MG/VIAL N217630 001 Nov 21, 2024 Nov NEWA
 >A> +! 500MG/VIAL N217630 002 Nov 21, 2024 Nov NEWA

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL
 DARIFENACIN HYDROBROMIDE
 @ ENDO OPERATIONS EQ 7.5MG BASE A091190 001 Mar 13, 2015 May CAHN
 @ EQ 15MG BASE A091190 002 Mar 13, 2015 May CAHN

DARUNAVIR

TABLET; ORAL
 DARUNAVIR
 AB ZYDUS LIFESCIENCES 600MG A214085 001 Dec 13, 2023 May CAHN
 AB 800MG A214085 002 Dec 13, 2023 May CAHN

DASATINIBTABLET; ORAL
DASATINIB

AB	APOTEX	20MG	A202103	001	Jun 10, 2016	Aug	CMFD
AB		50MG	A202103	002	Jun 10, 2016	Aug	CMFD
AB		70MG	A202103	003	Jun 10, 2016	Aug	CMFD
AB		80MG	A203180	001	Nov 23, 2021	Aug	CMFD
AB		100MG	A202103	004	Jun 10, 2016	Aug	CMFD
AB		140MG	A203180	002	Nov 23, 2021	Aug	CMFD

SPRYCEL

AB	+ BRISTOL MYERS SQUIBB	20MG	N021986	001	Jun 28, 2006	Aug	CTEC
AB	+	50MG	N021986	002	Jun 28, 2006	Aug	CTEC
AB	+	70MG	N021986	003	Jun 28, 2006	Aug	CTEC
AB	+	80MG	N021986	005	Oct 28, 2010	Aug	CTEC
AB	+!	100MG	N021986	004	May 30, 2008	Aug	CTEC
AB	+	140MG	N021986	006	Oct 28, 2010	Aug	CTEC

DECITABINEINJECTABLE; INTRAVENOUS
DECITABINE

AP	HETERO LABS LTD VI	50MG/VIAL	A215355	001	May 10, 2024	May	NEWA
----	--------------------	-----------	---------	-----	--------------	-----	------

DEFERASIROXTABLET, FOR SUSPENSION; ORAL
DEFERASIROX

AB	GLENMARK SPECLT	125MG	A209433	001	Jan 06, 2020	May	CAHN
AB		250MG	A209433	002	Jan 06, 2020	May	CAHN
AB		500MG	A209433	003	Jan 06, 2020	May	CAHN
AB	TEVA PHARMS USA	125MG	A207124	001	Sep 23, 2022	Jul	CMFD
AB		250MG	A207124	002	Sep 23, 2022	Jul	CMFD
AB		500MG	A207124	003	Sep 23, 2022	Jul	CMFD
AB	TORRENT	125MG	A209426	001	Nov 05, 2024	Oct	NEWA
AB		250MG	A209426	002	Nov 05, 2024	Oct	NEWA
AB		500MG	A209426	003	Nov 05, 2024	Oct	NEWA

DEFLAZACORTSUSPENSION; ORAL
DEFLAZACORT

AB	TRIS PHARMA INC	22.75MG/ML	A217813	001	Apr 25, 2024	Apr	NFTG
AB	EMFLAZA						
AB	+! PTC THERAP	22.75MG/ML	N208685	001	Feb 09, 2017	Apr	CFTG
AB	TABLET; ORAL						
AB	DEFLAZACORT						
AB	AUROBINDO PHARMA LTD	6MG	A217123	001	Feb 09, 2024	Feb	NFTG
AB		18MG	A217123	002	Feb 09, 2024	Feb	NFTG
AB		30MG	A217123	003	Feb 09, 2024	Feb	NFTG
AB		36MG	A217123	004	Feb 09, 2024	Feb	NFTG
AB	UPSHER SMITH LABS	6MG	A216720	001	Nov 05, 2024	Oct	NEWA
AB		18MG	A216720	002	Nov 05, 2024	Oct	NEWA
AB		30MG	A216720	003	Nov 05, 2024	Oct	NEWA
AB		36MG	A216720	004	Nov 05, 2024	Oct	NEWA
AB	EMFLAZA						
AB	+ PTC THERAP	6MG	N208684	001	Feb 09, 2017	Feb	CFTG
AB	+	18MG	N208684	002	Feb 09, 2017	Feb	CFTG
AB	+	30MG	N208684	003	Feb 09, 2017	Feb	CFTG
AB	+!	36MG	N208684	004	Feb 09, 2017	Feb	CFTG

DEOXYCHOLIC ACIDSOLUTION; SUBCUTANEOUS
DEOXYCHOLIC ACID

AP	WILSHIRE PHARMS INC	20MG/2ML (10MG/ML)	A212296	001	Apr 02, 2021	Jul	CAHN
AP	KYBELLA						
AP	+! ABBVIE	20MG/2ML (10MG/ML)	N206333	001	Apr 29, 2015	Jan	CAHN

DESIPRAMINE HYDROCHLORIDETABLET; ORAL
DESIPRAMINE HYDROCHLORIDE

AB	CHARTWELL RX	10MG	A072103	002	May 24, 1988	Mar	CAHN
AB		25MG	A072103	003	May 24, 1988	Mar	CAHN
AB		50MG	A072103	004	May 24, 1988	Mar	CAHN
AB		75MG	A072103	005	Jun 20, 1988	Mar	CAHN

<u>TABLET;ORAL</u>							
DESIPRAMINE HYDROCHLORIDE							
AB		100MG		A072103	001	Jun 20, 1988	Mar CAHN
AB		150MG		A072103	006	Jun 20, 1988	Mar CAHN
<u>DESLORATADINE</u>							
TABLET;ORAL							
DESLORATADINE							
	@ CHARTWELL RX	5MG		A078364	001	Dec 03, 2010	Jan CAHN
<u>DESMOPRESSIN ACETATE</u>							
INJECTABLE; INJECTION							
DESMOPRESSIN ACETATE							
	@ SUN PHARM INDS LTD	0.004MG/ML		A091280	001	Jan 25, 2013	Oct DISC
TABLET;ORAL							
DESMOPRESSIN ACETATE							
	@ ACTAVIS LABS FL INC	0.1MG		A076470	001	Jul 01, 2005	Feb DISC
	@	0.2MG		A076470	002	Jul 01, 2005	Feb DISC
AB	AUROBINDO PHARMA	0.1MG		A213095	001	Mar 21, 2024	Mar NEWA
AB		0.2MG		A213095	002	Mar 21, 2024	Mar NEWA
<u>DESOGESTREL; ETHINYL ESTRADIOL</u>							
TABLET;ORAL-28							
DESOGESTREL AND ETHINYL ESTRADIOL							
AB	NAARI PTE LTD	0.15MG;0.03MG		A207067	001	Sep 13, 2018	Apr CMFD
	@ XIROMED	0.15MG;0.03MG		A202085	001	May 20, 2015	Apr CAHN
EMOQUETTE							
	@ ENDO OPERATIONS	0.15MG;0.03MG		A076675	001	Feb 25, 2011	May CAHN
KIMIDESS							
	@ ENDO OPERATIONS	0.15MG,N/A;0.02MG,0.01MG		A076681	001	Apr 30, 2015	Aug DISC
AB		0.15MG,N/A;0.02MG,0.01MG		A076681	001	Apr 30, 2015	May CAHN
<u>DESONIDE</u>							
OINTMENT;TOPICAL							
DESONIDE							
	@ HIKMA	0.05%		A208836	001	Mar 27, 2017	Mar DISC
<u>DESOXIMETASONE</u>							
CREAM;TOPICAL							
DESOXIMETASONE							
	@ COSETTE	0.25%		A209595	001	Mar 04, 2020	Mar DISC
OINTMENT;TOPICAL							
DESOXIMETASONE							
	@ COSETTE	0.25%		A206740	001	Dec 23, 2016	Apr DISC
<u>DESVENLAFAXINE SUCCINATE</u>							
TABLET, EXTENDED RELEASE;ORAL							
DESVENLAFAXINE SUCCINATE							
	@ NORVIUM BIOSCIENCE	EQ 50MG BASE		A204095	001	Jun 29, 2015	Jun CAHN
	@	EQ 100MG BASE		A204095	002	Jun 29, 2015	Jun CAHN
<u>DEURUXOLITINIB PHOSPHATE</u>							
TABLET;ORAL							
LEQSELVI							
+!	SUN PHARM INDS INC	EQ 8MG BASE		N217900	001	Jul 25, 2024	Jul NEWA
<u>DEUTETRABENAZINE</u>							
TABLET, EXTENDED RELEASE;ORAL							
AUSTEDO XR							
+	TEVA	18MG		N216354	008	Jul 01, 2024	Jul NEWA
+		30MG		N216354	004	May 29, 2024	May NEWA
+		36MG		N216354	005	May 29, 2024	May NEWA
+		42MG		N216354	006	May 29, 2024	May NEWA
+		48MG		N216354	007	May 29, 2024	Oct CRLD
		48MG		N216354	007	May 29, 2024	May NEWA

DEXAMETHASONE

ELIXIR; ORAL

DEXAMETHASONE

AA	!	KANCHAN HLTHCARE	0.5MG/5ML	A 084754	001		Aug	CAHN
AA		RISING	0.5MG/5ML	A 090891	001	Jul 12, 2011	Sep	CAHN

TABLET; ORAL

DEXAMETHASONE

>D>	@	ABRAXEOLUS	0.25MG	A 088149	001	Apr 28, 1983	Nov	CAHN
	@		0.25MG	A 088149	001	Apr 28, 1983	Sep	CAHN
AB		COREPHARMA	0.5MG	A 218372	001	Sep 17, 2024	Sep	NEWA
AB			0.75MG	A 218372	002	Sep 17, 2024	Sep	NEWA
AB			1MG	A 218372	003	Sep 17, 2024	Sep	NEWA
AB			1.5MG	A 218372	004	Sep 17, 2024	Sep	NEWA
AB			2MG	A 218372	005	Sep 17, 2024	Sep	NEWA
AB			4MG	A 218372	006	Sep 17, 2024	Sep	NEWA
AB			6MG	A 218372	007	Sep 17, 2024	Sep	NEWA
	@	KEY THERAP	1.5MG	A 088237	001	Apr 28, 1983	May	DISC
BP			1.5MG	A 088237	001	Apr 28, 1983	Apr	CAHN
>A>	@	PANGEA	0.25MG	A 088149	001	Apr 28, 1983	Nov	CAHN
	@		0.25MG	A 088149	001	Apr 28, 1983	Jan	CAHN
AB		ZYDUS LIFESCIENCES	0.5MG	A 216282	001	Feb 07, 2024	Mar	CAHN
AB			0.75MG	A 216282	002	Feb 07, 2024	Mar	CAHN
AB			1MG	A 216284	001	May 09, 2024	May	CAHN
AB			1.5MG	A 216282	003	Feb 07, 2024	Mar	CAHN
AB			2MG	A 216283	001	Feb 07, 2024	Mar	CAHN
AB			4MG	A 216282	004	Feb 07, 2024	Mar	CAHN
AB			6MG	A 216282	005	Feb 07, 2024	Mar	CAHN
AB		ZYDUS PHARMS	0.5MG	A 216282	001	Feb 07, 2024	Jan	NEWA
AB			0.75MG	A 216282	002	Feb 07, 2024	Jan	NEWA
AB			1MG	A 216284	001	May 09, 2024	May	NEWA
AB			1.5MG	A 216282	003	Feb 07, 2024	Jan	NEWA
AB			2MG	A 216283	001	Feb 07, 2024	Jan	NEWA
AB			4MG	A 216282	004	Feb 07, 2024	Jan	NEWA
AB			6MG	A 216282	005	Feb 07, 2024	Jan	NEWA

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

	@	GENEYORK PHARMS	EQ 4MG PHOSPHATE/ML	A 214890	002	Jul 28, 2023	Jul	CMS1
	@		EQ 10MG PHOSPHATE/ML	A 214890	001	Jul 07, 2023	Feb	DISC
AP		HIKMA	EQ 4MG PHOSPHATE/ML	A 084282	001		Jun	CAHN
	@		EQ 4MG PHOSPHATE/ML	A 211451	001	Aug 01, 2023	Jul	DISC
AP	!		EQ 10MG PHOSPHATE/ML	A 087702	001	Sep 07, 1982	Jun	CAHN
AP		MICRO LABS	EQ 10MG PHOSPHATE/ML	A 217797	001	Mar 27, 2024	Mar	NEWA

DEXCHLORPHENIRAMINE MALEATE

SYRUP; ORAL

DEXCHLORPHENIRAMINE MALEATE

	+ @	PAI HOLDINGS PHARM	2MG/5ML	A 088251	001	Mar 23, 1984	Mar	DISC
		POLMON						
	!	CAPELLON PHARMS LLC	2MG/5ML	A 202520	001	Jul 16, 2018	Mar	CTEC
AA	!		2MG/5ML	A 202520	001	Jul 16, 2018	Mar	CHRS

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE; ORAL

DEXLANSOPRAZOLE

AB		MYLAN	30MG	A 205205	001	Jan 19, 2024	Jan	NEWA
AB			60MG	A 205205	002	Jan 19, 2024	Jan	NEWA

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

	@	WILSHIRE PHARMS INC	EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	A 212791	003	May 08, 2020	Jul	CAHN
AP			EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A 212791	001	Dec 04, 2019	Jul	CAHN
AP			EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A 212791	002	Dec 04, 2019	Jul	CAHN

SOLUTION; INTRAVENOUS

DEXMEDETOMIDINE HYDROCHLORIDE

AP	+!	HQ SPCLT PHARMA	EQ 1MG BASE/10ML (EQ 100MCG BASE/ML)	N 206628	002	Oct 21, 2015	Sep	CFTG
----	----	-----------------	--------------------------------------	----------	-----	--------------	-----	------

SOLUTION; INTRAVENOUS

AP	+	EQ 400MCG BASE/4ML (EQ 100MCG BASE/ML)	N206628	001	Oct 21, 2015	Sep CFTG
AP	SOMERSET	EQ 1MG BASE/10ML (EQ 100MCG BASE/ML)	A218112	002	Sep 24, 2024	Sep NFTG
AP		EQ 400MCG BASE/4ML (EQ 100MCG BASE/ML)	A218112	001	Sep 24, 2024	Sep NFTG

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL						
DEXEDRINE SPANSULE						
AB	+	IMPAX LABS INC	5MG	N017078	001	Aug CTNA
AB	+		10MG	N017078	002	Aug CTNA
AB	+	!	15MG	N017078	003	Aug CTNA
DEXTROAMPHETAMINE SULFATE						
	@	NORVIUM BIOSCIENCE	5MG	A206735	001	Jan 27, 2016 Jun CAHN
	@		10MG	A206735	002	Jan 27, 2016 Jun CAHN
	@		15MG	A206735	003	Jan 27, 2016 Jun CAHN
TABLET; ORAL						
DEXTROAMPHETAMINE SULFATE						
AA		AZURITY	2.5MG	A090533	001	Oct 25, 2011 Mar CAHN
AA			5MG	A090533	002	Oct 25, 2011 Mar CAHN
AA			7.5MG	A090533	003	Oct 25, 2011 Mar CAHN
AA			10MG	A090533	004	Oct 25, 2011 Mar CAHN
AA			15MG	A090533	005	Oct 25, 2011 Mar CAHN
AA			20MG	A090533	006	Oct 25, 2011 Mar CAHN
AA			30MG	A090533	007	Oct 25, 2011 Mar CAHN
	@	TRIS PHARMA INC	5MG	A206095	001	Aug 18, 2022 Jan DISC
	@		10MG	A206095	002	Aug 18, 2022 Jan DISC

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL						
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE						
AA	+	ANI PHARMS	15MG/5ML; 6.25MG/5ML	N011265	002	Apr 02, 1984 Sep CMFD

DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE

CAPSULE; ORAL						
DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE						
AB		HETERO LABS LTD III	20MG; 10MG	A218426	001	Aug 28, 2024 Aug NEWA

DEXTROSE

INJECTABLE; INJECTION						
DEXTROSE 5%						
>D>	AP	AM REGENT	50MG/ML	A217263	001	Apr 08, 2024 Nov DISC
>A>		@	50MG/ML	A217263	001	Apr 08, 2024 Nov DISC
	AP		50MG/ML	A217263	001	Apr 08, 2024 Apr CTNA
	AP		50MG/ML	A217263	001	Apr 08, 2024 Mar NEWA

DIAZEPAM

FILM; BUCCAL						
LIBERVANT						
	+	AQUESTIVE	5MG	N218623	001	Apr 26, 2024 Apr NEWA
	+		7.5MG	N218623	002	Apr 26, 2024 Apr NEWA
	+		10MG	N218623	003	Apr 26, 2024 Apr NEWA
	+		12.5MG	N218623	004	Apr 26, 2024 Apr NEWA
	+	!	15MG	N218623	005	Apr 26, 2024 Apr NEWA
INJECTABLE; INJECTION						
DIAZEPAM						
AP		ALEMBIC	10MG/2ML (5MG/ML)	A218450	001	Apr 25, 2024 Apr NEWA
AP		DR REDDYS	10MG/2ML (5MG/ML)	A218422	001	Jul 18, 2024 Jul NEWA
	@	HIKMA	5MG/ML (5MG/ML)	A070311	002	Dec 16, 1985 Jan NEWA
	@		10MG/2ML (5MG/ML)	A070311	003	Dec 16, 1985 Jan NEWA
AP			50MG/10ML (5MG/ML)	A070311	001	Dec 16, 1985 Jan CPOT
TABLET; ORAL						
DIAZEPAM						
	@	ENDO OPERATIONS	2MG	A070228	002	Sep 26, 1985 May CAHN
	@		5MG	A070228	003	Sep 26, 1985 May CAHN
	@		10MG	A070228	001	Sep 26, 1985 May CAHN
AB		NUVO PHARM	2MG	A070464	002	Sep 10, 2024 Aug NEWA
AB			5MG	A070464	003	Sep 10, 2024 Aug NEWA

DICHLORPHENAMIDE

TABLET;ORAL
 ORMALVI
 AB TORRENT 50MG A215924 001 Dec 29, 2022 Feb CTNA

DICLOFENAC POTASSIUM

FOR SOLUTION;ORAL
 DICLOFENAC POTASSIUM
 AB ENDO OPERATIONS 50MG A202964 001 May 02, 2016 May CAHN
 AB TARO 50MG A218011 001 Jun 14, 2024 Jun NEWA
 TABLET;ORAL
 CATAFLAM
 AB AMICI PHARMA 25MG A076561 002 Jul 21, 2021 Oct CAHN
 AB 50MG A076561 001 Mar 18, 2004 Oct CAHN

DICLOFENAC SODIUM

SOLUTION;TOPICAL
 DICLOFENAC SODIUM
 AB ! LUPIN PHARMS 2% A208021 001 Sep 20, 2022 Mar CHRS

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL
 DICLOFENAC SODIUM AND MISOPROSTOL
 @ SANDOZ 50MG;0.2MG A200158 001 May 09, 2013 Jul DISC
 @ 75MG;0.2MG A200158 002 May 09, 2013 Jul DISC

DICLOXACILLIN SODIUM

CAPSULE;ORAL
 DICLOXACILLIN SODIUM
 @ CHARTWELL RX EQ 125MG BASE A061454 002 Jul CAHN
 @ EQ 250MG BASE A061454 001 Jul CAHN
 @ EQ 500MG BASE A061454 003 Jul CAHN

DICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL
 DICYCLOMINE HYDROCHLORIDE
 AB ANNORA PHARMA 10MG A218018 001 Jul 01, 2024 Jun NEWA
 INJECTABLE;INJECTION
 BENTYL
 + @ ABBVIE 10MG/ML N008370 001 Oct 15, 1984 Apr DISC
 BENTYL PRESERVATIVE FREE
 + @ ABBVIE 10MG/ML N008370 002 Oct 15, 1984 Aug DISC
 DICYCLOMINE HYDROCHLORIDE
 AP ! FOSUN PHARMA 10MG/ML A210979 001 Jul 02, 2018 Apr CHRS
 AP SOMERSET THERAPS LLC 10MG/ML A214332 001 Nov 01, 2024 Oct NEWA
 AP 10MG/ML A214333 001 Nov 01, 2024 Oct NEWA
 DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE)
 AP ! HIKMA 10MG/ML A040465 001 Jun 30, 2003 Aug CHRS
 SYRUP;ORAL
 DICYCLOMINE HYDROCHLORIDE
 AA ! ENDO OPERATIONS 10MG/5ML A040169 001 Mar 24, 2005 Apr CAHN
 TABLET;ORAL
 DICYCLOMINE HYDROCHLORIDE
 AB ANNORA PHARMA 20MG A217566 001 May 07, 2024 Apr NEWA
 >A> AB RISING 20MG A218952 001 Nov 15, 2024 Nov NEWA

DIFLORASONE DIACETATE

CREAM;TOPICAL
 DIFLORASONE DIACETATE
 @ ANI PHARMS 0.05% A076263 001 Dec 20, 2002 Sep DISC
 OINTMENT;TOPICAL
 DIFLORASONE DIACETATE
 @ SAPTALIS PHARMS 0.05% A206572 001 Jul 24, 2015 Jun CAHN
 @ SCIEGEN PHARMS INC 0.05% A206572 001 Jul 24, 2015 Aug CAHN

DIFLUNISAL

TABLET; ORAL
DIFLUNISAL

HERITAGE PHARMA	250MG	A202845	002	Aug 16, 2024	Aug	NEWA
	375MG	A202845	003	Aug 16, 2024	Aug	NFTG

DIFLUPREDNATE

EMULSION; OPHTHALMIC
DIFLUPREDNATE

AB	EPIC PHARMA LLC	0.05%	A207284	001	May 14, 2024	May	NEWA
----	-----------------	-------	---------	-----	--------------	-----	------

DIGOXIN

ELIXIR; ORAL
DIGOXIN

AA	AMICI PHARMA	0.05MG/ML	A215209	001	Mar 11, 2022	Oct	CAHN
AA	VISTAPHARM LLC	0.05MG/ML	A213000	001	Oct 04, 2019	Feb	CAHN

INJECTABLE; INJECTION
DIGOXIN

AP	HIKMA	0.25MG/ML	A083391	001		Jun	CAHN
----	-------	-----------	---------	-----	--	-----	------

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION
DIHYDROERGOTAMINE MESYLATE

AP	CIPLA	1MG/ML	A212334	001	Sep 20, 2024	Sep	NEWA
----	-------	--------	---------	-----	--------------	-----	------

SPRAY, METERED; NASAL
DIHYDROERGOTAMINE MESYLATE
@ AMNEAL
TRUDHESA

+!	IMPEL PHARMS	0.725MG/SPRAY	N213436	001	Sep 02, 2021	Jun	CAHN
+!	JN BIDCO	0.725MG/SPRAY	N213436	001	Sep 02, 2021	Feb	CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
DILTIAZEM HYDROCHLORIDE

>A>	AB3	ALEMBIC	120MG	A216968	001	Nov 08, 2024	Nov	NEWA
	AB2		120MG	A218587	001	Oct 18, 2024	Oct	NEWA
>A>	AB3		180MG	A216968	002	Nov 08, 2024	Nov	NEWA
	AB2		180MG	A218587	002	Oct 18, 2024	Oct	NEWA
>A>	AB3		240MG	A216968	003	Nov 08, 2024	Nov	NEWA
	AB2		240MG	A218587	003	Oct 18, 2024	Oct	NEWA
>A>	AB3		300MG	A216968	004	Nov 08, 2024	Nov	NEWA
>A>	AB3		360MG	A216968	005	Nov 08, 2024	Nov	NEWA
>A>	AB4	CHARTWELL RX	120MG	A091022	001	Sep 28, 2012	Nov	CAHN
>A>	AB4		180MG	A091022	002	Sep 28, 2012	Nov	CAHN
>A>	AB4		240MG	A091022	003	Sep 28, 2012	Nov	CAHN
>A>	AB4		300MG	A091022	004	Sep 28, 2012	Nov	CAHN
>A>	AB4		360MG	A091022	005	Sep 28, 2012	Nov	CAHN
>A>	AB4		420MG	A091022	006	Sep 28, 2012	Nov	CAHN
	AB3	ENDO OPERATIONS	120MG	A074984	001	Dec 20, 1999	Apr	CAHN
	AB3		180MG	A074984	002	Dec 20, 1999	Apr	CAHN
	AB3		240MG	A074984	003	Dec 20, 1999	Apr	CAHN
	AB3		300MG	A074984	004	Dec 20, 1999	Apr	CAHN
	@		360MG	A209766	001	May 30, 2018	May	CAHN
>D>	AB4	SANDOZ	120MG	A091022	001	Sep 28, 2012	Nov	CAHN
>D>	AB4		180MG	A091022	002	Sep 28, 2012	Nov	CAHN
>D>	AB4		240MG	A091022	003	Sep 28, 2012	Nov	CAHN
>D>	AB4		300MG	A091022	004	Sep 28, 2012	Nov	CAHN
>D>	AB4		360MG	A091022	005	Sep 28, 2012	Nov	CAHN
>D>	AB4		420MG	A091022	006	Sep 28, 2012	Nov	CAHN
>D>	AB4	SUN PHARM	120MG	A090421	001	Nov 15, 2010	Nov	DISC
>A>	@		120MG	A090421	001	Nov 15, 2010	Nov	DISC
>D>	AB4		180MG	A090421	002	Nov 15, 2010	Nov	DISC
>A>	@		180MG	A090421	002	Nov 15, 2010	Nov	DISC
>D>	AB4		240MG	A090421	003	Nov 15, 2010	Nov	DISC
>A>	@		240MG	A090421	003	Nov 15, 2010	Nov	DISC
>D>	AB4		300MG	A090421	004	Nov 15, 2010	Nov	DISC
>A>	@		300MG	A090421	004	Nov 15, 2010	Nov	DISC
>D>	AB4		360MG	A090421	005	Nov 15, 2010	Nov	DISC
>A>	@		360MG	A090421	005	Nov 15, 2010	Nov	DISC
	@		360MG	A090492	005	Oct 28, 2011	Feb	DISC
AB2	UTOPIC PHARMS	120MG	A216304	001	Aug 08, 2022	Sep	CAHN	
AB2		180MG	A216304	002	Aug 08, 2022	Sep	CAHN	

CAPSULE, EXTENDED RELEASE;ORAL
DILTIAZEM HYDROCHLORIDE

AB2	TAZTIA XT	240MG	A216304	003	Aug 08, 2022	Sep	CAHN
	@ ACTAVIS LABS FL INC	120MG	A075401	001	Apr 10, 2003	Jul	DISC
	@	180MG	A075401	002	Apr 10, 2003	Jul	DISC
	@	240MG	A075401	003	Apr 10, 2003	Jul	DISC
	@	300MG	A075401	004	Apr 10, 2003	Jul	DISC
	@	360MG	A075401	005	Apr 10, 2003	Jul	DISC
INJECTABLE;INJECTION							
DILTIAZEM HYDROCHLORIDE							
AP	HIKMA	5MG/ML	A078538	001	Dec 17, 2008	Mar	CAHN
	@ HIKMA FARMACEUTICA	5MG/ML	A202651	001	Aug 09, 2012	Mar	DISC

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL
DIMETHYL FUMARATE

AB	MACLEODS PHARMS LTD	120MG	A210377	001	Jun 26, 2024	Jun	NEWA
AB		240MG	A210377	002	Jun 26, 2024	Jun	NEWA

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE;INJECTION
DIPHENHYDRAMINE HYDROCHLORIDE

AP	GLAND PHARMA LTD	50MG/ML	A218448	001	Mar 20, 2024	Mar	NEWA
	@ HIKMA	50MG/ML	A083183	001		Jun	CAHN
AP	! MYLAN INSTITUTIONAL	50MG/ML	A040498	001	Jul 12, 2005	May	CHRS

DIPYRIDAMOLE

TABLET;ORAL

DIPYRIDAMOLE

	@ CHARTWELL RX	25MG	A040898	001	Apr 23, 2008	Aug	CAHN
	@	50MG	A040898	002	Apr 23, 2008	Aug	CAHN
	@	75MG	A040898	003	Apr 23, 2008	Aug	CAHN
	@ GENUS	25MG	A040898	001	Apr 23, 2008	Jan	CAHN
	@	50MG	A040898	002	Apr 23, 2008	Jan	CAHN
	@	75MG	A040898	003	Apr 23, 2008	Jan	CAHN
AB	! IMPAX LABS	75MG	A040782	003	Jul 18, 2007	May	CHRS
PERSANTINE							
	+ @ BOEHRINGER INGELHEIM	25MG	N012836	003	Dec 22, 1986	May	DISC
	+ @	50MG	N012836	004	Feb 06, 1987	May	DISC
	+ @	75MG	N012836	005	Feb 06, 1987	May	DISC

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL

DIVALPROEX SODIUM

@ ENDO OPERATIONS	EQ 500MG VALPROIC ACID	A078411	001	Nov 03, 2008	May	CAHN
@ NORVIUM BIOSCIENCE	EQ 125MG VALPROIC ACID	A090062	001	Mar 17, 2009	Jun	CAHN
@	EQ 250MG VALPROIC ACID	A090062	002	Mar 17, 2009	Jun	CAHN
@	EQ 500MG VALPROIC ACID	A090062	003	Mar 17, 2009	Jun	CAHN

TABLET, EXTENDED RELEASE;ORAL

DIVALPROEX SODIUM

@ ENDO OPERATIONS	EQ 250MG VALPROIC ACID	A078445	001	Feb 26, 2009	May	CAHN
@	EQ 500MG VALPROIC ACID	A078445	002	Aug 04, 2009	May	CAHN
@ UTOPIC PHARMS	EQ 250MG VALPROIC ACID	A214462	001	Mar 15, 2021	Sep	CAHN
@	EQ 500MG VALPROIC ACID	A214462	002	Mar 15, 2021	Sep	CAHN

DOBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION
DOBUTAMINE HYDROCHLORIDE

AP	SLATE RUN PHARMA	EQ 12.5MG BASE/ML	A216131	001	Dec 21, 2022	Sep	CAHN
----	------------------	-------------------	---------	-----	--------------	-----	------

DOCETAXEL

INJECTABLE;INJECTION

DOCETAXEL

AP	ACIC PHARMS	80MG/4ML (20MG/ML)	A216677	002	Feb 28, 2024	Feb	NEWA
AP		20MG/ML (20MG/ML)	A216677	001	Feb 28, 2024	Feb	NEWA
AP	HERITAGE	80MG/4ML (20MG/ML)	A216677	002	Feb 28, 2024	Sep	CAHN
>A> AP		160MG/8ML (20MG/ML)	A216677	003	Nov 26, 2024	Nov	NEWA
AP		20MG/ML (20MG/ML)	A216677	001	Feb 28, 2024	Sep	CAHN
	@ NORVIUM BIOSCIENCE	20MG/ML (20MG/ML)	A203892	001	May 11, 2023	Jun	CAHN
	@	80MG/4ML (20MG/ML)	A203892	002	May 11, 2023	Jun	CAHN

SOLUTION;INTRAVENOUS								
BEIZRAY								
+!	ZHUHAI	80MG/4ML (20MG/ML)	N218711	001	Oct 23, 2024	Oct	NEWA	
DOCIVYX								
+!	AVYXA HOLDINGS	20MG/2ML (10MG/ML)	N215813	001	Nov 22, 2022	Apr	CMFD	
+ @		20MG/2ML (10MG/ML)	N215813	001	Nov 22, 2022	Apr	CTNA	
+ @		20MG/2ML (10MG/ML)	N215813	001	Nov 22, 2022	Jan	CAHN	
+!		80MG/8ML (10MG/ML)	N215813	002	Nov 22, 2022	Apr	CMFD	
+ @		80MG/8ML (10MG/ML)	N215813	002	Nov 22, 2022	Apr	CTNA	
+ @		80MG/8ML (10MG/ML)	N215813	002	Nov 22, 2022	Jan	CAHN	
+!		160MG/16ML (10MG/ML)	N215813	003	Nov 22, 2022	Apr	CMFD	
+ @		160MG/16ML (10MG/ML)	N215813	003	Nov 22, 2022	Apr	CTNA	
+ @		160MG/16ML (10MG/ML)	N215813	003	Nov 22, 2022	Jan	CAHN	
<u>DOLASETRON MESYLATE</u>								
TABLET;ORAL								
ANZEMET								
+ @	VALIDUS PHARMS	50MG	N020623	001	Sep 11, 1997	Jun	DISC	
<u>DOLUTEGRAVIR SODIUM</u>								
TABLET;ORAL								
TIVICAY								
+ @	VIIIV HLTHCARE	EQ 10MG BASE	N204790	002	Jun 09, 2016	Jan	DISC	
+ @		EQ 25MG BASE	N204790	003	Jun 09, 2016	Jan	DISC	
<u>DONEPEZIL HYDROCHLORIDE</u>								
SYSTEM;TRANSDERMAL								
ADLARITY								
+	CORIUM	5MG/DAY	N212304	001	Mar 11, 2022	Jun	CAHN	
+!		10MG/DAY	N212304	002	Mar 11, 2022	Jun	CAHN	
TABLET;ORAL								
DONEPEZIL HYDROCHLORIDE								
@	ENDO OPERATIONS	23MG	A202542	001	Jul 24, 2013	May	CAHN	
@	SUN PHARM INDS	5MG	A090493	001	May 31, 2011	May	DISC	
@		10MG	A090493	002	May 31, 2011	May	DISC	
TABLET, ORALLY DISINTEGRATING;ORAL								
DONEPEZIL HYDROCHLORIDE								
AB	!	MACLEODS PHARMS LTD	10MG	A201787	002	Dec 14, 2012	Mar	CHRS
	@	SANDOZ	5MG	A091198	001	May 10, 2011	Mar	DISC
	@		10MG	A091198	002	May 10, 2011	Mar	DISC
<u>DORZOLAMIDE HYDROCHLORIDE</u>								
SOLUTION/DROPS;OPHTHALMIC								
DORZOLAMIDE HYDROCHLORIDE								
@	HIKMA	EQ 2% BASE	A077846	001	Oct 28, 2008	Mar	DISC	
<u>DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE</u>								
SOLUTION/DROPS;OPHTHALMIC								
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE								
@	HIKMA	EQ 2% BASE;EQ 0.5% BASE	A077847	001	Oct 28, 2008	Mar	DISC	
<u>DOXAZOSIN MESYLATE</u>								
TABLET;ORAL								
DOXAZOSIN MESYLATE								
AB		AUROBINDO PHARMA USA	EQ 1MG BASE	A075509	001	Oct 19, 2000	Mar	CMFD
AB			EQ 2MG BASE	A075509	002	Oct 19, 2000	Mar	CMFD
AB			EQ 4MG BASE	A075509	003	Oct 19, 2000	Mar	CMFD
AB			EQ 8MG BASE	A075509	004	Oct 19, 2000	Mar	CMFD
<u>DOXEPIN HYDROCHLORIDE</u>								
CAPSULE;ORAL								
DOXEPIN HYDROCHLORIDE								
AB		ADAPTIS	EQ 150MG BASE	A213796	001	Apr 19, 2022	Sep	CAHN
AB		AIPING PHARM INC	EQ 10MG BASE	A213474	001	Jul 28, 2020	Sep	CAHN
AB			EQ 25MG BASE	A213474	002	Jul 28, 2020	Sep	CAHN
AB			EQ 50MG BASE	A213474	003	Jul 28, 2020	Sep	CAHN
AB			EQ 75MG BASE	A213474	004	Jul 28, 2020	Sep	CAHN
AB			EQ 100MG BASE	A213474	005	Jul 28, 2020	Sep	CAHN
	@	ENDO OPERATIONS	EQ 10MG BASE	A071422	002	Nov 09, 1987	Apr	CAHN
	@		EQ 25MG BASE	A071422	003	Nov 09, 1987	Apr	CAHN
	@		EQ 50MG BASE	A071422	004	Nov 09, 1987	Apr	CAHN
	@		EQ 75MG BASE	A071422	005	Nov 09, 1987	Apr	CAHN

CAPSULE;ORAL
DOXEPIN HYDROCHLORIDE

	@	EQ 100MG BASE	A071422	001	Nov 09, 1987	Apr	CAHN
AB	!	EQ 150MG BASE	A071422	006	Nov 09, 1987	Apr	CAHN
AB		LEADING	A211619	001	Mar 09, 2021	Aug	CAHN
AB		EQ 10MG BASE	A211619	001	Mar 09, 2021	Aug	CAHN
AB		EQ 25MG BASE	A211619	002	Mar 09, 2021	Aug	CAHN
AB		EQ 50MG BASE	A211619	003	Mar 09, 2021	Aug	CAHN
AB		EQ 75MG BASE	A211619	004	Mar 09, 2021	Aug	CAHN
AB		EQ 100MG BASE	A211619	005	Mar 09, 2021	Aug	CAHN
AB		VELZEN PHARMA PVT	A211618	001	Mar 01, 2021	Aug	CAHN

TABLET;ORAL
DOXEPIN HYDROCHLORIDE

	@	AUROBINDO PHARMA LTD	EQ 3MG BASE	A216041	001	Jul 25, 2024	Aug	DISC
AB			EQ 3MG BASE	A216041	001	Jul 25, 2024	Jul	NEWA
	@		EQ 6MG BASE	A216041	002	Jul 25, 2024	Aug	DISC
AB			EQ 6MG BASE	A216041	002	Jul 25, 2024	Jul	NEWA
AB		ZYDUS LIFESCIENCES	EQ 3MG BASE	A202761	001	Aug 16, 2023	Sep	CMFD
	@		EQ 3MG BASE	A202761	001	Aug 16, 2023	Jun	CAHN
AB			EQ 6MG BASE	A202761	002	Aug 16, 2023	Sep	CMFD
	@		EQ 6MG BASE	A202761	002	Aug 16, 2023	Jun	CAHN

DOXERCALCIFEROL

INJECTABLE;INJECTION
DOXERCALCIFEROL

	@	AMNEAL	2MCG/ML (2MCG/ML)	A208974	001	May 24, 2017	Jan	DISC
	@		4MCG/2ML (2MCG/ML)	A208974	002	May 24, 2017	Jan	DISC
	@		4MCG/2ML (2MCG/ML)	A208975	001	May 24, 2017	Jul	DISC
AP			4MCG/2ML (2MCG/ML)	A208975	001	May 24, 2017	Jan	CMFD

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION
DOXORUBICIN HYDROCHLORIDE

	+ @	PFIZER	150MG/75ML	N050629	003	Mar 28, 2011	Oct	DISC
--	-----	--------	------------	---------	-----	--------------	-----	------

INJECTABLE, LIPOSOMAL;INJECTION
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

AB		FORDOZ	20MG/10ML (2MG/ML)	A215178	001	Jul 16, 2024	Jul	NEWA
AB			50MG/25ML (2MG/ML)	A215178	002	Jul 16, 2024	Jul	NEWA
AB		LUPIN	20MG/10ML (2MG/ML)	A215178	001	Jul 16, 2024	Sep	CAHN
AB			50MG/25ML (2MG/ML)	A215178	002	Jul 16, 2024	Sep	CAHN

DOXYCYCLINE

CAPSULE;ORAL
DOXYCYCLINE

AB		ALEMBIC	40MG	A217674	001	Jun 27, 2024	Jun	NEWA
AB		APOTEX	40MG	A217170	001	Jul 11, 2024	Jul	NEWA
	@	COSETTE	EQ 50MG BASE	A204446	001	May 28, 2015	Apr	DISC
	@		EQ 75MG BASE	A204446	002	May 28, 2015	Apr	DISC
	@		EQ 100MG BASE	A204446	003	May 28, 2015	Apr	DISC
AB		DR REDDYS	40MG	A218034	001	Apr 08, 2024	Mar	NFTG
AB		LUPIN	40MG	A216631	001	Apr 08, 2024	Mar	NFTG

ORACEA

AB	+!	GALDERMA LABS LP	40MG	N050805	001	May 26, 2006	Mar	CFTG
----	----	------------------	------	---------	-----	--------------	-----	------

FOR SUSPENSION;ORAL
DOXYCYCLINE

AB	!	LUPIN LTD	EQ 25MG BASE/5ML	A201678	001	Mar 18, 2013	Jun	CHRS
----	---	-----------	------------------	---------	-----	--------------	-----	------

VIBRAMYCIN

	+ @	PFIZER	EQ 25MG BASE/5ML	N050006	001		Jun	DISC
--	-----	--------	------------------	---------	-----	--	-----	------

TABLET;ORAL
DOXYCYCLINE

	@	SOMERSET THERAPS LLC	EQ 50MG BASE	A065377	001	Nov 07, 2006	Sep	CAHN
	@		EQ 75MG BASE	A065377	002	Nov 07, 2006	Sep	CAHN
	@		EQ 100MG BASE	A065377	003	Nov 07, 2006	Sep	CAHN
	@		EQ 150MG BASE	A065427	001	Jun 07, 2007	Sep	CAHN

DOXYCYCLINE CALCIUM

SUSPENSION;ORAL
VIBRAMYCIN

	+ @	PFIZER	EQ 50MG BASE/5ML	N050480	001		Sep	DISC
--	-----	--------	------------------	---------	-----	--	-----	------

DOXYCYCLINE HYCLATE

	CAPSULE;ORAL						
	ACTICLATE CAP						
	+ @	CHARTWELL RX	EQ 75MG BASE	N208253	001	Apr 26, 2016	Jan CAHN
	INJECTABLE;INJECTION						
	DOXYCYCLINE HYCLATE						
AP		ACIC PHARMS	EQ 100MG BASE/VIAL	A217854	001	Jul 23, 2024	Jul NEWA
>A> AP		AMNEAL	EQ 100MG BASE/VIAL	A217487	001	Dec 04, 2024	Nov NEWA
AP		ENDO OPERATIONS	EQ 100MG BASE/VIAL	A216690	001	Dec 07, 2022	Oct CMFD
AP		HAINAN POLY	EQ 100MG BASE/VIAL	A217685	001	Jun 21, 2024	Jun NEWA
AP			EQ 200MG BASE/VIAL	A217685	002	Jun 21, 2024	Jun NEWA
AP		HERITAGE	EQ 100MG BASE/VIAL	A217854	001	Jul 23, 2024	Sep CAHN
AP		KINDOS	EQ 100MG BASE/VIAL	A218053	001	Oct 28, 2024	Oct NEWA
AP		LUPIN LTD	EQ 100MG BASE/VIAL	A217794	001	Mar 14, 2024	Mar NEWA
AP		SLATE RUN PHARMA	EQ 100MG BASE/VIAL	A217685	001	Jun 21, 2024	Sep CAHN
AP			EQ 200MG BASE/VIAL	A217685	002	Jun 21, 2024	Sep CAHN
	TABLET;ORAL						
	ACTICLATE						
AB	+ @	CHARTWELL RX	EQ 75MG BASE	N205931	001	Jul 25, 2014	Jan CAHN
AB	+!		EQ 150MG BASE	N205931	002	Jul 25, 2014	Jan CAHN
	DOXYCYCLINE HYCLATE						
AB		EPIC PHARMA LLC	EQ 50MG BASE	A062269	003	Oct 05, 1983	Oct CAHN
AB	!		EQ 100MG BASE	A062269	002	Nov 08, 1982	Oct CAHN
	@	NOSTRUM LABS INC	EQ 100MG BASE	A209560	001	Apr 15, 2024	May DISC
AB			EQ 100MG BASE	A209560	001	Apr 15, 2024	Apr NEWA
	@	ORYZA	EQ 100MG BASE	A213475	001	Mar 10, 2021	Aug CAHN
	@	TORRENT	EQ 75MG BASE	A214356	001	Apr 15, 2024	Apr DISC
AB			EQ 75MG BASE	A214356	001	Apr 15, 2024	Apr NEWA
	@		EQ 150MG BASE	A214356	002	Apr 15, 2024	Apr DISC
AB			EQ 150MG BASE	A214356	002	Apr 15, 2024	Apr NEWA
	TABLET, DELAYED RELEASE;ORAL						
	DORYX						
	+ @	MAYNE PHARMA	EQ 75MG BASE	N050795	001	May 06, 2005	Feb DISC
	+ @		EQ 150MG BASE	N050795	003	Jun 20, 2008	Feb DISC

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

	TABLET, DELAYED RELEASE;ORAL						
	DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE						
AB		ENDO OPERATIONS	10MG;10MG	A208518	001	Dec 06, 2017	Apr CAHN

DRONABINOL

	CAPSULE;ORAL						
	DRONABINOL						
	@	HIKMA	2.5MG	A079217	001	Jun 20, 2014	Mar DISC
	@		5MG	A079217	002	Jun 20, 2014	Mar DISC
	@		10MG	A079217	003	Jun 20, 2014	Mar DISC
	@	SVC PHARMA	2.5MG	A078292	001	Jun 27, 2008	Aug DISC
	@		5MG	A078292	002	Jun 27, 2008	Aug DISC
	@		10MG	A078292	003	Jun 27, 2008	Aug DISC
	SOLUTION;ORAL						
	SYNDROS						
	+ @	BENVIA OPERATIONS	5MG/ML	N205525	001	Mar 23, 2017	Aug DISC

DRONEDARONE HYDROCHLORIDE

	TABLET;ORAL						
	DRONEDARONE HYDROCHLORIDE						
AB		LUPIN	EQ 400MG BASE	A205904	001	Jan 31, 2024	Jan NFTG
		MULTAQ					
AB	+!	SANOFI AVENTIS US	EQ 400MG BASE	N022425	001	Jul 01, 2009	Jan CFTG

DROSPIRENONE

	TABLET;ORAL						
	DROSPIRENONE						
AB		LUPIN LTD	4MG	A216936	001	Sep 30, 2024	Sep NFTG
		SLYND					
AB	+!	EXELTIS USA INC	4MG	N211367	001	May 23, 2019	Sep CFTG

DROXIDOPA

CAPSULE;ORAL		DROXIDOPA					
AB	ADAPTIS	100MG	A215265	001	Nov 01, 2021	Oct	CAHN
AB		200MG	A215265	002	Nov 01, 2021	Oct	CAHN
AB		300MG	A215265	003	Nov 01, 2021	Oct	CAHN
AB	SOMERSET THERAPS LLC	100MG	A214543	001	May 05, 2021	Sep	CAHN
AB		200MG	A214543	002	May 05, 2021	Sep	CAHN
AB		300MG	A214543	003	May 05, 2021	Sep	CAHN
	@ UPSHER SMITH LABS	100MG	A213661	001	Feb 18, 2021	Apr	DISC
	@	200MG	A213661	002	Feb 18, 2021	Apr	DISC
	@	300MG	A213661	003	Feb 18, 2021	Apr	DISC
AB	YAMPA	100MG	A215265	001	Nov 01, 2021	Sep	CAHN
AB		200MG	A215265	002	Nov 01, 2021	Sep	CAHN
AB		300MG	A215265	003	Nov 01, 2021	Sep	CAHN

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL		DRIZALMA SPRINKLE					
+	SUN PHARM	EQ 20MG BASE	N212516	001	Jul 19, 2019	Apr	CMFD
+		EQ 30MG BASE	N212516	002	Jul 19, 2019	Apr	CMFD
+		EQ 40MG BASE	N212516	003	Jul 19, 2019	Apr	CMFD
+	!	EQ 60MG BASE	N212516	004	Jul 19, 2019	Apr	CMFD
DULOXETINE HYDROCHLORIDE							
	@ ANCHEN PHARMS	EQ 20MG BASE	A090780	001	Oct 28, 2015	Feb	DISC
	@	EQ 30MG BASE	A090780	002	Oct 28, 2015	Feb	DISC
	@	EQ 60MG BASE	A090780	003	Oct 28, 2015	Feb	DISC
	@ ENDO OPERATIONS	EQ 20MG BASE	A090780	001	Oct 28, 2015	May	CAHN
	@	EQ 30MG BASE	A090780	002	Oct 28, 2015	May	CAHN
	@	EQ 60MG BASE	A090780	003	Oct 28, 2015	May	CAHN
>D>	AB SUN PHARM	EQ 20MG BASE	A090745	001	Dec 11, 2013	Nov	DISC
>A>	@	EQ 20MG BASE	A090745	001	Dec 11, 2013	Nov	DISC
>D>	AB	EQ 30MG BASE	A090745	002	Dec 11, 2013	Nov	DISC
>A>	@	EQ 30MG BASE	A090745	002	Dec 11, 2013	Nov	DISC
>D>	AB	EQ 60MG BASE	A090745	003	Dec 11, 2013	Nov	DISC
>A>	@	EQ 60MG BASE	A090745	003	Dec 11, 2013	Nov	DISC

DUTASTERIDE

CAPSULE;ORAL		AVODART					
AB	+! WAYLIS THERAP	0.5MG	N021319	001	Nov 20, 2001	Mar	CAHN
DUTASTERIDE							
AB	CHARTWELL	0.5MG	A200899	001	Nov 20, 2015	Mar	CAHN
	@ NORVIUM BIOSCIENCE	0.5MG	A203241	001	Jun 14, 2016	Jun	CAHN
	@ VINTAGE	0.5MG	A202421	001	Nov 20, 2015	Feb	DISC

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL		DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE					
AB	AUROBINDO PHARMA	0.5MG;0.4MG	A213300	001	Jul 18, 2024	Jul	NEWA
AB	ENDO OPERATIONS	0.5MG;0.4MG	A202509	001	Feb 26, 2014	Apr	CAHN
JALYN							
AB	+! WAYLIS THERAP	0.5MG;0.4MG	N022460	001	Jun 14, 2010	Apr	CAHN

DYPHYLLINE

TABLET;ORAL		LUFYLLIN					
	@ NORVIUM BIOSCIENCE	200MG	A084566	001		Jul	CAHN
	@	400MG	A084566	002		Jul	CAHN

EDARAVONE

SOLUTION;INTRAVENOUS		EDARAVONE					
AP	DR REDDYS	60MG/100ML (0.6MG/ML)	A215917	001	May 06, 2024	Apr	NEWA
AP	GLAND PHARMA LTD	30MG/100ML (0.3MG/ML)	A216199	001	May 06, 2024	Apr	NFTG
AP		60MG/100ML (0.6MG/ML)	A216199	002	May 06, 2024	Apr	NFTG
AP	HIKMA	30MG/100ML (0.3MG/ML)	A215508	001	May 06, 2024	Apr	NFTG
AP	LONG GROVE PHARMS	30MG/100ML (0.3MG/ML)	A218354	001	May 06, 2024	Apr	NEWA
AP	XGEN PHARMS	30MG/100ML (0.3MG/ML)	A217565	001	Oct 31, 2024	Oct	NEWA
AP		60MG/100ML (0.6MG/ML)	A217565	002	Oct 31, 2024	Oct	NEWA

SOLUTION;INTRAVENOUS
RADICAVA

AP	+	!	! MITSUBISHI TANABE	30MG/100ML (0.3MG/ML)	N209176	001	May 05, 2017	Apr	CFTG
AP	+	!	!	60MG/100ML (0.6MG/ML)	N209176	002	Nov 15, 2018	Apr	CFTG

EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION
ENLON

	@	NORVIUM BIOSCIENCE	10MG/ML	A088873	001	Aug 06, 1985	Jul	CAHN
--	---	--------------------	---------	---------	-----	--------------	-----	------

EFAVIRENZ

TABLET;ORAL
EFAVIRENZ

AB		MACLEODS PHARMS LTD	600MG	A091579	001	May 10, 2024	May	NEWA
----	--	---------------------	-------	---------	-----	--------------	-----	------

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL
ATRIPLA

	+	@	GILEAD SCIENCES	600MG;200MG;300MG	N021937	001	Jul 12, 2006	Sep	DISC
			EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE						
AB	!		AUROBINDO PHARMA	600MG;200MG;300MG	A203041	001	Sep 04, 2018	Sep	CHRS
			EFAVIRENZ; EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE						
		@	STRIDES PHARMA	600MG;200MG;300MG	A201802	001	Oct 03, 2023	Mar	DISC
			EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE						
		@	MYLAN	600MG;200MG;300MG	A209061	001	Sep 05, 2024	Sep	DISC
AB				600MG;200MG;300MG	A209061	001	Sep 05, 2024	Aug	NEWA

EFINACONAZOLE

SOLUTION;TOPICAL
EFINACONAZOLE

AB		UMEDICA	10%	A211969	001	Jun 21, 2021	Aug	CAHN
	@	ZYDUS LIFESCIENCES	10%	A212178	001	Jul 15, 2022	May	CAHN

>D> ELACESTRANT DIHYDROCHLORIDE

>D> TABLET;ORAL
>D> ORSERDU

>D>	+		STEMLINE THERAP	EQ 86MG BASE	N217639	001	Jan 27, 2023	Nov	CAIN
>D>	+	!	!	EQ 345MG BASE	N217639	002	Jan 27, 2023	Nov	CAIN

>A> ELACESTRANT HYDROCHLORIDE

>A> TABLET;ORAL
>A> ORSERDU

>A>	+		STEMLINE THERAP	EQ 86MG BASE	N217639	001	Jan 27, 2023	Nov	CAIN
>A>	+	!	!	EQ 345MG BASE	N217639	002	Jan 27, 2023	Nov	CAIN

ELAFIBRANOR

TABLET;ORAL
IQIRVO

	+	!	IPSEN	80MG	N218860	001	Jun 10, 2024	Jun	NEWA
--	---	---	-------	------	---------	-----	--------------	-----	------

ELIGLUSTAT TARTRATE

CAPSULE;ORAL
ELIGLUSTAT TARTRATE

AB		APOTEX	EQ 84MG BASE	A212425	001	Jul 10, 2024	Jun	NEWA
>A>	AB	CIPLA	EQ 84MG BASE	A212369	001	Dec 10, 2024	Nov	NEWA

ELTROMBOPAG OLAMINE

FOR SUSPENSION;ORAL
ELTROMBOPAG OLAMINE

AB		ANNORA PHARMA	EQ 12.5MG ACID/PACKET	A216620	001	Apr 18, 2024	Apr	NFTG	
AB			EQ 25MG ACID/PACKET	A216620	002	Apr 18, 2024	Apr	NFTG	
		PROMACTA KIT							
AB	+	NOVARTIS	EQ 12.5MG ACID/PACKET	N207027	002	Sep 27, 2018	Apr	CFTG	
AB	+	!	!	EQ 25MG ACID/PACKET	N207027	001	Aug 24, 2015	Apr	CFTG

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL
DESCOVY

	+	GILEAD SCIENCES INC	120MG;EQ 15MG BASE	N208215	002	Jan 07, 2022	Sep	CTEC	
AB	+		120MG;EQ 15MG BASE	N208215	002	Jan 07, 2022	May	CFTG	
	+	!	!	200MG;EQ 25MG BASE	N208215	001	Apr 04, 2016	Sep	CTEC

	TABLET;ORAL						
	DESCOVY						
AB	+	200MG;EQ 25MG BASE	N208215	001	Apr 04, 2016	May	CFTG
		EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE					
	@	APOTEX 120MG;EQ 15MG BASE	A214053	001	May 17, 2024	Sep	DISC
AB		120MG;EQ 15MG BASE	A214053	001	May 17, 2024	May	NFTG
	@	200MG;EQ 25MG BASE	A214053	002	May 17, 2024	Sep	DISC
AB		200MG;EQ 25MG BASE	A214053	002	May 17, 2024	May	NFTG
	<u>ENALAPRIL MALEATE</u>						
	FOR SOLUTION;ORAL						
	EPANED KIT						
	+	@ AZURITY 1MG/ML	N204308	001	Aug 13, 2013	Mar	CAHN
	SOLUTION;ORAL						
	ENALAPRIL MALEATE						
AB		AMNEAL 1MG/ML	A212894	001	Jun 29, 2022	Mar	CMFD
	TABLET;ORAL						
	ENALAPRIL MALEATE						
AB		AIPING PHARM INC 2.5MG	A075178	002	Mar 23, 2001	Oct	CMFD
AB		5MG	A075178	001	Mar 23, 2001	Oct	CMFD
AB		10MG	A075178	003	Mar 23, 2001	Oct	CMFD
AB		20MG	A075178	004	Mar 23, 2001	Oct	CMFD
AB		UNIQUE PHARM 2.5MG	A218531	001	Sep 19, 2024	Sep	NEWA
AB		5MG	A218531	002	Sep 19, 2024	Sep	NEWA
AB		10MG	A218531	003	Sep 19, 2024	Sep	NEWA
AB		20MG	A218531	004	Sep 19, 2024	Sep	NEWA
	<u>ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE</u>						
	TABLET;ORAL						
	ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE						
	@	COSETTE 5MG;12.5MG	A075727	001	Sep 18, 2001	Apr	DISC
	@	10MG;25MG	A075727	002	Sep 18, 2001	Apr	DISC
	<u>ENSIFENTRINE</u>						
	SUSPENSION;INHALATION						
	OHTUVAYRE						
	+	VERONA PHARMA 3MG/2.5ML	N217389	001	Jun 26, 2024	Jun	NEWA
	<u>ENTECAVIR</u>						
	TABLET;ORAL						
	ENTECAVIR						
	@	PRINSTON INC 0.5MG	A208782	001	Oct 10, 2017	Sep	DISC
	@	1MG	A208782	002	Oct 10, 2017	Sep	DISC
	@	SWISS PHARM 0.5MG	A212106	001	Aug 10, 2020	Jul	CAHN
	@	1MG	A212106	002	Aug 10, 2020	Jul	CAHN
	@	VITRUVIAS 0.5MG	A212106	001	Aug 10, 2020	Jun	DISC
	@	1MG	A212106	002	Aug 10, 2020	Jun	DISC
AB		YUNG SHIN PHARM 0.5MG	A208195	001	Nov 10, 2021	Jun	CMFD
AB		1MG	A208195	002	Nov 10, 2021	Jun	CMFD
	<u>ENZALUTAMIDE</u>						
	CAPSULE;ORAL						
	ENZALUTAMIDE						
AB		ZYDUS PHARMS 40MG	A209667	001	Sep 26, 2024	Sep	NEWA
	XTANDI						
AB	+	ASTELLAS 40MG	N203415	001	Aug 31, 2012	Sep	CTEC
	<u>EPHEDRINE HYDROCHLORIDE</u>						
	SOLUTION;INTRAVENOUS						
	REZIPRES						
	+	@ DR REDDYS LABS SA 23.5MG/5ML (4.7MG/ML)	N213536	001	Jun 14, 2021	May	DISC
	<u>EPHEDRINE SULFATE</u>						
	SOLUTION;INTRAVENOUS						
	AKOVAZ						
AP	+	EXELA PHARMA 25MG/5ML (5MG/ML)	N208289	002	Aug 02, 2021	Oct	CFTG
	EPHEDRINE SULFATE						
AP		CAPLIN 50MG/ML (50MG/ML)	A219050	001	Jul 18, 2024	Jul	NEWA
	+	ENDO OPERATIONS 25MG/5ML (5MG/ML)	N213994	002	Apr 22, 2022	Apr	CAHN
	+	50MG/10ML (5MG/ML)	N213994	001	Oct 16, 2020	Apr	CAHN
AP		HIKMA 25MG/5ML (5MG/ML)	A217721	001	Oct 11, 2024	Oct	NFTG

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
EPINASTINE HYDROCHLORIDE
@ BRECKENRIDGE 0.05%

A 090870 001 Mar 14, 2011 Oct DISC

EPINEPHRINE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
EPINEPHRINE

AP AM REGENT EQ 30MG BASE/30ML (EQ 1MG BASE/ML) A 217192 001 Sep 06, 2024 Aug NEWA
+! BPI LABS 1MG/ML (1MG/ML) N 205029 005 Mar 04, 2024 Apr NEWA
+! 30MG/30ML (1MG/ML) N 205029 004 Feb 14, 2024 Feb NEWA

SOLUTION;INTRAVENOUS
EPINEPHRINE

+ @ BPI LABS 1MG/ML (1MG/ML) N 205029 003 May 12, 2023 Jun DISC

SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS
EPINEPHRINE

>D> +! BPI LABS 1MG/ML (1MG/ML) N 205029 001 Jul 29, 2014 Nov CFTG
>A> AP +! 1MG/ML (1MG/ML) N 205029 001 Jul 29, 2014 Nov CFTG
>A> AP FRESENIUS KABI USA 1MG/ML (1MG/ML) A 213708 001 Nov 20, 2024 Nov NFTG

SPRAY;NASAL
NEFFY

+! ARS PHARMS OPERATION 2MG/SPRAY N 214697 001 Aug 09, 2024 Aug NEWA

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION
XYLOCAINE W/ EPINEPHRINE

+ @ FRESENIUS KABI USA 0.01MG/ML;2% N 006488 003 Feb CRLD

EPIRUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION
EPIRUBICIN HYDROCHLORIDE

@ NORVIUM BIOSCIENCE 50MG/25ML (2MG/ML) A 065371 001 Nov 28, 2007 Jul CAHN
@ 200MG/100ML (2MG/ML) A 065371 002 Nov 28, 2007 Jul CAHN

EPLERENONE

TABLET;ORAL
EPLERENONE

>A> AB ADAPTIS 25MG A 212765 001 Aug 10, 2020 Nov CAHN
>A> AB 50MG A 212765 002 Aug 10, 2020 Nov CAHN
@ PRASCO 25MG A 203896 001 Feb 02, 2017 Mar DISC
@ 50MG A 203896 002 Feb 02, 2017 Mar DISC
>D> AB SLATE RUN PHARMA 25MG A 212765 001 Aug 10, 2020 Nov CAHN
AB 25MG A 212765 001 Aug 10, 2020 Feb CAHN
>D> AB 50MG A 212765 002 Aug 10, 2020 Nov CAHN
AB 50MG A 212765 002 Aug 10, 2020 Feb CAHN

EPLONTERSEN SODIUM

SOLUTION;SUBCUTANEOUS
WAINUA (AUTOINJECTOR)

+! ASTRAZENECA AB EQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML) N 217388 001 Dec 21, 2023 Feb CTNA
+! EQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML) N 217388 001 Dec 21, 2023 Jan CAHN

EPOPROSTENOL SODIUM

INJECTABLE;INJECTION
EPOPROSTENOL SODIUM

AP1 MEITHEAL EQ 0.5MG BASE/VIAL A 078396 001 Apr 23, 2008 Jan CAHN
AP1 EQ 1.5MG BASE/VIAL A 078396 002 Apr 23, 2008 Jan CAHN
AP2 MYLAN EQ 0.5MG BASE/VIAL A 213913 001 Jun 12, 2024 May NEWA
AP2 EQ 1.5MG BASE/VIAL A 213913 002 Jun 12, 2024 May NEWA

EPTIFIBATIDE

INJECTABLE;INJECTION
EPTIFIBATIDE

@ ACCORD HLTHCARE 2MG/ML A 205557 001 Nov 06, 2017 May DISC
@ 75MG/100ML A 205557 002 Nov 06, 2017 May DISC
AP HONG KONG 2MG/ML A 213599 001 May 09, 2024 May NEWA
AP 75MG/100ML A 213599 002 May 09, 2024 May NEWA

ERGOCALCIFEROL

CAPSULE;ORAL
DRISDOL

AA + ESJAY PHARMA 50,000 IU N003444 001 Oct CAHN

ERGOLOID MESYLATES

TABLET;ORAL
ERGOLOID MESYLATES
@ SUN PHARM INDUSTRIES 1MG

A081113 001 Oct 31, 1991 Jul DISC

ERGOTAMINE TARTRATE

TABLET;SUBLINGUAL
ERGOMAR

>A> ! PANGEA 2MG A087693 001 Feb 24, 1983 Nov CAHN
! 2MG A087693 001 Feb 24, 1983 Feb CAHN
>D> ! PHARMOBEDIENT 2MG A087693 001 Feb 24, 1983 Nov CAHN
! 2MG A087693 001 Feb 24, 1983 Sep CAHN

ERIBULIN MESYLATE

SOLUTION;INTRAVENOUS
ERIBULIN MESYLATE

AP BAXTER HLTHCARE CORP 1MG/2ML (0.5MG/ML) A217250 001 Oct 01, 2024 Sep NEWA
AP GLAND PHARMA LTD 1MG/2ML (0.5MG/ML) A218047 001 Apr 05, 2024 Mar NFTG
AP JIANGXI QINGFENG 1MG/2ML (0.5MG/ML) A218281 001 Jun 28, 2024 Jun NEWA
AP LONG GROVE PHARMS 1MG/2ML (0.5MG/ML) A214850 001 Jul 18, 2024 Jul NEWA
HALAVEN
AP +! EISAI INC 1MG/2ML (0.5MG/ML) N201532 001 Nov 15, 2010 Mar CFTG

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL
ERLOTINIB HYDROCHLORIDE

AB CHARTWELL RX EQ 25MG BASE A203843 001 Sep 13, 2024 Sep CAHN
AB EQ 150MG BASE A203843 002 Sep 13, 2024 Sep CAHN
AB HETERO LABS LTD V EQ 25MG BASE A209267 001 May 24, 2024 May NEWA
AB EQ 100MG BASE A209267 002 May 24, 2024 May NEWA
AB EQ 150MG BASE A209267 003 May 24, 2024 May NEWA
AB HIKMA EQ 25MG BASE A203843 001 Sep 13, 2024 Sep NEWA
AB EQ 150MG BASE A203843 002 Sep 13, 2024 Sep NEWA
@ NATCO PHARMA LTD EQ 25MG BASE A208488 001 Nov 05, 2019 Apr DISC
@ EQ 150MG BASE A208488 003 Nov 05, 2019 Aug DISC

ERTAPENEM SODIUM

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS
ERTAPENEM SODIUM

>D> AP QILU EQ 1GM BASE/VIAL A218067 001 Oct 31, 2024 Nov CAHN
AP EQ 1GM BASE/VIAL A218067 001 Oct 31, 2024 Oct NEWA
>A> AP QILU ANTIBIOTICS EQ 1GM BASE/VIAL A218067 001 Oct 31, 2024 Nov CAHN
@ SUN PHARM EQ 1GM BASE/VIAL A209145 001 May 02, 2023 Jan DISC

ERTUGLIFLOZIN

TABLET;ORAL
ERTUGLIFLOZIN

AB HETERO LABS LTD V 5MG A217071 001 Sep 17, 2024 Sep NEWA
AB 15MG A217071 002 Sep 17, 2024 Sep NEWA
STEGLATRO
AB + MSD SUB MERCK 5MG N209803 001 Dec 19, 2017 Sep CTEC
AB +! 15MG N209803 002 Dec 19, 2017 Sep CTEC

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS;ORAL
ERYTHROMYCIN

>D> AB AZURITY 250MG A062746 001 Dec 22, 1986 Nov CAHN
AB 250MG A062746 001 Dec 22, 1986 Mar CAHN
>A> AB CARNEGIE 250MG A062746 001 Dec 22, 1986 Nov CAHN

OINTMENT;OPHTHALMIC
ERYTHROMYCIN

AT ! BAUSCH AND LOMB 0.5% A064067 001 Jul 29, 1994 Mar CHRS
@ PADAGIS US 0.5% A062447 001 Sep 26, 1983 Mar DISC

TABLET;ORAL
ERYTHROMYCIN

>D>	AB	AZURITY	250MG	A 061621	001		Nov	CAHN
	AB		250MG	A 061621	001		Mar	CAHN
>D>	AB		500MG	A 061621	002		Nov	CAHN
	AB		500MG	A 061621	002		Mar	CAHN
>A>	AB	CARNEGIE	250MG	A 061621	001		Nov	CAHN
>A>	AB		500MG	A 061621	002		Nov	CAHN

TABLET, DELAYED RELEASE;ORAL
ERY-TAB

>D>	AB	AZURITY	250MG	A 062298	001		Nov	CAHN
	AB		250MG	A 062298	001		Mar	CAHN
>D>	AB		333MG	A 062298	003	Mar 29, 1982	Nov	CAHN
	AB		333MG	A 062298	003	Mar 29, 1982	Mar	CAHN
>D>	AB	!	500MG	A 062298	002		Nov	CAHN
	AB	!	500MG	A 062298	002		Mar	CAHN
>A>	AB	CARNEGIE	250MG	A 062298	001		Nov	CAHN
>A>	AB		333MG	A 062298	003	Mar 29, 1982	Nov	CAHN
>A>	AB	!	500MG	A 062298	002		Nov	CAHN
	AB	ERYTHROMYCIN TORRENT	333MG	A 211975	003	Aug 13, 2024	Aug	NEWA

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL
E.E.S.

>D>	AB	+	AZURITY	EQ 200MG BASE/5ML	N 050207	001		Nov	CAHN
>A>	AB	+	CARNEGIE	EQ 200MG BASE/5ML	N 050207	001		Nov	CAHN
			ERYPED						
>D>	AB	+	AZURITY	EQ 200MG BASE/5ML	N 050207	003	Mar 30, 1987	Nov	CAHN
>D>	AB	+	!	EQ 400MG BASE/5ML	N 050207	002		Nov	CAHN
>A>	AB	+	CARNEGIE	EQ 200MG BASE/5ML	N 050207	003	Mar 30, 1987	Nov	CAHN
>A>	AB	+	!	EQ 400MG BASE/5ML	N 050207	002		Nov	CAHN
			ERYTHROMYCIN ETHYLSUCCINATE						
		@	ENDO OPERATIONS	EQ 200MG BASE/5ML	A 211991	001	Oct 23, 2019	May	CAHN
		@		EQ 400MG BASE/5ML	A 211991	002	Oct 23, 2019	May	CAHN

TABLET;ORAL
E.E.S. 400

>D>		@	AZURITY	EQ 400MG BASE	A 061905	001		Nov	CAHN
		@		EQ 400MG BASE	A 061905	001		Mar	CAHN
>D>	BX	!		EQ 400MG BASE	A 061905	002	Aug 12, 1982	Nov	CAHN
	BX	!		EQ 400MG BASE	A 061905	002	Aug 12, 1982	Mar	CAHN
>A>		@	CARNEGIE	EQ 400MG BASE	A 061905	001		Nov	CAHN
>A>	BX	!		EQ 400MG BASE	A 061905	002	Aug 12, 1982	Nov	CAHN
			ERYTHROMYCIN ETHYLSUCCINATE						
>D>	BX	!	AZURITY	EQ 400MG BASE	A 061904	001		Nov	CAHN
	BX	!		EQ 400MG BASE	A 061904	001		Mar	CAHN
>A>	BX	!	CARNEGIE	EQ 400MG BASE	A 061904	001		Nov	CAHN

ERYTHROMYCIN LACTOBIONATE

INJECTABLE;INJECTION
ERYTHROMYCIN LACTOBIONATE

>A>	AP		GLAND PHARMA LTD	EQ 500MG BASE/VIAL	A 216761	001	Nov 19, 2024	Nov	NEWA
-----	----	--	------------------	--------------------	----------	-----	--------------	-----	------

ERYTHROMYCIN STEARATE

TABLET;ORAL
ERYTHROCIN STEARATE

		@	AZURITY	EQ 125MG BASE	A 060359	002		Mar	CAHN
		!		EQ 250MG BASE	A 060359	001		Mar	CAHN
		@		EQ 500MG BASE	A 060359	003		Mar	CAHN

ESCITALOPRAM OXALATE

TABLET;ORAL
ESCITALOPRAM OXALATE

>A>		@	AIPING PHARM INC	EQ 5MG BASE	A 077512	001	Sep 12, 2012	Nov	CAHN
>A>		@		EQ 10MG BASE	A 077512	002	Sep 12, 2012	Nov	CAHN
>A>		@		EQ 20MG BASE	A 077512	003	Sep 12, 2012	Nov	CAHN
>D>		@	ANIMA	EQ 5MG BASE	A 077512	001	Sep 12, 2012	Nov	CAHN
		@		EQ 5MG BASE	A 077512	001	Sep 12, 2012	Sep	CAHN
>D>		@		EQ 10MG BASE	A 077512	002	Sep 12, 2012	Nov	CAHN
		@		EQ 10MG BASE	A 077512	002	Sep 12, 2012	Sep	CAHN
>D>		@		EQ 20MG BASE	A 077512	003	Sep 12, 2012	Nov	CAHN
		@		EQ 20MG BASE	A 077512	003	Sep 12, 2012	Sep	CAHN

TABLET;ORAL

ESCITALOPRAM OXALATE

>D>	@ DASH PHARMS	EQ 5MG BASE	A 077550	001	May 14, 2015	Nov	CAHN
>D>	@	EQ 10MG BASE	A 077550	002	May 14, 2015	Nov	CAHN
>D>	@	EQ 20MG BASE	A 077550	003	May 14, 2015	Nov	CAHN
>A>	@ ESJAY PHARMA	EQ 5MG BASE	A 077550	001	May 14, 2015	Nov	CAHN
>A>	@	EQ 10MG BASE	A 077550	002	May 14, 2015	Nov	CAHN
>A>	@	EQ 20MG BASE	A 077550	003	May 14, 2015	Nov	CAHN
	@ PHARM ASSOC	EQ 5MG BASE	A 077512	001	Sep 12, 2012	Mar	DISC
	@	EQ 10MG BASE	A 077512	002	Sep 12, 2012	Mar	DISC
	@	EQ 20MG BASE	A 077512	003	Sep 12, 2012	Mar	DISC

ESLICARBAZEPINE ACETATE

TABLET;ORAL

ESLICARBAZEPINE ACETATE

	@ APOTEX	200MG	A 211236	001	Dec 07, 2023	Apr	DISC
	@	400MG	A 211236	002	Dec 07, 2023	Apr	DISC
	@	600MG	A 211236	003	Dec 07, 2023	Apr	DISC
	@	800MG	A 211236	004	Dec 07, 2023	Apr	DISC
	@ LUPIN LTD	200MG	A 211246	001	Mar 27, 2024	Sep	DISC
AB	@	200MG	A 211246	001	Mar 27, 2024	Mar	NEWA
	@	400MG	A 211246	002	Mar 27, 2024	Sep	DISC
AB	@	400MG	A 211246	002	Mar 27, 2024	Mar	NEWA
	@	600MG	A 211246	003	Mar 27, 2024	Sep	DISC
AB	@	600MG	A 211246	003	Mar 27, 2024	Mar	NEWA
	@	800MG	A 211246	004	Mar 27, 2024	Sep	DISC
AB	@	800MG	A 211246	004	Mar 27, 2024	Mar	NEWA
	@ TORRENT	200MG	A 211227	001	Feb 27, 2024	Mar	DISC
AB	@	200MG	A 211227	001	Feb 27, 2024	Feb	NEWA
	@	400MG	A 211227	002	Feb 27, 2024	Mar	DISC
AB	@	400MG	A 211227	002	Feb 27, 2024	Feb	NEWA
	@	600MG	A 211227	003	Feb 27, 2024	Mar	DISC
AB	@	600MG	A 211227	003	Feb 27, 2024	Feb	NEWA
	@	800MG	A 211227	004	Feb 27, 2024	Mar	DISC
AB	@	800MG	A 211227	004	Feb 27, 2024	Feb	NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

	@ GLENMARK SPECLT	EQ 20MG BASE	A 209495	001	May 10, 2019	Sep	DISC
	@	EQ 40MG BASE	A 209495	002	May 10, 2019	Sep	DISC
AB	MACLEODS PHARMS LTD	EQ 20MG BASE	A 208511	001	Oct 23, 2024	Oct	NEWA
AB	@	EQ 40MG BASE	A 208511	002	Oct 23, 2024	Oct	NEWA
>D> AB	SUN PHARM	EQ 20MG BASE	A 209735	001	Apr 30, 2018	Nov	DISC
>A>	@	EQ 20MG BASE	A 209735	001	Apr 30, 2018	Nov	DISC
>D> AB	@	EQ 40MG BASE	A 209735	002	Apr 30, 2018	Nov	DISC
>A>	@	EQ 40MG BASE	A 209735	002	Apr 30, 2018	Nov	DISC

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS

ESOMEPRAZOLE SODIUM

	@ ACCORD HLTHCARE	EQ 40MG BASE/VIAL	A 205379	001	Sep 25, 2015	May	DISC
	! GLAND PHARMA LTD	EQ 20MG BASE/VIAL	A 203349	001	Apr 01, 2020	May	CHRS
AP	! HAINAN POLY	EQ 40MG BASE/VIAL	A 215732	001	Feb 10, 2022	Aug	CHRS
AP	! SLATE RUN PHARMA	EQ 40MG BASE/VIAL	A 215732	001	Feb 10, 2022	Sep	CAHN
	@ SUN PHARM	EQ 40MG BASE/VIAL	A 200882	002	Mar 18, 2013	May	DISC
	NEXIUM IV						
	+ @ ASTRAZENECA	EQ 40MG BASE/VIAL	N 021689	002	Mar 31, 2005	Aug	DISC

ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL

CLIMARA

AB2	+ BAYER HLTHCARE	0.06MG/24HR	N 020375	006	May 27, 2003	Sep	CTEC
	ESTRADIOL						
AB2	MYLAN TECHNOLOGIES	0.06MG/24HR	A 075182	005	Jul 20, 2006	Oct	CTEC
AB2	ZYDUS PHARMS	0.025MG/24HR	A 202985	001	Mar 29, 2023	Sep	CMFD
AB2	@	0.0375MG/24HR	A 202985	002	Mar 29, 2023	Sep	CMFD
AB2	@	0.05MG/24HR	A 202985	003	Mar 29, 2023	Sep	CMFD
AB2	@	0.06MG/24HR	A 202985	004	Mar 29, 2023	Sep	CMFD
AB2	@	0.075MG/24HR	A 202985	005	Mar 29, 2023	Sep	CMFD
AB2	@	0.1MG/24HR	A 202985	006	Mar 29, 2023	Sep	CMFD

GEL;TRANSDERMAL
DIVIGEL

AB	+	VERTICAL PHARMS	0.1% (0.25GM/PACKET)	N022038	001	Jun 04, 2007	Jul CPOT
AB	+		0.1% (0.5GM/PACKET)	N022038	002	Jun 04, 2007	Jul NEWA
AB	+		0.1% (1GM/PACKET)	N022038	003	Jun 04, 2007	Jul NEWA
AB	+		0.1% (0.75GM/PACKET)	N022038	004	Aug 17, 2018	Jul NEWA
AB	+		0.1% (1.25GM/PACKET)	N022038	005	Dec 12, 2019	Jul NEWA

ESTRADIOL

AB		AMNEAL	0.1% (0.25GM/PACKET)	A216055	001	Jul 12, 2024	Jul NEWA
AB			0.1% (0.5GM/PACKET)	A216055	002	Jul 12, 2024	Jul NEWA
AB			0.1% (0.75GM/PACKET)	A216055	003	Jul 12, 2024	Jul NEWA
AB			0.1% (1GM/PACKET)	A216055	004	Jul 12, 2024	Jul NEWA
AB			0.1% (1.25GM/PACKET)	A216055	005	Jul 12, 2024	Jul NEWA
AB		CHEMO RESEARCH SL	0.1% (0.25GM/PACKET)	A211783	001	Aug 10, 2022	Jul CPOT
AB			0.1% (0.5GM/PACKET)	A211783	002	Aug 10, 2022	Jul NEWA
AB			0.1% (1GM/PACKET)	A211783	003	Aug 10, 2022	Jul NEWA
AB		NOVITIUM PHARMA	0.1% (0.25GM/PACKET)	A217610	001	Aug 24, 2023	Jul CPOT
AB			0.1% (0.5GM/PACKET)	A217610	002	Aug 24, 2023	Jul NEWA
AB			0.1% (0.75GM/PACKET)	A217610	003	Aug 24, 2023	Jul NEWA
AB			0.1% (1GM/PACKET)	A217610	004	Aug 24, 2023	Jul NEWA
AB			0.1% (1.25GM/PACKET)	A217610	005	Aug 24, 2023	Jul NEWA
AB		PADAGIS ISRAEL	0.1% (0.25GM/PACKET)	A216524	001	Nov 14, 2023	Jul CPOT
AB			0.1% (0.5GM/PACKET)	A216524	002	Nov 14, 2023	Jul NEWA
AB			0.1% (0.75GM/PACKET)	A216524	003	Nov 14, 2023	Jul NEWA
AB			0.1% (1GM/PACKET)	A216524	004	Nov 14, 2023	Jul NEWA
AB			0.1% (1.25GM/PACKET)	A216524	005	Nov 14, 2023	Jul NEWA
AB		QUAGEN	0.1% (0.25GM/PACKET)	A217863	001	Jul 12, 2024	Sep CAHN
AB			0.1% (0.5GM/PACKET)	A217863	002	Jul 12, 2024	Sep CAHN
AB			0.1% (0.75GM/PACKET)	A217863	003	Jul 12, 2024	Sep CAHN
AB			0.1% (1GM/PACKET)	A217863	004	Jul 12, 2024	Sep CAHN
AB			0.1% (1.25GM/PACKET)	A217863	005	Jul 12, 2024	Sep CAHN
AB		SOLARIS PHARMA CORP	0.1% (0.25GM/PACKET)	A217863	001	Jul 12, 2024	Jul NEWA
AB			0.1% (0.5GM/PACKET)	A217863	002	Jul 12, 2024	Jul NEWA
AB			0.1% (0.75GM/PACKET)	A217863	003	Jul 12, 2024	Jul NEWA
AB			0.1% (1GM/PACKET)	A217863	004	Jul 12, 2024	Jul NEWA
AB			0.1% (1.25GM/PACKET)	A217863	005	Jul 12, 2024	Jul NEWA

GEL, METERED;TRANSDERMAL
ESTRADIOL

AB		NOVITIUM PHARMA	0.06% (1.25GM/ACTIVATION)	A217882	001	Oct 23, 2024	Oct NEWA
AB		SOLARIS PHARMA CORP	0.06% (1.25GM/ACTIVATION)	A216160	001	Apr 22, 2024	Apr NFTG

ESTROGEL

AB	+	ASCEND THERAPS US	0.06% (1.25GM/ACTIVATION)	N021166	002	Feb 09, 2004	Apr CFTG
----	---	-------------------	---------------------------	---------	-----	--------------	----------

TABLET;VAGINAL
ESTRADIOL

AB		AUROBINDO PHARMA	10MCG	A216550	001	Aug 02, 2024	Jul NEWA
----	--	------------------	-------	---------	-----	--------------	----------

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE;VAGINAL
FEMRING

>D>	+	MILLICENT	EQ 0.05MG BASE/24HR	N021367	001	Mar 20, 2003	Nov CAHN
>D>	+		EQ 0.1MG BASE/24HR	N021367	002	Mar 20, 2003	Nov CAHN
>A>	+	MILLICENT PR	EQ 0.05MG BASE/24HR	N021367	001	Mar 20, 2003	Nov CAHN
>A>	+		EQ 0.1MG BASE/24HR	N021367	002	Mar 20, 2003	Nov CAHN

ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE

INJECTABLE;INTRAMUSCULAR
LUNELLE

	+	@ PHARMACIA AND UPJOHN	5MG/0.5ML;25MG/0.5ML	N020874	001	Oct 05, 2000	Feb CRLD
--	---	------------------------	----------------------	---------	-----	--------------	----------

ESTRADIOL VALERATE

INJECTABLE;INJECTION
DELESTROGEN

AO	+	ENDO OPERATIONS	10MG/ML	N009402	002		Apr CAHN
AO	+		20MG/ML	N009402	004		Apr CAHN
	+	@	40MG/ML	N009402	003		Sep DISC
AO	+		40MG/ML	N009402	003		Apr CAHN
		ESTRADIOL VALERATE					
AO	!	XIROMED	40MG/ML	A216656	003	Apr 28, 2023	Sep CHRS

<u>ESTRADIOL; NORETHINDRONE ACETATE</u>									
TABLET; ORAL									
ESTRADIOL AND NORETHINDRONE ACETATE									
AB	NAARI PTE LTD	1MG;0.5MG	A210233	001	Feb 28, 2018	Apr	CMFD		
<u>ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX</u>									
TABLET; ORAL									
MYFEMBREE									
+!	SUMITOMO PHARMA	1MG;0.5MG;40MG	N214846	001	May 26, 2021	Sep	CAHN		
<u>ESTRADIOL; NORGESTIMATE</u>									
TABLET; ORAL									
ESTRADIOL AND NORGESTIMATE									
@	BARR	1MG,1MG;N/A,0.09MG	A076812	001	Apr 29, 2005	Aug	DISC		
<u>ESTRAMUSTINE PHOSPHATE SODIUM</u>									
CAPSULE; ORAL									
EMCYT									
+	@ PHARMACIA AND UPJOHN	EQ 140MG PHOSPHATE	N018045	001		Jun	DISC		
<u>ESTROGENS, ESTERIFIED</u>									
TABLET; ORAL									
MENEST									
@	MONARCH PHARMS	0.3MG	A084951	001		Jul	DISC		
@		0.625MG	A084948	001		Jul	DISC		
@		1.25MG	A084950	001		Jul	DISC		
@		2.5MG	A084949	001		Jul	DISC		
<u>ESTROPIPATE</u>									
TABLET; ORAL									
ESTROPIPATE									
@	NORVIUM BIOSCIENCE	0.75MG	A040359	001	Aug 26, 1999	Oct	CAHN		
@		1.5MG	A040359	002	Aug 26, 1999	Oct	CAHN		
@		3MG	A040359	003	Aug 26, 1999	Oct	CAHN		
<u>ESZOPICLONE</u>									
TABLET; ORAL									
LUNESTA									
AB	+	WAYLIS THERAP	1MG	N021476	001	Dec 15, 2004	Apr	CAHN	
AB	+		2MG	N021476	002	Dec 15, 2004	Apr	CAHN	
AB	+	!	3MG	N021476	003	Dec 15, 2004	Apr	CAHN	
<u>ETHACRYNATE SODIUM</u>									
INJECTABLE; INJECTION									
ETHACRYNATE SODIUM									
AP	ENDO OPERATIONS	EQ 50MG BASE/VIAL	A205473	001	Jul 29, 2015	Apr	CAHN		
AP	STERIMAX	EQ 50MG BASE/VIAL	A208663	001	Jun 09, 2020	Mar	CAHN		
<u>ETHACRYNIC ACID</u>									
TABLET; ORAL									
ETHACRYNIC ACID									
AB	ADAPTIS	25MG	A205609	001	Jun 30, 2016	Sep	CAHN		
@	ENDO OPERATIONS	25MG	A208501	001	Jul 21, 2017	May	CAHN		
@	PAR PHARM INC	25MG	A208501	001	Jul 21, 2017	Apr	DISC		
<u>ETHAMBUTOL HYDROCHLORIDE</u>									
TABLET; ORAL									
MYAMBUTOL									
AB	+	KANCHAN HLTHCARE	100MG	N016320	001		Aug	CAHN	
	@		200MG	N016320	002		Aug	CAHN	
AB	+	!	400MG	N016320	003		Aug	CAHN	
	@		500MG	N016320	004		Aug	CAHN	
<u>ETHINYL ESTRADIOL; LEVONORGESTREL</u>									
TABLET; ORAL									
LEVONORGESTREL AND ETHINYL ESTRADIOL									
AB	XIROMED	0.03MG;0.15MG	A200490	001	Apr 21, 2015	Apr	CAHN		
AB3	LUPIN LTD	0.02MG;0.1MG	A217087	001	Feb 15, 2024	Feb	NEWA		

TABLET;ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

	@ XIROMED	0.02MG;0.1MG	A202247	001	Dec 08, 2014	Apr CAHN
	@	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A202970	001	Mar 23, 2018	May CAHN
	MYZILRA					
AB	ENDO OPERATIONS	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A077502	001	Nov 23, 2011	May CAHN
	ORSYTHIA					
	@ ENDO OPERATIONS	0.02MG;0.1MG	A077099	001	May 11, 2011	May CAHN

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL

ETHINYL ESTRADIOL AND NORELGESTROMIN

>D>	AB	ZYDUS NOVELTECH INC	0.035MG/24HR;0.15MG/24HR	A214594	001	Sep 14, 2023	Nov CAHN
>A>	AB	ZYDUS PHARMS	0.035MG/24HR;0.15MG/24HR	A214594	001	Sep 14, 2023	Nov CAHN

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-28

CYCLAFEM 0.5/35

	@ ENDO OPERATIONS	0.035MG;0.5MG	A203413	001	Dec 16, 2015	Apr CAHN
	CYCLAFEM 1/35					
	@ ENDO OPERATIONS	0.035MG;1MG	A076337	001	Nov 12, 2010	May CAHN
	CYCLAFEM 7/7/7					
	@ ENDO OPERATIONS	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A076338	001	Nov 16, 2010	May CAHN
	GILDAGIA					
AB	ENDO OPERATIONS	0.035MG;0.4MG	A078376	001	Nov 06, 2012	May CAHN
	NORETHINDRONE AND ETHINYL ESTRADIOL					
	@ XIROMED	0.035MG;0.4MG	A200897	001	May 11, 2015	Apr CAHN
	@	0.05MG;1MG	A203006	001	Aug 05, 2013	Apr CAHN

TABLET, CHEWABLE;ORAL

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	+!	TEVA BRANDED PHARM	0.025MG;0.8MG	N022573	001	Dec 22, 2010	Mar CAHN
----	----	--------------------	---------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE;ORAL

MERZEE

AB		WILSHIRE PHARMS INC	0.02MG;1MG	A212706	001	Dec 18, 2020	Jul CAHN
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
		@ AMNEAL PHARMS	0.02MG;1MG	A214292	001	Jul 20, 2021	Feb DISC

TABLET;ORAL

GILDESS 24 FE

AB		ENDO OPERATIONS	0.02MG;1MG	A090293	001	Dec 01, 2014	May CAHN
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL					
		@ XIROMED	0.0025MG;0.5MG	A207260	001	Feb 02, 2017	Apr CAHN
		@	0.005MG;1MG	A207259	001	Dec 27, 2016	Apr CAHN
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
		@ XIROMED	0.01MG,0.01MG;1MG,N/A	A205049	001	May 31, 2016	May CAHN
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
		@ XIROMED	0.02MG;1MG	A206120	001	Sep 12, 2017	May CAHN
		OSHIH					
		@ AUROBINDO PHARMA	0.02MG;1MG	A216558	001	Dec 06, 2023	May DISC

TABLET;ORAL-21

GILDESS 1.5/30

	@ ENDO OPERATIONS	0.03MG;1.5MG	A077075	002	Jul 24, 2012	May CAHN
	GILDESS 1/20					
	@ ENDO OPERATIONS	0.02MG;1MG	A077077	002	Jul 24, 2012	May CAHN

TABLET;ORAL-28

GILDESS FE 1.5/30

	@ ENDO OPERATIONS	0.03MG;1.5MG	A077075	001	Apr 28, 2005	May CAHN	
	GILDESS FE 1/20						
	@ ENDO OPERATIONS	0.02MG;1MG	A077077	001	May 20, 2005	May CAHN	
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL						
AB		XIROMED	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A205069	001	Jun 22, 2018	Apr CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

FEMLYV

	+!	MILLICENT PR	0.02MG;1MG	N218718	001	Jul 22, 2024	Jul NEWA
--	----	--------------	------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28		NORGESTIMATE AND ETHINYL ESTRADIOL							
	@ XIROMED	0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG	A202132	001	Sep 09, 2015	May	CAHN		
	@	0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG	A201897	001	Jan 27, 2016	May	CAHN		
AB	PREVIFEM ENDO OPERATIONS	0.035MG; 0.25MG	A076334	001	Jan 09, 2004	May	CAHN		
	TRI-PREVIFEM @ ENDO OPERATIONS	0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG	A076335	001	Mar 26, 2004	May	CAHN		

ETHOSUXIMIDE

CAPSULE; ORAL		ETHOSUXIMIDE							
AB	EPIC PHARMA LLC	250MG	A040686	001	May 28, 2008	Jan	CAHN		

ETODOLAC

CAPSULE; ORAL		ETODOLAC							
AB	IPCA LABS LTD	200MG	A205448	001	Aug 01, 2024	Jul	NEWA		
AB		300MG	A205448	002	Aug 01, 2024	Jul	NEWA		
TABLET; ORAL		ETODOLAC							
>D>	AB	ABRAXEOLUS	400MG	A074903	001	Apr 11, 1997	Nov	CAHN	
	AB		400MG	A074903	001	Apr 11, 1997	Sep	CAHN	
>D>	AB		500MG	A074903	002	Apr 19, 1999	Nov	CAHN	
	AB		500MG	A074903	002	Apr 19, 1999	Sep	CAHN	
	AB	ADAPTIS	400MG	A209888	001	Nov 30, 2018	Sep	CAHN	
	AB		500MG	A209888	002	Nov 30, 2018	Sep	CAHN	
>D>	AB	BAYSHORE PHARMS LLC	400MG	A210704	001	Dec 16, 2020	Nov	CAHN	
>D>	AB		500MG	A210704	002	Dec 16, 2020	Nov	CAHN	
	AB	EDENBRIDGE PHARMS	400MG	A209888	001	Nov 30, 2018	Jul	CMFD	
	AB		500MG	A209888	002	Nov 30, 2018	Jul	CMFD	
	AB	IPCA LABS LTD	400MG	A204729	001	May 01, 2024	Apr	NEWA	
	AB		500MG	A204729	002	May 01, 2024	Apr	NEWA	
>A>	AB	PANGEA	400MG	A074903	001	Apr 11, 1997	Nov	CAHN	
	AB		400MG	A074903	001	Apr 11, 1997	Jun	CAHN	
>A>	AB		500MG	A074903	002	Apr 19, 1999	Nov	CAHN	
	AB		500MG	A074903	002	Apr 19, 1999	Jun	CAHN	
>A>	AB	UNICHEM	400MG	A210704	001	Dec 16, 2020	Nov	CAHN	
>A>	AB		500MG	A210704	002	Dec 16, 2020	Nov	CAHN	
TABLET, EXTENDED RELEASE; ORAL		ETODOLAC							
>D>	AB	BAYSHORE PHARMS LLC	400MG	A212263	001	Nov 24, 2020	Nov	CAHN	
>D>	AB		500MG	A212263	002	Nov 24, 2020	Nov	CAHN	
>D>	AB		600MG	A212263	003	Nov 24, 2020	Nov	CAHN	
>A>	AB	UNICHEM	400MG	A212263	001	Nov 24, 2020	Nov	CAHN	
>A>	AB		500MG	A212263	002	Nov 24, 2020	Nov	CAHN	
>A>	AB		600MG	A212263	003	Nov 24, 2020	Nov	CAHN	

ETOMIDATE

INJECTABLE; INJECTION		ETOMIDATE							
	@ ENDO OPERATIONS	2MG/ML	A091297	001	Jun 20, 2012	May	CAHN		

ETOPOSIDE

CAPSULE; ORAL		VEPESID							
>D>	+ @ STRIDES PHARMA	50MG	N019557	001	Dec 30, 1986	Nov	CAHN		
>D>	+ @	100MG	N019557	002	Dec 30, 1986	Nov	CAHN		
>A>	+ @ STRIDES SOFTGELS	50MG	N019557	001	Dec 30, 1986	Nov	CAHN		
>A>	+ @	100MG	N019557	002	Dec 30, 1986	Nov	CAHN		

EXENATIDE SYNTHETIC

INJECTABLE; SUBCUTANEOUS		BYETTA							
>D>	+! ASTRAZENECA AB	300MCG/1.2ML (250MCG/ML)	N021773	001	Apr 28, 2005	Nov	CFTG		
>A>	AP +!	300MCG/1.2ML (250MCG/ML)	N021773	001	Apr 28, 2005	Nov	CFTG		
>D>	+!	600MCG/2.4ML (250MCG/ML)	N021773	002	Apr 28, 2005	Nov	CFTG		
>A>	AP +!	600MCG/2.4ML (250MCG/ML)	N021773	002	Apr 28, 2005	Nov	CFTG		

INJECTABLE;SUBCUTANEOUS
 >A> EXENATIDE SYNTHETIC
 >A> AP AMNEAL 300MCG/1.2ML (250MCG/ML) A206697 001 Nov 19, 2024 Nov NFTG
 >A> AP 600MCG/2.4ML (250MCG/ML) A206697 002 Nov 19, 2024 Nov NFTG

EZETIMIBE

TABLET;ORAL
 EZETIMIBE
 AB MACLEODS PHARMS LTD 10MG A211159 001 Apr 29, 2024 Apr NEWA

EZETIMIBE; SIMVASTATIN

TABLET;ORAL
 EZETIMIBE AND SIMVASTATIN
 AB AUROBINDO PHARMA USA 10MG;10MG A200082 001 Dec 17, 2020 Mar CMFD
 AB 10MG;20MG A200082 002 Dec 17, 2020 Mar CMFD
 AB 10MG;40MG A200082 003 Dec 17, 2020 Mar CMFD
 AB 10MG;80MG A200082 004 Dec 17, 2020 Mar CMFD
 >A> AB SCIEGEN PHARMS INC 10MG;10MG A211663 001 Dec 10, 2024 Nov NEWA
 >A> AB 10MG;20MG A211663 002 Dec 10, 2024 Nov NEWA
 >A> AB 10MG;40MG A211663 003 Dec 10, 2024 Nov NEWA
 >A> AB 10MG;80MG A211663 004 Dec 10, 2024 Nov NEWA

FAMOTIDINE

FOR SUSPENSION;ORAL
 FAMOTIDINE
 AB CEROVENE INC 40MG/5ML A217605 001 Jan 16, 2024 Jan NEWA
 AB EPIC PHARMA LLC 40MG/5ML A218344 001 Oct 16, 2024 Oct NEWA
 AB UNICHEM 40MG/5ML A217605 001 Jan 16, 2024 Sep CAHN
 TABLET;ORAL
 FAMOTIDINE
 AB MSN 20MG A217400 001 Aug 06, 2024 Jul NEWA
 AB 40MG A217400 002 Aug 06, 2024 Jul NEWA
 AB RISING 20MG A218181 001 Dec 22, 2023 Aug CAHN
 AB 40MG A218181 002 Dec 22, 2023 Aug CAHN

FAMOTIDINE; IBUPROFEN

TABLET;ORAL
 FAMOTIDINE AND IBUPROFEN
 @ TORRENT 26.6MG;800MG A215925 001 Mar 18, 2024 Mar NEWA
 IBUPROFEN AND FAMOTIDINE
 AB ! ALKEM LABS LTD 26.6MG;800MG A211890 001 Aug 03, 2021 Feb CHRS

FEBUXOSTAT

TABLET;ORAL
 FEBUXOSTAT
 @ LUPIN LTD 40MG A205406 001 Jan 17, 2024 Apr DISC
 AB 40MG A205406 001 Jan 17, 2024 Jan NEWA
 @ 80MG A205406 002 Jan 17, 2024 Apr DISC
 AB 80MG A205406 002 Jan 17, 2024 Jan NEWA
 BX MSN 40MG A210461 001 Dec 30, 2019 Jun CTEC
 BX 80MG A210461 002 Dec 30, 2019 Jun CTEC

FEDRATINIB HYDROCHLORIDE

CAPSULE;ORAL
 INREBIC
 +! BRISTOL-MYERS EQ 100MG BASE N212327 001 Aug 16, 2019 Feb CAHN

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL
 FELODIPINE
 AB ENDO OPERATIONS 2.5MG A200815 001 Oct 28, 2011 Apr CAHN
 AB 5MG A200815 002 Oct 28, 2011 Apr CAHN
 AB 10MG A200815 003 Oct 28, 2011 Apr CAHN

FENOFIBRATE

CAPSULE;ORAL
 FENOFIBRATE (MICRONIZED)
 AB CHARTWELL 67MG A211407 001 Jan 31, 2024 Mar CAHN
 AB 134MG A211407 002 Jan 31, 2024 Mar CAHN
 AB 200MG A211407 003 Jan 31, 2024 Mar CAHN
 @ INVAGEN PHARMS 67MG A207378 001 Mar 28, 2017 Mar DISC
 @ 134MG A207378 002 Mar 28, 2017 Mar DISC

CAPSULE;ORAL									
FENOFIBRATE (MICRONIZED)									
	@		200MG		A207378	003	Mar 28, 2017	Mar	DISC
AB		YOUNGTECH PHARMS INC	67MG		A211407	001	Jan 31, 2024	Jan	NEWA
AB			134MG		A211407	002	Jan 31, 2024	Jan	NEWA
AB			200MG		A211407	003	Jan 31, 2024	Jan	NEWA
TABLET;ORAL									
FENOFIBRATE									
AB	!	AUROBINDO PHARMA	145MG		A205118	002	May 05, 2016	Mar	CHRS
BX		CREEKWOOD PHARMS	40MG		A217732	001	Sep 07, 2023	Jun	CTEC
BX			120MG		A217732	002	Sep 07, 2023	Jun	CTEC
>A>	AB	MACLEODS PHARMS LTD	48MG		A210248	001	Nov 13, 2024	Nov	NEWA
>A>	AB		145MG		A210248	002	Nov 13, 2024	Nov	NEWA
AB	!	MYLAN PHARMS INC	120MG		A204475	002	Jun 23, 2016	May	CHRS
AB		RISING	48MG		A211122	001	Mar 18, 2020	Aug	CAHN
AB			54MG		A210606	001	Aug 17, 2018	Aug	CAHN
AB			145MG		A211122	002	Mar 18, 2020	Aug	CAHN
AB			160MG		A210606	002	Aug 17, 2018	Aug	CAHN
>D>	AB	SUN PHARM INDS LTD	54MG		A076635	001	Oct 31, 2005	Nov	DISC
>A>		@	54MG		A076635	001	Oct 31, 2005	Nov	DISC
>D>	AB		160MG		A076635	003	Oct 31, 2005	Nov	DISC
>A>		@	160MG		A076635	003	Oct 31, 2005	Nov	DISC
AB		YICHANG HUMANWELL	54MG		A218548	001	Apr 24, 2024	Apr	NEWA
AB			160MG		A218548	002	Apr 24, 2024	Apr	NEWA
FENOGLIDE									
	+ @	SALIX	40MG		N022118	001	Aug 10, 2007	May	DISC
	+ @		120MG		N022118	002	Aug 10, 2007	May	DISC
TRICOR									
	+ @	ABBVIE	48MG		N021656	001	Nov 05, 2004	Aug	DISC
	+ @		145MG		N021656	002	Nov 05, 2004	Mar	DISC
>D>		TRIGLIDE							
>D>	BX	+ SKYEPHARMA AG	160MG		N021350	002	May 07, 2005	Nov	DISC
>A>		+ @	160MG		N021350	002	May 07, 2005	Nov	DISC
<u>FENOLDOPAM MESYLATE</u>									
INJECTABLE;INJECTION									
CORLOPAM									
	+ @	HOSPIRA	EQ 10MG BASE/ML		N019922	001	Sep 23, 1997	May	DISC
FENOLDOPAM MESYLATE									
	@	HIKMA	EQ 10MG BASE/ML		A076582	001	Oct 12, 2004	May	DISC
	@	SANDOZ	EQ 10MG BASE/ML		A077155	001	Feb 15, 2005	May	DISC
<u>FENOPROFEN CALCIUM</u>									
CAPSULE;ORAL									
FENOPROFEN CALCIUM									
	@	MISEMER	EQ 200MG BASE		A215548	001	May 16, 2023	Aug	DISC
			EQ 200MG BASE		A215548	001	May 16, 2023	May	CTEC
	@		EQ 300MG BASE		A215548	002	May 16, 2023	Aug	DISC
	@		EQ 400MG BASE		A215548	003	May 16, 2023	Aug	DISC
		RISING	EQ 200MG BASE		A214475	002	Jul 26, 2024	Sep	NEWA
			EQ 300MG BASE		A214475	003	Jul 26, 2024	Sep	NEWA
	!		EQ 400MG BASE		A214475	001	Jul 18, 2022	Aug	CTEC
AB	!		EQ 400MG BASE		A214475	001	Jul 18, 2022	May	CHRS
NALFON									
	+ @	KEY THERAP	EQ 200MG BASE		N017604	003		May	DISC
AB	+		EQ 200MG BASE		N017604	003		Apr	CAHN
	+ @		EQ 400MG BASE		N017604	004	Jul 21, 2009	May	DISC
AB	+!		EQ 400MG BASE		N017604	004	Jul 21, 2009	Apr	CAHN
TABLET;ORAL									
FENOPROFEN CALCIUM									
	@	KEY THERAP	EQ 600MG BASE		A072267	001	Aug 17, 1988	May	DISC
	!		EQ 600MG BASE		A072267	001	Aug 17, 1988	Apr	CAHN
<u>FENTANYL</u>									
FILM, EXTENDED RELEASE;TRANSDERMAL									
FENTANYL-100									
AB		DIFGEN PHARMS	100MCG/HR		A077449	004	Oct 20, 2008	Sep	CAHN
FENTANYL-12									
AB		DIFGEN PHARMS	12.5MCG/HR		A077449	005	Sep 11, 2015	Sep	CAHN
FENTANYL-25									
AB		DIFGEN PHARMS	25MCG/HR		A077449	001	Oct 20, 2008	Sep	CAHN

FILM, EXTENDED RELEASE;TRANSDERMAL
FENTANYL-37

AB	DIFGEN PHARMS	37.5MCG/HR	A 077449	006	Dec 06, 2017	Sep CAHN
	FENTANYL-50					
AB	DIFGEN PHARMS	50MCG/HR	A 077449	002	Oct 20, 2008	Sep CAHN
	FENTANYL-62					
AB	DIFGEN PHARMS	62.5MCG/HR	A 077449	007	Dec 06, 2017	Sep CAHN
	FENTANYL-75					
AB	DIFGEN PHARMS	75MCG/HR	A 077449	003	Oct 20, 2008	Sep CAHN
	FENTANYL-87					
AB	DIFGEN PHARMS	87.5MCG/HR	A 077449	008	Dec 06, 2017	Sep CAHN

FENTANYL CITRATE

TABLET;BUCCAL, SUBLINGUAL
FENTORA

+ @	CEPHALON	EQ 0.1MG BASE	N 021947	001	Sep 25, 2006	Sep DISC
+ @		EQ 0.2MG BASE	N 021947	002	Sep 25, 2006	Sep DISC
+ @		EQ 0.4MG BASE	N 021947	003	Sep 25, 2006	Sep DISC
+ @		EQ 0.6MG BASE	N 021947	004	Sep 25, 2006	Sep DISC
+ @		EQ 0.8MG BASE	N 021947	005	Sep 25, 2006	Sep DISC

TROCHE/LOZENGE;TRANSMUCOSAL
ACTIQ

+ @	CEPHALON	EQ 0.2MG BASE	N 020747	001	Nov 04, 1998	Sep DISC
+ @		EQ 0.4MG BASE	N 020747	002	Nov 04, 1998	Sep DISC
+ @		EQ 0.6MG BASE	N 020747	003	Nov 04, 1998	Sep DISC
+ @		EQ 0.8MG BASE	N 020747	004	Nov 04, 1998	Sep DISC
+ @		EQ 1.2MG BASE	N 020747	005	Nov 04, 1998	Sep DISC
+ @		EQ 1.6MG BASE	N 020747	006	Nov 04, 1998	Sep DISC

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL
FESOTERODINE FUMARATE

@	ANI PHARMS	4MG	A 204504	001	Jan 04, 2023	Apr DISC
@		8MG	A 204504	002	Jan 04, 2023	Apr DISC

FIDAXOMICIN

TABLET;ORAL
DIFICID

+!	CUBIST PHARMS LLC	200MG	N 201699	001	May 27, 2011	Jul CTEC	
AB	+!	200MG	N 201699	001	May 27, 2011	Jan CFTG	
	FIDAXOMICIN						
	@	ACTAVIS LABS FL	200MG	A 208443	001	Jan 16, 2024	Jul DISC
AB		200MG	A 208443	001	Jan 16, 2024	Jan NEWA	

FINASTERIDE

TABLET;ORAL
FINASTERIDE

@	CIPLA	1MG	A 077335	001	Nov 20, 2014	Mar DISC
---	-------	-----	----------	-----	--------------	----------

FINASTERIDE; TADALAFIL

CAPSULE;ORAL
ENTADFI

+ @	BLUE WATER BIOTECH	5MG;5MG	N 215423	001	Dec 09, 2021	Sep DISC	
AB	+!	5MG;5MG	N 215423	001	Dec 09, 2021	Mar CFTG	
	FINASTERIDE AND TADALAFIL						
AB	ZYDUS	5MG;5MG	A 218232	001	Mar 15, 2024	Mar NFTG	
	@	ZYDUS LIFESCIENCES	5MG;5MG	A 218232	001	Mar 15, 2024	Sep DISC
AB		5MG;5MG	A 218232	001	Mar 15, 2024	May CAHN	

FINGOLIMOD HYDROCHLORIDE

CAPSULE;ORAL
FINGOLIMOD HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 0.5MG BASE	A 207983	001	Feb 28, 2024	Feb NEWA	
AB	BIOCON LTD	EQ 0.5MG BASE	A 207979	001	Dec 04, 2019	Feb CMFD	
>D>	AB	SUN PHARM	EQ 0.5MG BASE	A 208014	001	Dec 04, 2019	Nov DISC
>A>	@		EQ 0.5MG BASE	A 208014	001	Dec 04, 2019	Nov DISC

FLORTAUCIPIR F-18

SOLUTION; INTRAVENOUS
TAUVID

+ @ AVID RADIOPHARMS INC	30ML (8.1-51mCi/ML)	N212123	001	May 28, 2020	Jun DISC
+ @	50ML (8.1-51mCi/ML)	N212123	002	May 28, 2020	Jun DISC

FLUCONAZOLE

INJECTABLE; INJECTION
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

@ NORVIUM BIOSCIENCE	200MG/100ML (2MG/ML)	A076888	001	Mar 25, 2005	Jul CAHN
@	400MG/200ML (2MG/ML)	A076888	002	Mar 25, 2005	Jul CAHN

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION
FLUDARABINE PHOSPHATE

@ RISING	50MG/VIAL	A200648	001	Oct 16, 2012	Feb CAHN
----------	-----------	---------	-----	--------------	----------

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS
FLUDEOXYGLUCOSE F18

AP !	CARDINAL HEALTH 414	20-500mCi/ML	A203603	002	Sep 27, 2018	May CHRS
	@ SOFIE	20-500mCi/ML	A203665	001	Feb 14, 2013	May DISC

FLUDROCORTISONE ACETATE

TABLET; ORAL
FLUDROCORTISONE ACETATE

AB	@ CHARTWELL RX	0.1MG	A216013	001	Oct 27, 2022	Sep CAHN
AB	ZYDUS	0.1MG	A219251	001	Oct 16, 2024	Oct NEWA
AB	ZYDUS LIFESCIENCES	0.1MG	A219251	001	Oct 16, 2024	Oct CAHN

FLUNISOLIDE

AEROSOL, METERED; INHALATION
AEROSPAN HFA

+ @ NORVIUM BIOSCIENCE	0.078MG/INH	N021247	001	Jan 27, 2006	Oct CAHN
------------------------	-------------	---------	-----	--------------	----------

FLUOCINOLONE ACETONIDE

OIL; TOPICAL
FLUOCINOLONE ACETONIDE

AT	RISING	0.01%	A090982	001	Apr 25, 2016	Sep CAHN
AT		0.01%	A203377	001	Apr 25, 2016	Sep CAHN
AT	TARO	0.01%	A209336	001	May 19, 2016	Jan CAHN

OIL/DROPS; OTIC
FLAC

AT	ANDA REPOSITORY	0.01%	A210736	001	Apr 11, 2018	Sep CAHN
AT	RISING	0.01%	A203378	001	Apr 25, 2016	Sep CAHN
AT	TRUPHARMA	0.01%	A213264	001	Feb 05, 2021	Aug CAHN

SHAMPOO; TOPICAL
CAPEX

+ @ GALDERMA LABS LP	0.01%	N020001	001	Aug 27, 1990	May DISC
----------------------	-------	---------	-----	--------------	----------

FLUOCINONIDE

CREAM; TOPICAL
FLUOCINONIDE

@ AMNEAL	0.1%	A211111	001	Jun 04, 2018	Jul DISC
@ PADAGIS ISRAEL	0.1%	A090256	001	Jan 14, 2014	Jan DISC
+ @ TARO	0.05%	N019117	001	Jun 26, 1984	Aug CAHN

GEL; TOPICAL
FLUOCINONIDE

+ @ ALVOGEN	0.05%	N017373	001		May DISC
@ COSETTE	0.05%	A072537	001	Feb 07, 1989	Apr DISC
@ PADAGIS US	0.05%	A209030	001	Jun 19, 2018	Jan CAHN

OINTMENT; TOPICAL
LIDEX

>D>					
>D> AB	+ ALVOGEN	0.05%	N016909	002	Nov DISC
>A>	+ @	0.05%	N016909	002	Nov DISC

SOLUTION; TOPICAL
FLUOCINONIDE

@ COSETTE	0.05%	A071535	001	Dec 02, 1988	Apr DISC
-----------	-------	---------	-----	--------------	----------

FLUOROURACIL

CREAM; TOPICAL
CARAC

>A> +! EXTROVIS 0.5% N020985 001 Oct 27, 2000 Nov CAHN
>D> +! VALEANT PHARMS NORTH 0.5% N020985 001 Oct 27, 2000 Nov CAHN

EFUDEX

>D> AB +! BAUSCH 5% N016831 003 Nov CAHN
>A> AB +! EXTROVIS 5% N016831 003 Nov CAHN

INJECTABLE; INJECTION
FLUOROURACIL

AP EUGIA PHARMA SPECLTS 500MG/10ML (50MG/ML) A202668 001 Jul 17, 2012 Apr CMFD
AP 1GM/20ML (50MG/ML) A202668 002 Jul 17, 2012 Apr CMFD
AP 2.5GM/50ML (50MG/ML) A202669 001 Jul 17, 2012 Apr CMFD
AP 5GM/100ML (50MG/ML) A202669 002 Jul 17, 2012 Apr CMFD
AP KINDOS 2.5GM/50ML (50MG/ML) A216494 001 Sep 24, 2024 Sep NEWA

SOLUTION; TOPICAL
EFUDEX

>D> AT +! BAUSCH 2% N016831 001 Nov CAHN
>D> + @ 5% N016831 002 Nov CAHN
>A> AT +! EXTROVIS 2% N016831 001 Nov CAHN
>A> + @ 5% N016831 002 Nov CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

AB1 STRIDES PHARMA EQ 10MG BASE A076922 001 Dec 16, 2004 Sep CMFD
AB1 EQ 20MG BASE A076922 002 Dec 16, 2004 Sep CMFD
AB EQ 40MG BASE A076922 003 Dec 16, 2004 Sep CMFD
@ SUN PHARM INDS LTD EQ 40MG BASE A076990 001 Dec 13, 2004 Jan DISC

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

@ BAJAJ EQ 20MG BASE/5ML A075920 001 Jan 29, 2002 Mar CAHN
AA UPSHER SMITH LABS EQ 20MG BASE/5ML A216953 001 Nov 15, 2022 Sep CAHN

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

>A> @ ADAPTIS EQ 10MG BASE A211444 001 Sep 13, 2022 Nov CAHN
>A> @ EQ 20MG BASE A211444 002 Sep 13, 2022 Nov CAHN
AB ENDO OPERATIONS EQ 10MG BASE A203836 001 Aug 19, 2016 Apr CAHN
AB EQ 20MG BASE A203836 002 Aug 19, 2016 Apr CAHN
AB EQ 60MG BASE A209419 001 Nov 16, 2017 Apr CAHN
>D> @ SLATE RUN PHARMA EQ 10MG BASE A211444 001 Sep 13, 2022 Nov CAHN
>D> @ EQ 20MG BASE A211444 002 Sep 13, 2022 Nov CAHN
AB STRIDES PHARMA EQ 10MG BASE A212684 001 Apr 05, 2024 Mar NEWA
AB EQ 20MG BASE A212684 002 Apr 05, 2024 Mar NEWA
AB EQ 60MG BASE A212683 001 Sep 13, 2024 Sep NEWA
@ TEVA EQ 10MG BASE A075872 001 Jan 29, 2002 Jan DISC
@ EQ 20MG BASE A075872 002 Jan 04, 2019 Jan DISC
@ TEVA PHARMS USA EQ 60MG BASE A211051 001 Dec 03, 2018 Jan DISC
@ UPSHER SMITH LABS EQ 10MG BASE A211696 001 Jan 30, 2019 Jun DISC
@ EQ 20MG BASE A211696 002 Jan 30, 2019 Jun DISC

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

AB ENDO OPERATIONS EQ 25MG BASE;EQ 3MG BASE A077742 001 Nov 02, 2012 Apr CAHN
AB EQ 25MG BASE;EQ 6MG BASE A077742 002 Nov 02, 2012 Apr CAHN
AB EQ 25MG BASE;EQ 12MG BASE A077742 003 Nov 02, 2012 Apr CAHN
AB EQ 50MG BASE;EQ 6MG BASE A077742 004 Nov 02, 2012 Apr CAHN
AB EQ 50MG BASE;EQ 12MG BASE A077742 005 Nov 02, 2012 Apr CAHN

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

AO ENDO OPERATIONS 25MG/ML A203732 001 Jul 03, 2014 Apr CAHN

FLUPHENAZINE HYDROCHLORIDE

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE

AB ALEMBIC 1MG A218173 001 Jul 23, 2024 Jul NEWA
AB 2.5MG A218173 002 Jul 23, 2024 Jul NEWA
AB 5MG A218173 003 Jul 23, 2024 Jul NEWA

TABLET;ORAL

FLUPHENAZINE HYDROCHLORIDE

AB		10MG	A218173	004	Jul 23, 2024	Jul	NEWA
AB	CHARTWELL RX	1MG	A215141	001	Oct 20, 2021	Sep	CAHN
AB		2.5MG	A215141	002	Oct 20, 2021	Sep	CAHN
AB		5MG	A215141	003	Oct 20, 2021	Sep	CAHN
AB		10MG	A215141	004	Oct 20, 2021	Sep	CAHN
AB	RISING	1MG	A218283	001	Jun 07, 2024	May	NEWA
AB		2.5MG	A218283	002	Jun 07, 2024	May	NEWA
AB		5MG	A218283	003	Jun 07, 2024	May	NEWA
AB		10MG	A218283	004	Jun 07, 2024	May	NEWA
AB	ZAMEER PHARMS	1MG	A215141	001	Oct 20, 2021	Feb	CAHN
AB		2.5MG	A215141	002	Oct 20, 2021	Feb	CAHN
AB		5MG	A215141	003	Oct 20, 2021	Feb	CAHN
AB		10MG	A215141	004	Oct 20, 2021	Feb	CAHN

FLURBIPROFEN

TABLET;ORAL

FLURBIPROFEN

>A>	!	GENUS	100MG	A074431	001	May 31, 1995	Nov	CAHN
	@	NATCO PHARMA	50MG	A074358	001	Jun 20, 1994	Aug	CAHN
	@		100MG	A074358	002	Jun 20, 1994	Aug	CAHN
>D>	!	TEVA	100MG	A074431	001	May 31, 1995	Nov	CAHN

FLURPIRIDAZ F-18

SOLUTION;INTRAVENOUS

FLYRCADO

+!	GE HLTHCARE	5-55mCi/ML	N215168	001	Sep 27, 2024	Sep	NEWA
----	-------------	------------	---------	-----	--------------	-----	------

FLUTICASONE PROPIONATE

POWDER;INHALATION

ARMONAIR DIGIHALER

+ @	TEVA PHARM	0.055MG/INH	N208798	004	Feb 20, 2020	Jun	DISC
+ @		0.113MG/INH	N208798	005	Feb 20, 2020	Jun	DISC
+ @		0.232MG/INH	N208798	006	Feb 20, 2020	Jun	DISC

SPRAY, METERED;NASAL

FLUTICASONE PROPIONATE

@	HIKMA	0.05MG/SPRAY	A077570	001	Jan 16, 2008	Mar	DISC
---	-------	--------------	---------	-----	--------------	-----	------

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

POWDER;INHALATION

AIRDUO DIGIHALER

+ @	TEVA PHARM	0.055MG/INH;EQ 0.014MG BASE/INH	N208799	004	Jul 12, 2019	Jun	DISC
+ @		0.113MG/INH;EQ 0.014MG BASE/INH	N208799	005	Jul 12, 2019	Jun	DISC
+ @		0.232MG/INH;EQ 0.014MG BASE/INH	N208799	006	Jul 12, 2019	Jun	DISC

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL

FLUVOXAMINE MALEATE

AB	AJANTA PHARMA LTD	100MG	A219055	001	Oct 17, 2024	Oct	NEWA
AB		150MG	A219055	002	Oct 17, 2024	Oct	NEWA
AB	ENDO OPERATIONS	100MG	A091476	001	Mar 13, 2013	Apr	CAHN
AB		150MG	A091476	002	Mar 13, 2013	Apr	CAHN

TABLET;ORAL

FLUVOXAMINE MALEATE

AB	BIONPHARMA	25MG	A217917	001	Jan 22, 2024	Jan	NEWA
AB		50MG	A217917	002	Jan 22, 2024	Jan	NEWA
AB		100MG	A217917	003	Jan 22, 2024	Jan	NEWA

FOLIC ACID

TABLET;ORAL

FOLIC ACID

@	ENDO OPERATIONS	1MG	A040756	001	Jun 04, 2010	May	CAHN
---	-----------------	-----	---------	-----	--------------	-----	------

FONDAPARINUX SODIUM

INJECTABLE;SUBCUTANEOUS

FONDAPARINUX SODIUM

AP	HANGZHOU ZHONGMEI	2.5MG/0.5ML	A216493	001	Aug 19, 2024	Aug	NEWA
AP		5MG/0.4ML	A216493	002	Aug 19, 2024	Aug	NEWA
AP		7.5MG/0.6ML	A216493	003	Aug 19, 2024	Aug	NEWA
AP		10MG/0.8ML	A216493	004	Aug 19, 2024	Aug	NEWA

FORMOTEROL FUMARATE

	SOLUTION; INHALATION						
	FORMOTEROL FUMARATE						
AN	LEXENPHARM	0.02MG/2ML	A216426	001	Oct 22, 2024	Oct	NEWA
AN	MICRO LABS	0.02MG/2ML	A218304	001	Jun 26, 2024	Jun	NEWA
AN	RTEDOSE CORP	0.02MG/2ML	A216486	001	Nov 25, 2022	May	CAHN
AN	WILSHIRE PHARMS INC	0.02MG/2ML	A215621	001	Dec 13, 2022	Jul	CAHN

FOSAMPRENAVIR CALCIUM

	TABLET; ORAL						
	FOSAMPRENAVIR CALCIUM						
AB	! MYLAN	EQ 700MG BASE	A204060	001	Apr 15, 2016	Jan	CHRS
	LEXIVA						
	+ @ VIIV HLTHCARE	EQ 700MG BASE	N021548	001	Oct 20, 2003	Jan	DISC

FOSAPREPITANT DIMEGLUMINE

	POWDER; INTRAVENOUS						
	FOSAPREPITANT DIMEGLUMINE						
	@ ACCORD HLTHCARE	EQ 150MG BASE/VIAL	A204025	001	Aug 26, 2020	May	DISC
	@ GENEYORK PHARMS	EQ 150MG BASE/VIAL	A211624	001	Sep 05, 2019	Jul	CAHN
	@ NAVINTA LLC	EQ 150MG BASE/VIAL	A212957	002	Aug 20, 2020	Oct	DISC

FOSCARBIDOPA; FOSLEVODOPA

	SOLUTION; SUBCUTANEOUS						
	VYALEV						
	+! ABBVIE	120MG/10ML; 2400MG/10ML (12MG/ML; 240MG/ML)	N216962	001	Oct 16, 2024	Oct	NEWA

FOSCARNET SODIUM

	INJECTABLE; INJECTION						
	FOSCARNET SODIUM						
AP	AMNEAL	2.4GM/100ML	A216602	001	Mar 01, 2024	Feb	NEWA
>D> AP	BEIJING	2.4GM/100ML	A213987	001	Nov 29, 2023	Nov	CAHN
>A> AP	SCIECURE	2.4GM/100ML	A213987	001	Nov 29, 2023	Nov	CAHN

FOSFOMYCIN TROMETHAMINE

	FOR SOLUTION; ORAL						
	FOSFOMYCIN TROMETHAMINE						
AA	AMNEAL	EQ 3GM BASE/PACKET	A216600	001	Mar 25, 2024	Mar	NEWA

FOSPHENYTOIN SODIUM

	INJECTABLE; INJECTION						
	FOSPHENYTOIN SODIUM						
	@ NORVIUM BIOSCIENCE	EQ 50MG PHENYTOIN NA/ML	A078736	001	Jun 08, 2010	Jul	CAHN

FROVATRIPTAN SUCCINATE

	TABLET; ORAL						
	FROVA						
AB	+! ENDO OPERATIONS	EQ 2.5MG BASE	N021006	001	Nov 08, 2001	Apr	CAHN

FULVESTRANT

	SOLUTION; INTRAMUSCULAR						
	FULVESTRANT						
	@ AVYXA HOLDINGS	250MG/5ML (50MG/ML)	N210063	001	Aug 19, 2019	Oct	CAHN
AO	FRESENIUS KABI USA	250MG/5ML (50MG/ML)	N210326	001	May 20, 2019	Aug	CTEC
	@ TEVA PHARMS USA INC	250MG/5ML (50MG/ML)	N210063	001	Aug 19, 2019	Jun	DISC

FUROSEMIDE

	INJECTABLE; INJECTION						
	FUROSEMIDE						
AP	HIKMA	10MG/ML	N018267	001		Aug	CMFD
AP	SABA ILAC SANAYIVE	10MG/ML	A215856	001	Apr 02, 2024	Mar	NEWA
	TABLET; ORAL						
	FUROSEMIDE						
	@ ESJAY PHARMA	20MG	N018415	001	Jul 27, 1982	Oct	CAHN
	@	40MG	N018415	002	Jul 27, 1982	Oct	CAHN
	@	80MG	N018415	003	Nov 26, 1984	Oct	CAHN
	@ MYLAN	20MG	N018487	001		Sep	DISC
	@	40MG	N018487	002		Sep	DISC
	@	80MG	A070082	001	Oct 29, 1986	Sep	DISC

GABAPENTIN

CAPSULE;ORAL						
GABAPENTIN						
AB	RISING	100MG	A207099	001	Mar 24, 2017	Aug CAHN
AB		300MG	A207099	002	Mar 24, 2017	Aug CAHN
AB		400MG	A207099	003	Mar 24, 2017	Aug CAHN
	@ SUN PHARM INDS LTD	100MG	A077242	001	Aug 24, 2006	May DISC
	@	300MG	A077242	002	Aug 24, 2006	May DISC
	@	400MG	A077242	003	Aug 24, 2006	May DISC
SOLUTION;ORAL						
GABAPENTIN						
AA	ANNORA PHARMA	250MG/5ML	A217682	001	Jan 17, 2024	Jan NEWA
TABLET;ORAL						
GABAPENTIN						
AB2	ABON PHARMS LLC	600MG	A203643	001	Sep 09, 2024	Sep CAHN
AB1	ACTAVIS ELIZABETH	600MG	A075694	001	Oct 21, 2004	Jan CTEC
AB1		800MG	A075694	002	Oct 21, 2004	Jan CTEC
AB1	ALKEM LABS LTD	600MG	A206402	001	Dec 23, 2015	Jan CTEC
AB1		800MG	A206402	002	Dec 23, 2015	Jan CTEC
AB2	ANNORA PHARMA	300MG	A218075	001	Feb 26, 2024	Feb NEWA
AB2		600MG	A218075	002	Feb 26, 2024	Feb NEWA
AB1	APOTEX	100MG	A077894	001	Oct 10, 2006	Jan CTEC
AB1		300MG	A077894	002	Oct 10, 2006	Jan CTEC
AB1		400MG	A077894	003	Oct 10, 2006	Jan CTEC
AB1	ASCENT PHARMS INC	600MG	A214957	001	Oct 01, 2021	Jan CTEC
AB1		800MG	A214957	002	Oct 01, 2021	Jan CTEC
AB1	AUROBINDO PHARMA LTD	600MG	A200651	001	Oct 06, 2011	Jan CTEC
AB1		800MG	A200651	002	Oct 06, 2011	Jan CTEC
AB1	CSPC OUYI	600MG	A207057	001	Oct 26, 2017	Jan CTEC
AB1		800MG	A207057	002	Oct 26, 2017	Jan CTEC
AB1	GLENMARK PHARMS LTD	600MG	A077662	001	Aug 18, 2006	Jan CTEC
AB1		800MG	A077662	002	Aug 18, 2006	Jan CTEC
AB1	GRANULES	600MG	A217116	001	Mar 28, 2023	Jan CTEC
AB1		800MG	A217116	002	Mar 28, 2023	Jan CTEC
AB2	HUMANWELL	300MG	A216252	001	Feb 26, 2024	Feb NEWA
AB2		600MG	A216252	002	Feb 26, 2024	Feb NEWA
AB2	INCEPTA PHARMS LTD	600MG	A203643	001	Sep 09, 2024	Aug NEWA
	@ INVAGEN PHARMS	600MG	A202764	001	Oct 16, 2012	Mar DISC
AB1		600MG	A202764	001	Oct 16, 2012	Jan CTEC
	@	800MG	A202764	002	Oct 16, 2012	Mar DISC
AB1		800MG	A202764	002	Oct 16, 2012	Jan CTEC
AB1	IPCA LABS LTD	600MG	A209855	001	May 29, 2024	May NEWA
AB1		800MG	A209855	002	May 29, 2024	May NEWA
AB1	IVAX SUB TEVA PHARMS	100MG	A076017	001	Apr 28, 2004	Jan CTEC
AB1		300MG	A076017	002	Apr 28, 2004	Jan CTEC
AB1		400MG	A076017	003	Apr 28, 2004	Jan CTEC
AB1	LAURUS	600MG	A217965	001	Apr 08, 2024	Mar NEWA
AB1		800MG	A217965	002	Apr 08, 2024	Mar NEWA
AB1	RISING	600MG	A217995	001	Jul 19, 2023	Jan CTEC
AB1		800MG	A217995	002	Jul 19, 2023	Jan CTEC
AB1	RUBICON	600MG	A077661	004	Sep 13, 2006	Jan CTEC
AB1		800MG	A077661	005	Sep 13, 2006	Jan CTEC
AB1	SCIEGEN PHARMS INC	600MG	A205101	001	Feb 04, 2016	Jan CTEC
AB1		800MG	A205101	002	Feb 04, 2016	Jan CTEC
AB1	STRIDES PHARMA	600MG	A211313	001	Mar 04, 2024	Feb NEWA
AB1		800MG	A211313	002	Mar 04, 2024	Feb NEWA
	@ SUN PHARM INDS LTD	600MG	A077525	001	Aug 24, 2006	Oct DISC
AB1		600MG	A077525	001	Aug 24, 2006	Jan CTEC
	@	800MG	A077525	002	Aug 24, 2006	Oct DISC
AB1		800MG	A077525	002	Aug 24, 2006	Jan CTEC
AB2	ZYDUS PHARMS	300MG	A203934	001	Jan 24, 2024	Jan NEWA
AB2		600MG	A203934	002	Jan 24, 2024	Jan NEWA
AB1	ZYDUS PHARMS USA INC	600MG	A078926	001	Feb 11, 2011	Jan CTEC
AB1		800MG	A078926	002	Feb 11, 2011	Jan CTEC
GRALISE						
AB2	+! ALMATICA	300MG	N022544	001	Jan 28, 2011	Jan CTEC
AB2	+	600MG	N022544	002	Jan 28, 2011	Jan CTEC
BX	+	600MG	N022544	002	Jan 28, 2011	Jan CHRS
	+!	900MG	N022544	005	Apr 18, 2023	Jan CHRS
NEURONTIN						
AB1	+ VIATRIS	600MG	N020882	001	Oct 09, 1998	Jan CTEC
AB1	+!	800MG	N020882	002	Oct 09, 1998	Jan CTEC

GADOBUTROL

	SOLUTION; INTRAVENOUS						
	GADOBUTROL						
AP	HENGRUI PHARMA	1.20944GM/2ML (604.72MG/ML)	A216081	003	Nov 17, 2022	Jul	CMS1
AP		4.5354GM/7.5ML (604.72MG/ML)	A216081	004	Nov 17, 2022	Jul	CMS1
AP		6.0472GM/10ML (604.72MG/ML)	A216081	005	Nov 17, 2022	Jul	CMS1
AP		9.0708GM/15ML (604.72MG/ML)	A216081	006	Nov 17, 2022	Jul	CMS1

GADODIAMIDE

	INJECTABLE; INJECTION						
	OMNISCAN						
	+ @ GE HEALTHCARE	14.35GM/50ML (287MG/ML)	N022066	001	Sep 05, 2007	Mar	CRLD
	+ @	28.7GM/100ML (287MG/ML)	N022066	002	Sep 05, 2007	Mar	DISC

GADOTERATE MEGLUMINE

	SOLUTION; INTRAVENOUS						
	GADOTERATE MEGLUMINE						
AP	HAINAN POLY	1.8845GM/5ML (376.9MG/ML)	A218073	001	Jun 17, 2024	Jun	NEWA
AP		3.769GM/10ML (376.9MG/ML)	A218073	002	Jun 17, 2024	Jun	NEWA
AP		5.6535GM/15ML (376.9MG/ML)	A218073	003	Jun 17, 2024	Jun	NEWA
AP		7.538GM/20ML (376.9MG/ML)	A218073	004	Jun 17, 2024	Jun	NEWA
AP		37.69GM/100ML (376.9MG/ML)	A218073	005	Jun 17, 2024	Jun	NEWA

GANCICLOVIR SODIUM

	INJECTABLE; INJECTION						
	GANCICLOVIR SODIUM						
AP	ENDO OPERATIONS	EQ 500MG BASE/VIAL	A204950	001	Dec 06, 2016	May	CAHN

GATIFLOXACIN

	SOLUTION/DROPS; OPHTHALMIC						
	GATIFLOXACIN						
	@ HIKMA	0.5%	A203189	001	Sep 03, 2014	Mar	DISC

GEMCITABINE HYDROCHLORIDE

	INJECTABLE; INJECTION						
	GEMCITABINE HYDROCHLORIDE						
	@ ACCORD HLTHCARE	EQ 200MG BASE/VIAL	A091594	001	Jul 25, 2011	Apr	DISC
	@	EQ 1GM BASE/VIAL	A091594	002	Jul 25, 2011	Apr	DISC
	@	EQ 2GM BASE/VIAL	A091594	003	Jul 25, 2011	Apr	DISC

GEMFIBROZIL

	TABLET; ORAL						
	GEMFIBROZIL						
AB	EPIC PHARMA LLC	600MG	A078012	001	Mar 26, 2007	Oct	CAHN

GEPIRONE HYDROCHLORIDE

	TABLET, EXTENDED RELEASE; ORAL						
	EXXUA						
	+ @ FABRE KRAMER	EQ 18.2MG BASE	N021164	001	Sep 22, 2023	Jun	DISC
	+ @	EQ 36.3MG BASE	N021164	002	Sep 22, 2023	Jun	DISC
	+ @	EQ 54.5MG BASE	N021164	003	Sep 22, 2023	Jun	DISC
	+ @	EQ 72.6MG BASE	N021164	004	Sep 22, 2023	Jun	DISC

GIVINOSTAT HYDROCHLORIDE

	SUSPENSION; ORAL						
	DUVYZAT						
	+! ITALFARMACO SPA	EQ 8.86MG BASE/ML	N217865	001	Mar 21, 2024	Mar	NEWA

GLATIRAMER ACETATE

	INJECTABLE; SUBCUTANEOUS						
	GLATIRAMER ACETATE						
AP	SYNTHON PHARMS INC	20MG/ML	A203857	001	Sep 25, 2024	Sep	NEWA
AP		40MG/ML	A206873	001	Sep 25, 2024	Sep	NEWA

GLIPIZIDE

	TABLET; ORAL						
	GLIPIZIDE						
	@ ACCORD HLTHCARE	5MG	A074550	001	Sep 11, 1997	May	DISC
	@	10MG	A074550	002	Sep 11, 1997	May	DISC
	@ SANDOZ	5MG	A074305	001	Apr 07, 1995	Jun	DISC
	@	10MG	A074305	002	Apr 07, 1995	Jun	DISC

TABLET, EXTENDED RELEASE;ORAL

GLIPIZIDE

	@ ENDO OPERATIONS	5MG	A076159	002	Sep 20, 2013	May	CAHN
	@	10MG	A076159	001	Sep 20, 2013	May	CAHN
>D>	AB	UNIQUE	10MG	A204720	003	Dec 29, 2016	Nov CHRS
>A>	AB	!	10MG	A204720	003	Dec 29, 2016	Nov CHRS
>D>		GLUCOTROL XL					
>D>	AB	+ PFIZER	5MG	N020329	001	Apr 26, 1994	Nov DISC
>A>		+ @	5MG	N020329	001	Apr 26, 1994	Nov DISC

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

>D>	@ DASH PHARMS	2.5MG;250MG	A078083	001	Apr 12, 2007	Nov	CAHN
>D>	@	2.5MG;500MG	A078083	002	Apr 12, 2007	Nov	CAHN
>D>	@	5MG;500MG	A078083	003	Apr 12, 2007	Nov	CAHN
>A>	@ ESJAY PHARMA	2.5MG;250MG	A078083	001	Apr 12, 2007	Nov	CAHN
>A>	@	2.5MG;500MG	A078083	002	Apr 12, 2007	Nov	CAHN
>A>	@	5MG;500MG	A078083	003	Apr 12, 2007	Nov	CAHN

GLUCAGON

INJECTABLE;INJECTION

GLUCAGON

>D>	!	AMPHASTAR PHARMS INC	1MG/VIAL	A208086	001	Dec 28, 2020	Nov CTEC
>A>	AP	!	1MG/VIAL	A208086	001	Dec 28, 2020	Nov CTEC
>A>	AP	MYLAN LABS LTD	1MG/VIAL	A204468	001	Dec 12, 2024	Nov NEWA

GLUCAGON HYDROCHLORIDE

POWDER;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

GLUCAGON

	+!	FRESENIUS KABI USA	EQ 1MG BASE/VIAL	N201849	002	Sep 19, 2019	Apr CMS1
--	----	--------------------	------------------	---------	-----	--------------	----------

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

AB	HERITAGE	1.25MG;250MG	A079009	001	Jun 03, 2009	Feb	CMFD
AB		2.5MG;500MG	A079009	002	Jun 03, 2009	Feb	CMFD
AB		5MG;500MG	A079009	003	Jun 03, 2009	Feb	CMFD

GLYCEROL PHENYL BUTYRATE

LIQUID;ORAL

GLYCEROL PHENYL BUTYRATE

	@ ENDO OPERATIONS	1.1GM/ML	A205742	001	Dec 02, 2021	May	CAHN
--	-------------------	----------	---------	-----	--------------	-----	------

GLYCOPYRROLATE

INJECTABLE;INJECTION

GLYCOPYRROLATE

AP	NIVAGEN PHARMS INC	0.2MG/ML	A212591	001	Oct 13, 2021	Feb	CAHN
AP	OMNIVIUM PHARMS	0.2MG/ML	A212871	001	Nov 29, 2022	Sep	CAHN
AP	UMEDICA	0.2MG/ML	A212591	001	Oct 13, 2021	Aug	CAHN

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

GLYRX-PF

	+ @ EXELA PHARMA	0.6MG/3ML (0.2MG/ML)	N210997	004	Dec 14, 2020	Sep	DISC
--	------------------	----------------------	---------	-----	--------------	-----	------

SOLUTION;ORAL

GLYCOPYRROLATE

AA	CHARTWELL RX	1MG/5ML	A216368	001	Aug 28, 2024	Aug	NEWA
AA	GRANULES	1MG/5ML	A214735	001	Aug 19, 2024	Aug	NEWA
AA	SAPTALIS PHARMS	1MG/5ML	A216297	001	Oct 07, 2024	Sep	NEWA

TABLET;ORAL

GLYCOPYRROLATE

AA	ADAPTIS	1MG	A091182	001	Feb 03, 2014	Aug	CAHN
AA		2MG	A091182	002	Feb 03, 2014	Aug	CAHN
>A>	AA	APPCO	1MG	A207201	001	Jan 03, 2017	Nov CAHN
>A>	AA		2MG	A207201	002	Jan 03, 2017	Nov CAHN
>D>	AA	HERITAGE PHARMS INC	1MG	A207201	001	Jan 03, 2017	Nov CAHN
>D>	AA		2MG	A207201	002	Jan 03, 2017	Nov CAHN
	!	LGM PHARMA	1.5MG	A091522	001	Mar 12, 2012	Jul CHRS
AA	QUAGEN	1MG	A212696	001	Jul 10, 2024	Jun	NEWA
AA		2MG	A212696	002	Jul 10, 2024	Jun	NEWA
AA	VELZEN PHARMA PVT	1MG	A090195	001	Sep 21, 2012	Aug	CAHN
AA		2MG	A090195	002	Sep 21, 2012	Aug	CAHN

GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS
PREVDUO

+! AZURITY 0.6MG/3ML (0.2MG/ML);3MG/3ML (1MG/ML) N216903 001 Feb 23, 2023 Feb CAHN

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

AT NORDIC PHARMA 0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML A065187 001 Oct 28, 2005 Jun CAHN

GRANISETRON

INJECTABLE;SUBCUTANEOUS
SUSTOL

+! HERON THERAPS INC 10MG/0.4ML (10MG/0.4ML) N022445 001 Aug 09, 2016 Aug CMS1

GRISEOFULVIN, MICROSIZE

TABLET;ORAL
FULVICIN-U/F

AB CHARTWELL RX 250MG A060569 002 Jan CTEC
250MG A060569 002 Jan CAIN
AB 500MG A060569 001 Jan CTEC
500MG A060569 001 Jan CAIN
GRISEOFULVIN
AB SANDOZ 250MG A091592 001 Aug 07, 2013 Jan CTEC

GRISEOFULVIN, ULTRAMICROSIZE

TABLET;ORAL
FULVICIN P/G

AB CHARTWELL RX 125MG A061996 001 Jan CTEC
125MG A061996 001 Jan CAIN
AB 250MG A061996 002 Jan CTEC
250MG A061996 002 Jan CAIN
FULVICIN P/G 165
CHARTWELL RX 165MG A061996 003 Apr 06, 1982 Jan CAIN
FULVICIN P/G 330
CHARTWELL RX 330MG A061996 004 Apr 06, 1982 Jan CAIN

GUANFACINE HYDROCHLORIDE

TABLET;ORAL
GUANFACINE HYDROCHLORIDE

AB XIROMED EQ 1MG BASE A218326 001 Feb 23, 2024 Feb NEWA
AB EQ 2MG BASE A218326 002 Feb 23, 2024 Feb NEWA

TABLET, EXTENDED RELEASE;ORAL
GUANFACINE HYDROCHLORIDE

>A> AB UNICHEM EQ 1MG BASE A219033 001 Nov 19, 2024 Nov NEWA
>A> AB EQ 2MG BASE A219033 002 Nov 19, 2024 Nov NEWA
>A> AB EQ 3MG BASE A219033 003 Nov 19, 2024 Nov NEWA
>A> AB EQ 4MG BASE A219033 004 Nov 19, 2024 Nov NEWA

HALCINONIDE

OINTMENT;TOPICAL
HALOG

+ @ SUN PHARM INDS INC 0.1% N017824 001 Jan DISC

SOLUTION;TOPICAL
HALCINONIDE

ENCUBE 0.1% A217671 001 May 29, 2024 May NFTG

HALOG

+ @ SUN PHARM INDS INC 0.1% N017823 001 Jan DISC

HALOBETASOL PROPIONATE

LOTION;TOPICAL
ULTRAVATE

+ @ MICAL PHARMS 0.05% N208183 001 Nov 06, 2015 May CAHN
+ @ SUN PHARM INDUSTRIES 0.05% N208183 001 Nov 06, 2015 May DISC

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

AB	AIPING PHARM INC	2MG	A071130	001	Feb 17, 1987	Oct	CAHN
AB		5MG	A071130	002	Feb 17, 1987	Oct	CAHN
AB		10MG	A071130	003	May 12, 1987	Oct	CAHN
AB	AUROBINDO PHARMA LTD	0.5MG	A218789	001	Apr 19, 2024	Apr	NEWA
AB		1MG	A218789	002	Apr 19, 2024	Apr	NEWA
AB		2MG	A218789	003	Apr 19, 2024	Apr	NEWA
AB		5MG	A218789	004	Apr 19, 2024	Apr	NEWA
AB		10MG	A218789	005	Apr 19, 2024	Apr	NEWA
AB		20MG	A218789	006	Apr 19, 2024	Apr	NEWA
AB	CHARTWELL RX	0.5MG	A071209	002	Nov 17, 1986	Jan	CAHN
AB		1MG	A071209	003	Nov 17, 1986	Jan	CAHN
AB	@	2MG	A071209	004	Nov 17, 1986	Jan	CAHN
AB		5MG	A071209	001	Nov 17, 1986	Jan	CAHN
AB		10MG	A071210	001	Mar 11, 1988	Jan	CAHN
AB		20MG	A071211	001	Mar 11, 1988	Jan	CAHN
AB	MANKIND PHARMA	0.5MG	A216918	001	Apr 11, 2024	Apr	NEWA
AB		1MG	A216918	002	Apr 11, 2024	Apr	NEWA
AB		2MG	A216918	003	Apr 11, 2024	Apr	NEWA
AB		5MG	A216918	004	Apr 11, 2024	Apr	NEWA
AB		10MG	A216918	005	Apr 11, 2024	Apr	NEWA
AB		20MG	A216918	006	Apr 11, 2024	Apr	NEWA
AB	SCIEGEN PHARMS INC	5MG	A071130	002	Feb 17, 1987	May	CMS1
AB		10MG	A071130	003	May 12, 1987	May	CMS1

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

@	TEVA PHARMS USA	EQ 50MG BASE/ML	A075393	001	May 11, 1999	Jan	DISC
@		EQ 100MG BASE/ML	A075393	002	May 11, 1999	Jan	DISC

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALOPERIDOL

AA	RUBICON	EQ 2MG BASE/ML	A218371	001	Jan 31, 2024	Jan	NEWA
----	---------	----------------	---------	-----	--------------	-----	------

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

@	ASPEN GLOBAL INC	1,000 UNITS/ML	N000552	008		Jun	CAHN
@		5,000 UNITS/ML	N000552	009		Jun	CAHN
@		10,000 UNITS/ML	N000552	010		Jun	CAHN
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER							
+!	HOSPIRA	5,000 UNITS/100ML	N018916	006	Jan 31, 1984	Oct	CHRS
+		5,000 UNITS/100ML	N018916	006	Jan 31, 1984	Oct	CRLD
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5%							
+	@ FRESENIUS KABI USA	40 UNITS/ML	N017029	021	Aug 24, 2017	Sep	DISC
+!		40 UNITS/ML	N017029	021	Aug 24, 2017	Mar	NEWA
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%							
+!	FRESENIUS KABI USA	50 UNITS/ML	N017029	022	Aug 24, 2017	Mar	NEWA
+!		100 UNITS/ML	N017029	023	Aug 24, 2017	Mar	NEWA
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45%							
+!	FRESENIUS KABI USA	50 UNITS/ML	N017029	024	Aug 24, 2017	Mar	NEWA
+!		100 UNITS/ML	N017029	025	Aug 24, 2017	Mar	NEWA
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER							
+!	HOSPIRA	5,000 UNITS/100ML	N018916	007	Jan 31, 1984	Oct	CHRS
+		5,000 UNITS/100ML	N018916	007	Jan 31, 1984	Oct	CRLD
+!		10,000 UNITS/100ML	N018916	008	Jan 31, 1984	Oct	CHRS
+		10,000 UNITS/100ML	N018916	008	Jan 31, 1984	Oct	CRLD
LIQUAEMIN LOCK FLUSH							
@	ASPEN GLOBAL INC	100 UNITS/ML	N000552	007		Jun	CAHN
LIQUAEMIN SODIUM							
@	ASPEN GLOBAL INC	1,000 UNITS/ML	N000552	004		Jun	CAHN
@		5,000 UNITS/ML	N000552	003		Jun	CAHN
@		10,000 UNITS/ML	N000552	005		Jun	CAHN
@		20,000 UNITS/ML	N000552	001		Jun	CAHN
@		40,000 UNITS/ML	N000552	002		Jun	CAHN
LIQUAEMIN SODIUM PRESERVATIVE FREE							
@	ASPEN GLOBAL INC	1,000 UNITS/ML	N000552	011	Apr 11, 1986	Jun	CAHN

INJECTABLE; INJECTION

LIQUAEMIN SODIUM PRESERVATIVE FREE

@		5,000 UNITS/ML	N000552	012	Apr 11, 1986	Jun	CAHN
@		10,000 UNITS/ML	N000552	013	Apr 11, 1986	Jun	CAHN

HISTRELIN ACETATE

IMPLANT; SUBCUTANEOUS

SUPPRELIN LA

+!	ENDO OPERATIONS	50MG	N022058	001	May 03, 2007	Apr	CAHN
	VANTAS						
+	@ ENDO OPERATIONS	50MG	N021732	001	Oct 12, 2004	May	CAHN

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA	!	ABHAI LLC	1.5MG/5ML; 5MG/5ML	A207487	001	Feb 21, 2017	Mar	CHRS
	@	GENUS	1.5MG/5ML; 5MG/5ML	A040613	001	Feb 08, 2008	Apr	CAHN
	@	PAI HOLDINGS PHARM	1.5MG/5ML; 5MG/5ML	A040613	001	Feb 08, 2008	Mar	DISC
	@	SCIEGEN PHARMS INC	1.5MG/5ML; 5MG/5ML	A204765	001	Mar 06, 2017	Sep	CAHN

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

AP		ADRASTEIA PHARMA	20MG/ML	A203110	001	Jun 29, 2015	Feb	CAHN
AP	!	FRESENIUS KABI USA	20MG/ML	A040388	001	Mar 13, 2001	Aug	CHRS
	@	NORVIUM BIOSCIENCE	20MG/ML	A204680	001	Apr 28, 2016	Jun	CAHN
AP		RISING	20MG/ML	A040730	001	Apr 21, 2009	Aug	CHRS

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

AA		GLENMARK PHARMS LTD	10MG	A090527	001	May 29, 2009	Jul	CMS1
AA			25MG	A090527	002	May 29, 2009	Jul	CMS1
AA			50MG	A090527	003	May 29, 2009	Jul	CMS1
AA			100MG	A090527	004	May 29, 2009	Jul	CMS1
	@	INVAGEN PHARMS	10MG	A090255	001	Dec 15, 2008	Mar	DISC
	@		25MG	A090255	002	Dec 15, 2008	Mar	DISC
	@		50MG	A090255	003	Dec 15, 2008	Mar	DISC
	@		100MG	A090255	004	Dec 15, 2008	Mar	DISC
AA		MACLEODS PHARMS LTD	10MG	A211010	001	Aug 21, 2024	Aug	NEWA
AA			25MG	A211010	002	Aug 21, 2024	Aug	NEWA
AA			50MG	A211010	003	Aug 21, 2024	Aug	NEWA
AA			100MG	A211010	004	Aug 21, 2024	Aug	NEWA
	@	NORVIUM BIOSCIENCE	10MG	A090413	001	Dec 08, 2010	Jul	CAHN
	@		25MG	A090413	002	Dec 08, 2010	Jul	CAHN
	@		50MG	A090413	003	Dec 08, 2010	Jul	CAHN
	@		100MG	A090413	004	Dec 08, 2010	Jul	CAHN

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET; ORAL

ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE

AB		I3 PHARMS	37.5MG; 20MG	A215988	001	Jan 17, 2024	Jan	NEWA
----	--	-----------	--------------	---------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

>D>	AB	!	ACCORD HLTHCARE	12.5MG	A202556	001	Sep 24, 2012	Nov	CHRS
>A>	AB			12.5MG	A202556	001	Sep 24, 2012	Nov	CHRS
>D>	AB		IVAX SUB TEVA PHARMS	12.5MG	A083177	003	Sep 19, 2024	Nov	CRLD
>A>	AB	+		12.5MG	A083177	003	Sep 19, 2024	Nov	CRLD
	AB			12.5MG	A083177	003	Sep 19, 2024	Sep	NEWA
		@	PRINSTON INC	25MG	A040412	001	Mar 29, 2002	Aug	DISC
		@		50MG	A040412	002	Mar 29, 2002	Aug	DISC

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

AB		COREPHARMA	12.5MG; 10MG	A076674	001	Oct 05, 2004	Sep	CMFD
AB			12.5MG; 20MG	A076674	002	Oct 05, 2004	Sep	CMFD
AB			25MG; 20MG	A076674	003	Oct 05, 2004	Sep	CMFD

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

@	GRANULES	12.5MG;50MG	A218015	001	Sep 29, 2023	Mar	DISC
@		12.5MG;100MG	A218015	002	Sep 29, 2023	Mar	DISC
@		25MG;100MG	A218015	003	Sep 29, 2023	Mar	DISC

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET;ORAL

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

@	SUN PHARM INDS	25MG;50MG	A090654	001	Jan 19, 2012	May	DISC
@		25MG;100MG	A090654	002	Jan 19, 2012	May	DISC
@		50MG;100MG	A090654	003	Jan 19, 2012	May	DISC

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

HYDROCHLOROTHIAZIDE AND OLMESARTAN MEDOXOMIL

AB	ALKEM LABS LTD	12.5MG;20MG	A207037	001	Jul 11, 2024	Jul	NEWA
AB		12.5MG;40MG	A207037	002	Jul 11, 2024	Jul	NEWA
AB		25MG;40MG	A207037	003	Jul 11, 2024	Jul	NEWA
	OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE						
@	TEVA PHARMS USA	12.5MG;40MG	A200532	002	Apr 24, 2017	May	DISC

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	CHARTWELL RX	12.5MG;EQ 10MG BASE	A076374	001	Mar 31, 2004	Oct	CMFD
AB		12.5MG;EQ 20MG BASE	A076374	002	Mar 31, 2004	Oct	CMFD
AB		25MG;EQ 20MG BASE	A076374	003	Mar 31, 2004	Oct	CMFD
@	INVAGEN PHARMS	12.5MG;EQ 10MG BASE	A201356	001	Apr 20, 2011	Mar	DISC
@		12.5MG;EQ 20MG BASE	A201356	002	Apr 20, 2011	Mar	DISC
@		25MG;EQ 20MG BASE	A201356	003	Apr 20, 2011	Mar	DISC

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@	SCIEGEN PHARMS INC	5MG/5ML;60MG/5ML	A206661	001	Jan 23, 2019	Sep	CAHN
---	--------------------	------------------	---------	-----	--------------	-----	------

HYDROCORTISONE

TABLET;ORAL

HYDROCORTISONE

>A>	AB	HIBROW HLTHCARE	5MG	A217160	001	Nov 25, 2024	Nov	NEWA
>A>	AB		10MG	A217160	002	Nov 25, 2024	Nov	NEWA
>A>	AB		20MG	A217160	003	Nov 25, 2024	Nov	NEWA

HYDROCORTISONE ACETATE

CREAM;TOPICAL

MICORT-HC

>A>		LEGACY PHARMA	2.5%	A040396	001	Feb 27, 2001	Nov	CAHN
>D>		SEBELA IRELAND LTD	2.5%	A040396	001	Feb 27, 2001	Nov	CAHN

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

CREAM;TOPICAL

PRAMOSONE

>A>		LEGACY PHARMA	0.5%;1%	A083778	001		Nov	CAHN
>A>			1%;1%	A085368	001		Nov	CAHN
>D>		SEBELA IRELAND LTD	0.5%;1%	A083778	001		Nov	CAHN
>D>			1%;1%	A085368	001		Nov	CAHN

LOTION;TOPICAL

PRAMOSONE

>A>		LEGACY PHARMA	1%;1%	A085980	001		Nov	CAHN
>A>			2.5%;1%	A085979	001		Nov	CAHN
>D>		SEBELA IRELAND LTD	1%;1%	A085980	001		Nov	CAHN
>D>			2.5%;1%	A085979	001		Nov	CAHN

HYDROCORTISONE BUTYRATE

LOTION;TOPICAL

HYDROCORTISONE BUTYRATE

AB	!	LUPIN LTD	0.1%	A210209	001	Aug 17, 2018	Aug	CHRS
----	---	-----------	------	---------	-----	--------------	-----	------

LOTION; TOPICAL
 LOCOID

+ @ BAUSCH 0.1% N022076 001 May 18, 2007 Aug DISC

HYDROCORTISONE PROBUTATE

CREAM; TOPICAL
 PANDEL

+ @ ANI PHARMS 0.1% N020453 001 Feb 28, 1997 Oct DISC

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION
 HYDROCORTISONE SODIUM SUCCINATE

AP CIPLA EQ 100MG BASE/VIAL A214050 001 Sep 05, 2024 Aug NFTG
 SOLU-CORTEF
 AP +! PHARMACIA AND UPJOHN EQ 100MG BASE/VIAL N009866 001 Aug CFTG

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION
 DILAUDID

AP +! FRESENIUS KABI USA 0.2MG/ML N019034 006 Jan 16, 2020 Feb CFTG
 AP +! 0.5MG/0.5ML N019034 007 Feb 10, 2017 Feb CFTG
 +! 0.5MG/0.5ML N019034 007 Feb 10, 2017 Jan NEWA
 AP +! 4MG/ML N019034 005 Apr 30, 2009 Aug CMFD
 HYDROMORPHONE HYDROCHLORIDE
 AP HIKMA 0.2MG/ML A216899 001 Feb 09, 2024 Feb NFTG
 AP 0.5MG/0.5ML A216899 002 Feb 09, 2024 Feb NFTG
 AP 1MG/ML A216899 003 Feb 09, 2024 Feb NEWA
 AP 2MG/ML A216899 004 Feb 09, 2024 Feb NEWA
 AP HOSPIRA INC 4MG/ML N200403 003 Dec 01, 2011 Aug CTEC

SOLUTION; ORAL
 HYDROMORPHONE HYDROCHLORIDE

>D> @ CHARTWELL 5MG/5ML A207108 001 Apr 22, 2020 Nov CAHN
 @ 5MG/5ML A207108 001 Apr 22, 2020 Sep CAHN
 @ GENUS 5MG/5ML A207108 001 Apr 22, 2020 Jan CAHN
 >A> @ GENUS LIFESCIENCES 5MG/5ML A207108 001 Apr 22, 2020 Nov CAHN

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

>D> @ CHARTWELL 2MG A077471 002 Dec 09, 2009 Nov CAHN
 @ 2MG A077471 002 Dec 09, 2009 Sep CAHN
 >D> @ 4MG A077471 003 Dec 09, 2009 Nov CAHN
 @ 4MG A077471 003 Dec 09, 2009 Sep CAHN
 >D> @ 8MG A077471 001 Dec 09, 2009 Nov CAHN
 @ 8MG A077471 001 Dec 09, 2009 Sep CAHN
 @ GENUS 2MG A077471 002 Dec 09, 2009 Jan CAHN
 @ 4MG A077471 003 Dec 09, 2009 Jan CAHN
 @ 8MG A077471 001 Dec 09, 2009 Jan CAHN
 >A> @ GENUS LIFESCIENCES 2MG A077471 002 Dec 09, 2009 Nov CAHN
 >A> @ 4MG A077471 003 Dec 09, 2009 Nov CAHN
 >A> @ 8MG A077471 001 Dec 09, 2009 Nov CAHN

TABLET, EXTENDED RELEASE; ORAL

HYDROMORPHONE HYDROCHLORIDE
 OSMOTICA PHARM US 24MG

A205629 005 Oct 30, 2024 Oct NEWA

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL
 HYDROXYCHLOROQUINE SULFATE

AB ALLIED 200MG A040150 001 Jan 27, 1996 Jun CAHN
 AB ! APPCO 100MG A210441 002 Sep 19, 2022 Jun CHRS
 AB CREEKWOOD PHARMS 200MG A040150 001 Jan 27, 1996 Jul CAHN
 AB 200MG A040150 001 Jan 27, 1996 Apr CMFD
 @ 200MG A040150 001 Jan 27, 1996 Jan CAHN
 AB SENORES PHARMS 200MG A212902 001 May 14, 2020 Feb CAHN
 AB TEVA PHARMS 200MG A040081 001 Sep 30, 1994 Feb CMFD

HYDROXYPROPYL CELLULOSE

INSERT; OPHTHALMIC
 LACRISERT

+ @ BAUSCH AND LOMB INC 5MG N018771 001 Jul DISC

HYDROXYUREA

	CAPSULE;ORAL						
	DROXIA						
	+ @	CHEPLAPHARM	200MG	N016295	002	Feb 25, 1998	Oct DISC
	+ @		300MG	N016295	003	Feb 25, 1998	Oct DISC
	+ @		400MG	N016295	004	Feb 25, 1998	Oct DISC
	HYDROXYUREA						
AB		QILU	500MG	A218021	001	Mar 06, 2024	Feb NEWA
	SOLUTION;ORAL						
	XROMI						
	+!	NOVA LABS LTD	100MG/ML	N216593	001	Apr 04, 2024	Apr NEWA

HYDROXYZINE HYDROCHLORIDE

	SYRUP;ORAL						
	HYDROXYZINE HYDROCHLORIDE						
AA		APOZEAL PHARMS	10MG/5ML	A210634	001	Feb 26, 2019	Jun CMFD
AA		PAI HOLDINGS PHARM	10MG/5ML	A040391	001	Apr 10, 2002	Oct CMFD
	TABLET;ORAL						
	HYDROXYZINE HYDROCHLORIDE						
	@	INVAGEN PHARMS	10MG	A040812	001	Mar 12, 2008	Mar DISC
	@		25MG	A040812	002	Mar 12, 2008	Mar DISC
	@		50MG	A040812	003	Mar 12, 2008	Mar DISC

HYDROXYZINE PAMOATE

	CAPSULE;ORAL						
	HYDROXYZINE PAMOATE						
AB	!	HERITAGE PHARMA	EQ 50MG HYDROCHLORIDE	A201507	002	Jun 03, 2013	Jul CHRS
AB		SANDOZ	EQ 50MG HYDROCHLORIDE	A086183	001		Jul CHRS
	VISTARIL						
	+ @	PFIZER	EQ 100MG HYDROCHLORIDE	N011459	006		Jul CRLD

IBANDRONATE SODIUM

	INJECTABLE;INTRAVENOUS						
	IBANDRONATE SODIUM						
>A>	AP	CHEMI SPA	EQ 3MG BASE/3ML	A202235	001	Sep 02, 2014	Nov CAHN
>D>	AP	SAGENT PHARMS INC	EQ 3MG BASE/3ML	A202235	001	Sep 02, 2014	Nov CAHN
		@ SUN PHARM	EQ 3MG BASE/3ML	A090853	001	Feb 14, 2014	May DISC
	TABLET;ORAL						
	IBANDRONATE SODIUM						
	@	WATSON LABS TEVA	EQ 150MG BASE	A079003	001	Mar 20, 2012	May DISC

IBRUTINIB

	CAPSULE;ORAL						
	IBRUTINIB						
	@	ZYDUS LIFESCIENCES	70MG	A211344	001	Mar 31, 2021	Sep CAHN
	@		140MG	A211344	002	Mar 31, 2021	Sep CAHN
	TABLET;ORAL						
	IMBRUVICA						
	+!	PHARMACYCLICS LLC	420MG	N210563	003	Feb 16, 2018	Jan CHRS

IBUPROFEN

	TABLET;ORAL						
	IBUPROFEN						
>A>	AB	DR REDDYS	400MG	A075682	001	Nov 14, 2001	Nov CAHN
>A>	AB		600MG	A075682	002	Nov 14, 2001	Nov CAHN
>A>	AB	!	800MG	A075682	003	Nov 14, 2001	Nov CAHN
>D>	AB	DR REDDYS LA	400MG	A075682	001	Nov 14, 2001	Nov CAHN
>D>	AB		600MG	A075682	002	Nov 14, 2001	Nov CAHN
>D>	AB	!	800MG	A075682	003	Nov 14, 2001	Nov CAHN
	@	ENDO OPERATIONS	300MG	A071230	001	Oct 22, 1986	May CAHN
	@		400MG	A071231	001	Oct 22, 1986	May CAHN
	@		400MG	A071644	001	Feb 01, 1988	May CAHN
	@		600MG	A071232	001	Oct 22, 1986	May CAHN
	@		800MG	A072004	001	Nov 18, 1987	May CAHN
	@	SHANDONG XINHUA	300MG	A202413	004	Jul 05, 2024	Jul NEWA

IBUTILIDE FUMARATE

INJECTABLE; INJECTION
 IBUTILIDE FUMARATE
 AP AVET LIFESCIENCES 0.1MG/ML A204146 001 Apr 01, 2024 Mar NEWA

ICATIBANT ACETATE

INJECTABLE; SUBCUTANEOUS
 ICATIBANT ACETATE
 AP ALEMBIC EQ 30MG BASE/3ML (EQ 10MG BASE/ML) A213773 001 Jun 14, 2024 Jun NEWA
 AP WILSHIRE PHARMS INC EQ 30MG BASE/3ML (EQ 10MG BASE/ML) A211501 001 Sep 01, 2020 Jul CAHN

ICOSAPENT ETHYL

CAPSULE; ORAL
 ICOSAPENT ETHYL
 AB ASCENT PHARMS INC 1GM A216811 002 Feb 16, 2024 Feb NEWA
 >A> AB QILU 1GM A218899 001 Nov 20, 2024 Nov NEWA
 AB ZYDUS LIFESCIENCES 500MG A217656 001 Apr 20, 2023 Apr CAHN
 AB 1GM A217656 002 Apr 20, 2023 Apr CAHN

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
 IDARUBICIN HYDROCHLORIDE
 @ RISING 1MG/ML A200144 001 Oct 11, 2012 Feb CAHN

ILOPROST

SOLUTION; INHALATION
 VENTAVIS
 + @ ACTELION 10MCG/ML (10MCG/ML) N021779 002 Dec 08, 2005 Mar DISC
 + @ 20MCG/ML (20MCG/ML) N021779 003 Aug 07, 2009 Mar DISC
 SOLUTION; INTRAVENOUS
 AURLUMYN
 >A> +! BTG INTL 100MCG/ML (100MCG/ML) N217933 001 Feb 13, 2024 Nov CAHN
 >D> +! EICOS SCI 100MCG/ML (100MCG/ML) N217933 001 Feb 13, 2024 Nov CAHN
 +! 100MCG/ML (100MCG/ML) N217933 001 Feb 13, 2024 Feb NEWA

IMATINIB MESYLATE

SOLUTION; ORAL
 IMKELDI
 >A> +! SHORLA ONCOLOGY EQ 80MG BASE/ML N219097 001 Nov 22, 2024 Nov NEWA
 TABLET; ORAL
 IMATINIB MESYLATE
 >A> @ ALLIED EQ 100MG BASE A205990 001 Feb 08, 2019 Nov CAHN
 >A> @ EQ 400MG BASE A205990 002 Feb 08, 2019 Nov CAHN
 >D> @ BRECKENRIDGE EQ 100MG BASE A205990 001 Feb 08, 2019 Nov CAHN
 >D> @ EQ 400MG BASE A205990 002 Feb 08, 2019 Nov CAHN
 >A> @ ESJAY PHARMA EQ 100MG BASE A205990 001 Feb 08, 2019 Nov CAHN
 >A> @ EQ 400MG BASE A205990 002 Feb 08, 2019 Nov CAHN

IMETELSTAT SODIUM

POWDER; INTRAVENOUS
 RYTELO
 +! GERON EQ 47MG BASE/VIAL N217779 001 Jun 06, 2024 Jun NEWA
 +! EQ 188MG BASE/VIAL N217779 002 Jun 06, 2024 Jun NEWA

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL
 IMIPRAMINE HYDROCHLORIDE
 AB ! LEADING 50MG A040903 003 Oct 24, 2012 Apr CHRS
 + @ SPECGX LLC 10MG A087846 002 May 22, 1984 Apr DISC
 + @ 25MG A087846 003 May 22, 1984 Apr DISC
 TOFRANIL
 + @ SPECGX LLC 50MG A087846 001 May 22, 1984 Apr DISC

INAVOLISIB

TABLET; ORAL
 ITOVEBI
 + GENENTECH INC 3MG N219249 001 Oct 10, 2024 Oct NEWA
 +! 9MG N219249 002 Oct 10, 2024 Oct NEWA

INDIUM IN-111 CHLORIDE

INJECTABLE;INJECTION
INDIUM IN 111 CHLORIDE
+ @ CURIUM

5mCi/0.5ML

N019841 001 Sep 27, 1994 Sep DISC

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE;INJECTION
INDIUM IN-111 PENTETREOTIDE KIT
AP SUN PHARM INDS INC

3mCi/ML

A212785 001 Jul 01, 2024 Jun NFTG

OCTREOSCAN

AP +! CURIUM 3mCi/ML

N020314 001 Jun 02, 1994 Jun CFTG

INDOMETHACIN

CAPSULE, EXTENDED RELEASE;ORAL
INDOMETHACIN

@ MYLAN 75MG

A202139 001 Mar 20, 2014 Aug CAHN

SUPPOSITORY;RECTAL
INDOMETHACIN

>A> AB HIKMA 50MG

A215899 001 Nov 19, 2024 Nov NEWA

AB ZYDUS LIFESCIENCES 50MG

A216184 001 Aug 02, 2023 Apr CAHN

SUSPENSION;ORAL
INDOCIN

AB +! ZYLA 25MG/5ML

N018332 001 Oct 10, 1985 Jan CTEC

INDOMETHACIN

AB NOVITIUM PHARMA 25MG/5ML

A217883 001 Jan 12, 2024 Jan NEWA

INDOMETHACIN SODIUM

INJECTABLE;INJECTION
INDOMETHACIN SODIUM

>A> @ HIKMA EQ 1MG BASE/VIAL

A078713 001 Jul 16, 2008 Nov DISC

>A> AP EQ 1MG BASE/VIAL

A078713 001 Jul 16, 2008 Nov CAHN

>D> AP HOSPIRA EQ 1MG BASE/VIAL

A204118 001 Apr 19, 2016 Nov DISC

>A> @ EQ 1MG BASE/VIAL

A204118 001 Apr 19, 2016 Nov DISC

>D> AP ! NAVINTA LLC EQ 1MG BASE/VIAL

A206561 001 Jul 19, 2017 Nov DISC

>A> @ EQ 1MG BASE/VIAL

A206561 001 Jul 19, 2017 Nov DISC

>D> AP WEST-WARD PHARMS INT EQ 1MG BASE/VIAL

A078713 001 Jul 16, 2008 Nov CAHN

INOTERSEN SODIUM

SOLUTION;SUBCUTANEOUS
TEGSEDI

+ @ AKCEA THERAPS EQ 284MG BASE/1.5ML (EQ 189.3MG BASE/ML)

N211172 001 Oct 05, 2018 Sep DISC

IOBENGUANE I-131

SOLUTION;INTRAVENOUS
AZEDRA

+ @ PROGENICS PHARMS INC 15mCi/ML

N209607 001 Jul 30, 2018 Feb DISC

IOBENGUANE SULFATE I-123

SOLUTION;INTRAVENOUS
ADREVIEW

>D> +! GE HEALTHCARE 10mCi/5ML (2mCi/ML)

N022290 001 Sep 19, 2008 Nov CFTG

>A> AP +! 10mCi/5ML (2mCi/ML)

N022290 001 Sep 19, 2008 Nov CFTG

>A> IOBENGUANE I-123

>A> AP BWXT MEDCL 10mCi/5ML (2mCi/ML)

A213637 001 Dec 09, 2024 Nov NFTG

>A> IOMEPROL

SOLUTION;INTRA-ARTERIAL
IOMERVU

>A> +! BRACCO 15GM IODINE/50ML (300MG IODINE/ML)

N216016 002 Nov 27, 2024 Nov NEWA

>A> +! 17.5GM IODINE/50ML (350MG IODINE/ML)

N216016 006 Nov 27, 2024 Nov NEWA

>A> +! 20GM IODINE/50ML (400MG IODINE/ML)

N216016 010 Nov 27, 2024 Nov NEWA

>A> +! 25GM IODINE/100ML (250MG IODINE/ML)

N216016 001 Nov 27, 2024 Nov NEWA

>A> +! 30GM IODINE/100ML (300MG IODINE/ML)

N216016 003 Nov 27, 2024 Nov NEWA

>A> +! 35GM IODINE/100ML (350MG IODINE/ML)

N216016 007 Nov 27, 2024 Nov NEWA

>A> +! 40GM IODINE/100ML (400MG IODINE/ML)

N216016 011 Nov 27, 2024 Nov NEWA

>A> +! 60GM IODINE/150ML (400MG

N216016 012 Nov 27, 2024 Nov NEWA

>A> SOLUTION; INTRA-ARTERIAL
 >A> IOMERVU
 IODINE/ML)
 >A> +! 45GM IODINE/150ML (300MG N216016 004 Nov 27, 2024 Nov NEWA
 IODINE/ML)
 >A> +! 52.5GM IODINE/150ML (350MG N216016 008 Nov 27, 2024 Nov NEWA
 IODINE/ML)
 >A> +! 60GM IODINE/200ML (300MG N216016 005 Nov 27, 2024 Nov NEWA
 IODINE/ML)
 >A> +! 70GM IODINE/200ML (350MG N216016 009 Nov 27, 2024 Nov NEWA
 IODINE/ML)
 >A> +! 80GM IODINE/200ML (400MG N216016 013 Nov 27, 2024 Nov NEWA
 IODINE/ML)

>A> SOLUTION; INTRAVENOUS
 >A> IOMERVU
 >A> +! BRACCO 15GM IODINE/50ML (300MG IODINE/ML) N216017 002 Nov 27, 2024 Nov NEWA
 >A> +! 17.5GM IODINE/50ML (350MG N216017 006 Nov 27, 2024 Nov NEWA
 IODINE/ML)
 >A> +! 20GM IODINE/50ML (400MG IODINE/ML) N216017 010 Nov 27, 2024 Nov NEWA
 >A> +! 25GM IODINE/100ML (250MG N216017 001 Nov 27, 2024 Nov NEWA
 IODINE/ML)
 >A> +! 30GM IODINE/100ML (300MG N216017 003 Nov 27, 2024 Nov NEWA
 IODINE/ML)
 >A> +! 35GM IODINE/100ML (350MG N216017 007 Nov 27, 2024 Nov NEWA
 IODINE/ML)
 >A> +! 40GM IODINE/100ML (400MG N216017 011 Nov 27, 2024 Nov NEWA
 IODINE/ML)
 >A> +! 60GM IODINE/150ML (400MG N216017 012 Nov 27, 2024 Nov NEWA
 IODINE/ML)
 >A> +! 45GM IODINE/150ML (300MG N216017 004 Nov 27, 2024 Nov NEWA
 IODINE/ML)
 >A> +! 52.5GM IODINE/150ML (350MG N216017 008 Nov 27, 2024 Nov NEWA
 IODINE/ML)
 >A> +! 60GM IODINE/200ML (300MG N216017 005 Nov 27, 2024 Nov NEWA
 IODINE/ML)
 >A> +! 70GM IODINE/200ML (350MG N216017 009 Nov 27, 2024 Nov NEWA
 IODINE/ML)
 >A> +! 80GM IODINE/200ML (400MG N216017 013 Nov 27, 2024 Nov NEWA
 IODINE/ML)

IOPAMIDOL

INJECTABLE; INJECTION
 IOPAMIDOL
 AP HAINAN POLY 51% A217134 002 Apr 09, 2024 Mar NEWA
 AP 61% A217134 003 Apr 09, 2024 Mar NEWA
 AP 76% A217134 004 Apr 09, 2024 Mar NEWA
 ISOVUE-250
 AP +! BRACCO 51% N018735 007 Jul 06, 1992 Mar CTEC
 ISOVUE-300
 AP +! BRACCO 61% N018735 002 Dec 31, 1985 Mar CTEC
 ISOVUE-370
 AP +! BRACCO 76% N018735 003 Dec 31, 1985 Mar CTEC

IPRATROPIUM BROMIDE

SOLUTION; INHALATION
 IPRATROPIUM BROMIDE
 @ NORVIUM BIOSCIENCE 0.02% A074755 001 Jan 10, 1997 Jul CAHN
 SPRAY, METERED; NASAL
 IPRATROPIUM BROMIDE
 >A> AB RUBICON 0.042MG/SPRAY A219221 001 Nov 15, 2024 Nov NEWA

IRBESARTAN

TABLET; ORAL
 AVAPRO
 + @ SANOFI AVENTIS US 75MG N020757 001 Sep 30, 1997 Jul DISC
 IRBESARTAN
 AB IPKA LABS LTD 75MG A211056 001 May 22, 2024 May NEWA
 AB 150MG A211056 002 May 22, 2024 May NEWA
 AB 300MG A211056 003 May 22, 2024 May NEWA

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
 IRINOTECAN HYDROCHLORIDE
 @ HISUN PHARM HANGZHOU 40MG/2ML (20MG/ML)
 @ 100MG/5ML (20MG/ML)

A 090016 001 Jan 28, 2009 Jul DISC
 A 090016 002 Jan 28, 2009 Jul DISC

ISONIAZID

TABLET; ORAL
 ISONIAZID

>D> AA ! BARR 100MG
 >D> AA ! 300MG
 >A> AA ! GENUS 100MG
 >A> AA ! 300MG

A 080936 001 Nov CAHN
 A 080937 002 Nov CAHN
 A 080936 001 Nov CAHN
 A 080937 002 Nov CAHN

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION
 ISOPROTERENOL HYDROCHLORIDE

@ CIPLA 0.2MG/ML
 @ EUGIA PHARMA 0.2MG/ML
 AP GLAND PHARMA LTD 0.2MG/ML
 AP SOMERSET THERAPS LLC 0.2MG/ML

A 210322 001 Jun 12, 2018 Mar DISC
 A 211864 001 Feb 09, 2021 Jun DISC
 A 217648 001 Oct 03, 2024 Sep NEWA
 A 211590 001 Aug 06, 2024 Jul NEWA

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL
 DILATRATE-SR

+ @ ENDO OPERATIONS 40MG
 TABLET; ORAL

N 019790 001 Sep 02, 1988 May CAHN

ISONIAZID

AB ENDO OPERATIONS 40MG
 AB ZYDUS LIFESCIENCES 5MG
 AB 10MG
 AB 20MG
 AB 30MG
 AB 40MG

A 211290 001 Nov 23, 2021 Apr CAHN
 A 213057 001 Nov 20, 2019 Aug CAHN
 A 213057 002 Nov 20, 2019 Aug CAHN
 A 213057 003 Nov 20, 2019 Aug CAHN
 A 213057 004 Nov 20, 2019 Aug CAHN
 A 213057 005 Nov 20, 2019 Aug CAHN

ISOSORBIDE MONONITRATE

TABLET; ORAL

ISONIAZID

>D> AB ACTAVIS ELIZABETH 10MG
 >D> AB 20MG
 >A> AB GENUS 10MG
 >A> AB 20MG

A 075037 002 Oct 30, 1998 Nov CAHN
 A 075037 001 Oct 30, 1998 Nov CAHN
 A 075037 002 Oct 30, 1998 Nov CAHN
 A 075037 001 Oct 30, 1998 Nov CAHN

MONOKET

AB + OMNIVIUM PHARMS 10MG
 AB +! 20MG

N 020215 002 Jun 30, 1993 Jan CAHN
 N 020215 001 Jun 30, 1993 Jan CAHN

TABLET, EXTENDED RELEASE; ORAL

ISONIAZID

AB CHARTWELL MOLECULAR 120MG
 AB ! RICONPHARMA LLC 120MG
 AB SHANDONG 30MG
 AB 60MG
 AB 120MG
 @ ZYDUS PHARMS 30MG
 AB 30MG
 @ 60MG
 AB 60MG
 @ 120MG
 AB 120MG

A 075155 003 Aug 04, 2000 Mar CHRS
 A 210918 003 Nov 05, 2018 Mar CHRS
 A 214115 002 Feb 08, 2024 Feb NEWA
 A 214115 003 Feb 08, 2024 Feb NEWA
 A 214115 001 Apr 29, 2022 Mar CMFD
 A 218255 001 Feb 15, 2024 Aug DISC
 A 218255 001 Feb 15, 2024 Feb NEWA
 A 218255 002 Feb 15, 2024 Aug DISC
 A 218255 002 Feb 15, 2024 Feb NEWA
 A 218255 003 Feb 15, 2024 Aug DISC
 A 218255 003 Feb 15, 2024 Feb NEWA

ISOSULFAN BLUE

SOLUTION; SUBCUTANEOUS

ISONIAZID

AP AM REGENT 1%
 AP 50MG/5ML (10MG/ML)
 @ BELOTECA 1%
 @ 50MG/5ML (10MG/ML)
 @ EUGIA PHARMA 1%
 @ 50MG/5ML (10MG/ML)
 @ FRESENIUS KABI USA 1%
 @ 50MG/5ML (10MG/ML)
 AP MEITHEAL 1%

A 210294 001 May 17, 2023 May CDFR
 A 210294 001 May 17, 2023 May CPOT
 A 210714 001 Jan 16, 2019 May CDFR
 A 210714 001 Jan 16, 2019 May CPOT
 A 206831 001 Feb 02, 2016 May CDFR
 A 206831 001 Feb 02, 2016 May CPOT
 A 211869 001 Sep 08, 2022 May CDFR
 A 211869 001 Sep 08, 2022 May CPOT
 A 213130 001 Nov 03, 2021 May CDFR

SOLUTION;SUBCUTANEOUS
ISOSULFAN BLUE

AP		50MG/5ML (10MG/ML)	A213130	001	Nov 03, 2021	May CPOT
AP	MSN	1%	A216090	001	Sep 16, 2022	May CDFR
AP		50MG/5ML (10MG/ML)	A216090	001	Sep 16, 2022	May CPOT
AP	! MYLAN INSTITUTIONAL	1%	A090874	001	Jul 20, 2010	May CDFR
AP	!	50MG/5ML (10MG/ML)	A090874	001	Jul 20, 2010	May CPOT
	@ SOMERSET THERAPS LLC	1%	A210558	001	Jul 12, 2019	May CDFR
	@	50MG/5ML (10MG/ML)	A210558	001	Jul 12, 2019	May CPOT
	LYMPHAZURIN					
	+ @ COVIDIEN	1%	N018310	001		May CDFR
	+ @	50MG/5ML (10MG/ML)	N018310	001		May CPOT

ISOTRETINOIN

CAPSULE;ORAL
ISOTRETINOIN

AB2	AUROBINDO PHARMA	10MG	A218194	001	Jan 29, 2024	Jan NEWA
AB2		20MG	A218194	002	Jan 29, 2024	Jan NEWA
AB2		25MG	A218194	003	Jan 29, 2024	Jan NEWA
AB2		30MG	A218194	004	Jan 29, 2024	Jan NEWA
AB2		35MG	A218194	005	Jan 29, 2024	Jan NEWA
AB2		40MG	A218194	006	Jan 29, 2024	Jan NEWA

ITRACONAZOLE

CAPSULE;ORAL
ITRACONAZOLE

	@ ACCORD HLTHCARE	100MG	A205991	001	May 26, 2016	May DISC
	@ RISING	100MG	A205724	001	Dec 13, 2016	Apr CAHN

IVABRADINE HYDROCHLORIDE

TABLET;ORAL
IVABRADINE HYDROCHLORIDE

>A>	AB	ALEMBIC	EQ 5MG BASE	A215238	001	Nov 08, 2024	Nov NEWA
>A>	AB		EQ 7.5MG BASE	A215238	002	Nov 08, 2024	Nov NEWA
	AB	BIONPHARMA	EQ 5MG BASE	A213276	001	Sep 05, 2024	Aug NEWA
	AB		EQ 7.5MG BASE	A213276	002	Sep 05, 2024	Aug NEWA
	AB	INGENUS PHARMS LLC	EQ 5MG BASE	A214051	001	Dec 30, 2021	May CMFD
	AB		EQ 7.5MG BASE	A214051	002	Dec 30, 2021	May CMFD

IVERMECTIN

CREAM;TOPICAL
IVERMECTIN

AB	ZYDUS LIFESCIENCES	1%	A215210	001	Aug 02, 2022	Mar CAHN
----	--------------------	----	---------	-----	--------------	----------

TABLET;ORAL
IVERMECTIN

AB	SENORES PHARMS	3MG	A218324	001	Oct 16, 2024	Oct NEWA
----	----------------	-----	---------	-----	--------------	----------

KETAMINE HYDROCHLORIDE

INJECTABLE;INJECTION
KETALAR

AP	+ ENDO OPERATIONS	EQ 50MG BASE/ML	N016812	002		Aug CHRS
AP	+	EQ 100MG BASE/ML	N016812	003		Aug CHRS

KETAMINE HYDROCHLORIDE

AP	FRESENIUS KABI USA	EQ 10MG BASE/ML	A215808	001	Jan 13, 2023	Sep CMFD
AP		EQ 50MG BASE/ML	A215808	002	Jan 13, 2023	Sep CMFD
AP	! HIKMA	EQ 50MG BASE/ML	A074524	001	Mar 22, 1996	Aug CHRS
AP	!	EQ 100MG BASE/ML	A074524	002	Mar 22, 1996	Aug CHRS

KETOCONAZOLE

AEROSOL, FOAM;TOPICAL
KETOCONAZOLE

AB	! XIROMED	2%	A213601	001	May 21, 2021	Feb CHRS
----	-----------	----	---------	-----	--------------	----------

CREAM;TOPICAL
KETOCONAZOLE

AB	TRUPHARMA	2%	A215185	001	Nov 17, 2021	Aug CAHN
----	-----------	----	---------	-----	--------------	----------

SHAMPOO;TOPICAL
KETOCONAZOLE

AB	COSETTE	2%	A076942	001	Apr 11, 2005	Jul CAHN
AB	NOVITIUM PHARMA	2%	A218498	001	Sep 16, 2024	Sep NEWA

TABLET;ORAL								
KETOCONAZOLE								
AB	SENORES PHARMS	200MG	A075912	001	Jan 10, 2002	Feb	CAHN	
<u>KETOROLAC TROMETHAMINE</u>								
SOLUTION/DROPS;OPHTHALMIC								
KETOROLAC TROMETHAMINE								
AT	CAPLIN	0.5%	A218204	001	Mar 26, 2024	Mar	NEWA	
>D>	SUN PHARM	0.5%	A090017	001	Nov 05, 2009	Nov	DISC	
>A>	@	0.5%	A090017	001	Nov 05, 2009	Nov	DISC	
<u>L-GLUTAMINE</u>								
FOR SOLUTION;ORAL								
ENDARI								
AA	+ EMMAUS MEDCL	5GM/PACKET	N208587	001	Jul 07, 2017	Jun	CFTG	
L-GLUTAMINE								
AA	NOVITIUM PHARMA	5GM/PACKET	A215647	001	Jul 08, 2024	Jun	NFTG	
<u>LABETALOL HYDROCHLORIDE</u>								
SOLUTION;INTRAVENOUS								
LABETALOL HYDROCHLORIDE								
	+ @ HIKMA	10MG/2ML (5MG/ML)	N213330	005	Mar 18, 2022	Sep	DISC	
	+!	20MG/4ML (5MG/ML)	N213330	006	Aug 19, 2024	Aug	NEWA	
TABLET;ORAL								
LABETALOL HYDROCHLORIDE								
AB	ANDAS 5 HOLDING	100MG	A075215	001	Jul 29, 1999	Aug	CAHN	
AB		200MG	A075215	002	Jul 29, 1999	Aug	CAHN	
AB		300MG	A075215	003	Jul 29, 1999	Aug	CAHN	
	APPCO	400MG	A209603	004	Oct 18, 2024	Oct	NEWA	
AB	ENDO OPERATIONS	100MG	A200908	001	Jul 10, 2012	Apr	CAHN	
AB	!	200MG	A200908	002	Jul 10, 2012	Apr	CAHN	
AB		300MG	A200908	003	Jul 10, 2012	Apr	CAHN	
AB	HIBROW HLTHCARE	100MG	A207863	001	Feb 04, 2019	Sep	CAHN	
AB		200MG	A207863	002	Feb 04, 2019	Sep	CAHN	
AB		300MG	A207863	003	Feb 04, 2019	Sep	CAHN	
<u>LACOSAMIDE</u>								
SOLUTION;INTRAVENOUS								
LACOSAMIDE								
>A>	AP	ACELLA	200MG/20ML (10MG/ML)	A218464	001	Nov 14, 2024	Nov	NEWA
	AP	DR REDDYS	200MG/20ML (10MG/ML)	A217718	001	Mar 25, 2024	Mar	NEWA
	AP	HAINAN POLY	200MG/20ML (10MG/ML)	A217311	001	Feb 13, 2024	Feb	NEWA
	AP	HIKMA	200MG/20ML (10MG/ML)	A216806	001	Apr 05, 2024	Mar	NEWA
	AP	SOMERSET THERAPS LLC	200MG/20ML (10MG/ML)	A214960	001	Oct 09, 2024	Sep	NEWA
SOLUTION;ORAL								
LACOSAMIDE								
	@	AMNEAL PHARMS	10MG/ML	A204839	001	Mar 27, 2024	Apr	DISC
AA			10MG/ML	A204839	001	Mar 27, 2024	Mar	NEWA
AA	AUROBINDO PHARMA LTD	10MG/ML	A209224	001	Jan 24, 2024	Jan	NEWA	
AA	CHARTWELL RX	10MG/ML	A215154	001	May 15, 2024	May	NEWA	
>D>	AA	LEADING PHARMA	10MG/ML	A216461	001	Feb 06, 2023	Nov	CAHN
>A>	AA	MEDLEY PHARMS	10MG/ML	A216461	001	Feb 06, 2023	Nov	CAHN
TABLET;ORAL								
LACOSAMIDE								
	@	AMNEAL PHARMS	50MG	A204857	001	Mar 17, 2022	Oct	DISC
	@		100MG	A204857	002	Mar 17, 2022	Oct	DISC
	@		150MG	A204857	003	Mar 17, 2022	Oct	DISC
	@		200MG	A204857	004	Mar 17, 2022	Oct	DISC
AB	KANCHAN HLTHCARE	50MG	A218014	001	Apr 02, 2024	Sep	CAHN	
AB		100MG	A218014	002	Apr 02, 2024	Sep	CAHN	
AB		150MG	A218014	003	Apr 02, 2024	Sep	CAHN	
AB		200MG	A218014	004	Apr 02, 2024	Sep	CAHN	
AB	MACLEODS PHARMS LTD	50MG	A208466	001	May 24, 2024	May	NEWA	
AB		100MG	A208466	002	May 24, 2024	May	NEWA	
AB		150MG	A208466	003	May 24, 2024	May	NEWA	
AB		200MG	A208466	004	May 24, 2024	May	NEWA	
AB	MEDLEY PHARMS	50MG	A218014	001	Apr 02, 2024	Mar	NEWA	
AB		100MG	A218014	002	Apr 02, 2024	Mar	NEWA	
AB		150MG	A218014	003	Apr 02, 2024	Mar	NEWA	
AB		200MG	A218014	004	Apr 02, 2024	Mar	NEWA	
AB	UNICHEM	50MG	A213109	001	Sep 04, 2024	Aug	NEWA	
AB		100MG	A213109	002	Sep 04, 2024	Aug	NEWA	

TABLET;ORAL
LACOSAMIDE

AB		150MG	A213109	003	Sep 04, 2024	Aug	NEWA
AB		200MG	A213109	004	Sep 04, 2024	Aug	NEWA
	@ ZYDUS PHARMS	50MG	A204947	001	Dec 15, 2023	May	DISC
	@	100MG	A204947	002	Dec 15, 2023	May	DISC
	@	150MG	A204947	003	Dec 15, 2023	May	DISC
	@	200MG	A204947	004	Dec 15, 2023	May	DISC

LACTULOSE

SOLUTION;ORAL
LACTULOSE

AA	APOZEAL PHARMS	10GM/15ML	A207786	001	Jun 11, 2018	Jul	CMFD
	@ HIKMA	10GM/15ML	A074076	001	Jul 03, 1995	Mar	DISC
AA	! PHARM ASSOC	10GM/15ML	A074623	001	Jul 30, 1996	Mar	CHRS
	SOLUTION;ORAL, RECTAL						
	GENERLAC						
AA	CHARTWELL RX	10GM/15ML	A074603	001	Oct 31, 1996	Jun	CAHN
	LACTULOSE						
AA	APOZEAL PHARMS	10GM/15ML	A203762	001	Mar 27, 2015	Jul	CMFD
	@ PAI HOLDINGS PHARM	10GM/15ML	A074077	001	Jul 03, 1995	Feb	DISC

LAMIVUDINE

SOLUTION;ORAL
EPIVIR-HBV

	+ @ GLAXOSMITHKLINE	5MG/ML	N021004	001	Dec 08, 1998	Apr	DISC
	TABLET;ORAL						
	EPIVIR-HBV						
	+ @ GLAXOSMITHKLINE	100MG	N021003	001	Dec 08, 1998	Apr	DISC
	LAMIVUDINE						
AB	! APOTEX	100MG	A202941	001	Jan 02, 2014	Apr	CHRS
	@ MYLAN LABS LTD	150MG	A078545	001	Mar 05, 2019	Jan	DISC
	@	300MG	A078545	002	Mar 05, 2019	Jan	DISC
	@ NATCO	150MG	A204528	001	Mar 04, 2016	Jun	CAHN
	@	300MG	A204528	002	Mar 04, 2016	Jun	CAHN

LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL
COMBIVIR

	+ @ VIIV HLTHCARE	150MG;300MG	N020857	001	Sep 26, 1997	Jan	DISC
	LAMIVUDINE AND ZIDOVUDINE						
AB	EPIC PHARMA LLC	150MG;300MG	A206375	001	Apr 10, 2018	Sep	CAHN
AB	! HETERO LABS LTD III	150MG;300MG	A079124	001	Sep 17, 2015	Jan	CHRS
	@ NATCO	150MG;300MG	A204005	001	Aug 28, 2014	Jun	CAHN
	@ NORVIUM BIOSCIENCE	150MG;300MG	A079079	001	Aug 12, 2019	Jul	CAHN

LAMOTRIGINE

TABLET;ORAL
LAMOTRIGINE

AB	GLENMARK PHARMS LTD	25MG	A090169	001	May 04, 2012	Jul	CMS1
AB		25MG	A090169	001	May 12, 2012	Mar	CAHN
AB		100MG	A090169	002	May 04, 2012	Jul	CMS1
AB		100MG	A090169	002	May 12, 2012	Mar	CAHN
AB		150MG	A090169	003	May 04, 2012	Jul	CMS1
AB		150MG	A090169	003	May 12, 2012	Mar	CAHN
AB		200MG	A090169	004	May 04, 2012	Jul	CMS1
AB		200MG	A090169	004	May 12, 2012	Mar	CAHN
AB	IPCA LABS	25MG	A204499	001	Sep 26, 2024	Sep	NEWA
AB		100MG	A204499	002	Sep 26, 2024	Sep	NEWA
AB		150MG	A204499	003	Sep 26, 2024	Sep	NEWA
AB		200MG	A204499	004	Sep 26, 2024	Sep	NEWA
	@ NORVIUM BIOSCIENCE	25MG	A078443	001	Feb 11, 2009	Jul	CAHN
	@	100MG	A078443	002	Feb 11, 2009	Jul	CAHN
	@	150MG	A078443	003	Feb 11, 2009	Jul	CAHN
	@	200MG	A078443	004	Feb 11, 2009	Jul	CAHN

TABLET, EXTENDED RELEASE;ORAL
LAMOTRIGINE

AB	ALEMBIC	200MG	A211821	001	Oct 01, 2024	Sep	NEWA
AB		250MG	A211821	002	Oct 01, 2024	Sep	NEWA
AB		300MG	A211821	003	Oct 01, 2024	Sep	NEWA
	@ ANCHEN PHARMS	25MG	A201374	001	Dec 26, 2012	Feb	DISC
	@	50MG	A201374	002	Dec 26, 2012	Feb	DISC

TABLET, EXTENDED RELEASE;ORAL

LAMOTRIGINE

	@		100MG	A201374	003	Dec 26, 2012	Feb	DISC
	@		200MG	A201374	004	Dec 26, 2012	Feb	DISC
	@		250MG	A201374	005	Dec 26, 2012	Feb	DISC
	@		300MG	A201374	006	Dec 26, 2012	Feb	DISC
	@	ENDO OPERATIONS	25MG	A201374	001	Dec 26, 2012	May	CAHN
AB			25MG	A201791	001	Jan 18, 2013	Apr	CAHN
	@		50MG	A201374	002	Dec 26, 2012	May	CAHN
AB			50MG	A201791	002	Jan 18, 2013	Apr	CAHN
	@		100MG	A201374	003	Dec 26, 2012	May	CAHN
AB			100MG	A201791	003	Jan 18, 2013	Apr	CAHN
	@		200MG	A201374	004	Dec 26, 2012	May	CAHN
AB			200MG	A201791	004	Jan 18, 2013	Apr	CAHN
	@		250MG	A201374	005	Dec 26, 2012	May	CAHN
AB			250MG	A201791	005	Jan 18, 2013	Apr	CAHN
	@		300MG	A201374	006	Dec 26, 2012	May	CAHN
AB			300MG	A201791	006	Jan 18, 2013	Apr	CAHN
>A>	AB	SCIEGEN PHARMS INC	25MG	A202498	001	Jan 04, 2013	Nov	CAHN
>A>	AB		50MG	A202498	002	Jan 04, 2013	Nov	CAHN
>A>	AB		100MG	A202498	003	Jan 04, 2013	Nov	CAHN
>A>	AB		200MG	A202498	004	Jan 04, 2013	Nov	CAHN
>A>	AB		300MG	A202498	005	Jan 04, 2013	Nov	CAHN
>D>	AB	WOCKHARDT BIO AG	25MG	A202498	001	Jan 04, 2013	Nov	CAHN
>D>	AB		50MG	A202498	002	Jan 04, 2013	Nov	CAHN
>D>	AB		100MG	A202498	003	Jan 04, 2013	Nov	CAHN
>D>	AB		200MG	A202498	004	Jan 04, 2013	Nov	CAHN
>D>	AB		300MG	A202498	005	Jan 04, 2013	Nov	CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

LAMOTRIGINE

AB		ENDO OPERATIONS	25MG	A204158	001	Oct 27, 2015	Apr	CAHN
AB			50MG	A204158	002	Oct 27, 2015	Apr	CAHN
AB			100MG	A204158	003	Oct 27, 2015	Apr	CAHN
AB			200MG	A204158	004	Oct 27, 2015	Apr	CAHN
AB		IMPAX LABS INC	25MG	A200828	001	Jul 15, 2013	Oct	CMFD
AB			50MG	A200828	002	Jul 15, 2013	Oct	CMFD
AB			100MG	A200828	003	Jul 15, 2013	Oct	CMFD
AB			200MG	A200828	004	Jul 15, 2013	Oct	CMFD

>A> LANDIOLOL HYDROCHLORIDE

>A> POWDER; INTRAVENOUS

>A> RAPIBLYK

>A> +! AOP ORPHAN EQ 280MG BASE/VIAL N217202 001 Nov 22, 2024 Nov NEWA

LANREOTIDE ACETATE

SOLUTION; SUBCUTANEOUS

LANREOTIDE ACETATE

AB		INVAGEN PHARMS	EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)	A217193	001	May 21, 2024	May	NFTG
AB			EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)	A217193	002	May 21, 2024	May	NFTG
AB			EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)	A217193	003	May 21, 2024	May	NFTG
		SOMATULINE DEPOT						
AB	+!	IPSEN PHARMA	EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)	N022074	001	Aug 30, 2007	May	CFTG
AB	+!		EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)	N022074	002	Aug 30, 2007	May	CFTG
AB	+!		EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)	N022074	003	Aug 30, 2007	May	CFTG

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

>A>	@	ALLIED	15MG	A203964	001	Oct 17, 2018	Nov	CAHN
>A>	@		30MG	A203964	002	Oct 17, 2018	Nov	CAHN
>D>	@	BRECKENRIDGE	15MG	A203964	001	Oct 17, 2018	Nov	CAHN
>D>	@		30MG	A203964	002	Oct 17, 2018	Nov	CAHN
>A>	@	ESJAY PHARMA	15MG	A203964	001	Oct 17, 2018	Nov	CAHN
>A>	@		30MG	A203964	002	Oct 17, 2018	Nov	CAHN
AB		MACLEODS PHARMS LTD	15MG	A208671	001	Nov 04, 2024	Oct	NEWA
AB			30MG	A208671	002	Nov 04, 2024	Oct	NEWA
	@	SANDOZ	15MG	A090331	001	Apr 23, 2010	Sep	DISC
	@		30MG	A090331	002	Apr 23, 2010	Sep	DISC

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

@ SUN PHARM

15MG

A202637 001 Sep 13, 2013 May DISC

@

30MG

A091509 001 Sep 13, 2013 May DISC

LAPATINIB DITOSYLATE

TABLET;ORAL

LAPATINIB DITOSYLATE

AB TEVA PHARMS USA INC EQ 250MG BASE

A217968 001 Aug 16, 2024 Aug NEWA

LATANOPROST

EMULSION;OPHTHALMIC

XELPROS

+ @ SUN PHARM

0.005%

N206185 001 Sep 12, 2018 Sep DISC

SOLUTION/DROPS;OPHTHALMIC

LATANOPROST

>A> AT GLAND 0.005%

A218257 001 Nov 26, 2024 Nov NEWA

AT RYAN LABS 0.005%

A202077 001 Feb 11, 2013 Sep CAHN

LAZERTINIB MESYLATE

TABLET;ORAL

LAZCLUZE

+ JANSSEN BIOTECH

EQ 80MG BASE

N219008 001 Aug 19, 2024 Aug NEWA

+

EQ 240MG BASE

N219008 002 Aug 19, 2024 Aug NEWA

LEFAMULIN ACETATE

SOLUTION;INTRAVENOUS

XENLETA

#! NABRIVA

EQ 150MG BASE/15ML (EQ 10MG
BASE/ML)

N211673 001 Aug 19, 2019 Apr CMFD

LENALIDOMIDE

CAPSULE;ORAL

LENALIDOMIDE

AB NOVUGEN 2.5MG

A217281 001 Sep 11, 2024 Aug NEWA

AB 5MG

A217281 002 Sep 11, 2024 Aug NEWA

AB 10MG

A217281 003 Sep 11, 2024 Aug NEWA

AB 15MG

A217281 004 Sep 11, 2024 Aug NEWA

AB 20MG

A217281 005 Sep 11, 2024 Aug NEWA

AB 25MG

A217281 006 Sep 11, 2024 Aug NEWA

@ QILU 2.5MG

A217265 001 Feb 22, 2024 Jul DISC

AB 2.5MG

A217265 001 Feb 22, 2024 Feb NEWA

@ 5MG

A217265 002 Feb 22, 2024 Jul DISC

AB 5MG

A217265 002 Feb 22, 2024 Feb NEWA

@ 10MG

A217265 003 Feb 22, 2024 Jul DISC

AB 10MG

A217265 003 Feb 22, 2024 Feb NEWA

@ 15MG

A217265 004 Feb 22, 2024 Jul DISC

AB 15MG

A217265 004 Feb 22, 2024 Feb NEWA

@ 20MG

A217265 005 Feb 22, 2024 Jul DISC

AB 20MG

A217265 005 Feb 22, 2024 Feb NEWA

@ 25MG

A217265 006 Feb 22, 2024 Jul DISC

AB 25MG

A217265 006 Feb 22, 2024 Feb NEWA

LETERMOVIR

PELLETS;ORAL

PREVMIS

+ MSD

20MG/PACKET

N219104 001 Aug 30, 2024 Aug NEWA

+

120MG/PACKET

N219104 002 Aug 30, 2024 Aug NEWA

LETROZOLE

TABLET;ORAL

LETROZOLE

AB RYAN LABS 2.5MG

A091191 001 Jun 03, 2011 Sep CAHN

LEUCOVORIN CALCIUM

INJECTABLE;INJECTION

LEUCOVORIN CALCIUM

AP MEITHEAL EQ 50MG BASE/VIAL

A216590 001 Jul 19, 2023 Jun CAHN

AP EQ 100MG BASE/VIAL

A216590 002 Jul 19, 2023 Jun CAHN

AP EQ 200MG BASE/VIAL

A216590 003 Jul 19, 2023 Jun CAHN

AP EQ 350MG BASE/VIAL

A216590 004 Jul 19, 2023 Jun CAHN

AP EQ 500MG BASE/VIAL

A216590 005 Jul 19, 2023 Jun CAHN

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

LEUCOVORIN CALCIUM

@	ABIC	EQ 3MG BASE/ML (EQ 3MG BASE/ML)	A089352	001	Jun 01, 1988	Sep	CPOT
@		EQ 3MG BASE/ML	A089352	001	Jun 01, 1988	Sep	CDFR
!	FRESENIUS KABI USA	EQ 10MG BASE/ML	A207226	001	Jul 27, 2018	Sep	CDFR
!		EQ 10MG BASE/ML	A207241	001	Mar 14, 2018	Sep	CDFR
!		EQ 100MG BASE/10ML (EQ 10MG BASE/ML)	A207241	001	Mar 14, 2018	Sep	CPOT
!		EQ 500MG BASE/50ML (EQ 10MG BASE/ML)	A207226	001	Jul 27, 2018	Sep	CPOT
+	@ HOSPIRA	EQ 3MG BASE/ML (EQ 3MG BASE/ML)	N008107	001		Sep	CPOT
+	@	EQ 3MG BASE/ML	N008107	001		Sep	CDFR
@	NOVAST LABS	EQ 10MG BASE/ML	A210917	001	Nov 23, 2018	Sep	CDFR
@		EQ 500MG BASE/50ML (EQ 10MG BASE/ML)	A210917	001	Nov 23, 2018	Sep	CPOT
LEUCOVORIN CALCIUM PRESERVATIVE FREE							
@	HIKMA	EQ 10MG BASE/ML	A040347	001	Apr 25, 2000	Sep	CDFR
@		EQ 300MG BASE/30ML (EQ 10MG BASE/ML)	A040347	001	Apr 25, 2000	Sep	CPOT
@		EQ 500MG BASE/50ML (EQ 10MG BASE/ML)	A040347	002	Apr 25, 2000	Sep	NEWA
@	HOSPIRA	EQ 10MG BASE/ML	A040147	001	Jun 25, 1997	Sep	CDFR
@		EQ 100MG BASE/10ML (EQ 10MG BASE/ML)	A040147	001	Jun 25, 1997	Sep	CPOT
@		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A040147	002	Jun 25, 1997	Sep	NEWA
@	TEVA PARENTERAL	EQ 10MG BASE/ML	A040332	001	Jun 28, 1999	Sep	CDFR
@		EQ 500MG BASE/50ML (EQ 10MG BASE/ML)	A040332	001	Jun 28, 1999	Sep	CPOT
WELLCOVORIN							
@	GLAXOSMITHKLINE	EQ 5MG BASE/ML (EQ 5MG BASE/ML)	A087439	001	Oct 19, 1982	Sep	CPOT
@		EQ 5MG BASE/ML	A087439	001	Oct 19, 1982	Sep	CDFR
@		EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A087439	002	Oct 19, 1982	Sep	NEWA

LEUPROLIDE ACETATE

SOLUTION;SUBCUTANEOUS

LEUPROLIDE ACETATE

AP	AMNEAL	1MG/0.2ML	A215336	001	Oct 28, 2022	Jul	CDFR
AP		14MG/2.8ML (1MG/0.2ML)	A215336	001	Oct 28, 2022	Jul	CPOT
AP	EUGIA PHARMA	1MG/0.2ML	A212963	001	Jun 06, 2022	Jul	CDFR
AP		14MG/2.8ML (1MG/0.2ML)	A212963	001	Jun 06, 2022	Jul	CPOT
@	GENZYME	1MG/0.2ML	A075721	001	Nov 29, 2001	Jul	CDFR
@		14MG/2.8ML (1MG/0.2ML)	A075721	001	Nov 29, 2001	Jul	CPOT
AP	MEITHEAL	1MG/0.2ML	A075471	001	Oct 25, 2000	Jul	CDFR
AP		14MG/2.8ML (1MG/0.2ML)	A075471	001	Oct 25, 2000	Jul	CPOT
AP	RK PHARMA	1MG/0.2ML	A213829	001	Aug 13, 2021	Jul	CDFR
AP		14MG/2.8ML (1MG/0.2ML)	A213829	001	Aug 13, 2021	Jul	CPOT
AP	! SANDOZ	1MG/0.2ML	A074728	001	Aug 04, 1998	Jul	CDFR
AP	!	14MG/2.8ML (1MG/0.2ML)	A074728	001	Aug 04, 1998	Jul	CPOT
AP	SUN PHARM	1MG/0.2ML	A078885	001	Mar 09, 2009	Jul	CDFR
AP		14MG/2.8ML (1MG/0.2ML)	A078885	001	Mar 09, 2009	Jul	CPOT
AP	UBI	14MG/2.8ML (1MG/0.2ML)	A217957	001	Oct 17, 2024	Oct	NEWA
LUPRON							
+	@ ABBVIE ENDOCRINE INC	1MG/0.2ML	N019010	001	Apr 09, 1985	Jul	CDFR
+	@	14MG/2.8ML (1MG/0.2ML)	N019010	001	Apr 09, 1985	Jul	CPOT

LEVACETYLLEUCINE

FOR SUSPENSION;ORAL

AQNEURSA

+	!	INTRABIO	1GM/PACKET	N219132	001	Sep 24, 2024	Sep	NEWA
---	---	----------	------------	---------	-----	--------------	-----	------

LEVALBUTEROL HYDROCHLORIDE

SOLUTION;INHALATION

LEVALBUTEROL HYDROCHLORIDE

AN	MANKIND PHARMA	EQ 0.0103% BASE	A218770	001	Oct 21, 2024	Oct	NEWA
AN		EQ 0.021% BASE	A218770	002	Oct 21, 2024	Oct	NEWA
AN		EQ 0.042% BASE	A218770	003	Oct 21, 2024	Oct	NEWA
AN	! MYLAN SPECIALITY LP	EQ 0.25% BASE	A078309	001	Mar 20, 2009	Apr	CHRS
@	NORVIUM BIOSCIENCE	EQ 0.0103% BASE	A077800	001	Mar 15, 2013	Jul	CAHN
@		EQ 0.021% BASE	A077800	002	Mar 15, 2013	Jul	CAHN
@		EQ 0.042% BASE	A077800	003	Mar 15, 2013	Jul	CAHN
@	SUN PHARM	EQ 0.0103% BASE	A207820	001	Nov 05, 2018	May	DISC
@		EQ 0.021% BASE	A207820	002	Nov 05, 2018	May	DISC
@		EQ 0.042% BASE	A207820	003	Nov 05, 2018	May	DISC
AN	! TEVA PHARMS USA	EQ 0.0103% BASE	A090297	001	Apr 26, 2013	Apr	CHRS

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE							
AN	!	EQ 0.021% BASE	A090297	002	Apr 26, 2013	Apr	CHRS
AN	!	EQ 0.042% BASE	A090297	003	Apr 26, 2013	Apr	CHRS
XOPENEX							
+	@	HIKMA EQ 0.0103% BASE	N020837	003	Jan 30, 2002	Apr	DISC
+	@	EQ 0.021% BASE	N020837	001	Mar 25, 1999	Apr	DISC
+	@	EQ 0.042% BASE	N020837	002	Mar 25, 1999	Apr	DISC
+	@	EQ 0.25% BASE	N020837	004	Jul 18, 2003	Apr	DISC

LEVAMLODIPINE MALEATE

TABLET; ORAL

CONJUPRI							
+	@	CSPC OUYI EQ 2.5MG BASE	N212895	002	Dec 19, 2019	Sep	DISC
+		EQ 2.5MG BASE	N212895	002	Dec 19, 2019	Mar	CMFD
+	@	EQ 5MG BASE	N212895	003	Dec 19, 2019	Sep	DISC
+	!	EQ 5MG BASE	N212895	003	Dec 19, 2019	Mar	CMFD

LEVETIRACETAM

INJECTABLE; INTRAVENOUS

LEVETIRACETAM							
AP		ADRASTEIA PHARMA 500MG/5ML (100MG/ML)	A091485	001	Aug 05, 2011	Feb	CAHN
	@	SUN PHARM INDS LTD 500MG/5ML (100MG/ML)	A090754	001	Jun 16, 2010	May	DISC
AP		XGEN PHARMS 500MG/5ML (100MG/ML)	A091485	001	Aug 05, 2011	Jul	CAHN
LEVETIRACETAM IN SODIUM CHLORIDE							
AP		B BRAUN MEDICAL INC 500MG/100ML (5MG/ML)	A209705	001	Feb 27, 2024	Feb	NEWA
AP		1GM/100ML (10MG/ML)	A209705	002	Feb 27, 2024	Feb	NEWA
AP		1.5GM/100ML (15MG/ML)	A209705	003	Feb 27, 2024	Feb	NEWA
AP		BAXTER HLTHCARE CORP 500MG/100ML (5MG/ML)	A217059	001	Oct 02, 2023	Feb	CTNA
AP		1GM/100ML (10MG/ML)	A217059	002	Oct 02, 2023	Feb	CTNA
AP		1.5GM/100ML (15MG/ML)	A217059	003	Oct 02, 2023	Feb	CTNA
	@	FRESENIUS KABI USA 500MG/100ML (5MG/ML)	A208619	001	Jan 31, 2023	Mar	DISC
	@	1GM/100ML (10MG/ML)	A208619	002	Jan 31, 2023	Mar	DISC
	@	1.5GM/100ML (15MG/ML)	A208619	003	Jan 31, 2023	Mar	DISC
AP		HIKMA 500MG/100ML (5MG/ML)	A211356	001	Feb 12, 2024	Feb	NEWA
AP		1GM/100ML (10MG/ML)	A211356	002	Feb 12, 2024	Feb	NEWA
AP		1.5GM/100ML (15MG/ML)	A211356	003	Feb 12, 2024	Feb	NEWA

SOLUTION; ORAL

LEVETIRACETAM							
	@	HIKMA 100MG/ML	A090601	001	Feb 28, 2012	Mar	DISC
	@	STRIDES PHARMA 100MG/ML	A214673	001	Nov 20, 2023	May	DISC

TABLET; ORAL

LEVETIRACETAM							
	@	ACCORD HLTHCARE 250MG	A090843	001	Feb 14, 2011	May	DISC
	@	500MG	A090843	002	Feb 14, 2011	May	DISC
	@	750MG	A090843	003	Feb 14, 2011	May	DISC
	@	1GM	A090843	004	Feb 14, 2011	May	DISC
	@	GRANULES 250MG	A217878	001	Jun 13, 2023	Mar	DISC
	@	500MG	A217878	002	Jun 13, 2023	Mar	DISC
	@	750MG	A217878	003	Jun 13, 2023	Mar	DISC
	@	1GM	A217878	004	Jun 13, 2023	Mar	DISC
AB		INGENUS PHARMS LLC 250MG	A079042	001	Jan 15, 2009	Sep	CAHN
AB		500MG	A079042	002	Jan 15, 2009	Sep	CAHN
AB		750MG	A079042	003	Jan 15, 2009	Sep	CAHN
AB		1GM	A079042	004	Jan 15, 2009	Sep	CAHN
	@	INVAGEN PHARMS 250MG	A078234	001	Jan 15, 2009	Mar	DISC
	@	500MG	A078234	002	Jan 15, 2009	Mar	DISC
	@	750MG	A078234	003	Jan 15, 2009	Mar	DISC

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM							
	@	ADAPTIS 500MG	A202167	001	Sep 04, 2015	Sep	CAHN
	@	750MG	A202167	002	Sep 04, 2015	Sep	CAHN
	@	ANCHEN PHARMS 500MG	A091360	001	Oct 04, 2011	Feb	DISC
	@	750MG	A091360	002	Oct 04, 2011	Feb	DISC
	@	ENDO OPERATIONS 500MG	A091360	001	Oct 04, 2011	May	CAHN
	@	750MG	A091360	002	Oct 04, 2011	May	CAHN
	@	PHARMADAX INC 500MG	A201464	001	May 25, 2012	Sep	DISC
	@	750MG	A201464	002	May 25, 2012	Sep	DISC
	@	PRINSTON INC 500MG	A202533	001	Jul 20, 2012	Aug	DISC
	@	750MG	A202533	002	Jul 20, 2012	Aug	DISC

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
LEVOBUNOLOL HYDROCHLORIDE
@ CHARTWELL RX 0.5%

A074850 001 Oct 28, 1996 Jul CAHN

LEVOBUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
CHIROCAINE

+ @ PURDUE PHARMA LP EQ 2.5MG BASE/ML
+ @ EQ 5MG BASE/ML
+ @ EQ 7.5MG BASE/ML

N020997 001 Aug 05, 1999 Jun CRLD
N020997 002 Aug 05, 1999 Jun CRLD
N020997 003 Aug 05, 1999 Jun CRLD

LEVOCARNITINE

SOLUTION;ORAL
LEVOCARNITINE

AA @ HIKMA 1GM/10ML
RISING 1GM/10ML

A077399 001 Oct 25, 2007 Mar DISC
A076851 001 Aug 10, 2004 Sep CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL
LEVOCETIRIZINE DIHYDROCHLORIDE

AB IPCA LABS LTD 5MG

A204626 001 May 06, 2024 Apr NEWA

LEVOFLOXACIN

INJECTABLE; INJECTION
LEVOFLOXACIN

@ NORVIUM BIOSCIENCE EQ 500MG/20ML (EQ 25MG/ML)
@ EQ 750MG/30ML (EQ 25MG/ML)
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER
AP @ KNACK EQ 250MG/50ML (EQ 5MG/ML)
EQ 250MG/50ML (EQ 5MG/ML)
@ EQ 500MG/100ML (EQ 5MG/ML)
AP @ EQ 500MG/100ML (EQ 5MG/ML)
@ EQ 750MG/150ML (EQ 5MG/ML)
AP @ EQ 750MG/150ML (EQ 5MG/ML)

A200560 001 Jun 20, 2011 Jun CAHN
A200560 002 Jun 20, 2011 Jun CAHN
A216164 001 Jan 29, 2024 Jul DISC
A216164 001 Jan 29, 2024 Jan NEWA
A216164 002 Jan 29, 2024 Jul DISC
A216164 002 Jan 29, 2024 Jan NEWA
A216164 003 Jan 29, 2024 Jul DISC
A216164 003 Jan 29, 2024 Jan NEWA

TABLET;ORAL

LEVOFLOXACIN

>D> AB @ ANDA REPOSITORY 250MG
>A> @ 500MG
@ 750MG
@ CELLTRION 250MG
@ 500MG
@ 750MG
>D> AB SANDOZ 250MG
>A> @ 250MG
>D> AB 500MG
>A> @ 500MG
>D> AB 750MG
>A> @ 750MG

A090367 001 Jun 20, 2011 Sep CAHN
A090367 002 Jun 20, 2011 Sep CAHN
A090367 003 Jun 20, 2011 Sep CAHN
A090367 001 Jun 20, 2011 Apr DISC
A090367 002 Jun 20, 2011 Apr DISC
A090367 003 Jun 20, 2011 Apr DISC
A077438 001 Jun 20, 2011 Nov DISC
A077438 001 Jun 20, 2011 Nov DISC
A077438 002 Jun 20, 2011 Nov DISC
A077438 002 Jun 20, 2011 Nov DISC
A077438 003 Jun 20, 2011 Nov DISC
A077438 003 Jun 20, 2011 Nov DISC

LEVOLEUCOVORIN CALCIUM

POWDER; INTRAVENOUS
FUSILEV

+ @ ACROTECH BIOPHARMA EQ 50MG BASE/VIAL
+! EQ 50MG BASE/VIAL
LEVOLEUCOVORIN CALCIUM
@ MEITHEAL EQ 50MG BASE/VIAL

N020140 001 Mar 07, 2008 May DISC
N020140 001 Mar 07, 2008 Mar CTEC
A211003 001 Aug 22, 2019 Mar DISC

SOLUTION; INTRAVENOUS

LEVOLEUCOVORIN CALCIUM

@ NORVIUM BIOSCIENCE EQ 175MG BASE/17.5ML (EQ 10MG
BASE/ML)
@ EQ 250MG BASE/25ML (EQ 10MG
BASE/ML)
@ PRAXGEN EQ 175MG BASE/17.5ML (EQ 10MG
BASE/ML)

A203576 001 Oct 20, 2015 Jun CAHN
A203576 002 Oct 20, 2015 Jun CAHN
A213797 001 Nov 02, 2021 Jul CAHN

LEVONORGESTREL

SYSTEM; INTRAUTERINE
KYLEENA

+! BAYER HLTHCARE 19.5MG N208224 001 Sep 16, 2016 Jun CDFR
LILETTA

+! MEDICINES360 52MG N206229 001 Feb 26, 2015 Jun CDFR
MIRENA

+! BAYER HLTHCARE 52MG N021225 001 Dec 06, 2000 Jun CDFR
SKYLA

+! BAYER HLTHCARE 13.5MG N203159 001 Jan 09, 2013 Jun CDFR
TABLET; ORAL

LEVONORGESTREL
@ XIROMED 0.75MG A202740 001 Sep 02, 2016 May CAHN

LEVOTHYROXINE SODIUM

POWDER; INTRAVENOUS
LEVOTHYROXINE SODIUM

>A> AP @ ENDO OPERATIONS 200MCG/VIAL A205366 001 Dec 07, 2015 May CAHN
XIROMED 100MCG/VIAL A217495 001 Nov 29, 2024 Nov NEWA

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET; ORAL

LEVOTHYROXINE SODIUM

AB2	AUROBINDO PHARMA	0.137MG	A216414	001	Jul 16, 2024	Jul NEWA
AB2		0.15MG	A216414	002	Jul 16, 2024	Jul NEWA
AB2		0.175MG	A216414	003	Jul 16, 2024	Jul NEWA
AB2		0.2MG	A216414	004	Jul 16, 2024	Jul NEWA
AB2		0.3MG	A216414	005	Jul 16, 2024	Jul NEWA
AB1,	MACLEODS PHARMS LTD	0.025MG	A211417	001	Dec 21, 2022	Sep CTEC
AB2						
AB1,		0.05MG	A211417	002	Dec 21, 2022	Sep CTEC
AB2						
AB1,		0.075MG	A211417	003	Dec 21, 2022	Sep CTEC
AB2						
AB1,		0.088MG	A211417	004	Dec 21, 2022	Sep CTEC
AB2						
AB1,		0.1MG	A211417	005	Dec 21, 2022	Sep CTEC
AB2						
AB1,		0.112MG	A211417	006	Dec 21, 2022	Sep CTEC
AB2						
AB1,		0.125MG	A211417	007	Dec 21, 2022	Sep CTEC
AB2						
AB1,		0.137MG	A211417	008	Dec 21, 2022	Sep CTEC
AB2						
AB1,		0.15MG	A211417	009	Dec 21, 2022	Sep CTEC
AB2						
AB1,		0.175MG	A211417	010	Dec 21, 2022	Sep CTEC
AB2						
AB1,		0.2MG	A211417	011	Dec 21, 2022	Sep CTEC
AB2						
AB1,		0.3MG	A211417	012	Dec 21, 2022	Sep CTEC
AB2						
AB1,	WATSON LABS TEVA	0.025MG	A207588	001	May 10, 2022	Feb CTEC
AB2,						
AB3,						
AB4						
AB1,		0.05MG	A207588	002	May 10, 2022	Feb CTEC
AB2,						
AB3,						
AB4						
AB1,		0.075MG	A207588	003	May 10, 2022	Feb CTEC
AB2,						
AB3,						
AB4						
AB1,		0.088MG	A207588	004	May 10, 2022	Feb CTEC
AB2,						
AB3,						
AB4						
AB1,		0.1MG	A207588	005	May 10, 2022	Feb CTEC
AB2,						
AB3,						
AB4						
AB1,		0.112MG	A207588	006	May 10, 2022	Feb CTEC
AB2,						
AB3,						
AB4						

TABLET;ORAL

LEVOTHYROXINE SODIUM

AB1, AB2, AB3, AB4	0.125MG	A207588	007	May 10, 2022	Feb CTEC
AB1, AB2, AB3, AB4	0.137MG	A207588	008	May 10, 2022	Feb CTEC
AB1, AB2, AB3, AB4	0.15MG	A207588	009	May 10, 2022	Feb CTEC
AB1, AB2, AB3, AB4	0.175MG	A207588	010	May 10, 2022	Feb CTEC
AB1, AB2, AB3, AB4	0.2MG	A207588	011	May 10, 2022	Feb CTEC
AB1, AB2, AB3, AB4	0.3MG	A207588	012	May 10, 2022	Feb CTEC

LIDOCAINE

OINTMENT;TOPICAL

LIDOCAINE

AT	AUROBINDO PHARMA LTD	5%	A217117	001	Jun 18, 2024	Jun NEWA
	@ COSETTE	5%	A211019	001	Dec 12, 2018	Apr DISC
	@ GENEYORK PHARMS	5%	A212486	001	Oct 17, 2019	Jul CAHN

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE

AP	FRESENIUS KABI USA	1%	A088586	002		Apr CMS1
AP		2%	A088586	003		Apr CMS1
AP	+ INTL MEDICATION	1%	A083173	001		Aug CRLD
AP	LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE					
AP	HIKMA	1%	A084625	001		Jun CAHN
AP		2%	A084625	002		Jun CAHN

SOLUTION;ORAL

LIDOCAINE HYDROCHLORIDE VISCOUS

AT	PAI HOLDINGS PHARM	2%	A218138	001	Feb 20, 2024	Feb NEWA
----	--------------------	----	---------	-----	--------------	----------

SOLUTION;TOPICAL

LIDOCAINE HYDROCHLORIDE

AT	THE J MOLNER	4%	A218411	001	Apr 29, 2024	Apr NEWA
----	--------------	----	---------	-----	--------------	----------

LIDOCAINE; PRILOCAINE

CREAM;TOPICAL

LIDOCAINE AND PRILOCAINE

AB	@ HIKMA	2.5%;2.5%	A076290	001	Sep 25, 2003	Mar DISC
AB	PAI HOLDINGS PHARM	2.5%;2.5%	A205887	001	Jun 29, 2018	Jun CMFD
	@ RHODES PHARMS	2.5%;2.5%	A213253	001	Sep 21, 2020	Sep DISC
AB		2.5%;2.5%	A213253	001	Sep 21, 2020	Jun CMFD

LIDOCAINE; TETRACAINE

CREAM;TOPICAL

PLIAGLIS

+ @	CRESCITA THERAP	7%;7%	N021717	001	Jun 29, 2006	Jul CAHN
-----	-----------------	-------	---------	-----	--------------	----------

LIFITEGRAST

SOLUTION/DROPS;OPHTHALMIC

LIFITEGRAST

	@ EUGIA PHARMA	5%	A215063	001	Nov 07, 2023	May DISC	
>D>	AB	INGENUS PHARMS LLC	5%	A215058	001	Oct 03, 2024	Nov DISC
>A>		@	5%	A215058	001	Oct 03, 2024	Nov DISC
	AB		5%	A215058	001	Oct 03, 2024	Sep NFTG
	@ MICRO LABS	5%	A215081	001	Aug 04, 2023	May DISC	
	XIIDRA						
>D>	AB	+! BAUSCH AND LOMB INC	5%	N208073	001	Jul 11, 2016	Nov CTEC
>A>		+!	5%	N208073	001	Jul 11, 2016	Nov CTEC
	AB	+!	5%	N208073	001	Jul 11, 2016	Sep CFTG

SOLUTION/DROPS;OPHTHALMIC
 XIIDRA

	+	!	5%	N208073	001	Jul 11, 2016	May CTEC
AB	+	!	5%	N208073	001	Jul 11, 2016	Jan CAHN

LINAGLIPTIN

TABLET;ORAL

LINAGLIPTIN

AB			5MG	A208423	001	Sep 03, 2024	Aug NEWA
----	--	--	-----	---------	-----	--------------	----------

LINCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION

LINCOMYCIN HYDROCHLORIDE

AP			EQ 300MG BASE/ML	A212770	001	Mar 12, 2021	Jul CAHN
AP			EQ 300MG BASE/ML	A212770	001	Mar 12, 2021	May CMFD
	@		EQ 300MG BASE/ML	A063180	001	Apr 16, 1991	Sep CAHN

LINEZOLID

TABLET;ORAL

LINEZOLID

AB			600MG	A210378	001	Oct 10, 2024	Oct NEWA
----	--	--	-------	---------	-----	--------------	----------

LIOTHYRONINE SODIUM

INJECTABLE;INJECTION

TRIOSTAT

+ @ ENDO OPERATIONS

EQ 0.01MG BASE/ML

N020105 001 Dec 31, 1991 May CAHN

TABLET;ORAL

LIOTHYRONINE SODIUM

AB			EQ 0.005MG BASE	A218070	001	Feb 06, 2024	Mar CAHN
AB			EQ 0.005MG BASE	A218070	001	Feb 06, 2024	Feb CAHN
AB			EQ 0.025MG BASE	A218070	002	Feb 06, 2024	Mar CAHN
AB			EQ 0.025MG BASE	A218070	002	Feb 06, 2024	Feb CAHN
AB			EQ 0.05MG BASE	A218070	003	Feb 06, 2024	Mar CAHN
AB			EQ 0.05MG BASE	A218070	003	Feb 06, 2024	Feb CAHN
AB			EQ 0.005MG BASE	A218070	001	Feb 06, 2024	Jan NEWA
AB			EQ 0.025MG BASE	A218070	002	Feb 06, 2024	Jan NEWA
AB			EQ 0.05MG BASE	A218070	003	Feb 06, 2024	Jan NEWA
	@		EQ 0.005MG BASE	A090326	001	Jul 14, 2009	Jul CAHN
	@		EQ 0.025MG BASE	A090326	002	Jul 14, 2009	Jul CAHN
	@		EQ 0.05MG BASE	A090326	003	Jul 14, 2009	Jul CAHN
AB			EQ 0.005MG BASE	A214803	001	Jan 22, 2021	Aug CAHN
AB			EQ 0.025MG BASE	A214803	002	Jan 22, 2021	Aug CAHN
AB			EQ 0.05MG BASE	A214803	003	Jan 22, 2021	Aug CAHN

LIRAGLUTIDE

SOLUTION;SUBCUTANEOUS

SAXENDA

+

!

NOVO

18MG/3ML (6MG/ML)

N206321 001 Dec 23, 2014 Mar CAIN

VICTOZA

+

!

NOVO NORDISK INC

18MG/3ML (6MG/ML)

N022341 001 Jan 25, 2010 Mar CAIN

LISDEXAMFETAMINE DIMESYLATE

CAPSULE;ORAL

LISDEXAMFETAMINE DIMESYLATE

AB			10MG	A202802	001	Aug 25, 2023	Oct CMFD
	@		10MG	A202802	001	Aug 25, 2023	Feb DISC
AB			20MG	A202802	002	Aug 25, 2023	Oct CMFD
	@		20MG	A202802	002	Aug 25, 2023	Feb DISC
AB			30MG	A202802	003	Aug 25, 2023	Oct CMFD
	@		30MG	A202802	003	Aug 25, 2023	Feb DISC
AB			40MG	A202802	004	Aug 25, 2023	Oct CMFD
	@		40MG	A202802	004	Aug 25, 2023	Feb DISC
AB			50MG	A202802	005	Aug 25, 2023	Oct CMFD
	@		50MG	A202802	005	Aug 25, 2023	Feb DISC
AB			60MG	A202802	006	Aug 25, 2023	Oct CMFD
	@		60MG	A202802	006	Aug 25, 2023	Feb DISC
AB			70MG	A202802	007	Aug 25, 2023	Oct CMFD
	@		70MG	A202802	007	Aug 25, 2023	Feb DISC
>A>	AB		10MG	A218604	001	Nov 15, 2024	Nov NEWA
>A>	AB		20MG	A218604	002	Nov 15, 2024	Nov NEWA
>A>	AB		30MG	A218604	003	Nov 15, 2024	Nov NEWA
>A>	AB		40MG	A218604	004	Nov 15, 2024	Nov NEWA

CAPSULE;ORAL

LISDEXAMFETAMINE DIMESYLATE

>A>	AB		50MG	A218604	005	Nov 15, 2024	Nov	NEWA
>A>	AB		60MG	A218604	006	Nov 15, 2024	Nov	NEWA
>A>	AB		70MG	A218604	007	Nov 15, 2024	Nov	NEWA
	AB	HIKMA	10MG	A202827	007	Jan 17, 2024	Jan	NEWA
		@ SANDOZ	20MG	A202836	001	Jul 26, 2024	Aug	DISC
	AB		20MG	A202836	001	Jul 26, 2024	Jul	NEWA
		@	30MG	A202836	002	Jul 26, 2024	Aug	DISC
	AB		30MG	A202836	002	Jul 26, 2024	Jul	NEWA
		@	40MG	A202836	003	Jul 26, 2024	Aug	DISC
	AB		40MG	A202836	003	Jul 26, 2024	Jul	NEWA
		@	50MG	A202836	004	Jul 26, 2024	Aug	DISC
	AB		50MG	A202836	004	Jul 26, 2024	Jul	NEWA
		@	60MG	A202836	005	Jul 26, 2024	Aug	DISC
	AB		60MG	A202836	005	Jul 26, 2024	Jul	NEWA
		@	70MG	A202836	006	Jul 26, 2024	Aug	DISC
	AB		70MG	A202836	006	Jul 26, 2024	Jul	NEWA

TABLET, CHEWABLE;ORAL

LISDEXAMFETAMINE DIMESYLATE

	AB	MSN	10MG	A218306	001	Feb 02, 2024	Jan	NEWA
	AB		20MG	A218306	002	Feb 02, 2024	Jan	NEWA
	AB		30MG	A218306	003	Feb 02, 2024	Jan	NEWA
	AB		40MG	A218306	004	Feb 02, 2024	Jan	NEWA
	AB		50MG	A218306	005	Feb 02, 2024	Jan	NEWA
	AB		60MG	A218306	006	Feb 02, 2024	Jan	NEWA
	AB	TEVA PHARMS	10MG	A215415	001	Aug 25, 2023	Aug	CMFD
		@	10MG	A215415	001	Aug 25, 2023	Feb	DISC
	AB		20MG	A215415	002	Aug 25, 2023	Aug	CMFD
		@	20MG	A215415	002	Aug 25, 2023	Feb	DISC
	AB		30MG	A215415	003	Aug 25, 2023	Aug	CMFD
		@	30MG	A215415	003	Aug 25, 2023	Feb	DISC
	AB		40MG	A215415	004	Aug 25, 2023	Aug	CMFD
		@	40MG	A215415	004	Aug 25, 2023	Feb	DISC
	AB		50MG	A215415	005	Aug 25, 2023	Aug	CMFD
		@	50MG	A215415	005	Aug 25, 2023	Feb	DISC
	AB		60MG	A215415	006	Aug 25, 2023	Aug	CMFD
		@	60MG	A215415	006	Aug 25, 2023	Feb	DISC

LISINAPRIL

TABLET;ORAL

LISINAPRIL

		@ ACCORD HLTHCARE	2.5MG	A202554	001	Jul 30, 2013	May	DISC
		@	5MG	A202554	002	Jul 30, 2013	May	DISC
		@	10MG	A202554	003	Jul 30, 2013	May	DISC
		@	20MG	A202554	004	Jul 30, 2013	May	DISC
		@	30MG	A202554	005	Jul 30, 2013	May	DISC
		@	40MG	A202554	006	Jul 30, 2013	May	DISC

LITHIUM CITRATE

SYRUP;ORAL

LITHIUM CITRATE

		@ PAI HOLDINGS PHARM	EQ 300MG CARBONATE/5ML	A070755	001	May 21, 1986	Feb	DISC
AA	!	RUBICON	EQ 300MG CARBONATE/5ML	A218036	001	Aug 14, 2023	Mar	NEWA
	!		EQ 300MG CARBONATE/5ML	A218036	001	Aug 14, 2023	Mar	CTEC
AA	!		EQ 300MG CARBONATE/5ML	A218036	001	Aug 14, 2023	Feb	CHRS

LOFEXIDINE HYDROCHLORIDE

TABLET;ORAL

LOFEXIDINE HYDROCHLORIDE

	AB	INDOCO	EQ 0.18MG BASE	A218613	001	Aug 20, 2024	Aug	NFTG
		LUCEMYRA						
	AB	+! USWM	EQ 0.18MG BASE	N209229	001	May 16, 2018	Aug	CFTG

LOMITAPIDE MESYLATE

CAPSULE;ORAL

JUXTAPID

	+	CHIESI	EQ 5MG BASE	N203858	001	Dec 21, 2012	Jan	CAHN
	+		EQ 10MG BASE	N203858	002	Dec 21, 2012	Jan	CAHN
	+		EQ 20MG BASE	N203858	003	Dec 21, 2012	Jan	CAHN
	+		EQ 30MG BASE	N203858	004	Apr 23, 2015	Jan	CAHN
	+	@	EQ 40MG BASE	N203858	005	Apr 23, 2015	Jan	CAHN
	+	@	EQ 60MG BASE	N203858	006	Apr 23, 2015	Jan	CAHN

LOMUSTINE

CAPSULE;ORAL
GLEOSTINE

	+ @ LATINA PHARMA	5MG	N017588	004	Dec 19, 2014	Feb	CAHN
	+	10MG	N017588	001		Feb	CAHN
	+!	40MG	N017588	002		May	CHRS
	+	40MG	N017588	002		Feb	CAHN
	+	100MG	N017588	003		May	CHRS
	+!	100MG	N017588	003		Feb	CAHN

LONAFARNIB

CAPSULE;ORAL
ZOKINVY

	+ SENTYNL THERAPS INC	50MG	N213969	001	Nov 20, 2020	May	CAHN
	+!	75MG	N213969	002	Nov 20, 2020	May	CAHN

LOPINAVIR; RITONAVIR

TABLET;ORAL
LOPINAVIR AND RITONAVIR

AB	MACLEODS PHARMS LTD	100MG;25MG	A204739	001	Jul 25, 2024	Jul	NEWA
AB		200MG;50MG	A204739	002	Jul 25, 2024	Jul	NEWA
AB	MYLAN LABS LTD	100MG;25MG	A079074	001	Feb 07, 2024	Jan	NEWA
AB		200MG;50MG	A079074	002	Feb 07, 2024	Jan	NEWA

LORAZEPAM

CONCENTRATE;ORAL
LORAZEPAM

	@ HIKMA	2MG/ML	A200169	001	Jan 30, 2012	Mar	DISC
--	---------	--------	---------	-----	--------------	-----	------

INJECTABLE;INJECTION
LORAZEPAM

	@ ENDO OPERATIONS	2MG/ML	A074793	001	Mar 16, 2000	Apr	CAHN
	@	4MG/ML	A074793	002	Mar 16, 2000	Apr	CAHN
>A> AP	FRESENIUS KABI USA	2MG/ML	A217598	001	Nov 18, 2024	Nov	NEWA

TABLET;ORAL
LORAZEPAM

>D>	@ ANI PHARMS	0.5MG	A077396	001	Dec 13, 2006	Nov	CMFD
>A> AB		0.5MG	A077396	001	Dec 13, 2006	Nov	CMFD
>D>	@	1MG	A077396	002	Dec 13, 2006	Nov	CMFD
>A> AB		1MG	A077396	002	Dec 13, 2006	Nov	CMFD
>D>	@	2MG	A077396	003	Dec 13, 2006	Nov	CMFD
>A> AB		2MG	A077396	003	Dec 13, 2006	Nov	CMFD

LOSARTAN POTASSIUM

TABLET;ORAL
LOSARTAN POTASSIUM

	@ AIPING PHARM INC	25MG	A090544	001	Oct 06, 2010	Feb	CAHN
	@	50MG	A090544	002	Oct 06, 2010	Feb	CAHN
	@	100MG	A090544	003	Oct 06, 2010	Feb	CAHN
AB	APOTEX	25MG	A218551	001	Jun 04, 2024	May	NEWA
AB		50MG	A218551	002	Jun 04, 2024	May	NEWA
AB		100MG	A218551	003	Jun 04, 2024	May	NEWA
AB	CHARTWELL RX	25MG	A077424	001	Oct 06, 2010	Jan	CAHN
AB		50MG	A077424	002	Oct 06, 2010	Jan	CAHN
AB		100MG	A077424	003	Oct 06, 2010	Jan	CAHN

LOTEPREDNOL ETABONATE

GEL;OPHTHALMIC
LOTEPREDNOL ETABONATE

	@ HIKMA	0.5%	A213956	001	Nov 29, 2023	Oct	DISC
AB		0.5%	A213956	001	Nov 29, 2023	Apr	CAHN

SUSPENSION/DROPS;OPHTHALMIC
LOTEPREDNOL ETABONATE

AB	LUPIN LTD	0.5%	A215719	001	Apr 24, 2024	Apr	NEWA
AB	PADAGIS US	0.2%	A215203	001	Jul 10, 2024	Jun	NEWA

LUBIPROSTONE

CAPSULE;ORAL
LUBIPROSTONE

	@ ENDO OPERATIONS	8MCG	A201442	001	Jun 27, 2022	Apr	CAHN
	@	24MCG	A201442	002	Jun 27, 2022	Apr	CAHN

LURASIDONE HYDROCHLORIDE

TABLET;ORAL

LURASIDONE HYDROCHLORIDE

>A>	AB	ADAPTIS	20MG	A212091	001	Dec 28, 2020	Nov	CAHN
>A>	AB		40MG	A212091	002	Dec 28, 2020	Nov	CAHN
>A>	AB		60MG	A212091	003	Dec 28, 2020	Nov	CAHN
>A>	AB		80MG	A212091	004	Dec 28, 2020	Nov	CAHN
>A>	AB		120MG	A212091	005	Dec 28, 2020	Nov	CAHN
	AB	ANNORA PHARMA	20MG	A218174	001	Aug 21, 2024	Aug	NEWA
	AB		40MG	A218174	002	Aug 21, 2024	Aug	NEWA
	AB		60MG	A218174	003	Aug 21, 2024	Aug	NEWA
	AB		80MG	A218174	004	Aug 21, 2024	Aug	NEWA
	AB		120MG	A218174	005	Aug 21, 2024	Aug	NEWA
	AB	HERITAGE PHARMA AVET	20MG	A208058	001	Sep 04, 2019	Oct	CAHN
	AB		40MG	A208058	002	Sep 04, 2019	Oct	CAHN
	AB		60MG	A208058	003	Sep 04, 2019	Oct	CAHN
	AB		80MG	A208058	004	Sep 04, 2019	Oct	CAHN
	AB		120MG	A208058	005	Feb 28, 2023	Oct	CAHN
>A>	AB	JUBILANT GENERICS	20MG	A210388	001	Dec 06, 2024	Nov	NEWA
>A>	AB		40MG	A210388	002	Dec 06, 2024	Nov	NEWA
>A>	AB		60MG	A210388	003	Dec 06, 2024	Nov	NEWA
>A>	AB		80MG	A210388	004	Dec 06, 2024	Nov	NEWA
>A>	AB		120MG	A210388	005	Dec 06, 2024	Nov	NEWA
>D>	AB	SLATE RUN PHARMA	20MG	A212091	001	Dec 28, 2020	Nov	CAHN
	AB		20MG	A212091	001	Dec 28, 2020	Feb	CAHN
>D>	AB		40MG	A212091	002	Dec 28, 2020	Nov	CAHN
	AB		40MG	A212091	002	Dec 28, 2020	Feb	CAHN
>D>	AB		60MG	A212091	003	Dec 28, 2020	Nov	CAHN
	AB		60MG	A212091	003	Dec 28, 2020	Feb	CAHN
>D>	AB		80MG	A212091	004	Dec 28, 2020	Nov	CAHN
	AB		80MG	A212091	004	Dec 28, 2020	Feb	CAHN
>D>	AB		120MG	A212091	005	Dec 28, 2020	Nov	CAHN
	AB		120MG	A212091	005	Dec 28, 2020	Feb	CAHN

MACITENTAN

TABLET;ORAL

MACITENTAN

		@ APOTEX	10MG	A211195	001	Jan 09, 2024	Apr	DISC
		@ TORRENT	10MG	A211107	001	Aug 05, 2024	Aug	DISC
AB			10MG	A211107	001	Aug 05, 2024	Jul	NFTG
		@ ZYDUS LIFESCIENCES	10MG	A211224	001	Apr 06, 2021	May	CAHN
		OPSUMIT						
	+	ACTELION	10MG	N204410	001	Oct 18, 2013	Aug	CTEC
AB	+		10MG	N204410	001	Oct 18, 2013	Jul	CFTG
	+		10MG	N204410	001	Oct 18, 2013	Apr	CTEC

MACITENTAN; TADALAFIL

TABLET;ORAL

OPSYNVI

	+	ACTELION	10MG;20MG	N218490	001	Mar 22, 2024	Mar	NEWA
	+		10MG;40MG	N218490	002	Mar 22, 2024	Mar	NEWA

MAFENIDE ACETATE

FOR SOLUTION;TOPICAL

MAFENIDE ACETATE

	@	ENDO OPERATIONS	5%	A201511	001	Feb 12, 2013	May	CAHN
--	---	-----------------	----	---------	-----	--------------	-----	------

MAGNESIUM SULFATE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

	@	EXELA PHARMA	5GM/10ML (500MG/ML)	A206039	001	Dec 18, 2014	Aug	DISC
--	---	--------------	---------------------	---------	-----	--------------	-----	------

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION;ORAL

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

AA		TARO	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A206431	001	Mar 19, 2024	Mar	NEWA
		SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE						
AA		ANNORA PHARMA	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A212903	001	Oct 18, 2024	Oct	NEWA
AA		BIONPHARMA	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A204135	001	Jun 24, 2024	Jun	NEWA
AA		LANNETT CO INC	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A209941	001	Jul 15, 2024	Jul	NEWA
AA		PAI HOLDINGS	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A209941	001	Jul 15, 2024	Sep	CAHN
AA		TARO	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A206431	001	Mar 19, 2024	Jun	CMS1

MANNITOL

	INJECTABLE; INJECTION						
	OSMITROL 20% IN WATER IN PLASTIC CONTAINER						
AP	+!	BAXTER HLTHCARE	20GM/100ML	N013684	007		Jul CHRS
AP	+		20GM/100ML	N013684	007		Jul CRLD
	POWDER; INHALATION						
	ARIDOL KIT						
	+!	PHARMAXIS EUROPE	N/A, 5MG, 10MG, 20MG, 40MG	N022368	001	Oct 05, 2010	May CAHN
	BRONCHITOL						
	+!	PHARMAXIS EUROPE	40MG	N202049	001	Oct 30, 2020	Aug CAHN

MARALIXIBAT CHLORIDE

SOLUTION; ORAL
LIVMARLI

+! MIRUM EQ 19MG BASE/ML N214662 002 Jul 24, 2024 Jul NEWA

MARAVIROC

TABLET; ORAL
SELZENTRY

+ @ VIIV HLTHCARE 25MG N022128 003 Nov 04, 2016 Jan DISC
+ @ 75MG N022128 004 Nov 04, 2016 Jan DISC

MAVORIXAFOR

CAPSULE; ORAL
XOLREMDI

+! X4 PHARMS 100MG N218709 001 Apr 26, 2024 Apr NEWA

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

	MECLIZINE HYDROCHLORIDE						
AA		AMNEAL PHARMS	50MG	A201451	003	Feb 23, 2011	Mar CHRS
AA	!		50MG	A201451	003	Feb 23, 2011	Feb CMFD
	@	CHARTWELL RX	12.5MG	A205136	001	Feb 22, 2019	Sep CAHN
	@		25MG	A205136	002	Feb 22, 2019	Sep CAHN
	@		50MG	A205136	003	Feb 22, 2019	Sep CAHN
	@	INVAGEN PHARMS	12.5MG	A200432	001	Feb 17, 2022	Mar DISC
	@		25MG	A200432	002	Feb 17, 2022	Mar DISC
	@		50MG	A200432	003	Feb 17, 2022	Mar DISC
	@	WILSHIRE PHARMS INC	12.5MG	A205136	001	Feb 22, 2019	Jul DISC
	@		25MG	A205136	002	Feb 22, 2019	Jul DISC
	@		50MG	A205136	003	Feb 22, 2019	Jul DISC
	TABLET, CHEWABLE; ORAL						
	MECLIZINE HYDROCHLORIDE						
	@	INVAGEN PHARMS	25MG	A200791	001	Feb 17, 2022	Mar DISC

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION
MEDROXYPROGESTERONE ACETATE

AB HONG KONG 150MG/ML A076553 001 Jul 28, 2004 Jan CAHN

MEGESTROL ACETATE

SUSPENSION; ORAL
MEGACE ES

AB	+!	ENDO OPERATIONS	125MG/ML	N021778	001	Jul 05, 2005	May CAHN
	MEGESTROL ACETATE						
	@	CHARTWELL	125MG/ML	A204688	001	Dec 01, 2017	Mar CAHN
	@	HIKMA	40MG/ML	A203960	001	Jun 09, 2017	Mar DISC
AB		NOVITIUM PHARMA	40MG/ML	A077404	001	Feb 16, 2006	May CMFD

MELOXICAM

TABLET; ORAL
MELOXICAM

AB		AIPING PHARM INC	7.5MG	A077920	001	Jul 19, 2006	Jun CAHN
AB			15MG	A077920	002	Jul 19, 2006	Jun CAHN
AB		SCIEGEN PHARMS INC	7.5MG	A077920	001	Jul 19, 2006	Apr CMFD
AB			15MG	A077920	002	Jul 19, 2006	Apr CMFD
AB	!	ZYDUS PHARMS USA	15MG	A077921	002	Jul 19, 2006	Jan CTEC
	MOBIC						
	+ @	BOEHRINGER INGELHEIM	7.5MG	N020938	001	Apr 13, 2000	Jan DISC
	+ @		15MG	N020938	002	Aug 23, 2000	Jan DISC

MELPHALAN

TABLET; ORAL
MELPHALAN
@ ALVOGEN

2MG

A207809 001 Mar 22, 2017 May DISC

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION
MELPHALAN HYDROCHLORIDE

AP AVET LIFESCIENCES EQ 50MG BASE/VIAL
@ ENDO OPERATIONS EQ 50MG BASE/VIAL
AP HETERO LABS EQ 50MG BASE/VIAL

A206523 001 Oct 29, 2024 Oct NEWA
A204773 001 Aug 22, 2016 May CAHN
A215024 001 May 23, 2024 May NEWA

SOLUTION; INTRAVENOUS
IVRA

+! APOTEX EQ 90MG BASE/ML (EQ 90MG BASE/ML)

N217110 001 Aug 18, 2023 Jul CTNA

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
MEMANTINE HYDROCHLORIDE

@ ENDO OPERATIONS 7MG
@ 14MG
@ 21MG
@ 28MG
AB XIAMEN LP PHARM CO 21MG
AB ! ZYDUS PHARMS 28MG
NAMENDA XR
+ @ ABBVIE 14MG
+ @ 21MG
+ @ 28MG

A205784 001 Jun 09, 2017 Apr CAHN
A205784 002 Jun 09, 2017 Apr CAHN
A205784 003 Jun 09, 2017 Apr CAHN
A205784 004 Jun 09, 2017 Apr CAHN
A213985 004 Feb 06, 2024 Jan NEWA
A203293 004 Aug 03, 2017 Jul CHRS
N022525 002 Jun 21, 2010 Jul DISC
N022525 003 Jun 21, 2010 Jul DISC
N022525 004 Jun 21, 2010 Jul DISC

SOLUTION; ORAL
MEMANTINE HYDROCHLORIDE

@ SCIEGEN PHARMS INC 2MG/ML

A205446 001 Dec 07, 2015 Sep CAHN

TABLET; ORAL
MEMANTINE HYDROCHLORIDE

AB ACME LABS 5MG
AB 10MG
>D> AB ALLIED 5MG
>A> @ 5MG
AB 5MG
>D> AB 10MG
>A> @ 10MG
AB 10MG
AB RENATA 5MG
AB 10MG

A209527 001 May 07, 2018 Aug CAHN
A209527 002 May 07, 2018 Aug CAHN
A090073 001 Sep 04, 2015 Nov DISC
A090073 001 Sep 04, 2015 Nov DISC
A090073 001 Sep 04, 2015 Jul CAHN
A090073 002 Sep 04, 2015 Nov DISC
A090073 002 Sep 04, 2015 Nov DISC
A090073 002 Sep 04, 2015 Jul CAHN
A209527 001 May 07, 2018 Jan CAHN
A209527 002 May 07, 2018 Jan CAHN

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
DEMEROL

@ QUAGEN 25MG/ML
@ 50MG/ML
@ 75MG/ML
@ 100MG/ML

N005010 007 Sep CAHN
N005010 002 Sep CAHN
N005010 009 Sep CAHN
N005010 003 Sep CAHN

SYRUP; ORAL
DEMEROL

@ QUAGEN 50MG/5ML

N005010 005 Sep CAHN

TABLET; ORAL
DEMEROL

+ @ QUAGEN 50MG
+ @ 100MG

N005010 001 Sep CAHN
N005010 004 Sep CAHN

MEPERIDINE HYDROCHLORIDE

AA ! EPIC PHARMA LLC 50MG
! 50MG
AA GENUS 50MG
@ 50MG
@ 75MG
@ 100MG
@ 150MG

A040331 001 May 28, 1999 Feb CTEC
A040331 001 May 28, 1999 Feb CHRS
A040893 001 Jun 24, 2009 Feb CMFD
A040893 001 Jun 24, 2009 Jan CAHN
A040893 002 Jun 24, 2009 Jan CAHN
A040893 003 Jun 24, 2009 Jan CAHN
A040893 004 Jun 24, 2009 Jan CAHN

MEROPENEM

	INJECTABLE; INJECTION						
	MEROPENEM						
AP	QILU	500MG/VIAL	A216424	001	Jul 22, 2024	Jul	NEWA
AP		1GM/VIAL	A216424	002	Jul 22, 2024	Jul	NEWA

MESALAMINE

	CAPSULE, EXTENDED RELEASE; ORAL						
	MESALAMINE						
AB	NOVAST LABS	375MG	A218410	001	Aug 22, 2024	Aug	NEWA
	SUPPOSITORY; RECTAL						
	MESALAMINE						
AB	RISING	1GM	A207448	001	Apr 19, 2019	Sep	CAHN
	TABLET, DELAYED RELEASE; ORAL						
	MESALAMINE						
AB	ANNORA PHARMA	1.2GM	A216334	001	Feb 05, 2024	Jan	NEWA
AB	TEVA PHARMS INC	800MG	A213191	001	Aug 22, 2024	Aug	NEWA
AB	! ZYDUS PHARMS	800MG	A203286	001	Jul 21, 2017	Aug	CTEC

MESNA

	INJECTABLE; INTRAVENOUS						
	MESNA						
	@ RISING	100MG/ML	A203364	001	Jul 18, 2014	Feb	CAHN

METAPROTERENOL SULFATE

	SYRUP; ORAL						
	METAPROTERENOL SULFATE						
>D>	! CHARTWELL	10MG/5ML	A073632	001	Jul 22, 1992	Nov	CAHN
	!	10MG/5ML	A073632	001	Jul 22, 1992	Sep	CAHN
	! GENUS	10MG/5ML	A073632	001	Jul 22, 1992	Jan	CAHN
>A>	! GENUS LIFESCIENCES	10MG/5ML	A073632	001	Jul 22, 1992	Nov	CAHN

METARAMINOL BITARTRATE

	INJECTABLE; INJECTION						
	METARAMINOL BITARTRATE						
	AZURITY	EQ 10MG BASE/ML	A211304	001	Aug 24, 2021	Jul	CAHN

METAXALONE

	TABLET; ORAL						
	METAXALONE						
>D> BX	RISING	800MG	A208774	001	Sep 24, 2018	Nov	DISC
>A>	@	800MG	A208774	001	Sep 24, 2018	Nov	DISC
BX		800MG	A208774	001	Sep 24, 2018	Sep	CAHN

METFORMIN HYDROCHLORIDE

	TABLET; ORAL						
	METFORMIN HYDROCHLORIDE						
	@ AMNEAL PHARMS NY	500MG	A077880	001	Jun 05, 2006	Jul	DISC
	@	850MG	A077880	002	Jun 05, 2006	Jul	DISC
	@	1GM	A077880	003	Jun 05, 2006	Jul	DISC
	TABLET, EXTENDED RELEASE; ORAL						
	METFORMIN HYDROCHLORIDE						
AB2	AUROBINDO PHARMA	500MG	A209694	001	Oct 18, 2024	Oct	NEWA
AB2		1GM	A209694	002	Oct 18, 2024	Oct	NEWA
AB1	HARMAN FINOCHEM	500MG	A218673	001	Jul 05, 2024	Jun	NEWA
AB		750MG	A218673	002	Jul 05, 2024	Jun	NEWA
AB3	MACLEODS PHARMS LTD	1GM	A211163	001	Mar 13, 2024	Mar	NEWA
	@ UTOPIC PHARMS	500MG	A213394	001	Aug 03, 2021	Sep	CAHN
	@	1GM	A213394	002	Aug 03, 2021	Sep	CAHN

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

	TABLET; ORAL						
	PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE						
	@ CHARTWELL RX	500MG; EQ 15MG BASE	A091273	001	Apr 16, 2013	Jan	CAHN
	@	850MG; EQ 15MG BASE	A091273	002	Apr 16, 2013	Jan	CAHN

METFORMIN HYDROCHLORIDE; SITAGLIPTIN

TABLET, EXTENDED RELEASE;ORAL
ZITUVIMET XR

	+	ZYDUS	500MG;50MG	N216778	001	Jul 18, 2024	Jul	NEWA
	+		1GM;50MG	N216778	002	Jul 18, 2024	Jul	NEWA
	+	!	1GM;100MG	N216778	003	Jul 18, 2024	Jul	NEWA
	+	ZYDUS LIFESCIENCES	500MG;50MG	N216778	001	Jul 18, 2024	Aug	CAHN
	+		1GM;50MG	N216778	002	Jul 18, 2024	Aug	CAHN
	+	!	1GM;100MG	N216778	003	Jul 18, 2024	Aug	CAHN

METHADONE HYDROCHLORIDE

CONCENTRATE;ORAL
METHADONE HYDROCHLORIDE

AA		VISTAPHARM LLC	10MG/ML	A040088	001	Nov 30, 1994	Apr	CAHN
		SOLUTION;ORAL						
		METHADONE HYDROCHLORIDE						
		@ VISTAPHARM LLC	5MG/5ML	A090707	001	Jun 30, 2010	Jun	DISC
AA			5MG/5ML	A090707	001	Jun 30, 2010	Apr	CAHN
		@	10MG/5ML	A090707	002	Jun 30, 2010	Jun	DISC
AA			10MG/5ML	A090707	002	Jun 30, 2010	Apr	CAHN

TABLET;ORAL
METHADONE HYDROCHLORIDE

AA		ELITE LABS INC	5MG	A210484	001	Aug 02, 2018	Aug	CMFD
		@	5MG	A210484	001	Aug 02, 2018	Jun	CAHN
AA			10MG	A210484	002	Aug 02, 2018	Aug	CMFD
		@	10MG	A210484	002	Aug 02, 2018	Jun	CAHN
>A>	AA	HIKMA	5MG	A088108	001	Mar 08, 1983	Nov	CAHN
>A>	AA		10MG	A088109	001	Mar 08, 1983	Nov	CAHN
>D>	AA	ROXANE	5MG	A088108	001	Mar 08, 1983	Nov	CAHN
>D>	AA		10MG	A088109	001	Mar 08, 1983	Nov	CAHN
		@ VISTAPHARM LLC	5MG	A040241	001	May 29, 1998	Apr	CAHN
AA			10MG	A040241	002	May 29, 1998	Apr	CAHN
AA			10MG	A204166	001	Mar 16, 2020	Apr	CAHN

METHAZOLAMIDE

TABLET;ORAL
METHAZOLAMIDE

>A>	AB	CHARTWELL RX	25MG	A040036	001	Jun 30, 1993	Nov	CAHN
>A>	AB		50MG	A040036	002	Jun 30, 1993	Nov	CAHN
>D>	AB	SANDOZ	25MG	A040036	001	Jun 30, 1993	Nov	CAHN
>D>	AB		50MG	A040036	002	Jun 30, 1993	Nov	CAHN

METHENAMINE HIPPURATE

TABLET;ORAL
HIPREX

AB	+	ESJAY PHARMA	1GM	N017681	001		Oct	CAHN
		METHENAMINE HIPPURATE						
AB		JUBILANT CADISTA	1GM	A217675	001	Dec 01, 2023	Apr	CAHN

METHOCARBAMOL

SOLUTION;IM-IV
METHOCARBAMOL
@ NAVINTA LLC 1GM/10ML (100MG/ML)
@ NORVIUM BIOSCIENCE 1GM/10ML (100MG/ML)

A206071	001	Nov 24, 2017	Oct	DISC
A204404	001	Dec 05, 2014	Jul	CAHN

TABLET;ORAL
METHOCARBAMOL

>A>		@ AIPING PHARM INC	500MG	A084616	001		Nov	CAHN
>A>		@	750MG	A084615	001		Nov	CAHN
AA		ALLIED	500MG	A212623	001	Apr 30, 2021	Aug	CAHN
AA			750MG	A212623	002	Apr 30, 2021	Aug	CAHN
AA		DBL PHARMS	500MG	A203550	001	Feb 08, 2017	Feb	CAHN
AA			750MG	A203550	002	Feb 08, 2017	Feb	CAHN
>D>		@ FOSUN PHARMA	500MG	A084616	001		Nov	CAHN
>D>		@	750MG	A084615	001		Nov	CAHN
AA		HANGZHOU BINJIANG	500MG	A200958	001	Oct 21, 2011	Mar	CAHN
AA			750MG	A200958	002	Oct 21, 2011	Mar	CAHN
AB	!		1GM	A200958	003	Dec 06, 2021	Mar	CAHN
AA		HLTHCARE	500MG	A203550	001	Feb 08, 2017	Sep	CAHN
AA			750MG	A203550	002	Feb 08, 2017	Sep	CAHN
		ROBAXIN						
	+	@ ENDO OPERATIONS	500MG	N011011	004		May	CAHN

TABLET;ORAL
ROBAXIN-750

+ @ ENDO OPERATIONS 750MG N011011 006 May CAHN

METHOHEXITAL SODIUM

INJECTABLE; INJECTION
BREVITAL SODIUM

AP +! ENDO OPERATIONS 500MG/VIAL N011559 001 Sep CFTG

METHOHEXITAL SODIUM
AP STERISCIENCE 500MG/VIAL A215488 001 Oct 03, 2024 Sep NFTG
AP STERISCIENCE SPECLTS 500MG/VIAL A215488 001 Oct 03, 2024 Oct CAHN

METHOTREXATE SODIUM

INJECTABLE; INJECTION
METHOTREXATE SODIUM PRESERVATIVE FREE

>D> ! HIKMA EQ 1GM BASE/VIAL A040632 001 Aug 12, 2005 Nov CTEC
>A> AP ! EQ 1GM BASE/VIAL A040632 001 Aug 12, 2005 Nov CTEC

TABLET;ORAL
METHOTREXATE SODIUM

AB ALEMBIC EQ 2.5MG BASE A217552 001 Jun 03, 2024 May NEWA
@ AMNEAL PHARMS EQ 2.5MG BASE A210040 001 Dec 22, 2017 Sep DISC
AB ELITE LABS INC EQ 2.5MG BASE A216453 001 May 16, 2024 May NEWA
@ LOTUS PHARM CO LTD EQ 2.5MG BASE A209787 001 Apr 23, 2021 Apr DISC

METHSCOPOLAMINE BROMIDE

TABLET;ORAL
METHSCOPOLAMINE BROMIDE

AA ACE PHARMS 2.5MG A216786 001 Feb 01, 2024 Jan NEWA
AA 5MG A216786 002 Feb 01, 2024 Jan NEWA
>D> AA BAYSHORE PHARMS LLC 2.5MG A200602 001 Sep 24, 2012 Nov CAHN
>D> AA ! 5MG A200602 002 Sep 24, 2012 Nov CAHN
AA NE RX PHARMA 2.5MG A216786 001 Feb 01, 2024 May CAHN
AA 5MG A216786 002 Feb 01, 2024 May CAHN
>A> AA UNICHEM 2.5MG A200602 001 Sep 24, 2012 Nov CAHN
>A> AA ! 5MG A200602 002 Sep 24, 2012 Nov CAHN

METHYLDOPA

TABLET;ORAL
METHYLDOPA

@ CHARTWELL RX 250MG N018934 001 Jun 29, 1984 Feb DISC
250MG N018934 001 Jun 29, 1984 Jan CMFD
@ 500MG N018934 002 Jun 29, 1984 Feb DISC
! 500MG N018934 002 Jun 29, 1984 Jan CMFD
>D> @ RISING 250MG A070076 002 Apr 18, 1985 Nov CMFD
>A> 250MG A070076 002 Apr 18, 1985 Nov CMFD
>D> @ 500MG A070076 001 Apr 18, 1985 Nov CMFD
>A> ! 500MG A070076 001 Apr 18, 1985 Nov CMFD

METHYLENE BLUE

SOLUTION; INTRAVENOUS
METHYLENE BLUE

>A> AP NEXUS 50MG/10ML (5MG/ML) A217561 001 Nov 21, 2024 Nov NEWA
>A> AP STERISCIENCE 50MG/10ML (5MG/ML) A216955 001 Nov 22, 2024 Nov NEWA
AP ZYDUS LIFESCIENCES 10MG/2ML (5MG/ML) A215636 001 Dec 05, 2023 Apr CAHN
AP 50MG/10ML (5MG/ML) A215636 002 Dec 05, 2023 Apr CAHN

METHYLERGONOVINE MALEATE

TABLET;ORAL
METHYLERGONOVINE MALEATE

AB TRUPHARMA 0.2MG A212233 001 May 01, 2020 Sep CAHN

METHYLNALTREXONE BROMIDE

SOLUTION; SUBCUTANEOUS
METHYLNALTREXONE BROMIDE

AP ACTAVIS LLC 8MG/0.4ML (8MG/0.4ML) A208112 001 Aug 26, 2024 Aug NFTG
AP 12MG/0.6ML (12MG/0.6ML) A208112 002 Aug 26, 2024 Aug NFTG
RELISTOR
AP +! SALIX PHARMS 8MG/0.4ML (8MG/0.4ML) N021964 002 Sep 27, 2010 Aug CFTG
AP +! 12MG/0.6ML (12MG/0.6ML) N021964 003 Sep 27, 2010 Aug CFTG

METHYLPHENIDATE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL
COTEMPLA XR-ODT

+ @	NEOS THERAPS INC	34.6MG	N205489	004	Aug 19, 2024	Sep	DISC
+		34.6MG	N205489	004	Aug 19, 2024	Aug	NEWA

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
JORNAY PM

+	IRONSHORE PHARMS	20MG	N209311	001	Aug 08, 2018	Oct	CAHN
+		40MG	N209311	002	Aug 08, 2018	Oct	CAHN
+		60MG	N209311	003	Aug 08, 2018	Oct	CAHN
+		80MG	N209311	004	Aug 08, 2018	Oct	CAHN
+		100MG	N209311	005	Aug 08, 2018	Oct	CAHN

METHYLPHENIDATE HYDROCHLORIDE

>D>	AB2	TEVA PHARMS	40MG	A078873	001	Jul 19, 2012	Nov	DISC
>A>		@	40MG	A078873	001	Jul 19, 2012	Nov	DISC
>D>	AB2		50MG	A078873	002	Jul 19, 2012	Nov	DISC
>A>		@	50MG	A078873	002	Jul 19, 2012	Nov	DISC
>D>	AB2		60MG	A078873	003	Jul 19, 2012	Nov	DISC
>A>		@	60MG	A078873	003	Jul 19, 2012	Nov	DISC

SOLUTION;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AA	ANDA REPOSITORY	5MG/5ML	A210764	001	Apr 10, 2020	Sep	CAHN
AA		10MG/5ML	A210764	002	Apr 10, 2020	Sep	CAHN

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	CEDIPROF INC	5MG	A208737	001	Feb 01, 2019	Mar	CMFD
AB		10MG	A208737	002	Feb 01, 2019	Mar	CMFD
AB		20MG	A208737	003	Feb 01, 2019	Mar	CMFD

METHYLPREDNISOLONE

TABLET;ORAL

METHYLPREDNISOLONE

AB	ENDO OPERATIONS	4MG	A040183	001	Dec 22, 1998	Apr	CAHN
	@ PRAXGEN	4MG	A212262	001	Jun 27, 2019	Feb	DISC

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE ACETATE

AB	ENDO OPERATIONS	40MG/ML	A214297	001	Jan 21, 2022	Apr	CAHN
AB		80MG/ML	A214297	002	Jan 21, 2022	Apr	CAHN
AB	HONG KONG	40MG/ML	A040557	001	Feb 23, 2005	Jan	CAHN
AB		80MG/ML	A040557	002	Feb 23, 2005	Jan	CAHN
	@ TEVA PHARMS USA	40MG/ML	A040620	001	Oct 27, 2006	Jan	DISC
	@	80MG/ML	A040620	002	Oct 27, 2006	Jan	DISC
AB	WILSHIRE PHARMS INC	40MG/ML	A214870	002	May 10, 2023	Jul	CAHN
AB		80MG/ML	A214870	001	Jan 03, 2023	Jul	CAHN

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AA	! GENUS	EQ 5MG BASE/5ML	A072744	001	May 28, 1991	Apr	CAHN
----	---------	-----------------	---------	-----	--------------	-----	------

TABLET;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AB	AIPING PHARM INC	EQ 5MG BASE	A072215	002	Nov 05, 2024	Oct	NEWA
AB		EQ 10MG BASE	A072215	001	Jan 30, 1990	Oct	CMFD

METOLAZONE

TABLET;ORAL

METOLAZONE

>D>	AB	BAYSHORE PHARMS LLC	2.5MG	A214799	001	Mar 30, 2021	Nov	CAHN
>D>	AB		5MG	A214799	002	Mar 30, 2021	Nov	CAHN
>D>	AB		10MG	A214799	003	Mar 30, 2021	Nov	CAHN
	AB	CHEMISTRY HLTH	2.5MG	A218606	001	Apr 17, 2024	Sep	CAHN
	AB		5MG	A218606	002	Apr 17, 2024	Sep	CAHN
	AB		10MG	A218606	003	Apr 17, 2024	Sep	CAHN
	AB	LEADING	2.5MG	A218606	001	Apr 17, 2024	Apr	NEWA
	AB		5MG	A218606	002	Apr 17, 2024	Apr	NEWA
	AB		10MG	A218606	003	Apr 17, 2024	Apr	NEWA
	AB	MICRO LABS	2.5MG	A217563	001	Nov 06, 2024	Oct	NEWA

TABLET;ORAL
METOLAZONE

AB		5MG	A217563	002	Nov 06, 2024	Oct	NEWA
AB		10MG	A217563	003	Nov 06, 2024	Oct	NEWA
>A>	AB	UNICHEM	2.5MG	A214799	001	Mar 30, 2021	Nov CAHN
>A>	AB		5MG	A214799	002	Mar 30, 2021	Nov CAHN
>A>	AB		10MG	A214799	003	Mar 30, 2021	Nov CAHN

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL
METOPROLOL SUCCINATE

	@	GRANULES	EQ 25MG TARTRATE	A216509	001	Aug 07, 2023	Mar DISC
	@		EQ 50MG TARTRATE	A216509	002	Aug 07, 2023	Mar DISC
	@		EQ 100MG TARTRATE	A216509	003	Aug 07, 2023	Mar DISC
	@		EQ 200MG TARTRATE	A216509	004	Aug 07, 2023	Mar DISC
AB		SUNSHINE	EQ 25MG TARTRATE	A214004	004	May 23, 2024	May NEWA
AB		ZHEJIANG JUTAI PHARM	EQ 50MG TARTRATE	A214110	001	Jul 26, 2024	Jul NEWA
AB			EQ 100MG TARTRATE	A214110	002	Jul 26, 2024	Jul NEWA
AB			EQ 200MG TARTRATE	A214110	003	Jul 26, 2024	Jul NEWA

METRONIDAZOLE

GEL;TOPICAL
METROGEL

	+	@	GALDERMA LABS LP	0.75%	N019737	001	Nov 22, 1988	May DISC
			METRONIDAZOLE					
AB			AUROBINDO PHARMA LTD	1%	A218941	001	Oct 15, 2024	Oct NEWA
AB	!		COSETTE	0.75%	A078178	001	Jan 19, 2011	May CHRS

GEL;VAGINAL

			METRONIDAZOLE					
AB			ENCUBE	1.3%	A216795	001	Mar 18, 2024	Mar NFTG
			NUVESSA					
AB	+	!	CHEMO RESEARCH SL	1.3%	N205223	001	Mar 24, 2014	Mar CFTG

TABLET;ORAL

			METRONIDAZOLE					
AB			APPCO	250MG	A205245	001	Sep 23, 2015	Oct CAHN
AB				500MG	A205245	002	Sep 23, 2015	Oct CAHN
		@	FLAMINGO PHARMS	250MG	A207309	001	May 16, 2016	Mar DISC
		@		500MG	A207309	002	May 16, 2016	Mar DISC
			INNOGENIX	125MG	A070772	003	Oct 29, 2024	Oct NEWA

METYROSINE

CAPSULE;ORAL
METYROSINE

AB			LEADING	250MG	A215541	001	Sep 17, 2024	Sep NEWA
----	--	--	---------	-------	---------	-----	--------------	----------

MEXILETINE HYDROCHLORIDE

CAPSULE;ORAL
MEXILETINE HYDROCHLORIDE

AB			LEADING	150MG	A215876	001	Feb 27, 2023	Aug CAHN
AB				200MG	A215876	002	Feb 27, 2023	Aug CAHN
AB				250MG	A215876	003	Feb 27, 2023	Aug CAHN
AB			RISING	150MG	A215315	001	Aug 26, 2022	Oct CAHN
AB				200MG	A215315	002	Aug 26, 2022	Oct CAHN
AB				250MG	A215315	003	Aug 26, 2022	Oct CAHN
AB			ZENARA	150MG	A215315	001	Aug 26, 2022	Apr CAHN
AB				200MG	A215315	002	Aug 26, 2022	Apr CAHN
AB				250MG	A215315	003	Aug 26, 2022	Apr CAHN

MICAFUNGIN SODIUM

INJECTABLE;INTRAVENOUS
MICAFUNGIN SODIUM

	@		APOTEX	EQ 50MG BASE/VIAL	A208366	001	Nov 05, 2020	Jul DISC
	@			EQ 100MG BASE/VIAL	A208366	002	Nov 05, 2020	Jul DISC
AP			BIOCON PHARMA	EQ 50MG BASE/VIAL	A216438	001	May 29, 2024	May NEWA
AP				EQ 100MG BASE/VIAL	A216438	002	May 29, 2024	May NEWA

MIDAZOLAM

SOLUTION;INTRAVENOUS
MIDAZOLAM IN 0.8% SODIUM CHLORIDE

	+	@	EXELA PHARMA	50MG/50ML (1MG/ML)	N215868	001	Jul 20, 2022	May DISC
>D>		+	!	100MG/100ML (1MG/ML)	N215868	002	Jul 20, 2022	Nov DISC
>A>		+	@	100MG/100ML (1MG/ML)	N215868	002	Jul 20, 2022	Nov DISC

SOLUTION;INTRAVENOUS

MIDAZOLAM IN 0.9% SODIUM CHLORIDE						
AP	GLAND PHARMA LTD	50MG/50ML (1MG/ML)	A218993	001	Aug 12, 2024	Aug NEWA
AP		100MG/100ML (1MG/ML)	A218993	002	Aug 12, 2024	Aug NEWA

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION						
MIDAZOLAM HYDROCHLORIDE						
	@ ENDO OPERATIONS	EQ 1MG BASE/ML	A078141	001	May 30, 2008	Sep CAHN
	@	EQ 1MG BASE/ML	A078511	001	Nov 10, 2008	Sep CAHN
	@	EQ 5MG BASE/ML	A078141	002	May 30, 2008	Sep CAHN
	@	EQ 5MG BASE/ML	A078511	002	Nov 10, 2008	Sep CAHN
	@ FRESENIUS KABI USA	EQ 5MG BASE/ML	A208878	001	Mar 28, 2017	Jan DISC
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE						
AP	STERISCIENCE SPECLTS	EQ 1MG BASE/ML	A090315	001	Nov 29, 2010	Aug CAHN
AP		EQ 5MG BASE/ML	A090315	002	Nov 29, 2010	Aug CAHN
MIDOZALAM HYDROCHLORIDE						
AP	STERISCIENCE SPECLTS	EQ 1MG BASE/ML	A090316	001	May 04, 2011	Aug CAHN
AP		EQ 5MG BASE/ML	A090316	002	May 04, 2011	Aug CAHN
SYRUP; ORAL						
MIDAZOLAM HYDROCHLORIDE						
	@ PAI HOLDINGS	EQ 2MG BASE/ML	A075958	001	Sep 04, 2003	Jul CAHN

MIDODRINE HYDROCHLORIDE

TABLET; ORAL						
MIDODRINE HYDROCHLORIDE						
AB	ENDO OPERATIONS	2.5MG	A207169	001	Oct 29, 2018	Apr CAHN
AB		5MG	A207169	002	Oct 29, 2018	Apr CAHN
AB		10MG	A207169	003	Oct 29, 2018	Apr CAHN

MIDOSTAURIN

CAPSULE; ORAL						
MIDOSTAURIN						
AB	DR REDDYS	25MG	A215921	001	Jun 28, 2024	Jun NEWA
AB	LUPIN	25MG	A216015	001	May 10, 2024	May NEWA
	@ TEVA PHARMS	25MG	A216076	001	Apr 29, 2024	Oct DISC
AB		25MG	A216076	001	Apr 29, 2024	Apr NFTG
RYDAPT						
AB	+! NOVARTIS	25MG	N207997	001	Apr 28, 2017	Apr CFTG

MIGLUSTAT

CAPSULE; ORAL						
MIGLUSTAT						
	@ BRECKENRIDGE	100MG	A209325	001	Feb 03, 2022	Oct DISC

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL						
MILNACIPRAN HYDROCHLORIDE						
AB	HETERO LABS LTD V	12.5MG	A205147	001	Oct 03, 2024	Sep NFTG
AB		25MG	A205147	002	Oct 03, 2024	Sep NFTG
AB		50MG	A205147	003	Oct 03, 2024	Sep NFTG
AB		100MG	A205147	004	Oct 03, 2024	Sep NFTG
	@ ORYZA	12.5MG	A205071	001	Jan 27, 2016	Sep CAHN
	@	25MG	A205071	002	Jan 27, 2016	Sep CAHN
	@	50MG	A205071	003	Jan 27, 2016	Sep CAHN
	@	100MG	A205071	004	Jan 27, 2016	Sep CAHN
SAVELLA						
AB	+ ABBVIE	12.5MG	N022256	001	Jan 14, 2009	Sep CFTG
AB	+	25MG	N022256	002	Jan 14, 2009	Sep CFTG
AB	+!	50MG	N022256	003	Jan 14, 2009	Sep CFTG
AB	+	100MG	N022256	004	Jan 14, 2009	Sep CFTG

MINOCYCLINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL						
EMROSI						
>A>	+! DR REDDYS	40MG	N219015	001	Nov 01, 2024	Nov NEWA
INJECTABLE; INJECTION						
MINOCIN						
AP	+! REMPEX	EQ 100MG BASE/VIAL	N050444	001		Oct CFTG
MINOCYCLINE HYDROCHLORIDE						
AP	NEXUS PHARMS	EQ 100MG BASE/VIAL	A214934	001	Oct 24, 2024	Oct NFTG

TABLET;ORAL

MINOCYCLINE HYDROCHLORIDE

@	SUN PHARM INDUSTRIES	EQ 50MG BASE	A090217	001	Jan 29, 2016	Jul	DISC
@		EQ 75MG BASE	A090217	002	Jan 29, 2016	Jul	DISC
@		EQ 100MG BASE	A090217	003	Jan 29, 2016	Jul	DISC

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

AB	!	ALKEM LABS LTD	EQ 115MG BASE	A204453	007	Mar 16, 2018	Jul	CHRS
AB	!		EQ 135MG BASE	A204453	005	Sep 28, 2016	Jul	CHRS
AB		SANDOZ	EQ 135MG BASE	A090422	003	Aug 13, 2009	Jul	CHRS
AB		SUN PHARM	EQ 45MG BASE	A204394	001	Dec 30, 2015	Aug	CAHN
AB			EQ 55MG BASE	A204394	002	Oct 07, 2022	Aug	CAHN
AB			EQ 65MG BASE	A204394	003	Oct 07, 2022	Aug	CAHN
AB			EQ 80MG BASE	A204394	004	Dec 30, 2015	Aug	CAHN
AB			EQ 105MG BASE	A204394	005	Dec 30, 2015	Aug	CAHN
AB			EQ 115MG BASE	A204394	006	Oct 07, 2022	Aug	CAHN
AB			EQ 135MG BASE	A204394	007	Dec 30, 2015	Aug	CAHN
	@	SUN PHARM INDS LTD	EQ 45MG BASE	A091118	001	Sep 25, 2014	Jan	DISC
	@		EQ 65MG BASE	A091118	003	Dec 03, 2019	Jan	DISC
	@		EQ 80MG BASE	A091118	004	Sep 25, 2014	Jan	DISC
	@		EQ 90MG BASE	A091118	005	Sep 25, 2014	Jan	DISC
	@		EQ 105MG BASE	A091118	006	Sep 25, 2014	Jan	DISC
	@		EQ 115MG BASE	A091118	007	Dec 03, 2019	Jan	DISC
	@		EQ 135MG BASE	A091118	008	Sep 25, 2014	Jan	DISC
	@	ZYDUS PHARMS	EQ 45MG BASE	A203553	001	Nov 16, 2017	Jan	DISC
	@		EQ 55MG BASE	A203553	002	Jun 16, 2023	Jan	DISC
	@		EQ 65MG BASE	A203553	003	Jun 16, 2023	Jan	DISC
	@		EQ 80MG BASE	A203553	004	Nov 16, 2017	Jan	DISC
	@		EQ 90MG BASE	A203553	005	Nov 16, 2017	Jan	DISC
	@		EQ 105MG BASE	A203553	006	Nov 16, 2017	Jan	DISC
	@		EQ 115MG BASE	A203553	007	Jun 16, 2023	Jan	DISC
	@		EQ 135MG BASE	A203553	008	Nov 16, 2017	Jan	DISC
		MINOLIRA						
	@	EPI HLTH	EQ 105MG BASE	N209269	001	May 08, 2017	Jul	DISC
	@		EQ 135MG BASE	N209269	002	May 08, 2017	Jul	DISC
		SOLODYN						
	+	@ BAUSCH	EQ 55MG BASE	N050808	008	Aug 27, 2010	Jun	DISC
	+	@	EQ 65MG BASE	N050808	004	Jul 23, 2009	Jun	DISC
	+	@	EQ 80MG BASE	N050808	007	Aug 27, 2010	Jun	DISC
	+	@	EQ 105MG BASE	N050808	006	Aug 27, 2010	Jun	DISC
	+	@	EQ 115MG BASE	N050808	005	Jul 23, 2009	Jun	DISC

MINOXIDIL

TABLET;ORAL

MINOXIDIL

AB		ENDO OPERATIONS	2.5MG	A071826	001	Nov 14, 1988	Apr	CAHN
AB			10MG	A071839	001	Nov 14, 1988	Apr	CAHN

MIRABEGRON

TABLET, EXTENDED RELEASE;ORAL

MIRABEGRON

AB		ALKEM LABS LTD	25MG	A215948	001	Feb 12, 2024	Feb	NEWA
AB			50MG	A215948	002	Feb 12, 2024	Feb	NEWA
AB		ZYDUS PHARMS	25MG	A209488	001	Sep 29, 2022	Mar	CMFD
AB			50MG	A209488	002	Sep 29, 2022	Mar	CMFD

MIRTAZAPINE

TABLET;ORAL

MIRTAZAPINE

AB		AIPING PHARM INC	15MG	A076219	001	Jun 19, 2003	Feb	CAHN
AB			30MG	A076219	002	Jun 19, 2003	Feb	CAHN
AB			45MG	A076219	003	Jun 19, 2003	Feb	CAHN
AB		CHARTWELL RX	15MG	A076219	001	Jun 19, 2003	Jun	CAHN
AB			30MG	A076219	002	Jun 19, 2003	Jun	CAHN
AB			45MG	A076219	003	Jun 19, 2003	Jun	CAHN

MISOPROSTOL

TABLET;ORAL

MISOPROSTOL

AB		ACQ PHARMA	0.1MG	A210201	001	Jul 02, 2019	Oct	CMFD
AB			0.2MG	A210201	002	Jul 02, 2019	Oct	CMFD

MITOMYCIN

INJECTABLE; INJECTION
MITOMYCIN

AP	FRESENIUS KABI USA	5MG/VIAL	A211269	001	Apr 05, 2024	Mar	NEWA
AP		20MG/VIAL	A211269	002	Apr 05, 2024	Mar	NEWA
AP		40MG/VIAL	A211269	003	Apr 05, 2024	Mar	NEWA

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION
MITOXANTRONE HYDROCHLORIDE

@	RISING	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A201014	001	Dec 11, 2012	Mar	CAHN
---	--------	------------------------------------	---------	-----	--------------	-----	------

MOMETASONE FUROATE

LOTION; TOPICAL
MOMETASONE FUROATE

@	COSETTE	0.1%	A077678	001	Nov 21, 2007	Apr	DISC
---	---------	------	---------	-----	--------------	-----	------

OINTMENT; TOPICAL
MOMETASONE FUROATE

>D>	@	TORRENT	0.1%	A207899	001	Jul 13, 2018	Nov	CMFD
-----	---	---------	------	---------	-----	--------------	-----	------

>A>	AB		0.1%	A207899	001	Jul 13, 2018	Nov	CMFD
-----	----	--	------	---------	-----	--------------	-----	------

SPRAY, METERED; NASAL
MOMETASONE FUROATE

AB	AUROBINDO PHARMA	0.05MG/SPRAY	A215878	001	Mar 18, 2024	Mar	NEWA
----	------------------	--------------	---------	-----	--------------	-----	------

MONTELUKAST SODIUM

GRANULE; ORAL
MONTELUKAST SODIUM

@	TEVA PHARMS	EQ 4MG BASE/PACKET	A090955	001	Aug 03, 2012	Jan	DISC
---	-------------	--------------------	---------	-----	--------------	-----	------

TABLET; ORAL
MONTELUKAST SODIUM

AB	RISING	EQ 10MG BASE	A209012	001	Apr 24, 2017	Aug	CAHN
----	--------	--------------	---------	-----	--------------	-----	------

@	SANDOZ INC	EQ 10MG BASE	A200889	001	Aug 03, 2012	Jul	DISC
---	------------	--------------	---------	-----	--------------	-----	------

TABLET, CHEWABLE; ORAL
MONTELUKAST SODIUM

@	SANDOZ INC	EQ 4MG BASE	A091414	001	Aug 03, 2012	Sep	DISC
---	------------	-------------	---------	-----	--------------	-----	------

@		EQ 5MG BASE	A091414	002	Aug 03, 2012	Sep	DISC
---	--	-------------	---------	-----	--------------	-----	------

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL
MORPHINE SULFATE

UP	SHER SMITH LABS	10MG	A202104	001	Jun 03, 2013	Sep	CHRS
----	-----------------	------	---------	-----	--------------	-----	------

SOLUTION; INTRAMUSCULAR, INTRAVENOUS
MORPHINE SULFATE

+	@	FRESENIUS KABI USA	5MG/ML (5MG/ML)	N204223	003	Oct 30, 2013	Sep	DISC
---	---	--------------------	-----------------	---------	-----	--------------	-----	------

+	@		8MG/ML (8MG/ML)	N204223	004	Oct 30, 2013	Sep	DISC
---	---	--	-----------------	---------	-----	--------------	-----	------

SOLUTION; ORAL
MORPHINE SULFATE

@	HIKMA	100MG/5ML	A208809	001	Jul 06, 2017	Mar	DISC
---	-------	-----------	---------	-----	--------------	-----	------

@	PHARM ASSOC	10MG/5ML	A206573	002	Sep 12, 2023	Aug	DISC
---	-------------	----------	---------	-----	--------------	-----	------

@		100MG/5ML	A206573	001	Nov 14, 2016	Aug	DISC
---	--	-----------	---------	-----	--------------	-----	------

AA	WINDER LABS LLC	10MG/5ML	A211454	001	Feb 12, 2021	Jan	CMFD
----	-----------------	----------	---------	-----	--------------	-----	------

AA		20MG/5ML	A211454	002	Feb 12, 2021	Jan	CMFD
----	--	----------	---------	-----	--------------	-----	------

AA		100MG/5ML	A211454	003	Feb 12, 2021	Jan	CMFD
----	--	-----------	---------	-----	--------------	-----	------

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
MOXIFLOXACIN HYDROCHLORIDE

AT1	ADAPTIS	EQ 0.5% BASE	A202525	001	Mar 06, 2015	Aug	CAHN
-----	---------	--------------	---------	-----	--------------	-----	------

>D>	AT1	MYLAN	EQ 0.5% BASE	A206447	001	Mar 30, 2020	Nov	DISC
-----	-----	-------	--------------	---------	-----	--------------	-----	------

>A>	@		EQ 0.5% BASE	A206447	001	Mar 30, 2020	Nov	DISC
-----	---	--	--------------	---------	-----	--------------	-----	------

>A>	AT1	SOMERSET THERAPS LLC	EQ 0.5% BASE	A209698	001	Nov 14, 2024	Nov	NEWA
-----	-----	----------------------	--------------	---------	-----	--------------	-----	------

VIGAMOX

AT1	+	HARROW EYE	EQ 0.5% BASE	N021598	001	Apr 15, 2003	Jan	CAHN
-----	---	------------	--------------	---------	-----	--------------	-----	------

TABLET; ORAL
MOXIFLOXACIN HYDROCHLORIDE

@	NATCO	EQ 400MG BASE	A204635	001	Aug 31, 2015	Jun	CAHN
---	-------	---------------	---------	-----	--------------	-----	------

MYCOPHENOLATE MOFETIL

CAPSULE;ORAL

MYCOPHENOLATE MOFETIL

AB	HETERO LABS LTD V	250MG	A207022	001	Oct 22, 2024	Oct	NEWA
>A>	AB	WUXI	A214079	001	Nov 07, 2024	Nov	NEWA

FOR SUSPENSION;ORAL

MYCOPHENOLATE MOFETIL

AB	AUROBINDO PHARMA LTD	200MG/ML	A218227	001	Sep 26, 2024	Sep	NEWA
>D>	AB	HETERO LABS LTD V	A213955	001	Sep 11, 2023	Nov	CAHN
>A>	AB	RISING	A213955	001	Sep 11, 2023	Nov	CAHN

SUSPENSION;ORAL

MYHIBBIN

+	!	AZURITY	200MG/ML	N216482	001	May 01, 2024	May	NEWA
---	---	---------	----------	---------	-----	--------------	-----	------

TABLET;ORAL

MYCOPHENOLATE MOFETIL

	@	AMNEAL	500MG	A090606	001	Jul 16, 2010	Feb	DISC
AB		AUROBINDO PHARMA	500MG	A217937	001	Feb 20, 2024	Feb	NEWA
AB		HETERO LABS LTD V	500MG	A208119	001	Oct 22, 2024	Oct	NEWA

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE;INJECTION

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

AP		ENDO OPERATIONS	500MG/VIAL	A203575	001	Oct 28, 2016	Apr	CAHN
AP		STERISCIENCE SPECLTS	500MG/VIAL	A216390	001	Dec 23, 2022	Aug	CAHN

MYCOPHENOLIC SODIUM

TABLET, DELAYED RELEASE;ORAL

MYCOPHENOLIC SODIUM

AB		AUROBINDO PHARMA LTD	EQ 180MG BASE	A218603	001	Feb 27, 2024	Feb	NEWA
AB			EQ 360MG BASE	A218603	002	Feb 27, 2024	Feb	NEWA
AB		BIOCON PHARMA	EQ 180MG BASE	A217031	001	Nov 29, 2023	Jun	CAHN
AB			EQ 360MG BASE	A217031	002	Nov 29, 2023	Jun	CAHN
AB		NOVUGEN	EQ 180MG BASE	A216637	001	May 29, 2024	May	NEWA
AB			EQ 360MG BASE	A216637	002	May 29, 2024	May	NEWA
AB		SKG PHARMA	EQ 180MG BASE	A217031	001	Nov 29, 2023	Apr	CAHN
AB			EQ 360MG BASE	A217031	002	Nov 29, 2023	Apr	CAHN
AB		WANBANG BIOPHARMS	EQ 180MG BASE	A216637	001	May 29, 2024	Jun	CAHN
AB			EQ 360MG BASE	A216637	002	May 29, 2024	Jun	CAHN

NABILONE

CAPSULE;ORAL

CESAMET

+	@	BAUSCH	1MG	N018677	001	Dec 26, 1985	Aug	DISC
---	---	--------	-----	---------	-----	--------------	-----	------

NADOLOL

TABLET;ORAL

CORGARD

+	@	USWM	20MG	N018063	005	Oct 28, 1986	Aug	DISC
+	@		40MG	N018063	001		Aug	DISC
+	@		80MG	N018063	002		Aug	DISC

NADOLOL

AB	!	INVAGEN PHARMS	80MG	A203455	003	Dec 18, 2015	Aug	CHRS
----	---	----------------	------	---------	-----	--------------	-----	------

NAFTIFINE HYDROCHLORIDE

CREAM;TOPICAL

NAFTIN

>A>		+ @	LEGACY PHARMA	1%	N019599	001	Feb 29, 1988	Nov	CAHN
>A>	AB	+	!		N019599	002	Jan 13, 2012	Nov	CAHN
>D>		+ @	SEBELA IRELAND LTD	1%	N019599	001	Feb 29, 1988	Nov	CAHN
>D>	AB	+	!		N019599	002	Jan 13, 2012	Nov	CAHN

GEL;TOPICAL

NAFTIN

>A>	AB	+	!	LEGACY PHARMA	1%	N019356	001	Jun 18, 1990	Nov	CAHN
>A>	AB	+	!		2%	N204286	001	Jun 27, 2013	Nov	CAHN
>D>	AB	+	!	SEBELA IRELAND LTD	1%	N019356	001	Jun 18, 1990	Nov	CAHN
>D>	AB	+	!		2%	N204286	001	Jun 27, 2013	Nov	CAHN

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION							
NALBUPHINE HYDROCHLORIDE							
AP	SOMERSET THERAPS LLC	10MG/ML	A216049	001	Sep 19, 2024	Sep	NEWA
AP		10MG/ML	A216050	001	Sep 19, 2024	Sep	NEWA
AP		20MG/ML	A216049	002	Sep 19, 2024	Sep	NEWA
AP		20MG/ML	A216050	002	Sep 19, 2024	Sep	NEWA
NUBAIN							
+	@ ENDO OPERATIONS	10MG/ML	N018024	001		May	CAHN
+	@	20MG/ML	N018024	002	May 27, 1982	May	CAHN

NALMEFENE HYDROCHLORIDE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS								
NALMEFENE HYDROCHLORIDE								
!	CHENGDU SHUODE	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A216007	001	Nov 15, 2023	Jun	CMFD	
@		EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A216007	001	Nov 15, 2023	May	DISC	
AP		EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A216007	002	Nov 15, 2023	Jun	CMFD	
AP	@	EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A216007	002	Nov 15, 2023	May	DISC	
AP	!	PURDUE PHARMA LP	EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A212955	001	Feb 08, 2022	Jun	CTEC
!		EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A212955	001	Feb 08, 2022	May	CTEC	
SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS								
ZURNAI (AUTOINJECTOR)								
+	!	PURDUE PHARMA LP	EQ 1.5MG BASE/0.5ML (EQ 1.5MG BASE/0.5ML)	N218590	001	Aug 07, 2024	Aug	NEWA

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION								
NALOXONE HYDROCHLORIDE								
@	EUGIA PHARMA	0.4MG/ML	A212455	001	Oct 15, 2019	Jun	DISC	
AP	FRESENIUS KABI USA	0.4MG/ML	A213573	001	Apr 02, 2024	Mar	NEWA	
AP		1MG/ML	A213573	002	Apr 02, 2024	Mar	NEWA	
AP	HIKMA	0.4MG/ML	A212300	002	Mar 07, 2024	Mar	NEWA	
AP	MANKIND PHARMA	0.4MG/ML	A218404	001	Feb 29, 2024	Feb	NEWA	
SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS								
ZIMHI								
+	!	ZMI PHARMA	5MG/0.5ML (5MG/0.5ML)	N212854	001	Oct 15, 2021	May	CAHN
SPRAY; NASAL								
REZENOPY								
+	!	SUMMIT BIOSCI	10MG/SPRAY	N215487	001	Apr 19, 2024	Apr	NEWA
SPRAY, METERED; NASAL								
REXTOVY								
+	!	AMPHASTAR PHARMS INC	4MG/SPRAY	N208969	001	Mar 07, 2023	Apr	CMFD

NALTREXONE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR								
NALTREXONE								
@	TEVA PHARMS USA INC	380MG/VIAL	A213195	001	Jul 06, 2023	Jan	DISC	
VIVITROL								
+	!	ALKERMES	380MG/VIAL	N021897	001	Apr 13, 2006	Jan	CTEC

NAPROXEN

TABLET; ORAL							
NAPROXEN							
AB	ADAPTIS	250MG	A091416	001	Feb 14, 2011	Sep	CAHN
AB		375MG	A091416	002	Feb 14, 2011	Sep	CAHN
AB		500MG	A091416	003	Feb 14, 2011	Sep	CAHN
@	INVAGEN PHARMS	250MG	A091305	001	Aug 24, 2011	Mar	DISC
@		375MG	A091305	002	Aug 24, 2011	Mar	DISC
@		500MG	A091305	003	Aug 24, 2011	Mar	DISC
TABLET, DELAYED RELEASE; ORAL							
NAPROXEN							
AB	NOVITIUM PHARMA	375MG	A218497	001	Jun 12, 2024	May	NEWA
AB		500MG	A218497	002	Jun 12, 2024	May	NEWA
AB	TRUPHARMA	375MG	A216908	001	May 31, 2023	Sep	CAHN
AB		500MG	A216908	002	May 31, 2023	Sep	CAHN

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

@ SUN PHARM INDS LTD	EQ 2.5MG BASE	A091552	001	Feb 14, 2011	May	DISC
----------------------	---------------	---------	-----	--------------	-----	------

NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL

NEBIVOLOL HYDROCHLORIDE

>D>	@ AJANTA PHARMA LTD	EQ 2.5MG BASE	A213349	001	Mar 31, 2022	Nov	CAHN
>D>	@	EQ 5MG BASE	A213349	002	Mar 31, 2022	Nov	CAHN
>D>	@	EQ 10MG BASE	A213349	003	Mar 31, 2022	Nov	CAHN
>D>	@	EQ 20MG BASE	A213349	004	Mar 31, 2022	Nov	CAHN
	@ APOTEX	EQ 10MG BASE	A209741	001	Feb 27, 2024	May	DISC
AB	@	EQ 10MG BASE	A209741	001	Feb 27, 2024	Feb	NEWA
	@	EQ 20MG BASE	A209741	002	Feb 27, 2024	May	DISC
AB	@	EQ 20MG BASE	A209741	002	Feb 27, 2024	Feb	NEWA
>A>	@ CHARTWELL RX	EQ 2.5MG BASE	A213349	001	Mar 31, 2022	Nov	CAHN
>A>	@	EQ 5MG BASE	A213349	002	Mar 31, 2022	Nov	CAHN
>A>	@	EQ 10MG BASE	A213349	003	Mar 31, 2022	Nov	CAHN
>A>	@	EQ 20MG BASE	A213349	004	Mar 31, 2022	Nov	CAHN
AB	GLENMARK PHARMS LTD	EQ 2.5MG BASE	A203821	001	May 25, 2017	Jun	CMFD
AB		EQ 5MG BASE	A203821	002	May 25, 2017	Jun	CMFD
AB		EQ 10MG BASE	A203821	003	May 25, 2017	Jun	CMFD
AB		EQ 20MG BASE	A203821	004	May 25, 2017	Jun	CMFD
AB	MSN	EQ 2.5MG BASE	A217397	001	Oct 01, 2024	Sep	NEWA
AB		EQ 5MG BASE	A217397	002	Oct 01, 2024	Sep	NEWA
AB		EQ 10MG BASE	A217397	003	Oct 01, 2024	Sep	NEWA
AB		EQ 20MG BASE	A217397	004	Oct 01, 2024	Sep	NEWA
AB	UNICHEM	EQ 2.5MG BASE	A213830	001	Mar 15, 2022	Aug	CMFD
AB		EQ 5MG BASE	A213830	002	Mar 15, 2022	Aug	CMFD
AB		EQ 10MG BASE	A213830	003	Mar 15, 2022	Aug	CMFD
AB		EQ 20MG BASE	A213830	004	Mar 15, 2022	Aug	CMFD

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

@ CHARTWELL RX	50MG	A076302	001	Sep 16, 2003	Jun	CAHN
@	100MG	A076302	002	Sep 16, 2003	Jun	CAHN
@	150MG	A076302	003	Sep 16, 2003	Jun	CAHN
@	200MG	A076302	004	Sep 16, 2003	Jun	CAHN
@	250MG	A076302	005	Sep 16, 2003	Jun	CAHN

NELARABINE

INJECTABLE; INTRAVENOUS

NELARABINE

AP	ALEMBIC	250MG/50ML (5MG/ML)	A218554	001	Aug 01, 2024	Jul	NEWA
AP	MEITHEAL	250MG/50ML (5MG/ML)	A216038	001	Jan 10, 2023	Jun	CAHN
AP	MSN	250MG/50ML (5MG/ML)	A216948	001	Sep 13, 2024	Sep	NEWA
AP	XGEN PHARMS	250MG/50ML (5MG/ML)	A216510	001	Sep 05, 2024	Aug	NEWA

NEOMYCIN SULFATE

TABLET; ORAL

NEOMYCIN SULFATE

AA	ADRASTEIA PHARMA	500MG	A065220	001	Jul 28, 2006	Sep	CAHN
----	------------------	-------	---------	-----	--------------	-----	------

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

BLOXIVERZ

>D>	+ @ EXELA PHARMA	5MG/5ML (1MG/ML)	N204078	003	Oct 27, 2023	Nov	CMFD
>A>	+!	5MG/5ML (1MG/ML)	N204078	003	Oct 27, 2023	Nov	CMFD
	+ @	5MG/5ML (1MG/ML)	N204078	003	Oct 27, 2023	May	DISC

NEOSTIGMINE METHYLSULFATE

AP	ADAPTIS	5MG/10ML (0.5MG/ML)	A210652	001	Oct 01, 2021	Aug	CAHN
AP		10MG/10ML (1MG/ML)	A210652	002	Oct 01, 2021	Aug	CAHN
AP	ENDO OPERATIONS	5MG/10ML (0.5MG/ML)	A208405	001	Apr 26, 2017	Apr	CAHN
AP		10MG/10ML (1MG/ML)	A208405	002	Apr 26, 2017	Apr	CAHN
	@ EUGIA PHARMA	5MG/10ML (0.5MG/ML)	A213244	001	Nov 02, 2023	May	DISC
	@	10MG/10ML (1MG/ML)	A213244	002	Nov 02, 2023	May	DISC
AP	NIVAGEN PHARMS INC	5MG/10ML (0.5MG/ML)	A212627	001	Nov 03, 2022	Jan	CAHN
AP		10MG/10ML (1MG/ML)	A212627	002	Nov 03, 2022	Jan	CAHN
AP	UMEDICA	5MG/10ML (0.5MG/ML)	A212627	001	Nov 03, 2022	Aug	CAHN
AP		10MG/10ML (1MG/ML)	A212627	002	Nov 03, 2022	Aug	CAHN

NESIRITIDE

FOR SOLUTION; INTRAVENOUS
NATRECOR

+ @ SCIOS LLC 1.5MG/VIAL N020920 001 Aug 10, 2001 Mar CAIN

NEVIRAPINE

SUSPENSION; ORAL
NEVIRAPINE

AA ! AUROBINDO 50MG/5ML A077702 001 May 22, 2012 Jun CHRS

VIRAMUNE

+ @ BOEHRINGER INGELHEIM 50MG/5ML N020933 001 Sep 11, 1998 Jun DISC

TABLET; ORAL

NEVIRAPINE

@ NORVIUM BIOSCIENCE 200MG A078864 001 May 22, 2012 Jul CAHN

TABLET, EXTENDED RELEASE; ORAL

NEVIRAPINE

AB ! MACLEODS PHARMS LTD 400MG A206879 001 Oct 06, 2017 Jun CHRS

VIRAMUNE XR

+ @ BOEHRINGER INGELHEIM 100MG N201152 002 Nov 08, 2012 Jun DISC

+ @ 400MG N201152 001 Mar 25, 2011 Jun DISC

NIACIN

TABLET, EXTENDED RELEASE; ORAL

NIACIN

AB HIBROW HLTHCARE 500MG A213090 001 Aug 25, 2023 Jul CAHN

AB 750MG A213090 002 Aug 25, 2023 Jul CAHN

AB 1GM A213090 003 Aug 25, 2023 Jul CAHN

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

NICARDIPINE HYDROCHLORIDE

AB SKG PHARMA 20MG A218202 001 Apr 10, 2024 Mar NEWA

AB 30MG A218202 002 Apr 10, 2024 Mar NEWA

INJECTABLE; INJECTION

NICARDIPINE HYDROCHLORIDE

AP AMNEAL 25MG/10ML (2.5MG/ML) A215406 001 Oct 31, 2024 Oct NEWA

AP CHENGDU SHUODE 25MG/10ML (2.5MG/ML) A217548 001 Sep 06, 2024 Aug NEWA

AP RK PHARMA 25MG/10ML (2.5MG/ML) A090664 001 Nov 17, 2009 Feb CMFD

AP WOCHKHARDT 25MG/10ML (2.5MG/ML) A090671 001 Nov 17, 2009 Aug CMFD

INJECTABLE; INTRAVENOUS

CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER

AP +! CHIESI 40MG/200ML (0.2MG/ML) N019734 004 Nov 07, 2008 Apr CFTG

CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER

AP +! CHIESI 20MG/200ML (0.1MG/ML) N019734 003 Jul 31, 2008 Apr CFTG

NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE

AP INFORLIFE 40MG/200ML (0.2MG/ML) A203978 002 Apr 17, 2024 Apr NFTG

NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE

AP INFORLIFE 20MG/200ML (0.1MG/ML) A203978 001 Apr 17, 2024 Apr NFTG

NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

AP CIPLA 20MG/200ML (0.1MG/ML) A215592 001 Sep 24, 2024 Sep NFTG

AP 40MG/200ML (0.2MG/ML) A215592 002 Sep 24, 2024 Sep NFTG

AP +! HIKMA INTL PHARMS 20MG/200ML (0.1MG/ML) N022276 002 Apr 07, 2016 Sep CFTG

AP +! 40MG/200ML (0.2MG/ML) N022276 003 Apr 07, 2016 Sep CFTG

NICOTINE

INHALANT; ORAL

NICOTROL

+ @ PFIZER 4MG/CARTRIDGE N020714 001 May 02, 1997 Sep DISC

NIFEDIPINE

CAPSULE; ORAL

NIFEDIPINE

AB @ ACTAVIS ELIZABETH 20MG A072556 001 Sep 20, 1990 Aug DISC

AB VELZEN PHARMA PVT 10MG A073250 001 Oct 08, 1991 Aug CAHN

AB 20MG A074045 001 Apr 30, 1992 Aug CAHN

TABLET, EXTENDED RELEASE; ORAL

NIFEDIPINE

@ ENDO OPERATIONS 30MG A077899 001 Dec 13, 2006 May CAHN

@ 60MG A077899 002 Dec 13, 2006 May CAHN

@ 90MG A077899 003 May 25, 2012 May CAHN

TABLET, EXTENDED RELEASE;ORAL
NIFEDIPINE

@ SWISS PHARM	30MG	A216019	001	Nov 18, 2022	Jul CAHN
@	60MG	A216019	002	Nov 18, 2022	Jul CAHN

NILOTINIB HYDROCHLORIDE

CAPSULE;ORAL

NILOTINIB HYDROCHLORIDE

@ APOTEX	EQ 50MG BASE	A203640	001	Jan 05, 2024	Apr DISC
@	EQ 150MG BASE	A203640	002	Jan 05, 2024	Apr DISC
@	EQ 200MG BASE	A203640	003	Jan 05, 2024	Apr DISC

TASIGNA

+ NOVARTIS	EQ 50MG BASE	N022068	003	Mar 22, 2018	Apr CTEC
+	EQ 150MG BASE	N022068	002	Jun 17, 2010	Apr CTEC
+	EQ 200MG BASE	N022068	001	Oct 29, 2007	Apr CTEC

NILOTINIB TARTRATE

>A>	TABLET;ORAL					
>A>	DANZITEN					
>A>	+ AZURITY	EQ 71MG BASE	N219293	001	Nov 07, 2024	Nov NEWA
>A>	+	EQ 95MG BASE	N219293	002	Nov 07, 2024	Nov NEWA

NIMODIPINE

SOLUTION;ORAL
NIMODIPINE

>D>	ANNORA PHARMA	3MG/ML	A216937	001	Jul 09, 2024	Nov CHRS
>A>	!	3MG/ML	A216937	001	Jul 09, 2024	Nov CHRS
		3MG/ML	A216937	001	Jul 09, 2024	Jun NFTG

NIRAPARIB TOSYLATE

CAPSULE;ORAL
ZEJULA

+ @ GLAXOSMITHKLINE	EQ 100MG BASE	N208447	001	Mar 27, 2017	Feb DISC
---------------------	---------------	---------	-----	--------------	----------

NIRMATRELVIR; RITONAVIR

TABLET;ORAL
PAXLOVID (COPACKAGED)

+! PFIZER	150MG;100MG	N217188	001	May 25, 2023	Jul CHRS
-----------	-------------	---------	-----	--------------	----------

NIROGACESTAT HYDROBROMIDE

TABLET;ORAL
OGSIVEO

+ SPRINGWORKS	EQ 50MG BASE	N217677	001	Nov 27, 2023	Apr CHRS
+	EQ 100MG BASE	N217677	002	Apr 04, 2024	Apr NEWA
+	EQ 150MG BASE	N217677	003	Apr 04, 2024	Apr NEWA

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL
NISOLDIPINE

AB	@ AMTA	8.5MG	A216606	001	Apr 10, 2023	Sep DISC
		8.5MG	A216606	001	Apr 10, 2023	Jun CMFD

NITAZOXANIDE

FOR SUSPENSION;ORAL
ALINIA

+ @ ROMARK	100MG/5ML	N021498	001	Nov 22, 2002	Sep DISC
------------	-----------	---------	-----	--------------	----------

TABLET;ORAL
ALINIA

+ @ ROMARK	500MG	N021497	001	Jul 21, 2004	Sep DISC
------------	-------	---------	-----	--------------	----------

NITAZOXANIDE

AB	! RISING	500MG	A213820	001	Nov 27, 2020	Sep CTEC
	!	500MG	A213820	001	Nov 27, 2020	Sep CHRS

NITRIC OXIDE

GAS;INHALATION
INOMAX

+! MALLINCKRODT HOSP	4880PPM	N020845	004	Jan 17, 2023	May NEWA
----------------------	---------	---------	-----	--------------	----------

NOXIVENT

! LINDE GAS EQUIP	100PPM	A207141	001	Oct 02, 2018	May CHRS
-------------------	--------	---------	-----	--------------	----------

NITROFURANTOIN

SUSPENSION;ORAL
NITROFURANTOIN

>A>	AB	BIOCON PHARMA	25MG/5ML	A 218346	001	Oct 28, 2024	Nov CAHN
>D>	AB	CARNEGIE	25MG/5ML	A 218346	001	Oct 28, 2024	Nov CAHN
	AB		25MG/5ML	A 218346	001	Oct 28, 2024	Oct NEWA

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL
NITROFURANTOIN

		@ ACTAVIS LABS FL INC	25MG	A 091095	001	Jun 18, 2015	Feb DISC
		@	50MG	A 091095	002	Jun 18, 2015	Feb DISC
		@	100MG	A 091095	003	Jun 18, 2015	Feb DISC
AB		AUROBINDO PHARMA USA	25MG	A 077025	002	Oct 02, 2024	Sep NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

>D>	AB	MICRO LABS	75MG;25MG	A 217073	001	Nov 03, 2023	Nov CAHN
	AB		75MG;25MG	A 217073	001	Nov 03, 2023	Sep CAHN
>A>	AB	OMSAV PHARMA	75MG;25MG	A 217073	001	Nov 03, 2023	Nov CAHN

NITROGLYCERIN

OINTMENT;INTRA-ANAL
NITROGLYCERIN

>A>	AB	ACRUX DDS	0.4%	A 212222	001	Nov 29, 2024	Nov NEWA
	AB	COSETTE	0.4%	A 216103	001	Feb 16, 2024	Feb NFTG
		RECTIV					
	AB	+! ABBVIE	0.4%	N 021359	001	Jun 21, 2011	Feb CFTG
		TABLET;SUBLINGUAL NITROGLYCERIN					
	AB	VIWIT PHARM	0.3MG	A 218583	001	Oct 15, 2024	Oct NEWA
	AB		0.4MG	A 218583	002	Oct 15, 2024	Oct NEWA
	AB		0.6MG	A 218583	003	Oct 15, 2024	Oct NEWA

NIZATIDINE

CAPSULE;ORAL
NIZATIDINE

		@ NORVIUM BIOSCIENCE	150MG	A 075806	001	Jul 05, 2002	Aug CAHN
		@	300MG	A 075806	002	Jul 05, 2002	Aug CAHN

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION
NOREPINEPHRINE BITARTRATE

AP		DDREG PHARMA	EQ 1MG BASE/ML	A 218758	001	May 13, 2024	May NEWA
AP		RISING	EQ 1MG BASE/ML	A 218758	001	May 13, 2024	May CAHN
		@ SUN PHARM	EQ 1MG BASE/ML	A 211980	001	Jan 29, 2021	Oct DISC
		SOLUTION;INTRAVENOUS NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE					
	+!	LONG GROVE PHARMS	EQ 4MG BASE/250 ML (EQ 16MCG BASE/ML)	N 214628	001	Oct 06, 2022	Jan CMFD
	+!		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N 214628	002	Oct 06, 2022	Jan CMFD
	+!		EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N 214628	003	Oct 06, 2022	Jan CMFD

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL
NORTRIPTYLINE HYDROCHLORIDE

		@ RISING	EQ 10MG BASE	A 074234	001	Jul 26, 1993	Feb CAHN
		@	EQ 25MG BASE	A 074234	002	Jul 26, 1993	Feb CAHN
		@	EQ 50MG BASE	A 074234	003	Jul 26, 1993	Feb CAHN
		@	EQ 75MG BASE	A 074234	004	Jul 26, 1993	Feb CAHN

NYSTATIN

OINTMENT;TOPICAL
NYSTATIN

>D>		@ TORRENT	100,000 UNITS/GM	A 211838	001	Jan 28, 2019	Nov CMFD
>A>	AT		100,000 UNITS/GM	A 211838	001	Jan 28, 2019	Nov CMFD

		POWDER; TOPICAL							
		NYSTATIN							
AT		ADRASTEA PHARMA	100,000 UNITS/GM	A065175	001	Dec 17, 2004	Mar	CAHN	
		SUSPENSION; ORAL							
		NYSTATIN							
>D>	AA	! LEADING	100,000 UNITS/ML	A214346	001	Mar 10, 2022	Nov	CAHN	
	AA	!	100,000 UNITS/ML	A214346	001	Mar 10, 2022	Jul	CHRS	
>A>	AA	! MEDLEY PHARMS	100,000 UNITS/ML	A214346	001	Mar 10, 2022	Nov	CAHN	
		@ MLV	100,000 UNITS/ML	A062832	001	Dec 27, 1991	Sep	DISC	
		@ PAI HOLDINGS	100,000 UNITS/ML	A064042	001	Feb 28, 1994	Jul	CAHN	
AA		WOCKHARDT BIO AG	100,000 UNITS/ML	A062512	001	Oct 29, 1984	Jul	CHRS	
		TABLET; ORAL							
		NYSTATIN							
		@ SUN PHARM INDUSTRIES	500,000 UNITS	A062838	001	Dec 22, 1988	Aug	DISC	
		<u>NYSTATIN; TRIAMCINOLONE ACETONIDE</u>							
		CREAM; TOPICAL							
		MYKACET							
		@ COSETTE	100,000 UNITS/GM; 0.1%	A062367	001	May 28, 1985	Apr	DISC	
		OINTMENT; TOPICAL							
		MYKACET							
		@ COSETTE	100,000 UNITS/GM; 0.1%	A062733	001	Mar 06, 1987	Apr	DISC	
		<u>OCTREOTIDE ACETATE</u>							
		INJECTABLE; INJECTION							
		OCTREOTIDE ACETATE							
		@ SHUANGCHENG	EQ 0.1MG BASE/ML	A217860	001	May 02, 2024	Oct	DISC	
AP			EQ 0.1MG BASE/ML	A217860	001	May 02, 2024	Apr	NEWA	
AB		TEVA PHARMS USA INC	EQ 10MG BASE/VIAL	A210317	001	Dec 05, 2023	Jan	CTEC	
AB			EQ 20MG BASE/VIAL	A210317	002	Dec 05, 2023	Jan	CTEC	
AB			EQ 30MG BASE/VIAL	A210317	003	Dec 05, 2023	Jan	CTEC	
		SANDOSTATIN LAR							
AB	+	NOVARTIS	EQ 10MG BASE/VIAL	N021008	001	Nov 25, 1998	Jan	CTEC	
AB	+		EQ 20MG BASE/VIAL	N021008	002	Nov 25, 1998	Jan	CTEC	
AB	+		EQ 30MG BASE/VIAL	N021008	003	Nov 25, 1998	Jan	CTEC	
		SOLUTION; SUBCUTANEOUS							
		BYNFEZIA PEN							
>D>	+	SUN PHARM	7MG/2.8ML (2.5MG/ML)	N213224	001	Sep 27, 2024	Nov	CPOT	
>A>	+		EQ 7MG BASE/2.8ML (EQ 2.5MG BASE/ML)	N213224	001	Sep 27, 2024	Nov	CPOT	
	+		7MG/2.8ML (2.5MG/ML)	N213224	001	Sep 27, 2024	Sep	NEWA	
		<u>ODEVIXIBAT</u>							
		CAPSULE; ORAL							
		BYLVAY							
	+	IPSEN	0.4MG	N215498	002	Jul 20, 2021	Jan	CAHN	
	+		1.2MG	N215498	004	Jul 20, 2021	Jan	CAHN	
		CAPSULE, PELLETS; ORAL							
		BYLVAY							
	+	IPSEN	0.2MG	N215498	001	Jul 20, 2021	Jan	CAHN	
	+		0.6MG	N215498	003	Jul 20, 2021	Jan	CAHN	
		<u>OFLOXACIN</u>							
		SOLUTION/DROPS; OPHTHALMIC							
		OFLOXACIN							
AT		AMNEAL	0.3%	A211524	001	Mar 01, 2024	Feb	NEWA	
AT		CAPLIN	0.3%	A217904	001	Apr 12, 2024	Apr	NEWA	
AT		SOMERSET	0.3%	A213597	001	Aug 01, 2024	Jul	NEWA	
		SOLUTION/DROPS; OTIC							
		OFLOXACIN							
		@ HIKMA	0.3%	A076616	001	Mar 17, 2008	Mar	DISC	
AT		SOMERSET THERAPS LLC	0.3%	A216328	001	Oct 15, 2024	Oct	NEWA	
		TABLET; ORAL							
		OFLOXACIN							
		@ CHARTWELL RX	200MG	A076093	001	Sep 02, 2003	Sep	CAHN	
		@	300MG	A076093	002	Sep 02, 2003	Sep	CAHN	
AB			400MG	A076093	003	Sep 02, 2003	Sep	CAHN	

OLANZAPINE

TABLET; ORAL

OLANZAPINE

@	NATCO PHARMA	2.5MG	A076866	001	Apr 23, 2012	Aug	CAHN
@		5MG	A076866	002	Apr 23, 2012	Aug	CAHN
@		7.5MG	A076866	003	Apr 23, 2012	Aug	CAHN
@		10MG	A076866	004	Apr 23, 2012	Aug	CAHN
@		15MG	A076866	005	Apr 23, 2012	Aug	CAHN
@		20MG	A076866	006	Apr 23, 2012	Aug	CAHN
@	SUN PHARM INDS	2.5MG	A091038	001	Apr 23, 2012	May	DISC
@		5MG	A091038	002	Apr 23, 2012	May	DISC
@		7.5MG	A091038	003	Apr 23, 2012	May	DISC
@		10MG	A091038	004	Apr 23, 2012	May	DISC
@		15MG	A091038	005	Apr 23, 2012	May	DISC
@		20MG	A091038	006	Apr 23, 2012	May	DISC

TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

@	SUN PHARM INDS	5MG	A090881	001	Feb 28, 2012	May	DISC
@		10MG	A090881	002	Feb 28, 2012	May	DISC
@		15MG	A090881	003	Feb 28, 2012	May	DISC
@		20MG	A090881	004	Feb 28, 2012	May	DISC

OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL

AB	BRECKENRIDGE	5MG	A206227	001	Jan 25, 2024	Jan	NEWA	
AB		20MG	A206227	002	Jan 25, 2024	Jan	NEWA	
AB		40MG	A206227	003	Jan 25, 2024	Jan	NEWA	
>A>	AB	CADILA PHARMS LTD	5MG	A210682	001	Nov 08, 2024	Nov	NEWA
>A>	AB		20MG	A210682	002	Nov 08, 2024	Nov	NEWA
>A>	AB		40MG	A210682	003	Nov 08, 2024	Nov	NEWA
AB	CHARTWELL RX	5MG	A206227	001	Jan 25, 2024	Mar	CAHN	
AB		20MG	A206227	002	Jan 25, 2024	Mar	CAHN	
AB		40MG	A206227	003	Jan 25, 2024	Mar	CAHN	
AB	HETERO LABS LTD V	5MG	A205499	001	Oct 31, 2024	Oct	NEWA	
AB		20MG	A205499	002	Oct 31, 2024	Oct	NEWA	
AB		40MG	A205499	003	Oct 31, 2024	Oct	NEWA	
AB	INVENTIA	5MG	A208659	001	May 18, 2020	May	CMFD	
AB		20MG	A208659	002	May 18, 2020	May	CMFD	
AB		40MG	A208659	003	May 18, 2020	May	CMFD	

OLOPATADINE HYDROCHLORIDE

SPRAY, METERED; NASAL

OLOPATADINE HYDROCHLORIDE

@	HIKMA	0.665MG/SPRAY	A213757	001	Aug 19, 2020	Mar	DISC
---	-------	---------------	---------	-----	--------------	-----	------

OMACETAXINE MEPESUCCINATE

POWDER; SUBCUTANEOUS

SYNRIBO

+	@	TEVA PHARMS INTL	3.5MG/VIAL	N203585	001	Oct 26, 2012	Jun	DISC
---	---	------------------	------------	---------	-----	--------------	-----	------

OMEGA-3-ACID ETHYL ESTERS

CAPSULE; ORAL

OMEGA-3-ACID ETHYL ESTERS

AB	CHARTWELL	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A206455	001	Aug 07, 2019	Mar	CAHN
AB	WILSHIRE PHARMS INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A211345	001	Dec 07, 2023	Jul	CAHN

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE; ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AB	!	AJANTA PHARMA LTD	40MG;1.1GM	A204228	002	Jul 15, 2016	Mar	CHRS	
		ZEGERID							
	+	@	SALIX	20MG;1.1GM	N021849	001	Feb 27, 2006	Mar	DISC
	+	@		40MG;1.1GM	N021849	002	Feb 27, 2006	Mar	DISC

FOR SUSPENSION; ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AB	!	AJANTA PHARMA LTD	40MG/PACKET;1.68GM/PACKET	A205545	002	Jul 27, 2016	Mar	CHRS
----	---	-------------------	---------------------------	---------	-----	--------------	-----	------

FOR SUSPENSION;ORAL

ZEGERID

+ @	SALIX	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Mar	DISC
+ @		40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Mar	DISC

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

@	MYLAN	4MG	A078139	001	Jun 25, 2007	Jun	DISC
@		8MG	A078139	002	Jun 25, 2007	Jun	DISC
@	SUN PHARM INDS LTD	4MG	A078602	001	Feb 24, 2011	Jan	DISC
@		8MG	A078602	002	Feb 24, 2011	Jan	DISC

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

@	ACCORD HLTHCARE	EQ 2MG BASE/ML	A206845	001	Mar 10, 2016	May	DISC
---	-----------------	----------------	---------	-----	--------------	-----	------

SOLUTION;ORAL

ONDANSETRON HYDROCHLORIDE

@	PHARM ASSOC	EQ 4MG BASE/5ML	A078127	001	Jun 25, 2007	Feb	DISC
@	TARO	EQ 4MG BASE/5ML	A077009	001	Nov 30, 2007	May	DISC

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

@	CHARTWELL RX	EQ 4MG BASE	A077517	001	Jun 25, 2007	Jun	CAHN
@		EQ 8MG BASE	A077517	002	Jun 25, 2007	Jun	CAHN
@		EQ 24MG BASE	A077517	003	Jun 25, 2007	Jun	CAHN
>D> AB	SUN PHARM INDS (IN)	EQ 4MG BASE	A077050	001	Jun 25, 2007	Nov	DISC
>A>	@	EQ 4MG BASE	A077050	001	Jun 25, 2007	Nov	DISC
>D> AB		EQ 8MG BASE	A077050	002	Jun 25, 2007	Nov	DISC
>A>	@	EQ 8MG BASE	A077050	002	Jun 25, 2007	Nov	DISC

OPICAPONE

CAPSULE;ORAL

ONGENTYS

+	AMNEAL	25MG	N212489	001	Apr 24, 2020	Apr	CAHN
+	!	50MG	N212489	002	Apr 24, 2020	Apr	CAHN

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE;ORAL

ORPHENADRINE CITRATE

>D> AB	BAYSHORE PHARMS LLC	100MG	A091158	001	Jul 27, 2012	Nov	CAHN
	@ STEVENS J	100MG	A040368	001	Jun 23, 2000	Jun	CAHN
>A> AB	UNICHEM	100MG	A091158	001	Jul 27, 2012	Nov	CAHN

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

>A> AB	CEDIPROF INC	EQ 30MG BASE	A217451	001	Dec 03, 2024	Nov	NEWA
>A> AB		EQ 45MG BASE	A217451	002	Dec 03, 2024	Nov	NEWA
>A> AB		EQ 75MG BASE	A217451	003	Dec 03, 2024	Nov	NEWA
AB	LAURUS	EQ 30MG BASE	A218565	001	May 01, 2024	Apr	NEWA
AB		EQ 45MG BASE	A218565	002	May 01, 2024	Apr	NEWA
AB		EQ 75MG BASE	A218565	003	May 01, 2024	Apr	NEWA
AB	NANJING DAOQUN	EQ 30MG BASE	A217133	001	Oct 30, 2024	Oct	NEWA
AB		EQ 75MG BASE	A217133	002	Oct 30, 2024	Oct	NEWA

FOR SUSPENSION;ORAL

OSELTAMIVIR PHOSPHATE

AB	AUROBINDO PHARMA LTD	EQ 6MG BASE/ML	A218131	001	May 10, 2024	May	NEWA
AB	INVAGEN PHARMS	EQ 6MG BASE/ML	A212858	001	Aug 30, 2021	Sep	CAHN
	@ LEADING	EQ 6MG BASE/ML	A214949	001	Feb 28, 2022	Aug	CAHN
AB	ORYZA	EQ 6MG BASE/ML	A217303	001	Jul 02, 2024	Jun	NEWA

OSPEMIFENE

TABLET;ORAL

OSPEMIFENE

AB	HETERO LABS LTD V	60MG	A215574	001	Feb 13, 2024	Feb	NFTG
AB	OSPHERA						
AB	+! DUCHESNAY	60MG	N203505	001	Feb 26, 2013	Feb	CFTG

OXACILLIN SODIUM

INJECTABLE; INJECTION
OXACILLIN SODIUM

AP	!	FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A206198	001	Jul 20, 2020	Oct	CHRS
AP	!		EQ 2GM BASE/VIAL	A206198	002	Jul 20, 2020	Oct	CHRS
	@	SAGENT PHARMS	EQ 1GM BASE/VIAL	A091246	001	Mar 30, 2012	Oct	DISC
	@		EQ 2GM BASE/VIAL	A091246	002	Mar 30, 2012	Oct	DISC
	@	STERISCIENCE SPECPLTS	EQ 1GM BASE/VIAL	A091486	001	Aug 25, 2014	Aug	CAHN
AP			EQ 2GM BASE/VIAL	A091486	002	Aug 25, 2014	Aug	CAHN

OXALIPLATIN

INJECTABLE; INTRAVENOUS
ELOXATIN

	+	@ SANOFI AVENTIS US	50MG/10ML (5MG/ML)	N021759	001	Jan 31, 2005	Jun	DISC
	+	@	100MG/20ML (5MG/ML)	N021759	002	Jan 31, 2005	Jun	DISC

OXALIPLATIN

	@	ACTAVIS TOTOWA	50MG/VIAL	A078803	001	Aug 08, 2012	Sep	DISC
	@		100MG/VIAL	A078803	002	Aug 08, 2012	Sep	DISC
>D>	AP	EUGIA PHARMA	50MG/10ML (5MG/ML)	A205529	001	Sep 06, 2017	Nov	DISC
>A>		@	50MG/10ML (5MG/ML)	A205529	001	Sep 06, 2017	Nov	DISC
>D>	AP		100MG/20ML (5MG/ML)	A205529	002	Sep 06, 2017	Nov	DISC
>A>		@	100MG/20ML (5MG/ML)	A205529	002	Sep 06, 2017	Nov	DISC
AP	!	GLAND	50MG/10ML (5MG/ML)	A207325	001	Feb 10, 2017	Jun	CHRS
AP	!		100MG/20ML (5MG/ML)	A207325	002	Feb 10, 2017	Jun	CHRS
AP		KINDOS	50MG/10ML (5MG/ML)	A217348	001	Jan 11, 2024	Jan	NEWA
AP			100MG/20ML (5MG/ML)	A217348	002	Jan 11, 2024	Jan	NEWA
AP		MEITHEAL	50MG/10ML (5MG/ML)	A217348	001	Jan 11, 2024	Jun	CAHN
AP			100MG/20ML (5MG/ML)	A217348	002	Jan 11, 2024	Jun	CAHN
	@	NORVIUM BIOSCIENCE	50MG/VIAL	A200979	001	Aug 08, 2012	Jul	CAHN
	@		100MG/VIAL	A200979	002	Aug 08, 2012	Jul	CAHN

OXAPROZIN

TABLET; ORAL
OXAPROZIN

>D>	AB	ABRAXEOLUS	600MG	A075845	001	Jan 31, 2001	Nov	CAHN
	AB		600MG	A075845	001	Jan 31, 2001	Sep	CAHN
>A>	AB	PANGEA	600MG	A075845	001	Jan 31, 2001	Nov	CAHN
	AB		600MG	A075845	001	Jan 31, 2001	Jun	CAHN
		@ TEVA	600MG	A075849	001	Jul 03, 2002	Jan	DISC

OXAZEPAM

CAPSULE; ORAL
OXAZEPAM

AB		TRUPHARMA	10MG	A071026	002	Aug 10, 1987	Sep	CAHN
AB			15MG	A071026	003	Aug 10, 1987	Sep	CAHN
AB			30MG	A071026	001	Aug 10, 1987	Sep	CAHN

OXCARBAZEPINE

SUSPENSION; ORAL
OXCARBAZEPINE

AB		ALKEM LABS LTD	300MG/5ML	A213183	001	Mar 18, 2023	Mar	NEWA
AB		BIOCON PHARMA	300MG/5ML	A218278	001	Mar 01, 2024	Apr	CAHN
AB		CARNEGIE	300MG/5ML	A218278	001	Mar 01, 2024	Feb	NEWA
AB		KANCHAN HLTHCARE	300MG/5ML	A217782	001	Feb 14, 2024	Sep	CAHN
AB		MEDLEY PHARMS	300MG/5ML	A217782	001	Feb 14, 2024	Feb	NEWA
AB		RISING	300MG/5ML	A218278	001	Mar 01, 2024	Mar	CAHN

TABLET; ORAL

OXCARBAZEPINE

AB		ANI PHARMS	150MG	A078005	001	Dec 11, 2007	Jul	CMFD
AB			300MG	A078005	002	Dec 11, 2007	Jul	CMFD
AB			600MG	A078005	003	Dec 11, 2007	Jul	CMFD
AB		RUBICON	150MG	A207717	001	Mar 05, 2024	Feb	NEWA
AB			300MG	A207717	002	Mar 05, 2024	Feb	NEWA
AB			600MG	A207717	003	Mar 05, 2024	Feb	NEWA
	@	ZYDUS	150MG	A211747	001	Jul 03, 2023	Jan	DISC
	@		300MG	A211747	002	Jul 03, 2023	Jan	DISC
	@		600MG	A211747	003	Jul 03, 2023	Jan	DISC

TABLET, EXTENDED RELEASE; ORAL

OXCARBAZEPINE

	@	AJANTA PHARMA LTD	150MG	A217659	001	Feb 22, 2024	Aug	DISC
AB			150MG	A217659	001	Feb 22, 2024	Feb	NEWA
	@		300MG	A217659	002	Feb 22, 2024	Aug	DISC

TABLET, EXTENDED RELEASE;ORAL

OXCARBAZEPINE

AB		300MG	A217659	002	Feb 22, 2024	Feb	NEWA
	@	600MG	A217659	003	Feb 22, 2024	Aug	DISC
AB		600MG	A217659	003	Feb 22, 2024	Feb	NEWA
AB	APOTEX	150MG	A213369	001	Jul 13, 2023	Aug	CMFD
AB		300MG	A213369	002	Jul 13, 2023	Aug	CMFD
AB		600MG	A213369	003	Jul 13, 2023	Aug	CMFD
>A>	AB	RICONPHARMA LLC	A215796	001	Nov 22, 2024	Nov	NEWA
>A>	AB		A215796	002	Nov 22, 2024	Nov	NEWA
>A>	AB		A215796	003	Nov 22, 2024	Nov	NEWA
AB	+ SUPERNUS PHARMS	150MG	N202810	001	Oct 19, 2012	Feb	CTEC
AB	+	300MG	N202810	002	Oct 19, 2012	Feb	CTEC
AB	+!	600MG	N202810	003	Oct 19, 2012	Feb	CTEC

OXYBUTYNIN CHLORIDE

SYRUP;ORAL

OXYBUTYNIN CHLORIDE

@ PHARM ASSOC

5MG/5ML

A075137 001 Dec 18, 1998 Feb DISC

TABLET;ORAL

OXYBUTYNIN CHLORIDE

@ EYWA

5MG

A211062 001 Feb 06, 2019 Mar DISC

@ HIBROW HLTHCARE

5MG

A211062 001 Feb 06, 2019 Jul CAHN

AB TRUPHARMA

5MG

A210125 001 Sep 06, 2018 Sep CAHN

OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

@ HIKMA

5MG/5ML

A208817 001 Aug 10, 2017 Mar DISC

@

100MG/5ML

A208795 001 Aug 07, 2017 Mar DISC

+ @ VISTAPHARM LLC

5MG/5ML

N201194 001 Jan 12, 2012 Apr CAHN

@ XTTRIUM LABS INC

5MG/5ML

A206456 001 Jun 16, 2015 Mar CAHN

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

AB STRIDES PHARMA

5MG

A077712 003 Mar 02, 2009 Aug CMFD

AB

10MG

A077712 004 Apr 13, 2015 Aug CMFD

AB

15MG

A077712 001 Jan 31, 2007 Aug CMFD

AB

20MG

A077712 005 Apr 13, 2015 Aug CMFD

AB

30MG

A077712 002 Jan 31, 2007 Aug CMFD

@ SUN PHARM INDS INC

5MG

A090659 001 Apr 10, 2009 Jun DISC

@

10MG

A090659 005 Nov 06, 2012 Jun DISC

@

15MG

A090659 002 Apr 10, 2009 Jun DISC

@

20MG

A090659 004 Nov 06, 2012 Jun DISC

@

30MG

A090659 003 Apr 10, 2009 Jun DISC

ROXYBOND

PROTEGA PHARMS

10MG

N209777 004 Sep 05, 2024 Sep NEWA

OXYMETHOLONE

TABLET;ORAL

ANADROL-50

+ @ NORVIUM BIOSCIENCE 50MG

N016848 001 Jun CAHN

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

OPANA ER

+ @ ENDO OPERATIONS 5MG

N021610 001 Jun 22, 2006 May CAHN

+ @ 7.5MG

N021610 005 Feb 29, 2008 May CAHN

+ @ 10MG

N021610 002 Jun 22, 2006 May CAHN

+ @ 15MG

N021610 006 Feb 29, 2008 May CAHN

+ @ 20MG

N021610 003 Jun 22, 2006 May CAHN

+ @ 30MG

N021610 007 Feb 29, 2008 May CAHN

+ @ 40MG

N021610 004 Jun 22, 2006 May CAHN

OZANIMOD HYDROCHLORIDE

CAPSULE;ORAL

ZEPOSIA

+ BRISTOL EQ 0.23MG BASE

N209899 001 Mar 25, 2020 Jan CAHN

+ EQ 0.46MG BASE

N209899 002 Mar 25, 2020 Jan CAHN

+! EQ 0.92MG BASE

N209899 003 Mar 25, 2020 Jan CAHN

OZENOXACIN

CREAM; TOPICAL
XEPT

+ @ FERRER INTERNACIONAL 1% N208945 001 Dec 11, 2017 Oct DISC

PACLITAXEL

POWDER; INTRAVENOUS
ABRAXANE

AB +! BRISTOL-MYERS 100MG/VIAL N021660 001 Jan 07, 2005 Jan CTEC

PACLITAXEL

AB +! AM REGENT 100MG/VIAL N211875 001 Jul 27, 2022 Apr CTEC

AB HENGRUI PHARMA 100MG/VIAL A212700 001 Oct 08, 2024 Sep NEWA

AB +! TEVA PHARMS INC 100MG/VIAL N216338 001 May 11, 2023 Jan CMFD

PACRITINIB CITRATE

CAPSULE; ORAL
VONJO

>D> +! CTI BIOPHARMA CORP EQ 100MG BASE N208712 001 Feb 28, 2022 Nov CAHN

>A> +! SOBI EQ 100MG BASE N208712 001 Feb 28, 2022 Nov CAHN

PALBOCICLIB

TABLET; ORAL
IBRANCE

>D> AB + PFIZER 75MG N212436 001 Nov 01, 2019 Nov CTEC

>A> + 75MG N212436 001 Nov 01, 2019 Nov CTEC

AB + 75MG N212436 001 Nov 01, 2019 May CFTG

+ 75MG N212436 001 Nov 01, 2019 Jan CTEC

>D> AB + 100MG N212436 002 Nov 01, 2019 Nov CTEC

>A> + 100MG N212436 002 Nov 01, 2019 Nov CTEC

AB + 100MG N212436 002 Nov 01, 2019 May CFTG

+ 100MG N212436 002 Nov 01, 2019 Jan CTEC

>D> AB +! 125MG N212436 003 Nov 01, 2019 Nov CTEC

>A> +! 125MG N212436 003 Nov 01, 2019 Nov CTEC

AB +! 125MG N212436 003 Nov 01, 2019 May CFTG

+! 125MG N212436 003 Nov 01, 2019 Jan CTEC

>D> PALBOCICLIB

>D> AB SYNTHON PHARMS INC 75MG A215570 001 Jun 05, 2024 Nov DISC

>A> @ 75MG A215570 001 Jun 05, 2024 Nov DISC

AB 75MG A215570 001 Jun 05, 2024 May NFTG

>D> AB 100MG A215570 002 Jun 05, 2024 Nov DISC

>A> @ 100MG A215570 002 Jun 05, 2024 Nov DISC

AB 100MG A215570 002 Jun 05, 2024 May NFTG

>D> AB 125MG A215570 003 Jun 05, 2024 Nov DISC

>A> @ 125MG A215570 003 Jun 05, 2024 Nov DISC

AB 125MG A215570 003 Jun 05, 2024 May NFTG

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL
PALIPERIDONE

@ ACTAVIS LABS FL INC 1.5MG A202645 001 Aug 03, 2015 Jul DISC

@ 3MG A202645 002 Aug 03, 2015 Jul DISC

@ 6MG A202645 003 Aug 03, 2015 Jul DISC

@ 9MG A202645 004 Aug 03, 2015 Jul DISC

AB AJANTA PHARMA LTD 1.5MG A218514 001 Jun 26, 2024 Jun NEWA

AB 3MG A218514 002 Jun 26, 2024 Jun NEWA

AB 6MG A218514 003 Jun 26, 2024 Jun NEWA

AB 9MG A218514 004 Jun 26, 2024 Jun NEWA

AB ALEMBIC 1.5MG A218330 001 Sep 26, 2024 Sep NEWA

AB 3MG A218330 002 Sep 26, 2024 Sep NEWA

AB 6MG A218330 003 Sep 26, 2024 Sep NEWA

AB 9MG A218330 004 Sep 26, 2024 Sep NEWA

BX LUPIN LTD 1.5MG A208643 001 Jun 29, 2022 Jun CTEC

BX 3MG A208643 002 Jun 29, 2022 Jun CTEC

BX 6MG A208643 003 Jun 29, 2022 Jun CTEC

BX 9MG A208643 004 Jun 29, 2022 Jun CTEC

AB ZYDUS PHARMS 1.5MG A217445 001 Oct 08, 2024 Sep NEWA

AB 3MG A217445 002 Oct 08, 2024 Sep NEWA

AB 6MG A217445 003 Oct 08, 2024 Sep NEWA

AB 9MG A217445 004 Oct 08, 2024 Sep NEWA

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

ERZOFRI

+!	LUYE INNOMIND PHARMA	39MG/0.25ML (39MG/0.25ML)	N216352	001	Jul 26, 2024	Aug	CHRS
+		39MG/0.25ML (39MG/0.25ML)	N216352	001	Jul 26, 2024	Jul	NEWA
+!		78MG/0.5ML (78MG/0.5ML)	N216352	002	Jul 26, 2024	Aug	CHRS
+		78MG/0.5ML (78MG/0.5ML)	N216352	002	Jul 26, 2024	Jul	NEWA
+!		117MG/0.75ML (117MG/0.75ML)	N216352	003	Jul 26, 2024	Aug	CHRS
+		117MG/0.75ML (117MG/0.75ML)	N216352	003	Jul 26, 2024	Jul	NEWA
+!		156MG/ML (156MG/ML)	N216352	004	Jul 26, 2024	Aug	CHRS
+		156MG/ML (156MG/ML)	N216352	004	Jul 26, 2024	Jul	NEWA
+!		234MG/1.5ML (156MG/ML)	N216352	005	Jul 26, 2024	Aug	CHRS
+		234MG/1.5ML (156MG/ML)	N216352	005	Jul 26, 2024	Jul	NEWA
+!		351MG/2.25ML (156MG/ML)	N216352	006	Jul 26, 2024	Jul	NEWA

INVEGA SUSTENNA

AB	+	JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009	May	CTEC
AB	+		78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009	May	CTEC
AB	+		117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	May	CTEC
AB	+!		156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009	May	CTEC
AB	+		234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009	May	CTEC

INVEGA TRINZA

+!	JANSSEN PHARMS	273MG/0.875ML (273MG/0.875ML)	N207946	001	May 18, 2015	Aug	CHRS
+!		410MG/1.315ML (311.79MG/ML)	N207946	002	May 18, 2015	Aug	CHRS
+!		546MG/1.75ML (312MG/ML)	N207946	003	May 18, 2015	Aug	CHRS

PALIPERIDONE PALMITATE

AB		TEVA PHARMS USA	39MG/0.25ML (39MG/0.25ML)	A211149	001	Jul 06, 2021	May	CMFD
AB			78MG/0.5ML (78MG/0.5ML)	A211149	002	Jul 06, 2021	May	CMFD
AB			117MG/0.75ML (117MG/0.75ML)	A211149	003	Jul 06, 2021	May	CMFD
AB			156MG/ML (156MG/ML)	A211149	004	Jul 06, 2021	May	CMFD
AB			234MG/1.5ML (156MG/ML)	A211149	005	Jul 06, 2021	May	CMFD

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

AP		MEITHEAL	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A215861	001	Aug 14, 2023	Jun	CAHN
			SOLUTION; INTRAVENOUS					
			POSFREA					
+	@	AVYXA HOLDINGS	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050	001	Mar 01, 2016	Aug	CTNA
+	@		EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050	001	Mar 01, 2016	Aug	CRLD
	@		EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050	001	Mar 01, 2016	Apr	CAHN
+	!		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002	Mar 01, 2016	Aug	CTNA
+	!		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002	Mar 01, 2016	Aug	CMFD
	@		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002	Mar 01, 2016	Apr	CAHN

PALOPEGTERIPARATIDE

SOLUTION; SUBCUTANEOUS

YORVIPATH

+!	ASCENDIS PHARMA BONE	EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML)	N216490	001	Aug 09, 2024	Aug	NEWA
+		EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML)	N216490	002	Aug 09, 2024	Aug	NEWA
+		EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML)	N216490	003	Aug 09, 2024	Aug	NEWA

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

PANCURONIUM BROMIDE

!	DR REDDYS	1MG/ML	A072759	001	Jul 31, 1990	May	CTEC
@	HOSPIRA	1MG/ML	A072320	001	Jan 19, 1989	May	DISC

PANTOPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS

PANTOPRAZOLE SODIUM

AP		HANGZHOU ZHONGMEI	EQ 40MG BASE/VIAL	A209524	001	Aug 30, 2021	Mar	CAHN
	@	SUN PHARM	EQ 40MG BASE/VIAL	A077674	001	Aug 19, 2019	Feb	DISC

POWDER; INTRAVENOUS
PANTOPRAZOLE SODIUM

AP	FRESENIUS KABI USA	EQ 40MG BASE/VIAL	A216021	001	Aug 01, 2024	Jul	NEWA
AP	+! HIKMA	EQ 40MG BASE/VIAL	N209463	001	Jun 30, 2017	Jul	CFTG

SOLUTION; INTRAVENOUS
PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE

+!	BAXTER HLTHCARE CORP	EQ 40MG BASE/100ML (EQ 0.4MG BASE/ML)	N217512	001	Feb 14, 2024	Feb	NEWA
+!		EQ 40MG BASE/50ML (EQ 0.8MG BASE/ML)	N217512	002	Feb 14, 2024	Feb	NEWA
+!		EQ 80MG BASE/100ML (EQ 0.8MG BASE/ML)	N217512	003	Feb 14, 2024	Feb	NEWA

TABLET, DELAYED RELEASE; ORAL
PANTOPRAZOLE SODIUM

	@ MANKIND PHARMA	EQ 20MG BASE	A215880	002	Apr 25, 2024	Oct	DISC
AB		EQ 20MG BASE	A215880	002	Apr 25, 2024	Apr	NEWA

PARICALCITOL

SOLUTION; INTRAVENOUS
PARICALCITOL

	@ HOSPIRA	0.002MG/ML (0.002MG/ML)	N201657	001	Oct 21, 2014	May	DISC
	@	0.005MG/ML (0.005MG/ML)	N201657	002	Oct 21, 2014	May	DISC
	@	0.01MG/2ML (0.005MG/ML)	N201657	003	Oct 21, 2014	May	DISC

PAROXETINE HYDROCHLORIDE

SUSPENSION; ORAL
PAROXETINE HYDROCHLORIDE

>D>	AB	NOVITIUM PHARMA	EQ 10MG BASE/5ML	A215003	001	Sep 03, 2021	Nov	CTEC
>A>		!	EQ 10MG BASE/5ML	A215003	001	Sep 03, 2021	Nov	CHRS
>A>			EQ 10MG BASE/5ML	A215003	001	Sep 03, 2021	Nov	CTEC
		PAXIL						
>D>	AB	+! APOTEX	EQ 10MG BASE/5ML	N020710	001	Jun 25, 1997	Nov	DISC
>A>		+ @	EQ 10MG BASE/5ML	N020710	001	Jun 25, 1997	Nov	DISC

PAROXETINE MESYLATE

CAPSULE; ORAL
BRISDELLE

>A>	AB	+! LEGACY PHARMA	EQ 7.5MG BASE	N204516	001	Jun 28, 2013	Nov	CAHN
>D>	AB	+! SEBELA IRELAND LTD	EQ 7.5MG BASE	N204516	001	Jun 28, 2013	Nov	CAHN

PATIROMER SORBITE CALCIUM

POWDER; ORAL
VELTASSA

+	VIFOR PHARMA	EQ 1GM BASE/PACKET	N205739	004	Oct 02, 2023	Aug	CMFD
+	@	EQ 1GM BASE/PACKET	N205739	004	Oct 02, 2023	Feb	DISC
+!		EQ 16.8GM BASE/PACKET	N205739	002	Oct 21, 2015	Jul	CHRS
+	@	EQ 25.2GM BASE/PACKET	N205739	003	Oct 21, 2015	Jul	DISC

PAZOPANIB HYDROCHLORIDE

TABLET; ORAL
PAZOPANIB HYDROCHLORIDE

>A>	AB	EUGIA PHARMA	EQ 200MG BASE	A219034	001	Dec 04, 2024	Nov	NEWA
AB		NOVUGEN	EQ 200MG BASE	A218231	001	Apr 23, 2024	Apr	NEWA

PEGULICIANINE ACETATE

POWDER; INTRAVENOUS
LUMISIGHT

+!	LUMICELL	EQ 40MG BASE/VIAL	N214511	001	Apr 17, 2024	Apr	NEWA
----	----------	-------------------	---------	-----	--------------	-----	------

PEMETREXED DISODIUM

POWDER; INTRAVENOUS
PEMETREXED DISODIUM

AP	HETERO LABS LTD VI	EQ 100MG BASE/VIAL	A215460	001	Jun 14, 2024	Jun	NEWA
AP		EQ 500MG BASE/VIAL	A215460	002	Jun 14, 2024	Jun	NEWA
AP	RELIANCE LIFE	EQ 100MG BASE/VIAL	A211899	001	May 25, 2022	Jun	CAHN
AP		EQ 500MG BASE/VIAL	A211899	002	May 25, 2022	Jun	CAHN

<u>PENBUTOLOL SULFATE</u>									
TABLET; ORAL									
LEVATOL									
	+	@	ENDO OPERATIONS	10MG	N018976	001	Dec 30, 1987	May	CAHN
	+	@		20MG	N018976	004	Jan 05, 1989	May	CAHN
<u>PENCICLOVIR</u>									
CREAM; TOPICAL									
PENCICLOVIR									
AB			PADAGIS ISRAEL	1%	A212368	001	Sep 27, 2024	Sep	NEWA
<u>PENICILLAMINE</u>									
CAPSULE; ORAL									
LUXZYLA									
	@		ANI PHARMS	250MG	A209921	001	May 07, 2019	Aug	CTNA
AB				250MG	A209921	001	May 07, 2019	Aug	CTNA
PENICILLAMINE									
AB			ENDO OPERATIONS	250MG	A211231	001	Dec 23, 2019	Apr	CAHN
TABLET; ORAL									
PENICILLAMINE									
AB			ENDO OPERATIONS	250MG	A211196	001	Dec 23, 2019	Apr	CAHN
<u>PENICILLIN V POTASSIUM</u>									
TABLET; ORAL									
PENICILLIN V POTASSIUM									
AB	!		AUROBINDO PHARMA	EQ 500MG BASE	A065435	002	Apr 29, 2008	Jan	CHRS
	@		SANDOZ	EQ 250MG BASE	A064071	001	Nov 30, 1995	Jan	DISC
	@			EQ 500MG BASE	A064071	002	Nov 30, 1995	Jan	DISC
<u>PENTOXIFYLLINE</u>									
TABLET, EXTENDED RELEASE; ORAL									
PENTOXIFYLLINE									
AB			ANI PHARMS	400MG	A074878	001	Jul 09, 1997	Jan	CMFD
AB			RISING	400MG	A074425	001	Jul 08, 1997	Jun	CMFD
<u>PERMETHRIN</u>									
CREAM; TOPICAL									
PERMETHRIN									
	@		DR REDDYS LABS EU	5%	A209732	001	Aug 01, 2023	Jan	DISC
<u>PERPHENAZINE</u>									
TABLET; ORAL									
PERPHENAZINE									
AB			ENDO OPERATIONS	2MG	A040226	001	Dec 31, 1998	Apr	CAHN
AB				4MG	A040226	002	Dec 31, 1998	Apr	CAHN
AB				8MG	A040226	003	Dec 31, 1998	Apr	CAHN
AB				16MG	A040226	004	Dec 31, 1998	Apr	CAHN
AB			MACLEODS PHARMS LTD	2MG	A212545	001	May 06, 2024	Apr	NEWA
AB				4MG	A212545	002	May 06, 2024	Apr	NEWA
AB				8MG	A212545	003	May 06, 2024	Apr	NEWA
AB				16MG	A212545	004	May 06, 2024	Apr	NEWA
<u>PHENOXYBENZAMINE HYDROCHLORIDE</u>									
CAPSULE; ORAL									
PHENOXYBENZAMINE HYDROCHLORIDE									
AB	!		ENDO OPERATIONS	10MG	A204522	001	Jan 24, 2017	May	CAHN
<u>PHENTERMINE HYDROCHLORIDE</u>									
CAPSULE; ORAL									
ADIPEX-P									
	+	@	TEVA	37.5MG	A088023	001	Aug 02, 1983	Feb	DISC
PHENTERMINE HYDROCHLORIDE									
	@		INVAGEN PHARMS	15MG	A202858	001	Feb 14, 2014	Mar	DISC
	@			30MG	A202858	002	Feb 14, 2014	Mar	DISC
	@			30MG	A204414	001	May 05, 2014	Mar	DISC
	@			37.5MG	A202846	001	Feb 05, 2014	Mar	DISC
AA	!		NUVO PHARM	37.5MG	A205017	001	Sep 25, 2014	Feb	CHRS
TABLET; ORAL									
PHENTERMINE HYDROCHLORIDE									
AA			AUROBINDO PHARMA LTD	37.5MG	A203068	001	Aug 06, 2014	Sep	CAHN
	@		INVAGEN PHARMS	37.5MG	A202942	001	Feb 05, 2014	Mar	DISC

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

CAPSULE, EXTENDED RELEASE;ORAL

PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE

AB		ACTAVIS LABS FL INC	EQ 3.75MG BASE;23MG	A204982	001	Jun 25, 2024	Jun NFTG
AB			EQ 7.5MG BASE;46MG	A204982	002	Jun 25, 2024	Jun NFTG
AB			EQ 11.25MG BASE;69MG	A204982	003	Jun 25, 2024	Jun NFTG
AB			EQ 15MG BASE;92MG	A204982	004	Jun 25, 2024	Jun NFTG
		QSYMIA					
AB	+	VIVUS LLC	EQ 3.75MG BASE;23MG	N022580	001	Jul 17, 2012	Jun CFTG
	+		EQ 3.75MG BASE;23MG	N022580	001	Jul 17, 2012	May CAHN
AB	+		EQ 7.5MG BASE;46MG	N022580	002	Jul 17, 2012	Jun CFTG
	+		EQ 7.5MG BASE;46MG	N022580	002	Jul 17, 2012	May CAHN
AB	+		EQ 11.25MG BASE;69MG	N022580	003	Jul 17, 2012	Jun CFTG
	+		EQ 11.25MG BASE;69MG	N022580	003	Jul 17, 2012	May CAHN
AB	+		EQ 15MG BASE;92MG	N022580	004	Jul 17, 2012	Jun CFTG
	+		EQ 15MG BASE;92MG	N022580	004	Jul 17, 2012	May CAHN

PHENTOLAMINE MESYLATE

SOLUTION;OPHTHALMIC

RYZUMVI

+	!	FAMYGEN LIFE SCI	EQ 0.75% BASE	N217064	001	Sep 25, 2023	Jan CAHN
---	---	------------------	---------------	---------	-----	--------------	----------

PHENYLBUTAZONE

CAPSULE;ORAL

PHENYLBUTAZONE

		@ CHARTWELL RX	100MG	A087774	001	Jun 16, 1982	Aug CAHN
--	--	----------------	-------	---------	-----	--------------	----------

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

		@ ACCORD HLTHCARE	10MG/ML (10MG/ML)	A213237	001	Jul 01, 2020	May DISC
		@	50MG/5ML (10MG/ML)	A213237	002	Jul 01, 2020	May DISC
		@	100MG/10ML (10MG/ML)	A213237	003	Jul 01, 2020	May DISC
AP1		ASPIRO	10MG/ML (10MG/ML)	A218110	001	May 10, 2024	May NEWA
AP1			50MG/5ML (10MG/ML)	A218110	002	May 10, 2024	May NEWA
AP1			100MG/10ML (10MG/ML)	A218110	003	May 10, 2024	May NEWA
		@ ENDO OPERATIONS	10MG/ML (10MG/ML)	A210025	001	Dec 21, 2018	Apr CAHN
AP1			50MG/5ML (10MG/ML)	A210025	002	Dec 21, 2018	Apr CAHN
AP1			100MG/10ML (10MG/ML)	A210025	003	Dec 21, 2018	Apr CAHN
		@ HAINAN POLY	10MG/ML (10MG/ML)	A218412	001	Mar 14, 2024	Sep DISC
AP1			10MG/ML (10MG/ML)	A218412	001	Mar 14, 2024	Mar NEWA
		@	50MG/5ML (10MG/ML)	A218412	002	Mar 14, 2024	Sep DISC
AP1			50MG/5ML (10MG/ML)	A218412	002	Mar 14, 2024	Mar NEWA
		@	100MG/10ML (10MG/ML)	A218412	003	Mar 14, 2024	Sep DISC
AP1			100MG/10ML (10MG/ML)	A218412	003	Mar 14, 2024	Mar NEWA

SOLUTION/DROPS;OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

AT		CAPLIN	2.5%	A215183	001	May 23, 2024	May NEWA
AT			10%	A215183	002	May 23, 2024	May NEWA

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

AA	!	GENUS	5MG/5ML;6.25MG/5ML	A040654	001	Dec 07, 2006	Apr CAHN
		@ HIKMA	5MG/5ML;6.25MG/5ML	A040675	001	Dec 23, 2014	Mar DISC

>D> PHENYLEPHRINE HYDROCHLORIDE; TROPICAMIDE

>D> SPRAY, METERED;OPHTHALMIC

>D> MYDCOMBI

>D>	+	!	EYENOVIA	2.5%;1%	N215352	001	May 05, 2023	Nov DISC
>A>	+	@		2.5%;1%	N215352	001	May 05, 2023	Nov DISC

PHENYTOIN

SUSPENSION;ORAL

PHENYTOIN

		@ PAI HOLDINGS PHARM	125MG/5ML	A040420	001	Apr 19, 2002	Feb DISC
		@ VISTAPHARM	125MG/5ML	A040342	001	Jan 31, 2001	Apr DISC
		@	125MG/5ML	A040342	002	Aug 18, 2005	Apr DISC

TABLET, CHEWABLE;ORAL

PHENYTOIN

AB		TARO	50MG	A200565	001	Apr 17, 2014	Apr CAHN
----	--	------	------	---------	-----	--------------	----------

PHENYTOIN SODIUM

CAPSULE;ORAL
EXTENDED PHENYTOIN SODIUM

>D>	AB	SUN PHARM INDS	200MG EXTENDED	A 040731	001	Jun 30, 2008	Nov	DISC
>A>		@	200MG EXTENDED	A 040731	001	Jun 30, 2008	Nov	DISC
>D>	AB		300MG EXTENDED	A 040731	002	Jun 30, 2008	Nov	DISC
>A>		@	300MG EXTENDED	A 040731	002	Jun 30, 2008	Nov	DISC
		PHENYTEK						
>D>	AB	MYLAN	200MG EXTENDED	A 040298	002	Dec 06, 2001	Nov	CTEC
>A>			200MG EXTENDED	A 040298	002	Dec 06, 2001	Nov	CTEC
>D>	AB	!	300MG EXTENDED	A 040298	003	Dec 06, 2001	Nov	CTEC
>A>		!	300MG EXTENDED	A 040298	003	Dec 06, 2001	Nov	CTEC

INJECTABLE;INJECTION
PHENYTOIN SODIUM

AP	+	!	HIKMA	50MG/ML	A 084307	001		Jun	CAHN
----	---	---	-------	---------	----------	-----	--	-----	------

PHYTONADIONE

INJECTABLE;INJECTION
PHYTONADIONE

>A>	AB1	GLAND PHARMA LTD	10MG/ML	A 217386	001	Dec 10, 2024	Nov	NEWA	
		TABLET;ORAL PHYTONADIONE							
	AB	!	ZYDUS LIFESCIENCES	5MG	A 210189	001	Feb 20, 2019	Jul	CAHN

PIMAVANSERIN TARTRATE

CAPSULE;ORAL
NUPLAZID

	AB	+	!	ACADIA PHARMS INC	EQ 34MG BASE	N 210793	001	Jun 28, 2018	Jul	CTEC
	AB	+	!	ACADIA PHARMS INC	EQ 34MG BASE	N 210793	001	Jun 28, 2018	Jan	CFTG
				PIMAVANSERIN						
	AB			@ MSN	EQ 34MG BASE	A 214925	001	Jan 16, 2024	Feb	DISC
	AB			@ MSN	EQ 34MG BASE	A 214925	001	Jan 16, 2024	Jan	NEWA
	AB			@ ZYDUS	EQ 34MG BASE	A 214493	001	Jan 16, 2024	Jul	DISC
	AB			@ ZYDUS	EQ 34MG BASE	A 214493	001	Jan 16, 2024	Jan	CAHN
	AB			ZYDUS PHARMS	EQ 34MG BASE	A 214493	001	Jan 16, 2024	Jan	NEWA

TABLET;ORAL
NUPLAZID

	AB	+	!	ACADIA PHARMS INC	EQ 10MG BASE	N 207318	002	Jun 28, 2018	Jul	CTEC
	AB	+	!	ACADIA PHARMS INC	EQ 10MG BASE	N 207318	002	Jun 28, 2018	Jan	CFTG
				PIMAVANSERIN						
	AB			@ ZYDUS	EQ 10MG BASE	A 214502	001	Jan 16, 2024	Jul	DISC
	AB			@ ZYDUS	EQ 10MG BASE	A 214502	001	Jan 16, 2024	Jan	CAHN
	AB			ZYDUS PHARMS	EQ 10MG BASE	A 214502	001	Jan 16, 2024	Jan	NEWA

PIMOZIDE

TABLET;ORAL
PIMOZIDE

				ENDO OPERATIONS	1MG	A 204521	001	Sep 28, 2015	Apr	CAHN
				!	2MG	A 204521	002	Sep 28, 2015	Apr	CAHN

PINDOLOL

TABLET;ORAL
PINDOLOL

>D>	AB	BAYSHORE PHARMS LLC	5MG	A 211712	001	Aug 01, 2019	Nov	CAHN
>D>	AB		10MG	A 211712	002	Aug 01, 2019	Nov	CAHN
>A>	AB	UNICHEM	5MG	A 211712	001	Aug 01, 2019	Nov	CAHN
>A>	AB		10MG	A 211712	002	Aug 01, 2019	Nov	CAHN

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL
PIOGLITAZONE HYDROCHLORIDE

	AB			COREPHARMA	EQ 15MG BASE	A 210165	001	Jan 22, 2021	Jul	CAHN
	AB				EQ 30MG BASE	A 210165	002	Jan 22, 2021	Jul	CAHN
	AB				EQ 45MG BASE	A 210165	003	Jan 22, 2021	Jul	CAHN
				@ NORVIUM BIOSCIENCE	EQ 15MG BASE	A 076801	001	Aug 17, 2012	Sep	CAHN
				@	EQ 30MG BASE	A 076801	002	Aug 17, 2012	Sep	CAHN
				@	EQ 45MG BASE	A 076801	003	Aug 17, 2012	Sep	CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION						
PIPERACILLIN AND TAZOBACTAM						
	@ EUGIA PHARMA	EQ 12GM BASE/VIAL; EQ 1.5GM BASE/VIAL	A217409	002	Oct 12, 2023	Apr DISC
	@	EQ 36GM BASE/VIAL; EQ 4.5GM BASE/VIAL	A217409	001	Oct 12, 2023	Apr DISC
AP	STERISCIENCE SPECLTS	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A065458	001	Aug 15, 2014	Aug CAHN
AP		EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	A065458	002	Aug 15, 2014	Aug CAHN
AP		EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	A065458	003	Aug 15, 2014	Aug CAHN

PIROXICAM

CAPSULE; ORAL						
PIROXICAM						
	@ FLAMINGO PHARMS	10MG	A207938	001	Sep 09, 2016	Mar DISC
	@	20MG	A207938	002	Sep 09, 2016	Mar DISC

PITAVASTATIN CALCIUM

TABLET; ORAL						
PITAVASTATIN CALCIUM						
AB	AMNEAL PHARMS NY	EQ 1MG BASE	A205961	001	Aug 20, 2024	Aug NEWA
AB		EQ 2MG BASE	A205961	002	Aug 20, 2024	Aug NEWA
AB		EQ 4MG BASE	A205961	003	Aug 20, 2024	Aug NEWA
AB	HETERO LABS LTD V	EQ 1MG BASE	A205977	001	Apr 30, 2024	Apr NEWA
AB		EQ 2MG BASE	A205977	002	Apr 30, 2024	Apr NEWA
AB		EQ 4MG BASE	A205977	003	Apr 30, 2024	Apr NEWA

PIVMECILLINAM HYDROCHLORIDE

TABLET; ORAL						
PIVYA						
	+ @ UTILITY THERAP	EQ 185MG BASE	N216483	001	Apr 24, 2024	Aug DISC
	+!	EQ 185MG BASE	N216483	001	Apr 24, 2024	Apr NEWA

PLERIXAFOR

SOLUTION; SUBCUTANEOUS						
PLERIXAFOR						
AP	GLAND PHARMA LTD	24MG/1.2ML (20MG/ML)	A206644	001	May 03, 2024	Apr NEWA
AP	MEITHEAL	24MG/1.2ML (20MG/ML)	A215698	001	Jul 24, 2023	Jun CAHN
	@ ZYDUS PHARMS	24MG/1.2ML (20MG/ML)	A208980	001	Jul 26, 2023	May DISC

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL						
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE						
AA	NOVEL LABS INC	420GM/BOT; 1.48GM/BOT; 5.72GM/BOT; 11.2GM/BOT	A090019	001	May 27, 2009	Jun CMFD

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL						
COLYTE						
	@ NORVIUM BIOSCIENCE	120GM/PACKET; 1.49GM/PACKET; 3.36GM/PACKET; 2.92GM/PACKET; 11.36GM/PACKET	N018983	005	Oct 26, 1984	Jul CAHN
	@	227.1GM/PACKET; 2.82GM/PACKET; 6.36GM/PACKET; 5.53GM/PACKET; 21.5GM/PACKET	N018983	004	Oct 26, 1984	Jul CAHN
	@	227.1GM/BOT; 2.82GM/BOT; 6.36GM/BOT; 5.53GM/BOT; 21.5GM/BOT	N018983	010	Jan 31, 1989	Jul CAHN
	@	240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	N018983	007	Jun 12, 1987	Jul CAHN
	@	360GM/PACKET; 4.47GM/PACKET; 10.08GM/PACKET; 8.76GM/PACKET; 34.08GM/PACKET	N018983	006	Oct 26, 1984	Jul CAHN
COLYTE WITH FLAVOR PACKS						
	@ MYLAN SPECIALITY LP	240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	N018983	012	Oct 08, 1998	Apr DISC
	@ NORVIUM BIOSCIENCE	240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	N018983	012	Oct 08, 1998	Jul CAHN
COLYTE-FLAVORED						
	@ NORVIUM BIOSCIENCE	227.1GM/BOT; 2.82GM/BOT; 6.36GM/BOT; 5.53GM/BOT; 21.5GM/BOT	N018983	008	Nov 14, 1991	Jul CAHN
	@	240GM/BOT; 2.98GM/BOT; 6.72GM/BOT;	N018983	009	Nov 14, 1991	Jul CAHN

FOR SOLUTION;ORAL
COLYTE-FLAVORED

5.84GM/BOT;22.72GM/BOT

PEG 3350 AND ELECTROLYTES

NOVEL LABS INC 240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT A 090186 001 Jun 01, 2009 Apr CTEC

POLYMYXIN B SULFATE

INJECTABLE;INJECTION
POLYMYXIN B SULFATE

AP ADRASTEIA PHARMA EQ 500,000 UNITS BASE/VIAL A 063000 001 Sep 30, 1994 Feb CAHN

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT SOMERSET THERAPS LLC 10,000 UNITS/ML;EQ 1MG BASE/ML A 211572 001 Aug 05, 2024 Jul NEWA

POMALIDOMIDE

CAPSULE;ORAL
POMALIDOMIDE

AB	APOTEX	1MG	A 210164	001	Jun 11, 2024	May	NEWA
AB		2MG	A 210164	002	Jun 11, 2024	May	NEWA
AB		3MG	A 210164	003	Jun 11, 2024	May	NEWA
AB		4MG	A 210164	004	Jun 11, 2024	May	NEWA
AB	HETERO LABS LTD V	1MG	A 210236	001	Sep 26, 2024	Sep	NEWA
AB		2MG	A 210236	002	Sep 26, 2024	Sep	NEWA
AB		3MG	A 210236	003	Sep 26, 2024	Sep	NEWA
AB		4MG	A 210236	004	Sep 26, 2024	Sep	NEWA
	POMALYST						
AB	+ BRISTOL	1MG	N 204026	001	Feb 08, 2013	May	CTEC
AB	+	2MG	N 204026	002	Feb 08, 2013	May	CTEC
AB	+	3MG	N 204026	003	Feb 08, 2013	May	CTEC
AB	+!	4MG	N 204026	004	Feb 08, 2013	May	CTEC

PONESIMOD

TABLET;ORAL
PONVORY

+!	VANDA PHARMS INC	2MG	N 213498	001	Mar 18, 2021	May	CAHN
+		3MG	N 213498	002	Mar 18, 2021	May	CAHN
+		4MG	N 213498	003	Mar 18, 2021	May	CAHN
+		5MG	N 213498	004	Mar 18, 2021	May	CAHN
+		6MG	N 213498	005	Mar 18, 2021	May	CAHN
+		7MG	N 213498	006	Mar 18, 2021	May	CAHN
+		8MG	N 213498	007	Mar 18, 2021	May	CAHN
+		9MG	N 213498	008	Mar 18, 2021	May	CAHN
+		10MG	N 213498	009	Mar 18, 2021	May	CAHN
+		20MG	N 213498	010	Mar 18, 2021	May	CAHN

POSACONAZOLE

TABLET, DELAYED RELEASE;ORAL
POSACONAZOLE

AB	! AET PHARMA	100MG	A 213454	001	Feb 01, 2021	Aug	CHRS
AB	AUROBINDO PHARMA	100MG	A 217119	001	Jul 18, 2024	Jul	NEWA

POTASSIUM ACETATE

INJECTABLE;INJECTION
POTASSIUM ACETATE

>A> AP FRESENIUS KABI USA 2MEQ/ML A 217515 001 Nov 27, 2024 Nov NEWA

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
POTASSIUM CHLORIDE

@	ANCHEN PHARMS	8MEQ	A 202886	001	Dec 26, 2013	Feb	DISC
@		10MEQ	A 202886	002	Dec 26, 2013	Feb	DISC
@	ENDO OPERATIONS	8MEQ	A 202886	001	Dec 26, 2013	May	CAHN
@		10MEQ	A 202886	002	Dec 26, 2013	May	CAHN
@	GLENMARK PHARMS LTD	10MEQ	A 202868	001	Jan 19, 2016	Sep	DISC

FOR SOLUTION;ORAL

POKONZA

+	GENUS	10MEQ	N 208019	002	Aug 25, 2023	Jun	CAHN
AA	+ GENUS	20MEQ	N 208019	001	Aug 19, 2015	Jun	CAHN

	FOR SOLUTION;ORAL								
	POTASSIUM CHLORIDE								
	+!	40MEQ		N208019	003	Aug 25, 2023	Jun	CAHN	
	SOLUTION;ORAL								
	POTASSIUM CHLORIDE								
AA	STRIDES PHARMA	20MEQ/15ML		A211665	002	Jan 16, 2024	Jan	NEWA	
	TABLET, EXTENDED RELEASE;ORAL								
	POTASSIUM CHLORIDE								
	@ CHARTWELL RX	10MEQ		A206630	001	Mar 29, 2019	May	CAHN	
	@	15MEQ		A206630	002	Mar 29, 2019	May	CAHN	
	@	20MEQ		A206630	003	Mar 29, 2019	May	CAHN	
AB2	MACLEODS PHARMS LTD	8MEQ		A212987	001	Sep 06, 2024	Aug	NEWA	
AB2		10MEQ		A212987	002	Sep 06, 2024	Aug	NEWA	
AB1		10MEQ		A216269	001	May 09, 2024	May	NEWA	
AB1		15MEQ		A216269	002	May 09, 2024	May	NEWA	
AB1		20MEQ		A216269	003	May 09, 2024	May	NEWA	
	! RUBICON	15MEQ		A215725	003	Aug 22, 2024	Aug	NEWA	
AB2	TWI PHARMS	8MEQ		A218979	001	Oct 28, 2024	Oct	NEWA	
AB2		10MEQ		A218979	002	Oct 28, 2024	Oct	NEWA	
	<u>POTASSIUM CITRATE</u>								
	TABLET, EXTENDED RELEASE;ORAL								
	POTASSIUM CITRATE								
AB	HIBROW HLTHCARE	5MEQ		A214426	001	Feb 19, 2021	Jul	CAHN	
AB		10MEQ		A214426	002	Feb 19, 2021	Jul	CAHN	
AB		15MEQ		A214426	003	Feb 19, 2021	Jul	CAHN	
	@ TORRENT	5MEQ		A213986	001	Feb 06, 2024	Feb	DISC	
AB		5MEQ		A213986	001	Feb 06, 2024	Jan	NEWA	
	@	10MEQ		A213986	002	Feb 06, 2024	Feb	DISC	
AB		10MEQ		A213986	002	Feb 06, 2024	Jan	NEWA	
	@	15MEQ		A213986	003	Feb 06, 2024	Feb	DISC	
AB		15MEQ		A213986	003	Feb 06, 2024	Jan	NEWA	
	<u>POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC</u>								
	SOLUTION;INTRAVENOUS								
	POTASSIUM PHOSPHATES								
	+ @ CMP DEV LLC	4.5GM/15ML (300MG/ML);2.65GM/15ML (175MG/ML)		N212121	001	Sep 19, 2019	Oct	DISC	
AP	SOMERSET THERAPS LLC	1.18GM/5ML (236MG/ML);1.12GM/5ML (224MG/ML)		A217726	001	Jul 11, 2024	Jun	NEWA	
AP		3.54GM/15ML (236MG/ML);3.36GM/15ML (224MG/ML)		A217726	002	Jul 11, 2024	Jun	NEWA	
	POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE								
	+! AMNEAL	1.18GM/250ML (4.72MG/ML);1.12GM/250ML		N218343	001	Jul 26, 2024	Jul	NEWA	
	<u>PRALSETINIB</u>								
	CAPSULE;ORAL								
	GAVRETO								
	+! BLUEPRINT MEDICINES	100MG		N213721	001	Sep 04, 2020	Feb	CAHN	
	+! RIGEL PHARMS	100MG		N213721	001	Sep 04, 2020	Jun	CAHN	
	<u>PRAMIPEXOLE DIHYDROCHLORIDE</u>								
	TABLET;ORAL								
	PRAMIPEXOLE DIHYDROCHLORIDE								
AB	GLENMARK PHARMS LTD	0.125MG		A090781	001	Oct 08, 2010	Mar	CAHN	
AB	!	0.25MG		A090781	002	Oct 08, 2010	Mar	CAHN	
AB		0.5MG		A090781	003	Oct 08, 2010	Mar	CAHN	
AB		0.75MG		A090781	006	Sep 11, 2015	Mar	CAHN	
AB		1MG		A090781	004	Oct 08, 2010	Mar	CAHN	
AB		1.5MG		A090781	005	Oct 08, 2010	Mar	CAHN	
	@ NATCO	0.125MG		A077854	001	Oct 08, 2010	Aug	CAHN	
	@	0.25MG		A077854	002	Oct 08, 2010	Aug	CAHN	
	@	0.5MG		A077854	003	Oct 08, 2010	Aug	CAHN	
	@	1MG		A077854	004	Oct 08, 2010	Aug	CAHN	
	@	1.5MG		A077854	005	Oct 08, 2010	Aug	CAHN	
	TABLET, EXTENDED RELEASE;ORAL								
	MIRAPEX ER								
	+ @ BOEHRINGER INGELHEIM	0.375MG		N022421	001	Feb 19, 2010	Aug	DISC	
	+ @	0.75MG		N022421	002	Feb 19, 2010	Aug	DISC	
	+ @	1.5MG		N022421	003	Feb 19, 2010	Aug	DISC	
	+ @	2.25MG		N022421	006	Jun 17, 2011	Aug	DISC	
	+ @	3MG		N022421	004	Feb 19, 2010	Aug	DISC	

TABLET, EXTENDED RELEASE;ORAL									
MIRAPEX ER									
	+	@		3.75MG		N022421	007	Jun 17, 2011	Aug DISC
	+	@		4.5MG		N022421	005	Feb 19, 2010	Aug DISC
PRAMIPEXOLE DIHYDROCHLORIDE									
AB	!	DR REDDYS		0.375MG		A203354	001	Aug 07, 2015	Aug CHRS
	@	ENDO OPERATIONS		0.375MG		A202206	001	Feb 06, 2014	May CAHN
	@			0.75MG		A202206	002	Feb 06, 2014	May CAHN
	@			1.5MG		A202206	003	Feb 06, 2014	May CAHN
	@			2.25MG		A202206	004	Feb 06, 2014	May CAHN
	@			3MG		A202206	005	Feb 06, 2014	May CAHN
	@			3.75MG		A202206	006	Feb 06, 2014	May CAHN
	@			4.5MG		A202206	007	Feb 06, 2014	May CAHN
<u>PRAZIQUANTEL</u>									
TABLET;ORAL									
BILTRICIDE									
	+	@	BAYER HLTHCARE	600MG		N018714	001	Dec 29, 1982	Sep DISC
AB	+			600MG		N018714	001	Dec 29, 1982	Jun CHRS
PRAZIQUANTEL									
	!	ENDO OPERATIONS		600MG		A208820	001	Nov 27, 2017	Sep CTEC
AB	!			600MG		A208820	001	Nov 27, 2017	Jun CHRS
AB				600MG		A208820	001	Nov 27, 2017	Apr CAHN
<u>PRAZOSIN HYDROCHLORIDE</u>									
CAPSULE;ORAL									
PRAZOSIN HYDROCHLORIDE									
	@	LANNETT CO INC		EQ 1MG BASE		A214083	001	Jan 03, 2024	Jul DISC
	@			EQ 2MG BASE		A214083	002	Jan 03, 2024	Jul DISC
	@			EQ 5MG BASE		A214083	003	Jan 03, 2024	Jul DISC
AB		MSN		EQ 1MG BASE		A216727	001	Sep 17, 2024	Sep NEWA
AB				EQ 2MG BASE		A216727	002	Sep 17, 2024	Sep NEWA
AB				EQ 5MG BASE		A216727	003	Sep 17, 2024	Sep NEWA
<u>PREDNISOLONE</u>									
SYRUP;ORAL									
PREDNISOLONE									
	@	HIKMA		15MG/5ML		A040401	001	Feb 27, 2003	Mar DISC
	@	PHARM ASSOC		15MG/5ML		A040399	001	Mar 05, 2003	Feb DISC
TABLET;ORAL									
PREDNISOLONE									
	+	@	HEATHER	5MG		A080326	001		Oct CRLD
AB			ZHEJIANG XIANJU	5MG		A218083	001	May 02, 2024	Apr NEWA
<u>PREDNISOLONE ACETATE</u>									
SUSPENSION;ORAL									
FLO-PRED									
	@	TARO		EQ 5MG BASE/5ML		N022067	001	Jan 17, 2008	Aug CAHN
	@			EQ 15MG BASE/5ML		N022067	002	Jan 17, 2008	Aug CAHN
SUSPENSION/DROPS;OPHTHALMIC									
PREDNISOLONE ACETATE									
AB		LUPIN LTD		1%		A216935	001	Aug 02, 2024	Jul NFTG
<u>PREDNISOLONE SODIUM PHOSPHATE</u>									
SOLUTION;ORAL									
PREDNISOLONE SODIUM PHOSPHATE									
	@	ENDO OPERATIONS		EQ 15MG BASE/5ML		A079010	001	May 26, 2009	May CAHN
	@	HIKMA		EQ 5MG BASE/5ML		A075183	001	Mar 26, 2003	Mar DISC
	@	PHARM ASSOC		EQ 30MG BASE/5ML		A204962	001	Mar 11, 2020	Mar DISC
	@	PHARMOBEDIENT		EQ 15MG BASE/5ML		A076895	001	Oct 04, 2004	Sep CAHN
<u>PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM</u>									
SOLUTION/DROPS;OPHTHALMIC									
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE									
	@	GENUS		EQ 0.23% PHOSPHATE;10%		A073630	001	May 27, 1993	Aug CAHN
<u>PREDNISONE</u>									
SOLUTION;ORAL									
PREDNISONE INTENSOL									
	+	!	HIKMA	5MG/ML		A088810	001	Feb 20, 1985	Jan CRLD

TABLET;ORAL

PREDNISONE							
BX	CHARTWELL MOLECULAR	20MG	A 084275	001			Jul CMFD
AB	ENDO OPERATIONS	1MG	A 040584	001	Dec 21, 2004		Apr CAHN
AB		2.5MG	A 040581	001	Dec 21, 2004		Apr CAHN
AB		5MG	A 040256	001	Jul 12, 2002		Apr CAHN
AB		10MG	A 040256	002	Jul 12, 2002		Apr CAHN
AB		20MG	A 040392	001	Feb 12, 2003		Apr CAHN
	@ GENEYORK PHARMS	1MG	A 211496	001	Dec 28, 2018		Feb DISC
	@	2.5MG	A 210525	004	Dec 07, 2018		Feb DISC
	@	5MG	A 210525	005	Dec 07, 2018		Feb DISC
	@	10MG	A 210525	001	Dec 04, 2018		Feb DISC
	@	20MG	A 210525	002	Dec 04, 2018		Feb DISC
	@	50MG	A 210525	003	Dec 04, 2018		Feb DISC
AB	STRIDES PHARMA	2.5MG	A 208412	004	Nov 20, 2020		Jun CMS1
AB		5MG	A 208412	005	Nov 20, 2020		Jun CMS1

TABLET, DELAYED RELEASE;ORAL

PREDNISONE							
	@ ACTAVIS LABS FL INC	1MG	A 204867	001	Apr 25, 2017		Oct DISC
		1MG	A 204867	001	Apr 25, 2017		Oct CTEC
	@	2MG	A 204867	002	Apr 25, 2017		Oct DISC
		2MG	A 204867	002	Apr 25, 2017		Oct CTEC
	@	5MG	A 204867	003	Apr 25, 2017		Oct DISC
!		5MG	A 204867	003	Apr 25, 2017		Oct CHRS
		5MG	A 204867	003	Apr 25, 2017		Oct CTEC
RAYOS							
+	@ HORIZON	1MG	N 202020	001	Jul 26, 2012		Oct DISC
+	@	2MG	N 202020	002	Jul 26, 2012		Oct DISC
+	@	5MG	N 202020	003	Jul 26, 2012		Oct DISC

PREGABALIN

CAPSULE;ORAL							
PREGABALIN							
AB	ACME LABS	50MG	A 210585	001	Dec 26, 2019		Aug CAHN
AB		75MG	A 210585	002	Dec 26, 2019		Aug CAHN
AB		100MG	A 210585	003	Dec 26, 2019		Aug CAHN
AB		150MG	A 210585	004	Dec 26, 2019		Aug CAHN
AB		200MG	A 210585	005	Dec 26, 2019		Aug CAHN
AB		300MG	A 210585	006	Dec 26, 2019		Aug CAHN
AB	ADAPTIS	25MG	A 208113	001	May 17, 2024		Aug CAHN
AB		50MG	A 208113	002	May 17, 2024		Aug CAHN
AB		75MG	A 208113	004	May 17, 2024		Aug CAHN
AB		100MG	A 208113	005	May 17, 2024		Aug CAHN
AB		150MG	A 208113	003	May 17, 2024		Aug CAHN
AB		200MG	A 208113	006	May 17, 2024		Aug CAHN
AB		225MG	A 208113	007	May 17, 2024		Aug CAHN
AB		300MG	A 208113	008	May 17, 2024		Aug CAHN
	@ CADILA PHARMS LTD	25MG	A 206452	001	Jul 12, 2023		Jan DISC
	@	50MG	A 206452	002	Jul 12, 2023		Jan DISC
	@	75MG	A 206452	003	Jul 12, 2023		Jan DISC
	@	100MG	A 206452	004	Jul 12, 2023		Jan DISC
	@	150MG	A 206452	005	Jul 12, 2023		Jan DISC
	@	200MG	A 206452	006	Jul 12, 2023		Jan DISC
	@	225MG	A 206452	007	Jul 12, 2023		Jan DISC
	@	300MG	A 206452	008	Jul 12, 2023		Jan DISC
AB	CHANGZHOU PHARM	25MG	A 214322	008	Sep 26, 2024		Sep NEWA
	@ CIPLA	25MG	A 212280	001	Jan 10, 2020		May DISC
	@	50MG	A 212280	002	Jan 10, 2020		May DISC
	@	75MG	A 212280	003	Jan 10, 2020		May DISC
	@	100MG	A 212280	004	Jan 10, 2020		May DISC
	@	150MG	A 212280	005	Jan 10, 2020		May DISC
	@	200MG	A 212280	006	Jan 10, 2020		May DISC
	@	225MG	A 212280	007	Jan 10, 2020		May DISC
	@	300MG	A 212280	008	Jan 10, 2020		May DISC
AB	ESKAYEF	25MG	A 212988	001	Mar 08, 2022		Oct CAHN
AB		50MG	A 212988	002	Mar 08, 2022		Oct CAHN
AB		75MG	A 212988	003	Mar 08, 2022		Oct CAHN
AB		100MG	A 212988	004	Mar 08, 2022		Oct CAHN
AB		150MG	A 212988	005	Mar 08, 2022		Oct CAHN
AB		200MG	A 212988	006	Mar 08, 2022		Oct CAHN
AB		225MG	A 212988	007	Mar 08, 2022		Oct CAHN
AB		300MG	A 212988	008	Mar 08, 2022		Oct CAHN
AB	INDOCO	25MG	A 208113	001	May 17, 2024		May NEWA

CAPSULE;ORAL
PREGABALIN

AB		50MG	A208113	002	May 17, 2024	May	NEWA	
AB		75MG	A208113	004	May 17, 2024	May	NEWA	
AB		100MG	A208113	005	May 17, 2024	May	NEWA	
AB		150MG	A208113	003	May 17, 2024	May	NEWA	
AB		200MG	A208113	006	May 17, 2024	May	NEWA	
AB		225MG	A208113	007	May 17, 2024	May	NEWA	
AB		300MG	A208113	008	May 17, 2024	May	NEWA	
>A>	AB	MACLEODS PHARMS LTD	25MG	A205924	001	Nov 12, 2024	Nov	NEWA
>A>	AB		50MG	A205924	002	Nov 12, 2024	Nov	NEWA
>A>	AB		75MG	A205924	003	Nov 12, 2024	Nov	NEWA
>A>	AB		100MG	A205924	004	Nov 12, 2024	Nov	NEWA
>A>	AB		150MG	A205924	005	Nov 12, 2024	Nov	NEWA
>A>	AB		200MG	A205924	006	Nov 12, 2024	Nov	NEWA
>A>	AB		225MG	A205924	007	Nov 12, 2024	Nov	NEWA
>A>	AB		300MG	A205924	008	Nov 12, 2024	Nov	NEWA
AB		RK PHARMA	25MG	A212988	001	Mar 08, 2022	Aug	CAHN
AB			50MG	A212988	002	Mar 08, 2022	Aug	CAHN
AB			75MG	A212988	003	Mar 08, 2022	Aug	CAHN
AB			100MG	A212988	004	Mar 08, 2022	Aug	CAHN
AB			150MG	A212988	005	Mar 08, 2022	Aug	CAHN
AB			200MG	A212988	006	Mar 08, 2022	Aug	CAHN
AB			225MG	A212988	007	Mar 08, 2022	Aug	CAHN
AB			300MG	A212988	008	Mar 08, 2022	Aug	CAHN
AB		@ STRIDES PHARMA	25MG	A209883	001	Jan 24, 2024	Jul	DISC
AB		@	25MG	A209883	001	Jan 24, 2024	Jan	NEWA
AB		@	50MG	A209883	002	Jan 24, 2024	Jul	DISC
AB		@	50MG	A209883	002	Jan 24, 2024	Jan	NEWA
AB		@	75MG	A209883	003	Jan 24, 2024	Jul	DISC
AB		@	75MG	A209883	003	Jan 24, 2024	Jan	NEWA
AB		@	100MG	A209883	004	Jan 24, 2024	Jul	DISC
AB		@	100MG	A209883	004	Jan 24, 2024	Jan	NEWA
AB		@	150MG	A209883	005	Jan 24, 2024	Jul	DISC
AB		@	150MG	A209883	005	Jan 24, 2024	Jan	NEWA
AB		@	200MG	A209883	006	Jan 24, 2024	Jul	DISC
AB		@	200MG	A209883	006	Jan 24, 2024	Jan	NEWA
AB		@	225MG	A209883	007	Jan 24, 2024	Jul	DISC
AB		@	225MG	A209883	007	Jan 24, 2024	Jan	NEWA
AB		@	300MG	A209883	008	Jan 24, 2024	Jul	DISC
AB		@	300MG	A209883	008	Jan 24, 2024	Jan	NEWA
AB		@ SUN PHARM	25MG	A091157	001	Nov 29, 2019	Jan	DISC
AB		@	50MG	A091157	002	Nov 29, 2019	Jan	DISC
AB		@	75MG	A091157	003	Nov 29, 2019	Jan	DISC
AB		@	100MG	A091157	004	Nov 29, 2019	Jan	DISC
AB		@	150MG	A091157	005	Nov 29, 2019	Jan	DISC
AB		@	200MG	A091157	006	Nov 29, 2019	Jan	DISC
AB		@	225MG	A091157	007	Nov 29, 2019	Jan	DISC
AB		@	300MG	A091157	008	Nov 29, 2019	Jan	DISC
AB		@ TEVA PHARMS	25MG	A091219	001	Jul 19, 2019	Aug	DISC
AB		@	50MG	A091219	002	Jul 19, 2019	Aug	DISC
AB		@	75MG	A091224	001	Jul 19, 2019	Aug	DISC
AB		@	100MG	A091224	002	Jul 19, 2019	Aug	DISC
AB		@	150MG	A091224	003	Jul 19, 2019	Aug	DISC
AB		@	200MG	A091224	004	Jul 19, 2019	Aug	DISC
AB		@	225MG	A091224	005	Jul 19, 2019	Aug	DISC
AB		@	300MG	A091224	006	Jul 19, 2019	Aug	DISC

SOLUTION;ORAL

PREGABALIN

AA		ANDA REPOSITORY	20MG/ML	A212604	001	Feb 18, 2022	Sep	CAHN
----	--	-----------------	---------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE;ORAL

PREGABALIN

	@	NORVIUM BIOSCIENCE	330MG	A211431	001	Jul 02, 2021	Jun	CAHN
--	---	--------------------	-------	---------	-----	--------------	-----	------

PRIMAQUINE PHOSPHATE

TABLET;ORAL

PRIMAQUINE PHOSPHATE

>D>	AB	BAYSHORE PHARMS LLC	EQ 15MG BASE	A204476	001	Feb 25, 2014	Nov	CAHN
>A>	AB	UNICHEM	EQ 15MG BASE	A204476	001	Feb 25, 2014	Nov	CAHN

PRIMIDONE

	SUSPENSION;ORAL					
	MYSOLINE					
	+ @ FHTA	250MG/5ML	N010401	001		Jan CAHN
	TABLET;ORAL					
	PRIMIDONE					
AB	CARNEGIE	50MG	A218366	001	Jan 23, 2024	Jan NEWA
AB		250MG	A218366	002	Jan 23, 2024	Jan NEWA

PROBENECID; SULOPENEM ETZADROXIL

	TABLET;ORAL					
	ORLYNVAH					
	+! ITERUM THERAP	500MG;500MG	N213972	001	Oct 25, 2024	Oct NEWA

PROCAINAMIDE HYDROCHLORIDE

	INJECTABLE;INJECTION					
	PROCAINAMIDE HYDROCHLORIDE					
AP	GLAND PHARMA LTD	100MG/ML	A218135	001	Jul 22, 2024	Jul NEWA
AP		500MG/ML	A218135	002	Jul 22, 2024	Jul NEWA
	@ HIKMA	100MG/ML	A089029	001	Apr 17, 1986	Jun CAHN

PROCHLORPERAZINE EDISYLATE

	INJECTABLE;INJECTION					
	PROCHLORPERAZINE EDISYLATE					
	@ HIKMA	EQ 5MG BASE/ML	A213630	001	Nov 22, 2022	Jul DISC
AP	SOMERSET THERAPS LLC	EQ 5MG BASE/ML	A212257	001	Sep 13, 2024	Sep NEWA

PROCHLORPERAZINE MALEATE

	TABLET;ORAL					
	PROCHLORPERAZINE MALEATE					
AB	AJANTA PHARMA LTD	EQ 5MG BASE	A218515	001	May 09, 2024	Apr NEWA
AB		EQ 10MG BASE	A218515	002	May 09, 2024	Apr NEWA
AB	LEADING	EQ 5MG BASE	A218912	001	Sep 30, 2024	Sep NEWA
AB		EQ 10MG BASE	A218912	002	Sep 30, 2024	Sep NEWA

PROGESTERONE

	INJECTABLE;INJECTION					
	PROGESTERONE					
	@ ACCORD HLTHCARE	50MG/ML	A217707	001	Nov 21, 2023	Jul DISC

PROMETHAZINE HYDROCHLORIDE

	INJECTABLE;INJECTION					
	PROMETHAZINE HYDROCHLORIDE					
AP	+! HIKMA	25MG/ML	A083312	001		Jun CAHN
AP	+!	50MG/ML	A083312	002		Jun CAHN

PROPAFENONE HYDROCHLORIDE

	CAPSULE, EXTENDED RELEASE;ORAL					
	PROPAFENONE HYDROCHLORIDE					
AB	SINOTHERAPEUTICS INC	225MG	A210339	001	Jan 04, 2019	May CTEC
AB		325MG	A210339	002	Jan 04, 2019	May CTEC
AB		425MG	A210339	003	Jan 04, 2019	May CTEC
	@ TWI PHARMS	225MG	A212928	001	Jun 18, 2020	Aug DISC
AB		225MG	A212928	001	Jun 18, 2020	Mar CAHN
	@	325MG	A212928	002	Jun 18, 2020	Aug DISC
AB		325MG	A212928	002	Jun 18, 2020	Mar CAHN
	@	425MG	A212928	003	Jun 18, 2020	Aug DISC
AB		425MG	A212928	003	Jun 18, 2020	Mar CAHN
	TABLET;ORAL					
	PROPAFENONE HYDROCHLORIDE					
	@ SUN PHARM INDUSTRIES	150MG	A075998	001	Nov 29, 2001	Jul DISC
	@	225MG	A075998	002	Nov 29, 2001	Jul DISC
	@	300MG	A075998	003	Nov 29, 2001	Jul DISC

PROPARACAINE HYDROCHLORIDE

	SOLUTION/DROPS;OPHTHALMIC					
	PROPARACAINE HYDROCHLORIDE					
AT	SOMERSET THERAPS LLC	0.5%	A215816	001	Aug 09, 2024	Aug NEWA

PROPOFOL

INJECTABLE; INJECTION
PROPOFOL

AB	AMNEAL	10MG/ML	A217525	001	Aug 15, 2024	Aug	NEWA
AB	ASPIRO	10MG/ML	A217013	001	Jun 20, 2024	Jun	NEWA

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
PROPRANOLOL HYDROCHLORIDE

	@ LUPIN LTD	60MG	A204349	001	Jan 12, 2024	Apr	DISC
AB		60MG	A204349	001	Jan 12, 2024	Jan	NEWA
	@	80MG	A204349	002	Jan 12, 2024	Apr	DISC
AB		80MG	A204349	002	Jan 12, 2024	Jan	NEWA
	@	120MG	A204349	003	Jan 12, 2024	Apr	DISC
AB		120MG	A204349	003	Jan 12, 2024	Jan	NEWA
	@	160MG	A204349	004	Jan 12, 2024	Apr	DISC
AB		160MG	A204349	004	Jan 12, 2024	Jan	NEWA

SOLUTION; ORAL
HEMANGEOL

+! PIERRE FABRE 4.28MG/ML

N205410	001	Mar 14, 2014	May	CAHN
---------	-----	--------------	-----	------

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

	@ AIPING PHARM INC	90MG	A071288	001	Oct 22, 1986	Jul	CAHN
AB	ENDO OPERATIONS	10MG	A070221	002	Aug 01, 1986	Apr	CAHN
AB		20MG	A070221	003	Aug 01, 1986	Apr	CAHN
AB		40MG	A070221	004	Aug 01, 1986	Apr	CAHN
AB		60MG	A070221	005	Sep 24, 1986	Apr	CAHN
AB		80MG	A070221	001	Apr 14, 1986	Apr	CAHN

PROPYLTHIOURACIL

TABLET; ORAL

PROPYLTHIOURACIL

AB	+! ENDO OPERATIONS	50MG	N006188	001		Apr	CAHN
----	--------------------	------	---------	-----	--	-----	------

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET; ORAL

CORPHED

@ CHARTWELL RX 60MG; 2.5MG

A088602	001	Apr 11, 1985	Aug	CAHN
---------	-----	--------------	-----	------

PYRIDOSTIGMINE BROMIDE

TABLET; ORAL

PYRIDOSTIGMINE BROMIDE

AB	ANI PHARMS	60MG	A040512	001	Oct 08, 2003	Jan	CMFD
AB	MLV	30MG	A211181	002	May 14, 2019	Mar	CAHN
AB		60MG	A211181	001	Jul 20, 2018	Mar	CAHN

TABLET, EXTENDED RELEASE; ORAL

PYRIDOSTIGMINE BROMIDE

@ AMNEAL 105MG
105MG

N217604	001	Oct 04, 2024	Oct	DISC
N217604	001	Oct 04, 2024	Oct	NEWA

PYRIMETHAMINE

TABLET; ORAL

PYRIMETHAMINE

AB	SANALUZ	25MG	A207127	001	Feb 28, 2020	Sep	CAHN
----	---------	------	---------	-----	--------------	-----	------

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

>A>	@ CHARTWELL RX	EQ 25MG BASE	A078679	001	Dec 14, 2012	Nov	CAHN
>A>	@	EQ 50MG BASE	A078679	002	Dec 14, 2012	Nov	CAHN
>A>	@	EQ 100MG BASE	A078679	003	Dec 14, 2012	Nov	CAHN
>A>	@	EQ 150MG BASE	A078679	004	Dec 14, 2012	Nov	CAHN
>A>	@	EQ 200MG BASE	A078679	005	Dec 14, 2012	Nov	CAHN
>A>	@	EQ 300MG BASE	A078679	006	Dec 14, 2012	Nov	CAHN
>A>	@	EQ 400MG BASE	A078679	007	Dec 14, 2012	Nov	CAHN
AB	IPCA LABS LTD	EQ 25MG BASE	A205983	001	May 20, 2024	May	NEWA
AB		EQ 50MG BASE	A205983	002	May 20, 2024	May	NEWA
AB		EQ 100MG BASE	A205983	003	May 20, 2024	May	NEWA
AB		EQ 200MG BASE	A205983	004	May 20, 2024	May	NEWA
AB		EQ 300MG BASE	A205983	005	May 20, 2024	May	NEWA
AB		EQ 400MG BASE	A205983	006	May 20, 2024	May	NEWA

TABLET;ORAL

QUETIAPINE FUMARATE

>D>	@ SANDOZ	EQ 25MG BASE	A 078679	001	Dec 14, 2012	Nov	CAHN
	@	EQ 25MG BASE	A 078679	001	Dec 14, 2012	Sep	DISC
>D>	@	EQ 50MG BASE	A 078679	002	Dec 14, 2012	Nov	CAHN
	@	EQ 50MG BASE	A 078679	002	Dec 14, 2012	Sep	DISC
>D>	@	EQ 100MG BASE	A 078679	003	Dec 14, 2012	Nov	CAHN
	@	EQ 100MG BASE	A 078679	003	Dec 14, 2012	Sep	DISC
>D>	@	EQ 150MG BASE	A 078679	004	Dec 14, 2012	Nov	CAHN
	@	EQ 150MG BASE	A 078679	004	Dec 14, 2012	Sep	DISC
>D>	@	EQ 200MG BASE	A 078679	005	Dec 14, 2012	Nov	CAHN
	@	EQ 200MG BASE	A 078679	005	Dec 14, 2012	Sep	DISC
>D>	@	EQ 300MG BASE	A 078679	006	Dec 14, 2012	Nov	CAHN
	@	EQ 300MG BASE	A 078679	006	Dec 14, 2012	Sep	DISC
>D>	@	EQ 400MG BASE	A 078679	007	Dec 14, 2012	Nov	CAHN
	@	EQ 400MG BASE	A 078679	007	Dec 14, 2012	Sep	DISC
AB	SCIEGEN PHARMS INC	EQ 25MG BASE	A 090960	001	Mar 27, 2012	Sep	CAHN
AB		EQ 50MG BASE	A 090960	002	Mar 27, 2012	Sep	CAHN
AB		EQ 100MG BASE	A 090960	003	Mar 27, 2012	Sep	CAHN
AB		EQ 200MG BASE	A 090960	004	Mar 27, 2012	Sep	CAHN
AB		EQ 300MG BASE	A 090960	005	Mar 27, 2012	Sep	CAHN
AB		EQ 400MG BASE	A 090960	006	Mar 27, 2012	Sep	CAHN

TABLET, EXTENDED RELEASE;ORAL

QUETIAPINE FUMARATE

	@ ENDO OPERATIONS	EQ 50MG BASE	A 090482	001	May 09, 2017	May	CAHN
	@	EQ 150MG BASE	A 090482	002	May 09, 2017	May	CAHN
	@	EQ 150MG BASE	A 090757	001	Dec 01, 2017	May	CAHN
	@	EQ 200MG BASE	A 090482	003	May 09, 2017	May	CAHN
	@	EQ 200MG BASE	A 090757	002	Dec 01, 2017	May	CAHN
	@	EQ 300MG BASE	A 090482	004	May 09, 2017	May	CAHN
	@	EQ 300MG BASE	A 090757	003	Dec 01, 2017	May	CAHN
	@	EQ 400MG BASE	A 090482	005	May 09, 2017	May	CAHN
	@	EQ 400MG BASE	A 090757	004	Dec 01, 2017	May	CAHN
>A> AB	GRAVITI PHARMS	EQ 50MG BASE	A 211144	001	Nov 26, 2024	Nov	NEWA
>A> AB		EQ 150MG BASE	A 211144	002	Nov 26, 2024	Nov	NEWA
>A> AB		EQ 200MG BASE	A 211144	003	Nov 26, 2024	Nov	NEWA
>A> AB		EQ 300MG BASE	A 211144	004	Nov 26, 2024	Nov	NEWA
>A> AB		EQ 400MG BASE	A 211144	005	Nov 26, 2024	Nov	NEWA
	@ PAR PHARM	EQ 50MG BASE	A 090482	001	May 09, 2017	Feb	DISC
	@	EQ 150MG BASE	A 090482	002	May 09, 2017	Feb	DISC
	@	EQ 200MG BASE	A 090482	003	May 09, 2017	Feb	DISC
	@	EQ 300MG BASE	A 090482	004	May 09, 2017	Feb	DISC
	@	EQ 400MG BASE	A 090482	005	May 09, 2017	Feb	DISC
>D> AB	PHARMADAX INC	EQ 50MG BASE	A 206260	001	May 09, 2017	Nov	DISC
>A>	@	EQ 50MG BASE	A 206260	001	May 09, 2017	Nov	DISC
>D> AB		EQ 150MG BASE	A 206260	002	May 09, 2017	Nov	DISC
>A>	@	EQ 150MG BASE	A 206260	002	May 09, 2017	Nov	DISC
>D> AB		EQ 200MG BASE	A 206260	003	May 09, 2017	Nov	DISC
>A>	@	EQ 200MG BASE	A 206260	003	May 09, 2017	Nov	DISC
>D> AB		EQ 300MG BASE	A 206260	004	May 09, 2017	Nov	DISC
>A>	@	EQ 300MG BASE	A 206260	004	May 09, 2017	Nov	DISC
>D> AB		EQ 400MG BASE	A 206260	005	May 09, 2017	Nov	DISC
>A>	@	EQ 400MG BASE	A 206260	005	May 09, 2017	Nov	DISC
AB	PRINSTON INC	EQ 400MG BASE	A 208781	005	Mar 11, 2024	Mar	NEWA

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

AB	CHARTWELL RX	EQ 5MG BASE	A 076803	001	Mar 02, 2005	Jul	CMFD
AB		EQ 10MG BASE	A 076803	002	Mar 02, 2005	Jul	CMFD
AB		EQ 20MG BASE	A 076803	003	Mar 02, 2005	Jul	CMFD
AB		EQ 40MG BASE	A 076803	004	Mar 02, 2005	Jul	CMFD
	@ INVAGEN PHARMS	EQ 5MG BASE	A 078457	001	Aug 24, 2007	Mar	DISC
	@	EQ 10MG BASE	A 078457	002	Aug 24, 2007	Mar	DISC
	@	EQ 20MG BASE	A 078457	003	Aug 24, 2007	Mar	DISC
	@	EQ 40MG BASE	A 078457	004	Aug 24, 2007	Mar	DISC

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE

AB	HIBROW HLTHCARE	324MG	A 212589	001	Sep 17, 2021	Sep	CAHN
----	-----------------	-------	----------	-----	--------------	-----	------

QUINIDINE SULFATE

TABLET;ORAL

QUINIDINE SULFATE

@ CHARTWELL RX 300MG A089839 001 Sep 29, 1988 Jul CAHN

QUININE SULFATE

CAPSULE;ORAL

QUALAQUIN

+ @ SUN PHARM INDUSTRIES 324MG N021799 001 Aug 12, 2005 Aug DISC

AB ! QUININE SULFATE

NOVAST LABS 324MG A204372 001 Jul 22, 2015 Aug CHRS

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL

ACIPHEX

+ @ WAYLIS THERAP 10MG N020973 001 May 29, 2002 Apr CAHN

AB +!

20MG N020973 002 Aug 19, 1999 Apr CAHN

RAMELTEON

TABLET;ORAL

RAMELTEON

AB ANDAS 5 HOLDING 8MG A215435 001 Aug 24, 2022 Aug CAHN

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

@ ACCORD HLTHCARE 1.25MG A202392 001 Apr 15, 2014 May DISC

@ 2.5MG A202392 002 Apr 15, 2014 May DISC

@ 5MG A202392 003 Apr 15, 2014 May DISC

@ 10MG A202392 004 Apr 15, 2014 May DISC

RANITIDINE HYDROCHLORIDE

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

@ LANNETT CO INC EQ 15MG BASE/ML A091288 001 Dec 09, 2010 Mar DISC

@ PHARM ASSOC EQ 15MG BASE/ML A077405 001 Sep 21, 2007 Mar DISC

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

@ ENDO OPERATIONS EQ 150MG BASE A075180 001 Jan 28, 1999 May CAHN

@ EQ 300MG BASE A075180 002 Jan 28, 1999 May CAHN

@ PAR PHARM EQ 150MG BASE A075180 001 Jan 28, 1999 Feb DISC

@ EQ 300MG BASE A075180 002 Jan 28, 1999 Feb DISC

RANOLAZINE

GRANULES, EXTENDED RELEASE;ORAL

ASPRUZYO SPRINKLE

+ @ SPIL 500MG N216018 001 Feb 28, 2022 Aug DISC

+ @ 1GM N216018 002 Feb 28, 2022 Aug DISC

TABLET, EXTENDED RELEASE;ORAL

RANOLAZINE

>D> AB ALLIED 500MG A213517 001 Apr 27, 2022 Nov CAHN

AB 500MG A213517 001 Apr 27, 2022 Sep CAHN

>D> AB 1GM A213517 002 Apr 27, 2022 Nov CAHN

AB 1GM A213517 002 Apr 27, 2022 Sep CAHN

>A> AB I3 PHARMS 500MG A213517 001 Apr 27, 2022 Nov CAHN

>A> AB 1GM A213517 002 Apr 27, 2022 Nov CAHN

@ PIRAMAL 500MG A213085 001 Jul 25, 2023 Jan DISC

@ 1GM A213085 002 Jul 25, 2023 Jan DISC

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

AB MACLEODS PHARMS LTD EQ 0.5MG BASE A208866 001 Jun 28, 2024 Jun NEWA

AB EQ 1MG BASE A208866 002 Jun 28, 2024 Jun NEWA

@ RYAN LABS EQ 0.5MG BASE A201942 001 Nov 18, 2021 Sep CAHN

@ EQ 1MG BASE A201942 002 Nov 18, 2021 Sep CAHN

AB SKG PHARMA EQ 0.5MG BASE A218163 001 Apr 09, 2024 Mar NEWA

AB EQ 1MG BASE A218163 002 Apr 09, 2024 Mar NEWA

REGADENOSON

SOLUTION; INTRAVENOUS
REGADENOSON

AP	GE HEALTHCARE	0.4MG/5ML (0.08MG/ML)	A215955	001	Aug 05, 2024	Jul	NEWA
AP	INDIES PHARMA	0.4MG/5ML (0.08MG/ML)	A218054	001	Aug 22, 2024	Aug	NEWA

REMIFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION
REMIFENTANIL HYDROCHLORIDE

AP	NIVAGEN PHARMS INC	EQ 1MG BASE/VIAL	A215635	001	Jun 28, 2024	Jun	NEWA
AP		EQ 2MG BASE/VIAL	A215635	002	Jun 28, 2024	Jun	NEWA
AP		EQ 5MG BASE/VIAL	A215635	003	Jun 28, 2024	Jun	NEWA

REPOTRECTINIB

CAPSULE; ORAL
AUGTYRO

	+ BRISTOL	160MG	N218213	002	Jun 11, 2024	Jul	NEWA
--	-----------	-------	---------	-----	--------------	-----	------

RESMETIROM

TABLET; ORAL
REZDIFFRA

	+ MADRIGAL	60MG	N217785	001	Mar 14, 2024	Mar	NEWA
	+	80MG	N217785	002	Mar 14, 2024	Mar	NEWA
	+!	100MG	N217785	003	Mar 14, 2024	Mar	NEWA

RETAPAMULIN

OINTMENT; TOPICAL
ALTABAX

	+ @ ALMIRALL	1%	N022055	001	Apr 12, 2007	May	DISC
--	--------------	----	---------	-----	--------------	-----	------

>A> REVUMENIB CITRATE

>A> TABLET; ORAL
>A> REVUFORJ

>A>	+ SYNDAX	EQ 25MG BASE	N218944	001	Nov 15, 2024	Nov	NEWA
>A>	+	EQ 110MG BASE	N218944	002	Nov 15, 2024	Nov	NEWA
>A>	+!	EQ 160MG BASE	N218944	003	Nov 15, 2024	Nov	NEWA

REZAFUNGIN ACETATE

POWDER; INTRAVENOUS
REZZAYO

	+! MUNDIPHARMA	EQ 200MG BASE/VIAL	N217417	001	Mar 22, 2023	Jun	CAHN
--	----------------	--------------------	---------	-----	--------------	-----	------

RIFAMPIN

CAPSULE; ORAL
RIFAMPIN

	@ HIKMA	150MG	A065028	001	Mar 14, 2001	Mar	DISC
	@	300MG	A065028	002	Mar 14, 2001	Mar	DISC

RIFAMYCIN SODIUM

TABLET, DELAYED RELEASE; ORAL
AEMCOLO

>A>	+ @ COSMO TECHNOLOGIES	EQ 194MG BASE	N210910	001	Nov 16, 2018	Nov	CAHN
>D>	+ @ REDHILL	EQ 194MG BASE	N210910	001	Nov 16, 2018	Nov	CAHN
	+ @	EQ 194MG BASE	N210910	001	Nov 16, 2018	Oct	DISC

RILPIVIRINE HYDROCHLORIDE

TABLET, FOR SUSPENSION; ORAL
EDURANT PED

	+ @ JANSSEN PRODS	EQ 2.5MG BASE	N219016	001	Mar 15, 2024	Aug	DISC
	+!	EQ 2.5MG BASE	N219016	001	Mar 15, 2024	Mar	NEWA

RILUZOLE

FILM; ORAL
EXSERVAN

	+ @ AQUESTIVE	50MG	N212640	001	Nov 22, 2019	Sep	DISC
--	---------------	------	---------	-----	--------------	-----	------

SUSPENSION; ORAL
RILUZOLE

AB	ALKEM LABS LTD	50MG/10ML	A216035	001	Aug 22, 2024	Aug	NFTG
AB	+! ITALFARMACO SA	50MG/10ML	N209080	001	Sep 05, 2018	Aug	CFTG

	TABLET;ORAL						
	RILUTEK						
	+ @ COVIS	50MG	N020599	001	Dec 12, 1995	May	DISC
	RILUZOLE						
AB	! ALKEM LABS LTD	50MG	A204048	001	Mar 30, 2016	May	CHRS
	@ SUN PHARM INDS LTD	50MG	A091417	001	Jun 18, 2013	Oct	DISC
	<u>RISEDRONATE SODIUM</u>						
	TABLET;ORAL						
	RISEDRONATE SODIUM						
EX	AUROBINDO PHARMA	150MG	A206768	001	Oct 21, 2016	Jun	CTEC
	<u>RISPERIDONE</u>						
	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR						
	RISVAN						
	+ @ LABS FARMS ROVI SA	75MG	N214835	001	Mar 29, 2024	Oct	DISC
	+	75MG	N214835	001	Mar 29, 2024	Mar	NEWA
	+ @	100MG	N214835	002	Mar 29, 2024	Oct	DISC
	+!	100MG	N214835	002	Mar 29, 2024	Mar	NEWA
	RYKINDO						
	+ SHANDONG LUYE	12.5MG	N212849	001	Jan 13, 2023	Sep	CHRS
	+	37.5MG	N212849	003	Jan 13, 2023	Sep	CHRS
	+	50MG	N212849	004	Jan 13, 2023	Sep	CHRS
	INJECTABLE;INTRAMUSCULAR						
	RISPERDAL CONSTA						
AB	+ JANSSEN PHARMS	12.5MG/VIAL	N021346	004	Apr 12, 2007	Jan	CMS1
AB	+!	25MG/VIAL	N021346	001	Oct 29, 2003	Jan	CMS1
AB	+	37.5MG/VIAL	N021346	002	Oct 29, 2003	Jan	CMS1
AB	+	50MG/VIAL	N021346	003	Oct 29, 2003	Jan	CMS1
	RISPERIDONE						
AB	TEVA PHARMS USA INC	12.5MG/VIAL	A214068	001	Dec 05, 2023	Jan	CMS1
AB		25MG/VIAL	A214068	002	Dec 05, 2023	Jan	CMS1
AB		37.5MG/VIAL	A214068	003	Dec 05, 2023	Jan	CMS1
AB		50MG/VIAL	A214068	004	Dec 05, 2023	Jan	CMS1
	SOLUTION;ORAL						
	RISPERIDONE						
	@ HIKMA	1MG/ML	A076904	001	Jul 29, 2009	Mar	DISC
	@ PHARM ASSOC	1MG/ML	A077719	001	Jul 29, 2009	Feb	DISC
	@ SCIEGEN PHARMS INC	1MG/ML	A078909	001	Jul 29, 2009	Sep	CAHN
	TABLET;ORAL						
	RISPERIDONE						
AB	ALLIED	0.25MG	A078871	001	Oct 09, 2008	Jul	CAHN
AB		0.5MG	A078871	002	Oct 09, 2008	Jul	CAHN
AB		1MG	A078871	003	Oct 09, 2008	Jul	CAHN
AB		2MG	A078871	004	Oct 09, 2008	Jul	CAHN
AB		3MG	A078871	005	Oct 09, 2008	Jul	CAHN
AB		4MG	A078871	006	Oct 09, 2008	Jul	CAHN
AB	ESJAY PHARMA	0.25MG	A078871	001	Oct 09, 2008	Oct	CAHN
AB		0.5MG	A078871	002	Oct 09, 2008	Oct	CAHN
AB		1MG	A078871	003	Oct 09, 2008	Oct	CAHN
AB		2MG	A078871	004	Oct 09, 2008	Oct	CAHN
AB		3MG	A078871	005	Oct 09, 2008	Oct	CAHN
AB		4MG	A078871	006	Oct 09, 2008	Oct	CAHN
AB	IPCA LABS LTD	0.25MG	A205104	001	Jun 26, 2024	Jun	NEWA
AB		0.5MG	A205104	002	Jun 26, 2024	Jun	NEWA
AB		1MG	A205104	003	Jun 26, 2024	Jun	NEWA
AB		2MG	A205104	004	Jun 26, 2024	Jun	NEWA
AB		3MG	A205104	005	Jun 26, 2024	Jun	NEWA
AB		4MG	A205104	006	Jun 26, 2024	Jun	NEWA
AB	NOVITIUM PHARMA	0.25MG	A078871	001	Oct 09, 2008	Aug	CAHN
AB		0.5MG	A078871	002	Oct 09, 2008	Aug	CAHN
AB		1MG	A078871	003	Oct 09, 2008	Aug	CAHN
AB		2MG	A078871	004	Oct 09, 2008	Aug	CAHN
AB		3MG	A078871	005	Oct 09, 2008	Aug	CAHN
AB		4MG	A078871	006	Oct 09, 2008	Aug	CAHN
AB	RENATA	0.25MG	A078707	001	Dec 29, 2008	Feb	CAHN
AB		0.5MG	A078707	002	Dec 29, 2008	Feb	CAHN
AB		1MG	A078707	003	Dec 29, 2008	Feb	CAHN
AB		2MG	A078707	004	Dec 29, 2008	Feb	CAHN
AB		3MG	A078707	005	Dec 29, 2008	Feb	CAHN
AB		4MG	A078707	006	Dec 29, 2008	Feb	CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
RISPERIDONE

	ENDO OPERATIONS	0.25MG	A077494	001	Apr 30, 2009	Apr	CAHN
AB		0.5MG	A077494	002	Apr 30, 2009	Apr	CAHN
AB		1MG	A077494	003	Oct 26, 2009	Apr	CAHN
AB		2MG	A077494	004	Apr 30, 2009	Apr	CAHN
AB		3MG	A077494	005	Apr 30, 2009	Apr	CAHN
AB		4MG	A077494	006	Apr 30, 2009	Apr	CAHN

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

RIVASTIGMINE TARTRATE

	@ SUN PHARM	EQ 1.5MG BASE	A077131	001	Oct 22, 2007	Oct	DISC
	@	EQ 3MG BASE	A077131	002	Oct 22, 2007	Oct	DISC
	@	EQ 4.5MG BASE	A077131	003	Oct 22, 2007	Oct	DISC
	@	EQ 6MG BASE	A077131	004	Oct 22, 2007	Oct	DISC

SOLUTION;ORAL

EXELON

	+ @ NOVARTIS	EQ 2MG BASE/ML	N021025	001	Apr 21, 2000	Apr	CRLD
--	--------------	----------------	---------	-----	--------------	-----	------

RIZATRIPTAN BENZOATE

FILM;ORAL

RIZAFILM

	+ @ GENSCO	EQ 10MG BASE	N205394	001	Apr 14, 2023	Jun	DISC
--	------------	--------------	---------	-----	--------------	-----	------

TABLET;ORAL

RIZATRIPTAN BENZOATE

	@ GLENMARK PHARMS LTD	EQ 5MG BASE	A201967	001	Dec 31, 2012	Aug	DISC
	@	EQ 10MG BASE	A201967	002	Dec 31, 2012	Aug	DISC
	@ INVAGEN PHARMS	EQ 5MG BASE	A204339	001	Jul 01, 2013	Apr	DISC
	@	EQ 10MG BASE	A204339	002	Jul 01, 2013	Apr	DISC
	@ NATCO PHARMA LTD	EQ 5MG BASE	A200482	001	Dec 31, 2012	Aug	DISC
	@	EQ 10MG BASE	A200482	002	Dec 31, 2012	Aug	DISC

TABLET, ORALLY DISINTEGRATING;ORAL

RIZATRIPTAN BENZOATE

>A>	@ CHARTWELL RX	EQ 5MG BASE	A078739	001	Jul 01, 2013	Nov	CAHN
>A>	@	EQ 10MG BASE	A078739	002	Jul 01, 2013	Nov	CAHN
	@ GLENMARK PHARMS LTD	EQ 5MG BASE	A201914	001	Jul 01, 2013	Aug	DISC
	@	EQ 10MG BASE	A201914	002	Jul 01, 2013	Aug	DISC
>D>	@ SANDOZ	EQ 5MG BASE	A078739	001	Jul 01, 2013	Nov	CAHN
>D>	@	EQ 10MG BASE	A078739	002	Jul 01, 2013	Nov	CAHN

ROCURONIUM BROMIDE

INJECTABLE;INJECTION

ROCURONIUM BROMIDE

	@ HIKMA	50MG/5ML (10MG/ML)	A217034	001	May 24, 2023	Jul	DISC
AP	SHANDONG	50MG/5ML (10MG/ML)	A215684	001	Jul 12, 2024	Jul	NEWA
AP		100MG/10ML (10MG/ML)	A215684	002	Jul 12, 2024	Jul	NEWA
AP	STERISCIENCE	50MG/5ML (10MG/ML)	A217092	001	Jul 22, 2024	Jul	NEWA

ROFLUMILAST

CREAM;TOPICAL

ZORYVE

	+! ARCUTIS	0.15%	N215985	002	Jul 09, 2024	Jul	NEWA
--	------------	-------	---------	-----	--------------	-----	------

TABLET;ORAL

ROFLUMILAST

	@ BRECKENRIDGE	250MCG	A208236	002	Oct 19, 2023	Jul	DISC
AB	TORRENT	250MCG	A208272	002	Oct 18, 2024	Oct	NEWA

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION

ROPIVACAINE HYDROCHLORIDE

AP	CAPLIN	200MG/100ML (2MG/ML)	A212808	005	May 23, 2024	May	NEWA
AP		400MG/200ML (2MG/ML)	A212808	006	May 23, 2024	May	NEWA
AP	HIKMA	200MG/100ML (2MG/ML)	A211907	001	Aug 15, 2024	Aug	NEWA
AP		400MG/200ML (2MG/ML)	A211907	002	Aug 15, 2024	Aug	NEWA
AP		500MG/100ML (5MG/ML)	A211907	003	Aug 15, 2024	Aug	NEWA
	@ HOSPIRA	20MG/10ML (2MG/ML)	A090194	001	Sep 23, 2014	May	DISC
	@	40MG/20ML (2MG/ML)	A090194	005	Sep 23, 2014	May	DISC
	@	100MG/10ML (10MG/ML)	A090194	004	Sep 23, 2014	May	DISC
	@	150MG/30ML (5MG/ML)	A090194	002	Sep 23, 2014	May	DISC
	@	150MG/20ML (7.5MG/ML)	A090194	003	Sep 23, 2014	May	DISC
	@	200MG/20ML (10MG/ML)	A090194	006	Sep 23, 2014	May	DISC

SOLUTION; INJECTION

ROPIVACAINE HYDROCHLORIDE

AP	KINDOS	20MG/10ML (2MG/ML)	A218713	001	Jul 30, 2024	Jul	NEWA
AP		40MG/20ML (2MG/ML)	A218713	002	Jul 30, 2024	Jul	NEWA
AP		100MG/20ML (5MG/ML)	A218713	003	Jul 30, 2024	Jul	NEWA
AP		100MG/10ML (10MG/ML)	A218713	004	Jul 30, 2024	Jul	NEWA
AP		150MG/30ML (5MG/ML)	A218713	005	Jul 30, 2024	Jul	NEWA
AP		150MG/20ML (7.5MG/ML)	A218713	006	Jul 30, 2024	Jul	NEWA
AP		200MG/20ML (10MG/ML)	A218713	007	Jul 30, 2024	Jul	NEWA

ROSUVASTATIN CALCIUM

TABLET; ORAL

ROSUVASTATIN CALCIUM

AB	MACLEODS PHARMS LTD	EQ 5MG BASE	A207296	001	Nov 06, 2024	Oct	NEWA
AB		EQ 10MG BASE	A207296	002	Nov 06, 2024	Oct	NEWA
AB		EQ 20MG BASE	A207296	003	Nov 06, 2024	Oct	NEWA
AB		EQ 40MG BASE	A207296	004	Nov 06, 2024	Oct	NEWA
	@ SANDOZ	EQ 5MG BASE	A079171	001	Jul 19, 2016	Jan	DISC
	@	EQ 10MG BASE	A079171	002	Jul 19, 2016	Jan	DISC
	@	EQ 20MG BASE	A079171	003	Jul 19, 2016	Jan	DISC
	@	EQ 40MG BASE	A079171	004	Jul 19, 2016	Jan	DISC
	@ SUN PHARM	EQ 5MG BASE	A079169	001	Jul 19, 2016	Oct	DISC
	@	EQ 10MG BASE	A079169	002	Jul 19, 2016	Oct	DISC
	@	EQ 20MG BASE	A079169	003	Jul 19, 2016	Oct	DISC

RUCAPARIB CAMSYLATE

TABLET; ORAL

RUBRACA

+	PHARMAAND	EQ 200MG BASE	N209115	001	Dec 19, 2016	Jul	CAHN
+		EQ 250MG BASE	N209115	003	May 01, 2017	Jul	CAHN
+	!	EQ 300MG BASE	N209115	002	Dec 19, 2016	Jul	CAHN

SACUBITRIL; VALSARTAN

CAPSULE, PELLETS; ORAL

ENTRESTO SPRINKLE

+	NOVARTIS	6MG; 6MG	N218591	001	Apr 12, 2024	Apr	NEWA
+	!	15MG; 16MG	N218591	002	Apr 12, 2024	Apr	NEWA

TABLET; ORAL

ENTRESTO

AB	+ NOVARTIS PHARMS CORP	24MG; 26MG	N207620	001	Jul 07, 2015	May	CFTG
AB	+	49MG; 51MG	N207620	002	Jul 07, 2015	May	CFTG
AB	+	97MG; 103MG	N207620	003	Jul 07, 2015	May	CFTG

SACUBITRIL AND VALSARTAN

AB	ALEMBIC	24MG; 26MG	A213682	001	May 28, 2024	May	NFTG
AB		49MG; 51MG	A213682	002	May 28, 2024	May	NFTG
AB		97MG; 103MG	A213682	003	May 28, 2024	May	NFTG
AB	ALKEM LABS LTD	24MG; 26MG	A213764	001	Sep 16, 2024	Sep	NEWA
AB		49MG; 51MG	A213764	002	Sep 16, 2024	Sep	NEWA
AB		97MG; 103MG	A213764	003	Sep 16, 2024	Sep	NEWA
AB	BIOCON PHARMA	24MG; 26MG	A213680	001	Aug 30, 2024	Aug	NEWA
AB		49MG; 51MG	A213680	002	Aug 30, 2024	Aug	NEWA
AB		97MG; 103MG	A213680	003	Aug 30, 2024	Aug	NEWA
AB	CRYSTAL	24MG; 26MG	A213605	001	May 28, 2024	May	NFTG
AB		49MG; 51MG	A213605	002	May 28, 2024	May	NFTG
AB		97MG; 103MG	A213605	003	May 28, 2024	May	NFTG
AB	LAURUS	24MG; 26MG	A213676	001	May 28, 2024	May	NFTG
AB		49MG; 51MG	A213676	002	May 28, 2024	May	NFTG
AB		97MG; 103MG	A213676	003	May 28, 2024	May	NFTG
AB	MACLEODS PHARMS LTD	24MG; 26MG	A213728	001	Oct 16, 2024	Oct	NEWA
AB		49MG; 51MG	A213728	002	Oct 16, 2024	Oct	NEWA
AB		97MG; 103MG	A213728	003	Oct 16, 2024	Oct	NEWA
AB	MSN	24MG; 26MG	A213748	001	Jul 24, 2024	Jul	NEWA
AB		49MG; 51MG	A213748	002	Jul 24, 2024	Jul	NEWA
AB		97MG; 103MG	A213748	003	Jul 24, 2024	Jul	NEWA
AB	TORRENT	24MG; 26MG	A213604	001	Aug 22, 2024	Oct	CMFD
	@	24MG; 26MG	A213604	001	Aug 22, 2024	Sep	DISC
AB		24MG; 26MG	A213604	001	Aug 22, 2024	Aug	NEWA
AB		49MG; 51MG	A213604	002	Aug 22, 2024	Oct	CMFD
	@	49MG; 51MG	A213604	002	Aug 22, 2024	Sep	DISC
AB		49MG; 51MG	A213604	002	Aug 22, 2024	Aug	NEWA
AB		97MG; 103MG	A213604	003	Aug 22, 2024	Oct	CMFD
	@	97MG; 103MG	A213604	003	Aug 22, 2024	Sep	DISC
AB		97MG; 103MG	A213604	003	Aug 22, 2024	Aug	NEWA

TABLET;ORAL

SACUBITRIL AND VALSARTAN

AB	ZYDUS PHARMS	24MG;26MG	A213719	001	Jul 09, 2024	Jun NEWA
AB		49MG;51MG	A213719	002	Jul 09, 2024	Jun NEWA
AB		97MG;103MG	A213719	003	Jul 09, 2024	Jun NEWA

SAFINAMIDE MESYLATE

TABLET;ORAL

SAFINAMIDE MESYLATE

AB	PRINSTON INC	EQ 50MG BASE	A215739	001	Apr 25, 2024	Apr NEWA
AB		EQ 100MG BASE	A215739	002	Apr 25, 2024	Apr NEWA
KADAGO						
AB	+ MDD US	EQ 50MG BASE	N207145	001	Mar 21, 2017	Apr CTEC
AB	+!	EQ 100MG BASE	N207145	002	Mar 21, 2017	Apr CTEC

SAXAGLIPTIN HYDROCHLORIDE

TABLET;ORAL

SAXAGLIPTIN

	@ AMNEAL	EQ 2.5MG BASE	A205941	001	Jul 31, 2023	Feb DISC
	@	EQ 5MG BASE	A205941	002	Jul 31, 2023	Feb DISC

SCOPOLAMINE

SYSTEM;TRANSDERMAL

SCOPOLAMINE

AB	RHODES PHARMS	1MG/72HR	A215329	001	May 06, 2024	Apr NEWA
AB	ZYDUS PHARMS	1MG/72HR	A217893	001	Aug 29, 2024	Aug NEWA

SECNIDAZOLE

GRANULE;ORAL

SOLOSEC

	+! EVOFEM INC	2GM/PACKET	N209363	001	Sep 15, 2017	Sep CAHN
--	---------------	------------	---------	-----	--------------	----------

SELADELPAR LYSINE

CAPSULE;ORAL

LIVDELZI

	+! CYMABAY	EQ 10MG BASE	N217899	001	Aug 14, 2024	Aug NEWA
	+! GILEAD SCIENCES INC	EQ 10MG BASE	N217899	001	Aug 14, 2024	Sep CAHN

SELEGILINE HYDROCHLORIDE

CAPSULE;ORAL

ELDEPRYL

	+ @ NORVIUM BIOSCIENCE	5MG	N020647	001	May 15, 1996	Aug CAHN
--	------------------------	-----	---------	-----	--------------	----------

TABLET;ORAL

SELEGILINE HYDROCHLORIDE

>D>	@ DASH PHARMS NATCO	5MG	A074866	001	Nov 26, 1997	Nov CAHN
>A>	@ ESJAY PHARMA	5MG	A074866	001	Nov 26, 1997	Nov CAHN
>A> AB	I3 PHARMS	5MG	A074672	001	Apr 01, 1997	Nov CAHN
	@ KENTON	5MG	A074912	001	Apr 30, 1998	May CAHN
>D> AB	MLV	5MG	A074672	001	Apr 01, 1997	Nov CAHN
AB		5MG	A074672	001	Apr 01, 1997	Sep CAHN
	+ @ NORVIUM BIOSCIENCE	5MG	N019334	001	Jun 05, 1989	Aug CAHN

SELEXIPAG

TABLET;ORAL

SELEXIPAG

	@ ZYDUS LIFESCIENCES	0.2MG	A214302	001	Dec 21, 2022	May CAHN
	@	0.4MG	A214302	002	Dec 21, 2022	May CAHN
	@	0.6MG	A214302	003	Dec 21, 2022	May CAHN
	@	0.8MG	A214302	004	Dec 21, 2022	May CAHN
	@	1MG	A214302	005	Dec 21, 2022	May CAHN
	@	1.2MG	A214302	006	Dec 21, 2022	May CAHN
	@	1.4MG	A214302	007	Dec 21, 2022	May CAHN
	@	1.6MG	A214302	008	Dec 21, 2022	May CAHN

SELPERCATINIB

TABLET;ORAL

RETEVMO

	+ LOXO ONCOL ELI LILLY	40MG	N218160	001	Apr 10, 2024	Apr NEWA
		80MG	N218160	002	Apr 10, 2024	Apr NEWA
		120MG	N218160	003	Apr 10, 2024	Apr NEWA
	+!	160MG	N218160	004	Apr 10, 2024	Apr NEWA

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

@	APPCO	EQ 25MG BASE	A077713	001	Feb 06, 2007	May	CAHN
@		EQ 50MG BASE	A077713	002	Feb 06, 2007	May	CAHN
@		EQ 100MG BASE	A077713	003	Feb 06, 2007	May	CAHN

SEVELAMER CARBONATE

FOR SUSPENSION;ORAL

SEVELAMER CARBONATE

AB	INVAGEN PHARMS	800MG/PACKET	A206234	001	Jul 12, 2024	Jul	NEWA
AB		2.4GM/PACKET	A206234	002	Jul 12, 2024	Jul	NEWA
AB	MACLEODS PHARMS LTD	800MG/PACKET	A207291	001	Apr 25, 2024	Apr	NEWA
AB		2.4GM/PACKET	A207291	002	Apr 25, 2024	Apr	NEWA

TABLET;ORAL

SEVELAMER CARBONATE

@	ANXIN	800MG	A212970	001	Apr 09, 2020	Apr	DISC
AB	SHANDONG XINHUA	800MG	A215998	001	Oct 24, 2024	Oct	NEWA
@	SINOTHERAPEUTICS INC	800MG	A212970	001	Apr 09, 2020	Aug	CAHN
AB	STRIDES PHARMA	800MG	A211915	001	May 09, 2024	May	NEWA

SILDENAFIL CITRATE

FOR SUSPENSION;ORAL

SILDENAFIL CITRATE

>D>	AB	GRANULES	EQ 10MG BASE/ML	A214556	001	Dec 01, 2023	Nov	DISC
>A>	@		EQ 10MG BASE/ML	A214556	001	Dec 01, 2023	Nov	DISC
	AB	INVAGEN PHARMS	EQ 10MG BASE/ML	A213041	001	Aug 06, 2020	Sep	CAHN
	AB	SOMERSET THERAPS LLC	EQ 10MG BASE/ML	A213814	001	Apr 29, 2021	Sep	CAHN

SUSPENSION;ORAL

LIQREV

+	@	CMP DEV LLC	EQ 10MG BASE/ML	N214952	001	Apr 28, 2023	Jul	DISC
---	---	-------------	-----------------	---------	-----	--------------	-----	------

TABLET;ORAL

SILDENAFIL CITRATE

@	MYLAN PHARMS INC	EQ 20MG BASE	A201150	001	Nov 09, 2012	Apr	DISC
BX	UMEDICA	EQ 25MG BASE	A209302	003	Jun 15, 2021	Jun	CTEC
BX		EQ 50MG BASE	A209302	001	Aug 25, 2020	Jun	CTEC
BX		EQ 100MG BASE	A209302	002	Aug 25, 2020	Jun	CTEC

SILODOSIN

CAPSULE;ORAL

RAPAFLO

AB	+!	ABBVIE	4MG	N022206	001	Oct 08, 2008	Oct	CAHN
AB	+		8MG	N022206	002	Oct 08, 2008	Oct	CAHN
		SILODOSIN						
AB		CHARTWELL RX	4MG	A204726	001	Mar 31, 2017	Mar	CAHN
AB			8MG	A204726	002	Mar 31, 2017	Mar	CAHN

SILVER SULFADIAZINE

CREAM;TOPICAL

SSD

>A>	AB	+!	DR REDDYS	1%	N018578	001	Feb 25, 1982	Nov	CAHN
>D>	AB	+!	DR REDDYS LA	1%	N018578	001	Feb 25, 1982	Nov	CAHN
	AB	+!		1%	N018578	001	Feb 25, 1982	Jan	CRLD
	AB	!		1%	N018578	001	Feb 25, 1982	Jan	CHRS

SSD AF

>A>	@	DR REDDYS	1%	N018578	003	Jul 11, 1990	Nov	CAHN
>D>	@	DR REDDYS LA	1%	N018578	003	Jul 11, 1990	Nov	CAHN

SIMVASTATIN

SUSPENSION;ORAL

FLOLIPID

+	SALERNO PHARMS	20MG/5ML	N206679	001	Apr 21, 2016	Apr	CAHN
+	!	40MG/5ML	N206679	002	Apr 21, 2016	Apr	CAHN

TABLET;ORAL

SIMVASTATIN

>A>	AB	YILING	10MG	A211394	001	Nov 27, 2024	Nov	NEWA
>A>	AB		20MG	A211394	002	Nov 27, 2024	Nov	NEWA
>A>	AB		40MG	A211394	003	Nov 27, 2024	Nov	NEWA
>A>	AB		80MG	A211394	004	Nov 27, 2024	Nov	NEWA

SINCALIDE

INJECTABLE; INJECTION		KINEVAC					
AP	+!	BRACCO	0.005MG/VIAL	N017697	001		May CTEC
POWDER; INTRAVENOUS		KINEVAC					
AP	+!	BRACCO	0.005MG/VIAL	N017697	001		May CDFR
SINCALIDE							
AP	+!	MAIA PHARMS INC	0.005MG/VIAL	N210850	001	Nov 22, 2022	May CTEC

SIROLIMUS

SOLUTION; ORAL		SIROLIMUS					
AA		HETERO LABS LTD V	1MG/ML	A215080	001	Sep 16, 2024	Sep NEWA

SODIUM ACETATE

INJECTABLE; INJECTION		SODIUM ACETATE					
AP		FRESENIUS KABI USA	400MEQ/100ML (4MEQ/ML)	A206687	001	Oct 30, 2017	Apr CPOT
AP		MILLA PHARMS	400MEQ/100ML (4MEQ/ML)	A214805	002	Aug 25, 2023	Apr CPOT
SOLUTION; INTRAVENOUS		SODIUM ACETATE					
AP	!	FRESENIUS KABI USA	400MEQ/100ML (4MEQ/ML)	A206687	001	Oct 30, 2017	Apr CDFR
AP		HIKMA	40MEQ/20ML (2MEQ/ML)	A216920	001	Mar 15, 2024	Mar NEWA
AP			100MEQ/50ML (2MEQ/ML)	A216920	002	Mar 15, 2024	Mar NEWA
AP			200MEQ/100ML (2MEQ/ML)	A216920	003	Mar 15, 2024	Mar NEWA
AP	+!	HOSPIRA	2MEQ/ML	N018893	001	May 04, 1983	Mar CDFR
AP	+!		40MEQ/20ML (2MEQ/ML)	N018893	001	May 04, 1983	Mar CPOT
AP	+!		100MEQ/50ML (2MEQ/ML)	N018893	002	Sep 02, 2014	Mar CMS1
AP	+!		200MEQ/100ML (2MEQ/ML)	N018893	003	Sep 02, 2014	Mar CMS1
AP		MILLA PHARMS	2MEQ/ML	A214805	001	May 04, 2021	Mar CDFR
AP			40MEQ/20ML (2MEQ/ML)	A214805	004	Jan 22, 2024	Mar CMS1
AP			100MEQ/50ML (2MEQ/ML)	A214805	001	May 04, 2021	Mar CPOT
AP			200MEQ/100ML (2MEQ/ML)	A214805	003	May 04, 2021	Mar CMS1
AP			400MEQ/100ML (4MEQ/ML)	A214805	002	Aug 25, 2023	Apr CDFR

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; INTRAVENOUS		AMMONUL					
	+ @	BAUSCH	10%;10% (5GM/50ML;5GM/50ML)	N020645	001	Feb 17, 2005	Jul DISC
SODIUM PHENYLACETATE AND SODIUM BENZOATE							
AP	!	AILEX PHARMS LLC	10%;10% (5GM/50ML;5GM/50ML)	A207096	001	Feb 24, 2016	Jul CHRS

SODIUM BICARBONATE

INJECTABLE; INJECTION		SODIUM BICARBONATE					
AP		LONG GROVE PHARMS	1MEQ/ML	A216042	001	Feb 27, 2024	Jun CAHN
AP		NIVAGEN PHARMS INC	1MEQ/ML	A216042	001	Feb 27, 2024	Feb NEWA
AP		STERISCIENCE	1MEQ/ML	A217594	001	Jun 28, 2023	Apr CMFD
	@		1MEQ/ML	A217594	001	Jun 28, 2023	Jan DISC

SODIUM CHLORIDE

SOLUTION; INJECTION		SODIUM CHLORIDE 0.9%					
	@	HIKMA	90MG/10ML (9MG/ML)	A201850	001	Jan 20, 2012	Mar DISC
SOLUTION; IRRIGATION		SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
AT		FRESENIUS KABI USA	900MG/100ML	A213688	001	Jun 24, 2024	Jun NEWA

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS		SODIUM FLUORIDE F-18					
AP	!	PETNET	10-200mCi/ML	A203890	001	Sep 28, 2015	Jan CHRS

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION		SODIUM NITROPRUSSIDE					
AP		SLATE RUN PHARMA	25MG/ML	A214199	001	Aug 25, 2020	Sep CAHN

SOLUTION;INTRAVENOUS							
SODIUM NITROPRUSSIDE							
	SLATE RUN PHARMA	10MG/50ML (0.2MG/ML)	A215846	001	Aug 26, 2022	Sep	CAHN
AP		20MG/100ML (0.2MG/ML)	A215846	002	Aug 26, 2022	Sep	CAHN
AP		50MG/100ML (0.5MG/ML)	A215846	003	Aug 26, 2022	Sep	CAHN
<u>SODIUM PHENYL BUTYRATE</u>							
POWDER;ORAL							
SODIUM PHENYL BUTYRATE							
AB	ENDO OPERATIONS	3GM/TEASPOONFUL	A203918	001	Jun 15, 2016	Apr	CAHN
TABLET;ORAL							
SODIUM PHENYL BUTYRATE							
AB	ENDO OPERATIONS	500MG	A204395	001	Apr 15, 2016	Apr	CAHN
<u>SODIUM PHENYL BUTYRATE; TAURURSODIOL</u>							
FOR SUSPENSION;ORAL							
RELYVRIO							
	+ @ AMYLYX	3GM/PACKET; 1GM/PACKET	N216660	001	Sep 29, 2022	Oct	DISC
<u>SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS</u>							
INJECTABLE;INJECTION							
SODIUM PHOSPHATES							
AP	AM REGENT	142MG/ML;276MG/ML	A218314	001	Jun 21, 2024	Jun	NEWA
SOLUTION;INTRAVENOUS							
SODIUM PHOSPHATES							
AP	AM REGENT	142MG/ML;276MG/ML	A218314	001	Jun 21, 2024	Sep	CDFR
AP		1.34GM/5ML;1.38GM/5ML (268MG/ML;276MG/ML)	A218314	001	Jun 21, 2024	Sep	CPOT
AP	! FRESENIUS KABI USA	142MG/ML;276MG/ML	A209997	001	Mar 30, 2022	Sep	CDFR
AP	!	1.34GM/5ML;1.38GM/5ML (268MG/ML;276MG/ML)	A209997	001	Mar 30, 2022	Sep	CPOT
SODIUM PHOSPHATES IN PLASTIC CONTAINER							
AP	+! HOSPIRA	142MG/ML;276MG/ML	N018892	001	May 10, 1983	Sep	CDFR
AP	+!	4.02GM/15ML;4.14GM/15ML (268MG/ML;276MG/ML)	N018892	001	May 10, 1983	Sep	CPOT
<u>SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE</u>							
SOLUTION;INTRAVENOUS							
SODIUM PHOSPHATES							
AP	AM REGENT	1.34GM/5ML;1.38GM/5ML (268MG/ML;276MG/ML)	A218314	001	Jun 21, 2024	Sep	CAIN
AP		4.02GM/15ML;4.14GM/15ML (268MG/ML;276MG/ML)	A218314	002	Jun 21, 2024	Sep	NEWA
AP		13.4GM/50ML;13.8GM/50ML (268MG/ML;276MG/ML)	A218314	003	Jun 21, 2024	Sep	NEWA
AP	! FRESENIUS KABI USA	1.34GM/5ML;1.38GM/5ML (268MG/ML;276MG/ML)	A209997	001	Mar 30, 2022	Sep	CAIN
AP		4.02GM/15ML;4.14GM/15ML (268MG/ML;276MG/ML)	A209997	002	Mar 30, 2022	Sep	NEWA
AP	!	13.4GM/50ML;13.8GM/50ML (268MG/ML;276MG/ML)	A209997	003	Mar 30, 2022	Sep	NEWA
SODIUM PHOSPHATES IN PLASTIC CONTAINER							
AP	+! HOSPIRA	4.02GM/15ML;4.14GM/15ML (268MG/ML;276MG/ML)	N018892	001	May 10, 1983	Sep	CAIN
<u>SOFPIRONIUM BROMIDE</u>							
GEL, METERED;TOPICAL							
SOFDRA							
	+! BOTANIX SB	EQ 12.45% BASE (EQ 72MG BASE/ACTUATION)	N217347	001	Jun 18, 2024	Jun	NEWA
<u>SOLIFENACIN SUCCINATE</u>							
TABLET;ORAL							
SOLIFENACIN SUCCINATE							
AB	JUBILANT GENERICS	5MG	A205484	001	Oct 02, 2024	Sep	NEWA
AB		10MG	A205484	002	Oct 02, 2024	Sep	NEWA
AB	MACLEODS PHARMS LTD	5MG	A204374	001	Feb 20, 2024	Feb	NEWA
AB		10MG	A204374	002	Feb 20, 2024	Feb	NEWA

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SOTALOL HYDROCHLORIDE

>A>	@	ESJAY PHARMA	80MG	A 075237	001	May 01, 2000	Nov	CAHN
>A>	@		120MG	A 075237	002	May 01, 2000	Nov	CAHN
>A>	@		160MG	A 075237	003	May 01, 2000	Nov	CAHN
>A>	@		240MG	A 075237	004	May 01, 2000	Nov	CAHN
>D>	@	NATCO PHARMA USA	80MG	A 075237	001	May 01, 2000	Nov	CAHN
>D>	@		120MG	A 075237	002	May 01, 2000	Nov	CAHN
>D>	@		160MG	A 075237	003	May 01, 2000	Nov	CAHN
>D>	@		240MG	A 075237	004	May 01, 2000	Nov	CAHN
	@	RISING	80MG	A 075725	001	Dec 19, 2000	Feb	CAHN
	@		120MG	A 075725	002	Dec 19, 2000	Feb	CAHN
	@		160MG	A 075725	003	Dec 19, 2000	Feb	CAHN
	@		240MG	A 075725	004	Dec 19, 2000	Feb	CAHN

SOTORASIB

TABLET; ORAL

LUMAKRAS

+	@	AMGEN INC	240MG	N 214665	003	Jun 26, 2024	Jul	NEWA
---	---	-----------	-------	----------	-----	--------------	-----	------

SOYBEAN OIL

INJECTABLE; INJECTION

NUTRILIPID 10%

+	@	B BRAUN	10%	N 019531	001	May 28, 1993	Jul	DISC
---	---	---------	-----	----------	-----	--------------	-----	------

SPINOSAD

SUSPENSION; TOPICAL

NATROBA

+	!	CIPHER	0.9%	N 022408	001	Jan 18, 2011	Aug	CAHN
---	---	--------	------	----------	-----	--------------	-----	------

STERILE WATER FOR INJECTION

LIQUID; N/A

STERILE WATER FOR INJECTION

AP		AM REGENT	100% (5ML)	A 217341	003	Feb 09, 2024	Feb	NEWA
----	--	-----------	------------	----------	-----	--------------	-----	------

STERILE WATER FOR IRRIGATION

LIQUID; IRRIGATION

STERILE WATER FOR IRRIGATION

AT		FRESENIUS KABI USA	100%	A 216123	001	Aug 12, 2024	Aug	NFTG
----	--	--------------------	------	----------	-----	--------------	-----	------

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

SUCCINYLCHOLINE CHLORIDE

	@	ACCORD HLTHCARE	20MG/ML	A 213705	001	May 20, 2020	May	DISC
AP		ADAPTIS	20MG/ML	A 214308	001	May 22, 2020	Aug	CAHN
AP		BAXTER HLTHCARE CORP	20MG/ML	A 218878	001	Sep 24, 2024	Sep	NEWA
	@	EUGIA PHARMA	20MG/ML	A 217808	001	Oct 16, 2023	Apr	DISC
AP		NIVAGEN PHARMS INC	20MG/ML	A 211625	001	May 19, 2020	Jan	CAHN
AP		UMEDICA	20MG/ML	A 211625	001	May 19, 2020	Aug	CAHN

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

SUCCINYLCHOLINE CHLORIDE

AP		DR REDDYS	100MG/5ML (20MG/ML)	A 218467	001	Jan 17, 2024	Jan	NEWA
AP	+	HIKMA	100MG/5ML (20MG/ML)	N 215143	001	Aug 20, 2021	Jan	CFTG
AP		STERISCIENCE	100MG/5ML (20MG/ML)	A 217873	001	Jul 09, 2024	Jun	NEWA

SUCRALFATE

SUSPENSION; ORAL

SUCRALFATE

AB		ABON PHARMS LLC	1GM/10ML	A 216726	001	Mar 21, 2024	Mar	NEWA
>A>	AB	COSETTE	1GM/10ML	A 217126	001	Nov 13, 2024	Nov	NEWA
AB		PD PARTNERS	1GM/10ML	A 213549	001	Jan 17, 2024	Jan	NEWA
AB		STRIDES PHARMA	1GM/10ML	A 216474	001	May 21, 2024	May	NEWA
AB		VISTAPHARM LLC	1GM/10ML	A 211884	001	Mar 15, 2022	Apr	CAHN

SUFENTANIL CITRATE

>D>		TABLET; SUBLINGUAL						
>D>		DSUVIA						
>D>	+	VERTICAL PHARMS	EQ 0.03MG BASE	N 209128	001	Nov 02, 2018	Nov	DISC
>A>	+	@	EQ 0.03MG BASE	N 209128	001	Nov 02, 2018	Nov	DISC

SUGAMMADEX SODIUMSOLUTION; INTRAVENOUS
SUGAMMADEX SODIUM

@ ZYDUS PHARMS	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214290	001	Oct 04, 2023	Mar DISC
@	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A214290	002	Oct 04, 2023	Mar DISC

SULFACETAMIDE SODIUMSOLUTION/DROPS; OPHTHALMIC
SULFACETAMIDE SODIUM

AT	!	BAUSCH AND LOMB	10%	A040066	001	Dec 28, 1994	Oct CHRS
----	---	-----------------	-----	---------	-----	--------------	----------

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB	!	AUROBINDO PHARMA	200MG/5ML; 40MG/5ML	A091348	001	Jun 08, 2010	Mar CHRS
	@	HIKMA	200MG/5ML; 40MG/5ML	A074650	001	Dec 29, 1997	Mar DISC

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

>A>	@	AIPING PHARM INC	400MG; 80MG	A070889	001	Nov 13, 1986	Nov CAHN
>A>	@		800MG; 160MG	A070890	001	Nov 13, 1986	Nov CAHN
>D>	@	FOSUN PHARMA	400MG; 80MG	A070889	001	Nov 13, 1986	Nov CAHN
>D>	@		800MG; 160MG	A070890	001	Nov 13, 1986	Nov CAHN

SULFANILAMIDECREAM; VAGINAL
AVC

+ @	NORVIUM BIOSCIENCE	15%	N006530	003	Jan 27, 1987	Jun CAHN
-----	--------------------	-----	---------	-----	--------------	----------

SUPPOSITORY; VAGINAL
AVC

@	NORVIUM BIOSCIENCE	1.05GM	N006530	004	Jan 27, 1987	Jun CAHN
---	--------------------	--------	---------	-----	--------------	----------

SUMATRIPTANSPRAY; NASAL
SUMATRIPTAN

AB		ADAPTIS	20MG/SPRAY	A208967	001	Feb 17, 2021	Sep CAHN
----	--	---------	------------	---------	-----	--------------	----------

SUMATRIPTAN SUCCINATEINJECTABLE; SUBCUTANEOUS
SUMATRIPTAN SUCCINATE

AP		CAPLIN	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A213998	001	Jul 13, 2021	Jun CAHN
	@	ENDO OPERATIONS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077332	001	Oct 09, 2009	May CAHN
	@		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077871	001	Jul 09, 2009	May CAHN
AP	!	EUGIA PHARMA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A202758	001	Apr 23, 2013	Jan CHRS
	@	PAR PHARM	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077332	001	Oct 09, 2009	Feb DISC
>A>	AP	STERISCIENCE	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A215651	001	Nov 21, 2024	Nov NEWA
>D>	AB	SUN PHARM	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090358	001	Jun 21, 2011	Nov DISC
>A>	@		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090358	001	Jun 21, 2011	Nov DISC
		SUMAVEL DOSEPRO					
	+ @	ENDO OPERATIONS	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N022239	002	Nov 26, 2013	May CAHN
	+ @		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022239	001	Jul 15, 2009	May CAHN

SUNITINIB MALATECAPSULE; ORAL
SUNITINIB MALATE

AB		EUGIA PHARMA	EQ 12.5MG BASE	A218615	001	Mar 14, 2024	Mar NEWA
AB			EQ 25MG BASE	A218615	002	Mar 14, 2024	Mar NEWA
AB			EQ 37.5MG BASE	A218615	003	Mar 14, 2024	Mar NEWA
AB			EQ 50MG BASE	A218615	004	Mar 14, 2024	Mar NEWA
AB		NOVUGEN	EQ 12.5MG BASE	A218012	001	Aug 21, 2023	May CMFD
	@		EQ 12.5MG BASE	A218012	001	Aug 21, 2023	Feb DISC
AB			EQ 25MG BASE	A218012	002	Aug 21, 2023	May CMFD
	@		EQ 25MG BASE	A218012	002	Aug 21, 2023	Feb DISC

CAPSULE;ORAL
SUNITINIB MALATE

AB		EQ 37.5MG BASE	A218012	003	Aug 21, 2023	May	CMFD
	@	EQ 37.5MG BASE	A218012	003	Aug 21, 2023	Feb	DISC
AB		EQ 50MG BASE	A218012	004	Aug 21, 2023	May	CMFD
	@	EQ 50MG BASE	A218012	004	Aug 21, 2023	Feb	DISC
AB	WANBANG BIOPHARMS	EQ 12.5MG BASE	A218012	001	Aug 21, 2023	Aug	CAHN
AB		EQ 25MG BASE	A218012	002	Aug 21, 2023	Aug	CAHN
AB		EQ 37.5MG BASE	A218012	003	Aug 21, 2023	Aug	CAHN
AB		EQ 50MG BASE	A218012	004	Aug 21, 2023	Aug	CAHN

TACROLIMUS

CAPSULE;ORAL
TACROLIMUS

>D>	@	CONCORD BIOTECH LTD	EQ 0.5MG BASE	A213112	001	Nov 10, 2020	Nov	CMFD
>A>	AB		EQ 0.5MG BASE	A213112	001	Nov 10, 2020	Nov	CMFD

CAPSULE, EXTENDED RELEASE;ORAL
ASTAGRAF XL

AB	+	ASTELLAS	EQ 0.5MG BASE	N204096	001	Jul 19, 2013	Jan	CFTG
AB	+		EQ 1MG BASE	N204096	002	Jul 19, 2013	Jan	CFTG
AB	+	!	EQ 5MG BASE	N204096	003	Jul 19, 2013	Jan	CFTG

TACROLIMUS

AB		CHENGDU	EQ 0.5MG BASE	A215012	001	Jan 25, 2024	Jan	NFTG
AB			EQ 1MG BASE	A215012	002	Jan 25, 2024	Jan	NFTG
AB			EQ 5MG BASE	A215012	003	Jan 25, 2024	Jan	NFTG

TADALAFIL

TABLET;ORAL
CIALIS

	+	@	LILLY	2.5MG	N021368	004	Jan 07, 2008	Sep	DISC
--	---	---	-------	-------	---------	-----	--------------	-----	------

TADALAFIL

>A>	AB1	FOURRTS LABS	2.5MG	A217606	001	Aug 13, 2024	Nov	CAHN
	AB1		2.5MG	A217606	001	Aug 13, 2024	Aug	NEWA
>A>	AB1		5MG	A217606	002	Aug 13, 2024	Nov	CAHN
	AB1		5MG	A217606	002	Aug 13, 2024	Aug	NEWA
>A>	AB1		10MG	A217606	003	Aug 13, 2024	Nov	CAHN
	AB1		10MG	A217606	003	Aug 13, 2024	Aug	NEWA
>A>	AB1		20MG	A217606	004	Aug 13, 2024	Nov	CAHN
	AB1		20MG	A217606	004	Aug 13, 2024	Aug	NEWA
	AB1	HANGZHOU BINJIANG	2.5MG	A208824	001	Oct 27, 2020	Mar	CAHN
	AB1		5MG	A208824	002	Oct 27, 2020	Mar	CAHN
	AB1		10MG	A208824	003	Oct 27, 2020	Mar	CAHN
	AB1		20MG	A208824	004	Oct 27, 2020	Mar	CAHN
>D>	AB1	HIBROW HLTHCARE	2.5MG	A217606	001	Aug 13, 2024	Nov	CAHN
	AB1		2.5MG	A217606	001	Aug 13, 2024	Sep	CAHN
>D>	AB1		5MG	A217606	002	Aug 13, 2024	Nov	CAHN
	AB1		5MG	A217606	002	Aug 13, 2024	Sep	CAHN
>D>	AB1		10MG	A217606	003	Aug 13, 2024	Nov	CAHN
	AB1		10MG	A217606	003	Aug 13, 2024	Sep	CAHN
>D>	AB1		20MG	A217606	004	Aug 13, 2024	Nov	CAHN
	AB1		20MG	A217606	004	Aug 13, 2024	Sep	CAHN
>A>	AB1	SHANDONG	2.5MG	A216279	002	Dec 04, 2024	Nov	NEWA
>A>	AB1		5MG	A216279	003	Dec 04, 2024	Nov	NEWA
>A>	AB1		10MG	A216279	004	Dec 04, 2024	Nov	NEWA
	AB1		20MG	A216279	001	Mar 04, 2024	Feb	NEWA
	BX	UMEDICA	2.5MG	A211298	001	Oct 23, 2020	Jun	CTEC
	BX		5MG	A211298	002	Oct 23, 2020	Jun	CTEC
	BX		10MG	A211298	003	Oct 23, 2020	Jun	CTEC
	BX		20MG	A211298	004	Oct 23, 2020	Jun	CTEC

TABLET, CHEWABLE;ORAL
CHEWTADZY

	+	@	B BETTER	5MG	N218527	001	Jun 28, 2024	Aug	DISC
	+			5MG	N218527	001	Jun 28, 2024	Jun	NEWA
	+	@		10MG	N218527	002	Jun 28, 2024	Aug	DISC
	+			10MG	N218527	002	Jun 28, 2024	Jun	NEWA
	+	@		20MG	N218527	003	Jun 28, 2024	Aug	DISC
	+	!		20MG	N218527	003	Jun 28, 2024	Jun	NEWA

TALAZOPARIB TOSYLATE

CAPSULE;ORAL

TALZENNA

	+	PFIZER	EQ 0.1MG BASE	N217439	001	Mar 07, 2024	Mar	NEWA
	+		EQ 0.25MG BASE	N217439	002	Mar 07, 2024	Mar	NEWA
	+		EQ 0.35MG BASE	N217439	003	Mar 07, 2024	Mar	NEWA
	+		EQ 0.5MG BASE	N217439	004	Mar 07, 2024	Mar	NEWA
	+		EQ 0.75MG BASE	N217439	005	Mar 07, 2024	Mar	NEWA
	+	!	EQ 1MG BASE	N217439	006	Mar 07, 2024	Mar	NEWA

TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

TAMSULOSIN HYDROCHLORIDE

		@ ENDO OPERATIONS	0.4MG	A202010	001	Jan 04, 2013	May	CAHN
		@ NORVIUM BIOSCIENCE	0.4MG	A090408	001	Apr 27, 2010	Jul	CAHN
>A>	AB	SCIEGEN PHARMS INC	0.4MG	A078938	001	Apr 27, 2010	Nov	CAHN
		@ SUN PHARM INDS LTD	0.4MG	A090931	001	Jul 15, 2010	Oct	DISC
>D>	AB	WOCKHARDT	0.4MG	A078938	001	Apr 27, 2010	Nov	CAHN

TAVABOROLE

SOLUTION;TOPICAL

KERYDIN

	+	@ ANACOR PHARMS INC	5%	N204427	001	Jul 07, 2014	Mar	DISC
		TAVABOROLE						
AB	!	ENCUBE	5%	A211297	001	Oct 13, 2020	Mar	CHRS

TAZAROTENE

CREAM;TOPICAL

TAZAROTENE

AB		PADAGIS ISRAEL	0.05%	A217075	001	Jul 15, 2024	Jul	NFTG
		TAZORAC						
AB	+	! ALLERGAN	0.05%	N021184	001	Sep 29, 2000	Jul	CFTG

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE;INJECTION

MYOVUE

	+	! MEDI-PHYSICS	N/A	N020372	001	Feb 09, 1996	Jun	CAHN
		MYOVUE 30ML						
	+	! MEDI-PHYSICS	N/A	N020372	002	Jul 07, 2005	Jun	CAHN

TEDUGLUTIDE

POWDER;SUBCUTANEOUS

GATTEX KIT

	+	! TAKEDA PHARMS USA	5MG/VIAL	N203441	001	Dec 21, 2012	Mar	CAIN
--	---	---------------------	----------	---------	-----	--------------	-----	------

TELMISARTAN

TABLET;ORAL

TELMISARTAN

AB		MANKIND PHARMA	20MG	A218157	001	Oct 15, 2024	Oct	NEWA
AB			40MG	A218157	002	Oct 15, 2024	Oct	NEWA
AB			80MG	A218157	003	Oct 15, 2024	Oct	NEWA

TEMAZEPAM

CAPSULE;ORAL

TEMAZEPAM

		@ AMNEAL PHARMS	7.5MG	A203482	001	May 23, 2016	Oct	DISC
		@	15MG	A203482	002	May 23, 2016	Oct	DISC
		@	22.5MG	A203482	003	May 23, 2016	Oct	DISC
		@	30MG	A203482	004	May 23, 2016	Oct	DISC
AB		CHARTWELL RX	15MG	A071427	001	Jan 12, 1988	Jan	CAHN
AB			30MG	A071428	001	Jan 12, 1988	Jan	CAHN

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

>D>	AB	!	ACCORD HLTHCARE	250MG	A201528	006	Feb 27, 2017	Nov	CHRS
>A>	AB			250MG	A201528	006	Feb 27, 2017	Nov	CHRS
>D>	AB		AMNEAL PHARMS	250MG	A203691	006	May 08, 2015	Nov	CHRS
>A>	AB	!		250MG	A203691	006	May 08, 2015	Nov	CHRS
	AB		HETERO LABS LTD V	5MG	A210030	001	Aug 23, 2024	Aug	NEWA
	AB			20MG	A210030	002	Aug 23, 2024	Aug	NEWA

CAPSULE;ORAL								
TEMOZOLOMIDE								
AB		100MG		A210030	003	Aug 23, 2024	Aug	NEWA
AB		140MG		A210030	004	Aug 23, 2024	Aug	NEWA
AB		180MG		A210030	005	Aug 23, 2024	Aug	NEWA
AB		250MG		A210030	006	Aug 23, 2024	Aug	NEWA
	@ NIVAGEN PHARMS INC	5MG		A213328	001	Nov 23, 2021	Sep	DISC
	@	20MG		A213328	002	Nov 23, 2021	Sep	DISC
	@	100MG		A213328	003	Nov 23, 2021	Sep	DISC
	@	140MG		A213328	004	Nov 23, 2021	Sep	DISC
	@	180MG		A213328	005	Nov 23, 2021	Sep	DISC
	@	250MG		A213328	006	Nov 23, 2021	Sep	DISC
<u>TENAPANOR HYDROCHLORIDE</u>								
TABLET;ORAL								
XPHOZAH								
	+ @ ARDELYX INC	EQ 10MG BASE		N213931	001	Oct 17, 2023	Apr	DISC
<u>TENOFOVIR ALAFENAMIDE FUMARATE</u>								
TABLET;ORAL								
TENOFOVIR ALAFENAMIDE FUMARATE								
	@ APOTEX	EQ 25MG BASE		A213867	001	Mar 21, 2024	May	DISC
AB		EQ 25MG BASE		A213867	001	Mar 21, 2024	Mar	NEWA
<u>TENOFOVIR DISOPROXIL FUMARATE</u>								
TABLET;ORAL								
TENOFOVIR DISOPROXIL FUMARATE								
AB	MYLAN LABS LTD	300MG		A079071	001	Feb 29, 2024	Feb	NEWA
AB	NORVIUM BIOSCIENCE	300MG		A079071	001	Feb 29, 2024	Sep	CAHN
<u>TERAZOSIN HYDROCHLORIDE</u>								
CAPSULE;ORAL								
TERAZOSIN HYDROCHLORIDE								
AB	BIONPHARMA	EQ 1MG BASE		A075667	001	Jul 28, 2000	Jan	CMFD
AB		EQ 2MG BASE		A075667	002	Jul 28, 2000	Jan	CMFD
AB		EQ 5MG BASE		A075667	003	Jul 28, 2000	Jan	CMFD
AB		EQ 10MG BASE		A075667	004	Jul 28, 2000	Jan	CMFD
SOLUTION;ORAL								
TEZRULY								
	+! NOVITIUM PHARMA	EQ 1MG BASE/ML		N218139	001	Jul 29, 2024	Oct	CMFD
	+ @	EQ 1MG BASE/ML		N218139	001	Jul 29, 2024	Aug	DISC
	+!	EQ 1MG BASE/ML		N218139	001	Jul 29, 2024	Jul	NEWA
<u>TERBINAFINE</u>								
GEL;TOPICAL								
LAMISIL								
	@ KARO HLTHCARE	1%		N020846	001	Apr 29, 1998	Feb	CAHN
<u>TERBINAFINE HYDROCHLORIDE</u>								
SOLUTION;TOPICAL								
LAMISIL								
	@ KARO HLTHCARE	1%		N020749	001	Oct 17, 1997	Feb	CAHN
TABLET;ORAL								
TERBINAFINE HYDROCHLORIDE								
	@ CIPLA	EQ 250MG BASE		A077137	001	Jul 02, 2007	Mar	DISC
<u>TERBUTALINE SULFATE</u>								
INJECTABLE;INJECTION								
TERBUTALINE SULFATE								
AP	AREVA PHARMS	1MG/ML		A200122	001	Nov 08, 2013	Apr	CAHN
<u>TERIFLUNOMIDE</u>								
TABLET;ORAL								
TERIFLUNOMIDE								
	@ AMNEAL PHARMS CO	7MG		A209613	001	Sep 28, 2018	May	DISC
	@	14MG		A209613	002	Sep 28, 2018	May	DISC
	@ MYLAN	7MG		A209702	001	Feb 28, 2020	Sep	CAHN
	@	7MG		A209702	001	Feb 28, 2020	Apr	DISC
	@	14MG		A209702	002	Feb 28, 2020	Sep	CAHN
	@	14MG		A209702	002	Feb 28, 2020	Apr	DISC
	@ TORRENT	7MG		A209697	001	Apr 04, 2024	Oct	DISC
AB		7MG		A209697	001	Apr 04, 2024	Mar	NEWA

TABLET; ORAL									
TERIFLUNOMIDE									
	@	14MG	A209697	002	Apr 04, 2024	Oct	DISC		
AB		14MG	A209697	002	Apr 04, 2024	Mar	NEWA		
<u>TERIPARATIDE</u>									
SOLUTION; SUBCUTANEOUS									
TERIPARATIDE									
	+!	ALMAJECT	0.6MG/2.4ML (0.25MG/ML)	N218771	001	Jun 04, 2024	Jun	NEWA	
<u>TESTOSTERONE</u>									
GEL; TRANSDERMAL									
ANDROGEL									
>D>	+ @	BESINS HLTHCARE	1.62% (20.25MG/1.25GM PACKET)	N022309	002	Sep 07, 2012	Nov	CMFD	
>A>	AB2	+	1.62% (20.25MG/1.25GM PACKET)	N022309	002	Sep 07, 2012	Nov	CMFD	
	AB2	+	1.62% (40.5MG/2.5GM PACKET)	N022309	003	Sep 07, 2012	Oct	CMFD	
	AB1	+	25MG/2.5GM PACKET	N021015	001	Feb 28, 2000	Oct	CMFD	
	AB1	+	50MG/5GM PACKET	N021015	002	Feb 28, 2000	Oct	CMFD	
TESTIM									
	AB2	+!	ENDO OPERATIONS	50MG/5GM PACKET	N021454	001	Oct 31, 2002	Apr	CAHN
TESTOSTERONE									
	AB1		ENCUBE	25MG/2.5GM PACKET	A212984	003	Jul 11, 2024	Oct	NEWA
GEL, METERED; TRANSDERMAL									
ANDROGEL									
	AB1	+	BESINS HLTHCARE	12.5MG/1.25GM ACTUATION	N021015	003	Sep 26, 2003	Oct	CMFD
TESTOSTERONE									
	!	ACTAVIS LABS UT INC	10MG/0.5GM ACTUATION	A204571	001	Aug 05, 2015	Jan	CTEC	
AB	!		10MG/0.5GM ACTUATION	A204571	001	Aug 05, 2015	Jan	CHRS	
AB1	!		12.5MG/1.25GM ACTUATION	A076737	003	Mar 09, 2015	Apr	CTEC	
AB1			ENCUBE	12.5MG/1.25GM ACTUATION	A212984	002	Feb 09, 2024	Apr	NEWA
PELLET; IMPLANTATION									
TESTOPEL									
	!	ENDO OPERATIONS	75MG	A080911	001		Apr	CAHN	
SOLUTION, METERED; TRANSDERMAL									
TESTOSTERONE									
AT			ENCUBE	30MG/1.5ML ACTUATION	A212301	001	Jan 11, 2021	Apr	CAHN
AT			FEMPHARM	30MG/1.5ML ACTUATION	A212301	001	Jan 11, 2021	Mar	CAHN
<u>TESTOSTERONE CYPIONATE</u>									
INJECTABLE; INJECTION									
TESTOSTERONE CYPIONATE									
	@	SUN PHARM INDS LTD	100MG/ML	A201720	001	Jun 03, 2013	Oct	DISC	
	@		200MG/ML	A201720	002	Jun 03, 2013	Oct	DISC	
	@	WATSON PHARMS INC	200MG/ML	A086030	001		Sep	DISC	
SOLUTION; INTRAMUSCULAR									
AZMIRO									
	+!	AZURITY	200MG/ML (200MG/ML)	N216318	001	Jun 02, 2022	Oct	CTNA	
	+!		200MG/ML (200MG/ML)	N216318	001	Jun 02, 2022	Sep	CMFD	
	+ @		200MG/ML (200MG/ML)	N216318	001	Jun 02, 2022	Jul	CAHN	
<u>TESTOSTERONE ENANTHATE</u>									
INJECTABLE; INJECTION									
TESTOSTERONE ENANTHATE									
AO		EUGIA PHARMA	200MG/ML	A212659	001	Feb 28, 2024	Feb	NEWA	
AO			200MG/ML	A212659	001	Feb 28, 2024	Feb	NEWA	
AO	!	HIKMA FARMACEUTICA	200MG/ML	A091120	001	Sep 18, 2012	Sep	CHRS	
	@	WATSON PHARMS INC	200MG/ML	A085598	001		Sep	DISC	
<u>TESTOSTERONE UNDECANOATE</u>									
CAPSULE; ORAL									
TLANDO									
	+!	VERITY	112.5MG	N208088	001	Mar 28, 2022	Jan	CAHN	
INJECTABLE; INTRAMUSCULAR									
AVEED									
	+!	ENDO OPERATIONS	750MG/3ML (250MG/ML)	N022219	001	Mar 05, 2014	Apr	CAHN	

TETRABENAZINE

TABLET; ORAL

TETRABENAZINE

>A>	AB	ADAPTIS	12.5MG	A213316	001	Jan 22, 2020	Nov	CAHN
>A>	AB		25MG	A213316	002	Jan 22, 2020	Nov	CAHN
>D>	AB	SLATE RUN PHARMA	12.5MG	A213316	001	Jan 22, 2020	Nov	CAHN
	AB		12.5MG	A213316	001	Jan 22, 2020	Feb	CAHN
>D>	AB		25MG	A213316	002	Jan 22, 2020	Nov	CAHN
	AB		25MG	A213316	002	Jan 22, 2020	Feb	CAHN

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

ACHROMYCIN V

AB	+	AVET	250MG	N050278	003		Oct	CMFD
AB	+		500MG	N050278	001		Oct	CMFD

SUSPENSION; ORAL

SUMYCIN

@ ENDO OPERATIONS

125MG/5ML

A060400 001

May CAHN

TABLET; ORAL

SUMYCIN

STRIDES PHARMA

250MG

A061147 001

Jan CMFD

!

500MG

A061147 004

Jan CMFD

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

THEO-24

ENDO OPERATIONS

100MG

A087943 002 Aug 22, 1983

Apr CAHN

+

200MG

A087943 001 Aug 22, 1983

Apr CAHN

300MG

A087943 003 Aug 22, 1983

Apr CAHN

!

400MG

A087943 004 Feb 28, 1992

Apr CAHN

TABLET, EXTENDED RELEASE; ORAL

THEOCHRON

>D>		NOSTRUM PHARMS LLC	100MG	A087400	003	Feb 21, 1985	Nov	CTNA
>D>			200MG	A087400	004	Feb 21, 1985	Nov	CTNA
>D>	AB		300MG	A087400	002	Jan 11, 1983	Nov	CTNA
>D>	AB		450MG	A087400	005	Aug 09, 2023	Nov	CTNA
>A>		THEOPHYLLINE						
>A>		NOSTRUM PHARMS LLC	100MG	A087400	003	Feb 21, 1985	Nov	CTNA
>A>			200MG	A087400	004	Feb 21, 1985	Nov	CTNA
>A>	AB		300MG	A087400	002	Jan 11, 1983	Nov	CTNA
>A>	AB		450MG	A087400	005	Aug 09, 2023	Nov	CTNA
		@ RHODES PHARMS	600MG	A040086	001	Apr 15, 1996	Jul	DISC
	AB	STRIDES PHARMA	300MG	A215312	001	Sep 05, 2024	Aug	NEWA
	AB		450MG	A215312	002	Sep 05, 2024	Aug	NEWA
	AB	VELZEN PHARMA PVT	300MG	A214950	001	Jan 30, 2023	Aug	CAHN
	AB		450MG	A214950	002	Jan 30, 2023	Aug	CAHN
	AB	ZYDUS LIFESCIENCES	300MG	A218063	001	May 21, 2024	May	CAHN
	AB		450MG	A218063	002	May 21, 2024	May	CAHN
	AB	ZYDUS PHARMS	300MG	A218063	001	May 21, 2024	May	NEWA
	AB		450MG	A218063	002	May 21, 2024	May	NEWA

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HYDROCHLORIDE

AP		ASPIRO	100MG/ML	A218471	001	Nov 06, 2024	Oct	NEWA
AP		STERISCIENCE	100MG/ML	A217181	001	Oct 29, 2024	Oct	NEWA

THIOTEPA

POWDER; INTRACAVITARY, INTRAVENOUS, INTRAVESICAL

THIOTEPA

AP		BELOTECA	15MG/VIAL	A217559	001	Aug 20, 2024	Aug	NEWA
AP		MEITHEAL	15MG/VIAL	A216037	001	Dec 26, 2023	Jun	CAHN
AP			100MG/VIAL	A216037	002	Dec 26, 2023	Jun	CAHN

SOLUTION; INTRAVENOUS

TEPYLUTE

+! SHORLA 15MG/1.5ML (10MG/ML)

N216984 001 Jun 25, 2024 Jun NEWA

TICAGRELOR

TABLET; ORAL		TICAGRELOR					
AB	DR REDDYS	90MG		A208541	001	Oct 29, 2024	Oct NEWA
AB	PRINSTON INC	90MG		A208599	001	Aug 16, 2024	Aug NEWA

TIGECYCLINE

POWDER; INTRAVENOUS		TIGECYCLINE					
	@ ACCORD HLTHCARE INC	50MG/VIAL		N208744	001	Jan 18, 2018	May DISC

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC		BETIMOL					
	+! THEA PHARMA	0.25%		N020439	001	Mar 31, 1995	Oct CPOT
AT	+!	0.5%		N020439	002	Mar 31, 1995	Oct CPOT
AT	+!	EQ 0.5% BASE		N020439	002	Mar 31, 1995	Oct CTEC
SOLUTION/DROPS; OPHTHALMIC		TIMOLOL					
	@ EPIC PHARMA LLC	0.25%		A205309	001	Sep 30, 2016	Oct CPOT
	@	0.5%		A205309	002	Sep 30, 2016	Oct CPOT
AT	SOMERSET	0.5%		A216654	001	Oct 10, 2024	Oct NEWA

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC		TIMOLOL MALEATE					
	@ AMNEAL	EQ 0.25% BASE		A216343	001	May 23, 2024	Jun DISC
AB		EQ 0.25% BASE		A216343	001	May 23, 2024	May NEWA
	@	EQ 0.5% BASE		A216343	002	May 23, 2024	Jun DISC
AB		EQ 0.5% BASE		A216343	002	May 23, 2024	May NEWA
AB	SOMERSET THERAPS LLC	EQ 0.25% BASE		A210640	001	Sep 16, 2024	Sep NEWA
AB		EQ 0.5% BASE		A210640	002	Sep 16, 2024	Sep NEWA
SOLUTION/DROPS; OPHTHALMIC		TIMOLOL MALEATE					
	@ BAUSCH AND LOMB	EQ 0.25% BASE		A074778	001	Mar 25, 1997	Oct DISC
	@	EQ 0.5% BASE		A074776	001	Mar 25, 1997	Oct DISC
AT1	CAPLIN	EQ 0.5% BASE		A218460	001	Aug 07, 2024	Jul NEWA
AT1	SOMERSET	EQ 0.25% BASE		A217764	002	Jul 03, 2024	Jun NEWA
AT1		EQ 0.5% BASE		A217764	001	Jul 03, 2024	Jun NEWA
AT2	SOMERSET THERAPS LLC	EQ 0.5% BASE		A216653	001	Jul 03, 2024	Jun NEWA

TIOPRONIN

TABLET, DELAYED RELEASE; ORAL		THIOLA EC					
AB	+ MISSION PHARMACAL	100MG		N211843	001	Jun 28, 2019	Jan CFTG
TABLET, DELAYED RELEASE; ORAL		TIOPRONIN					
AB	ENDO OPERATIONS	100MG		A217219	001	Feb 24, 2023	Jun CMFD
AB		300MG		A217219	002	Feb 24, 2023	Jun CMFD
AB	TEVA PHARMS INC	100MG		A216456	001	Jul 22, 2024	Jul NEWA
AB		300MG		A216456	002	Jul 22, 2024	Jul NEWA
AB	TORRENT	100MG		A216990	001	Jan 30, 2024	Jan NFTG
AB		300MG		A216990	002	Jan 30, 2024	Jan NEWA

TIRZEPATIDE

SOLUTION; SUBCUTANEOUS		MOUNJARO					
	+! ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)		N215866	007	Jul 28, 2023	Jan NEWA
	+!	5MG/0.5ML (5MG/0.5ML)		N215866	008	Jul 28, 2023	Jan NEWA
	+!	7.5MG/0.5ML (7.5MG/0.5ML)		N215866	009	Jul 28, 2023	Jan NEWA
	+!	10MG/0.5ML (10MG/0.5ML)		N215866	010	Jul 28, 2023	Jan NEWA
	+!	12.5MG/0.5ML (12.5MG/0.5ML)		N215866	011	Jul 28, 2023	Jan NEWA
	+!	15MG/0.5ML (15MG/0.5ML)		N215866	012	Jul 28, 2023	Jan NEWA
SOLUTION; SUBCUTANEOUS		MOUNJARO (AUTOINJECTOR)					
	+! ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)		N215866	001	May 13, 2022	Jan CTNA
	+!	5MG/0.5ML (5MG/0.5ML)		N215866	002	May 13, 2022	Jan CTNA
	+!	7.5MG/0.5ML (7.5MG/0.5ML)		N215866	003	May 13, 2022	Jan CTNA
	+!	10MG/0.5ML (10MG/0.5ML)		N215866	004	May 13, 2022	Jan CTNA
	+!	12.5MG/0.5ML (12.5MG/0.5ML)		N215866	005	May 13, 2022	Jan CTNA
	+!	15MG/0.5ML (15MG/0.5ML)		N215866	006	May 13, 2022	Jan CTNA
SOLUTION; SUBCUTANEOUS		ZEPBOUND					
	+! ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)		N217806	007	Mar 28, 2024	Mar NEWA
	+!	5MG/0.5ML (5MG/0.5ML)		N217806	008	Mar 28, 2024	Mar NEWA

SOLUTION; SUBCUTANEOUS							
ZEPBOUND							
	+	!	7.5MG/0.5ML (7.5MG/0.5ML)	N217806	009	Mar 28, 2024	Mar NEWA
	+	!	10MG/0.5ML (10MG/0.5ML)	N217806	010	Mar 28, 2024	Mar NEWA
	+	!	12.5MG/0.5ML (12.5MG/0.5ML)	N217806	011	Mar 28, 2024	Mar NEWA
	+	!	15MG/0.5ML (15MG/0.5ML)	N217806	012	Mar 28, 2024	Mar NEWA
ZEPBOUND (AUTOINJECTOR)							
	+	!	ELI LILLY AND CO 2.5MG/0.5ML (2.5MG/0.5ML)	N217806	001	Nov 08, 2023	Mar CTNA
	+	!	5MG/0.5ML (5MG/0.5ML)	N217806	002	Nov 08, 2023	Mar CTNA
	+	!	7.5MG/0.5ML (7.5MG/0.5ML)	N217806	003	Nov 08, 2023	Mar CTNA
	+	!	10MG/0.5ML (10MG/0.5ML)	N217806	004	Nov 08, 2023	Mar CTNA
	+	!	12.5MG/0.5ML (12.5MG/0.5ML)	N217806	005	Nov 08, 2023	Mar CTNA
	+	!	15MG/0.5ML (15MG/0.5ML)	N217806	006	Nov 08, 2023	Mar CTNA
<u>TIZANIDINE HYDROCHLORIDE</u>							
CAPSULE; ORAL							
TIZANIDINE HYDROCHLORIDE							
AB			APPCO EQ 4MG BASE	A213365	001	May 13, 2024	May NEWA
AB			EQ 6MG BASE	A213365	002	May 13, 2024	May NEWA
		@	ENDO OPERATIONS EQ 2MG BASE	A207199	001	Mar 14, 2017	May CAHN
		@	EQ 4MG BASE	A207199	002	Mar 14, 2017	May CAHN
		@	EQ 6MG BASE	A207199	003	Mar 14, 2017	May CAHN
AB			SOMERSET THERAPS LLC EQ 4MG BASE	A213365	001	May 13, 2024	Sep CAHN
AB			EQ 6MG BASE	A213365	002	May 13, 2024	Sep CAHN
TABLET; ORAL							
TIZANIDINE HYDROCHLORIDE							
		@	ENDO OPERATIONS EQ 2MG BASE	A207170	001	Jan 26, 2017	May CAHN
		@	EQ 4MG BASE	A207170	002	Jan 26, 2017	May CAHN
AB			GRAVITI PHARMS EQ 4MG BASE	A218920	002	Aug 07, 2024	Jul NEWA
AB			EQ 2MG BASE	A218920	001	Aug 07, 2024	Jul NEWA
<u>TOBRAMYCIN</u>							
SOLUTION; INHALATION							
TOBRAMYCIN							
		@	NORVIUM BIOSCIENCE 300MG/5ML	A209554	001	Oct 13, 2017	Oct CAHN
SOLUTION/DROPS; OPHTHALMIC							
TOBRAMYCIN							
AT		!	SOMERSET THERAPS LLC 0.3%	A207444	001	Jun 28, 2017	Apr CHRS
			TOBREX				
		+	@ NOVARTIS 0.3%	N050541	001		Apr DISC
<u>TOBRAMYCIN SULFATE</u>							
INJECTABLE; INJECTION							
TOBRAMYCIN SULFATE							
AP			SLATE RUN PHARMA EQ 1.2GM BASE/VIAL	A217029	001	Feb 01, 2023	Sep CAHN
<u>TOFACITINIB CITRATE</u>							
SOLUTION; ORAL							
TOFACITINIB CITRATE							
		@	HIKMA EQ 1MG BASE/ML	A216878	001	Sep 25, 2023	Oct DISC
AA			EQ 1MG BASE/ML	A216878	001	Sep 25, 2023	Apr CAHN
			XELJANZ				
	+	!	PFIZER EQ 1MG BASE/ML	N213082	001	Sep 25, 2020	Oct CTEC
TABLET, EXTENDED RELEASE; ORAL							
TOFACITINIB							
		@	AUROBINDO PHARMA LTD EQ 11MG BASE	A218462	001	Jun 03, 2024	Jun DISC
AB			EQ 11MG BASE	A218462	001	Jun 03, 2024	May NEWA
			XELJANZ XR				
	+		PFIZER EQ 11MG BASE	N208246	001	Feb 23, 2016	Jun CTEC
AB		+	EQ 11MG BASE	N208246	001	Feb 23, 2016	May CTEC
<u>TOLAZAMIDE</u>							
TABLET; ORAL							
TOLAZAMIDE							
		@	NATCO 250MG	A070259	001	Jan 02, 1986	Aug CAHN
		@	500MG	A070259	003	Mar 17, 1986	Aug CAHN

TOLCAPONE

TABLET;ORAL

TOLCAPONE

@ ENDO OPERATIONS	100MG	A204584	001	Mar 26, 2015	May CAHN
@ PAR PHARM INC	100MG	A204584	001	Mar 26, 2015	Mar DISC

TOLMETIN SODIUM

CAPSULE;ORAL

TOLMETIN SODIUM

@ CHARTWELL RX	EQ 400MG BASE	A073462	001	Apr 30, 1992	Aug CAHN
! RISING	EQ 400MG BASE	A073393	001	May 27, 1993	Oct CHRS

TABLET;ORAL

TOLMETIN SODIUM

@ CHARTWELL RX	EQ 200MG BASE	A073588	001	Jul 31, 1992	Aug CAHN
@	EQ 600MG BASE	A074002	001	Sep 27, 1993	Aug CAHN

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

TOLTERODINE TARTRATE

AB UNICHEM	2MG	A216917	001	Aug 27, 2024	Aug NEWA
AB	4MG	A216917	002	Aug 27, 2024	Aug NEWA
AB UTOPIC PHARMS	2MG	A213858	001	Feb 02, 2021	Sep CAHN
AB	4MG	A213858	002	Feb 02, 2021	Sep CAHN

TOPIRAMATE

CAPSULE;ORAL

TOPIRAMATE

AB ALKEM LABS LTD	15MG	A218482	001	Jun 13, 2024	Jun NEWA
AB	25MG	A218482	002	Jun 13, 2024	Jun NEWA
@ CHARTWELL RX	15MG	A079206	001	Oct 14, 2009	Aug CAHN
@	25MG	A079206	002	Oct 14, 2009	Aug CAHN
AB GLENMARK PHARMS LTD	15MG	A217869	001	Jul 16, 2024	Jul NEWA
AB	25MG	A217869	002	Jul 16, 2024	Jul NEWA
AB SENORES PHARMS	15MG	A218642	001	Oct 10, 2024	Oct NEWA
AB	25MG	A218642	002	Oct 10, 2024	Oct NEWA
AB STRIDES PHARMA	15MG	A078418	001	Oct 14, 2009	Apr CMFD
AB	25MG	A078418	002	Oct 14, 2009	Apr CMFD
ZYDUS PHARMS USA INC	50MG	A078877	003	Oct 23, 2024	Oct NFTG

CAPSULE, EXTENDED RELEASE;ORAL

TOPIRAMATE

@ AJANTA PHARMA LTD	25MG	A215663	001	Aug 15, 2023	Feb DISC
@	50MG	A215663	002	Aug 15, 2023	Feb DISC
@	100MG	A215663	003	Aug 15, 2023	Feb DISC
@	200MG	A215663	004	Aug 15, 2023	Feb DISC
>A> AB2 AMTA	25MG	A218695	001	Dec 03, 2024	Nov NEWA
>A> AB2	50MG	A218695	002	Dec 03, 2024	Nov NEWA
>A> AB2	100MG	A218695	003	Dec 03, 2024	Nov NEWA
>A> AB2	150MG	A218695	004	Dec 03, 2024	Nov NEWA
>A> AB2	200MG	A218695	005	Dec 03, 2024	Nov NEWA
AB1 LUPIN LTD	25MG	A215561	001	Jul 11, 2024	Jul NEWA
AB1	50MG	A215561	002	Jul 11, 2024	Jul NEWA
AB1	100MG	A215561	003	Jul 11, 2024	Jul NEWA
AB1	200MG	A215561	004	Jul 11, 2024	Jul NEWA
AB2 XIAMEN LP PHARM CO	25MG	A215638	001	Nov 05, 2024	Oct NEWA
AB2	50MG	A215638	002	Nov 05, 2024	Oct NEWA
AB2	100MG	A215638	003	Nov 05, 2024	Oct NEWA
AB2	150MG	A215638	004	Nov 05, 2024	Oct NEWA
AB2	200MG	A215638	005	Nov 05, 2024	Oct NEWA

SOLUTION;ORAL

EPRONTIA

AB +! AZURITY	25MG/ML	N214679	001	Nov 05, 2021	Oct CFTG
---------------	---------	---------	-----	--------------	----------

TOPIRAMATE

AB ALKEM LABS LTD	25MG/ML	A217795	001	Oct 31, 2024	Oct NFTG
-------------------	---------	---------	-----	--------------	----------

TABLET;ORAL

TOPIRAMATE

@ AIPING PHARM INC	25MG	A078499	001	Jan 07, 2010	Feb CAHN
@	50MG	A078499	002	Jan 07, 2010	Feb CAHN
@	100MG	A078499	003	Jan 07, 2010	Feb CAHN
@	200MG	A078499	004	Jan 07, 2010	Feb CAHN
@ SUN PHARM INDS LTD	25MG	A076327	001	Mar 27, 2009	Jan DISC
@	100MG	A076327	002	Mar 27, 2009	Jan DISC

	TABLET;ORAL								
	TOPIRAMATE								
	@	200MG		A076327	003	Mar 27, 2009	Jan	DISC	
	<u>TOPOTECAN HYDROCHLORIDE</u>								
	INJECTABLE; INJECTION								
	TOPOTECAN HYDROCHLORIDE								
	@ RISING	EQ 4MG BASE/VIAL		A091542	001	Aug 28, 2012	Mar	CAHN	
	SOLUTION; INTRAVENOUS								
	TOPOTECAN HYDROCHLORIDE								
	@ MEITHEAL	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)		N022453	001	Dec 20, 2012	Sep	DISC	
	<u>TOREMIFENE CITRATE</u>								
	TABLET;ORAL								
	FARESTON								
	+ @ KYOWA KIRIN	EQ 60MG BASE		N020497	001	May 29, 1997	Aug	DISC	
	TOREMIFENE CITRATE								
AB	! RISING	EQ 60MG BASE		A208813	001	Dec 04, 2018	Aug	CHRS	
	<u>TORSEMIDE</u>								
	SOLUTION; INTRAVENOUS								
	DEMADEX								
	+ @ ROCHE	50MG/5ML (10MG/ML)		N020137	002	Aug 23, 1993	Mar	CDFR	
	+ @	20MG/2ML (10MG/ML)		N020137	001	Aug 23, 1993	Mar	CDFR	
	TORSEMIDE								
	@ AM REGENT	20MG/2ML (10MG/ML)		A090656	001	Apr 21, 2010	Mar	CDFR	
	@	50MG/5ML (10MG/ML)		A090656	002	Apr 21, 2010	Mar	CDFR	
	@ WEST-WARD PHARMS INT	20MG/2ML (10MG/ML)		A078007	001	Jun 11, 2008	Mar	CDFR	
	@	50MG/5ML (10MG/ML)		A078007	002	Jun 11, 2008	Mar	CDFR	
	TABLET;ORAL								
	DEMADEX								
	+ @ NORVIUM BIOSCIENCE	5MG		N020136	001	Aug 23, 1993	Jul	CAHN	
	+ @	10MG		N020136	002	Aug 23, 1993	Jul	CAHN	
	+ @	20MG		N020136	003	Aug 23, 1993	Jul	CAHN	
	+ @	100MG		N020136	004	Aug 23, 1993	Jul	CAHN	
	TORSEMIDE								
AB	HERITAGE	5MG		A076894	001	May 31, 2005	Sep	CAHN	
AB		10MG		A076894	002	May 31, 2005	Sep	CAHN	
AB		20MG		A076894	003	May 31, 2005	Sep	CAHN	
AB		100MG		A076894	004	May 31, 2005	Sep	CAHN	
	<u>TOVORAFENIB</u>								
	FOR SUSPENSION;ORAL								
	OJEMDA								
	+! DAY ONE BIOPHARMS	25MG/ML		N218033	001	Apr 23, 2024	Apr	NEWA	
	TABLET;ORAL								
	OJEMDA								
	+! DAY ONE BIOPHARMS	100MG		N217700	001	Apr 23, 2024	Apr	NEWA	
	<u>TRAMADOL HYDROCHLORIDE</u>								
	SOLUTION;ORAL								
	QDOLO								
	+ @ ATHENA	5MG/ML		N214044	001	Sep 01, 2020	Oct	DISC	
	TABLET;ORAL								
	TRAMADOL HYDROCHLORIDE								
AB	GRAVITI PHARMS	100MG		A075968	002	Aug 02, 2024	Jul	NEWA	
	RUBICON	75MG		A208708	004	Apr 04, 2024	Mar	NFTG	
>D>	AB	100MG		A208708	002	Jun 28, 2019	Nov	CHRS	
>A>	AB	! 100MG		A208708	002	Jun 28, 2019	Nov	CHRS	
	AB	100MG		A208708	002	Jun 28, 2019	Jul	CTEC	
>D>	AB	! SUN PHARM INDS INC 50MG		A075964	001	Jun 19, 2002	Nov	CHRS	
>A>	AB	50MG		A075964	001	Jun 19, 2002	Nov	CHRS	
	TABLET, EXTENDED RELEASE;ORAL								
	TRAMADOL HYDROCHLORIDE								
	@ ENDO OPERATIONS	100MG		A200491	001	Jun 27, 2012	Apr	CAHN	
	@	200MG		A200491	002	Jun 27, 2012	Apr	CAHN	
	@	300MG		A200491	003	Jun 27, 2012	Apr	CAHN	
>D>	AB1	! LUPIN LTD 100MG		A200503	001	Aug 29, 2011	Nov	CTEC	
>A>		! 100MG		A200503	001	Aug 29, 2011	Nov	CTEC	
>D>	AB1	200MG		A200503	002	Aug 29, 2011	Nov	CTEC	
>A>		200MG		A200503	002	Aug 29, 2011	Nov	CTEC	
>D>	AB1	300MG		A200503	003	Aug 29, 2011	Nov	CTEC	

TABLET, EXTENDED RELEASE;ORAL
TRAMADOL HYDROCHLORIDE

>A>		300MG	A200503	003	Aug 29, 2011	Nov	CTEC
	@ SUN PHARM	100MG	A091607	001	Dec 30, 2011	May	DISC
>D>	AB1	100MG	A201384	001	Dec 07, 2011	Nov	DISC
>A>	@	100MG	A201384	001	Dec 07, 2011	Nov	DISC
>D>	AB1	200MG	A201384	002	Dec 07, 2011	Nov	DISC
>A>	@	200MG	A201384	002	Dec 07, 2011	Nov	DISC
	@	300MG	A091607	003	Dec 30, 2011	May	DISC
>D>	AB1	300MG	A201384	003	Dec 07, 2011	Nov	DISC
>A>	@	300MG	A201384	003	Dec 07, 2011	Nov	DISC

TRAMETINIB DIMETHYL SULFOXIDE

TABLET;ORAL
MEKINIST

	+ NOVARTIS	EQ 0.5MG	N204114	001	May 29, 2013	Aug	CTEC
AB	+	EQ 0.5MG	N204114	001	May 29, 2013	Jul	CFTG
	+!	EQ 2MG	N204114	003	May 29, 2013	Aug	CTEC
AB	+!	EQ 2MG	N204114	003	May 29, 2013	Jul	CFTG
	TRAMETINIB DIMETHYL SULFOXIDE						
	@ NOVUGEN	EQ 0.5MG	A219002	001	Aug 06, 2024	Aug	DISC
AB		EQ 0.5MG	A219002	001	Aug 06, 2024	Jul	NFTG
	@	EQ 2MG	A219002	002	Aug 06, 2024	Aug	DISC
AB		EQ 2MG	A219002	002	Aug 06, 2024	Jul	NFTG

TRANEXAMIC ACID

INJECTABLE; INJECTION
TRANEXAMIC ACID

AP	HERITAGE	100MG/ML	A202436	001	Feb 11, 2014	Sep	CAHN
	SOLUTION; INTRAVENOUS						
	TRANEXAMIC ACID						
AP	FRESENIUS KABI USA	1GM/100ML (10MG/ML)	A218242	001	Aug 15, 2024	Aug	NEWA
AP	GLAND PHARMA LTD	1GM/100ML (10MG/ML)	A218599	001	Apr 16, 2024	Apr	NEWA
AP	NEXUS	1GM/100ML (10MG/ML)	A216877	001	Apr 16, 2024	Apr	NEWA

TABLET;ORAL
TRANEXAMIC ACID

AB	RUBICON	650MG	A218320	001	Jun 11, 2024	May	NEWA
----	---------	-------	---------	-----	--------------	-----	------

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC
TRAVOPROST

AT	GLAND PHARMA LTD	0.004%	A218159	001	Jul 12, 2024	Jul	NEWA
	@ LUPIN LTD	0.004%	A207040	001	May 03, 2024	Oct	DISC
AT		0.004%	A207040	001	May 03, 2024	Apr	NEWA
AT	SOMERSET THERAPS LLC	0.004%	A217228	001	Sep 23, 2024	Sep	NEWA

TRAZODONE HYDROCHLORIDE

SOLUTION;ORAL
RALDESY

>A>	+! KAMAT	10MG/ML	N218637	001	Nov 26, 2024	Nov	NEWA
-----	----------	---------	---------	-----	--------------	-----	------

TABLET;ORAL
TRAZODONE HYDROCHLORIDE

	@ AIPING PHARM INC	100MG	A072483	001	Apr 30, 1990	Sep	CAHN
AB	CROSSMEDIKA SA	50MG	A211116	001	May 20, 2024	May	NEWA
AB		100MG	A211116	002	May 20, 2024	May	NEWA
AB		150MG	A211116	003	May 20, 2024	May	NEWA
AB		300MG	A211116	004	May 20, 2024	May	NEWA
AB	GRANULES	50MG	A218988	001	Aug 08, 2024	Aug	NEWA
AB		100MG	A218988	002	Aug 08, 2024	Aug	NEWA
AB		150MG	A218988	003	Aug 08, 2024	Aug	NEWA
AB		300MG	A218988	004	Aug 08, 2024	Aug	NEWA
AB	GRAVITI PHARMS	50MG	A217740	001	Aug 27, 2024	Aug	NEWA
AB		100MG	A217740	002	Aug 27, 2024	Aug	NEWA
AB		150MG	A217740	003	Aug 27, 2024	Aug	NEWA
AB		300MG	A217740	004	Aug 27, 2024	Aug	NEWA

TREPROSTINIL

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS
REMODULIN

	+! UNITED THERAP	0.2MG/ML	N021272	007	Sep 28, 2023	Oct	CDFR
	+!	0.4MG/ML	N021272	008	Sep 28, 2023	Oct	CDFR
AP	+!	1MG/ML	N021272	001	May 21, 2002	Oct	CDFR

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS
REMOTULIN

AP	+	2.5MG/ML	N021272	002	May 21, 2002	Oct	CDFR
AP	+	5MG/ML	N021272	003	May 21, 2002	Oct	CDFR
AP	+	10MG/ML	N021272	004	May 21, 2002	Oct	CDFR

TREPROSTINIL

AP		ALEMBIC GLOBAL	1MG/ML	A211574	001	Feb 11, 2021	Oct	CDFR
AP			2.5MG/ML	A211574	002	Feb 11, 2021	Oct	CDFR
AP			5MG/ML	A211574	003	Feb 11, 2021	Oct	CDFR
AP			10MG/ML	A211574	004	Feb 11, 2021	Oct	CDFR
AP		DR REDDYS	1MG/ML	A210214	001	May 22, 2020	Oct	CDFR
AP			2.5MG/ML	A210214	002	May 22, 2020	Oct	CDFR
AP			5MG/ML	A210214	003	May 22, 2020	Oct	CDFR
AP			10MG/ML	A210214	004	May 22, 2020	Oct	CDFR
AP		ENDO OPERATIONS	1MG/ML	A209382	001	Sep 24, 2019	Oct	CDFR
AP			2.5MG/ML	A209382	002	Sep 24, 2019	Oct	CDFR
AP			5MG/ML	A209382	003	Sep 24, 2019	Oct	CDFR
AP			10MG/ML	A209382	004	Sep 24, 2019	Oct	CDFR
AP		SANDOZ	1MG/ML	A203649	001	Nov 30, 2017	Oct	CDFR
AP			2.5MG/ML	A203649	002	Nov 30, 2017	Oct	CDFR
AP			5MG/ML	A203649	003	Nov 30, 2017	Oct	CDFR
AP			10MG/ML	A203649	004	Nov 30, 2017	Oct	CDFR
AP		TEVA PHARMS USA	1MG/ML	A206648	001	Sep 26, 2019	Oct	CDFR
AP			2.5MG/ML	A206648	002	Sep 26, 2019	Oct	CDFR
AP			5MG/ML	A206648	003	Sep 26, 2019	Oct	CDFR
AP			10MG/ML	A206648	004	Sep 26, 2019	Oct	CDFR

POWDER; INHALATION

TYVASO DPI

>D>	+	UNITED THERAP	0.016MG/INH	N214324	001	May 23, 2022	Nov	CHRS
>A>	+		0.016MG/INH	N214324	001	May 23, 2022	Nov	CHRS
	+		0.08MG/INH	N214324	005	Oct 24, 2024	Oct	NEWA

TRETINOIN

CAPSULE; ORAL

TRETINOIN

AB		ENDO OPERATIONS	10MG	A201687	001	Oct 24, 2012	Apr	CAHN
		CREAM; TOPICAL						
		TRETINOIN						
AB		ALEMBIC	0.1%	A217804	001	Apr 29, 2024	Apr	NEWA
AB		ZYDUS LIFESCIENCES	0.1%	A218561	001	Apr 25, 2024	Apr	NEWA

GEL; TOPICAL

TRETINOIN

		@ NORVIUM BIOSCIENCE	0.1%	A202026	001	Jul 17, 2013	Aug	CAHN
--	--	----------------------	------	---------	-----	--------------	-----	------

TRIAMCINOLONE ACETONIDE

INJECTABLE; INJECTION

TRIAMCINOLONE ACETONIDE

>A>	AB	HIKMA	40MG/ML	A215254	001	Dec 09, 2024	Nov	NEWA
		OINTMENT; TOPICAL						
		TRIAMCINOLONE ACETONIDE						
		@ AUROBINDO PHARMA LTD	0.1%	A211315	001	Mar 18, 2020	Jan	CAHN
		@	0.5%	A211315	002	Mar 18, 2020	Jan	CAHN
		@ COSETTE	0.5%	A208925	001	Oct 06, 2017	Apr	DISC
		PASTE; DENTAL						
		TRIAMCINOLONE ACETONIDE						
AT		RISING	0.1%	A040771	001	Jul 01, 2010	Sep	CAHN

TRIAMCINOLONE HEXACETONIDE

INJECTABLE; INJECTION

ARISTOSPAN

		+ @ ANIKA THERAPS INC	5MG/ML	N016466	001		Oct	CAHN
		+ @	20MG/ML	N016466	002		Oct	CAHN

TRIAMTERENE

CAPSULE; ORAL

TRIAMTERENE

>D>		@ BIOCON GENERICS	50MG	A214768	001	Jul 06, 2022	Nov	CMFD
>A>	AB		50MG	A214768	001	Jul 06, 2022	Nov	CMFD
		@	50MG	A214768	001	Jul 06, 2022	Oct	CAHN
>D>		@	100MG	A214768	002	Jul 06, 2022	Nov	CMFD
>A>	AB		100MG	A214768	002	Jul 06, 2022	Nov	CMFD
		@	100MG	A214768	002	Jul 06, 2022	Oct	CAHN

CAPSULE;ORAL
 TRIAMTERENE

@ HIBROW HLTHCARE	50MG	A214768	001	Jul 06, 2022	Sep CAHN
@	100MG	A214768	002	Jul 06, 2022	Sep CAHN

TRIAZOLAM

TABLET;ORAL
 TRIAZOLAM

@ HIKMA	0.125MG	A074224	001	Jun 01, 1994	Feb DISC
@	0.25MG	A074224	002	Jun 01, 1994	Feb DISC

TRIENTINE HYDROCHLORIDE

CAPSULE;ORAL
 TRIENTINE HYDROCHLORIDE

AB	ENDO OPERATIONS	250MG	A210096	001	Sep 25, 2019	Apr CAHN
----	-----------------	-------	---------	-----	--------------	----------

TRIFLUOPERAZINE HYDROCHLORIDE

CONCENTRATE;ORAL
 TRIFLUOPERAZINE HYDROCHLORIDE

@ CHARTWELL RX	EQ 10MG BASE/ML	A085787	001	Apr 15, 1982	Aug CAHN
----------------	-----------------	---------	-----	--------------	----------

TRILACICLIB DIHYDROCHLORIDE

POWDER;INTRAVENOUS
 COSELA

+!	PHARMACOSMOS	EQ 300MG BASE/VIAL	N214200	001	Feb 12, 2021	Sep CAHN
----	--------------	--------------------	---------	-----	--------------	----------

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE;ORAL
 TRIMETHOBENZAMIDE HYDROCHLORIDE

AB	!	AVET LIFESCIENCES	300MG	A205950	001	Nov 21, 2023	Aug CHRS
AB	!	HERITAGE PHARMA AVET	300MG	A205950	001	Nov 21, 2023	Oct CAHN
	@	SUN PHARM INDUSTRIES	300MG	A076570	001	Aug 28, 2003	Aug DISC

INJECTABLE;INJECTION
 TIGAN

+!	ENDO OPERATIONS	100MG/ML	N017530	001		Apr CAHN
----	-----------------	----------	---------	-----	--	----------

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION;ORAL
 PRIMSOL

@ PANGEA	EQ 25MG BASE/5ML	N074374	001	Jun 23, 1995	Oct CAHN
+ @	EQ 50MG BASE/5ML	N074973	001	Jan 24, 2000	Oct CAHN

TRIMIPRAMINE MALEATE

CAPSULE;ORAL
 TRIMIPRAMINE MALEATE

AB		BRECKENRIDGE	EQ 25MG BASE	A208127	001	Apr 15, 2016	Mar CAHN
AB	!		EQ 50MG BASE	A208127	002	Apr 15, 2016	Mar CAHN
AB			EQ 100MG BASE	A208127	003	Apr 15, 2016	Mar CAHN

TROMETHAMINE

SOLUTION;INJECTION
 THAM

>D>	+!	HOSPIRA	18GM/500ML (3.6GM/100ML)	N013025	002		Nov CFTG
>A>	AP	+!	18GM/500ML (3.6GM/100ML)	N013025	002		Nov CFTG
>A>		TROMETHAMINE					
>A>	AP	B BRAUN MEDICAL INC	18GM/500ML (3.6GM/100ML)	A211558	001	Dec 09, 2024	Nov NFTG

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
 TROSPIUM CHLORIDE

AB		UTOPIIC PHARMS	60MG	A214760	001	Apr 30, 2021	Sep CAHN
----	--	----------------	------	---------	-----	--------------	----------

TABLET;ORAL
 TROSPIUM CHLORIDE

AB		CHARTWELL RX	20MG	A215781	001	Feb 16, 2022	Sep CAHN
AB		MACLEODS PHARMS LTD	20MG	A206472	001	Jun 18, 2024	Jun NEWA
AB		ZAMEER PHARMS	20MG	A215781	001	Feb 16, 2022	Feb CAHN

TROSPIMUM CHLORIDE; XANOMELINE TARTRATE

CAPSULE;ORAL

COBENFY

	+	BRISTOL-MYERS	20MG;EQ 50MG BASE	N216158	001	Sep 26, 2024	Sep NEWA
	+		20MG;EQ 100MG BASE	N216158	002	Sep 26, 2024	Sep NEWA
	+	!	30MG;EQ 125MG BASE	N216158	003	Sep 26, 2024	Sep NEWA

UMECLIDINIUM BROMIDE

POWDER; INHALATION

INCRUSE ELLIPTA

	+	!	GLAXO GRP ENGLAND	EQ 0.0625MG BASE/INH	N205382	001	Apr 30, 2014	Jan CPOT
--	---	---	-------------------	----------------------	---------	-----	--------------	----------

UPADACITINIB

SOLUTION;ORAL

RINVOQ LQ

	+	!	ABBVIE	1MG/ML	N218347	001	Apr 26, 2024	Apr NEWA
--	---	---	--------	--------	---------	-----	--------------	----------

UREA, C-14

CAPSULE;ORAL

PYTEST

	+	@	AVENT	1uCi	N020617	001	May 09, 1997	Sep DISC
--	---	---	-------	------	---------	-----	--------------	----------

URSODIOL

CAPSULE;ORAL

URSODIOL

AB			HIBROW HLTHCARE	300MG	A212452	001	Oct 30, 2019	Jul CAHN
	!		LGM PHARMA	200MG	A205789	001	May 08, 2020	Aug CHRS

TABLET;ORAL

URSODIOL

AB			ENDO OPERATIONS	250MG	A202540	001	Feb 14, 2013	Apr CAHN
AB				500MG	A202540	002	Feb 14, 2013	Apr CAHN
AB			EPIC PHARMA LLC	250MG	A214717	001	Aug 14, 2024	Aug NEWA
AB				500MG	A214717	002	Aug 14, 2024	Aug NEWA

VADADUSTAT

TABLET;ORAL

VAFSEO

	+		AKEBIA	150MG	N215192	001	Mar 27, 2024	Mar NEWA
	+			300MG	N215192	002	Mar 27, 2024	Mar NEWA
	+	!		450MG	N215192	003	Mar 27, 2024	Mar NEWA

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

		@	CIPLA	EQ 500MG BASE	A077135	001	May 24, 2010	Apr DISC
		@		EQ 1GM BASE	A077135	002	May 24, 2010	Apr DISC
AB			GRAVITI PHARMS	EQ 500MG BASE	A079012	001	May 24, 2010	Jun CAHN
AB				EQ 1GM BASE	A079012	002	May 24, 2010	Jun CAHN
		@	SANDOZ	EQ 500MG BASE	A077478	001	May 24, 2010	Sep DISC
		@		EQ 1GM BASE	A077478	002	May 24, 2010	Sep DISC

VALBENZAZINE TOSYLATE

CAPSULE;ORAL

INGREZZA

AB	+		NEUROCRINE	EQ 40MG BASE	N209241	001	Apr 11, 2017	Mar CFTG
AB	+			EQ 60MG BASE	N209241	003	Apr 23, 2021	Jul CFTG
AB	+	!		EQ 80MG BASE	N209241	002	Oct 04, 2017	Mar CFTG

INGREZZA SPRINKLE

	+		NEUROCRINE	EQ 40MG BASE	N218390	001	Apr 30, 2024	Apr NEWA
	+			EQ 60MG BASE	N218390	002	Apr 30, 2024	Apr NEWA
	+	!		EQ 80MG BASE	N218390	003	Apr 30, 2024	Apr NEWA

VALBENZAZINE TOSYLATE

AB			LUPIN LTD	EQ 40MG BASE	A216064	001	Apr 05, 2024	Mar NFTG
AB				EQ 80MG BASE	A216064	002	Apr 05, 2024	Mar NFTG
AB			ZYDUS	EQ 40MG BASE	A216137	001	Aug 07, 2024	Jul NEWA
AB				EQ 60MG BASE	A216137	002	Aug 07, 2024	Jul NFTG
AB				EQ 80MG BASE	A216137	003	Aug 07, 2024	Jul NEWA

VALGANCICLOVIR HYDROCHLORIDE

TABLET; ORAL

VALGANCICLOVIR HYDROCHLORIDE

AB	GPP	EQ 450MG BASE	A212876	001	Jun 11, 2024	May	NEWA
AB	SOMERSET THERAPS LLC	EQ 450MG BASE	A212876	001	Jun 11, 2024	Sep	CAHN

VALPROIC ACID

CAPSULE; ORAL

VALPROIC ACID

@ EYWA	250MG
@ HIBROW HLTHCARE	250MG
@ SUN PHARM INDS LTD	250MG

A207611	001	Aug 05, 2019	Mar	DISC
A207611	001	Aug 05, 2019	Jul	CAHN
A091037	001	Feb 22, 2013	May	DISC

SYRUP; ORAL

VALPROIC ACID

AA	@ HIKMA	250MG/5ML	A074060	001	Jan 13, 1995	Mar	DISC
	QUAGEN	250MG/5ML	A090517	001	May 28, 2010	Jan	CAHN

A074060	001	Jan 13, 1995	Mar	DISC
A090517	001	May 28, 2010	Jan	CAHN

VALRUBICIN

SOLUTION; INTRAVESICAL

VALSTAR PRESERVATIVE FREE

AO	+! ENDO OPERATIONS	40MG/ML	N020892	001	Sep 25, 1998	Apr	CAHN
----	--------------------	---------	---------	-----	--------------	-----	------

N020892	001	Sep 25, 1998	Apr	CAHN
---------	-----	--------------	-----	------

VALSARTAN

TABLET; ORAL

VALSARTAN

AB	RYAN LABS	40MG	A218169	001	Aug 05, 2024	Oct	CAHN
AB		80MG	A218169	002	Aug 05, 2024	Oct	CAHN
AB		160MG	A218169	003	Aug 05, 2024	Oct	CAHN
AB		320MG	A218169	004	Aug 05, 2024	Oct	CAHN
AB	ZENARA	40MG	A218169	001	Aug 05, 2024	Jul	NEWA
AB		80MG	A218169	002	Aug 05, 2024	Jul	NEWA
AB		160MG	A218169	003	Aug 05, 2024	Jul	NEWA
AB		320MG	A218169	004	Aug 05, 2024	Jul	NEWA
AB	ZYDUS LIFESCIENCES	40MG	A218991	001	Jul 22, 2024	Jul	NEWA
AB		80MG	A218991	002	Jul 22, 2024	Jul	NEWA
AB		160MG	A218991	003	Jul 22, 2024	Jul	NEWA
AB		320MG	A218991	004	Jul 22, 2024	Jul	NEWA

A218169	001	Aug 05, 2024	Oct	CAHN
A218169	002	Aug 05, 2024	Oct	CAHN
A218169	003	Aug 05, 2024	Oct	CAHN
A218169	004	Aug 05, 2024	Oct	CAHN
A218169	001	Aug 05, 2024	Jul	NEWA
A218169	002	Aug 05, 2024	Jul	NEWA
A218169	003	Aug 05, 2024	Jul	NEWA
A218169	004	Aug 05, 2024	Jul	NEWA
A218991	001	Jul 22, 2024	Jul	NEWA
A218991	002	Jul 22, 2024	Jul	NEWA
A218991	003	Jul 22, 2024	Jul	NEWA
A218991	004	Jul 22, 2024	Jul	NEWA

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOMYCIN HYDROCHLORIDE

@ PAI HOLDINGS PHARM	EQ 125MG BASE
@	EQ 250MG BASE

A065478	001	Apr 09, 2012	Feb	DISC
A065478	002	Apr 09, 2012	Feb	DISC

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

AP	HIKMA	EQ 500MG BASE/VIAL	A204107	001	Dec 28, 2015	Sep	CAHN
AP		EQ 1GM BASE/VIAL	A204107	002	Dec 28, 2015	Sep	CAHN
	@ MEDIMETRIKS PHARMS	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Aug	CAHN
	@	EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Aug	CAHN
	@ PHARM ASSOC	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Feb	DISC
	@	EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Feb	DISC
	@ SANDOZ INC	EQ 5GM BASE/VIAL	A201048	001	Aug 10, 2012	Apr	DISC
	@	EQ 10GM BASE/VIAL	A201048	002	Aug 10, 2012	Apr	DISC
AP	SLATE RUN PHARMA	EQ 500MG BASE/VIAL	A212332	001	Jun 12, 2019	Sep	CAHN
AP		EQ 1GM BASE/VIAL	A212332	002	Jun 12, 2019	Sep	CAHN
AP		EQ 5GM BASE/VIAL	A215821	001	Nov 18, 2021	Sep	CAHN
AP		EQ 10GM BASE/VIAL	A215821	002	Nov 18, 2021	Sep	CAHN

A204107	001	Dec 28, 2015	Sep	CAHN
A204107	002	Dec 28, 2015	Sep	CAHN
A065401	001	Jun 30, 2008	Aug	CAHN
A065401	002	Jun 30, 2008	Aug	CAHN
A065401	001	Jun 30, 2008	Feb	DISC
A065401	002	Jun 30, 2008	Feb	DISC
A201048	001	Aug 10, 2012	Apr	DISC
A201048	002	Aug 10, 2012	Apr	DISC
A212332	001	Jun 12, 2019	Sep	CAHN
A212332	002	Jun 12, 2019	Sep	CAHN
A215821	001	Nov 18, 2021	Sep	CAHN
A215821	002	Nov 18, 2021	Sep	CAHN

VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	EQ 500MG BASE/100ML	N050671	001	Apr 29, 1993	Feb	CTNA
+!		EQ 750MG BASE/150ML	N050671	002	Dec 20, 2010	Feb	CTNA
+!		EQ 1GM BASE/200ML	N050671	003	Mar 01, 1999	Feb	CTNA

N050671	001	Apr 29, 1993	Feb	CTNA
N050671	002	Dec 20, 2010	Feb	CTNA
N050671	003	Mar 01, 1999	Feb	CTNA

POWDER; INTRAVENOUS

VANCOMYCIN HYDROCHLORIDE

+!	MYLAN LABS LTD	EQ 1.75GM BASE/VIAL	N209481	005	Jun 26, 2024	Jul	NEWA
+!		EQ 2GM BASE/VIAL	N209481	006	Jun 26, 2024	Jul	NEWA

N209481	005	Jun 26, 2024	Jul	NEWA
N209481	006	Jun 26, 2024	Jul	NEWA

SOLUTION; INTRAVENOUS

VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	EQ 500MG BASE/100ML (EQ 5MG BASE/ML)	N050671	001	Apr 29, 1993	Feb	CPOT
+!		EQ 500MG BASE/100ML	N050671	001	Apr 29, 1993	Feb	CDFR
+!		EQ 750MG BASE/150ML (EQ 5MG	N050671	002	Dec 20, 2010	Feb	CPOT

N050671	001	Apr 29, 1993	Feb	CPOT
N050671	001	Apr 29, 1993	Feb	CDFR
N050671	002	Dec 20, 2010	Feb	CPOT

SOLUTION; INTRAVENOUS

VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER

		BASE/ML)						
+	!	EQ 750MG BASE/150ML	N050671	002	Dec 20, 2010	Feb	CDFR	
+	!	EQ 1GM BASE/200ML (EQ 5MG BASE/ML)	N050671	003	Mar 01, 1999	Feb	CPOT	
+	!	EQ 1GM BASE/200ML	N050671	003	Mar 01, 1999	Feb	CDFR	
+	!	EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML)	N050671	004	Jan 25, 2024	Feb	NEWA	
+	!	EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML)	N050671	005	Jan 25, 2024	Feb	NEWA	

VARENICLINE TARTRATE

TABLET; ORAL

VARENICLINE TARTRATE

AB		AJANTA PHARMA LTD	EQ 0.5MG BASE	A213019	001	Mar 19, 2024	Mar	NEWA
AB			EQ 1MG BASE	A213019	002	Mar 19, 2024	Mar	NEWA
AB		AVALANCHE PHARM	EQ 0.5MG BASE	A217283	001	Mar 06, 2024	Feb	NEWA
AB			EQ 1MG BASE	A217283	002	Mar 06, 2024	Feb	NEWA
AB		BIONPHARMA	EQ 0.5MG BASE	A217283	001	Mar 06, 2024	Oct	CAHN
AB			EQ 1MG BASE	A217283	002	Mar 06, 2024	Oct	CAHN
AB		DR REDDYS	EQ 0.5MG BASE	A215931	001	Oct 01, 2024	Sep	NEWA
AB			EQ 1MG BASE	A215931	002	Oct 01, 2024	Sep	NEWA
AB		INDOCO	EQ 0.5MG BASE	A219106	001	Oct 29, 2024	Oct	NEWA
AB			EQ 1MG BASE	A219106	002	Oct 29, 2024	Oct	NEWA
>D>	AB	LEADING PHARMA	EQ 0.5MG BASE	A217151	001	Jul 25, 2023	Nov	CAHN
>D>	AB		EQ 1MG BASE	A217151	002	Jul 25, 2023	Nov	CAHN
>A>	AB	MACLEODS PHARMS LTD	EQ 0.5MG BASE	A215048	001	Dec 09, 2024	Nov	NEWA
>A>	AB		EQ 1MG BASE	A215048	002	Dec 09, 2024	Nov	NEWA
>A>	AB	MEDLEY PHARMS	EQ 0.5MG BASE	A217151	001	Jul 25, 2023	Nov	CAHN
>A>	AB		EQ 1MG BASE	A217151	002	Jul 25, 2023	Nov	CAHN
AB		MYLAN	EQ 0.5MG BASE	A202019	001	Feb 28, 2024	Feb	NEWA
AB			EQ 1MG BASE	A202019	002	Feb 28, 2024	Feb	NEWA
AB		PIRAMAL	EQ 0.5MG BASE	A217115	001	Jul 23, 2024	Sep	CAHN
AB			EQ 1MG BASE	A217115	002	Jul 23, 2024	Sep	CAHN
AB		SLATE RUN PHARMA	EQ 0.5MG BASE	A217115	001	Jul 23, 2024	Jul	NEWA
AB			EQ 1MG BASE	A217115	002	Jul 23, 2024	Jul	NEWA

VASOPRESSIN

SOLUTION; INTRAVENOUS

VASOPRESSIN

AP		DR REDDYS	20UNITS/ML (20UNITS/ML)	A213988	001	May 08, 2024	Apr	NEWA
AP		GLAND PHARMA LTD	20UNITS/ML (20UNITS/ML)	A216963	001	Feb 09, 2024	Feb	NEWA
		VASOPRESSIN IN SODIUM CHLORIDE 0.9%						
+	!	LONG GROVE PHARMS	20UNITS/100ML (0.2UNITS/ML)	N217766	001	Jul 11, 2024	Jul	NEWA
+	!		40UNITS/100ML (0.4UNITS/ML)	N217766	002	Jul 11, 2024	Jul	NEWA
+	!		50UNITS/50ML (1UNIT/ML)	N217766	003	Jul 11, 2024	Jul	NEWA

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

AB		ALEMBIC	EQ 37.5MG BASE	A217767	001	Jun 06, 2024	May	NEWA
AB			EQ 75MG BASE	A217767	002	Jun 06, 2024	May	NEWA
AB			EQ 150MG BASE	A217767	003	Jun 06, 2024	May	NEWA
		@ ANCHEN PHARMS	EQ 37.5MG BASE	A078087	001	Mar 16, 2012	May	CAHN
		@	EQ 75MG BASE	A078087	002	Mar 16, 2012	May	CAHN
		@	EQ 150MG BASE	A078087	003	Mar 16, 2012	May	CAHN
		@ NOSTRUM PHARMS LLC	EQ 37.5MG BASE	A200430	001	Apr 04, 2023	May	DISC
		@	EQ 75MG BASE	A200430	002	Apr 04, 2023	May	DISC
		@	EQ 150MG BASE	A200430	003	Apr 04, 2023	May	DISC
		@ VALEANT PHARMS NORTH	EQ 37.5MG BASE	A090071	001	Apr 15, 2011	Oct	DISC
		@	EQ 75MG BASE	A090071	002	Apr 15, 2011	Oct	DISC
		@	EQ 150MG BASE	A090071	003	Apr 15, 2011	Oct	DISC

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

		@ AMNEAL PHARMS	EQ 25MG BASE	A079098	001	May 11, 2010	Jun	DISC
		@	EQ 37.5MG BASE	A079098	002	May 11, 2010	Jun	DISC
		@	EQ 50MG BASE	A079098	003	May 11, 2010	Jun	DISC
		@	EQ 75MG BASE	A079098	004	May 11, 2010	Jun	DISC
		@	EQ 100MG BASE	A079098	005	May 11, 2010	Jun	DISC
		@ NORVIUM BIOSCIENCE	EQ 25MG BASE	A077166	001	Jun 13, 2008	Sep	CAHN
		@	EQ 37.5MG BASE	A077166	002	Jun 13, 2008	Sep	CAHN
		@	EQ 50MG BASE	A077166	003	Jun 13, 2008	Sep	CAHN
		@	EQ 75MG BASE	A077166	004	Jun 13, 2008	Sep	CAHN

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

@ EQ 100MG BASE A 077166 005 Jun 13, 2008 Sep CAHN

TABLET, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

>D> AB SUN PHARM EQ 37.5MG BASE A 091272 001 Aug 18, 2010 Nov DISC
 >A> @ EQ 37.5MG BASE A 091272 001 Aug 18, 2010 Nov DISC
 >D> AB EQ 75MG BASE A 091272 002 Aug 18, 2010 Nov DISC
 >A> @ EQ 75MG BASE A 091272 002 Aug 18, 2010 Nov DISC
 >D> AB EQ 150MG BASE A 091272 003 Aug 18, 2010 Nov DISC
 >A> @ EQ 150MG BASE A 091272 003 Aug 18, 2010 Nov DISC
 >D> AB EQ 225MG BASE A 091272 004 Jan 08, 2019 Nov DISC
 >A> @ EQ 225MG BASE A 091272 004 Jan 08, 2019 Nov DISC
 @ SWISS PHARM EQ 75MG BASE A 214423 001 Jan 04, 2022 Aug CAHN
 @ EQ 150MG BASE A 214423 002 Jan 04, 2022 Aug CAHN

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VERELAN

AB + AZURITY 120MG N 019614 001 May 29, 1990 Aug CAHN
 AB + 180MG N 019614 003 Jan 09, 1992 Aug CAHN
 AB + 240MG N 019614 002 May 29, 1990 Aug CAHN
 +! 360MG N 019614 004 May 10, 1996 Aug CAHN
 VERELAN PM
 + AZURITY 100MG N 020943 001 Nov 25, 1998 Aug CAHN
 + 200MG N 020943 002 Nov 25, 1998 Aug CAHN
 +! 300MG N 020943 003 Nov 25, 1998 Aug CAHN

INJECTABLE;INJECTION

VERAPAMIL HYDROCHLORIDE

>D> @ FRESenius KABI USA 2.5MG/ML A 216471 001 Apr 23, 2024 Nov CMFD
 >A> AP 2.5MG/ML A 216471 001 Apr 23, 2024 Nov CMFD
 @ 2.5MG/ML A 216471 001 Apr 23, 2024 May DISC
 AP 2.5MG/ML A 216471 001 Apr 23, 2024 Apr NEWA
 AP HERITAGE 2.5MG/ML A 215829 001 Mar 17, 2022 Sep CAHN

SOLUTION;INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

AP NEPHRON 5MG/2ML (2.5MG/ML) A 213352 002 Sep 16, 2020 Apr CAHN
 AP 10MG/4ML (2.5MG/ML) A 213352 001 Mar 17, 2020 Apr CAHN

VERICIGUAT

TABLET;ORAL

VERQUVO

>D> + MERCK SHARP DOHME 2.5MG N 214377 001 Jan 19, 2021 Nov CAHN
 >D> + 5MG N 214377 002 Jan 19, 2021 Nov CAHN
 >D> +! 10MG N 214377 003 Jan 19, 2021 Nov CAHN
 >A> + MSD 2.5MG N 214377 001 Jan 19, 2021 Nov CAHN
 >A> + 5MG N 214377 002 Jan 19, 2021 Nov CAHN
 >A> +! 10MG N 214377 003 Jan 19, 2021 Nov CAHN

VERTEPORFIN

INJECTABLE;INJECTION

VISUDYNE

+! BAUSCH LOMB IRELAND 15MG/VIAL N 021119 001 Apr 12, 2000 Jul CAHN

VIGABATRIN

FOR SOLUTION;ORAL

VIGABATRIN

@ PROPEL PHARMA 500MG/PACKET A 213390 001 Jul 29, 2021 Oct DISC

SOLUTION;ORAL

VIGAFYDE

+! PYROS PHARMS 100MG/ML N 217684 001 Jun 17, 2024 Jun NEWA

TABLET;ORAL

VIGABATRIN

AB RYAN LABS 500MG A 215519 001 Apr 28, 2023 Sep CAHN

VINORELBINE TARTRATE

INJECTABLE;INJECTION

VINORELBINE TARTRATE

@ RISING EQ 10MG BASE/ML A 200148 001 Aug 31, 2012 Mar CAHN

VORAPAXAR SULFATE

TABLET;ORAL
ZONTIVITY

+ @ KEY THERAP	EQ 2.08MG BASE	N204886	001	May 08, 2014	May	DISC
+!	EQ 2.08MG BASE	N204886	001	May 08, 2014	Apr	CAHN

VORASIDENIB

TABLET;ORAL
VORANIGO

+ SERVIER	10MG	N218784	001	Aug 06, 2024	Aug	NEWA
+!	40MG	N218784	002	Aug 06, 2024	Aug	NEWA

VORICONAZOLE

INJECTABLE;INTRAVENOUS
VORICONAZOLE

AP	ASPIRO	200MG/VIAL	A218533	001	Apr 03, 2024	Mar	NEWA
AP	CHARTWELL RX	200MG/VIAL	N208562	001	Mar 09, 2017	Sep	CAHN
	@ NORVIUM BIOSCIENCE	200MG/VIAL	A210849	001	Oct 11, 2022	Jul	CAHN

VOXELOTOR

TABLET;ORAL
OXBRYTA

+ @ GLOBAL BLOOD THERAPS	300MG	N213137	002	Oct 14, 2022	Oct	DISC
+ @	500MG	N213137	001	Nov 25, 2019	Oct	DISC

TABLET, FOR SUSPENSION;ORAL
OXBRYTA

+ @ GLOBAL BLOOD THERAPS	300MG	N216157	001	Dec 17, 2021	Oct	DISC
--------------------------	-------	---------	-----	--------------	-----	------

WARFARIN SODIUM

TABLET;ORAL
WARFARIN SODIUM

@ BARR	1MG	A040145	001	Mar 26, 1997	Jun	DISC
@	2MG	A040145	002	Mar 26, 1997	Jun	DISC
@	2.5MG	A040145	003	Mar 26, 1997	Jun	DISC
@	3MG	A040145	008	Nov 05, 1998	Jun	DISC
@	4MG	A040145	004	Mar 26, 1997	Jun	DISC
@	5MG	A040145	005	Mar 26, 1997	Jun	DISC
@	6MG	A040145	009	Nov 05, 1998	Jun	DISC
@	7.5MG	A040145	006	Mar 26, 1997	Jun	DISC
@	10MG	A040145	007	Mar 26, 1997	Jun	DISC

ZINC CHLORIDE

INJECTABLE;INJECTION
ZINC CHLORIDE

AP	SOMERSET	EQ 1MG ZINC/ML	A216152	001	Oct 16, 2024	Oct	NEWA
----	----------	----------------	---------	-----	--------------	-----	------

ZINC SULFATE

SOLUTION;INTRAVENOUS
ZINC SULFATE

AP	APOTEX	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	A218059	002	Oct 28, 2024	Oct	NEWA
AP		EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A218059	001	Jun 10, 2024	May	NEWA
AP	NIVAGEN PHARMS INC	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	A214597	001	Jul 05, 2024	Jun	NEWA
AP		EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A214597	002	Jul 05, 2024	Jun	NEWA
AP		EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A214597	003	Jul 05, 2024	Jun	NEWA
AP	SOMERSET THERAPS LLC	EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A216135	001	Jul 17, 2024	Jul	NEWA
AP		EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A216135	002	Jul 17, 2024	Jul	NEWA

ZOLEDRONIC ACID

INJECTABLE;INTRAVENOUS
ZOLEDRONIC ACID

@ HOSPIRA	EQ 4MG BASE/5ML	A090621	001	Mar 19, 2015	May	DISC
-----------	-----------------	---------	-----	--------------	-----	------

ZOLMITRIPTAN

SPRAY;NASAL
ZOLMITRIPTAN

AB	! PADAGIS ISRAEL	5MG/SPRAY	A212469	002	Sep 30, 2021	Feb	CHRS
----	------------------	-----------	---------	-----	--------------	-----	------

TABLET;ORAL
ZOLMITRIPTAN

	@ INVAGEN PHARMS	2.5MG	A204284	001	Apr 09, 2014	Mar	DISC
	@	5MG	A204284	002	Apr 09, 2014	Mar	DISC
AB	SOMERSET THERAPS LLC	2.5MG	A206973	001	Jun 30, 2017	Sep	CAHN

TABLET;ORAL						
ZOLMITRIPTAN						
AB		5MG		A206973	002	Jun 30, 2017 Sep CAHN
<u>ZOLPIDEM TARTRATE</u>						
TABLET;ORAL						
ZOLPIDEM TARTRATE						
	@ INVAGEN PHARMS	5MG		A078184	001	Sep 07, 2007 Mar DISC
	@	10MG		A078184	002	Sep 07, 2007 Mar DISC
TABLET;SUBLINGUAL						
ZOLPIDEM TARTRATE						
AB	ENDO OPERATIONS	1.75MG		A204229	001	Sep 11, 2017 Apr CAHN
AB		3.5MG		A204229	002	Sep 11, 2017 Apr CAHN
AB		5MG		A201509	001	Aug 01, 2016 May CAHN
AB		10MG		A201509	002	Aug 01, 2016 May CAHN
TABLET, EXTENDED RELEASE;ORAL						
ZOLPIDEM TARTRATE						
	@ ENDO OPERATIONS	6.25MG		A078148	002	Apr 14, 2011 May CAHN
	@	12.5MG		A078148	001	Dec 03, 2010 May CAHN

ACETAMINOPHEN

SUPPOSITORY;RECTAL

ACEPHEN

@ COSETTE	120MG	N018060	001		Mar	DISC
@	325MG	A072344	001	Mar 27, 1992	Mar	DISC
@	650MG	A072237	001	Mar 27, 1992	Mar	DISC

ACETAMINOPHEN

+ @ TARO	650MG	N018337	001		Oct	DISC
----------	-------	---------	-----	--	-----	------

TABLET, EXTENDED RELEASE;ORAL

ACETAMINOPHEN

>D>	SUN PHARM INDS LTD	650MG	A078569	001	Dec 14, 2011	Nov	DISC
>A>	@	650MG	A078569	001	Dec 14, 2011	Nov	DISC

ACETAMINOPHEN; IBUPROFEN

TABLET;ORAL

ACETAMINOPHEN AND IBUPROFEN

@ AUROBINDO PHARMA LTD	250MG;125MG	A218359	001	Mar 26, 2024	Sep	DISC
	250MG;125MG	A218359	001	Mar 26, 2024	Apr	CTNA
	250MG;125MG	A218359	001	Mar 26, 2024	Mar	NEWA
DR REDDYS	250MG;125MG	A218247	001	Aug 23, 2024	Aug	NEWA
GLENMARK PHARMS LTD	250MG;125MG	A218311	001	Apr 26, 2024	Apr	NEWA

ALCAFTADINE

SOLUTION/DROPS;OPHTHALMIC

ALCAFTADINE

ALEMBIC	0.25%	A209290	001	Oct 02, 2024	Sep	NEWA
GLAND PHARMA LTD	0.25%	A209706	001	Mar 01, 2024	Feb	NEWA

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE

AMNEAL	0.2055MG/SPRAY	A216576	001	Jun 05, 2024	May	NEWA
@ PADAGIS ISRAEL	0.2055MG/SPRAY	A216801	001	May 08, 2024	May	DISC
	0.2055MG/SPRAY	A216801	001	May 08, 2024	Apr	NEWA
AZELASTINE HYDROCHLORIDE ALLERGY						
APOTEX	0.2055MG/SPRAY	A216421	001	May 29, 2024	May	NEWA
AZELASTINE HYDROCHLORIDE CHILDREN'S ALLERGY						
APOTEX	0.2055MG/SPRAY	A216421	002	May 29, 2024	May	NEWA

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE

DR REDDYS LABS SA	0.025%	A216361	001	Feb 16, 2024	Feb	NFTG
LUMIFY PRESERVATIVE FREE						
+! BAUSCH AND LOMB INC	0.025%	N218424	001	Apr 19, 2024	Apr	NEWA

CETIRIZINE HYDROCHLORIDE

SOLUTION;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

AMNEAL PHARMS	5MG/5ML	A090765	002	Oct 07, 2009	Feb	CDFR
@ APOZEAL PHARMS	5MG/5ML	A090474	002	Mar 30, 2009	Feb	CDFR
AUROBINDO PHARMA	5MG/5ML	A090750	002	Feb 02, 2010	Feb	CDFR
BAJAJ	5MG/5ML	A091327	001	Oct 17, 2011	Feb	CDFR
CHARTWELL MOLECULAR	5MG/5ML	A091130	001	Apr 22, 2011	Feb	CDFR
@ CHARTWELL RX	5MG/5ML	A090378	002	May 09, 2008	Feb	CDFR
@ CYPRESS PHARM	5MG/5ML	A090300	001	Oct 10, 2008	Feb	CDFR
HETERO LABS LTD III	5MG/5ML	A210622	001	Mar 13, 2019	Feb	CDFR
PERRIGO R AND D	5MG/5ML	A204226	001	Sep 09, 2013	Feb	CDFR
	5MG/5ML	A090254	002	Apr 09, 2008	Feb	CDFR
@ PHARM ASSOC	5MG/5ML	A090188	002	Apr 22, 2008	Feb	CDFR
QUAGEN	5MG/5ML	A212266	001	May 16, 2019	Feb	CDFR
@ RANBAXY LABS LTD	5MG/5ML	A090183	002	Apr 24, 2008	Feb	CDFR
TARO	5MG/5ML	A090182	002	Apr 22, 2008	Feb	CDFR
	5MG/5ML	A201546	001	May 20, 2011	Feb	CDFR
@ TRIS PHARMA INC	5MG/5ML	A090572	001	Nov 16, 2012	Feb	CDFR

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

AMNEAL PHARMS	5MG/5ML	A090765	001	Oct 07, 2009	Feb	CDFR
@ APOZEAL PHARMS	5MG/5ML	A090474	001	Mar 30, 2009	Feb	CDFR
AUROBINDO PHARMA	5MG/5ML	A090750	001	Feb 02, 2010	Feb	CDFR
BAJAJ	5MG/5ML	A091327	002	Oct 17, 2011	Feb	CDFR

<u>SOLUTION;ORAL</u>					
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
CHARTWELL MOLECULAR	5MG/5ML	A091130	002	Apr 22, 2011	Feb CDFR
@ CHARTWELL RX	5MG/5ML	A090378	001	May 09, 2008	Feb CDFR
@ CYPRESS PHARM	5MG/5ML	A090300	002	Oct 10, 2008	Feb CDFR
PERRIGO R AND D	5MG/5ML	A090254	001	Apr 09, 2008	Feb CDFR
@ PHARM ASSOC	5MG/5ML	A090188	001	Apr 22, 2008	Feb CDFR
@ RANBAXY LABS LTD	5MG/5ML	A090183	001	Apr 24, 2008	Feb CDFR
TARO	5MG/5ML	A090182	001	Apr 22, 2008	Feb CDFR
	5MG/5ML	A201546	002	May 20, 2011	Feb CDFR
@ TRIS PHARMA INC	5MG/5ML	A090572	002	Nov 16, 2012	Feb CDFR
<u>TABLET;ORAL</u>					
CETIRIZINE HYDROCHLORIDE					
INDOCO	10MG	A218895	001	Oct 03, 2024	Sep NEWA
<u>TABLET, CHEWABLE;ORAL</u>					
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY					
@ SUN PHARM	5MG	A090142	001	Aug 30, 2011	Mar DISC
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
@ SUN PHARM	5MG	A090142	003	Aug 30, 2011	Mar DISC
<u>CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE</u>					
<u>TABLET, EXTENDED RELEASE;ORAL</u>					
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE					
PPI-DAC	5MG;120MG	A210719	001	Nov 16, 2018	Jun CAHN
UNICHEM	5MG;120MG	A210507	001	Sep 10, 2024	Aug NEWA
<u>CLOTRIMAZOLE</u>					
<u>CREAM;VAGINAL</u>					
TRIVAGIZOLE 3					
TARO	2%	N021143	001	Apr 12, 2000	Mar CAHN
<u>DICLOFENAC SODIUM</u>					
<u>GEL;TOPICAL</u>					
DICLOFENAC SODIUM					
CIPLA	1%	A209903	001	Aug 03, 2018	Jul CMKT
@ HIKMA	1%	A209484	001	Nov 21, 2018	Mar DISC
<u>DIPHENHYDRAMINE CITRATE; IBUPROFEN</u>					
<u>TABLET;ORAL</u>					
IBUPROFEN AND DIPHENHYDRAMINE CITRATE					
PLD ACQUISITIONS LLC	38MG;200MG	A211404	001	Apr 11, 2024	Apr NEWA
<u>DOCOSANOL</u>					
<u>CREAM;TOPICAL</u>					
DOCOSANOL					
AUROBINDO PHARMA LTD	10%	A217090	001	Mar 01, 2024	Feb NEWA
P AND L DEVELOPMENT	10%	A212385	001	Oct 07, 2022	Mar CAHN
<u>ESOMEPRAZOLE MAGNESIUM</u>					
<u>CAPSULE, DELAYED RELEASE;ORAL</u>					
ESOMEPRAZOLE MAGNESIUM					
ANDA REPOSITORY	EQ 20MG BASE	A216149	001	Mar 15, 2023	Sep CAHN
DR REDDYS	EQ 20MG BASE	A207198	001	Apr 30, 2024	Apr NEWA
GLENMARK SPECLT	EQ 20MG BASE	A218092	001	Jun 11, 2024	May NEWA
GUARDIAN DRUG	EQ 20MG BASE	A216149	001	Mar 15, 2023	Feb CAHN
<u>TABLET, DELAYED RELEASE;ORAL</u>					
ESOMEPRAZOLE MAGNESIUM					
AUROBINDO PHARMA LTD	EQ 20MG BASE	A214473	001	Jul 12, 2023	Apr CMFD
@	EQ 20MG BASE	A214473	001	Jul 12, 2023	Jan DISC
<u>FAMOTIDINE</u>					
<u>TABLET;ORAL</u>					
FAMOTIDINE					
CONTRACT PHARMACAL	10MG	A218003	001	May 28, 2024	May NEWA
	20MG	A218003	002	May 28, 2024	May NEWA
GRAVITI PHARMS	10MG	A218461	001	Mar 14, 2024	Mar NEWA
	20MG	A218461	002	Mar 14, 2024	Mar NEWA
@ SUN PHARM INDS LTD	10MG	A090283	001	Nov 17, 2009	Apr DISC
@	20MG	A090283	002	Nov 17, 2009	Apr DISC

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLUTICASONE PROPIONATE

AUROBINDO PHARMA LTD 0.05MG/SPRAY

A217088 001 May 10, 2024 May NEWA

@ HIKMA 0.05MG/SPRAY

A208024 001 Apr 17, 2019 Mar DISC

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

>D> @ AUROBINDO PHARMA LTD EQ 200MG FREE ACID AND POTASSIUM A215777 001 Sep 14, 2023 Nov CMFD

>A> EQ 200MG FREE ACID AND POTASSIUM A215777 001 Sep 14, 2023 Nov CMFD

@ EQ 200MG FREE ACID AND POTASSIUM A215777 001 Sep 14, 2023 Mar DISC

PATHEON SOFTGELS EQ 200MG FREE ACID AND POTASSIUM A217236 001 Feb 13, 2024 Mar CAHN

EQ 200MG FREE ACID AND POTASSIUM A217236 001 Feb 13, 2024 Feb NEWA

SALT

SUSPENSION;ORAL

IBUPROFEN

>A> ANNORA PHARMA 100MG/5ML A210602 001 Nov 23, 2018 Sep CAHN

PAI HOLDINGS PHARM 100MG/5ML A214789 001 Nov 08, 2024 Nov NEWA

SUSPENSION/DROPS;ORAL

IBUPROFEN

@ AUROBINDO PHARMA LTD 40MG/ML A213506 001 Apr 08, 2024 Oct DISC

40MG/ML A213506 001 Apr 08, 2024 Mar NEWA

TABLET;ORAL

IBUPROFEN

@ ADAPTIS 200MG A071265 001 Oct 15, 1986 Sep CAHN

@ 200MG A071265 002 Sep 10, 1987 Sep CAHN

200MG A072299 001 Jul 01, 1988 Sep CAHN

>A> DR REDDYS 200MG A075661 001 Dec 12, 2001 Nov CAHN

>D> DR REDDYS LA 200MG A075661 001 Dec 12, 2001 Nov CAHN

ENDO OPERATIONS 200MG A071229 001 Apr 01, 1987 May CAHN

@ 200MG A071639 001 Feb 02, 1988 May CAHN

@ 200MG A072249 001 Jan 10, 1989 May CAHN

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC

KETOTIFEN FUMARATE

>D> BAYSHORE PHARMS LLC EQ 0.025% BASE A204059 001 Jun 01, 2020 Nov CAHN

>A> UNICHEM EQ 0.025% BASE A204059 001 Jun 01, 2020 Nov CAHN

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

NAARI PTE LTD 1.5MG A207660 001 May 02, 2019 Apr CMFD

@ XIROMED 0.75MG A202740 001 Sep 02, 2016 May CAHN

1.5MG A202739 001 Oct 31, 2014 May CAHN

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

@ SUN PHARM INDS LTD 2MG;125MG A077500 001 Sep 06, 2006 May DISC

LORATADINE

SUSPENSION;ORAL

LORATADINE

+! TARO 1MG/ML N021734 001 Oct 04, 2005 Aug CAHN

TABLET;ORAL

LORATADINE

ANDA REPOSITORY 10MG A207569 001 Mar 12, 2019 Sep CAHN

>A> MARKSANS PHARMA 10MG A219223 001 Nov 21, 2024 Nov NEWA

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

LORATADINE AND PSEUDOEPHEDRINE SULFATE

BIONPHARMA 10MG;240MG A218017 001 May 14, 2024 May NEWA

MICONAZOLE NITRATE

CREAM;VAGINAL

MICONAZOLE NITRATE

@ COSETTE 2%

A074366 001 Feb 22, 1996 Apr DISC

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

M-ZOLE 3 COMBINATION PACK

COSETTE 2%,200MG

A074926 001 Apr 16, 1999 Jun CAHN

SUPPOSITORY;VAGINAL

MICONAZOLE NITRATE

COSETTE 100MG

A073507 001 Nov 19, 1993 Jun CAHN

@ 100MG

A074414 001 Apr 30, 1997 Apr DISC

MINOXIDIL

AEROSOL, FOAM;TOPICAL

MINOXIDIL (FOR MEN)

AUROBINDO PHARMA 5%

A218616 001 Apr 22, 2024 Apr NEWA

MINOXIDIL (FOR WOMEN)

AUROBINDO PHARMA 5%

A218616 002 Apr 22, 2024 Apr NEWA

SOLUTION;TOPICAL

MINOXIDIL (FOR MEN)

@ AUROBINDO PHARMA LTD 2%

A074767 001 Feb 28, 1997 Oct DISC

MINOXIDIL (FOR WOMEN)

>A> @ AUROBINDO PHARMA LTD 2%

A074767 002 Nov 25, 1997 Nov DISC

>A> TARO 2%

A218175 001 Nov 26, 2024 Nov NEWA

MOMETASONE FUROATE

SPRAY, METERED;NASAL

MOMETASONE FUROATE

@ APOTEX 0.05MG/SPRAY

A217438 001 Apr 23, 2024 Sep DISC

0.05MG/SPRAY

A217438 001 Apr 23, 2024 Apr NEWA

>A> AUROBINDO PHARMA 0.05MG/SPRAY

A217498 001 Nov 22, 2024 Nov NEWA

NALOXONE HYDROCHLORIDE

SPRAY, METERED;NASAL

NALOXONE HYDROCHLORIDE

AMNEAL 4MG/SPRAY

A217992 001 Apr 23, 2024 Apr NEWA

TEVA PHARMS USA 4MG/SPRAY

A209522 001 Apr 19, 2019 Jun CMKT

NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM

@ SUN PHARM INDS LTD 220MG

A091183 001 May 20, 2011 Jan DISC

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE

AUROBINDO PHARMA 220MG;120MG

A211360 001 Jun 01, 2022 Jul CMFD

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL

NICOTINE

DIFGEN PHARMS 7MG/24HR

A074612 002 Jul 28, 2003 Sep CAHN

14MG/24HR

A074612 003 Oct 20, 1997 Sep CAHN

21MG/24HR

A074612 001 Oct 20, 1997 Sep CAHN

NICOTINE POLACRILEX

TROCHE/LOZENGE;ORAL

NICORETTE

+ HALEON US HOLDINGS EQ 2MG BASE

N022360 001 May 18, 2009 Jan CAHN

+! EQ 4MG BASE

N022360 002 May 18, 2009 Jan CAHN

NICOTINE POLACRILEX

PPI-DAC EQ 2MG BASE

A090711 001 Jul 10, 2009 Jun CAHN

EQ 2MG BASE

A203690 001 Oct 09, 2012 Jun CAHN

EQ 4MG BASE

A090711 002 Jul 10, 2009 Jun CAHN

EQ 4MG BASE

A203690 002 Oct 09, 2012 Jun CAHN

NORGESTRELTABLET;ORAL
OPILL

+! LABORATOIRE HRA 0.075MG N017031 001 Feb CMFD

OLOPATADINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
OLOPATADINE HYDROCHLORIDEGLENMARK PHARMS INC EQ 0.1% BASE
SOMERSET THERAPS LLC EQ 0.1% BASEA200810 001 Jun 28, 2017 Aug CMFD
A206306 001 Dec 07, 2015 Apr CMKTOMEPRAZOLE MAGNESIUMCAPSULE, DELAYED RELEASE;ORAL
OMEPRAZOLE MAGNESIUM>D> SPIL EQ 20MG BASE
>A> @ EQ 20MG BASEA210593 001 Jul 20, 2018 Nov DISC
A210593 001 Jul 20, 2018 Nov DISCOMEPRAZOLE; SODIUM BICARBONATEFOR SUSPENSION;ORAL
OMEPRAZOLE AND SODIUM BICARBONATE

DR REDDYS 20MG/PACKET;1.68GM/PACKET

A217784 001 May 09, 2024 May NFTG

POLYETHYLENE GLYCOL 3350FOR SOLUTION;ORAL
POLYETHYLENE GLYCOL 3350PPI-DAC 17GM/PACKET
17GM/SCOOPFULA090685 001 Oct 06, 2009 Jun CAHN
A090685 002 Oct 06, 2009 Jun CAHNPOVIDONE-IODINESPONGE;TOPICAL
E-Z SCRUB 201

+ @ BECTON DICKINSON 20% N019240 001 Nov 29, 1985 Feb DISC

E-Z SCRUB 241

+ @ BECTON DICKINSON 10% N019476 001 Jan 07, 1987 Feb DISC

TERBINAFINEGEL;TOPICAL
LAMISIL AT

+! KARO HLTHCARE 1% N021958 001 Jul 24, 2006 Feb CAHN

TERBINAFINE HYDROCHLORIDECREAM;TOPICAL
LAMISIL

+! KARO HLTHCARE 1% N020980 001 Mar 09, 1999 Feb CAHN

SOLUTION;TOPICAL

LAMISIL AT

+! KARO HLTHCARE 1% N021124 001 Mar 17, 2000 Feb CAHN

SPRAY;TOPICAL

LAMISIL AT

+! KARO HLTHCARE 1% N021124 002 Mar 17, 2000 Feb CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND
RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 11 NOVEMBER 2024

NO NOVEMBER 2024 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO NOVEMBER 2024 APPROVALS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743 001	11977067	Apr 30, 2038	DP			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 001	7855211	Sep 28, 2031	DS DP U-2135			
	7855211	Sep 28, 2031	DS DP U-3242			
	7855211	Sep 28, 2031	DS DP U-3265			
	7855211	Sep 28, 2031	DS DP U-3546			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 002	7855211	Sep 28, 2031	DS DP U-2135			
	7855211	Sep 28, 2031	DS DP U-3242			
	7855211	Sep 28, 2031	DS DP U-3265			
	7855211	Sep 28, 2031	DS DP U-3546			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 003	7855211	Sep 28, 2031	DS DP U-2135			
	7855211	Sep 28, 2031	DS DP U-3242			
	7855211	Sep 28, 2031	DS DP U-3265			
	7855211	Sep 28, 2031	DS DP U-3546			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 004	7855211	Sep 28, 2031	DS DP U-1981			
	7855211	Sep 28, 2031	DS DP U-2135			
	7855211	Sep 28, 2031	DS DP U-3242			
	7855211	Sep 28, 2031	DS DP U-3265			
	7855211	Sep 28, 2031	DS DP U-3546			
<u>ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA</u>						
N 216793 001	11986468	Jul 28, 2037	U-2830			
	11986469	Jul 28, 2037	U-2830			
	11992486	Jul 28, 2037	U-2830			
<u>ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA</u>						
N 216793 002	11986468	Jul 28, 2037	U-2830			
	11986469	Jul 28, 2037	U-2830			
	11992486	Jul 28, 2037	U-2830			
<u>ACETAMINOPHEN; IBUPROFEN - ACETAMINOPHEN AND IBUPROFEN</u>						
A 218311 001					PC	Nov 03, 2024
<u>ACETAMINOPHEN; IBUPROFEN - ADVIL DUAL ACTION WITH ACETAMINOPHEN</u>						
N 211733 001	11918693	Jul 09, 2041	DP			
<u>ACETAMINOPHEN; IBUPROFEN SODIUM - COMBOGESIC IV</u>						
N 215320 001	11896567	Oct 26, 2031	U-3744			
	11896567	Oct 26, 2031	U-3745			
	12083087	Jul 17, 2035	U-3744			
	12083087	Jul 17, 2035	U-3745			
<u>ACETYLCYSTEINE LYSINE - LEGUBETI</u>						
N 215040 001					NP	Feb 13, 2027
<u>ACETYLCYSTEINE LYSINE - LEGUBETI</u>						
N 215040 002					NP	Feb 13, 2027
<u>ACYCLOVIR - ACYCLOVIR</u>						
A 212361 001					CGT	Jun 12, 2024
<u>ADAGRASIB - KRAZATI</u>						
N 216340 001	10689377	May 17, 2037	DS DP U-3490			
	10689377	May 17, 2037	DS DP U-3953			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ADAGRASIB - KRAZATI</u>						
N 216340 001	10689377	May 17, 2037	DS DP U-3490			
	10689377	May 17, 2037	DS DP U-3953			
<u>ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - CABTREQ</u>						
N 216632 001	>A> 12128059	Jul 31, 2040	DP U-3713			
	>A> 12133859	Jul 31, 2040	DP			
	>A> 12138278	Jul 31, 2040	DP			
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434 001					I-947 ODE-477	Apr 18, 2027 Apr 18, 2031
<u>ALPELISIB - PIORAY</u>						
N 212526 001	8227462	Apr 29, 2033	DS DP U-3809		I-937	Jan 18, 2027
<u>ALPELISIB - PIORAY</u>						
N 212526 002	8227462	Apr 29, 2033	DS DP U-3809		I-937	Jan 18, 2027
<u>ALPELISIB - PIORAY</u>						
N 212526 003	8227462	Apr 29, 2033	DS DP U-3809		I-937	Jan 18, 2027
<u>ALPELISIB - VIJOICE</u>						
N 218466 001	8227462	Apr 29, 2033	DS DP			
	8476268	Sep 10, 2029	DS DP			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001	11903908	Jun 17, 2034	U-3822			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002	11903908	Jun 17, 2034	U-3822			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 001	11890261	Feb 15, 2038	U-2497			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 002	11890261	Feb 15, 2038	U-2497			
<u>AMIKACIN SULFATE - ARIKAYCE KIT</u>						
N 207356 001	12016873	May 15, 2035	U-2414			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ</u>						
N 208081 001					>A> D-194	Oct 04, 2027
<u>AMLODIPINE BENZOATE - KATERZIA</u>						
N 211340 001	11918685	Oct 06, 2037	U-3447			
	11918685	Oct 06, 2037	U-3448			
	12053461	Oct 06, 2037	DP			
<u>AMLODIPINE BESYLATE - NORLIOVA</u>						
N 214439 001	12005141	Feb 24, 2041	DP U-3309			
	12005141	Feb 24, 2041	DP U-3310			
<u>AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN - TALICIA</u>						
N 213004 001	11878011	May 27, 2042	U-3816			
	11931463	Feb 12, 2034	DP U-3866			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 001	9839619	Jun 28, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 002	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 003	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 004	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 005	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 006	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 001	11896562	Mar 10, 2037	U-3299			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 002	11896562	Mar 10, 2037	U-3299			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 003	11896562	Mar 10, 2037	U-3299			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 004	11896562	Mar 10, 2037	U-3299			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 001	11963952	Jan 30, 2040	U-3901			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 002	11963952	Jan 30, 2040	U-3901			
<u>APREMILAST - OTEZLA</u>						
N 205437 001	10092541	May 29, 2034	U-2403		I-884	Dec 20, 2024
	10092541	May 29, 2034	U-2659		M-299	Jul 20, 2026
	10092541*PED	Nov 29, 2034			NPP	Apr 25, 2027
	7427638	Feb 16, 2028	DS DP		ODE-248	Jul 19, 2026
	7427638*PED	Aug 16, 2028			PED	Jan 19, 2027
	9872854	May 29, 2034	U-2232		PED	Jan 20, 2027
	9872854	May 29, 2034	U-2233		PED	Oct 25, 2027
	9872854*PED	Nov 29, 2034				
<u>APREMILAST - OTEZLA</u>						
N 205437 002	10092541	May 29, 2034	U-2403		I-884	Dec 20, 2024
	10092541	May 29, 2034	U-2659		M-299	Jul 20, 2026
	10092541*PED	Nov 29, 2034			NPP	Apr 25, 2027
	7427638	Feb 16, 2028	DS DP		ODE-248	Jul 19, 2026
	7427638*PED	Aug 16, 2028			PED	Jan 19, 2027
	9872854	May 29, 2034	U-2232		PED	Jan 20, 2027
	9872854	May 29, 2034	U-2233		PED	Oct 25, 2027
	9872854*PED	Nov 29, 2034				
<u>APREMILAST - OTEZLA</u>						
N 205437 003	10092541	May 29, 2034	U-2403		I-884	Dec 20, 2024
	10092541	May 29, 2034	U-2659		M-299	Jul 20, 2026
	10092541*PED	Nov 29, 2034			NPP	Apr 25, 2027
	7427638	Feb 16, 2028	DS DP		ODE-248	Jul 19, 2026
	7427638*PED	Aug 16, 2028			PED	Jan 19, 2027
	9872854	May 29, 2034	U-2232		PED	Jan 20, 2027
	9872854	May 29, 2034	U-2233		PED	Oct 25, 2027
	9872854*PED	Nov 29, 2034				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APREPITANT - CINVANTI</u>						
N 209296 001	>A> 12115254	Sep 18, 2035	DP			
	>A> 12115255	Sep 18, 2035	DP			
<u>APREPITANT - APONVIE</u>						
N 216457 001	11878074	Sep 18, 2035	U-3787			
	>A> 12115254	Sep 18, 2035	DP			
	>A> 12115255	Sep 18, 2035	DP			
<u>APROCITENTAN - TRYVIO</u>						
N 217686 001	10919881	Feb 26, 2038	DS DP		NCE	Mar 22, 2029
	11174247	Nov 06, 2037	U-3879			
	11680058	Jul 26, 2038	U-3878			
	11787782	Mar 02, 2038	U-3877			
	8324232	Sep 21, 2029	DS DP U-3878			
<u>ARIMOCLOMOL CITRATE - MIPLYFFA</u>						
N 214927 001	11045460	Aug 19, 2029	U-4021		NCE	Sep 20, 2029
	9289472	Aug 11, 2029	U-4021		ODE-496	Sep 20, 2031
	9884058	Jun 26, 2029	U-4021			
<u>ARIMOCLOMOL CITRATE - MIPLYFFA</u>						
N 214927 002	11045460	Aug 19, 2029	U-4021		NCE	Sep 20, 2029
	9289472	Aug 11, 2029	U-4021		ODE-496	Sep 20, 2031
	9884058	Jun 26, 2029	U-4021			
<u>ARIMOCLOMOL CITRATE - MIPLYFFA</u>						
N 214927 003	11045460	Aug 19, 2029	U-4021		NCE	Sep 20, 2029
	9289472	Aug 11, 2029	U-4021		ODE-496	Sep 20, 2031
	9884058	Jun 26, 2029	U-4021			
<u>ARIMOCLOMOL CITRATE - MIPLYFFA</u>						
N 214927 004	11045460	Aug 19, 2029	U-4021		NCE	Sep 20, 2029
	9289472	Aug 11, 2029	U-4021		ODE-496	Sep 20, 2031
	9884058	Jun 26, 2029	U-4021			
<u>ARIPIRAZOLE - OPIPZA</u>						
N 216655 001	>A> 11331315	Nov 03, 2040	DP			
	>A> 11701352	Dec 15, 2041	DP			
<u>ARIPIRAZOLE - OPIPZA</u>						
N 216655 002	>A> 11331315	Nov 03, 2040	DP			
	>A> 11701352	Dec 15, 2041	DP			
<u>ARIPIRAZOLE - OPIPZA</u>						
N 216655 003	>A> 11331315	Nov 03, 2040	DP			
	>A> 11701352	Dec 15, 2041	DP			
<u>ARIPIRAZOLE - ABILIFY ASIMTUFII</u>						
N 217006 001	12016927	Apr 23, 2033	DP U-3245			
	12016927	Apr 23, 2033	DP U-543			
<u>ARIPIRAZOLE - ABILIFY ASIMTUFII</u>						
N 217006 002	12016927	Apr 23, 2033	DP U-3245			
	12016927	Apr 23, 2033	DP U-543			
<u>ARTESUNATE - ARTESUNATE</u>						
N 213036 001	12121506	Feb 16, 2044	DP			
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 001					>A> I-953	Oct 29, 2027
					>A> I-954	Oct 29, 2027
					>A> ODE-499	Oct 29, 2031
					>A> ODE-500	Oct 29, 2031

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 001					>A> I-953 >A> I-954 >A> ODE-499 >A> ODE-500	Oct 29, 2027 Oct 29, 2027 Oct 29, 2031 Oct 29, 2031
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 002					>A> I-953 >A> I-954 >A> ODE-499 >A> ODE-500	Oct 29, 2027 Oct 29, 2027 Oct 29, 2031 Oct 29, 2031
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 003	11407735 8829195	May 14, 2040 May 13, 2033	DS DS U-1374		NCE ODE*	Oct 29, 2026 Oct 29, 2028
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - PLENVU</u>						
N 209381 001	12083179	Sep 10, 2033	DP U-2310			
<u>ATOGEPAANT - QULIPTA</u>						
N 215206 003	12090148	Jul 29, 2041	U-3534			
<u>ATORVASTATIN CALCIUM - ATORVALIO</u>						
N 213260 001	11925704	Jun 07, 2037	DP U-3853			
<u>ATROPINE SULFATE - ATROPINE SULFATE</u>						
A 217791 001					CGT	Dec 04, 2024
<u>AVACINCAPTAD PEGOL SODIUM - IZERVAY</u>						
N 217225 001	12016875	Jul 11, 2034	U-3673			
<u>AVACOPAN - TAVNEOS</u>						
N 214487 001	11951214	Nov 27, 2039	DP			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 001	11964980 11999744 12060354	Apr 10, 2040 Apr 10, 2040 Mar 08, 2042	DS DP U-3168 U-2726			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 002	11964980 11999744 12060354	Apr 10, 2040 Apr 10, 2040 Mar 08, 2042	DS DP U-3168 U-2726			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 003	11964980 12060354	Apr 10, 2040 Mar 08, 2042	DS DP U-2726			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 004	11964980 11999744 11999744	Apr 10, 2040 Apr 10, 2040 Apr 10, 2040	DS DP U-3168 U-3506			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 005	11964980 11999744	Apr 10, 2040 Apr 10, 2040	DS DP U-3168			
<u>AVATROMBOPAG MALEATE - DOPTELET</u>						
N 210238 001	7638536	Jul 28, 2027	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592	Jan 07, 2026	DS DP U-2244		NPP	Jan 26, 2027
	7112592	Jan 07, 2026	DS DP U-2508			
	7112592	Jan 07, 2026	DS DP U-282			
	7112592	Jan 07, 2026	DS DP U-3818			
<u>AXITINIB - INLYTA</u>						
N 202324 001	10570202	Feb 03, 2035	U-2844			
	10570202*PED	Aug 03, 2035				
	10869924	Jan 12, 2037	U-3044			
	10869924*PED	Jul 12, 2037				
	6534524	Apr 29, 2025	DS DP			
	6534524*PED	Oct 29, 2025				
	8791140	Dec 14, 2030	DS			
	8791140*PED	Jun 14, 2031				
<u>AXITINIB - INLYTA</u>						
N 202324 002	10570202	Feb 03, 2035	U-2844			
	10570202*PED	Aug 03, 2035				
	10869924	Jan 12, 2037	U-3044			
	10869924*PED	Jul 12, 2037				
	6534524	Apr 29, 2025	DS DP			
	6534524*PED	Oct 29, 2025				
	8791140	Dec 14, 2030	DS			
	8791140*PED	Jun 14, 2031				
<u>AZACITIDINE - ONUREG</u>						
N 214120 001	12053482	May 14, 2029	U-2950			
<u>AZACITIDINE - ONUREG</u>						
N 214120 002	12053482	May 14, 2029	U-2950			
<u>BACLOFEN - LYVISPAH</u>						
N 215422 001	11850225	Sep 29, 2041	DP U-3488			
	11850225	Sep 29, 2041	DP U-3489			
	11931328	Jul 29, 2039	DP			
<u>BACLOFEN - LYVISPAH</u>						
N 215422 002	11850225	Sep 29, 2041	DP U-3488			
	11850225	Sep 29, 2041	DP U-3489			
	11931328	Jul 29, 2039	DP			
<u>BACLOFEN - LYVISPAH</u>						
N 215422 003	11850225	Sep 29, 2041	DP U-3488			
	11850225	Sep 29, 2041	DP U-3489			
	11931328	Jul 29, 2039	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 001	12064438	Oct 09, 2039	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 002	12064438	Oct 09, 2039	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 003	12064438	Oct 09, 2039	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 001	11925648	Apr 21, 2041	DP			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 001	8158616	May 31, 2032	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BARICITINIB - OLUMIANT</u>						
N 207924 002	8158616	May 31, 2032	DS DP			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 003	8158616	May 31, 2032	DS DP			
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER</u>						
N 207921 001	11865247	Jan 26, 2038	DP			
	11896759	Jan 26, 2038	DP			
	11957832	May 05, 2041	DP			
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER</u>						
N 207921 002	11865247	Jan 26, 2038	DP			
	11896759	Jan 26, 2038	DP			
	11957832	May 05, 2041	DP			
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001					M-306	Jun 21, 2027
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 002					M-306	Jun 21, 2027
<u>BELUMOSUDIL MESYLATE - REZUROCK</u>						
N 214783 001	12097202	Jul 14, 2042	U-4014			
<u>BELZUTIFAN - WELIREG</u>						
N 215383 001	RE49948	Sep 05, 2034	DS DP U-3201		I-931	Dec 14, 2026
	RE49948	Sep 05, 2034	DS DP U-3780			
<u>BEMPEDOIC ACID - NEXLETOL</u>						
N 211616 001	11744816	Mar 14, 2036	U-3883		I-943	Mar 22, 2027
	11926584	Jun 19, 2040	U-3873		I-944	Mar 22, 2027
	7335799	Dec 03, 2030	DS			
<u>BEMPEDOIC ACID; EZETIMIBE - NEXLIZET</u>						
N 211617 001	10912751	Mar 14, 2036	U-3224		I-943	Mar 22, 2027
	10912751	Mar 14, 2036	U-3884		I-945	Mar 22, 2027
	11744816	Mar 14, 2036	U-3692			
	11744816	Mar 14, 2036	U-3883			
	11926584	Jun 19, 2040	U-3873			
	7335799	Dec 03, 2030	DS			
<u>BENDAMUSTINE HYDROCHLORIDE - BELRAPZO</u>						
N 205580 001	11872214	Jan 28, 2031	DP			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	11872214	Jan 28, 2031	DP			
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 001	11795176	Jan 13, 2042	DS U-713			
	9763953	Dec 01, 2026	U-713			
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 002	11795176	Jan 13, 2042	DS U-713			
	9763953	Dec 01, 2026	U-713			
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 003	11795176	Jan 13, 2042	DS U-713			
	9763953	Dec 01, 2026	U-713			
<u>BENZOYL PEROXIDE - EPSOLAY</u>						
N 214510 001	11865100	Feb 19, 2040	U-3357			
	11877997	Feb 19, 2040	U-3356			
	11986456	Feb 19, 2040	U-3947			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BENZOYL PEROXIDE - EPSOLAY</u>						
N 214510 001	11865100	Feb 19, 2040	U-3357			
	11877997	Feb 19, 2040	U-3356			
	11986456	Feb 19, 2040	U-3947			
<u>BENZOYL PEROXIDE; TRETINOIN - TWYNEO</u>						
N 214902 001	12053546	Jun 29, 2032	DP			
	12070629	Dec 30, 2030	DP U-3987			
	>A> 12133919	May 23, 2041	DP U-3987			
<u>BERDAZIMER SODIUM - ZELSUVMI</u>						
N 217424 001	10258564	Nov 22, 2034	U-3797		NCE	Jan 05, 2029
	10258564	Nov 22, 2034	U-3798			
	10258564	Nov 22, 2034	U-3799			
	10265334	Jul 03, 2032	DP			
	10322081	Jul 10, 2035	U-3793			
	10322081	Jul 10, 2035	U-3794			
	10322081	Jul 10, 2035	U-3795			
	10322081	Jul 10, 2035	U-3796			
	10376538	Aug 20, 2030	DP			
	10736839	Jul 10, 2035	U-3790			
	10736839	Jul 10, 2035	U-3791			
	10736839	Jul 10, 2035	U-3792			
	11040006	Jul 10, 2035	DP U-3789			
	11285098	Feb 28, 2034	DP			
	11723858	Jul 10, 2035	DP U-3788			
	8282967	May 30, 2026	DS			
	8956658	May 30, 2026	DS			
	9289442	Jul 03, 2032	DP U-3803			
	9526738	Sep 03, 2031	DP			
	9737561	Aug 20, 2030	U-3802			
	9855211	Feb 27, 2034	DP U-3800			
	9855211	Feb 27, 2034	DP U-3801			
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 001 >A>	12116346	Mar 09, 2035	DS			
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 002 >A>	12116346	Mar 09, 2035	DS			
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001					I-942 M-305 ODE-468	Feb 23, 2027 Apr 24, 2027 Feb 23, 2031
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 002	7390791	Apr 17, 2025	DS DP		I-942 ODE-468	Feb 23, 2027 Feb 23, 2031
	7390791*PED	Oct 17, 2025				
	8754065	Aug 15, 2032	DS DP U-257			
	8754065*PED	Feb 15, 2033				
	9296769	Aug 15, 2032	DS DP U-257			
	9296769*PED	Feb 15, 2033				
<u>BINIMETINIB - MEKTOVI</u>						
N 210498 001	7777050	Mar 13, 2025	DS DP			
<u>BIRCH TRITERPENES - FILSUEVZ</u>						
N 215064 001	11083733	Jan 04, 2039	DP		NCE	Dec 18, 2028
	11266660	Jan 04, 2039	U-3811		ODE-460	Dec 18, 2030
	8828444	Jun 21, 2025	DP			
	9352041	Nov 24, 2030	U-3811			
	9827214	Nov 24, 2030	U-3811			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BIVALIRUDIN - ANGIOMAX RTU</u>						
N 211215 001	11903993	May 20, 2039	U-3817			
	11918622	May 20, 2039	U-3817			
	11992514	May 20, 2039	DP			
<u>BORTEZOMIB - BORTEZOMIB</u>						
N 215331 001	12005069	Sep 23, 2042	DP			
<u>BORTEZOMIB - BORTEZOMIB</u>						
N 215331 002	12005069	Sep 23, 2042	DP			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	10307419*PED	Apr 12, 2033			M-14	May 08, 2027
	7888362	Apr 12, 2026	DS	Y	PED	Nov 10, 2026
	7888362*PED	Oct 12, 2026			PED	Nov 08, 2027
	8349840	Apr 12, 2026	DP U-1529			
	8349840*PED	Oct 12, 2026				
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	10307419*PED	Apr 12, 2033			M-14	May 08, 2027
	7888362	Apr 12, 2026	DS	Y	PED	Nov 10, 2026
	7888362*PED	Oct 12, 2026			PED	Nov 08, 2027
	8349840	Apr 12, 2026	DP U-1529			
	8349840*PED	Oct 12, 2026				
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	10307419*PED	Apr 12, 2033			M-14	May 08, 2027
	7888362	Apr 12, 2026	DS	Y	PED	Nov 10, 2026
	7888362*PED	Oct 12, 2026			PED	Nov 08, 2027
	8349840	Apr 12, 2026	DP U-1529			
	8349840*PED	Oct 12, 2026				
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	10307419*PED	Apr 12, 2033			M-14	May 08, 2027
	7888362	Apr 12, 2026	DS	Y	PED	Nov 10, 2026
	7888362*PED	Oct 12, 2026			PED	Nov 08, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004	8349840	Apr 12, 2026	DP U-1529			
	8349840*PED	Oct 12, 2026				
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005	10307419	Oct 12, 2032	DP		I-913	May 10, 2026
	10307419*PED	Apr 12, 2033			M-14	May 08, 2027
	7888362	Apr 12, 2026	DS	Y	PED	Nov 10, 2026
	7888362*PED	Oct 12, 2026			PED	Nov 08, 2027
	8349840	Apr 12, 2026	DP U-1529			
	8349840*PED	Oct 12, 2026				
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006	7888362	Apr 12, 2026	DS	Y	I-913	May 10, 2026
	7888362*PED	Oct 12, 2026			M-14	May 08, 2027
	8349840	Apr 12, 2026	DP U-1529		PED	Nov 10, 2026
	8349840*PED	Oct 12, 2026			PED	Nov 08, 2027
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	8618109*PED	Oct 12, 2026				
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	9839637*PED	Oct 12, 2026				
	RE48059	Dec 23, 2028	DS			
	RE48059*PED	Jun 23, 2029				
<u>BRIMONIDINE TARTRATE - LUMIFY PRESERVATIVE FREE</u>						
N 218424 001	11596600	Jul 27, 2029	U-2222			
	8293742	Jul 14, 2030	U-2222			
	9259425	Jul 14, 2030	U-2222			
<u>BROMFENAC SODIUM - BROMFENAC SODIUM</u>						
A 206027 001					PC	Jul 06, 2024
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	11666567	Apr 30, 2032	U-4015			
	11666567	Apr 30, 2032	U-4016			
	11666567	Apr 30, 2032	U-4017			
	11666567	Apr 30, 2032	U-4018			
<u>BUDESONIDE - EOHILIA</u>						
N 213976 001	10293052	Nov 22, 2028	DP		NP	Feb 09, 2027
	11197822	Nov 09, 2026	DP		ODE-466	Feb 09, 2031
	11260064	Jan 10, 2039	DP			
	11357859	Nov 12, 2028	U-3820			
	11413296	Nov 09, 2026	DP			
	11564934	Jan 10, 2039	U-3820			
	8324192	Aug 03, 2029	U-3820			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE - EOHILIA</u>						
N 213976 001	8497258	Nov 09, 2026	U-3820			
	8679545	Nov 09, 2026	DP			
	8975243	Nov 09, 2026	U-3820			
	9050368	Aug 01, 2029	DP			
	9119863	Nov 09, 2026	U-3820			
<u>BUDESONIDE - TARPEYO</u>						
N 215935 001	11896719	Jan 23, 2043	U-3810		ODE-464	Dec 20, 2030
	8491932	May 07, 2029	DP U-3269			
	8491932	May 07, 2029	DP U-3781			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001	11918565	Feb 02, 2043	U-3841		I-929	Nov 09, 2026
	11925706	Jan 22, 2041	DP U-3380			
	11931459	Mar 17, 2042	U-3839			
	11931459	Mar 17, 2042	U-3840			
	>A> 12144890	Jan 22, 2041	DP U-4033			
	>A> 12151024	Jan 22, 2041	DP U-4037			
	>A> 12156940	Jul 02, 2044	DP			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	11918565	Feb 02, 2043	U-3841		I-929	Nov 09, 2026
	11925706	Jan 22, 2041	DP U-3380			
	11931459	Mar 17, 2042	U-3839			
	11931459	Mar 17, 2042	U-3840			
	>A> 12144890	Jan 22, 2041	DP U-4033			
	>A> 12151024	Jan 22, 2041	DP U-4037			
	>A> 12156940	Jul 02, 2044	DP			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 001					I-933	Jan 23, 2027
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 002					I-933	Jan 23, 2027
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 003					I-933	Jan 23, 2027
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 004					I-933	Jan 23, 2027
<u>BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY</u>						
N 215430 001	11883373	Jan 23, 2043	U-3419			
	11896563	Dec 01, 2041	U-3419			
	11925636	Jan 20, 2043	U-3419			
	11969421	Nov 05, 2034	U-3419			
	11986444	Feb 15, 2043	U-3419			
	12036191	Feb 15, 2043	U-3419			
	12042473	Feb 23, 2043	U-3419			
	12109178	Nov 05, 2034	U-3419			
	>A> 12146889	Feb 23, 2043	U-3419			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	11998542	Jul 02, 2034	U-1583			
	12048769	Nov 08, 2027	U-1585			
<u>CABOTEGRAVIR - APRETUDE</u>						
N 215499 001	>A> 12138264	Sep 15, 2031	DP			
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 001	>A> 12138264	Sep 15, 2031	DP U-3348			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 002	>A> 12138264	Sep 15, 2031	DP U-3348			
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756 001	>A> 12128039	Feb 10, 2032	DP U-1617			
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756 002	>A> 12128039	Feb 10, 2032	DP U-1617			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	>A> 12128039	Feb 10, 2032	DP U-1220			
	>A> 12128039	Feb 10, 2032	DP U-1480			
	>A> 12128039	Feb 10, 2032	DP U-2488			
	>A> 12128039	Feb 10, 2032	DP U-3225			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002	>A> 12128039	Feb 10, 2032	DP U-1220			
	>A> 12128039	Feb 10, 2032	DP U-1480			
	>A> 12128039	Feb 10, 2032	DP U-2488			
	>A> 12128039	Feb 10, 2032	DP U-3225			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003	>A> 12128039	Feb 10, 2032	DP U-1220			
	>A> 12128039	Feb 10, 2032	DP U-1480			
	>A> 12128039	Feb 10, 2032	DP U-2488			
	>A> 12128039	Feb 10, 2032	DP U-3225			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	11154509	Apr 25, 2028	U-3815			
	9498486	Apr 25, 2028	U-3814			
<u>CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV</u>						
N 212690 001	11986446	Mar 15, 2033	U-3017		ODE-361	Jul 21, 2027
	11986446	Mar 15, 2033	U-3324		PED	Jan 21, 2028
	>A> 12139233	Feb 22, 2041	U-4044			
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	11865102	Apr 26, 2039	DS DP U-2781			
	11865102	Apr 26, 2039	DS DP U-3236			
	11865102	Apr 26, 2039	DS DP U-3277			
	11963937	Jun 17, 2035	U-2780			
	11963937	Jun 17, 2035	U-2781			
	12064399	Jun 17, 2035	U-3988			
	12064399	Jun 17, 2035	U-3989			
	12102619	Mar 01, 2041	U-3233			
<u>CANTHARIDIN - YCANTH</u>						
N 212905 001					NCE	Jul 21, 2028
<u>CAPMATINIB HYDROCHLORIDE - TABRECTA</u>						
N 213591 001	12084449	Nov 19, 2027	U-2813			
	7767675	Nov 19, 2032	DS DP			
<u>CAPMATINIB HYDROCHLORIDE - TABRECTA</u>						
N 213591 002	12084449	Nov 19, 2027	U-2813			
	7767675	Nov 19, 2032	DS DP			
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 001	10098845	Oct 07, 2034	DP U-219		NP	Aug 07, 2027
	10292935	Oct 07, 2034	DP U-219			
	10688058	Oct 07, 2034	DP U-219			
	10973769	Oct 07, 2034	DP U-219			
	10987313	Oct 07, 2034	DP U-219			
	11357733	Oct 07, 2034	DP			
	11622941	Oct 07, 2034	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 001	11666538	Oct 07, 2034	DP U-219			
	11986449	Dec 21, 2041	U-219			
	12064521	Oct 07, 2034	DP			
	12109185	Dec 21, 2041	U-1649			
	12109185	Dec 21, 2041	U-219			
	12109185	Dec 21, 2041	U-4004			
	12109185	Dec 21, 2041	U-4005			
>A>	12128141	Oct 07, 2034	DP U-219			
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 002	10098845	Oct 07, 2034	DP U-219		NP	Aug 07, 2027
	10292935	Oct 07, 2034	DP U-219			
	10688058	Oct 07, 2034	DP U-219			
	10973769	Oct 07, 2034	DP U-219			
	10987313	Oct 07, 2034	DP U-219			
	11357733	Oct 07, 2034	DP			
	11622941	Oct 07, 2034	DP			
	11666538	Oct 07, 2034	DP U-219			
	11986449	Dec 21, 2041	U-219			
	12064521	Oct 07, 2034	DP			
	12109185	Dec 21, 2041	U-1649			
	12109185	Dec 21, 2041	U-219			
	12109185	Dec 21, 2041	U-4004			
	12109185	Dec 21, 2041	U-4005			
>A>	12128141	Oct 07, 2034	DP U-219			
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 003	10098845	Oct 07, 2034	DP U-219		NP	Aug 07, 2027
	10292935	Oct 07, 2034	DP U-219			
	10688058	Oct 07, 2034	DP U-219			
	10973769	Oct 07, 2034	DP U-219			
	10987313	Oct 07, 2034	DP U-219			
	11357733	Oct 07, 2034	DP			
	11622941	Oct 07, 2034	DP			
	11666538	Oct 07, 2034	DP U-219			
	11986449	Dec 21, 2041	U-219			
	12064521	Oct 07, 2034	DP			
	12109185	Dec 21, 2041	U-1649			
	12109185	Dec 21, 2041	U-219			
	12109185	Dec 21, 2041	U-4004			
	12109185	Dec 21, 2041	U-4005			
>A>	12128141	Oct 07, 2034	DP U-219			
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 004	10098845	Oct 07, 2034	DP U-219		NP	Aug 07, 2027
	10292935	Oct 07, 2034	DP U-219			
	10688058	Oct 07, 2034	DP U-219			
	10973769	Oct 07, 2034	DP U-219			
	10987313	Oct 07, 2034	DP U-219			
	11357733	Oct 07, 2034	DP			
	11622941	Oct 07, 2034	DP			
	11666538	Oct 07, 2034	DP U-219			
	11986449	Dec 21, 2041	U-219			
	12064521	Oct 07, 2034	DP			
	12109185	Dec 21, 2041	U-1649			
	12109185	Dec 21, 2041	U-219			
	12109185	Dec 21, 2041	U-4004			
	12109185	Dec 21, 2041	U-4005			
>A>	12128141	Oct 07, 2034	DP U-219			
<u>CEDAZURIDINE; DECITABINE - INQOVI</u>						
N 212576 001	11963971	Feb 24, 2041	DP			
<u>CEFEPIME HYDROCHLORIDE; ENMETAZOACTAM - EXBLIFEP</u>						
N 216165 001	11124526	Nov 07, 2034	U-3852		NCE	Feb 22, 2029
	7687488	Dec 03, 2027	DS DP U-3851		GAIN	Feb 22, 2034

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CEFPIME HYDROCHLORIDE; ENMETAZOBACTAM - EXBLIFEP</u>						
N 216165 001	11124526	Nov 07, 2034	U-3852		NCE	Feb 22, 2029
	7687488	Dec 03, 2027	DS DP U-3851		GAIN	Feb 22, 2034
<u>CEFTOBIPROLE MEDOCARIL SODIUM - ZEVTERA</u>						
N 218275 001					NCE GAIN	Apr 03, 2029 Apr 03, 2034
<u>CEPHALEXIN - CEPHALEXIN</u>						
A 218817 001					>A> CGT	Apr 09, 2025
<u>CEPHALEXIN - CEPHALEXIN</u>						
A 218817 002					>A> CGT	Apr 09, 2025
<u>CILASTATIN SODIUM; IMIPENEM; RELEBACTAM - RECARBRIO</u>						
N 212819 001	8487093	Mar 21, 2033	DS DP U-2586			
	8487093	Mar 21, 2033	DS DP U-2587			
	8487093	Mar 21, 2033	DS DP U-2840			
<u>CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI</u>						
N 208352 001	11992472	Mar 15, 2033	U-1			
<u>CLASCOTERONE - WINLEVI</u>						
N 213433 001	11938141	Jul 24, 2028	DP			
	>A> 8143240	Jan 12, 2026	U-2942			
	8865690	Jul 24, 2025	U-2942			
	9211295	May 31, 2025	DP			
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
N 218158 001	10588913	May 09, 2036	DP		NP	Mar 04, 2027
	11376262	May 09, 2036	DP U-19			
<u>CLOMIPHENE CITRATE - CLOMIPHENE CITRATE</u>						
A 216739 001					>A> CGT	May 18, 2025
<u>CLONIDINE HYDROCHLORIDE - ONYDA XR</u>						
N 217645 001	11918689	Jul 28, 2041	DP U-3944			
	8062667	Mar 29, 2029	DP			
<u>COLCHICINE - LODOCO</u>						
N 215727 001	10130585	May 09, 2034	U-3642			
	10206891	Nov 01, 2033	U-3641			
	10265281	Nov 01, 2033	U-3639			
	10842762	Nov 01, 2033	U-3640			
	11026899	Nov 01, 2033	U-3639			
	11026900	Nov 01, 2033	U-3639			
	11026901	Nov 01, 2033	U-3638			
	11944594	Nov 01, 2033	U-3864			
	11944595	Nov 01, 2033	U-3867			
	11944595	Nov 01, 2033	U-3868			
	9744144	Nov 01, 2033	U-3643			
<u>COPPER - PARAGARD T 380A</u>						
N 018680 001					D-193	Jun 28, 2027
<u>COPPER CU-64 DOTATATE - DETECTNET</u>						
N 213227 001	12102696	Sep 03, 2041	DP			
<u>CORTICOTROPIN - ACTHAR GEL (AUTOINJECTOR)</u>						
N 008372 003	11752199	Feb 25, 2041	U-3686			
	11752199	Feb 25, 2041	U-3687			
	11752199	Feb 25, 2041	U-3688			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CORTICOTROPIN - ACTHAR GEL (AUTOINJECTOR)</u>						
N 008372 004	11752199	Feb 25, 2041	U-3686			
	11752199	Feb 25, 2041	U-3687			
	11752199	Feb 25, 2041	U-3688			
<u>CORTICOTROPIN - PURIFIED CORTROPHIN GEL</u>						
N 008975 001	12102662	Oct 27, 2043	U-3904			
	12102662	Oct 27, 2043	U-3905			
	12102662	Oct 27, 2043	U-3906			
	12102662	Oct 27, 2043	U-3907			
	12102662	Oct 27, 2043	U-3908			
	12102662	Oct 27, 2043	U-3909			
	12102662	Oct 27, 2043	U-3910			
	12102662	Oct 27, 2043	U-3911			
	12102662	Oct 27, 2043	U-3912			
	12102662	Oct 27, 2043	U-3913			
	12102662	Oct 27, 2043	U-3914			
	12102662	Oct 27, 2043	U-3915			
	12102662	Oct 27, 2043	U-3916			
	12102662	Oct 27, 2043	U-3917			
	12102662	Oct 27, 2043	U-3918			
	12102662	Oct 27, 2043	U-3919			
	12102662	Oct 27, 2043	U-3920			
	12102662	Oct 27, 2043	U-3921			
	12102662	Oct 27, 2043	U-3922			
	12102662	Oct 27, 2043	U-3923			
	12102662	Oct 27, 2043	U-3924			
	12102662	Oct 27, 2043	U-3925			
	12102662	Oct 27, 2043	U-3926			
<u>CORTICOTROPIN - PURIFIED CORTROPHIN GEL</u>						
N 008975 002	11975047	Oct 27, 2043	U-3904			
	11975047	Oct 27, 2043	U-3905			
	11975047	Oct 27, 2043	U-3906			
	11975047	Oct 27, 2043	U-3907			
	11975047	Oct 27, 2043	U-3908			
	11975047	Oct 27, 2043	U-3909			
	11975047	Oct 27, 2043	U-3910			
	11975047	Oct 27, 2043	U-3911			
	11975047	Oct 27, 2043	U-3912			
	11975047	Oct 27, 2043	U-3913			
	11975047	Oct 27, 2043	U-3914			
	11975047	Oct 27, 2043	U-3915			
	11975047	Oct 27, 2043	U-3916			
	11975047	Oct 27, 2043	U-3917			
	11975047	Oct 27, 2043	U-3918			
	11975047	Oct 27, 2043	U-3919			
	11975047	Oct 27, 2043	U-3920			
	11975047	Oct 27, 2043	U-3921			
	11975047	Oct 27, 2043	U-3922			
	11975047	Oct 27, 2043	U-3923			
	11975047	Oct 27, 2043	U-3924			
	11975047	Oct 27, 2043	U-3925			
	11975047	Oct 27, 2043	U-3926			
	12102662	Oct 27, 2043	U-3904			
	12102662	Oct 27, 2043	U-3905			
	12102662	Oct 27, 2043	U-3906			
	12102662	Oct 27, 2043	U-3907			
	12102662	Oct 27, 2043	U-3908			
	12102662	Oct 27, 2043	U-3909			
	12102662	Oct 27, 2043	U-3910			
	12102662	Oct 27, 2043	U-3911			
	12102662	Oct 27, 2043	U-3912			
	12102662	Oct 27, 2043	U-3913			
	12102662	Oct 27, 2043	U-3914			
	12102662	Oct 27, 2043	U-3915			
	12102662	Oct 27, 2043	U-3916			
	12102662	Oct 27, 2043	U-3917			
	12102662	Oct 27, 2043	U-3918			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CORTICOTROPIN - PURIFIED CORTROPHIN GEL</u>						
N 008975 002	12102662	Oct 27, 2043	U-3919			
	12102662	Oct 27, 2043	U-3920			
	12102662	Oct 27, 2043	U-3921			
	12102662	Oct 27, 2043	U-3922			
	12102662	Oct 27, 2043	U-3923			
	12102662	Oct 27, 2043	U-3924			
	12102662	Oct 27, 2043	U-3925			
	12102662	Oct 27, 2043	U-3926			
<u>CUPRIC CHLORIDE - CUPRIC CHLORIDE</u>						
A 216113 001					CGT	Dec 21, 2024
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - TRALEMENT</u>						
N 209376 001	11975022	Jul 01, 2041	U-3899			
	11998565	Jul 01, 2041	DP			
	>A> 12150956	Jul 01, 2041	U-3899			
	>A> 12150957	Jul 01, 2041	U-3899			
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - TRALEMENT</u>						
N 209376 002	11975022	Jul 01, 2041	U-3899			
	11998565	Jul 01, 2041	DP			
	>A> 12150956	Jul 01, 2041	U-3899			
	>A> 12150957	Jul 01, 2041	U-3899			
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - MULTRYS</u>						
N 209376 003	11975022	Jul 01, 2041	U-3900			
	11998565	Jul 01, 2041	DP			
	>A> 12150956	Jul 01, 2041	U-3900			
	>A> 12150957	Jul 01, 2041	U-3900			
<u>CYCLOSPORINE - RESTASIS MULTIDOSE</u>						
N 050790 002	8629111	Aug 27, 2024	DP		Y	
	8633162	Aug 27, 2024	U-1479		Y	
	8642556	Aug 27, 2024	DP		Y	
	8648048	Aug 27, 2024	U-1483		Y	
	8685930	Aug 27, 2024	DP		Y	
	9248191	Aug 27, 2024	U-1479		Y	
<u>CYCLOSPORINE - CEQUA</u>						
N 210913 001	11951153	Feb 28, 2037	U-1483			
<u>CYCLOSPORINE - VEVYE</u>						
N 217469 001	12059449	Apr 01, 2042	DP U-1483			
<u>CYSTEINE HYDROCHLORIDE - ELCYS</u>						
N 210660 001	11969439	Jan 15, 2039	U-2752			
<u>CYSTEINE HYDROCHLORIDE - NOURESS</u>						
N 212535 001	11642370	Jan 15, 2039	DP			
	11648262	Jan 15, 2039	DP			
	11679125	Jan 15, 2039	DP			
	11684636	Jan 15, 2039	DP			
	11826383	Jan 15, 2039	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001					I-908 ODE-428 PED PED	Mar 16, 2026 Mar 16, 2030 Sep 16, 2026 Sep 16, 2030
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002					I-908 ODE-428 PED	Mar 16, 2026 Mar 16, 2030 Sep 16, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002					PED	Sep 16, 2030
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 217514 001	11504333	Jun 29, 2038	DP		NP	Mar 16, 2026
	11504333*PED	Dec 29, 2038			ODE-428	Mar 16, 2030
	7994185	Jan 20, 2030	DS DP		PED	Sep 16, 2026
	7994185*PED	Jul 20, 2030			PED	Sep 16, 2030
	8415345	Jan 20, 2030	DS DP			
	8415345*PED	Jul 20, 2030				
	8703781	Oct 15, 2030	DS DP U-3565			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025	U-3565			
	8835443*PED	Dec 10, 2025				
<u>DANICOPAN - VOYDEYA</u>						
N 218037 001	12076319	Aug 02, 2038		U-3933	NCE	Mar 29, 2029
	9796741	Feb 25, 2035	DS	U-3933	ODE-476	Mar 29, 2031
<u>DANICOPAN - VOYDEYA</u>						
N 218037 002	12076319	Aug 02, 2038		U-3933	NCE	Mar 29, 2029
	9796741	Feb 25, 2035	DS	U-3933	ODE-476	Mar 29, 2031
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001	6515117	Oct 04, 2025	DS DP U-2139		M-298	May 08, 2026
	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Nov 08, 2026
	7456254	Jun 30, 2025	U-2139		PED	Dec 12, 2027
	7456254*PED	Dec 30, 2025				
	7851502	Aug 19, 2028	DP			
	7851502*PED	Feb 19, 2029				
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8221786	Mar 21, 2028	DP			
	8221786*PED	Sep 21, 2028				
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2139			
	8361972	Mar 21, 2028	U-493			
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025	U-2139			
	8431685*PED	Oct 13, 2025				
	8461105	Apr 13, 2025	U-2139			
	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	8716251	Mar 21, 2028	DP			
	8716251*PED	Sep 21, 2028				
	8721615	Jan 18, 2030	DP	Y		
	8721615*PED	Jul 18, 2030				
	8906851	Aug 18, 2026	U-2139			
	8906851*PED	Feb 18, 2027				
	9238076	Apr 15, 2024	U-2139			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	10973836	Mar 09, 2040	U-3127		M-298	May 08, 2026
	10973836*PED	Sep 09, 2040			NPP	Jun 12, 2027
	11826376	Jul 18, 2039	U-3766		PED	Nov 08, 2026
	11826376*PED	Jan 18, 2040			PED	Dec 12, 2027
	11903955	Mar 09, 2040	U-3825			
	11903955*PED	Sep 09, 2040				
	6515117	Oct 04, 2025	DS DP U-2139			
	6515117	Oct 04, 2025	DS DP U-493			
	6515117*PED	Apr 04, 2026				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	7456254	Jun 30, 2025	U-2139			
	7456254*PED	Dec 30, 2025				
	7851502	Aug 19, 2028	DP			
	7851502*PED	Feb 19, 2029				
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8221786	Mar 21, 2028	DP			
	8221786*PED	Sep 21, 2028				
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2139			
	8361972	Mar 21, 2028	U-493			
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025	U-2139			
	8431685*PED	Oct 13, 2025				
	8461105	Apr 13, 2025	U-2139			
	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	8716251	Mar 21, 2028	DP			
	8716251*PED	Sep 21, 2028				
	8721615	Jan 18, 2030	DP	Y		
	8721615*PED	Jul 18, 2030				
	8906851	Aug 18, 2026	U-2139			
	8906851*PED	Feb 18, 2027				
	9238076	Apr 15, 2024	U-2139			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 001	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 002	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 003	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 004	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 005	6515117	Oct 04, 2025	DS DP U-493		NPP	Jun 12, 2027
	6515117*PED	Apr 04, 2026			PED	Dec 12, 2027
	7919598	Dec 16, 2029	DS			
	7919598*PED	Jun 16, 2030				
	8501698	Jun 20, 2027	DP U-493			
	8501698*PED	Dec 20, 2027				
	8685934	May 26, 2030	U-1522			
	8685934*PED	Nov 26, 2030				
	9616028	Nov 12, 2030	DP			
	9616028*PED	May 12, 2031				
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874 001	>A> 6515117	Oct 04, 2025	DS DP U-493			
	>A> 6515117*PED	Apr 04, 2026				
	>A> 7919598	Dec 16, 2029	DS			
	>A> 7919598*PED	Jun 16, 2030				
	>A> 8501698	Jun 20, 2027	DP U-493			
	>A> 8501698*PED	Dec 20, 2027				
	>A> 8716251	Mar 21, 2028	DP			
	>A> 8716251*PED	Sep 21, 2028				
	>A> 9616028	Nov 12, 2030	DP			
	>A> 9616028*PED	May 12, 2031				
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874 002	>A> 6515117	Oct 04, 2025	DS DP U-493			
	>A> 6515117*PED	Apr 04, 2026				
	>A> 7919598	Dec 16, 2029	DS			
	>A> 7919598*PED	Jun 16, 2030				
	>A> 8501698	Jun 20, 2027	DP U-493			
	>A> 8501698*PED	Dec 20, 2027				
	>A> 8716251	Mar 21, 2028	DP			
	>A> 8716251*PED	Sep 21, 2028				
	>A> 9616028	Nov 12, 2030	DP			
	>A> 9616028*PED	May 12, 2031				
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874 003	>A> 6515117	Oct 04, 2025	DS DP U-493			
	>A> 6515117*PED	Apr 04, 2026				
	>A> 7919598	Dec 16, 2029	DS			
	>A> 7919598*PED	Jun 16, 2030				
	>A> 8501698	Jun 20, 2027	DP U-493			
	>A> 8501698*PED	Dec 20, 2027				
	>A> 8716251	Mar 21, 2028	DP			
	>A> 8716251*PED	Sep 21, 2028				
	>A> 9616028	Nov 12, 2030	DP			
	>A> 9616028*PED	May 12, 2031				
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874 004	>A> 6515117	Oct 04, 2025	DS DP U-493			
	>A> 6515117*PED	Apr 04, 2026				
	>A> 7919598	Dec 16, 2029	DS			
	>A> 7919598*PED	Jun 16, 2030				
	>A> 8501698	Jun 20, 2027	DP U-493			
	>A> 8501698*PED	Dec 20, 2027				
	>A> 8716251	Mar 21, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874 004	>A> 8716251*PED	Sep 21, 2028				
	>A> 9616028	Nov 12, 2030	DP			
	>A> 9616028*PED	May 12, 2031				
<u>DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>						
N 209091 001	>A> 6515117	Oct 04, 2025	DS DP U-493			
	>A> 6515117*PED	Apr 04, 2026				
	>A> 7919598	Dec 16, 2029	DS			
	>A> 7919598*PED	Jun 16, 2030				
	>A> 8221786	Mar 21, 2028	DP			
	>A> 8221786*PED	Sep 21, 2028				
	>A> 8361972	Mar 21, 2028			U-1976	
	>A> 8361972	Mar 21, 2028			U-1977	
	>A> 8361972	Mar 21, 2028			U-493	
	>A> 8361972*PED	Sep 21, 2028				
	>A> 8501698	Jun 20, 2027	DP U-1976			
	>A> 8501698	Jun 20, 2027	DP U-1977			
	>A> 8501698	Jun 20, 2027	DP U-493			
	>A> 8501698*PED	Dec 20, 2027				
	>A> 8716251	Mar 21, 2028	DP			
	>A> 8716251*PED	Sep 21, 2028				
<u>DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>						
N 209091 002	>A> 6515117	Oct 04, 2025	DS DP U-493			
	>A> 6515117*PED	Apr 04, 2026				
	>A> 7919598	Dec 16, 2029	DS			
	>A> 7919598*PED	Jun 16, 2030				
	>A> 8221786	Mar 21, 2028	DP			
	>A> 8221786*PED	Sep 21, 2028				
	>A> 8361972	Mar 21, 2028			U-493	
	>A> 8361972*PED	Sep 21, 2028				
	>A> 8501698	Jun 20, 2027	DP U-493			
	>A> 8501698*PED	Dec 20, 2027				
	>A> 8716251	Mar 21, 2028	DP			
	>A> 8716251*PED	Sep 21, 2028				
<u>DAPTOMYCIN - DAPTOMYCIN</u>						
N 217415 001	12053502	Aug 28, 2038			U-3981	
<u>DAPTOMYCIN - DAPTOMYCIN</u>						
N 217415 002	12053502	Aug 28, 2038			U-3981	
<u>DARIDOREXANT HYDROCHLORIDE - OUVIVIO</u>						
N 214985 001					M-310	Sep 30, 2027
<u>DARIDOREXANT HYDROCHLORIDE - OUVIVIO</u>						
N 214985 002					M-310	Sep 30, 2027
<u>DASATINIB - DASATINIB</u>						
A 202103 001					PC	Mar 02, 2025
<u>DASATINIB - DASATINIB</u>						
A 202103 002					PC	Mar 02, 2025
<u>DASATINIB - DASATINIB</u>						
A 202103 003					PC	Mar 02, 2025
<u>DASATINIB - DASATINIB</u>						
A 202103 004					PC	Mar 02, 2025
<u>DASATINIB - DASATINIB</u>						
A 203180 001					PC	Mar 02, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DASATINIB - DASATINIB</u>						
A 203180 002					PC	Mar 02, 2025
<u>DASATINIB - PHYRAGO</u>						
N 216099 001					M-307	Dec 05, 2026
<u>DASATINIB - PHYRAGO</u>						
N 216099 002					M-307	Dec 05, 2026
<u>DASATINIB - PHYRAGO</u>						
N 216099 003					M-307	Dec 05, 2026
<u>DASATINIB - PHYRAGO</u>						
N 216099 004					M-307	Dec 05, 2026
<u>DASATINIB - PHYRAGO</u>						
N 216099 005					M-307	Dec 05, 2026
<u>DASATINIB - PHYRAGO</u>						
N 216099 006					M-307	Dec 05, 2026
<u>DELAFLOXACIN MEGLUMINE - BAXDELA</u>						
N 208611 001	12036219	Jun 02, 2034	U-3967			
	>A> 12138257	May 01, 2032	DP			
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 001	11963995	May 21, 2029	U-2327			
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 002	11963995	May 21, 2029	U-2327			
<u>DESMOPRESSIN ACETATE - NOCTIVA</u>						
N 201656 001	12090190	Jun 15, 2030	DP U-4003			
<u>DESMOPRESSIN ACETATE - NOCTIVA</u>						
N 201656 002	12090190	Jun 15, 2030	DP U-4003			
<u>DEURUXOLITINIB PHOSPHATE - LEQSELVI</u>						
N 217900 001	10561659	May 04, 2037	U-3976		NCE	Jul 25, 2029
	11919907	May 21, 2041	DP U-3976			
	12076323	May 04, 2037	U-3976			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 001	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 002	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 003	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 001	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 002	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 003	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 004	10959996	Mar 07, 2036	U-3055			
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	11813232	Mar 15, 2038	DP			
	11813232*PED	Sep 15, 2038				
	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 005	10959996	Mar 07, 2036	U-3055			
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	11813232	Mar 15, 2038	DP			
	11813232*PED	Sep 15, 2038				
	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 006	10959996	Mar 07, 2036	U-3055			
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	11813232	Mar 15, 2038	DP			
	11813232*PED	Sep 15, 2038				
	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 007	10959996	Mar 07, 2036	U-3055			
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				
	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	11813232	Mar 15, 2038	DP			
	11813232*PED	Sep 15, 2038				
	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 008	10959996	Mar 07, 2036	U-3055			
	10959996*PED	Sep 07, 2036				
	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
	11311488	Jun 10, 2041	DP U-1995			
	11311488	Jun 10, 2041	DP U-3055			
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	11446291*PED	Sep 07, 2036				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTETRABENAZINE - AUSTEDO XR</u>						
N 216354 008	11564917	Mar 07, 2036	U-1995			
	11564917*PED	Sep 07, 2036				
	11648244	Mar 07, 2036	U-1995			
	11648244*PED	Sep 07, 2036				
	11813232	Mar 15, 2038	DP			
	11813232*PED	Sep 15, 2038				
	12016858	Mar 07, 2036	U-1995			
	12016858	Mar 07, 2036	U-3055			
	12016858*PED	Sep 07, 2036				
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE</u>						
A 218112 001					CGT	Mar 30, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE</u>						
A 218112 002					CGT	Mar 30, 2025
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 001	11890272	Jul 17, 2040	U-3756			
	11890272	Jul 17, 2040	U-3935			
	11998528	Jan 12, 2043	U-3935			
	11998529	Jul 17, 2040	U-3935			
	12090140	Jan 12, 2043	U-3986			
	12109196	Jul 17, 2040	U-3935			
	>A> 12138247	Jan 12, 2043	U-4029			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 002	11890272	Jul 17, 2040	U-3756			
	11890272	Jul 17, 2040	U-3935			
	11998528	Jan 12, 2043	U-3935			
	11998529	Jul 17, 2040	U-3935			
	12090140	Jan 12, 2043	U-3986			
	12109196	Jul 17, 2040	U-3935			
	>A> 12138247	Jan 12, 2043	U-4029			
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 001	11273131	Jun 18, 2038	DP		NP	Apr 26, 2027
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 002	11273131	Jun 18, 2038	DP		NP	Apr 26, 2027
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 003	11273131	Jun 18, 2038	DP		NP	Apr 26, 2027
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 004	11273131	Jun 18, 2038	DP		NP	Apr 26, 2027
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 005	11273131	Jun 18, 2038	DP		NP	Apr 26, 2027
<u>DOCETAXEL - BEIZRAY</u>						
N 218711 001	>A> 11419842	May 16, 2036	DP U-4027			
	>A> 11419842	May 16, 2036	DP U-4028			
	>A> 11419842	May 16, 2036	DP U-881			
	>A> 11419842	May 16, 2036	DP U-937			
	>A> 11419842	May 16, 2036	DP U-946			
	>A> 12090134	May 16, 2036	DP U-4027			
	>A> 12090134	May 16, 2036	DP U-4028			
	>A> 12090134	May 16, 2036	DP U-881			
	>A> 12090134	May 16, 2036	DP U-937			
	>A> 12090134	May 16, 2036	DP U-946			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DOCETAXEL - BEIZRAY</u>						
N 218711 001	>A> 12090135	May 16, 2036	DP			
<u>DOLUTEGRAVIR SODIUM; LAMIVUDINE - DOVATO</u>						
N 211994 001					NPP	Apr 05, 2027
<u>DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE - JULUCA</u>						
N 210192 001	12011506	Sep 05, 2038	DP			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 001	8168209	Nov 22, 2025	DP		Y	
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641		Y	
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641		Y	
	8283379*PED	May 22, 2026				
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 002	8168209	Nov 22, 2025	DP		Y	
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641		Y	
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641		Y	
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP		Y	
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-1641		Y	
	8362085*PED	May 22, 2026				
	8598233	Nov 22, 2025	DP		Y	
	8598233*PED	May 22, 2026				
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 004	8168209	Nov 22, 2025	DP		Y	
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641		Y	
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641		Y	
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP		Y	
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-1641		Y	
	8362085*PED	May 22, 2026				
	8598233	Nov 22, 2025	DP		Y	
	8598233*PED	May 22, 2026				
<u>DORAVIRINE - PIFELTRO</u>						
N 210806 001	>A> 8486975	Aug 30, 2032	DS DP U-2394			
	>A> 8486975	Aug 30, 2032	DS DP U-2630			
	>A> 8486975	Aug 30, 2032	DS DP U-3308			
<u>DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE - DELSTRIGO</u>						
N 210807 001	>A> 8486975	Aug 30, 2032	DS DP U-2395			
	>A> 8486975	Aug 30, 2032	DS DP U-2629			
	>A> 8486975	Aug 30, 2032	DS DP U-3307			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 001	12083090	May 18, 2027	U-620			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 002	12083090	May 18, 2027	U-620			
<u>DROSPIRENONE - SLYND</u>						
N 211367 001	11951213	Jun 28, 2031	U-2553			
	12090231	Jun 28, 2031	U-2553			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DROSPIRENONE - DROSPIRENONE</u>						
N 216285 001	11951213	Jun 28, 2031	U-2553			
	12090231	Jun 28, 2031	U-2553			
<u>DROSPIRENONE; ESTETROL - NEXTSTELLIS</u>						
N 214154 001	11957694	Jun 17, 2036	DP			
	11964055	Jun 17, 2036	DP			
	>A> 7732430	Mar 02, 2026	DP U-3152			
<u>EDARAVONE - RADICAVA ORS</u>						
N 215446 001	11957660	Nov 01, 2039	DP		ODE-144	May 12, 2029
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 001					M-14	Oct 18, 2026
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 002					M-14	Oct 18, 2026
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 003					M-14	Oct 18, 2026
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	11872218	Jan 03, 2028	U-1969			
<u>EFLORNITHINE HYDROCHLORIDE - IWILFIN</u>						
N 215500 001					NP ODE-462	Dec 13, 2026 Dec 13, 2030
<u>ELACESTRANT HYDROCHLORIDE - ORSERDU</u>						
N 217639 001	8399520	Dec 25, 2025	DS DP U-3523			
<u>ELACESTRANT HYDROCHLORIDE - ORSERDU</u>						
N 217639 002	8399520	Dec 25, 2025	DS DP U-3523			
<u>ELAFIBRANOR - IOIRVO</u>						
N 218860 001	11185519	Mar 30, 2037	U-3955		NCE	Jun 10, 2029
	11331292	Mar 30, 2037	U-1854		ODE-486	Jun 10, 2031
	11850223	Mar 30, 2037	U-1854			
	11857523	Mar 30, 2037	U-3955			
	7632870	Sep 09, 2024	DP			
	7943661	Sep 09, 2024	DS DP			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 001	12102637	Aug 20, 2038	DP			
	7419983	Jul 06, 2029	DS DP U-2360			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450 002	12102637	Aug 20, 2038	DP			
	7419983	Jul 06, 2029	DS DP U-2360			
<u>ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)</u>						
N 213388 001	12083227	Aug 20, 2038	DP U-2842			
	7419983	Jul 06, 2029	DS DP			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	10081621	Mar 25, 2031	DP U-3032			
	10081621	Mar 25, 2031	DP U-3157			
	10239867	Apr 09, 2027	DS DP U-3033			
	10239867	Apr 09, 2027	DS DP U-3158			
	10758534	Oct 06, 2035	DS DP U-3028			
	10758534	Oct 06, 2035	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-3028			
	10793547	Dec 08, 2037	DS DP U-3144			
	8324242	Aug 05, 2027	U-3028			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	8324242	Aug 05, 2027	U-3144			
	8354427	Jul 06, 2026	U-3029			
	8354427	Jul 06, 2026	U-3145			
	8415387	Nov 12, 2027	U-3028			
	8415387	Nov 12, 2027	U-3144			
	8598181	May 01, 2027	U-3028			
	8598181	May 01, 2027	U-3144			
	8629162	Jun 24, 2025	U-3030			
	8629162	Jun 24, 2025	U-3146			
	9670163	Dec 28, 2026	DP U-3031			
	9670163	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-3031			
	9931334	Dec 28, 2026	DP U-3155			
	9974781	Apr 09, 2027	DP U-3028			
	9974781	Apr 09, 2027	DP U-3144			
<u>ELTROMBOPAG CHOLINE - ALVAIZ</u>						
N 216774 001	11072586	Nov 05, 2038	DS DP U-3936			
	11072586	Nov 05, 2038	DS DP U-3937			
	11072586	Nov 05, 2038	DS DP U-3938			
<u>ELTROMBOPAG CHOLINE - ALVAIZ</u>						
N 216774 002	11072586	Nov 05, 2038	DS DP U-3936			
	11072586	Nov 05, 2038	DS DP U-3937			
	11072586	Nov 05, 2038	DS DP U-3938			
<u>ELTROMBOPAG CHOLINE - ALVAIZ</u>						
N 216774 003	11072586	Nov 05, 2038	DS DP U-3936			
	11072586	Nov 05, 2038	DS DP U-3937			
	11072586	Nov 05, 2038	DS DP U-3938			
<u>ELTROMBOPAG CHOLINE - ALVAIZ</u>						
N 216774 004	11072586	Nov 05, 2038	DS DP U-3936			
	11072586	Nov 05, 2038	DS DP U-3937			
	11072586	Nov 05, 2038	DS DP U-3938			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	12097187	Mar 14, 2033	U-3475			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001 >A>	12115179	Feb 11, 2030	U-4023			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002 >A>	12115179	Feb 11, 2030	U-4023			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001 >A>	12115179	Feb 11, 2030	U-4023			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002 >A>	12115179	Feb 11, 2030	U-4023			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 001 >A>	12115179	Feb 11, 2030	U-4023			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 002 >A>	12115179	Feb 11, 2030	U-4023			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 003 >A>	12115179	Feb 11, 2030	U-4023			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 004 >A>	12115179	Feb 11, 2030	U-4023			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	>A> 12115179	Feb 11, 2030	U-4023			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	>A> 12115179	Feb 11, 2030	U-4023			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	>A> 12115179	Feb 11, 2030	U-4023			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	>A> 12115179	Feb 11, 2030	U-4023			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	>A> 12115179	Feb 11, 2030	U-4023			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	>A> 12115179	Feb 11, 2030	U-4023			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	>A> 12115179	Feb 11, 2030	U-4023			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	>A> 12115179	Feb 11, 2030	U-4023			
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 002					ODE-457	Jan 07, 2029
<u>ENSIFENTRINE - OHTUVAYRE</u>						
N 217389 001	10945950	Sep 15, 2035	DP		NCE	Jun 26, 2029
	9062047	Aug 21, 2031	DS U-3962			
	9956171	Sep 15, 2035	DP U-3962			
<u>EPHEDRINE SULFATE - EPHEDRINE SULFATE</u>						
N 213994 002	12029710	Jan 22, 2040	U-3963			
<u>EPINEPHRINE - NEFFY</u>						
N 214697 001	10576156	Feb 06, 2038	DP			
	10682414	Feb 06, 2039	U-3979			
	11173209	Feb 06, 2038	U-3979			
	11191838	Feb 06, 2039	DP U-3979			
	11717571	Feb 06, 2039	U-3979			
	11744895	Feb 06, 2039	U-3979			
	11918655	Feb 06, 2039	DP U-3979			
<u>EPINEPHRINE - ADRENALIN</u>						
N 215875 001	12133837	Mar 21, 2039	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 215875 002	12133837	Mar 21, 2039	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 215875 003	12133837	Mar 21, 2039	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 215875 004	12133837	Mar 21, 2039	DP			
<u>EPINEPHRINE - ADRENALIN</u>						
N 215875 005	12133837	Mar 21, 2039	DP			
<u>EPLONTERSEN SODIUM - WAINUA (AUTOINJECTOR)</u>						
N 217388 001	10683499	Aug 25, 2034	DS DP U-2378		NCE	Dec 21, 2028
	8101743	Apr 01, 2025	DS DP		ODE-461	Dec 21, 2030
	9127276	May 01, 2034	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EPLONTERSEN SODIUM - WAINUA (AUTOINJECTOR)</u>						
N 217388 001	9181549	May 01, 2034	DS			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 001	10478494	Aug 13, 2036	U-3902		I-930	Jan 19, 2027
	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
	10898482	Feb 09, 2036	DP U-3805			
	10898482	Feb 09, 2036	DP U-3806			
	10898482	Feb 09, 2036	DP U-3807			
	11077106	Feb 02, 2038	U-3196			
	11077106	Feb 02, 2038	U-3808			
	11684620	Feb 09, 2036	U-3805			
	11684620	Feb 09, 2036	U-3806			
	11684620	Feb 09, 2036	U-3807			
	12037644	Oct 18, 2035	U-3972			
	9464071	Apr 28, 2031	U-3805			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 002	10478494	Aug 13, 2036	U-3902		I-930	Jan 19, 2027
	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
	10898482	Feb 09, 2036	DP U-3805			
	10898482	Feb 09, 2036	DP U-3806			
	10898482	Feb 09, 2036	DP U-3807			
	11077106	Feb 02, 2038	U-3196			
	11077106	Feb 02, 2038	U-3808			
	11684620	Feb 09, 2036	U-3805			
	11684620	Feb 09, 2036	U-3806			
	11684620	Feb 09, 2036	U-3807			
	12037644	Oct 18, 2035	U-3972			
	9464071	Apr 28, 2031	U-3805			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 003	10478494	Aug 13, 2036	U-3902		I-930	Jan 19, 2027
	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
	10898482	Feb 09, 2036	DP U-3805			
	10898482	Feb 09, 2036	DP U-3806			
	10898482	Feb 09, 2036	DP U-3807			
	11077106	Feb 02, 2038	U-3196			
	11077106	Feb 02, 2038	U-3808			
	11684620	Feb 09, 2036	U-3805			
	11684620	Feb 09, 2036	U-3806			
	11684620	Feb 09, 2036	U-3807			
	12037644	Oct 18, 2035	U-3972			
	9464071	Apr 28, 2031	U-3805			
<u>ERYTHROMYCIN - ERYTHROMYCIN</u>						
A 211975 003					CGT	Apr 22, 2025
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	11883526	Feb 18, 2040	U-3812			
	11883526	Feb 18, 2040	U-3813			
<u>ESTRADIOL - ESTRADIOL</u>						
A 216160 001					CGT	Oct 23, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 001	>A> 10258630	Nov 21, 2032	U-2316			
	>A> 10258630	Nov 21, 2032	U-2317			
	>A> 10398708	Nov 21, 2032	U-2317			
	>A> 10398708	Nov 21, 2032	U-2614			
	>A> 10471072	Nov 21, 2032	U-2316			
	>A> 10471072	Nov 21, 2032	U-2317			
	>A> 10568891	Nov 21, 2032	U-2316			
	>A> 10568891	Nov 21, 2032	U-2317			
	>A> 10668082	Nov 21, 2032	U-2316			
	>A> 10668082	Nov 21, 2032	U-2317			
	>A> 10888516	Nov 21, 2032	U-2316			
	>A> 10888516	Nov 21, 2032	U-2317			
	>A> 11065197	Nov 21, 2032	DP			
	>A> 11116717	Nov 21, 2032	DP			
	>A> 11123283	Nov 21, 2032	DP			
	>A> 9180091	Nov 21, 2032	DP U-2316			
	>A> 9180091	Nov 21, 2032	DP U-2317			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 002	>A> 10258630	Nov 21, 2032	U-2316			
	>A> 10258630	Nov 21, 2032	U-2317			
	>A> 10398708	Nov 21, 2032	U-2317			
	>A> 10398708	Nov 21, 2032	U-2614			
	>A> 10471072	Nov 21, 2032	U-2316			
	>A> 10471072	Nov 21, 2032	U-2317			
	>A> 10568891	Nov 21, 2032	U-2316			
	>A> 10568891	Nov 21, 2032	U-2317			
	>A> 10668082	Nov 21, 2032	U-2316			
	>A> 10668082	Nov 21, 2032	U-2317			
	>A> 10888516	Nov 21, 2032	U-2316			
	>A> 10888516	Nov 21, 2032	U-2317			
	>A> 11065197	Nov 21, 2032	DP			
	>A> 11116717	Nov 21, 2032	DP			
	>A> 11123283	Nov 21, 2032	DP			
	>A> 9180091	Nov 21, 2032	DP U-2316			
	>A> 9180091	Nov 21, 2032	DP U-2317			
<u>ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE</u>						
N 214846 001	11957684	Sep 29, 2037	U-3129			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 001	11865179	Nov 21, 2032	DS DP			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 002	11865179	Nov 21, 2032	DS DP			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 001	11959486	Jun 27, 2034	DP U-2014			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 002	11959486	Jun 27, 2034	DP U-2014			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 003	11959486	Jun 27, 2034	DP U-2014			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - FEMLYV</u>						
N 218718 001				NP		Jul 22, 2027
<u>ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA</u>						
N 209627 001	11850251	Jun 21, 2039	U-3785			
<u>ETRASIMOD ARGININE - VELSIPITY</u>						
N 216956 001	11884626	Jun 21, 2036	U-3731			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENFLURAMINE HYDROCHLORIDE - FINTEPLA</u>						
N 212102 001	12097206	May 03, 2033	U-4013			
	12097206*PED	Nov 03, 2033				
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	7612109	Feb 05, 2025	DS DP			
	>A> 7754702	Feb 15, 2028			U-1432	
	>A> 7754702	Feb 15, 2028			U-3312	
	>A> 7754702	Feb 15, 2028			U-3313	
	>A> 7754702	Feb 15, 2028			U-3314	
	>A> 7754702	Feb 15, 2028			U-3636	
	>A> 8895612	Jan 08, 2027			U-1620	
	>A> 8895612	Jan 08, 2027			U-3115	
	>A> 8895612	Jan 08, 2027			U-3116	
	>A> 8895612	Jan 08, 2027			U-3315	
	>A> 8895612	Jan 08, 2027			U-3316	
	>A> 8895612	Jan 08, 2027			U-3635	
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 002	7612109	Feb 05, 2025	DS DP			
	>A> 7754702	Feb 15, 2028			U-2555	
	>A> 7754702	Feb 15, 2028			U-2556	
	>A> 7754702	Feb 15, 2028			U-2557	
	>A> 7754702	Feb 15, 2028			U-3312	
	>A> 7754702	Feb 15, 2028			U-3313	
	>A> 7754702	Feb 15, 2028			U-3314	
	>A> 7754702	Feb 15, 2028			U-3636	
	>A> 8895612	Jan 08, 2027			U-1620	
	>A> 8895612	Jan 08, 2027			U-3050	
	>A> 8895612	Jan 08, 2027			U-3051	
	>A> 8895612	Jan 08, 2027			U-3115	
	>A> 8895612	Jan 08, 2027			U-3116	
	>A> 8895612	Jan 08, 2027			U-3315	
	>A> 8895612	Jan 08, 2027			U-3316	
	>A> 8895612	Jan 08, 2027			U-3635	
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 003	7612109	Feb 05, 2025	DS DP			
	>A> 7754702	Feb 15, 2028			U-2555	
	>A> 7754702	Feb 15, 2028			U-2556	
	>A> 7754702	Feb 15, 2028			U-2557	
	>A> 7754702	Feb 15, 2028			U-3312	
	>A> 7754702	Feb 15, 2028			U-3313	
	>A> 7754702	Feb 15, 2028			U-3314	
	>A> 7754702	Feb 15, 2028			U-3636	
	>A> 8895612	Jan 08, 2027			U-1620	
	>A> 8895612	Jan 08, 2027			U-3050	
	>A> 8895612	Jan 08, 2027			U-3051	
	>A> 8895612	Jan 08, 2027			U-3115	
	>A> 8895612	Jan 08, 2027			U-3116	
	>A> 8895612	Jan 08, 2027			U-3315	
	>A> 8895612	Jan 08, 2027			U-3316	
	>A> 8895612	Jan 08, 2027			U-3635	
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 004	7612109	Feb 05, 2025	DS DP			
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 001	11851504	Mar 25, 2029	DS DP			
	12030962	Mar 25, 2029	DS DP			
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 002	11851504	Mar 25, 2029	DS DP			
	12030962	Mar 25, 2029	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 003	11851504	Mar 25, 2029	DS DP			
	12030962	Mar 25, 2029	DS DP			
<u>FERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001					NPP PED	Jul 01, 2027 Jan 01, 2028
<u>FIDAXOMICIN - DIFICID</u>						
N 213138 001	8586551*PED	Jan 15, 2024				
<u>FINERENONE - KERENDIA</u>						
N 215341 001	RE49826	Jul 29, 2035	DS			
<u>FINERENONE - KERENDIA</u>						
N 215341 002	RE49826	Jul 29, 2035	DS			
<u>FLOTUFOLASTAT F-18 GALLIUM - POSLUMA</u>						
N 216023 001	12036290	Nov 27, 2041	DP U-3614			
	12036290	Nov 27, 2041	DP U-3615			
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054 001	11980674	Apr 23, 2042		U-2450		
<u>FLUOROMETHOLONE - FLUOROMETHOLONE</u>						
A 216348 001					CGT	Jul 07, 2024
<u>FLURPIRIDAZ F-18 - FLYRCADO</u>						
N 215168 001	7344702	May 26, 2026	DS		NCE	Sep 27, 2029
	8226929	Jun 21, 2028		U-4011		
	8936777	Jun 30, 2031		U-4011		
	9161997	Feb 04, 2026	DS DP	U-4011		
	9603951	May 02, 2031		U-4011		
	9687571	Nov 01, 2032		DP U-4011		
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 001	7500444	Feb 26, 2026	DP		Y	
	7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 002	7500444	Feb 26, 2026	DP		Y	
	7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 004	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 005	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 007	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 008	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	12083270	Apr 04, 2031	U-2133		I-940	Mar 15, 2027
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 006	11969544	Aug 20, 2039	DP			
	11969544*PED	Feb 20, 2040				
<u>FOSAPREPITANT DIMEGLUMINE - FOCINVEZ</u>						
N 216686 001	12042504	Jan 11, 2039	DP			
<u>FOSCARBIDOPA; FOSLEVODOPA - VYALEV</u>						
N 216962 001	>A> 10174061	Oct 21, 2035	DP U-4030			
	>A> 10730895	Oct 21, 2035	DS			
	>A> 9446059	Oct 21, 2035	DS DP U-4030			
<u>FOSTEMSAVIR TROMETHAMINE - RUKOBIA</u>						
N 212950 001	8168615	Jul 13, 2029	DP			
<u>FRUQUINTINIB - FRUZAOLA</u>						
N 217564 001					NCE	Nov 08, 2028
<u>FRUQUINTINIB - FRUZAOLA</u>						
N 217564 002					NCE	Nov 08, 2028
<u>FUROSEMIDE - FUROSCIX</u>						
N 209988 001					NP	Oct 07, 2025
<u>GALLIUM GA-68 GOZETOTIDE - LOCAMETZ</u>						
N 215841 001	12109277	Mar 09, 2036	U-4002			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GANAXOLONE - ZTALMY</u>						
N 215904 001	>A> 12144801	Aug 10, 2037	U-4034			
<u>GILTERITINIB FUMARATE - XOSPATA</u>						
N 211349 001	11938130	Jul 01, 2036	DP			
	11938131	Jul 01, 2036	DP			
	11938132	Jul 01, 2036	DP			
	11938133	Jul 01, 2036	DP			
	11944620	Jul 01, 2036	DP			
	8969336	Nov 28, 2032	DS DP			
<u>GIVINOSTAT HYDROCHLORIDE - DUVYZAT</u>						
N 217865 001	10688047	Oct 28, 2036	DP U-3885		NCE	Mar 21, 2029
	7329689	Jan 15, 2025	DS DP		ODE-473	Mar 21, 2031
	9421184	Feb 03, 2032	U-3885			
	9867799	Feb 03, 2032	U-3885			
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656 001	11891372	Apr 13, 2036	U-3254			
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656 002	11891372	Apr 13, 2036	U-3254			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	8404215	Mar 09, 2032	U-1383	Y		
	9254278	Sep 22, 2030	U-1816			
	9326966	Sep 22, 2030	U-1816			
<u>GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE - PREVDUO</u>						
N 216903 001	11938217	Oct 25, 2038	DP			
	>A> 12151020	Oct 25, 2038	DP			
<u>GOLODIRSEN - VYONDYS 53</u>						
N 211970 001	RE47691	Jun 28, 2028	DP			
<u>HALOBETASOL PROPIONATE - HALOBETASOL PROPIONATE</u>						
A 215266 001					PC	Jun 24, 2024
<u>HALOBETASOL PROPIONATE - BRYHALI</u>						
N 209355 001	11957753	Nov 02, 2031	DP			
	11986527	Nov 02, 2031	U-2625			
	12076403	Nov 02, 2031	DP			
<u>HALOBETASOL PROPIONATE; TAZAROTENE - DUOBRII</u>						
N 209354 001	11957753	Nov 02, 2031	DP			
	11986527	Nov 02, 2031	U-2625			
	12076403	Nov 02, 2031	DP			
<u>HEPARIN SODIUM; TAUROLIDINE - DEFENCATH</u>						
N 214520 001					NCE GAIN	Nov 15, 2028 Nov 15, 2033
<u>HEPARIN SODIUM; TAUROLIDINE - DEFENCATH</u>						
N 214520 002					NCE GAIN	Nov 15, 2028 Nov 15, 2033
<u>HYDROCORTISONE SODIUM SUCCINATE - HYDROCORTISONE SODIUM SUCCINATE</u>						
A 214050 001					CGT	Mar 25, 2025
<u>HYDROMORPHONE HYDROCHLORIDE - HYDROMORPHONE HYDROCHLORIDE</u>						
A 216899 001					PC	Apr 12, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE	
<u>HYDROMORPHONE HYDROCHLORIDE - HYDROMORPHONE HYDROCHLORIDE</u>							
A 216899	002				PC	Nov 11, 2024	
<u>HYDROMORPHONE HYDROCHLORIDE - HYDROMORPHONE HYDROCHLORIDE</u>							
A 216899	003				PC	Dec 02, 2024	
<u>HYDROXYUREA - XROMI</u>							
N 216593	001				NP ODE-470	Apr 04, 2027 Apr 04, 2031	
<u>IBRUTINIB - IMBRUVICA</u>							
N 205552	001	8754090	Jun 03, 2031	U-1456	Y	M-14	Aug 24, 2025
		8754090*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>							
N 205552	002	8754090	Jun 03, 2031	U-1456	Y	M-14	Aug 24, 2025
		8754090*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>							
N 210563	001	8476284	Dec 28, 2026	U-1650		M-14	Aug 24, 2025
		8476284	Dec 28, 2026	U-1946			
		8476284	Dec 28, 2026	U-2241			
		8476284*PED	Jun 28, 2027				
		8497277	Dec 28, 2026	U-1491			
		8497277	Dec 28, 2026	U-1650			
		8497277	Dec 28, 2026	U-1946			
		8497277	Dec 28, 2026	U-2241			
		8497277	Dec 28, 2026	U-2242			
		8497277	Dec 28, 2026	U-3422			
		8497277*PED	Jun 28, 2027				
		8952015	Dec 28, 2026	U-1491			
		8952015	Dec 28, 2026	U-1650			
		8952015	Dec 28, 2026	U-1946			
		8952015	Dec 28, 2026	U-2241			
		8952015	Dec 28, 2026	U-2242			
		8952015*PED	Jun 28, 2027				
<u>IBRUTINIB - IMBRUVICA</u>							
N 210563	002	8476284	Dec 28, 2026	U-1650		M-14	Aug 24, 2025
		8476284	Dec 28, 2026	U-1946			
		8476284	Dec 28, 2026	U-2241			
		8476284*PED	Jun 28, 2027				
		8497277	Dec 28, 2026	U-1491			
		8497277	Dec 28, 2026	U-1650			
		8497277	Dec 28, 2026	U-1946			
		8497277	Dec 28, 2026	U-2241			
		8497277	Dec 28, 2026	U-2242			
		8497277	Dec 28, 2026	U-3422			
		8497277*PED	Jun 28, 2027				
		8952015	Dec 28, 2026	U-1491			
		8952015	Dec 28, 2026	U-1650			
		8952015	Dec 28, 2026	U-1946			
		8952015	Dec 28, 2026	U-2241			
		8952015	Dec 28, 2026	U-2242			
		8952015*PED	Jun 28, 2027				
<u>IBRUTINIB - IMBRUVICA</u>							
N 210563	003	8476284	Dec 28, 2026	U-1650		M-14	Aug 24, 2025
		8476284	Dec 28, 2026	U-1946			
		8476284	Dec 28, 2026	U-2241			
		8476284*PED	Jun 28, 2027				
		8497277	Dec 28, 2026	U-1491			
		8497277	Dec 28, 2026	U-1650			
		8497277	Dec 28, 2026	U-1946			
		8497277	Dec 28, 2026	U-2241			
		8497277	Dec 28, 2026	U-2242			
		8497277	Dec 28, 2026	U-3422			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	8497277*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8952015*PED	Jun 28, 2027				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004					M-14	Aug 24, 2025
<u>IBRUTINIB - IMBRUVICA</u>						
N 217003 001	10004746	Jun 03, 2031	U-3846			
	10004746	Jun 03, 2031	U-3847			
	10004746	Jun 03, 2031	U-3848			
	10004746	Jun 03, 2031	U-3849			
	10016435	Jun 03, 2031	U-3845			
	10463668	Oct 24, 2034	U-2970			
	10478439	Jun 03, 2031	U-2666			
	10478439	Jun 03, 2031	U-2970			
	10478439	Jun 03, 2031	U-3422			
	10478439	Jun 03, 2031	U-3842			
	10478439	Jun 03, 2031	U-3843			
	10478439	Jun 03, 2031	U-3844			
	10478439	Jun 03, 2031	U-3845			
	10478439*PED	Dec 03, 2031				
	10695350	Oct 24, 2034	U-2970			
	10751342	Jun 03, 2031	U-2666			
	10751342	Jun 03, 2031	U-3842			
	10751342	Jun 03, 2031	U-3843			
	10751342	Jun 03, 2031	U-3844			
	11672803	Jun 03, 2031	U-2666			
	11672803	Jun 03, 2031	U-3842			
	11672803	Jun 03, 2031	U-3843			
	11672803	Jun 03, 2031	U-3844			
	8476284	Dec 28, 2026	U-3843			
	8476284	Dec 28, 2026	U-3844			
	8476284	Dec 28, 2026	U-3845			
	8497277	Dec 28, 2026	U-2666			
	8497277	Dec 28, 2026	U-2970			
	8497277	Dec 28, 2026	U-3422			
	8497277	Dec 28, 2026	U-3842			
	8497277	Dec 28, 2026	U-3843			
	8497277	Dec 28, 2026	U-3844			
	8497277	Dec 28, 2026	U-3845			
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027	U-2666			
	8563563	Apr 26, 2027	U-3842			
	8563563	Apr 26, 2027	U-3843			
	8563563	Apr 26, 2027	U-3844			
	8563563	Apr 26, 2027	U-3845			
	8703780	Dec 28, 2026	U-2666			
	8703780	Dec 28, 2026	U-3842			
	8952015	Dec 28, 2026	U-2666			
	8952015	Dec 28, 2026	U-3842			
	8952015	Dec 28, 2026	U-3843			
	8952015	Dec 28, 2026	U-3844			
	8952015	Dec 28, 2026	U-3845			
	8999999	Jun 03, 2031	U-2666			
	8999999	Jun 03, 2031	U-3842			
	8999999	Jun 03, 2031	U-3843			
	8999999	Jun 03, 2031	U-3844			
	9125889	Jun 03, 2031	U-3845			
	9795604	Oct 24, 2034	U-2970			
	9795604	Oct 24, 2034	U-3422			
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031	U-3846			
	9801881	Jun 03, 2031	U-3847			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 217003 001	9801883	Jun 03, 2031	U-2666			
	9801883	Jun 03, 2031	U-3842			
	9801883	Jun 03, 2031	U-3843			
	9801883	Jun 03, 2031	U-3844			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 001					NPP	May 11, 2026
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002					NPP	May 11, 2026
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 003					NPP	May 11, 2026
<u>ILOPERIDONE - FANAPT</u>						
N 022192 001					I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192 002					I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192 003					I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192 004					I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192 005					I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192 006					I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192 007					I-939	Apr 02, 2027
<u>ILOPROST - AURLUMYN</u>						
N 217933 001					NP ODE-465	Feb 13, 2027 Feb 13, 2031
<u>IMATINIB MESYLATE - IMKELDI</u>						
N 219097 001 >A>	11957681	Apr 27, 2040	DP			
<u>IMETELSTAT SODIUM - RYTELO</u>						
N 217779 001	7494982	Dec 27, 2025	DS DP		ODE-482	Jun 06, 2031
	9375485	Mar 15, 2033	U-3956			
	9388415	Sep 09, 2024	U-3956			
	9388416	Sep 09, 2024	U-3956			
<u>IMETELSTAT SODIUM - RYTELO</u>						
N 217779 002	7494982	Dec 27, 2025	DS DP		ODE-482	Jun 06, 2031
	9375485	Mar 15, 2033	U-3956			
	9388415	Sep 09, 2024	U-3956			
	9388416	Sep 09, 2024	U-3956			
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 001	11850245	Apr 30, 2030	U-1455			
	11850245	Apr 30, 2030	U-172			
<u>INAVOLISIB - ITOVEBI</u>						
N 219249 001 >A>	10851091	Jul 01, 2036	DS DP		>A> NCE	Oct 10, 2029
	>A> 11028100	Apr 26, 2038	DS DP			
	>A> 11760753	Jul 01, 2036	U-4024			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INAVOLISIB - ITOVEBI</u>						
N 219249 001	>A> 8242104	Sep 27, 2030	DS DP			
	>A> 8343955	Sep 27, 2030		U-4024		
	>A> 9650393	Jul 01, 2036	DS DP	U-4024		
<u>INAVOLISIB - ITOVEBI</u>						
N 219249 002	>A> 10851091	Jul 01, 2036	DS DP		>A> NCE	Oct 10, 2029
	>A> 11028100	Apr 26, 2038	DS DP			
	>A> 11760753	Jul 01, 2036		U-4024		
	>A> 8242104	Sep 27, 2030	DS DP			
	>A> 8343955	Sep 27, 2030		U-4024		
	>A> 9650393	Jul 01, 2036	DS DP	U-4024		
<u>INDOMETHACIN - INDOMETHACIN</u>						
A 217883 001					CGT	Jul 10, 2024
<u>IPTACOPAN HYDROCHLORIDE - FABHALTA</u>						
N 218276 001	10093663	Jul 14, 2034		U-3980	I-949	Aug 07, 2027
	11723901	Aug 30, 2038		U-3980	NCE	Dec 05, 2028
	11951101	Jul 15, 2041		U-3895	ODE-456	Dec 05, 2030
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	11344552	Aug 19, 2036		U-3824	I-932	Feb 13, 2027
	12059497	Oct 15, 2036	DP		ODE-463	Feb 13, 2031
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 001					NPP	Dec 08, 2026
					ODE-454	Dec 08, 2030
					ODE-458	Dec 08, 2030
					PED	Jun 08, 2027
					PED	Jun 08, 2031
					PED	Jun 08, 2031
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 002					NPP	Dec 08, 2026
					ODE-454	Dec 08, 2030
					ODE-458	Dec 08, 2030
					PED	Jun 08, 2027
					PED	Jun 08, 2031
					PED	Jun 08, 2031
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207501 001					NPP	Dec 08, 2026
					ODE-453	Dec 08, 2030
					ODE-459	Dec 08, 2030
					PED	Jun 08, 2027
					PED	Jun 08, 2031
					PED	Jun 08, 2031
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	10058546	Jul 15, 2033		U-3022		
	10058546	Jul 15, 2033		U-3023		
	10081621	Mar 25, 2031	DP	U-3024		
	10081621	Mar 25, 2031	DP	U-3025		
	10206877	Apr 14, 2035	DP	U-3026		
	10206877	Apr 14, 2035	DP	U-3027		
	11951212	Apr 14, 2035	DP	U-3894		
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 002	10058546	Jul 15, 2033		U-3022		
	10058546	Jul 15, 2033		U-3023		
	10081621	Mar 25, 2031	DP	U-3024		
	10081621	Mar 25, 2031	DP	U-3025		
	10206877	Apr 14, 2035	DP	U-3026		
	10206877	Apr 14, 2035	DP	U-3027		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	12065432	Dec 04, 2028	U-3984			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	12065432	Dec 04, 2028	U-3984			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 001	12065432	Dec 04, 2028	U-3983			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 002	12065432	Dec 04, 2028	U-3983			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 003	12065432	Dec 04, 2028	U-3983			
<u>LACOSAMIDE - MOTPOLY XR</u>						
N 216185 001	11337943	Jun 05, 2040	DP U-3660			
	11337943	Jun 05, 2040	DP U-3954			
	11883374	Jun 05, 2040	DP U-3660			
	11883374	Jun 05, 2040	DP U-3954			
	12042474	Jun 05, 2040	DP U-3660			
	12042474	Jun 05, 2040	DP U-3954			
<u>LACOSAMIDE - MOTPOLY XR</u>						
N 216185 002	11337943	Jun 05, 2040	DP U-3660			
	11337943	Jun 05, 2040	DP U-3954			
	11883374	Jun 05, 2040	DP U-3660			
	11883374	Jun 05, 2040	DP U-3954			
	12042474	Jun 05, 2040	DP U-3660			
	12042474	Jun 05, 2040	DP U-3954			
<u>LACOSAMIDE - MOTPOLY XR</u>						
N 216185 003	11337943	Jun 05, 2040	DP U-3660			
	11337943	Jun 05, 2040	DP U-3954			
	11883374	Jun 05, 2040	DP U-3660			
	11883374	Jun 05, 2040	DP U-3954			
	12042474	Jun 05, 2040	DP U-3660			
	12042474	Jun 05, 2040	DP U-3954			
<u>LANSOPRAZOLE - LANSOPRAZOLE</u>						
N 208025 001	11986554	Apr 21, 2036	DP			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 001	12071423	Jul 06, 2040	DP			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 002	12071423	Jul 06, 2040	DP			
<u>LATANOPROST - IYUZEH</u>						
N 216472 001	8637054	Jul 08, 2031	DP U-446			
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259 001	11020385	Mar 14, 2034	U-1524			
<u>LATANOPROSTENE BUNOD - VYZULTA</u>						
N 207795 001	8058467	Feb 21, 2029	DS U-2144			
<u>LAZERTINIB MESYLATE - LAZCLUZE</u>						
N 219008 001	11453656	Apr 18, 2038	DS DP		NCE	Aug 19, 2029
	11850248	Aug 01, 2041	U-3985			
	11879013	May 21, 2040	U-3985			
	11981659	Apr 18, 2038	U-3985			
	9593098	Oct 13, 2035	DS DP U-3985			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAZERTINIB MESYLATE - LAZCLUZE</u>						
N 219008 002	11453656	Apr 18, 2038	DS DP		NCE	Aug 19, 2029
	11850248	Aug 01, 2041		U-3985		
	11879013	May 21, 2040		U-3985		
	11981659	Apr 18, 2038		U-3985		
	9593098	Oct 13, 2035	DS DP	U-3985		
<u>LEMBorexant - DAYVIGO</u>						
N 212028 001	10702529	Oct 21, 2035	DP			
	11026944	Oct 21, 2035	DP			
<u>LEMBorexant - DAYVIGO</u>						
N 212028 002	10702529	Oct 21, 2035	DP			
	11026944	Oct 21, 2035	DP			
<u>LENACAPAVIR SODIUM - SUNLENCA</u>						
N 215973 001	11944611	Jun 04, 2041		U-3507		
<u>LENACAPAVIR SODIUM - SUNLENCA</u>						
N 215974 001	11944611	Jun 04, 2041	DS DP	U-3507		
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	10259791	Aug 26, 2035	DS		I-868	Aug 10, 2024
	10259791*PED	Feb 26, 2036			M-14	Apr 03, 2027
	10407393	Aug 26, 2035	DS		M-269	Jul 21, 2024
	10407393*PED	Feb 26, 2036			M-272	Dec 19, 2024
	11090386	Feb 23, 2036		U-3519	ODE-196	Aug 15, 2025
	11090386*PED	Aug 23, 2036			PED	Feb 15, 2026
	11186547	Aug 26, 2035	DS		PED	Oct 03, 2027
	11186547*PED	Feb 26, 2036				
	12083112	Mar 03, 2036		U-3996		
	12083112	Mar 03, 2036		U-3997		
	7253286	Oct 24, 2025	DS DP			
	7253286*PED	Apr 24, 2026				
	7612208	Sep 19, 2026	DS DP			
	7612208*PED	Mar 19, 2027				
	9006256	Jul 27, 2027		U-1695		
	9006256*PED	Jan 27, 2028				
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	10259791	Aug 26, 2035	DS		I-868	Aug 10, 2024
	10259791*PED	Feb 26, 2036			M-14	Apr 03, 2027
	10407393	Aug 26, 2035	DS		M-269	Jul 21, 2024
	10407393*PED	Feb 26, 2036			M-272	Dec 19, 2024
	11090386	Feb 23, 2036		U-3519	ODE-196	Aug 15, 2025
	11090386*PED	Aug 23, 2036			PED	Feb 15, 2026
	11186547	Aug 26, 2035	DS		PED	Oct 03, 2027
	11186547*PED	Feb 26, 2036				
	12083112	Mar 03, 2036		U-3996		
	12083112	Mar 03, 2036		U-3997		
	7253286	Oct 24, 2025	DS DP			
	7253286*PED	Apr 24, 2026				
	7612208	Sep 19, 2026	DS DP			
	7612208*PED	Mar 19, 2027				
	9006256	Jul 27, 2027		U-1695		
	9006256*PED	Jan 27, 2028				
<u>LETtermovir - PREVYMIS</u>						
N 209939 001	RE46791	Jan 18, 2029	DS DP		NPP	Aug 30, 2027
					ODE-495	Aug 30, 2031
					ODE-497	Aug 30, 2031
<u>LETtermovir - PREVYMIS</u>						
N 209939 002	RE46791	Jan 18, 2029	DS DP		NPP	Aug 30, 2027
					ODE-495	Aug 30, 2031
					ODE-497	Aug 30, 2031

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 002	RE46791	Jan 18, 2029	DS DP		NPP ODE-495 ODE-497	Aug 30, 2027 Aug 30, 2031 Aug 30, 2031
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 001	RE46791	Jan 18, 2029	DS DP		NPP ODE-495 ODE-497	Aug 30, 2027 Aug 30, 2031 Aug 30, 2031
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 002	RE46791	Jan 18, 2029	DS DP		NPP ODE-495 ODE-497	Aug 30, 2027 Aug 30, 2031 Aug 30, 2031
<u>LETERMOVIR - PREVYMIS</u>						
N 219104 001	RE46791	Jan 18, 2029	DS DP		NP ODE* ODE* ODE-495 ODE-497	Aug 30, 2027 Nov 08, 2024 Jun 05, 2030 Aug 30, 2031 Aug 30, 2031
<u>LETERMOVIR - PREVYMIS</u>						
N 219104 002	RE46791	Jan 18, 2029	DS DP		NP ODE* ODE* ODE-495 ODE-497	Aug 30, 2027 Nov 08, 2024 Jun 05, 2030 Aug 30, 2031 Aug 30, 2031
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISQALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935 001	12064434	Apr 14, 2036	DP		I-951	Sep 17, 2027
	8962630	Dec 09, 2029	U-2505			
	8962630	Dec 09, 2029	U-3264			
	8962630	Dec 09, 2029	U-3998			
	9416136	Aug 20, 2029	U-2505			
	9416136	Aug 20, 2029	U-3264			
	9416136	Aug 20, 2029	U-3998			
	9868739	Nov 09, 2031	U-2505			
	9868739	Nov 09, 2031	U-3264			
	9868739	Nov 09, 2031	U-3998			
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020517 003	9617303	Mar 22, 2028	U-4001			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021343 001	11931559	Dec 22, 2041	DS			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021379 001	11931559	Dec 22, 2041	DS			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021488 001	11931559	Dec 22, 2041	DS			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021731 001	11931559	Dec 22, 2041	DS			
<u>LEUPROLIDE ACETATE - FENSOLVI KIT</u>						
N 213150 001	11931559	Dec 22, 2041	DS			
<u>LEUPROLIDE MESYLATE - CAMCEVI KIT</u>						
N 211488 001	>A> 12133878	Dec 18, 2037	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVACETYLLEUCINE - AONEURSA</u>						
N 219132 001					NCE ODE-498	Sep 24, 2029 Sep 24, 2031
<u>LEVOKETOCONAZOLE - RECORLEV</u>						
N 214133 001	11903940	Mar 02, 2040	U-3821			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 001					M-304	Mar 24, 2026
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 002					M-304	Mar 24, 2026
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 003					M-304	Mar 24, 2026
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 004					M-304	Mar 24, 2026
<u>LEVONORGESTREL - MIRENA</u>						
N 021225 001	11850182	Sep 14, 2029	DP U-3819			
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001	11850182	Sep 14, 2029	DP U-3819			
<u>LEVONORGESTREL - LILETTA</u>						
N 206229 001	12004992	Oct 06, 2033	DS			
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224 001	11850182	Sep 14, 2029	DP U-3819			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	11911388	Apr 10, 2030	U-3854			
<u>LISINAPRIL - OBRELIS</u>						
N 208401 001	>A> 12128083	Nov 06, 2035	DP			
<u>LOFEXIDINE HYDROCHLORIDE - LOFEXIDINE HYDROCHLORIDE</u>						
A 218613 001					CGT	Feb 24, 2025
<u>LONAFARNIB - ZOKINVY</u>						
N 213969 001	7838531	Jul 26, 2025	U-3070			
	8828356	Oct 17, 2025	U-3070			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LONAFARNIB - ZOKINVY</u>						
N 213969 002	7838531	Jul 26, 2025	U-3070			
	8828356	Oct 17, 2025	U-3070			
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565 001	11872318	May 03, 2033	DP			
	>A> 12115246	May 03, 2033	DP U-4025			
<u>LOTEPREDNOL ETABONATE - EYSUVIS</u>						
N 210933 001	11872318	May 03, 2033	DP			
	>A> 12115246	May 03, 2033	DP U-2985			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001	11980617	Oct 27, 2039	U-3940			
	12070459	Aug 30, 2039	DP U-3362			
	12070459	Aug 30, 2039	DP U-3363			
	12090155	Jul 07, 2040	DP U-4000			
	12122792	Dec 10, 2040	DP U-4019			
	12122792	Dec 10, 2040	DP U-4020			
	12128043	Aug 30, 2039	DP U-3362			
	12128043	Aug 30, 2039	DP U-3363			
	8598119	Dec 28, 2029	U-543		Y	
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 002	11980617	Oct 27, 2039	U-3940			
	12122792	Dec 10, 2040	DP U-4019			
	12122792	Dec 10, 2040	DP U-4020			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 003	11980617	Oct 27, 2039	U-3940			
	12122792	Dec 10, 2040	DP U-4019			
	12122792	Dec 10, 2040	DP U-4020			
<u>LUTETIUM LU 177 DOTATATE - LUTATHERA</u>						
N 208700 001	10596276	Jul 25, 2038	DP		NPP	Apr 23, 2027
	10596276*PED	Jan 25, 2039			ODE-166	Jan 26, 2025
	10596278	Jul 25, 2038	DP		ODE-479	Apr 23, 2031
	10596278*PED	Jan 25, 2039			PED	Jul 26, 2025
	11904027	Jul 25, 2038	DP		PED	Oct 23, 2027
	11904027*PED	Jan 25, 2039			PED	Oct 23, 2031
	>A> 12144873	Jul 25, 2038	U-4036			
	>A> 12144873*PED	Jan 25, 2039				
	>A> 12151003	Jul 25, 2038	DP U-4036			
	>A> 12151003*PED	Jan 25, 2039				
	>A> 12161732	Jul 25, 2038	DP U-4036			
<u>LUTETIUM LU-177 VIPIVOTIDE TETRAJETAN - PLUVICTO</u>						
N 215833 001	11951190	Nov 12, 2035	U-3345			
<u>MACITENTAN; TADALAFIL - OPSYNVI</u>						
N 218490 001	10946015	Sep 11, 2026	DP U-3881		NP	Mar 22, 2027
	7094781	Dec 05, 2025	DS DP		ODE-475	Mar 22, 2031
	8268847	Apr 18, 2029	DP U-3882			
<u>MACITENTAN; TADALAFIL - OPSYNVI</u>						
N 218490 002	10946015	Sep 11, 2026	DP U-3881		NP	Mar 22, 2027
	7094781	Dec 05, 2025	DS DP		ODE-475	Mar 22, 2031
	8268847	Apr 18, 2029	DP U-3882			
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 214662 001	10512657	Oct 26, 2032	U-3850		I-938	Mar 13, 2027
	11229647	Feb 12, 2040	U-3290		ODE-471	Mar 13, 2031
	11229647	Feb 12, 2040	U-3974			
	11229661	Oct 26, 2032	U-3850			
	11260053	May 26, 2031	U-3290			
	11260053	May 26, 2031	U-3974			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 214662 001	11376251	Oct 26, 2032	U-3290			
	11376251	Oct 26, 2032	U-3974			
	11497745	Feb 12, 2040	U-3290			
	11497745	Feb 12, 2040	U-3974			
	11918578	Feb 12, 2040	U-3290			
	11918578	Feb 12, 2040	U-3974			
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 214662 002	10512657	Oct 26, 2032	U-3973		NCE	Sep 29, 2026
	11229661	Oct 26, 2032	U-3973		ODE*	Sep 29, 2028
					ODE*	Mar 13, 2030
					ODE*	Mar 13, 2031
					ODE-490	Jul 24, 2031
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 001	RE50050	Jun 19, 2034	DS DP			
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 002	RE50050	Jun 19, 2034	DS DP			
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 003	RE50050	Jun 19, 2034	DS DP			
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 004	RE50050	Jun 19, 2034	DS DP			
<u>MAVORIXAFOR - XOLREMDI</u>						
N 218709 001	10548889	Dec 11, 2038	DP		NCE	Apr 26, 2029
	10610527	Dec 22, 2036	U-3932		ODE-480	Apr 26, 2031
	10953003	Dec 14, 2036	DP			
	11045461	Dec 11, 2038	DP			
	11219621	Dec 22, 2036	U-3932			
	12115156	Dec 11, 2038	DP			
<u>METAXALONE - METAXALONE</u>						
N 022503 001	11918559	Jul 29, 2039	DP			
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	11969503	Jan 02, 2033	DP			
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630 001					M-303	Jan 08, 2027
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630 002					M-303	Jan 08, 2027
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	11911518	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	11911518	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	11911518	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	11911518	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	11911518	Mar 23, 2032	U-2357			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - RELEXXII</u>						
N 216117 001	>A> 10265308	Feb 03, 2037	DP U-4032			
	>A> 10695336	Feb 03, 2037	U-4032			
	>A> 9707217	Feb 03, 2037	DP			
	>A> 9827234	Feb 03, 2037	U-4032			
	>A> 9855258	Feb 03, 2037	DP U-4032			
<u>METHYLPHENIDATE HYDROCHLORIDE - RELEXXII</u>						
N 216117 002	>A> 10265308	Feb 03, 2037	DP U-4032			
	>A> 10695336	Feb 03, 2037	U-4032			
	>A> 9707217	Feb 03, 2037	DP			
	>A> 9827234	Feb 03, 2037	U-4032			
	>A> 9855258	Feb 03, 2037	DP U-4032			
<u>METHYLPHENIDATE HYDROCHLORIDE - RELEXXII</u>						
N 216117 003	>A> 10265308	Feb 03, 2037	DP U-4032			
	>A> 10695336	Feb 03, 2037	U-4032			
	>A> 9707217	Feb 03, 2037	DP			
	>A> 9827234	Feb 03, 2037	U-4032			
	>A> 9855258	Feb 03, 2037	DP U-4032			
<u>METHYLPHENIDATE HYDROCHLORIDE - RELEXXII</u>						
N 216117 004	>A> 10265308	Feb 03, 2037	DP U-4032			
	>A> 10695336	Feb 03, 2037	U-4032			
	>A> 9707217	Feb 03, 2037	DP			
	>A> 9827234	Feb 03, 2037	U-4032			
	>A> 9855258	Feb 03, 2037	DP U-4032			
<u>METHYLPHENIDATE HYDROCHLORIDE - RELEXXII</u>						
N 216117 005	>A> 10265308	Feb 03, 2037	DP U-4032			
	>A> 10695336	Feb 03, 2037	U-4032			
	>A> 9707217	Feb 03, 2037	DP			
	>A> 9827234	Feb 03, 2037	U-4032			
	>A> 9855258	Feb 03, 2037	DP U-4032			
<u>METHYLPHENIDATE HYDROCHLORIDE - RELEXXII</u>						
N 216117 006	>A> 10265308	Feb 03, 2037	DP U-4032			
	>A> 10695336	Feb 03, 2037	U-4032			
	>A> 9707217	Feb 03, 2037	DP			
	>A> 9827234	Feb 03, 2037	U-4032			
	>A> 9855258	Feb 03, 2037	DP U-4032			
<u>METHYLPHENIDATE HYDROCHLORIDE - RELEXXII</u>						
N 216117 007	>A> 10265308	Feb 03, 2037	DP U-4032			
	>A> 10695336	Feb 03, 2037	U-4032			
	>A> 9707217	Feb 03, 2037	DP			
	>A> 9827234	Feb 03, 2037	U-4032			
	>A> 9855258	Feb 03, 2037	DP U-4032			
<u>MIFEPRISTONE - MIFEPRISTONE</u>						
A 211436 001					PC	Jul 17, 2024
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	11969435	Jun 19, 2037	U-1643			
	12097210	Jun 19, 2037	U-1643			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	11903938	Aug 17, 2038	DS U-2371			
	12042488	May 30, 2038	DS			
	12042489	May 30, 2038	DS U-2371			
	12042490	May 30, 2038	U-2371			
	12109205	May 30, 2038	DS U-2371			
	RE48608	Oct 20, 2031	U-2371			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MINOCYCLINE HYDROCHLORIDE - MINOCIN</u>						
N 050444 001	11944634	Oct 16, 2032	DP			
<u>MINOCYCLINE HYDROCHLORIDE - ZILXI</u>						
N 213690 001	>A> 12138311	Oct 01, 2030	U-1631			
<u>MINOCYCLINE HYDROCHLORIDE - EMROSI</u>						
N 219015 001	>A> 10905664	Jan 07, 2039	U-4043			
	>A> 11191740	Jan 07, 2039	U-4043			
	>A> 11364212	Jan 07, 2039	U-4043			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	12059409	Sep 28, 2029	DP			
	12097189	Sep 28, 2029	U-2996			
	12097189	Sep 28, 2029	U-3670			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	12059409	Sep 28, 2029	DP			
	12097189	Sep 28, 2029	U-2996			
	12097189	Sep 28, 2029	U-3670			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 001	11878049	Jul 31, 2041	U-3782			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 002	11878049	Jul 31, 2041	U-3782			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 003	11878049	Jul 31, 2041	U-3782			
<u>MOMELOTINIB DIHYDROCHLORIDE - OJJAARA</u>						
N 216873 001	11963962	Dec 02, 2040	U-3928			
<u>MOMELOTINIB DIHYDROCHLORIDE - OJJAARA</u>						
N 216873 002	11963962	Dec 02, 2040	U-3928			
<u>MOMELOTINIB DIHYDROCHLORIDE - OJJAARA</u>						
N 216873 003	11963962	Dec 02, 2040	U-3928			
<u>MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE - RYALTRIS</u>						
N 211746 001	12064442	Sep 04, 2034	U-3297			
<u>MONOMETHYL FUMARATE - BAFIERTAM</u>						
N 210296 001	11903918	Feb 27, 2035	U-1384			
<u>MYCOPHENOLATE MOFETIL - MYHIBBIN</u>						
N 216482 001	11931455	Aug 16, 2039	DP U-1752			
	12097284	Aug 16, 2039	DP			
	12097285	Aug 16, 2039	DP U-1752			
<u>NALBUPHINE HYDROCHLORIDE - NALBUPHINE HYDROCHLORIDE</u>						
A 216049 001					CGT	Mar 30, 2025
<u>NALBUPHINE HYDROCHLORIDE - NALBUPHINE HYDROCHLORIDE</u>						
A 216049 002					CGT	Mar 30, 2025
<u>NALBUPHINE HYDROCHLORIDE - NALBUPHINE HYDROCHLORIDE</u>						
A 216050 001					CGT	Mar 24, 2025
<u>NALBUPHINE HYDROCHLORIDE - NALBUPHINE HYDROCHLORIDE</u>						
A 216050 002					CGT	Mar 24, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALMEFENE HYDROCHLORIDE - ZURNAI (AUTOINJECTOR)</u>						
N 218590 001	10279131	Jul 31, 2031	DP		NP	Aug 07, 2027
	10357609	Aug 21, 2031	DP			
	10478560	Jan 24, 2026	DP			
	10881798	Feb 11, 2034	DP			
	10905827	Aug 21, 2031	DP			
	11185642	Aug 28, 2031	DP			
	11191908	Oct 18, 2035	DP			
	11446440	Aug 21, 2031	DP			
	11446441	Jan 24, 2026	DP			
	11813435	Feb 25, 2035	DP			
	11857547	Nov 05, 2039	DP			
	11865112	Nov 05, 2039	DP	U-3630		
	8021335	Oct 04, 2026	DP			
	8496619	Aug 21, 2031	DP			
	8562564	Jan 24, 2026	DP			
	9180259	Jan 24, 2026	DP			
	9364610	Aug 21, 2031	DP			
	9364611	Aug 21, 2031	DP			
	9446195	Aug 21, 2031	DP			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
<u>NALOXONE HYDROCHLORIDE - KLOXXADO</u>						
N 212045 001	>A> 11975096	Aug 26, 2034	DP		NP	Apr 29, 2024
<u>NALOXONE HYDROCHLORIDE - REZENOPY</u>						
N 215487 001					NP	Apr 19, 2027
<u>NALOXONE HYDROCHLORIDE - RIVIVE</u>						
N 217722 001	11806428	May 11, 2032	DP			
<u>NETARSUDIL MESYLATE - RHOPRESSA</u>						
N 208254 001	11020385	Mar 14, 2034		U-1524		
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	12042494	Nov 18, 2030	DP	U-3522		
<u>NICARDIPINE HYDROCHLORIDE - NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE</u>						
A 215592 001					>A> CGT	May 21, 2025
<u>NICARDIPINE HYDROCHLORIDE - NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE</u>						
A 215592 002					>A> CGT	May 21, 2025
<u>NILOTINIB TARTRATE - DANZITEN</u>						
N 219293 001	>A> 10874671	Feb 18, 2040	DP			
	>A> 11793809	Feb 18, 2040	DP			
<u>NILOTINIB TARTRATE - DANZITEN</u>						
N 219293 002	>A> 10874671	Feb 18, 2040	DP			
	>A> 11793809	Feb 18, 2040	DP			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 001	11872211	May 19, 2043		U-3754	NCE	Nov 27, 2028
	11884634	Aug 09, 2039	DP		ODE-452	Nov 27, 2030
	11884635	Aug 09, 2039	DP			
	11905255	Aug 09, 2039	DP			
	11925619	May 19, 2043		U-3754		
	11925620	May 19, 2043		U-3754		
	11938116	May 19, 2043		U-3754		
	11951096	May 19, 2043		U-3754		
	11957662	May 19, 2043		U-3754		
	12011434	May 19, 2043		U-3754		
	12011435	May 19, 2043		U-3754		
	12036207	May 19, 2043		U-3754		
	12110277	Jul 08, 2042	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 001	12116347	Aug 09, 2039	DP			
>A>	12138246	May 19, 2043	U-3754			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 002	10590087	Aug 09, 2039	DS		NCE	Nov 27, 2028
	10710966	Aug 09, 2039	DS	U-3754	ODE*	Nov 27, 2030
	10941118	Aug 09, 2039	DS	U-3754		
	11504354	Jul 08, 2042	DP			
	11612588	Jul 08, 2042	DP	U-3754		
	11807611	Sep 08, 2042	DP	U-3754		
	11820748	Aug 09, 2039	DP			
	11844780	Sep 08, 2042	DP	U-3754		
	11845732	Aug 09, 2039	DS	U-3754		
	11872211	May 19, 2043		U-3754		
	11884634	Aug 09, 2039	DP			
	11884635	Aug 09, 2039	DP			
	11905255	Aug 09, 2039	DP			
	11925619	May 19, 2043		U-3754		
	11925620	May 19, 2043		U-3754		
	11938116	May 19, 2043		U-3754		
	11951096	May 19, 2043		U-3754		
	11957662	May 19, 2043		U-3754		
	12011434	May 19, 2043		U-3754		
	12011435	May 19, 2043		U-3754		
	12036207	May 19, 2043		U-3754		
	12110277	Jul 08, 2042	DP			
	12116347	Aug 09, 2039	DP			
>A>	12138246	May 19, 2043	U-3754			
	7342118	Aug 18, 2025	DS			
	7795447	Aug 18, 2025	DS			
	7951958	Mar 11, 2025	DS			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 003	10590087	Aug 09, 2039	DS		NCE	Nov 27, 2028
	10710966	Aug 09, 2039	DS	U-3754	ODE*	Nov 27, 2030
	10941118	Aug 09, 2039	DS	U-3754		
	11504354	Jul 08, 2042	DP			
	11612588	Jul 08, 2042	DP	U-3754		
	11807611	Sep 08, 2042	DP	U-3754		
	11820748	Aug 09, 2039	DP			
	11844780	Sep 08, 2042	DP	U-3754		
	11845732	Aug 09, 2039	DS	U-3754		
	11872211	May 19, 2043		U-3754		
	11884634	Aug 09, 2039	DP			
	11884635	Aug 09, 2039	DP			
	11905255	Aug 09, 2039	DP			
	11925619	May 19, 2043		U-3754		
	11925620	May 19, 2043		U-3754		
	11938116	May 19, 2043		U-3754		
	11951096	May 19, 2043		U-3754		
	11957662	May 19, 2043		U-3754		
	12011434	May 19, 2043		U-3754		
	12011435	May 19, 2043		U-3754		
	12036207	May 19, 2043		U-3754		
	12110277	Jul 08, 2042	DP			
	12116347	Aug 09, 2039	DP			
>A>	12138246	May 19, 2043	U-3754			
	7342118	Aug 18, 2025	DS			
	7795447	Aug 18, 2025	DS			
	7951958	Mar 11, 2025	DS			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	11931377	Jun 03, 2029	DS DP	U-3903		
	11931377*PED	Dec 03, 2029				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 004	11931377	Jun 03, 2029	DS DP U-3903			
<u>NITROGLYCERIN - NITROGLYCERIN</u>						
A 216103 001					CGT	Aug 21, 2024
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE</u>						
N 214313 001	12097170	Mar 08, 2041	DP U-3995			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE</u>						
N 214313 002	12097170	Mar 08, 2041	DP U-3995			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE</u>						
N 214313 003	12097170	Mar 08, 2041	DP U-3995			
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 001	12013403	Mar 04, 2036	U-1941			
	12013403	Mar 04, 2036	U-1942			
	12013403	Mar 04, 2036	U-1943			
	12013403	Mar 04, 2036	U-1944			
	12013403	Mar 04, 2036	U-2093			
	12013403	Mar 04, 2036	U-2094			
	8361977	Dec 23, 2030	DS DP			
<u>OCTREOTIDE ACETATE - MYCAPSSA</u>						
N 208232 001	11857595	Feb 03, 2036	U-3784		ODE-474	Jun 26, 2027
	11890316	Dec 28, 2040	U-3232			
	11969471	Sep 17, 2029	DP			
	11986529	Sep 17, 2029	U-2857			
<u>OCTREOTIDE ACETATE - BYNFEZIA PEN</u>						
N 213224 001	10342850	May 15, 2038	DP			
	11052196	Nov 03, 2040	U-4007			
	11052196	Nov 03, 2040	U-4008			
	11052196	Nov 03, 2040	U-4009			
	11246991	Nov 03, 2040	U-4007			
	11246991	Nov 03, 2040	U-4008			
	11246991	Nov 03, 2040	U-4009			
	11534553	Nov 03, 2040	U-4007			
	11534553	Nov 03, 2040	U-4008			
	11534553	Nov 03, 2040	U-4009			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 001	12091394	Jun 20, 2039	DS			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 002	12091394	Jun 20, 2039	DS			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 003	12091394	Jun 20, 2039	DS			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 004	12091394	Jun 20, 2039	DS			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 001	11951111	Nov 12, 2041	U-3886			
	11951111	Nov 12, 2041	U-3887			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 002	11951111	Nov 12, 2041	U-3886			
	11951111	Nov 12, 2041	U-3887			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 003	11951111	Nov 12, 2041	U-3886			
	11951111	Nov 12, 2041	U-3887			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 004	11951111	Nov 12, 2041	U-3886			
	11951111	Nov 12, 2041	U-3887			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	11970530	Oct 25, 2041	U-3929			
	11970530	Oct 25, 2041	U-3930			
	11970530	Oct 25, 2041	U-3931			
	11975001	Oct 07, 2029	DP			
	12048695	Oct 07, 2029	DP			
>A>	12144810	Oct 07, 2029	DP			
	7449464	Sep 08, 2027	DS DP			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	11970530	Oct 25, 2041	U-3929			
	11970530	Oct 25, 2041	U-3930			
	11970530	Oct 25, 2041	U-3931			
	11975001	Oct 07, 2029	DP			
	12048695	Oct 07, 2029	DP			
>A>	12144810	Oct 07, 2029	DP			
	7449464	Sep 08, 2027	DS DP			
<u>OLICERIDINE - OLINVYK</u>						
N 210730 001	11931350	Mar 23, 2032	DS U-2986			
<u>OLICERIDINE - OLINVYK</u>						
N 210730 002	11931350	Mar 23, 2032	DS U-2986			
<u>OLICERIDINE - OLINVYK</u>						
N 210730 003	11931350	Mar 23, 2032	DS U-2986			
<u>OLIVE OIL; SOYBEAN OIL - CLINOLIPID 20%</u>						
N 204508 001					NPP	Apr 24, 2027
<u>OLUTASIDENIB - REZLIDHIA</u>						
N 215814 001	12053463	May 16, 2039	DS DP			
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209816 001	7553828	Jun 02, 2025	DS			
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209817 001	7553828	Jun 02, 2025	DS			
<u>OMAVELOXOLONE - SKYCLARYS</u>						
N 216718 001	11919838	Apr 20, 2029	U-3862			
	11919838	Apr 20, 2029	U-3863			
<u>OMEPRAZOLE; SODIUM BICARBONATE - KONVOMEF</u>						
N 213593 001	11911473	Jul 16, 2039	U-623			
	11911473	Jul 16, 2039	U-624			
	12042539	Jul 16, 2039	DP			
<u>OPICAPONE - ONGENTYS</u>						
N 212489 001	10583130	Mar 31, 2030	U-3869			
>A>	12129247	Jan 11, 2032	U-4038			
	8168793	Apr 02, 2029	DS DP U-3869			
	8524746	Jul 14, 2029	U-3869			
	9550759	Jul 26, 2026	U-3870			
	9550759	Jul 26, 2026	U-3871			
	9550759	Jul 26, 2026	U-3872			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OPICAPONE - ONGENTYS</u>						
N 212489 001	9630955	Dec 12, 2032	DS DP U-3869			
	9745290	Oct 10, 2027	DP U-3869			
<u>OPICAPONE - ONGENTYS</u>						
N 212489 002	10583130	Mar 31, 2030	U-3869			
	>A> 12129247	Jan 11, 2032	U-4038			
	8168793	Apr 02, 2029	DS DP U-3869			
	8524746	Jul 14, 2029	U-3869			
	9550759	Jul 26, 2026	U-3870			
	9550759	Jul 26, 2026	U-3871			
	9550759	Jul 26, 2026	U-3872			
	9630955	Dec 12, 2032	DS DP U-3869			
	9745290	Oct 10, 2027	DP U-3869			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	10183020	Jan 02, 2035	DP U-1777		I-941	Feb 16, 2027
	10183020	Jan 02, 2035	DP U-2289		>A> I-952	Sep 25, 2027
	10183020	Jan 02, 2035	DP U-3016			
	10183020	Jan 02, 2035	DP U-3823			
	10183020	Jan 02, 2035	DP U-4010			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	8946235	Aug 08, 2032	DS DP U-3823			
	8946235	Aug 08, 2032	DS DP U-4010			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-3823			
	9732058	Jul 25, 2032	DS DP U-4010			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	10183020	Jan 02, 2035	DP U-1777		I-941	Feb 16, 2027
	10183020	Jan 02, 2035	DP U-2289		>A> I-952	Sep 25, 2027
	10183020	Jan 02, 2035	DP U-3016			
	10183020	Jan 02, 2035	DP U-3823			
	10183020	Jan 02, 2035	DP U-4010			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	8946235	Aug 08, 2032	DS DP U-3823			
	8946235	Aug 08, 2032	DS DP U-4010			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-3823			
	9732058	Jul 25, 2032	DS DP U-4010			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	11896599	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	11896599	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	11896599	Apr 13, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	11964056	Aug 24, 2027	DP			
	12060361	Mar 30, 2025	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	11964056	Aug 24, 2027	DP			
	12060361	Mar 30, 2025	DP U-1556			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	11964056	Aug 24, 2027	DP			
	12060361	Mar 30, 2025	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	11964056	Aug 24, 2027	DP			
	12060361	Mar 30, 2025	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	11964056	Aug 24, 2027	DP			
	12060361	Mar 30, 2025	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	11964056	Aug 24, 2027	DP			
	12060361	Mar 30, 2025	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	11964056	Aug 24, 2027	DP			
	12060361	Mar 30, 2025	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 200534 001					M-14	Jul 21, 2024
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 200535 001					M-14	Jul 21, 2024
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 200535 002					M-14	Jul 21, 2024
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 201194 001					M-14	Jul 21, 2024
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 004	10314788	Aug 12, 2028	DP			
	7955619	Aug 12, 2028	DP			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 001	10239846	Nov 15, 2030	U-3740		M-309	Aug 30, 2027
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 002	10239846	Nov 15, 2030	U-3740		M-309	Aug 30, 2027
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 003	10239846	Nov 15, 2030	U-3740		M-309	Aug 30, 2027
<u>PALIPERIDONE PALMITATE - ERZOFRI</u>						
N 216352 001	11666573	Sep 24, 2039	U-3968			
	11666573	Sep 24, 2039	U-3969			
	12128049	Oct 26, 2038	U-3968			
	12128049	Oct 26, 2038	U-3969			
<u>PALIPERIDONE PALMITATE - ERZOFRI</u>						
N 216352 002	11666573	Sep 24, 2039	U-3968			
	11666573	Sep 24, 2039	U-3969			
	12128049	Oct 26, 2038	U-3968			
	12128049	Oct 26, 2038	U-3969			
<u>PALIPERIDONE PALMITATE - ERZOFRI</u>						
N 216352 003	11666573	Sep 24, 2039	U-3968			
	11666573	Sep 24, 2039	U-3969			
	12128049	Oct 26, 2038	U-3968			
	12128049	Oct 26, 2038	U-3969			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALIPERIDONE PALMITATE - ERZOFRI</u>						
N 216352 004	11666573	Sep 24, 2039	U-3968			
	11666573	Sep 24, 2039	U-3969			
	12128049	Oct 26, 2038	U-3968			
	12128049	Oct 26, 2038	U-3969			
<u>PALIPERIDONE PALMITATE - ERZOFRI</u>						
N 216352 005	11666573	Sep 24, 2039	U-3968			
	11666573	Sep 24, 2039	U-3969			
	12128049	Oct 26, 2038	U-3968			
	12128049	Oct 26, 2038	U-3969			
<u>PALIPERIDONE PALMITATE - ERZOFRI</u>						
N 216352 006	11666573	Sep 24, 2039	U-3968			
	11666573	Sep 24, 2039	U-3969			
	12128049	Oct 26, 2038	U-3968			
	12128049	Oct 26, 2038	U-3969			
<u>PALOPEGTERIPARATIDE - YORVIPATH</u>						
N 216490 001	11590207	Sep 28, 2037	U-3982		NP	Aug 09, 2027
	11759504	Sep 28, 2037	DP		ODE-492	Aug 09, 2031
	11857603	Sep 28, 2037	U-3982			
	11890326	Sep 28, 2037	DS DP			
	11918628	Sep 28, 2037	DS DP			
	8906847	Apr 30, 2031	DS DP U-3982			
<u>PALOPEGTERIPARATIDE - YORVIPATH</u>						
N 216490 002	11590207	Sep 28, 2037	U-3982		NP	Aug 09, 2027
	11759504	Sep 28, 2037	DP		ODE-492	Aug 09, 2031
	11857603	Sep 28, 2037	U-3982			
	11890326	Sep 28, 2037	DS DP			
	11918628	Sep 28, 2037	DS DP			
	8906847	Apr 30, 2031	DS DP U-3982			
<u>PALOPEGTERIPARATIDE - YORVIPATH</u>						
N 216490 003	11590207	Sep 28, 2037	U-3982		NP	Aug 09, 2027
	11759504	Sep 28, 2037	DP		ODE-492	Aug 09, 2031
	11857603	Sep 28, 2037	U-3982			
	11890326	Sep 28, 2037	DS DP			
	11918628	Sep 28, 2037	DS DP			
	8906847	Apr 30, 2031	DS DP U-3982			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 001	12023312	Aug 31, 2031	U-3966			
>A>	12138245	Jun 08, 2037	U-4031			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 002	12023312	Aug 31, 2031	U-3966			
>A>	12138245	Jun 08, 2037	U-4031			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 003	12023312	Aug 31, 2031	U-3966			
>A>	12138245	Jun 08, 2037	U-4031			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 004	12023312	Aug 31, 2031	U-3966			
>A>	12138245	Jun 08, 2037	U-4031			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 005	12023312	Aug 31, 2031	U-3966			
>A>	12138245	Jun 08, 2037	U-4031			
<u>PANTOPRAZOLE SODIUM - PROTONIX IV</u>						
N 020988 001					NPP	Aug 12, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PATISIRAN SODIUM - ONPATTRO</u>						
N 210922 001					M-270	Jan 13, 2026
<u>PEGCETACOPLAN - EMPAVELI</u>						
N 215014 001	11844841	Dec 09, 2038	DP U-3172			
	11844841	Dec 09, 2038	DP U-3173			
	11844841	Dec 09, 2038	DP U-3174			
<u>PEGCETACOPLAN - SYFOVRE</u>						
N 217171 001	11903994	Feb 22, 2037	U-3826			
	11903994	Feb 22, 2037	U-3827			
	11903994	Feb 22, 2037	U-3828			
<u>PEGULICIANINE ACETATE - LUMISIGHT</u>						
N 214511 001	10285759	Dec 08, 2031	U-3890		NCE	Apr 17, 2029
	9032965	Dec 08, 2031	U-3890			
	9155471	Oct 12, 2031	U-3890			
	9532835	Dec 08, 2031	U-3890			
	9763577	Sep 14, 2034	DS DP U-3890			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	11857646	Mar 16, 2037	U-665			
	11925695	Mar 16, 2037	U-665			
<u>PERFLUTREN - DEFINITY RT</u>						
N 021064 002	11857646	Mar 16, 2037	U-665			
	11925695	Mar 16, 2037	U-665			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580 001					M-308	Sep 13, 2027
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580 002					M-308	Sep 13, 2027
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580 003					M-308	Sep 13, 2027
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580 004					M-308	Sep 13, 2027
<u>PHENTOLAMINE MESYLATE - RYZUMVI</u>						
N 217064 001	10278918	Jan 31, 2034	DP			
	10772829	Jan 31, 2034	DP			
	11090261	Jan 31, 2034	DP			
	11400077	Oct 25, 2039	U-3804			
	11844858	Jan 31, 2034	DP			
	9795560	Jan 31, 2034	DP			
<u>PHENYLEPHRINE HYDROCHLORIDE; TROPICAMIDE - MYDCOMBI</u>						
N 215352 001	11839487	Jul 15, 2031	U-3685			
<u>PIFLUFOLASTAT F-18 - PYLARIFY</u>						
N 214793 001	11851407	Jun 09, 2037	DS DP U-3130			
<u>PILOCARPINE HYDROCHLORIDE - OLOSI</u>						
N 217836 001	11974986	Aug 18, 2037	U-3741			
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 001	12109193	Sep 14, 2041	DP		ODE-451	Dec 01, 2030
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 002	12109193	Sep 14, 2041	DP		ODE-451	Dec 01, 2030
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 001					NPP ODE-489	Jun 21, 2027 Jun 21, 2031
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 002					NPP ODE-489	Jun 21, 2027 Jun 21, 2031
<u>PLECANATIDE - TRULANCE</u>						
N 208745 001	>A> 12146003	Jun 05, 2034	DP			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001					I-934 ODE-472	Mar 19, 2027 Mar 19, 2031

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002					I-934 ODE-472	Mar 19, 2027 Mar 19, 2031
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003					I-934 ODE-472	Mar 19, 2027 Mar 19, 2031
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 004					I-934 ODE-472	Mar 19, 2027 Mar 19, 2031
<u>PONESIMOD - PONVORY</u>						
N 213498 001	11951097 RE43728	Oct 10, 2042 Nov 16, 2025	U-3891 DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 002	11951097 RE43728	Oct 10, 2042 Nov 16, 2025	U-3891 DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 003	11951097 RE43728	Oct 10, 2042 Nov 16, 2025	U-3891 DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 004	11951097 RE43728	Oct 10, 2042 Nov 16, 2025	U-3891 DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 005	11951097 RE43728	Oct 10, 2042 Nov 16, 2025	U-3891 DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 006	11951097 >A> RE43728	Oct 10, 2042 Nov 16, 2025	U-3891 DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 007	11951097 >A> RE43728	Oct 10, 2042 Nov 16, 2025	U-3891 DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 008	11951097 >A> RE43728	Oct 10, 2042 Nov 16, 2025	U-3891 DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 009	11951097 >A> RE43728	Oct 10, 2042 Nov 16, 2025	U-3891 DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 010	11951097 >A> RE43728	Oct 10, 2042 Nov 16, 2025	U-3891 DS DP			
<u>PRALSETINIB - GAVRETO</u>						
N 213721 001	11872192 11963958	Apr 03, 2039 Apr 03, 2039	U-2952 U-2828			
<u>PREDNISOLONE ACETATE - PREDNISOLONE ACETATE</u>						
A 216935 001					CGT	Apr 09, 2025
<u>PROBENECID; SULOPENEM ETZADROXIL - ORLYNVAH</u>						
N 213972 001	>A> 11478428	Dec 23, 2039	DP U-4026		>A> NCE	Oct 25, 2029
	>A> 11554112	Apr 01, 2039	U-4026		>A> GAIN	Oct 25, 2034
	>A> 12109197	Apr 01, 2039	U-4026			
	>A> 7795243	Jun 03, 2029	DS DP U-4026			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PROBENECID; SULOPENEM ETZADROXIL - ORLYNVAH</u>						
N 213972 001	>A> 11478428	Dec 23, 2039	DP U-4026		>A> NCE	Oct 25, 2029
	>A> 11554112	Apr 01, 2039	U-4026		>A> GAIN	Oct 25, 2034
	>A> 12109197	Apr 01, 2039	U-4026			
	>A> 7795243	Jun 03, 2029	DS DP U-4026			
<u>PYRIDOSTIGMINE BROMIDE - PYRIDOSTIGMINE BROMIDE</u>						
N 217604 001	10881617	Jun 18, 2038	DP			
	10925833	Jun 18, 2038	DP			
	10987311	Jun 18, 2038	DP			
	11229606	Jun 18, 2038	DP			
	11478425	Jun 18, 2038	DP U-4012			
	11666536	Jun 18, 2038	DP			
	11911515	Jun 18, 2038	DP			
	12042559	Jun 18, 2038	DP			
<u>RELUGOLIX - ORGOVYX</u>						
N 214621 001	12097198	Sep 29, 2037	U-3020			
	>A> 12144809	Sep 29, 2037	U-4035			
<u>REMDESIVIR - VEKLURY</u>						
N 214787 001	10065958	Sep 16, 2031	DS		D-183	Jan 21, 2025
	10065958*PED	Mar 16, 2032			M-301	Jul 13, 2026
	10675296	Jul 10, 2038	DP		NCE	Oct 22, 2025
	10675296*PED	Jan 10, 2039			NPP	Apr 25, 2025
	10695361	Sep 16, 2036	U-3831		PED	Jul 21, 2025
	10695361	Sep 16, 2036	U-3832		PED	Oct 25, 2025
	10695361*PED	Mar 16, 2037			PED	Apr 22, 2026
	11007208	Sep 16, 2036	U-3831		PED	Jan 13, 2027
	11007208	Sep 16, 2036	U-3832			
	11007208*PED	Mar 16, 2037				
	11266681	Jul 10, 2038	U-3831			
	11266681	Jul 10, 2038	U-3832			
	11266681*PED	Jan 10, 2039				
	11382926	Sep 16, 2036	U-3831			
	11382926	Sep 16, 2036	U-3832			
	11382926*PED	Mar 16, 2037				
	11491169	May 28, 2041	U-3835			
	11491169	May 28, 2041	U-3836			
	11491169*PED	Nov 28, 2041				
	11492353	Dec 08, 2031	DS			
	11492353*PED	Jun 08, 2032				
	11903953	May 28, 2041	U-3835			
	11903953	May 28, 2041	U-3836			
	11903953*PED	Nov 28, 2041				
	11975012	May 28, 2041	U-3835			
	11975012	May 28, 2041	U-3836			
	11975012*PED	Nov 28, 2041				
	11975017	Jul 10, 2038	DP			
	11975017*PED	Jan 10, 2039				
	8008264	Sep 06, 2029	DS DP			
	8008264*PED	Mar 06, 2030				
	8318682	Apr 22, 2029	DS DP			
	8318682*PED	Oct 22, 2029				
	9724360	Oct 29, 2035	DS DP			
	9724360*PED	Apr 29, 2036				
	9949994	Oct 29, 2035	DS			
	9949994*PED	Apr 29, 2036				
	RE46762	Apr 22, 2029	DS DP			
	RE46762*PED	Oct 22, 2029				
<u>REMDESIVIR - VEKLURY</u>						
N 214787 002	10065958	Sep 16, 2031	DS		D-183	Jan 21, 2025
	10065958*PED	Mar 16, 2032			M-301	Jul 13, 2026
	10695361	Sep 16, 2036	U-3829		NCE	Oct 22, 2025
	10695361	Sep 16, 2036	U-3830		NPP	Apr 25, 2025
	10695361*PED	Mar 16, 2037			PED	Jul 21, 2025
	11007208	Sep 16, 2036	U-3829		PED	Oct 25, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>REMDESIVIR - VEKLURY</u>						
N 214787 002	11007208	Sep 16, 2036	U-3830		PED	Apr 22, 2026
	11007208*PED	Mar 16, 2037			PED	Jan 13, 2027
	11382926	Sep 16, 2036	U-3829			
	11382926	Sep 16, 2036	U-3830			
	11382926*PED	Mar 16, 2037				
	11491169	May 28, 2041	U-3833			
	11491169	May 28, 2041	U-3834			
	11491169*PED	Nov 28, 2041				
	11492353	Dec 08, 2031	DS			
	11492353*PED	Jun 08, 2032				
	11903953	May 28, 2041	U-3833			
	11903953	May 28, 2041	U-3834			
	11903953*PED	Nov 28, 2041				
	11975012	May 28, 2041	U-3833			
	11975012	May 28, 2041	U-3834			
	11975012*PED	Nov 28, 2041				
	8008264	Sep 06, 2029	DS DP			
	8008264*PED	Mar 06, 2030				
	8318682	Apr 22, 2029	DS DP			
	8318682*PED	Oct 22, 2029				
	9724360	Oct 29, 2035	DS DP			
	9724360*PED	Apr 29, 2036				
	9949994	Oct 29, 2035	DS			
	9949994*PED	Apr 29, 2036				
	RE46762	Apr 22, 2029	DS DP			
	RE46762*PED	Oct 22, 2029				
<u>REMIMAZOLAM BESYLATE - BYFAVO</u>						
N 212295 001	9827251	Jan 13, 2034	U-2968			
<u>REPOTRECTINIB - AUGTYRO</u>						
N 218213 001	11452725	Jul 24, 2036	U-3755		NCE	Nov 15, 2028
	11452725	Jul 24, 2036	U-3961		ODE-455	Nov 15, 2030
					ODE-483	Jun 13, 2031
					ODE-488	Jun 13, 2031
<u>REPOTRECTINIB - AUGTYRO</u>						
N 218213 002	10294242	Jul 05, 2036	DS		NCE	Nov 15, 2028
	11452725	Jul 24, 2036	U-3755		ODE*	Nov 15, 2030
	11452725	Jul 24, 2036	U-3961		ODE-488	Jun 13, 2031
	9714258	Jan 23, 2035	DS DP			
<u>RESMETIROM - REZDIFFRA</u>						
N 217785 001	10376517	Sep 17, 2033	U-3861		NCE	Mar 14, 2029
	11564926	Sep 17, 2033	DS DP U-3861			
	11986481	Sep 17, 2033	U-3861			
	7452882	Sep 12, 2026	DS DP			
	9266861	Sep 17, 2033	DS DP			
<u>RESMETIROM - REZDIFFRA</u>						
N 217785 002	10376517	Sep 17, 2033	U-3861		NCE	Mar 14, 2029
	11564926	Sep 17, 2033	DS DP U-3861			
	11986481	Sep 17, 2033	U-3861			
	7452882	Sep 12, 2026	DS DP			
	9266861	Sep 17, 2033	DS DP			
<u>RESMETIROM - REZDIFFRA</u>						
N 217785 003	10376517	Sep 17, 2033	U-3861		NCE	Mar 14, 2029
	11564926	Sep 17, 2033	DS DP U-3861			
	11986481	Sep 17, 2033	U-3861			
	7452882	Sep 12, 2026	DS DP			
	9266861	Sep 17, 2033	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	12048692	Aug 29, 2039	U-2440			
	7288657	Oct 31, 2028	DS			
<u>REVUMENIB CITRATE - REVUFORJ</u>						
N 218944 001					>A> NCE	Nov 15, 2029
<u>REVUMENIB CITRATE - REVUFORJ</u>						
N 218944 002					>A> NCE	Nov 15, 2029
<u>REVUMENIB CITRATE - REVUFORJ</u>						
N 218944 003					>A> NCE	Nov 15, 2029
<u>RIBOCICLIB SUCCINATE - KISOALI</u>						
N 209092 001	12064434	Apr 14, 2036	DP		I-950	Sep 17, 2027
	8962630	Dec 09, 2029	U-1981			
	8962630	Dec 09, 2029	U-2355			
	8962630	Dec 09, 2029	U-2356			
	8962630	Dec 09, 2029	U-3265			
	8962630	Dec 09, 2029	U-3266			
	8962630	Dec 09, 2029	U-3975			
	8962630	Dec 09, 2029	U-3999			
	9416136	Aug 20, 2029	U-1981			
	9416136	Aug 20, 2029	U-2355			
	9416136	Aug 20, 2029	U-2356			
	9416136	Aug 20, 2029	U-3265			
	9416136	Aug 20, 2029	U-3266			
	9416136	Aug 20, 2029	U-3975			
	9416136	Aug 20, 2029	U-3999			
	9868739	Nov 09, 2031	U-1981			
	9868739	Nov 09, 2031	U-2355			
	9868739	Nov 09, 2031	U-2356			
	9868739	Nov 09, 2031	U-3265			
	9868739	Nov 09, 2031	U-3266			
	9868739	Nov 09, 2031	U-3975			
	9868739	Nov 09, 2031	U-3999			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	7125879	Apr 21, 2025	DS DP U-1153			
	7125879	Apr 21, 2025	DS DP U-1307			
	7125879	Apr 21, 2025	DS DP U-1740			
	7125879	Apr 21, 2025	DS DP U-3353			
	7125879	Apr 21, 2025	DS DP U-3874			
	7125879*PED	Oct 21, 2025				
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT PED</u>						
N 219016 001	11065198	Oct 23, 2037	DP			
	7125879	Apr 21, 2025	DS DP U-3874			
<u>RIPRETINIB - QINLOCK</u>						
N 213973 001	11896585	Dec 30, 2040	DP			
	11903933	Dec 30, 2040	DP			
	11911370	Dec 30, 2040	DP			
	11918564	Dec 30, 2040	DP			
	11969414	Feb 08, 2041	U-3897			
	11969415	Dec 30, 2040	U-3219			
	12023325	Aug 12, 2040	U-3960			
	12023326	Aug 12, 2040	U-3959			
	12023327	Aug 12, 2040	U-3958			
	12023328	Dec 30, 2040	U-3957			
	12059410	Aug 12, 2040	U-3153			
	12059411	Aug 12, 2040	U-3971			
	12064422	Dec 30, 2040	U-3219			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RISDIPLAM - EVRYSDI</u>						
N 213535 001	11938136	Nov 08, 2036	DP			
	>A> 12122789	Apr 15, 2041	DS DP			
<u>RISPERIDONE - UZEDY</u>						
N 213586 001	>A> 12128132	Sep 11, 2040	DP U-543			
<u>RISPERIDONE - UZEDY</u>						
N 213586 002	>A> 12128132	Sep 11, 2040	DP U-543			
<u>RISPERIDONE - UZEDY</u>						
N 213586 003	>A> 12128132	Sep 11, 2040	DP U-543			
<u>RISPERIDONE - UZEDY</u>						
N 213586 004	>A> 12128132	Sep 11, 2040	DP U-543			
<u>RISPERIDONE - UZEDY</u>						
N 213586 005	>A> 12128132	Sep 11, 2040	DP U-543			
<u>RISPERIDONE - UZEDY</u>						
N 213586 006	>A> 12128132	Sep 11, 2040	DP U-543			
<u>RISPERIDONE - UZEDY</u>						
N 213586 007	>A> 12128132	Sep 11, 2040	DP U-543			
<u>RISPERIDONE - RISVAN</u>						
N 214835 001	10058504	May 31, 2031	DP		NP	Mar 29, 2027
	10085936	May 31, 2031	DP			
	10182982	May 31, 2031	U-3943			
	10195138	May 31, 2031	U-3943			
	10335366	May 31, 2031	DP			
	10463607	May 31, 2031	DP			
	10881605	May 31, 2031	DP			
	11007139	May 31, 2031	U-3942			
	11173110	May 31, 2031	U-3941			
	11241377	May 31, 2031	U-3939			
	11752092	May 31, 2031	U-3941			
	11752093	May 31, 2031	DP			
	11752094	May 31, 2031	U-3942			
	11759416	May 31, 2031	U-3939			
<u>RISPERIDONE - RISVAN</u>						
N 214835 002	10058504	May 31, 2031	DP		NP	Mar 29, 2027
	10085936	May 31, 2031	DP			
	10182982	May 31, 2031	U-3943			
	10195138	May 31, 2031	U-3943			
	10335366	May 31, 2031	DP			
	10463607	May 31, 2031	DP			
	10881605	May 31, 2031	DP			
	11007139	May 31, 2031	U-3942			
	11173110	May 31, 2031	U-3941			
	11241377	May 31, 2031	U-3939			
	11752092	May 31, 2031	U-3941			
	11752093	May 31, 2031	DP			
	11752094	May 31, 2031	U-3942			
	11759416	May 31, 2031	U-3939			
<u>RITLECITINIB TOSYLATE - LITFULO</u>						
N 215830 001	12077533	Dec 03, 2034	U-3994			
	12116368	Oct 17, 2041	DS			
<u>RIVAROXABAN - XARELTO</u>						
N 215859 001	7157456	Aug 28, 2024	DS DP			
	7157456*PED	Feb 28, 2025				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ROFLUMILAST - ZORYVE</u>						
N 215985 001	11992480	Jun 07, 2037	U-3748			
	12005051	Jun 07, 2037	U-3748			
	12005052	Jun 07, 2037	DP			
	12011437	Jun 07, 2037	DP			
	12016848	Jun 07, 2037	DP			
	12042487	Jun 07, 2037	DP			
<u>ROFLUMILAST - ZORYVE</u>						
N 215985 002	10940142	Jun 07, 2037	DP		NS	Jul 09, 2027
	11129818	Aug 25, 2037	U-3970			
	11793796	Jun 07, 2037	DP			
	11819496	Jun 07, 2037	U-3970			
	11992480	Jun 07, 2037	U-3970			
	12005051	Jun 07, 2037	U-3970			
	12005052	Jun 07, 2037	DP			
	12011437	Jun 07, 2037	DP			
	12016848	Jun 07, 2037	DP			
	12042487	Jun 07, 2037	DP			
	9884050	Jun 07, 2037	DP			
	9907788	Jun 07, 2037	U-3970			
<u>ROFLUMILAST - ZORYVE</u>						
N 217242 001	11992480	Jun 07, 2037	U-3773		NP	Dec 15, 2026
	12005051	Jun 07, 2037	U-3773			
	12005052	Jun 07, 2037	DP			
	12011437	Jun 07, 2037	DP			
	12016848	Jun 07, 2037	DP			
	12042487	Jun 07, 2037	DP			
<u>SACUBITRIL; VALSARTAN - ENTRESTO SPRINKLE</u>						
N 218591 001	10722471	Feb 02, 2037	DP U-3896			
	8101659	Jan 15, 2025	DP			
	8877938	May 27, 2027	DS DP			
	9388134	Nov 08, 2026	U-1723			
<u>SACUBITRIL; VALSARTAN - ENTRESTO SPRINKLE</u>						
N 218591 002	10722471	Feb 02, 2037	DP U-3896			
	8101659	Jan 15, 2025	DP			
	8877938	May 27, 2027	DS DP			
	9388134	Nov 08, 2026	U-1723			
<u>SELADELPAR LYSINE - LIVDELZI</u>						
N 217899 001	10272058	Mar 19, 2035	U-1854		NCE	Aug 14, 2029
	11406611	Mar 19, 2035	U-1854		ODE-486	Aug 14, 2031
	11596614	Mar 19, 2035	U-1854			
	7301050	Aug 02, 2025	DS DP			
	7709682	Sep 13, 2026	DS			
	9486428	Mar 19, 2035	U-1854			
<u>SELENIOS ACID - SELENIOS ACID</u>						
N 209379 001	11998565	Jul 01, 2041	DP			
	>A> 12150957	Jul 01, 2041	U-4039			
<u>SELENIOS ACID - SELENIOS ACID</u>						
N 209379 002	11998565	Jul 01, 2041	DP			
	>A> 12150957	Jul 01, 2041	U-4039			
<u>SELENIOS ACID - SELENIOS ACID</u>						
N 209379 003	11998565	Jul 01, 2041	DP			
	>A> 12150957	Jul 01, 2041	U-4039			
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 001	10137124	Oct 10, 2037	U-3450		NPP	May 29, 2027
	10137124	Oct 10, 2037	U-3949		ODE-484	May 29, 2031
	10137124	Oct 10, 2037	U-3950		ODE-485	May 29, 2031

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 001	10137124	Oct 10, 2037	U-3951		ODE-487	May 29, 2031
	10172851	Oct 10, 2037	U-3450			
	10172851	Oct 10, 2037	U-3949			
	10172851	Oct 10, 2037	U-3950			
	10172851	Oct 10, 2037	U-3951			
	10584124	Oct 10, 2038	DS U-3450			
	10584124	Oct 10, 2038	DS U-3949			
	10584124	Oct 10, 2038	DS U-3950			
	10584124	Oct 10, 2038	DS U-3951			
	10786489	Oct 10, 2038	DP U-3450			
	10786489	Oct 10, 2038	DP U-3949			
	10786489	Oct 10, 2038	DP U-3950			
	10786489	Oct 10, 2038	DP U-3951			
>A>	12138250	Oct 10, 2038	U-3949			
>A>	12138250	Oct 10, 2038	U-3950			
>A>	12138250	Oct 10, 2038	U-3951			
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 002	10137124	Oct 10, 2037	U-3450		NPP	May 29, 2027
	10137124	Oct 10, 2037	U-3949		ODE-484	May 29, 2031
	10137124	Oct 10, 2037	U-3950		ODE-485	May 29, 2031
	10137124	Oct 10, 2037	U-3951		ODE-487	May 29, 2031
	10172851	Oct 10, 2037	U-3450			
	10172851	Oct 10, 2037	U-3949			
	10172851	Oct 10, 2037	U-3950			
	10172851	Oct 10, 2037	U-3951			
	10584124	Oct 10, 2038	DS U-3450			
	10584124	Oct 10, 2038	DS U-3949			
	10584124	Oct 10, 2038	DS U-3950			
	10584124	Oct 10, 2038	DS U-3951			
	10786489	Oct 10, 2038	DP U-3450			
	10786489	Oct 10, 2038	DP U-3949			
	10786489	Oct 10, 2038	DP U-3950			
	10786489	Oct 10, 2038	DP U-3951			
>A>	12138250	Oct 10, 2038	U-3949			
>A>	12138250	Oct 10, 2038	U-3950			
>A>	12138250	Oct 10, 2038	U-3951			
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 001	10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	10137124	Oct 10, 2037	U-3450			
	10137124	Oct 10, 2037	U-3949			
	10137124	Oct 10, 2037	U-3950			
	10137124	Oct 10, 2037	U-3951			
	10172851	Oct 10, 2037	U-3450			
	10172851	Oct 10, 2037	U-3949			
	10172851	Oct 10, 2037	U-3950			
	10172851	Oct 10, 2037	U-3951			
>A>	12138250	Oct 10, 2038	U-3949			
>A>	12138250	Oct 10, 2038	U-3950			
>A>	12138250	Oct 10, 2038	U-3951			
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 002	10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	10137124	Oct 10, 2037	U-3450			
	10137124	Oct 10, 2037	U-3949			
	10137124	Oct 10, 2037	U-3950			
	10137124	Oct 10, 2037	U-3951			
	10172851	Oct 10, 2037	U-3450			
	10172851	Oct 10, 2037	U-3949			
	10172851	Oct 10, 2037	U-3950			
	10172851	Oct 10, 2037	U-3951			
>A>	12138250	Oct 10, 2038	U-3949			
>A>	12138250	Oct 10, 2038	U-3950			
>A>	12138250	Oct 10, 2038	U-3951			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELPERCATINIB - RETEVMQ</u>						
N 218160 003	10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	10137124	Oct 10, 2037	U-3450			
	10137124	Oct 10, 2037	U-3949			
	10137124	Oct 10, 2037	U-3950			
	10137124	Oct 10, 2037	U-3951			
	10172851	Oct 10, 2037	U-3450			
	10172851	Oct 10, 2037	U-3949			
	10172851	Oct 10, 2037	U-3950			
	10172851	Oct 10, 2037	U-3951			
	>A> 12138250	Oct 10, 2038	U-3949			
	>A> 12138250	Oct 10, 2038	U-3950			
	>A> 12138250	Oct 10, 2038	U-3951			
<u>SELPERCATINIB - RETEVMQ</u>						
N 218160 004	10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	10137124	Oct 10, 2037	U-3450			
	10137124	Oct 10, 2037	U-3949			
	10137124	Oct 10, 2037	U-3950			
	10137124	Oct 10, 2037	U-3951			
	10172851	Oct 10, 2037	U-3450			
	10172851	Oct 10, 2037	U-3949			
	10172851	Oct 10, 2037	U-3950			
	10172851	Oct 10, 2037	U-3951			
	>A> 12138250	Oct 10, 2038	U-3949			
	>A> 12138250	Oct 10, 2038	U-3950			
	>A> 12138250	Oct 10, 2038	U-3951			
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 001	7425637	Mar 13, 2025	DS			
	8178693	Mar 13, 2025	DS DP			
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 002	7425637	Mar 13, 2025	DS			
	8178693	Mar 13, 2025	DS DP			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 001					I-935	Mar 08, 2027
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 002					I-935	Mar 08, 2027
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 003					I-935	Mar 08, 2027
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 004					I-935	Mar 08, 2027
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 005	12029779	Oct 10, 2038	U-3162		I-935	Mar 08, 2027
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 021845 001					ODE-469	Jan 31, 2030
<u>SILDENAFIL CITRATE - LIOREV</u>						
N 214952 001	12005062	Dec 24, 2038	DP U-3582			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 001	11944602	Jul 24, 2036	U-3889			
	12071402	Jan 05, 2032	DP			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 002	11944602	Jul 24, 2036	U-3889			
	12071402	Jan 05, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SIPONIMOD - MAYZENT</u>						
N 209884 002	11944602	Jul 24, 2036	U-3889			
	12071402	Jan 05, 2032	DP			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 003	11944602	Jul 24, 2036	U-3889			
	12071402	Jan 05, 2032	DP			
<u>SIROLIMUS - FYARRO</u>						
N 213312 001	12061183	Mar 05, 2036	DP			
	>A> 12133844	Jun 29, 2036	U-4040			
	>A> 12133844	Jun 29, 2036	U-4041			
	>A> 12133844	Jun 29, 2036	U-4042			
<u>SODIUM ACETATE - SODIUM ACETATE</u>						
A 216920 001					CGT	Nov 16, 2024
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	11986446	Mar 15, 2033	U-3324			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 001	11896572	Jul 21, 2037	DP		ODE-494	Oct 16, 2031
	11986451	Jul 21, 2037	U-3934			
	12097175	Jul 21, 2037	DP			
	12097176	Jul 21, 2037	U-4006			
	12109186	Jul 21, 2037	DP			
	12115142	Jul 21, 2037	DP			
	12115143	Jul 21, 2037	DP			
	12115144	Jul 21, 2037	DP			
	12115145	Jul 21, 2037	DP			
	>A> 12128021	Jul 21, 2037	U-4022			
	>A> 12138239	Jul 21, 2037	DP			
	>A> 12144793	Jul 21, 2037	DP			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 002	11896572	Jul 21, 2037	DP		ODE-494	Oct 16, 2031
	11986451	Jul 21, 2037	U-3934			
	12097175	Jul 21, 2037	DP			
	12097176	Jul 21, 2037	U-4006			
	12109186	Jul 21, 2037	DP			
	12115142	Jul 21, 2037	DP			
	12115143	Jul 21, 2037	DP			
	12115144	Jul 21, 2037	DP			
	12115145	Jul 21, 2037	DP			
	>A> 12128021	Jul 21, 2037	U-4022			
	>A> 12138239	Jul 21, 2037	DP			
	>A> 12144793	Jul 21, 2037	DP			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 003	11896572	Jul 21, 2037	DP		ODE-494	Oct 16, 2031
	11986451	Jul 21, 2037	U-3934			
	12097175	Jul 21, 2037	DP			
	12097176	Jul 21, 2037	U-4006			
	12109186	Jul 21, 2037	DP			
	12115142	Jul 21, 2037	DP			
	12115143	Jul 21, 2037	DP			
	12115144	Jul 21, 2037	DP			
	12115145	Jul 21, 2037	DP			
	>A> 12128021	Jul 21, 2037	U-4022			
	>A> 12138239	Jul 21, 2037	DP			
	>A> 12144793	Jul 21, 2037	DP			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 004	11896572	Jul 21, 2037	DP		ODE-494	Oct 16, 2031
	11986451	Jul 21, 2037	U-3934			
	12097175	Jul 21, 2037	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 004	12097176	Jul 21, 2037	U-4006			
	12109186	Jul 21, 2037	DP			
	12115142	Jul 21, 2037	DP			
	12115143	Jul 21, 2037	DP			
	12115144	Jul 21, 2037	DP			
	12115145	Jul 21, 2037	DP			
>A>	12128021	Jul 21, 2037	U-4022			
>A>	12138239	Jul 21, 2037	DP			
>A>	12144793	Jul 21, 2037	DP			
<u>SODIUM THIOSULFATE - PEDMARK</u>						
N 212937 001	11964018	Jul 01, 2039	U-3898			
	11992530	Jul 01, 2039	U-3948			
	11998604	Jul 01, 2039	U-3952			
<u>SOPFIRONIUM BROMIDE - SOFDRA</u>						
N 217347 001	10383846	Mar 14, 2034	U-2398		NCE	Jun 20, 2029
	10947192	May 22, 2034	U-2398			
	10952990	May 22, 2034	U-2398			
	10959983	May 22, 2034	U-2398			
	10961191	May 22, 2034	U-2398			
	11026919	May 22, 2034	DP U-2398			
	11034652	May 22, 2034	DP U-2398			
	11052067	May 22, 2034	DP U-2398			
	11084788	May 22, 2034	DP U-2398			
	11123325	Jul 20, 2037	DP U-2398			
	11566000	May 22, 2040	DS DP			
	11584715	May 22, 2040	DS DP			
	8147809	Mar 26, 2027	DS DP			
	8628759	Nov 13, 2026	U-2398			
	9220707	Mar 14, 2034	U-2398			
	9492429	Mar 14, 2034	DP U-2398			
	9895350	Mar 14, 2034	U-2398			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	11857528	Mar 19, 2040	U-3521			
	11865098	Jun 01, 2038	U-2548			
	11872203	Dec 30, 2042	U-3693			
	11872204	Dec 30, 2042	U-3693			
	11969404	Mar 19, 2040	U-3892			
	11986454	Mar 19, 2040	U-3775			
	11986455	Mar 19, 2040	U-3521			
	11998639	Sep 05, 2037	DP U-2548			
	12005036	Dec 30, 2042	U-3693			
	12036194	Dec 30, 2042	U-3693			
	12064411	Dec 30, 2042	U-3693			
	12090126	Dec 30, 2042	U-3693			
	12102609	Dec 30, 2042	U-3693			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	11857528	Mar 19, 2040	U-3521			
	11865098	Jun 01, 2038	U-2548			
	11872203	Dec 30, 2042	U-3693			
	11872204	Dec 30, 2042	U-3693			
	11969404	Mar 19, 2040	U-3892			
	11986454	Mar 19, 2040	U-3775			
	11986455	Mar 19, 2040	U-3521			
	11998639	Sep 05, 2037	DP U-2548			
	12005036	Dec 30, 2042	U-3693			
	12036194	Dec 30, 2042	U-3693			
	12064411	Dec 30, 2042	U-3693			
	12090126	Dec 30, 2042	U-3693			
	12102609	Dec 30, 2042	U-3693			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 003	10519146	May 21, 2038	DS DP		NCE	May 28, 2026
	11236091	May 20, 2040	DS DP U-3306		ODE*	May 28, 2028
	11426404	Sep 15, 2040	U-3306			
	11827635	May 20, 2040	DS DP U-3306			
<u>SPARSENTAN - FILSPARI</u>						
N 216403 001	9993461	Mar 29, 2030	U-3269		ODE-493	Sep 05, 2031
	9993461	Mar 29, 2030	U-3993			
<u>SPARSENTAN - FILSPARI</u>						
N 216403 002	9993461	Mar 29, 2030	U-3269		ODE-493	Sep 05, 2031
	9993461	Mar 29, 2030	U-3993			
<u>SUFENTANIL CITRATE - DSUVIA</u>						
N 209128 001	12033733	Mar 16, 2030	DP			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 001	>A> RE44733	Jan 27, 2026	DS DP U-1794			
	>A> RE44733*PED	Jul 27, 2026				
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 002	>A> RE44733	Jan 27, 2026	DS DP U-1794			
	>A> RE44733*PED	Jul 27, 2026				
<u>SUMATRIPTAN - TOSYMRA</u>						
N 210884 001	12090139	Jun 16, 2030	DP			
<u>SUMATRIPTAN SUCCINATE - ZEMBRACE SYMTOUCH</u>						
N 208223 001	12097183	Jan 29, 2036	DP			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 001	11980623	May 29, 2033	DP			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 002	11980623	May 29, 2033	DP			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 003	11980623	May 29, 2033	DP			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 004	11980623	May 29, 2033	DP			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 001	12083103	May 30, 2028	U-2678			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 002	12083103	May 30, 2028	U-2678			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 003	12083103	May 30, 2028	U-2678			
<u>TADALAFIL - TADLIQ</u>						
N 214522 001	11975006	Dec 24, 2038	DP U-3397			
<u>TAFAMIDIS - VYNDAMAX</u>						
N 212161 001	7214695	Dec 19, 2025	DS DP			
	7214696	Dec 19, 2025	U-2524			
<u>TAFAMIDIS MEGLUMINE - VYNDAQEL</u>						
N 211996 001	7214695	Dec 19, 2025	DS DP			
	7214696	Dec 19, 2025	U-2524			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TAFAMIDIS MEGLUMINE - VYNDAQEL</u>						
N 211996 001	7214695	Dec 19, 2025	DS DP			
	7214696	Dec 19, 2025	U-2524			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 001	10189837	Oct 20, 2031	DS DP		I-920	Jun 20, 2026
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 002	10189837	Oct 20, 2031	DS DP		I-920	Jun 20, 2026
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 003	10189837	Oct 20, 2031	DS DP			
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 004	10189837	Oct 20, 2031	DS DP		I-920	Jun 20, 2026
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 005	10189837	Oct 20, 2031	DS DP			
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 006	10189837	Oct 20, 2031	DS DP			
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304 001					NPP PED	Jul 03, 2026 Jan 03, 2027
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304 002					NPP PED	Jul 03, 2026 Jan 03, 2027
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304 003					NPP PED	Jul 03, 2026 Jan 03, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 001	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
	11344512*PED	Oct 21, 2028				
	8536130	Sep 22, 2028	U-1276			
	8536130*PED	Mar 22, 2029				
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 002	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
	11344512*PED	Oct 21, 2028				
	8536130	Sep 22, 2028	U-1276			
	8536130*PED	Mar 22, 2029				
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 003	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
	11344512*PED	Oct 21, 2028				
	8536130	Sep 22, 2028	U-1276			
	8536130*PED	Mar 22, 2029				
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 004	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
	11344512*PED	Oct 21, 2028				
	8536130	Sep 22, 2028	U-1276			
	8536130*PED	Mar 22, 2029				
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 005	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
	11344512*PED	Oct 21, 2028				
	8536130	Sep 22, 2028	U-1276			
	8536130*PED	Mar 22, 2029				
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 203794 001					NPP	Jul 03, 2026
					PED	Jan 03, 2027
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	11826339	Jan 25, 2033	U-3342			
	11826339	Jan 25, 2033	U-3343			
	11918556	Apr 07, 2033	U-3342			
	11918556	Apr 07, 2033	U-3343			
	11918557	Jan 25, 2033	U-3003			
	11918557	Jan 25, 2033	U-3865			
	12049457	Feb 12, 2035	DS DP			
<u>TASIMELTEON - HETLIOZ LO</u>						
N 214517 001	11826339	Jan 25, 2033	U-3342			
	11918556	Apr 07, 2033	U-3342			
	11918557	Jan 25, 2033	U-3003			
	12049457	Feb 12, 2035	DS DP			
<u>TAZAROTENE - TAZAROTENE</u>						
A 217075 001					CGT	Mar 08, 2025
<u>TAZAROTENE - ARAZLO</u>						
N 211882 001	>A> 12128137	May 11, 2038	DP U-2368			
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	10155002	Sep 12, 2031	U-2736			
	10420775	Sep 12, 2031	U-2736			
	10420775	Sep 12, 2031	U-2852			
	10420775	Sep 12, 2031	U-2853			
	11052093	Apr 13, 2032	DS DP U-2736			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	11052093	Apr 13, 2032	DS DP U-2852			
	11052093	Apr 13, 2032	DS DP U-2853			
	11491163	Apr 11, 2033	U-2736			
	11491163	Apr 11, 2033	U-2852			
	11491163	Apr 11, 2033	U-2853			
	8765732	Sep 12, 2031	U-2852			
	8765732	Sep 12, 2031	U-2853			
	9090562	Sep 12, 2031	DS DP			
	9549931	Sep 12, 2031	U-2736			
	9549931	Sep 12, 2031	U-2852			
	9549931	Sep 12, 2031	U-2853			
	9855275	Sep 12, 2031	U-2736			
<u>TECOVIRIMAT - TPOXX</u>						
N 208627 001	11890270	Aug 08, 2032	U-2346			
<u>TENAPANOR HYDROCHLORIDE - IBSRELA</u>						
N 211801 001	12016856	Dec 30, 2029	DS DP			
<u>TENAPANOR HYDROCHLORIDE - XPHOZAH</u>						
N 213931 001	12016856	Dec 30, 2029	DS DP			
<u>TENAPANOR HYDROCHLORIDE - XPHOZAH</u>						
N 213931 002	12016856	Dec 30, 2029	DS DP			
<u>TENAPANOR HYDROCHLORIDE - XPHOZAH</u>						
N 213931 003	12016856	Dec 30, 2029	DS DP			
<u>TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY</u>						
N 208464 001	8754065	Aug 15, 2032	DS DP U-1275			
	8754065	Aug 15, 2032	DS DP U-3880			
	8754065	Aug 15, 2032	DS DP U-999			
	8754065*PED	Feb 15, 2033				
	9296769	Aug 15, 2032	DS DP U-1275			
	9296769	Aug 15, 2032	DS DP U-3880			
	9296769	Aug 15, 2032	DS DP U-999			
	9296769*PED	Feb 15, 2033				
<u>TERAZOSIN HYDROCHLORIDE - TEZRULY</u>						
N 218139 001	11224572	Jan 18, 2042	DP U-3990			
	11224572	Jan 18, 2042	DP U-3991			
<u>TESTOSTERONE CYPIONATE - AZMIRO</u>						
N 216318 001	>A> 12138271	Mar 25, 2039	DP			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 001	11844804	Jun 04, 2033	U-2418			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 002	11844804	Jun 04, 2033	U-2418			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 003	11844804	Jun 04, 2033	U-2418			
<u>TESTOSTERONE UNDECANOATE - TLANDO</u>						
N 208088 001	12011503	Oct 16, 2040	DP U-3964			
	12011503	Oct 16, 2040	DP U-3965			
<u>THEOPHYLLINE - THEOPHYLLINE</u>						
A 215312 001				CGT		Mar 26, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>THIOTEPA - TEPYLUTE</u>						
N 216984 001	11975013	Aug 16, 2041	DP			
<u>TIRBANIBULIN - KLISYRI</u>						
N 213189 001					D-192	Jun 07, 2027
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 007	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 008	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 009	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 010	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 011	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 012	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 001	11918623	Jun 14, 2039		U-3855	M-82	Oct 18, 2027
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 002	11918623	Jun 14, 2039		U-3855	M-82	Oct 18, 2027
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 003	11918623	Jun 14, 2039		U-3855	M-82	Oct 18, 2027
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 004	11918623	Jun 14, 2039		U-3855	M-82	Oct 18, 2027
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 005	11918623	Jun 14, 2039		U-3855	M-82	Oct 18, 2027
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 006	11918623	Jun 14, 2039		U-3855	M-82	Oct 18, 2027
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 007	11357820	Jun 14, 2039	DP		M-82	Oct 18, 2027
	11918623	Jun 14, 2039		U-3855	NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 008	11357820	Jun 14, 2039	DP		M-82	Oct 18, 2027
	11918623	Jun 14, 2039		U-3855	NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 009	11357820	Jun 14, 2039	DP		M-82	Oct 18, 2027
	11918623	Jun 14, 2039		U-3855	NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 010	11357820	Jun 14, 2039	DP		M-82	Oct 18, 2027
	11918623	Jun 14, 2039	U-3855		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 011	11357820	Jun 14, 2039	DP		M-82	Oct 18, 2027
	11918623	Jun 14, 2039	U-3855		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 012	11357820	Jun 14, 2039	DP		M-82	Oct 18, 2027
	11918623	Jun 14, 2039	U-3855		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 001	6821987	Apr 26, 2025	DS DP	U-3100		
	7166722	Nov 16, 2024	DS DP			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 002	6821987	Apr 26, 2025	DS DP	U-3100		
	7166722	Nov 16, 2024	DS DP			
<u>TOPIRAMATE - EPRONTIA</u>						
N 214679 001	11911362	Aug 21, 2040	DP	U-3413		
	11911362	Aug 21, 2040	DP	U-3414		
	11911362	Aug 21, 2040	DP	U-3415		
<u>TOVORAFENIB - OJEMDA</u>						
N 217700 001	10426782	Jun 23, 2035	DP		NCE	Apr 23, 2029
	8293752	Aug 04, 2031	DS DP		ODE-478	Apr 23, 2031
<u>TOVORAFENIB - OJEMDA</u>						
N 218033 001	10426782	Jun 23, 2035	DP		NCE	Apr 23, 2029
	8293752	Aug 04, 2031	DS DP		ODE-478	Apr 23, 2031
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001					I-908	Mar 16, 2026
					ODE-428	Mar 16, 2030
					PED	Sep 16, 2026
					PED	Sep 16, 2030
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002					I-908	Mar 16, 2026
					ODE-428	Mar 16, 2030
					PED	Sep 16, 2026
					PED	Sep 16, 2030
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003					I-908	Mar 16, 2026
					ODE-428	Mar 16, 2030
					PED	Sep 16, 2026
					PED	Sep 16, 2030
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 217513 001	7378423	May 29, 2027	DS DP		NP	Mar 16, 2026
	7378423*PED	Nov 29, 2027			ODE-428	Mar 16, 2030
	8703781	Oct 15, 2030	DS DP	U-3564	PED	Sep 16, 2026
	8703781*PED	Apr 15, 2031			PED	Sep 16, 2030
	8835443	Jun 10, 2025		U-3564		
	8835443*PED	Dec 10, 2025				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TRAVOPROST - IDOSE TR</u>						
N 218010 001					NP	Dec 13, 2026
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	11826327	Feb 03, 2042	U-3749			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 001	11826327	Feb 03, 2042	U-3749		NP	May 23, 2025
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 002	11826327	Feb 03, 2042	U-3749		NP	May 23, 2025
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 003	11826327	Feb 03, 2042	U-3749		NP	May 23, 2025
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 004	11826327	Feb 03, 2042	U-3749		NP	May 23, 2025
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 005	>A> 10130685	Aug 23, 2025	DP			
	>A> 10421729	Apr 01, 2035	DP			
	>A> 10772883	Jun 11, 2030	DP			
	>A> 11723887	Dec 15, 2028	DS			
	>A> 11826327	Feb 03, 2042	U-3749			
	>A> 9593066	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	9604901	Dec 15, 2028	DS	Y		
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 005	9604901	Dec 15, 2028	DS	Y		
<u>TRILACICLIB DIHYDROCHLORIDE - COSELA</u>						
N 214200 001	11040042	Oct 25, 2031	DP			
<u>TROFINETIDE - DAYBUE</u>						
N 217026 001	11827600	Jul 12, 2042	DS DP U-3556			
<u>TROSPIMUM CHLORIDE; XANOMELINE TARTRATE - COBENFY</u>						
N 216158 001	10238643	Jul 21, 2030	DP		NCE	Sep 26, 2029
	10265311	Jul 21, 2030	U-3513			
	10369143	Jul 21, 2030	U-3513			
	10369144	Jul 21, 2030	DP U-3513			
	10695339	Jul 21, 2030	U-3513			
	10925832	Sep 27, 2039	DP			
	10933020	Sep 27, 2039	DP U-3513			
	11452692	Sep 27, 2039	U-3513			
	11471413	Sep 27, 2039	U-3513			
	11890378	Sep 27, 2039	DP U-3513			
<u>TROSPIMUM CHLORIDE; XANOMELINE TARTRATE - COBENFY</u>						
N 216158 002	10238643	Jul 21, 2030	DP		NCE	Sep 26, 2029
	10265311	Jul 21, 2030	U-3513			
	10369143	Jul 21, 2030	U-3513			
	10369144	Jul 21, 2030	DP U-3513			
	10695339	Jul 21, 2030	U-3513			
	10925832	Sep 27, 2039	DP			
	10933020	Sep 27, 2039	DP U-3513			
	11452692	Sep 27, 2039	U-3513			
	11471413	Sep 27, 2039	U-3513			
	11890378	Sep 27, 2039	DP U-3513			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TROSPIUM CHLORIDE; XANOMELINE TARTRATE - COBENFY</u>						
N 216158 003	10238643	Jul 21, 2030	DP		NCE	Sep 26, 2029
	10265311	Jul 21, 2030	U-3513			
	10369143	Jul 21, 2030	U-3513			
	10369144	Jul 21, 2030	DP U-3513			
	10695339	Jul 21, 2030	U-3513			
	10925832	Sep 27, 2039	DP			
	10933020	Sep 27, 2039	DP U-3513			
	11452692	Sep 27, 2039	U-3513			
	11471413	Sep 27, 2039	U-3513			
	11890378	Sep 27, 2039	DP U-3513			
<u>TUCATINIB - TUKYSA</u>						
N 213411 001	11207324	Apr 27, 2038	U-3783			
	11666572	Apr 27, 2038	U-3783			
	12048698	Apr 27, 2038	U-3783			
<u>TUCATINIB - TUKYSA</u>						
N 213411 002	11207324	Apr 27, 2038	U-3783			
	11666572	Apr 27, 2038	U-3783			
	12048698	Apr 27, 2038	U-3783			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 001	11857542	Dec 22, 2041	U-3786			
	11925709	Jan 30, 2035	DP			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 002	11925709	Jan 30, 2035	DP			
	12070450	Dec 22, 2041	U-3992			
<u>UPADACITINIB - RINVOO</u>						
N 211675 001	11365198	Oct 17, 2036	U-3275		I-946	Apr 26, 2027
	11365198	Oct 17, 2036	U-3946		NPP	Apr 26, 2027
	11512092	Oct 17, 2036	U-3275		ODE-481	Apr 26, 2031
	11512092	Oct 17, 2036	U-3371			
	11512092	Oct 17, 2036	U-3487			
	11512092	Oct 17, 2036	U-3946			
	11773106	Oct 17, 2036	U-3275			
	11773106	Oct 17, 2036	U-3371			
	11773106	Oct 17, 2036	U-3487			
	11773106	Oct 17, 2036	U-3946			
	11976077	Oct 17, 2036	U-3298			
	11993605	Oct 17, 2036	U-3275			
	11993605	Oct 17, 2036	U-3946			
	11993606	Oct 17, 2036	U-3487			
	12077545	Oct 17, 2036	DP			
	12103933	Oct 17, 2036	DP			
	>A> 12110297	Oct 17, 2036	DP			
	>A> 12110298	Oct 17, 2036	DS DP			
	8962629	Jan 15, 2031	DS U-3255			
	8962629	Jan 15, 2031	DS U-3275			
	8962629	Jan 15, 2031	DS U-3341			
	8962629	Jan 15, 2031	DS U-3371			
	8962629	Jan 15, 2031	DS U-3624			
	8962629	Jan 15, 2031	DS U-3945			
	8962629	Jan 15, 2031	DS U-3946			
	RE47221	Aug 16, 2033	DS			
<u>UPADACITINIB - RINVOO</u>						
N 211675 002	12077545	Oct 17, 2036	DP		I-946	Apr 26, 2027
	12091415	Oct 17, 2036	DP		NPP	Apr 26, 2027
	>A> 12110298	Oct 17, 2036	DS DP		ODE-481	Apr 26, 2031
	>A> 12116373	Oct 17, 2036	DP			
	RE47221	Aug 16, 2033	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>UPADACITINIB - RINVOO</u>						
N 211675 003	12077545	Oct 17, 2036	DP		I-946	Apr 26, 2027
	>A> 12110298	Oct 17, 2036	DS DP		NPP	Apr 26, 2027
	>A> 12134621	Oct 17, 2036	DP		ODE-481	Apr 26, 2031
	RE47221	Aug 16, 2033	DS			
<u>UPADACITINIB - RINVOO LQ</u>						
N 218347 001	10981923	Oct 17, 2036	DS		NCE	Aug 16, 2024
	11186584	Oct 17, 2036	DS		NP	Apr 26, 2027
	11661425	Oct 17, 2036	DS		ODE-481	Apr 26, 2031
	11680069	Oct 17, 2036	DS			
	11718627	Oct 17, 2036	DS			
	11773105	Oct 17, 2036	DS			
	12110298	Oct 17, 2036	DS			
	8962629	Jan 15, 2031	DS	U-3945		
	8962629	Jan 15, 2031	DS	U-3946		
	9951080	Oct 17, 2036	DS			
	RE47221	Aug 16, 2033	DS			
<u>VADADUSTAT - VAFSEO</u>						
N 215192 001	10149842	Nov 14, 2034	DS DP		NCE	Mar 27, 2029
	11065237	Nov 14, 2034	DS DP	U-3876		
	11324734	Mar 31, 2036	DP			
	11844756	Mar 31, 2036		U-3876		
	11857543	Jun 09, 2034		U-3876		
	7811595	Mar 13, 2028	DS DP			
	8323671	Apr 03, 2028		U-3876		
	8343952	Aug 14, 2027	DS DP			
	8598210	Jun 26, 2027	DS DP			
	8940773	Jun 26, 2027		U-3876		
	9701636	Nov 14, 2034	DS DP			
	9987262	Nov 14, 2034		U-3876		
	RE47437	Jun 26, 2027	DS DP			
<u>VADADUSTAT - VAFSEO</u>						
N 215192 002	10149842	Nov 14, 2034	DS DP		NCE	Mar 27, 2029
	11065237	Nov 14, 2034	DS DP	U-3876		
	11324734	Mar 31, 2036	DP			
	11844756	Mar 31, 2036		U-3876		
	11857543	Jun 09, 2034		U-3876		
	7811595	Mar 13, 2028	DS DP			
	8323671	Apr 03, 2028		U-3876		
	8343952	Aug 14, 2027	DS DP			
	8598210	Jun 26, 2027	DS DP			
	8940773	Jun 26, 2027		U-3876		
	9701636	Nov 14, 2034	DS DP			
	9987262	Nov 14, 2034		U-3876		
	RE47437	Jun 26, 2027	DS DP			
<u>VADADUSTAT - VAFSEO</u>						
N 215192 003	10149842	Nov 14, 2034	DS DP		NCE	Mar 27, 2029
	11065237	Nov 14, 2034	DS DP	U-3876		
	11324734	Mar 31, 2036	DP			
	11844756	Mar 31, 2036		U-3876		
	11857543	Jun 09, 2034		U-3876		
	7811595	Mar 13, 2028	DS DP			
	8323671	Apr 03, 2028		U-3876		
	8343952	Aug 14, 2027	DS DP			
	8598210	Jun 26, 2027	DS DP			
	8940773	Jun 26, 2027		U-3876		
	9701636	Nov 14, 2034	DS DP			
	9987262	Nov 14, 2034		U-3876		
	RE47437	Jun 26, 2027	DS DP			
<u>VALBENAZINE TOSYLATE - INGREZZA SPRINKLE</u>						
N 218390 001	10065952	Oct 28, 2036	DS DP	U-1995	I-925	Aug 18, 2026
	10065952	Oct 28, 2036	DS DP	U-3055		
	10844058	Oct 28, 2036	DS DP	U-1995		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VALBENAZINE TOSYLATE - INGREZZA SPRINKLE</u>						
N 218390 001	10844058	Oct 28, 2036	DS DP U-3055			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-3055			
	10851104	Oct 28, 2036	DS U-1995			
	10851104	Oct 28, 2036	DS U-3055			
	10857137	Oct 10, 2037	U-1995			
	10857148	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10874648	Oct 10, 2037	U-3055			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11026939	Sep 18, 2038	DP U-3055			
	11040029	Oct 10, 2037	U-1995			
	11311532	Sep 18, 2038	DP U-1995			
	11311532	Sep 18, 2038	DP U-3055			
	11439629	Oct 10, 2037	U-3055			
	11654142	Nov 14, 2038	U-3055			
	8039627	Apr 11, 2031	DS DP			
	8357697	Nov 08, 2027	U-1995			
	8357697	Nov 08, 2027	U-3055			
<u>VALBENAZINE TOSYLATE - INGREZZA SPRINKLE</u>						
N 218390 002	10065952	Oct 28, 2036	DS DP U-1995		I-925	Aug 18, 2026
	10065952	Oct 28, 2036	DS DP U-3055			
	10844058	Oct 28, 2036	DS DP U-1995			
	10844058	Oct 28, 2036	DS DP U-3055			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-3055			
	10851104	Oct 28, 2036	DS U-1995			
	10851104	Oct 28, 2036	DS U-3055			
	10857137	Oct 10, 2037	U-1995			
	10857148	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10874648	Oct 10, 2037	U-3055			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11026939	Sep 18, 2038	DP U-3055			
	11040029	Oct 10, 2037	U-1995			
	11311532	Sep 18, 2038	DP U-1995			
	11311532	Sep 18, 2038	DP U-3055			
	11439629	Oct 10, 2037	U-3055			
	11654142	Nov 14, 2038	U-3055			
	8039627	Apr 11, 2031	DS DP			
	8357697	Nov 08, 2027	U-1995			
	8357697	Nov 08, 2027	U-3055			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VALBENAZINE TOSYLATE - INGREZZA SPRINKLE</u>						
N 218390 003	10065952	Oct 28, 2036	DS DP U-1995		I-925	Aug 18, 2026
	10065952	Oct 28, 2036	DS DP U-3055			
	10844058	Oct 28, 2036	DS DP U-1995			
	10844058	Oct 28, 2036	DS DP U-3055			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-3055			
	10851104	Oct 28, 2036	DS U-1995			
	10851104	Oct 28, 2036	DS U-3055			
	10857137	Oct 10, 2037	U-1995			
	10857148	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10874648	Oct 10, 2037	U-3055			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3055			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11026939	Sep 18, 2038	DP U-3055			
	11040029	Oct 10, 2037	U-1995			
	11311532	Sep 18, 2038	DP U-1995			
	11311532	Sep 18, 2038	DP U-3055			
	11439629	Oct 10, 2037	U-3055			
	11654142	Nov 14, 2038	U-3055			
	8039627	Apr 11, 2031	DS DP			
	8357697	Nov 08, 2027	U-1995			
	8357697	Nov 08, 2027	U-3055			
<u>VAMOROLONE - AGAMREE</u>						
N 215239 001	11690853	Mar 07, 2033	U-3747			
<u>VARENICLINE TARTRATE - TYRVAYA</u>						
N 213978 001	11903941	Oct 19, 2035	U-1900			
	11903942	Oct 19, 2035	DP			
	11903943	Oct 19, 2035	U-1900			
	11911380	Oct 19, 2035	U-1900			
<u>VIBEGRON - GEMTESA</u>						
N 213006 001	12102638	Mar 22, 2040	U-3045			
<u>VIGABATRIN - VIGAFYDE</u>						
N 217684 001	12016857	Aug 16, 2039	DP			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 001 >A>	12121523	Sep 04, 2029	U-727			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 002 >A>	12121523	Sep 04, 2029	U-727			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 003 >A>	12121523	Sep 04, 2029	U-727			
<u>VOCLOSPORIN - LUPKYNIS</u>						
N 213716 001	7332472	Oct 17, 2025	DS DP U-3056			
<u>VONOPRAZAN FUMARATE - VOQUEZNA</u>						
N 215151 001					I-948	Jul 17, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VORASIDENIB - VORANIGO</u>						
N 218784 001	10172864	Jul 11, 2034	DS DP		NCE	Aug 06, 2029
	11345677	Jan 16, 2039	DS DP U-3978		ODE-491	Aug 06, 2031
	11844758	Dec 04, 2035	U-3977			
	9579324	Jul 11, 2034	DS			
<u>VORASIDENIB - VORANIGO</u>						
N 218784 002	10172864	Jul 11, 2034	DS DP		NCE	Aug 06, 2029
	11345677	Jan 16, 2039	DS DP U-3978		ODE-491	Aug 06, 2031
	11844758	Dec 04, 2035	U-3977			
	9579324	Jul 11, 2034	DS			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 001	10646550	Aug 01, 2036	DP U-3927			
	11590204	Aug 01, 2036	DP U-3927			
	11911446	Aug 01, 2036	U-3927			
	8198242	Jun 11, 2030	DS DP U-3927			
	RE48267	May 20, 2030	U-3927			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 002	10646550	Aug 01, 2036	DP U-3927			
	11590204	Aug 01, 2036	DP U-3927			
	11911446	Aug 01, 2036	U-3927			
	8198242	Jun 11, 2030	DS DP U-3927			
	RE48267	May 20, 2030	U-3927			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 003	10646550	Aug 01, 2036	DP U-3927			
	11590204	Aug 01, 2036	DP U-3927			
	11911446	Aug 01, 2036	U-3927			
	8198242	Jun 11, 2030	DS DP U-3927			
	RE48267	May 20, 2030	U-3927			
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 001	11944612	Dec 02, 2036	U-3893			
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 002	11944612	Dec 02, 2036	U-3893			
<u>VOXELOTOR - OXBRYTA</u>						
N 216157 001	11944612	Dec 02, 2036	U-3893			
<u>VUTRISIRAN SODIUM - AMVUTTRA</u>						
N 215515 001	12049628	Jul 28, 2036	DS DP U-3396			
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	10570139	Apr 22, 2034	U-1745		I-936	Mar 07, 2027
	10570139	Apr 22, 2034	U-2145		ODE-467	Mar 07, 2031
	10570139	Apr 22, 2034	U-2537			
	10570139	Apr 22, 2034	U-2666			
	10570139	Apr 22, 2034	U-3063			
	10570139	Apr 22, 2034	U-3486			
	10570139	Apr 22, 2034	U-3860			
	11142528	Apr 22, 2034	DP U-1745			
	11142528	Apr 22, 2034	DP U-2145			
	11142528	Apr 22, 2034	DP U-2537			
	11142528	Apr 22, 2034	DP U-2666			
	11142528	Apr 22, 2034	DP U-3063			
	11142528	Apr 22, 2034	DP U-3486			
	11142528	Apr 22, 2034	DP U-3860			
	11701357	Jun 24, 2039	U-3860			
	11786531	Jan 19, 2043	U-3715			
	11786531	Jan 19, 2043	U-3716			
	11786531	Jan 19, 2043	U-3717			
	11786531	Jan 19, 2043	U-3718			
	11786531	Jan 19, 2043	U-3719			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	11786531	Jan 19, 2043	U-3720			
	11786531	Jan 19, 2043	U-3875			
	11851437	Aug 15, 2037	DS DP			
	11884674	Aug 15, 2037	U-1745			
	11884674	Aug 15, 2037	U-2145			
	11884674	Aug 15, 2037	U-2537			
	11884674	Aug 15, 2037	U-2666			
	11884674	Aug 15, 2037	U-3063			
	11884674	Aug 15, 2037	U-3486			
	11884674	Aug 15, 2037	U-3860			
	11896596	Jan 19, 2043	U-3715			
	11896596	Jan 19, 2043	U-3716			
	11896596	Jan 19, 2043	U-3717			
	11896596	Jan 19, 2043	U-3718			
	11896596	Jan 19, 2043	U-3719			
	11896596	Jan 19, 2043	U-3720			
	11896596	Jan 19, 2043	U-3875			
	11911386	Jan 19, 2043	U-3715			
	11911386	Jan 19, 2043	U-3716			
	11911386	Jan 19, 2043	U-3717			
	11911386	Jan 19, 2043	U-3718			
	11911386	Jan 19, 2043	U-3719			
	11911386	Jan 19, 2043	U-3720			
	11911386	Jan 19, 2043	U-3875			
	11970500	Aug 15, 2037	U-1745			
	11970500	Aug 15, 2037	U-2145			
	11970500	Aug 15, 2037	U-2537			
	11970500	Aug 15, 2037	U-2666			
	11970500	Aug 15, 2037	U-3063			
	11970500	Aug 15, 2037	U-3486			
	11970500	Aug 15, 2037	U-3860			
	9447106	Apr 22, 2034	DS DP U-1745			
	9447106	Apr 22, 2034	DS DP U-2145			
	9447106	Apr 22, 2034	DS DP U-2537			
	9447106	Apr 22, 2034	DS DP U-2666			
	9447106	Apr 22, 2034	DS DP U-3063			
	9447106	Apr 22, 2034	DS DP U-3486			
	9447106	Apr 22, 2034	DS DP U-3860			
<u>ZILUCOPLAN SODIUM - ZILBRYSO</u>						
N 216834 001	11965040	Jun 12, 2035	DP			
<u>ZILUCOPLAN SODIUM - ZILBRYSO</u>						
N 216834 002	11965040	Jun 12, 2035	DP			
<u>ZILUCOPLAN SODIUM - ZILBRYSO</u>						
N 216834 003	11965040	Jun 12, 2035	DP			
<u>ZINC CHLORIDE - ZINC CHLORIDE</u>						
A 216152 001					>A> CGT	Apr 14, 2025
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 001	11884696	Dec 24, 2037	U-2552			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 002	11884696	Dec 24, 2037	U-2552			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 003	11884696	Dec 24, 2037	U-2552			

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 44TH Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm